<SEC-DOCUMENT>0001564590-21-014190.txt : 20210318
<SEC-HEADER>0001564590-21-014190.hdr.sgml : 20210318
<ACCEPTANCE-DATETIME>20210318165137
ACCESSION NUMBER:		0001564590-21-014190
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210318
DATE AS OF CHANGE:		20210318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AVROBIO, Inc.
		CENTRAL INDEX KEY:			0001681087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				810710585
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38537
		FILM NUMBER:		21754975

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 300, SUITE 201
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		7819626030

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 300, SUITE 201
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AvroBio, Inc.
		DATE OF NAME CHANGE:	20160729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>avro-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T19:55:42.1923533+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6fb2e3cb4db74b44b876e8a9aa22350a -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:avro="http://www.avrobio.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
avro-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001681087_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001681087_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001681087_20200101_20201231">0001681087</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001681087_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000278" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000279" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000280" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000281" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">2020-01-01</ix:nonNumeric>
			<ix:nonNumeric id="F_000282" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">2020-01-01</ix:nonNumeric>
			<ix:nonNumeric id="F_000283" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">2020-01-01</ix:nonNumeric>
			<ix:nonNumeric id="F_000284" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000285" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000286" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000564" name="avro:OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" contextRef="C_0001681087_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001681087_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001681087_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:PreferredStockValue" contextRef="C_0001681087_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:PreferredStockValue" contextRef="C_0001681087_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000271" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000272" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Lesser of lease term</ix:nonNumeric>
			<ix:nonNumeric id="F_000454" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001681087_20200101_20201231">P6Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000455" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001681087_20190101_20191231">P5Y7M13D</ix:nonNumeric>
			<ix:nonNumeric id="F_000472" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001681087_20190101_20191231">P8Y5M4D</ix:nonNumeric>
			<ix:nonNumeric id="F_000473" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001681087_20200101_20201231">P7Y7M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000474" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001681087_20200101_20201231">P5Y4M24D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="avro-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001681087_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001681087_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001681087_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001681087_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_avroSegment">
				<xbrli:measure>avro:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UniversityOfManchesterAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:MPSIILicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UniversityOfManchesterAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:MPSIILicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-30</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217GBP">
				<xbrli:measure>iso4217:GBP</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_iso4217CAD">
				<xbrli:measure>iso4217:CAD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:FabrylicenseagreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-01-27</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127_20160127">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:FabrylicenseagreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-27</xbrli:startDate>
					<xbrli:endDate>2016-01-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-27</xbrli:startDate>
					<xbrli:endDate>2016-01-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-01-27</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170801_20170831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-08-01</xbrli:startDate>
					<xbrli:endDate>2017-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20171002_20171002">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:GenstemTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-02</xbrli:startDate>
					<xbrli:endDate>2017-10-02</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:GenstemTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:GenstemTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20161117_20161117">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:LundUniversityRightsHoldersAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-11-17</xbrli:startDate>
					<xbrli:endDate>2016-11-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:LundUniversityRightsHoldersAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:LundUniversityRightsHoldersAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20180112_20180112">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-12</xbrli:startDate>
					<xbrli:endDate>2018-01-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001681087_20180112">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-01-12</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20200609_20200609">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-09</xbrli:startDate>
					<xbrli:endDate>2020-06-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20180831_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-31</xbrli:startDate>
					<xbrli:endDate>2018-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20200609">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20200601_20200601">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-01</xbrli:startDate>
					<xbrli:endDate>2020-06-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20200601">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:JulyTwoThousandNineteenFollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:JulyTwoThousandNineteenFollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:JulyTwoThousandNineteenFollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:FebruaryTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:FebruaryTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:FebruaryTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200601_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:NovemberTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:NovemberTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:NovemberTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandNineteenInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandNineteenInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandTwentyInducementPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandTwentyInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandFifteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandFifteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200416">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandNineteenInducementPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandNineteenInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandTwentyInducementPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandTwentyInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2037Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2037Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2039Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2039Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_avroOrphanDrugCreditMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">avro:OrphanDrugCreditMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2033Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2033Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avro:RestrictedStockAwardsAndUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avro:RestrictedStockAwardsAndUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapAwardTypeAxis_avroStockPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20160127_20160127">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avro:StockPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-27</xbrli:startDate>
					<xbrli:endDate>2016-01-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20180701_20180731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-07-01</xbrli:startDate>
					<xbrli:endDate>2018-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avro:OfficersAndBoardMembersMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:SubleaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001681087</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avro:OfficersAndBoardMembersMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:SubleaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-top:Double 2.25pt;padding-top:1pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:44.29%;margin-right:44.25%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;<ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001681087_20200101_20201231">10-K</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:44.29%;margin-right:44.25%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:DocumentAnnualReport" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">ANNUAL REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES EXCHANGE ACT OF&#160;1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001681087_20200101_20201231" format="ixt:datemonthdayyearen">December&#160;31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001681087_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric> </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:DocumentTransitionReport" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number <ix:nonNumeric id="F_000019" name="dei:EntityFileNumber" contextRef="C_0001681087_20200101_20201231">001-38537</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:44.29%;margin-right:44.25%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001681087_20200101_20201231">AVROBIO,&#160;INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:44.29%;margin-right:44.25%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001681087_20200101_20201231">81-0710585</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityAddressAddressLine1" contextRef="C_0001681087_20200101_20201231">One Kendall Square</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressAddressLine2" contextRef="C_0001681087_20200101_20201231">Building 300</ix:nonNumeric>, <ix:nonNumeric id="F_000023" name="dei:EntityAddressAddressLine3" contextRef="C_0001681087_20200101_20201231">Suite 201</ix:nonNumeric></p></td>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityAddressCityOrTown" contextRef="C_0001681087_20200101_20201231">Cambridge</ix:nonNumeric>, <ix:nonNumeric id="F_000025" name="dei:EntityAddressStateOrProvince" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:EntityAddressPostalZipCode" contextRef="C_0001681087_20200101_20201231">02139</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000027" name="dei:CityAreaCode" contextRef="C_0001681087_20200101_20201231">617</ix:nonNumeric>) <ix:nonNumeric id="F_000028" name="dei:LocalPhoneNumber" contextRef="C_0001681087_20200101_20201231">914-8420</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:33.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style="width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:32.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top" style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:33.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:Security12bTitle" contextRef="C_0001681087_20200101_20201231">Common Stock, $0.0001 par value per share</ix:nonNumeric></p></td>
<td valign="top" style="width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:32.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001681087_20200101_20201231">AVRO</ix:nonNumeric></p></td>
<td valign="top" style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000034" name="dei:SecurityExchangeName" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">None </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:44.29%;margin-right:44.25%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000015" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001681087_20200101_20201231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000017" name="dei:EntityVoluntaryFilers" contextRef="C_0001681087_20200101_20201231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000016" name="dei:EntityCurrentReportingStatus" contextRef="C_0001681087_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000032" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001681087_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:16.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:61.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:19.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.5pt;">
<td valign="middle" style="width:16.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:61.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:19.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:16.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:61.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom" style="width:19.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntitySmallBusiness" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:1.5pt;">
<td valign="middle" style="width:16.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:61.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:19.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:16.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:19.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging&#160;growth&#160;company</p></td>
<td valign="bottom" style="width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityExTransitionPeriod" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160; <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000035" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000018" name="dei:EntityShellCompany" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000011" name="dei:EntityPublicFloat" contextRef="C_0001681087_20200630" decimals="0" format="ixt:numdotdecimal">533,953,963</ix:nonFraction> as of June&#160;30, 2020 (based on a closing price of $17.45 share as quoted by the Nasdaq Global Select Market as of such date). In determining the market value of non-affiliate common stock, shares of the registrant&#8217;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registrant had <ix:nonFraction unitRef="U_xbrlishares" id="F_000010" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001681087_20210309" decimals="INF" format="ixt:numdotdecimal">41,622,060</ix:nonFraction> shares of Common Stock, $0.0001 par value per share, outstanding as of March&#160;9, 2021. </p><ix:nonNumeric id="F_000212" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive Proxy Statement for its 2021 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of December&#160;31, 2020. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K for the Fiscal Year Ended December&#160;31, 2020 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.68%;"></td>
<td style="width:86.08%;"></td>
<td style="width:5.24%;"></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:left;margin-top:0pt;border-top:none 0pt;padding-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;No.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:underline;">PART I</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART II</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">Reserved</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:underline;">PART III</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:underline;">PART IV</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits and Financial Statement Schedules</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of the Material Risks Associated with Our Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have incurred net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We will need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Business interruptions resulting from the coronavirus disease (COVID-19) pandemic or similar public health crises have caused and may continue to cause a disruption of the development of our product candidates and adversely impact our business. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our lentiviral-based gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our product candidates and the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Even if we complete the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.5%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Only certain of our clinical trials, including the Phase 2 clinical trial of AVR-RD-01 for Fabry disease and the Phase 1/2 clinical trial of AVR-RD-02 for Gaucher disease type 1, utilize our commercial-scale plato<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> platform. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We face significant competition in our industry and there can be no assurance that our product candidates, if approved, will achieve acceptance in the market over existing established therapies. In addition, our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our ability to successfully market or commercialize any of our product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs or otherwise adversely affect our business.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We expect to rely on third parties to conduct some or all aspects of our vector production, product manufacturing, protocol development, research and preclinical and clinical testing, and these third parties may not perform satisfactorily. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We are dependent on a limited number of suppliers for some of our components and materials used in our product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of licenses granted to us by others. In particular, we have in-licensed certain intellectual property rights and know-how relevant to AVR-RD-01 for our Fabry program, AVR-RD-02 for our Gaucher type 1 program and AVR-RD-05 for our Hunter program, but do not own any patents or patent applications covering these product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We and our independent registered public accounting firm previously identified a material weakness in our internal control over financial reporting, which has now been remediated. Nevertheless, if we experience additional material weaknesses or deficiencies in the future or otherwise fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our investors&#8217; confidence and our stock price. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summary risk factors described above should be read together with the text of the full risk factors below, in the section Item1A entitled &#8220;Risk Factors&#8221; and the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Forward-looking Information </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements may be identified by such forward-looking terminology as &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed to,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;strives,&#8221; &#8220;should,&#8221; or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the impact of the COVID-19 pandemic on our clinical trial programs, clinical supply and business generally, as well as our plans and expectations with respect to the timing and resumption of any development activities that were or may be temporarily paused as a result of the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing, progress and results of preclinical studies and clinical trials for our programs and product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the existence or absence of side effects or other properties relating to our product candidates which could delay or prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences following any potential marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the durability of effects from our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing, scope or likelihood of regulatory filings and approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to develop and advance product candidates into, and successfully complete, clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the implementation of our business model and our strategic plans for our business, product candidates, technology and plato platform&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our commercialization, marketing and manufacturing capabilities and strategy&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the pricing and reimbursement of our product candidates, if approved&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the scalability and commercial viability of our manufacturing methods and processes, including our move to a closed, automated system&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the rate and degree of market acceptance and clinical utility of our product candidates, in particular, and gene therapy, in general&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to establish or maintain collaborations or strategic relationships or obtain additional funding&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our competitive position&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the scope of protection we and/or our licensors are able to establish and maintain for intellectual property rights covering our current and future product candidates, as well as any statements as to whether we do or do not infringe, misappropriate or otherwise violate any third-party intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our financial performance&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments and projections relating to our competitors and our industry, including other lentiviral-based gene therapy companies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectations related to the use of our cash reserves&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to avoid any findings of material weaknesses or significant deficiencies in the future&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the impact of laws and regulations, including without limitation recently enacted tax reform legislation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectations regarding the time during which we are an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our forward-looking statements are as of the date of this Annual Report on Form 10-K only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Annual Report on Form&#160;10-K or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report on Form 10-K, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Annual Report on Form 10-K that modify or impact any of the forward-looking statements contained in this Annual Report on Form 10-K will be deemed to modify or supersede such statements in this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Note Regarding Trademarks</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">All brand names or trademarks appearing in this report are the property of their respective holders. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unless the context requires otherwise, references in this Annual Report on Form&#160;10-K to the &#8220;Company,&#8221; &#8220;AVROBIO,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to AVROBIO, Inc. Our &#8220;board of directors&#8221; refers to the board of directors of AVROBIO, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item&#160;1. Business</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease.&#160;&#160;Our company is focused on developing potentially curative <span style="font-style:italic;">ex vivo</span> lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Our gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is defective in the target disease. We believe that our approach, which is designed to transform stem cells from patients into therapeutic products, has the potential to provide curative benefit for a range of diseases. Our initial focus is on a group of rare genetic diseases referred to as lysosomal disorders, some of which today are primarily managed with enzyme replacement therapies, or ERTs. These lysosomal disorders have well-understood biologies, identified patient populations, established standards of care yet with significant unmet needs, and represent large market opportunities with approximately $4.8&#160;billion in worldwide net sales in 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial pipeline is comprised of six lentiviral-based gene therapy programs: AVR-RD-01 for the treatment of Fabry disease&#59; AVR-RD-04 for the treatment of cystinosis&#59; AVR-RD-02 for the treatment of Gaucher disease type 1&#59; AVR-RD-05 for the treatment of Hunter syndrome&#59; AVR-RD-06 for the treatment of Gaucher disease type 3&#59; and AVR-RD-03 for the treatment of Pompe disease. AVR-RD-01 is currently being evaluated for the treatment of Fabry disease in an investigator-sponsored Phase&#160;1 clinical trial and a Company-sponsored Phase 2 clinical trial. Five patients have been dosed in the investigator-sponsored Phase 1 clinical trial of AVR-RD-01, and enrollment is complete. Five patients have been dosed in our Company-sponsored Phase 2 clinical trial of AVR-RD-01, which we refer to as the FAB-GT clinical trial, and we are actively recruiting additional potential patients for our currently active sites in Australia, Canada and the United States. AVR-RD-04 is currently being studied <span style="Background-color:#FFFFFF;color:#000000;">for the treatment of cystinosis</span> <span style="Background-color:#FFFFFF;color:#000000;">by our collaborators at the University of California, San Diego, or UCSD, in a Phase 1/2 investigator-sponsored clinical trial, and three patients have been dosed.</span> One patient has been dosed in our Company-sponsored Phase 1/2 clinical trial of AVR-RD-02 for the treatment of Gaucher disease, which we refer to as the Guard1 clinical trial, and we are actively recruiting in Australia and Canada, with additional sites planned in the United States, Israel and Europe. AVR-RD-05 is being studied for the treatment of Hunter syndrome by our collaborators at The University of Manchester, and a Phase 1/2 investigator-sponsored clinical trial is expected to commence in the first half of 2022. In November 2020, we announced a new preclinical program, AVR-RD-06 for the treatment of Gaucher disease type 3, and we expect to request a meeting with the Food and Drug Administration, or FDA, this year to discuss a potential path to the clinic. Our AVR-RD-03 program for Pompe disease is currently in preclinical development, and in 2020 we completed IND-enabling proof-of-concept preclinical studies, with toxicology studies expected to be completed in 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its first clinical use in 2003, lentiviral-based gene therapy has been studied in several third parties&#8217; clinical trials for rare diseases such as transfusion-dependent beta thalassemia, cerebral adrenoleukodystrophy, or CALD, metachromatic leukodystrophy, or MLD, and adenosine deaminase severe combined immunodeficiency, or ADA-SCID. Initially, the use of <span style="font-style:italic;">ex vivo</span> lentiviral-based gene therapies was restricted primarily to the most severe diseases where the risks of the typical requirement for ablating the patients&#8217; bone marrow had a clinically justifiable risk/benefit profile. To date, over 350 patients have been treated with lentiviral-based gene therapies in third parties&#8217; and our rare disease clinical trials, and we believe the technology can be developed for other serious conditions based on a rigorous risk/benefit assessment. The ablation procedure, also known as the conditioning regimen, is typically an essential step in the <span style="font-style:italic;">ex vivo</span> gene therapy treatment procedure and is administered prior to the gene therapy. The higher the level of conditioning, the greater the potential risk of more serious complications, such as veno-occlusive disease. However, we believe the risk of more serious complications can be managed through utilization of<span style="font-size:12pt;"> </span>a precision busulfan dosing program, which we refer to as Target Concentration Intervention, or TCI. TCI is designed to enable careful titrating of exposure to the conditioning drug to a specific area under the curve, or AuC. The conditioning regimen utilized as part of our plato platform includes TCI to assess how rapidly the individual patient metabolizes the conditioning agent so physicians can adjust the dose as needed, with a goal of minimizing side effects while maximizing the potential of durable engraftment. We believe our approach, utilizing a single myeloablative conditioning agent, busulfan, coupled with TCI designed to titrate to a specific AuC, has the potential to extend the reach of our gene therapies to a broad range of diseases as first-line therapies. Our goal is to broaden the applicability of lentiviral-based gene therapy by initially targeting monogenic diseases with an identified gene, recognized biology and that could potentially benefit from the sustained systemic delivery of an active protein. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plato is our gene therapy platform designed to provide the foundation for the potential worldwide commercialization of our gene therapies, if approved. It is an </span><span style="font-style:italic;">ex vivo</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> gene therapy platform incorporating multiple upgrades including a four-plasmid lentiviral vector designed to optimize vector copy number, transduction efficiency and resulting enzyme activity&#59; a closed, automated manufacturing system designed to improve consistency and predictability of the drug product&#59; and a personalized approach to conditioning </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TCI</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="Background-color:#FFFFFF;color:#000000;">Two patients in our </span><span style="Background-color:#FFFFFF;color:#000000;">FAB-GT</span><span style="Background-color:#FFFFFF;color:#000000;"> clinical trial of&#160;AVR-RD-01&#160;and</span><span style="Background-color:#FFFFFF;color:#000000;"> one patient in our </span><span style="Background-color:#FFFFFF;color:#000000;">Guard1</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;clinical trial of AVR-RD-02</span><span style="Background-color:#FFFFFF;color:#000000;"> have been dosed with drug product manufactured utilizing the plato platform</span><span style="Background-color:#FFFFFF;color:#000000;">, and we intend to utilize the plato platform with these process changes for all future patients enrolling in these two clinical trials. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our innovations in viral vector design, cellular manufacturing, cryopreservation, conditioning and other related processes are important steps towards advancing the field of lentiviral-based gene therapy and realizing its full potential to treat a number of diseases. We plan to continue leveraging advancements in stem cell transplantation with the goal of improving patient tolerability of our lentiviral-based gene therapies.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are initially targeting rare lysosomal disorders in which the current standard of care provides the mechanistic proof that the enzymes or proteins produced endogenously following treatment with our gene therapies can offer benefit to patients. Typically, in lysosomal disorders, a gene mutation results in the deficiency or malfunctioning of an enzyme or other protein. This results in the inability of lysosomes to properly process cellular materials such as damaged organelles. As a result, substrates and their metabolites accumulate to toxic levels in the body&#8217;s cells and, in turn, disrupt the function of multiple tissues and organs. Fabry disease, Gaucher disease (types 1 and 3), Hunter syndrome and Pompe disease are currently primarily managed by bi-weekly (or weekly in the case of Hunter syndrome), multi-hour infusions with ERTs that seek to exogenously replace the missing functional enzyme. However, given their pharmacokinetics, most ERTs typically remain in the plasma only for a short period of time and thus are not ideal because they are only dosed weekly or every two weeks. Cystinosis is currently treated with two oral formulations of cysteamine that must be taken orally every 12 or six hours, leading to significant pill burden and compliance challenges. Further, oral cysteamine treatment has no effect on ocular cystine crystals deposits, thus requiring patients to be treated with topical cysteamine eye drops which must be applied each hour the patient is awake. These existing therapies manage, rather than cure, the underlying diseases and, as a result, patients continue to have disease progression. Further, the frequent, periodic and life-long dosing schedule required for ERTs and cysteamine results in significant costs for the healthcare system and is burdensome for the patient. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our gene therapies leverage the well-understood mechanism of ERTs by transforming a patient&#8217;s own cells into a drug product that enables the patient to express functional enzyme or other protein and mirror the biology seen in an otherwise healthy individual. We believe that a single dose of our gene therapies may provide meaningful life-long benefit to these patients and potentially halt the progression of these diseases while also potentially providing significant health economic advantages. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our programs leverage years of extensive preclinical and early clinical research by leading researchers, as well as our internal research and ongoing clinical efforts. The status of our initial lentiviral-based gene therapy programs is reflected below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gan5qj4us5ce000001.jpg" title="" alt="" style="width:510px;height:311px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, AVR-RD-01 for the treatment of Fabry disease, is derived from hematopoietic stem cells to which the gene encoding plasma &#945;-galactosidase A, or AGA, is added in an <span style="font-style:italic;">ex</span> <span style="font-style:italic;">vivo</span> process using a lentiviral vector. <span style="Background-color:#FFFFFF;color:#000000;">In February 2021, we reported that a kidney biopsy taken at 12 months post-treatment from the fourth patient in the Phase 2 FAB-GT trial, who was the first in the trial dosed with our plato platform, showed a 100 percent&#160;reduction from baseline in the average number of </span>globotriaosylceramide,<span style="Background-color:#FFFFFF;color:#000000;"> or Gb3, inclusions per peritubular capillary, or PTC. </span>These data followed our 2019 announcement that at 12 months post-treatment the first patient in the FAB-GT clinical trial exhibited an 87% reduction in the average number of Gb3 inclusions per PTC as compared to baseline. <span style="Background-color:#FFFFFF;color:#000000;">In addition, in February 2021 we reported data from the first four patients in the FAB-GT trial measured as of 29, 24, 18 and 12 months, respectively, indicating sustained increased leukocyte and plasma enzyme activity, suggesting that these patients are now producing an endogenous supply of AGA, as well as decreased plasma </span>lyso-globotriaosylsphingosine, or <span style="Background-color:#FFFFFF;color:#000000;">lyso-Gb3, levels in three of four patients, a key biomarker for monitoring Fabry disease. </span>We have opened two U.S. sites for our ongoing FAB-GT clinical trial of AVR-RD-01, and we are actively recruiting potential patients for our sites in Australia, Canada and the United States. We have submitted a briefing book to the FDA outlining our proposal for a potential accelerated approval strategy for AVR-RD-01, including a proposed randomized confirmatory clinical trial of Fabry patients who are being treated with ERT. We expect to meet with the FDA in the first quarter of 2021 to discuss our proposal. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we announced initial clinical data from the first three patients dosed in the investigator-sponsored Phase 1/2 trial of AVR-RD-04, our investigational gene therapy for cystinosis. As of January 20, 2021, all three patients had discontinued cysteamine pills and eye drops and remained cysteamine-independent out as far as 16 months post-treatment. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also announced in February 2021 clinical data from the first patient dosed in our Phase 1/2 Guard1 clinical trial of&#160;AVR-RD-02&#160;for Gaucher disease type 1.<span style="color:#000000;"> The first patient exhibited a 44% reduction in plasma&#160;glucosylsphingosine, or lyso-Gb1,&#160;levels six months post-administration of&#160;AVR-RD-02&#160;as compared to baseline while on ERT. Lyso-Gb1&#160;is considered a surrogate marker for disease activity and treatment response for Gaucher disease type 1. In addition, we announced that at six months post-treatment the first patient exhibited a 49% reduction in chitotriosidase levels as compared to baseline while on ERT. Chitotriosidase is a biomarker of macrophage activation that is found in high levels in Gaucher patients where the macrophages have accumulated an excess lipid burden. </span>This clinical trial is actively recruiting in Australia and Canada, with additional sites planned in the <span style="color:#000000;">United States, Israel and Europe</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to seek opportunities to expand our approach to other rare and non-rare diseases. We plan to identify and develop future product candidates through our own internal research efforts as well as through collaborations with leading researchers worldwide. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Expertise </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are led by biopharmaceutical experts with extensive experience in gene and cellular therapy, and rare diseases. Our team has broad expertise in the clinical, regulatory and commercialization aspects of rare diseases as well as process development and manufacturing for cellular therapies. Members of our management team have held senior positions at Amgen, AstraZeneca, AveXis, Biogen, bluebird bio, GlaxoSmithKline, Lonza, Novartis, Sanofi Genzyme, Shire, Spark Therapeutics, and other companies pursuing development, manufacturing and commercialization of gene, cellular and other therapies to treat rare diseases. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to develop and commercialize lentiviral-based gene therapies that free patients from a lifetime of genetic disease. Key elements of our strategy include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Rapidly advance our pipeline targeting lysosomal disorders.</span><span style="font-size:10pt;color:#000000;"> We are initially targeting lysosomal disorders and are developing a deep pipeline of six gene therapies to treat Fabry disease, cystinosis, Gaucher disease type 1, Hunter syndrome, Gaucher disease type 3 and Pompe disease. We intend to continue rapidly advancing these programs in parallel and to obtain clinical data that could potentially support regulatory filings around the world. Specifically, we intend to pursue pathways for accelerated review and approval of our product candidates by the FDA and international regulatory authorities through programs such as the Regenerative Medicine Advanced Therapies, or RMAT, program in the United States. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Continue implementing and enhancing our industry-leading plato platform with its personalized approach to conditioning, enhanced vector technology and automated, closed manufacturing processes.</span><span style="font-size:10pt;color:#000000;"> Our end-to-end plato platform is designed to provide the foundation for worldwide commercialization of our gene therapies, if </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">approved. </span><span style="font-size:10pt;color:#000000;">We believe our innovations in viral vector design, cellular manufacturing, cryopreservation, and other related processes are important steps towards advancing the field of lentiviral-based gene therapy and realizing its full potential to treat a number of diseases. </span><span style="font-size:10pt;color:#000000;">Plato </span><span style="font-size:10pt;color:#000000;">incorporates a</span><span style="font-size:10pt;color:#000000;"> four-plasmid lentiviral vector designed to optimize vector copy number, transduction efficiency and resulting enzyme activity</span><span style="font-size:10pt;color:#000000;">. </span><span style="font-size:10pt;color:#000000;">In combination with this vector, in some indications we use a number of proprietary peptide tag technologies to enhance uptake of therapeutic protein in key tissues. </span><span style="font-size:10pt;color:#000000;">W</span><span style="font-size:10pt;color:#000000;">e have</span><span style="font-size:10pt;color:#000000;"> also</span><span style="font-size:10pt;color:#000000;"> developed a manufacturing process that we believe is both reproducible and scalable</span><span style="font-size:10pt;color:#000000;">, and we believe </span><span style="font-size:10pt;color:#000000;">this technology</span><span style="font-size:10pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">could</span><span style="font-size:10pt;color:#000000;"> enable us to deliver our gene therapies to patients</span><span style="font-size:10pt;color:#000000;">, if approved,</span><span style="font-size:10pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">in quantities sufficient for global commercial supply</span><span style="font-size:10pt;color:#000000;">. </span><span style="font-size:10pt;color:#000000;">In addition, we believe our</span><span style="font-size:10pt;color:#000000;"> personalized</span><span style="font-size:10pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">approach to conditioning using busulfan with </span><span style="font-size:10pt;color:#000000;">a precision dosing program called Target Concentration Intervention</span><span style="font-size:10pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">could </span><span style="font-size:10pt;color:#000000;">enable us to deliver durable, &#8216;head-to-toe&#8217; treatment of symptoms and early intervention in the treatment of lysosomal disorders. We will continue to leverage advancements in stem cell transplantation in order to improve patient tolerability of our lentiviral-based gene therapies. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Build global infrastructure to reach patients across the world.</span><span style="font-size:10pt;color:#000000;"> Lysosomal disorders afflict patients globally and we intend to continue building global infrastructure in order to provide treatment to patients around the world. This infrastructure includes clinical sites, specialist physicians and researchers, suppliers and contract manufacturing organizations. We are currently conducting clinical trials across multiple geographies, including the United States, Canada and Australia, with plans to potentially expand to other geographies including Europe and Israel. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Leverage our approach beyond our initial indications.</span><span style="font-size:10pt;color:#000000;"> We are initially developing gene therapies for the treatment of six different lysosomal disorders and believe that we will gain significant learnings and technical insights from these programs. We intend to leverage our technology and insights to treat a number of rare and non-rare diseases where we believe our lentiviral approach has transformative potential. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Approach </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We develop gene therapies utilizing our <span style="font-style:italic;">ex vivo </span>lentiviral-based approach to transform a patient&#8217;s own stem cells into a drug product. Our investigational gene therapies employ lentiviral vectors that are designed to result in stable integration of the desired genes in the chromosomes of stem cells such that they are permanently maintained in the cell and can be reproduced as the cell divides. We focus on delivering our lentiviral-based gene therapies to patient-derived hematopoietic stem cells, which are primitive stem cells that develop into all types of blood cells, including white blood cells, red blood cells and platelets. To accomplish this, we harvest a patient&#8217;s hematopoietic stem cells and modify them <span style="font-style:italic;">ex vivo</span> to add the equivalent of a functional copy of the gene that is defective in the target disease. We then infuse the genetically modified cells back into the patient. Our gene therapies are designed to be administered to the patient as a one-time therapy following a TCI conditioning regimen. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on employing our approach to treat and potentially cure lysosomal disorders. These disorders have well-understood biologies, identified patient populations, established standards of care that leave many patients with significant unmet medical needs, and represent large markets with approximately $4.8&#160;billion in worldwide net sales in 2020. We believe our <span style="font-style:italic;">ex vivo </span>lentiviral-based gene therapy approach can be industrialized into a robust, scalable and, if approved, commercially viable process that will allow us to deliver our potentially curative therapies to patients across the world. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advantages of Ex-Vivo Lentiviral-Based Gene Therapy Approach </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe ex-vivo lentiviral-based gene therapy provides numerous advantages, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Durable benefit.</span><span style="font-size:10pt;color:#000000;"> We believe lentiviral vectors have the potential to provide life-long benefits with a single dose. Lentiviral vectors can integrate stably into the genome of hematopoietic stem cells and, when these cells replicate, they pass the integrated genes on to their progeny cells. Across the industry, efficacy in patients treated with lentiviral gene therapies has been demonstrated for longer than 12 years. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Systemic therapeutic effect.</span><span style="font-size:10pt;color:#000000;"> Progeny cells circulate systemically and may migrate into tissues and therefore have the ability to provide therapeutic benefit to affected tissues and organs throughout the body. In addition, we believe that our personalized busulfan conditioning regimen has the potential to allow the therapeutic benefits of our gene therapies to cross the blood-brain barrier and treat symptoms arising in the central nervous system. These often severe symptoms are typically unaddressed by the current standards-of-care for lysosomal disorders. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Broad patient applicability.</span><span style="font-size:10pt;color:#000000;"> Lentiviral-based gene therapies have been used to deliver treatments to patients of all ages, including children, and to patients who may be ineligible for other types of gene therapy due to the presence </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">of preexisting antibodies that detect viral vectors and trigger the immune system to destroy the vector and cells infected by the vector. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Restoration of protein function.</span><span style="font-size:10pt;color:#000000;"> By contrast to the standard-of-care enzyme replacement therapy, which seeks to clear toxic substrate as a key symptom of a non-functioning gene, restoration of gene function may deliver a wide array of additional biochemical benefits throughout the body. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">History of tolerability in clinical trials.</span><span style="font-size:10pt;color:#000000;"> To our knowledge, no instances of insertional oncogenesis or leukemogenesis from lentiviral vectors have been documented in clinical trials of lentiviral gene therapies, with more than 350 total patients treated. To date, we have not seen any unexpected safety events in 14 patients across our four clinical trials, with the longest follow-up more than 3.5 years to date.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Larger and varied payloads.</span><span style="font-size:10pt;color:#000000;"> In contrast to other viral vectors, lentiviral vectors have the capacity to carry larger gene sequences, which allow them to potentially address a large variety of indications. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Strategic Selection of Our Initial Indications </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are approximately 50 identified lysosomal disorders, which are characterized by an abnormal toxic build-up of substrates and their metabolites in the body&#8217;s cells. We are currently targeting Fabry disease, cystinosis, Gaucher disease type 1, Hunter syndrome, Gaucher disease type 3 and Pompe disease. Each of these disorders affects a meaningful number of patients, has a suboptimal standard of care with unmet medical need and, we believe, is appropriate for lentiviral-based gene therapy. We believe our approach has the potential to address the shortcomings of existing therapies that, despite chronic dosing, cannot halt or reverse disease progression, restore normal lifespan or adequately address symptoms arising in both the peripheral tissues and the central nervous system. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expanding the Utility of Lentiviral-Based Gene Therapy with TCI-Enabled Conditioning Regimen </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A core part of our approach is to expand the use of lentiviral-based gene therapy to treat numerous lysosomal disorders. We believe conditioning is an essential step to optimize these treatments as it is designed to clear space in the patient&#8217;s bone marrow and central nervous system for cells carrying the therapeutic gene. This maximizes the potential for their long-term engraftment which may enhance durability of therapeutic effect. We believe that we will be able to demonstrate durable effects in our targeted diseases utilizing a single myeloablative agent, busulfan, which we have transitioned to as part of implementing our plato platform. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have pioneered precision dosing of busulfan in gene therapy as a single agent in a single treatment cycle, with the goal of enhancing the patient experience. A body of research has identified an optimal exposure range for busulfan (Bu-90), which we plan to implement for the patients enrolled in our Company-sponsored clinical trials. Our approach is to personalize conditioning to each patient using TCI, a precision dosing program. TCI is designed to allow for continually controlled exposure by assessing via simple blood draws how rapidly the individual patient metabolizes busulfan, to inform further administration. Use of busulfan in a conditioning regimen causes adverse side effects and can transiently compromise the patient&#8217;s immune system, known as neutropenia, and ability to form blood clots, known as thrombocytopenia. The higher the level of conditioning, the greater the potential risk of more serious complications, such as veno-occlusive disease. However, we believe our approach to conditioning has the potential for reduced, predictable and manageable short- and long-term toxicities and maximized long-term engraftment. If realized, we believe these benefits may promote lentiviral-based gene therapy as a therapeutic option for less acutely severe diseases or diseases with approved therapies in which large unmet medical needs remain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our approach has the potential to extend the reach of our gene therapies to a broad range of lysosomal disorders as first-line therapies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">plato: Our Commercial-Scale Platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to developing first-line gene therapies, an important key to our strategy is to continuously improve our technology and production processes and to leverage these improvements across our gene therapies, if approved. Plato is designed to provide the foundation for the potential worldwide commercialization of our gene therapies. It is an <span style="font-style:italic;">ex vivo</span> gene therapy platform incorporating multiple upgrades including a four-plasmid lentiviral vector designed to optimize vector copy number, transduction efficiency and resulting enzyme activity&#59; a closed, automated manufacturing system designed to improve consistency and predictability of the drug product&#59; and a personalized approach to conditioning using busulfan with TCI, which is designed to optimize safety and engraftment. We have submitted data on our upgraded lentiviral vector and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">automated manufacturing process</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the applicable regulatory authorities in the United States</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Canada</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which allow</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> us </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incorporat</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such elements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> into our FAB-GT and Guard1 clinical trials in those jurisdictions</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Australia</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="Background-color:#FFFFFF;color:#000000;">Plato has been used to dose a total of three patients in our clinical trials, and we</span><span style="Background-color:#FFFFFF;color:#000000;"> intend to utilize the plato platform for all future patients enrolling in </span><span style="Background-color:#FFFFFF;color:#000000;">the FAB-GT and Guard1 clinical trials</span><span style="Background-color:#FFFFFF;color:#000000;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our plato platform may lead to better patient outcomes and will represent a significant advance in our industry towards achieving the quality and scale required for global commercialization of gene therapies.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our plato platform is designed to feature: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Large scale vector production:</span><span style="font-size:10pt;color:#000000;"> We currently have manufacturing capabilities, through contract manufacturing organizations, or CMOs, at 200-liter bioreactor scale, with vector production capable of treating a substantial number of patients per year. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Global reach</span><span style="font-size:10pt;color:#000000;">: Our automated, closed system for manufacturing is designed to allow for the flexible production of our gene therapies. The automated, closed manufacturing system is portable with proprietary AVROBIO algorithms which allow for efficient establishment of manufacturing capabilities in multiple geographies that can be expanded or adjusted as our global supply requirements evolve. We believe this approach will facilitate global manufacturing and shipping of our gene therapies, and will promote access to our products by patients and caregivers. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Quality of manufacturing</span><span style="font-size:10pt;color:#000000;">: Our platform is designed to utilize current good manufacturing practices, or cGMP, and we believe our automated, closed manufacturing system may result in less production variability and reduce the risk of operator error, while enhancing the potency of the drug product. We believe these features will improve the quality of our gene therapies that are produced. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Patient convenience</span><span style="font-size:10pt;color:#000000;">: Our gene therapies are cryopreserved, which is a feature designed to promote a longer shelf-life. We believe that a longer shelf-life will allow patients and clinics to schedule treatment sessions with greater convenience. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Cost containment</span><span style="font-size:10pt;color:#000000;">: Our platform is designed to control fixed and variable expenses associated with manufacturing our gene therapies. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the plato platform will form the backbone of our future commercialization efforts and our goal to take gene therapy mainstream. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Next Generation Vector Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have utilized our core expertise in the development and optimization of lentiviral vectors to improve the vectors used in our gene therapies. We have made and expect to continue to make enhancements to our lentiviral vectors to improve safety, efficacy and efficiency. For example, clinical trials of AVR-RD-01 have primarily utilized our original academic three-plasmid-produced lentiviral vector, which we refer to as LV1. However, we dosed the fourth and fifth patient in our ongoing FAB-GT clinical trial of AVR-RD-01 and the first patient in our ongoing Guard1 clinical trial of AVR-RD-02 using our proprietary four-plasmid lentiviral vector, which we refer to as LV2, and expect to dose all future patients in these trials with LV2. Our goal is to employ vectors that are state-of-the-art and that can be produced in a cost-effective and scalable manner.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Automated, Closed Manufacturing System </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our team has significant experience in cell processing and commercial-scale cellular therapy manufacturing. We have developed and are implementing a detailed plan for more cost efficient and scalable manufacturing of our gene therapies. In contrast to a number of other gene therapy companies that have not developed their commercial scale plans from the outset, we have executed on our plans to move to a closed suspension bioreactor system for vector production, as well as a closed, automated system for manufacturing our gene therapy product. Our move to a closed, automated manufacturing system was completed in 2019 as part of implementing upgrades from our plato platform, and the fourth and fifth patients in our ongoing FAB-GT clinical trial of AVR-RD-01 and the first patient in our ongoing Guard1 clinical trial of AVR-RD-02 were each dosed using this system. We believe our plato platform features the first automated, closed manufacturing system in CD34+ gene therapy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing approach is intended to allow for the production of drug product using relatively small, self-contained devices, which may reduce our reliance on large traditional clean rooms that are expensive to establish and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maintain</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We believe our manufacturing approach may result in greater flexibility in the location of manufacture and help to control costs associated with traditional manufacturing. In addition, we believe our automated manufacturing process may reduce operator error and yield greater consistency and less variability in the manufactured drug product. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have one CMO partner in the United States and two partners in Australia for the production of AVR-RD-01 and AVR-RD-02 drug product. We also are in the process of establishing a CMO partnership in Europe.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Optimization of Conditioning Regimen </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conditioning regimen that we first employed utilized melphalan, a common chemotherapy drug, to ablate the patient&#8217;s bone marrow. As part of the upgrades to our plato platform, we transitioned to utilizing busulfan, another chemotherapy drug, that has been in use since the 1950&#8217;s. Busulfan is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic stem cell transplantation for chronic myeloid leukemia. Busulfan is routinely used in conditioning regimens before allogeneic stem cell transplantations for both malignant and non-malignant conditions. It has also been used as a single-agent, or in combination with an immunosuppressive agent, such as cyclophosphamide, in conditioning regimens prior to <span style="font-style:italic;">ex vivo</span> gene therapy transplants. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the transition to busulfan for our conditioning regimen may confer several advantages. For example, busulfan will permit utilization of TCI in our conditioning regimen, thereby enabling physicians to personalize the dosing to each patient by titrating over four days to potentially enhance patient tolerability to the conditioning procedure and promote cell engraftment. By contrast, melphalan is administered once with no TCI, and may cause concern of conditioning-related toxicity across patients due to individual differences in metabolism of the drug. In addition, we believe that the utilization of busulfan in our single-agent myeloablative conditioning regimen has the potential to allow our gene therapies to cross the blood-brain barrier, a feature which may yield therapeutic benefit in diseases that have a central nervous system component, such as Fabry disease, Gaucher disease type 3, Hunter syndrome, Pompe disease and other rare and non-rare diseases. Finally, our busulfan conditioning regimen is designed to create more space in the ablated bone marrow compared to melphalan and may increase the average VCN of the patient bone marrow following treatment with the drug product, which are features that we believe will promote better cell engraftment and durability of the gene therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware that there have been cases of therapy-related myelodysplastic syndrome, or t-MDS, a type of blood disorder that is a potential precursor to acute myeloid leukemia, in patients with preexisting cancer where busulfan treatment was posited to be a contributing factor to this secondary malignancy. However, we have reviewed over 700 published cases of busulfan exposure preceding bone marrow transplant, hematopoietic cell transplant, or <span style="font-style:italic;">ex-vivo</span> gene therapy for non-malignant indications, of which 649 were from peer-reviewed literature. Based on our review of these cases, we found only one case of t-MDS, which involved a report from December 2018 that a patient with preexisting sickle cell disease developed t-MDS. In that case, busulfan treatment was posited to be a contributing factor. We believe that due to the presence of other confounding factors in the patient, the cause of that patient&#8217;s t-MDS has not been conclusively determined. In response to these potential risks, we are investigating a plan to potentially implement molecular cytogenetic screening. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the busulfan conditioning regimen is more intensive than the original conditioning regimen that utilizes melphalan, we believe it is still milder than some of the more aggressive conditioning regimens associated with gene therapies for other diseases, such as when busulfan is used in combination with cyclophosphamide, used at a higher dose, or when TCI is not applied. Furthermore, we believe our conditioning regimen may produce the desired effect while potentially allowing for a limited hospital stay. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">plato Data</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, we announced data from the fourth patient dosed in our ongoing FAB-GT clinical trial of&#160;AVR-RD-01, who was the first patient dosed using our plato platform.</span><span style="color:#000000;"> At 12-months post-gene therapy, this patient exhibited plasma and leukocyte AGA enzyme levels that were 4.2x and 6.3x higher, respectively, than the mean plasma and leukocyte AGA activity levels of the other three dosed patients in the FAB-GT clinical trial measured as of 12-months post-gene therapy. Additionally, the fourth patient&#8217;s</span><span style="Background-color:#FFFFFF;"> kidney biopsy taken at 12 months post-treatment showed a 100% clearance of Gb3 substrate.</span><span style="color:#000000;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advantages of Our Approach over Existing Therapies </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our gene therapy solutions offer several potential advantages over existing therapies for lysosomal disorders, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Curative impact that has the potential to halt or reverse disease progression.</span><span style="font-size:10pt;color:#000000;"> Existing ERTs for Fabry, Gaucher, Hunter and Pompe, and oral therapies for cystinosis, provide some therapeutic benefit to patients. However, because of their suboptimal pharmacokinetics, these ERTs only transiently increase plasma enzyme levels and the therapies for cystinosis require multiple doses throughout the day. In contrast, our lentiviral-based gene therapies are designed to enable the body to constantly produce the functional enzyme or other protein. This can potentially halt pathological damage and, depending on the targeted indication and organ system, may even reverse disease progression. Our lentiviral-based gene therapies may provide potentially curative treatment to patients. This concept is illustrated in the graphs below. </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gan5qj4us5ce000002.jpg" title="" alt="" style="width:608px;height:246px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.64%;text-indent:-3.64%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Durable, single-dose treatment.</span><span style="font-size:10pt;color:#000000;"> Our gene therapies offer the potential for a single dose to replace life-long, bi-weekly infusions or daily oral therapies that are often accompanied by numerous side effects and impact patients&#8217; quality of life. Our gene therapies are designed to transform the patient&#8217;s own cells into a drug product that enables the continuous delivery of functional enzyme or other protein throughout the body after a single dose. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Reduced treatment cost over a patient&#8217;s lifetime. </span><span style="font-size:10pt;color:#000000;">Existing ERTs and oral therapies can cost millions of dollars over a patient&#8217;s lifetime because these therapies require frequent doses of expensive treatments to manage symptoms. Our single-dose gene therapies are designed to replace the costly chronic intravenous and oral therapies that are the current standard of care for patients with lysosomal disorders. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVR-RD-01, Our Gene Therapy for Fabry Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-01 for the treatment of Fabry disease. We manufacture AVR-RD-01 from stem cells that are first harvested from the patient, modified to add the gene that encodes for AGA, and then infused into the patient. AVR-RD-01 is currently being evaluated in an investigator-sponsored Phase&#160;1 clinical trial and a Company-sponsored Phase 2 clinical trial. A total of 10 patients have been dosed across both trials as of March&#160;1, 2021.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disease Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fabry disease is a rare lysosomal disorder associated with significant morbidity and early mortality. It is caused by a gene defect that causes a deficiency of AGA, which breaks down a particular type of fat in the body&#8217;s cells known as globotriaosylceramide, or Gb3. As Gb3 and other related substrates increase in patients with Fabry disease, these become toxic to the patient&#8217;s cells. Gb3 and other glycosphingolipids accumulate and result in damage to the kidneys, heart and brain. Accumulation of Gb3 in tissues such as the heart and the vascular system can lead to life threatening vascular blockages and thus stroke and heart attacks. In addition, high levels of Gb3 substrate accumulation in the kidney can cause kidney failure. Gb3 can also accumulate in other tissues, such as the nervous system where it leads to debilitating pain. Due to end-stage renal disease and other life-threatening complications associated with Fabry disease, the average life expectancy in affected males is approximately 58 years of age. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most patients with Fabry disease begin experiencing chronic pain in childhood but are often not diagnosed with Fabry disease until their twenties, due to a broad variation in patient symptoms. Over 1,000 gene mutations associated with Fabry disease have been identified. It is estimated that Fabry disease is diagnosed in approximately one in 40,000 males and one in 118,000 females in the United States, but studies have suggested that a larger number of patients may be undiagnosed. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fabry disease is an X-linked disorder, meaning the gene that is responsible is located on the X chromosome. Because males have only one X chromosome, an abnormal copy of the gene that causes Fabry disease is sufficient to cause the disease.&#160;However, unlike other X-linked disorders, where female carriers of an abnormal gene are usually unaffected, Fabry disease also often causes significant morbidity in females who inherit one abnormal copy and one normal copy of the gene associated with the disease. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fabry disease is primarily treated with periodic infusions of ERT consisting of AGA enzyme over the patient&#8217;s lifetime. The most commonly prescribed ERTs for Fabry disease are Fabrazyme, marketed by Sanofi Genzyme, and Replagal, marketed by Shire, which was acquired by Takeda Pharmaceutical Company Ltd. In 2020, Fabrazyme and Replagal generated worldwide net sales of approximately &#8364;817&#160;million euros and &#165;51.6&#160;billion Japanese yen, respectively. We estimate that the average five-year cost to the healthcare system per Fabry patient prescribed standard of care treatment in the United States is approximately $1.7 million. In addition, because ERTs are not curative and only slow, but do not halt, the progression of disease, patients deteriorate and the healthcare system incurs significant costs associated with recurring medical interventions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although ERT provides therapeutic benefit and can reduce Gb3 substrate levels and extend a patient&#8217;s life expectancy, ERT requires chronic infusions throughout the patient&#8217;s life. Patients prescribed ERT generally receive an infusion every other week. However, because of their suboptimal pharmacokinetics, ERTs only temporarily increase plasma enzyme levels. As a result, patients with Fabry disease prescribed ERT continue to have disease progression, including ongoing decline in renal function, potentially including renal failure, cardiovascular disease and ongoing debilitating pain including periods of severe pain crisis. Physicians report that patients have recurrence of symptoms as the therapeutic effect of ERT wanes between bi-weekly treatments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alternatives to ERT for patients with Fabry disease are limited. Galafold (migalastat), an oral therapy marketed by Amicus, was approved by the European Medicines Agency, or EMA, in May 2016, and by the FDA in August 2018. Amicus has reported that only 35% to 50% of the gene mutations associated with Fabry disease are amenable to migalastat. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Solution </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-01 to halt or reverse disease progression and potentially provide a functional cure to patients with Fabry disease with a single dose of the patient&#8217;s own hematopoietic stem cells modified in an <span style="font-style:italic;">ex vivo</span> procedure. AVR-RD-01 is a lentiviral-based gene therapy that contains a codon-optimized human gene and is designed to maximize the likelihood of sustained AGA production by hematopoietic stem cells and their progeny. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that AVR-RD-01 offers a promising treatment for Fabry disease for the following reasons: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">One-time delivery.</span><span style="font-size:10pt;color:#000000;"> Lentiviral-based gene therapy provides the potential to transform a patient&#8217;s own cells into a drug product that enables the continuous delivery of active enzyme throughout the body after a single dose. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Proven biology.</span><span style="font-size:10pt;color:#000000;"> Years of observations of patients prescribed ERT indicate that even partial plasma AGA activity is associated with improved outcomes. Increased AGA enzyme activity is able to reduce Gb3 levels in multiple cells and tissues supporting the ability of AGA in the plasma to enter lysosomes and degrade Gb3 in a process referred to as cross correction. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Wide therapeutic window. </span><span style="font-size:10pt;color:#000000;">We believe that even partial enzyme activity, if continuous, has the potential to provide long-term therapeutic benefit. A wide range of levels of plasma AGA activity has been demonstrated to be both safe and effective in preclinical studies, reducing the need for precise regulation of enzyme expression levels and reinforcing that overexpression of AGA is not associated with increased safety risks. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Mutation </span><span style="font-style:italic;font-size:10pt;color:#000000;">i</span><span style="font-style:italic;font-size:10pt;color:#000000;">ndependent.</span><span style="font-size:10pt;color:#000000;"> AVR-RD-01 is designed to increase plasma </span><span style="font-size:10pt;color:#000000;">and leukocyte </span><span style="font-size:10pt;color:#000000;">AGA levels in a patient&#8217;s cells, regardless of which of the more than 1,000 specific mutations underlie the patient&#8217;s disease. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ongoing Multicenter Investigator-Sponsored Clinical Trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an ongoing Phase 1 clinical trial of AVR-RD-01 being conducted by the University Health Network, or UHN, and sponsored by Fabry Disease Clinical Research and Therapeutics, or FACTs, at three centers in Canada, a total of five patients with Fabry disease who have been treated with ERT for at least six months have been enrolled, and enrollment is complete. The protocol for this clinical trial originally provided that ERT for these patients would be suspended one month prior to receiving AVR-RD-01 and then resumed one month after the AVR-RD-01 treatment and continued at bi-weekly intervals. The trial protocol was subsequently amended to allow the investigator team, at their discretion, to discontinue ERT six months after treatment with AVR-RD-01. Three of the five patients in the clinical trial have discontinued the regular bi-weekly treatments with ERT and all three remain off ERT as of January 11, 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary goal for this clinical trial is to assess the safety and toxicity of AVR-RD-01 as measured by the frequency or severity of clinically notable abnormal vital signs and laboratory values and the frequency or severity of treatment-related adverse events. The safety of our initial, academic-based conditioning regimen is also being assessed in this clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A secondary objective for this clinical trial is to obtain preliminary efficacy signals of AVR-RD-01 therapy as assessed by AGA enzyme activity. Plasma and leukocyte AGA enzyme activity derived from administration of ERT decreases rapidly after administration with no residual plasma or leukocyte activity remaining approximately one day after treatment. To evaluate the ability of AVR-RD-01 to increase enzyme activity, the level of AGA activity was assessed in a patient immediately prior to the administration of the patient&#8217;s next dose of ERT, when limited or no plasma or leukocyte AGA activity from previously-administered ERT dose would be expected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All five patients in this clinical trial have been dosed. To date, the treatment was generally well-tolerated with no serious adverse events, or SAEs, related to the study drug. In addition, in all five patients, all of whom are males with classic Fabry disease, the level of plasma and leukocyte AGA enzyme activity began to rise after infusion. In each of the patients, plasma and leukocyte AGA enzyme activity was observed to increase from nearly undetectable levels before treatment to a peak within approximately three to six months after treatment, followed by a decline and trending to stabilize to levels above the range for males with classical Fabry disease, defined as less than 1 nmol/hr/ml. We believe that the steep initial increase reflects AGA enzyme activity from the early progeny of the transduced stem cells, while the subsequent decline and stabilization in AGA enzyme levels reflect a shift from short term progenitor cells towards the gradual secretion of AGA enzyme by long-term engraftment cells that become more predominant over time. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AGA Enzyme Activity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of 42 months after receiving AVR-RD-01, the first patient&#8217;s plasma and leukocyte AGA enzyme activity levels continued to be above the range for males with classical Fabry disease. Based on the level of endogenously produced enzyme activity, at the 18-month follow-up visit for this patient, the investigator team for the trial made a clinical decision to discontinue the bi-weekly ERT and the patient remains off ERT as of 42 months post-treatment with AVR-RD-01. Additionally, the third and fourth patients in this clinical trial discontinued ERT and both remain off ERT as of 24 months post-treatment with AVR-RD-01. The second and fifth patients have elected to continue receiving concurrent ERT. Plasma and leukocyte AGA enzyme activity levels in all five patients remained above the range for males with classical Fabry disease, defined as less than 1 nmol/hr/ml, as of 42 months, 36 months, 24 months, 24 months and 18 months after treatment, respectively. We believe these results, particularly from the patients in the trial with longer-term AGA data points reported, support the potential of AVR-RD-01 to drive functional enzyme production for long durations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lyso-Gb3 Levels</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The substrate, Gb3, and its toxic metabolite, known as lyso-Gb3, are considered surrogate markers for disease activity and treatment response for Fabry disease. In the case of ERT-na&#239;ve patients and patients who have discontinued ERT, we believe that reductions in Gb3 levels following treatment with gene therapy are likely driven by the therapeutic effect of gene therapy. <span style="Background-color:#FFFFFF;color:#000000;">In four of the five patients in the Phase 1 clinical trial of&#160;AVR-RD-01,&#160;we have observed plasma&#160;lyso-Gb3&#160;at levels post-treatment that are lower than the levels observed when the patient received only ERT prior to administration of&#160;AVR-RD-01,&#160;which we refer to as baseline ERT levels. We define baseline ERT for these Phase 1 patients as the mean of the plasma&#160;lyso-Gb3&#160;values reported prior to initiating mobilization. Based on the latest interim data we presented in February 2021, these four Phase 1 patients exhibited reductions in plasma&#160;lyso-Gb3&#160;levels ranging between 25% and 48% compared to </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">their baseline ERT levels. With respect to the fourth patient, who discontinued ERT six months following administration of&#160;AVR-RD-01,&#160;we observed an initial decline in plasma&#160;lyso-Gb3&#160;levels through six months post-treatment compared to baseline ERT, and a </span><span style="Background-color:#FFFFFF;color:#000000;">35</span><span style="Background-color:#FFFFFF;color:#000000;">% increase in plasma&#160;lyso-Gb3&#160;levels at </span><span style="Background-color:#FFFFFF;color:#000000;">24 </span><span style="Background-color:#FFFFFF;color:#000000;">months post-treatment compared to baseline ERT. This patient&#8217;s plasma&#160;lyso-Gb3&#160;levels remain within the range for the Fabry disease patients on ERT observed in this Phase 1 clinical trial.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Vector Copy Number</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VCN, which is expressed as VCN per diploid genome, refers to the average number of copies of the lentiviral-vector inserted gene that are integrated into the genome of a cell, and is another measure that can be used to help assess the durability of a gene therapy. We believe that different diseases may require varying levels of VCN based on the underlying condition, and therefore VCN measurements across different diseases should be assessed separately. For example, a VCN of 0.1 may represent 5% to 10% of all nucleated circulating blood cells carrying one to two copies of the inserted gene, which we believe may be sufficient to result in clinically meaningful AGA enzyme activity in the case of Fabry disease, as suggested by our interim data from our ongoing clinical trials of AVR-RD-01. <span style="Background-color:#FFFFFF;color:#000000;">Based on the latest interim data we presented in February 2021, these five Phase 1 patients exhibited VCN levels of 0.04, 0.16, 0.24, 0.12 and 0.86 at </span>42 months, 36 months, 24 months, 24 months and 18 months after treatment, respectively<span style="Background-color:#FFFFFF;color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Safety Data</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary interim safety data indicate AVR-RD-01 has been generally well-tolerated with no SAEs related to the study drug.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse events, or AEs, were consistent with expectations for the melphalan conditioning regimen prescribed by the study protocol. As of the most recent safety cut-off date of November 26, 2020, there were 94 AEs reported, 14 of which were Grade 3 or 4. <span style="Background-color:#FFFFFF;">The remainder of the AEs were Grade 2 or Grade 1.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two SAEs were reported through the safety data cut-off date of November 26, 2020, which included one report of AE Grade 3 febrile neutropenia and one report of AE Grade 2 thrombophlebitis, each occurring following the conditioning regimen and treatment with AVR-RD-01. Both SAEs have subsequently resolved without clinical sequelae. One event, the development of a left thigh mass, was originally reported as an SAE but has now been considered by the study investigator as not serious and has resolved in the patient. No new AEs have been reported for the first patient since January 2018, the second patient since May 2018, the third patient since August 2018, the fourth patient since March 2019 or the fifth patient since August 2019. In addition, investigators observed a temporary suppression of absolute neutrophil counts and platelets, which is an expected consequence of the conditioning regimen. These decreases were transient and not associated with any negative long-term impact on the patients. Neutrophil and platelet counts recovered after dosing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Pre-existing&#160;low&#160;anti-AGA&#160;antibody titers have been detected in four patients in the Phase 1 trial. We believe none of these are of clinical relevance. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because this clinical trial is ongoing, safety and efficacy data are preliminary and subject to change. As is typical in open-label studies in which interim reports are provided, the data are regularly reviewed and validated. As a result, certain data may change over time, including reductions or increases in the number of reported safety events, until the database is locked at the end of the study.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ongoing Phase&#160;2 Multinational Clinical Trial (FAB-GT)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are sponsoring an open label, multinational Phase&#160;2 clinical trial of AVR-RD-01, which we refer to as the FAB-GT clinical trial. This study was initiated in June 2018 in Australia and enrollment in this Phase&#160;2 clinical trial is ongoing. Eight to 12 treatment-na&#239;ve males, 16 to 50 years old, with Fabry disease are expected to be enrolled in this trial. Our objectives for this trial are to assess safety and efficacy as measured by multiple indicators, such as AGA enzyme activity, Gb3 and lyso-Gb3 levels in blood and various tissues, kidney and cardiac function, gastrointestinal symptoms, and pain and quality of life scores. All enrolled patients will receive a single treatment with AVR-RD-01 and will be followed for 48 weeks to measure safety and efficacy. We have opened two U.S. sites for our ongoing FAB-GT clinical trial and are actively recruiting potential patients for our sites in Australia, Canada and the United States. We are also engaged in discussions with the Pharmaceuticals and Medical Devices Agency, or PMDA, regarding potential future clinical development of AVR-RD-01 in Japan.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients have been dosed in the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FAB-GT</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trial. For the fourth</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and fifth</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patient</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we transitioned the lentiviral vector from LV1 to our optimized proprietary LV2 from our plato platform. All future patients in this clinical trial will be dosed using the plato platform, which we believe will further improve the efficacy and further enhance the safety of our lentiviral-based gene therapy. Because the transition to LV2 only impacts the </span><span style="font-style:italic;">ex vivo</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cell transduction process, and not the actual AGA enzyme that is produced by the transduced cells, or drug product, we believe this transition will be supported with </span><span style="font-style:italic;">in vitro</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> comparability studies. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Kidney Biopsy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary efficacy endpoint of our FAB-GT clinical trial is the change from baseline in the average number of Gb3 inclusions per peritubular capillary, or PTC, as measured in a patient kidney biopsy one year (48 weeks) after treatment with AVR-RD-01. Gb3, also referred to as GL-3, is a type of fatty substrate that builds in the cells of Fabry patients, resulting in damage to organs such as kidneys and heart. PTCs, also referred to as kidney interstitial capillaries, or KICs, in Fabry clinical trials, convey blood after filtration in the glomeruli, enabling the blood to eventually exit the kidney and return to the circulatory system. In February 2021, we announced that the fourth patient in our FAB-GT clinical trial exhibited a reduction from an average of 4.02 Gb3 inclusions per PTC at baseline to zero inclusions per PTC one year after administration of AVR-RD-01, representing a 100% clearance of Gb3 substrate. These data followed our 2019 announcement that the first patient in the FAB-GT clinical trial exhibited a reduction from an average of 3.55 Gb3 inclusions per PTC at baseline to an average of 0.47 inclusions per PTC one year after administration of AVR-RD-01, representing an 87% reduction and a numerical decrease of 3.08. The assessments for these two patients were each made by two blinded pathologists who independently scored digital images of the sectioned kidneys from the 12-month biopsies. <span style="Background-color:#FFFFFF;color:#000000;">The second patient in the </span>FAB-GT<span style="Background-color:#FFFFFF;color:#000000;"> clinical trial&#160;has an N215S genotype, which is associated with a late-onset cardiac variant phenotype. This patient&#8217;s cardiac variant phenotype does not typically result in Gb3 accumulation in the kidney, and accordingly this patient&#8217;s kidney biopsy had low levels of Gb3 and&#160;lyso-Gb3&#160;at all measurements, including at baseline. Although we expect that data obtained from this patient will not provide meaningful insight on the primary efficacy endpoint in our </span>FAB-GT<span style="Background-color:#FFFFFF;color:#000000;"> clinical trial, including kidney biopsies, other important efficacy and safety measures continue to be derived from data collected from this patient.&#160;A kidney biopsy was conducted on the third patient in the </span>FAB-GT<span style="Background-color:#FFFFFF;color:#000000;"> clinical trial, but due to human error in processing the biopsy sample at the external laboratory vendor, the kidney Gb3 inclusions could not be evaluated and will not be available. The fifth patient in this clinical trial was dosed in February 2021 and we expect to have kidney biopsy data available for that patient in the first half of 2022.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following figure illustrates the decrease in average Gb3 inclusions per PTC for the first and fourth patients in the Phase 2 FAB-GT clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 <span style="color:#000000;">FAB-GT</span>: Patients 1 and 4 substrate reduction in kidney biopsy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gan5qj4us5ce000003.jpg" title="" alt="" style="width:657px;height:280px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;font-style:italic;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-weight:bold;font-size:10pt;font-style:italic;font-family:Times New Roman;text-transform:none;font-variant: normal;">Baseline<span style="font-weight:normal;">: The last available, non-missing observation prior to AVR-RD-01 infusion</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;;font-weight:bold;font-size:10pt;font-style:italic;font-family:Times New Roman;text-transform:none;font-variant: normal;">Note:<span style="font-weight:normal;"> With respect to Fabry disease clinical trials, Gb3 inclusions per PTC is interchangeable with GL-3 inclusions per KIC</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lyso-Gb3 Levels</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first patient in our FAB-GT trial had an 86% reduction in plasma lyso-Gb3 levels as of 29 months post-treatment with AVR-RD-01, the third patient had a plasma lyso-Gb3 reduction of 55% as of 19 months post-treatment, and the fourth patient had a plasma lyso-Gb3 reduction of 69% as of 12 months post-treatment with AVR-RD-01, in each case as compared to baseline. The second patient has an N215S genotype, which is associated with a late-onset cardiac variant phenotype and <span style="Background-color:#FFFFFF;color:#000000;">does not typically result in Gb3 accumulation in the kidney or skin. </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AGA Enzyme Activity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first two patients in our FAB-GT clinical trial, for whom we have presented data out to 29 and 24 months, respectively, plasma and leukocyte AGA enzyme activity was observed to increase from nearly undetectable levels before treatment to a peak within three months after treatment, followed by a decline and trending to stabilize to levels above the range for males with Fabry disease, defined as less than 1 nmol/hr/ml. The third patient in the FAB-GT trial exhibited a rapid increase in plasma and leukocyte AGA enzyme activity from nearly undetectable levels before treatment to a peak within the first seven days after treatment in the case of plasma enzyme activity and within the first 14 days after treatment in the case of leukocyte enzyme activity, followed by a decline and subsequent increase which is trending toward a stable level above the range for males with Fabry disease at 18 months after treatment. The fourth patient in the FAB-GT trial, who was dosed with the plato platform, exhibited a rapid increase in AGA enzyme activity post-treatment and had not exhibited a substantial decline in AGA levels at 12 months after treatment. Similar to the results observed in the investigator-led Phase 1 trial of AVR-RD-01, we believe that the steep initial increase reflects AGA enzyme activity from the early progeny of the transduced stem cells, while the subsequent decline and stabilization in AGA enzyme levels reflect a shift from short-term progenitor cells towards the gradual secretion of AGA enzyme by long-term engraftment cells that become more predominant over time.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Skin Biopsy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin biopsies have been performed in the FAB-GT trial and evaluated by two independent blinded readers<span style="font-weight:bold;font-style:italic;"> </span>using a standard scoring system for Gb3 accumulation and clearance. The scoring system has a range of zero to three, with a score of zero representing none or trace accumulation, and a score of three representing severe accumulation. The first patient scored a three at baseline, a two at six months after treatment with AVR-RD-01 and a one at 12 months post-treatment with AVR-RD-01. The second patient in the FAB-GT trial, whose cardiac variant phenotype does not typically result in Gb3 accumulation in the kidney and skin,<span style="Background-color:#FFFFFF;color:#000000;"> scored a zero at baseline and at six months </span>post-treatment with AVR-RD-01<span style="Background-color:#FFFFFF;color:#000000;">. The third patient scored a two at baseline and a two at six months </span>post-treatment with AVR-RD-01. After consideration of the clinical relevance of substrate inclusion in the skin of Fabry patients and the lack of direct, strong correlation with substrate in the kidney, we have changed this trial&#8217;s exclusion criteria so that patients with no or minimal substrate in their skin at screening will still be eligible to participate in the clinical trial. We expect to continue collecting skin biopsy data as an exploratory measurement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Vector Copy Number</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The first four patients in our </span><span style="color:#000000;">FAB-GT</span><span style="Background-color:#FFFFFF;"> clinical trial have exhibited consistent VCN trends following administration of AVR-RD-01. Based on the latest interim data we presented in February 2021, these four </span><span style="color:#000000;">FAB-GT</span><span style="Background-color:#FFFFFF;"> patients exhibited VCN levels of 0.04, 0.06, 0.19 and 0.95 at </span><span style="color:#000000;">29 months, 18 months, 19 months and 12 months after treatment, respectively</span><span style="Background-color:#FFFFFF;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Kidney and Cardiac Function</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Secondary endpoints of our </span><span style="color:#000000;">FAB-GT</span><span style="Background-color:#FFFFFF;"> trial include measurements of kidney function, as measured by estimated glomerular filtration rate, or eGFR, and measured glomerular filtration rate, or mGFR, as well as measures of cardiac function, as assessed by Left Ventricular Mass Index, or LVMI. eGFR is determined using the Chronic Kidney Disease Epidemiology Collaboration, or&#160;CKD-EPI,&#160;formula and mGFR is determined using plasma clearance of iohexol. The left ventricular mass, or LVM, is assessed by cardiac magnetic resonance imaging, or cardiac MRI, which is an imaging technology that enables&#160;non-invasive&#160;assessment of the function and structure of the heart. In general, for a patient with Fabry disease, an increase over time in LVM could potentially be expected. Improving patient outcomes by slowing or halting the progression of organ damage is a key mission of our Company and our investigational gene therapy programs. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, we presented eGFR data for all five patients in the Phase 1 clinical trial of AVR-RD-01 and the first four patients in our </span><span style="color:#000000;">FAB-GT</span><span style="Background-color:#FFFFFF;"> clinical trial. We believe these data suggest that eight out of nine patients are exhibiting stable kidney function, with the first patient from the Phase 1 clinical trial out 42 months post-treatment. One patient, who remains </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">on ERT as of January 11, 2021, entered the Phase 1 clinical trial with advanced kidney disease and a baseline eGFR level of less than 50 mL/min/1.73m</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></span><span style="Background-color:#FFFFFF;">. As expected, this patient&#8217;s kidney function has not stabilized.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Also in February 2021, we presented mean average data on measures of cardiac function and structure in all four patients in the </span><span style="color:#000000;">FAB-GT</span><span style="Background-color:#FFFFFF;"> clinical trial at 12-months post-treatment as compared to mean baseline. The mean measurements of ejection fraction, end diastolic volume, cardiac output and LVMI at 12-months post-treatment showed an average percent change from baseline of 2.2%, 0.2%, 0.8% and 9.8%, respectively.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Safety Data</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary interim safety data from the ongoing FAB-GT study indicate that AVR-RD-01 has been generally well-tolerated in the first four patients enrolled in the study. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the safety cut-off date of December 7, 2020, there were 111 AEs reported, 22 of which were Grade 3 or 4. <span style="Background-color:#FFFFFF;">The remainder of the AEs were Grade 2 or Grade 1. </span>No AEs were deemed by the investigator to be possibly, probably, or definitely related to drug product. AEs in this study can be assigned to more than one causality assessment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 7, 2020, six SAEs were reported, one pre-treatment and five post-treatment. No events were related to AVR-RD-01 and five events were related to the conditioning regimen. All six SAEs subsequently resolved without clinical sequelae. After beginning stem cell mobilization but prior to undergoing the conditioning regimen and treatment with AVR&#8209;RD&#8209;01, the first patient experienced a seizure. In addition, during a scheduled protocol visit after dosing, the same patient experienced nausea and vomiting, dehydration and was admitted to the hospital for fluid hydration. Because this event warranted hospital admission, the event was categorized as an SAE. An additional SAE of febrile neutropenia was reported in each of the second and third patient post-treatment. The fourth patient experienced two post-treatment SAEs of culture negative fevers and mucositis Grade 2. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the above, each of the FAB-GT patients experienced a temporary suppression of absolute neutrophil counts and platelets, which is an expected consequence of the conditioning regimen. These decreases were transient and not associated with any negative long-term impact on the patients. Neutrophil and platelet counts recovered after dosing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because this clinical trial is ongoing, safety and efficacy data are preliminary and subject to change. As is typical in open-label studies in which interim reports are provided, the data are regularly reviewed and validated. As a result, certain data may change over time, including reductions or increases in the number of reported safety events, until the database is locked at the end of the study.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVR-RD-04, Our Gene Therapy for Cystinosis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together with UCSD, we are developing CTNS-RD-04, which we refer to as AVR-RD-04, for the treatment of patients with cystinosis. AVR-RD-04 is manufactured from hematopoietic stem cells that are first harvested from the patient, modified to add the gene that encodes for cystinosin, and then infused into the patient. <span style="Background-color:#FFFFFF;color:#000000;">AVR-RD-04&#160;is currently being studied by our collaborators at UCSD in a Phase 1/2 investigator-sponsored clinical trial.&#160;</span>As of March 1, 2021 three patients have been dosed with AVR-RD-04 and as of January 20, 2021 all three remained off cysteamine pills and eye drops. &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disease Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cystinosis is a rare, genetic, autosomal recessive, lysosomal disorder caused by the accumulation of the amino acid cystine that is produced in the lysosomes of cells as the result of protein degradation. Cystine is normally transported through the lysosomal membrane to the cytosol where it is reutilized after its transformation to cysteine. In cystinosis, cystine accumulates inside the lysosomes because of a defect in the gene that encodes cystinosin, a protein that transports cystine across the lysosomal membrane. Cystine is poorly soluble and forms crystals as its concentration increases. These crystals build up and cause complications in many organs and tissues. The kidneys and eyes are especially vulnerable to damage, and the muscles, thyroid, pancreas and testes may also be affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most severe form of cystinosis begins in infancy, causing poor growth and a particular type of kidney damage in which certain molecules, such as glucose, amino acids, phosphate, and bicarbonate, that should be reabsorbed into the bloodstream are instead eliminated in the urine. These renal problems ultimately lead to impaired growth and may result in soft, bowed bones, especially in the legs. By the time the patient is approximately two years old, cystine crystals may be present in the cornea, and the buildup of these crystals in the eye causes pain and an increased sensitivity to light. Untreated </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">children with cystinosis may experience complete kidney failure by the age of ten. Other signs and symptoms that may occur in untreated patients, especially after adolescence, include muscle deterioration, blindness, inability to swallow, diabetes, thyroid and nervous system problems. More than 90% of untreated patients require a kidney transplant before the age of 20. It is estimated that cystinosis disease is diagnosed in approximately one in 170,000 people. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cystinosis is currently treated with oral formulations of cysteamine that enter the lysosome and stimulate the breakdown of cystine into products that do not require the cystinosin protein to be transported. Oral treatment can delay the development of kidney failure by six to ten years if it is started at a very early age, however it cannot prevent kidney failure or the development of other complications, such as the formation of cystine crystals in the cornea. The most commonly prescribed oral therapies for cystinosis are Procysbi (delayed release cysteamine bitartrate), marketed by Horizon Orphan, and Cystagon (cysteamine bitartrate), marketed by Mylan and Recordati S.p.A. In 2020, Procysbi generated worldwide net sales of approximately $170&#160;million. We estimate that the average five-year cost to the healthcare system per cystinosis patient prescribed standard of care treatment in the United States is approximately $4.3 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Procysbi and Cystagon must be taken orally every 12 or six hours, respectively, leading to significant pill burden and compliance challenges. Because cysteamine works by directly binding to cystine, rather than through a typical small molecule that inhibits an enzyme or receptor, a substantial quantity is required. For adults, this can mean taking at least 12 capsules twice a day, every day. Oral therapy with cysteamine is associated with a high degree of noncompliance due to the frequency with which it must be dosed and the accompanying nausea, as well as the acrid sulfur smell that it produces in the breath and body. It has been estimated that only one third of patients are able to adhere to the strict dosing schedule. Studies have shown that adherence diminishes over time in adolescents and adults despite disease impact. Further, oral cysteamine treatment has no effect on ocular cystine crystals deposits, thus requiring patients to be treated with topical cysteamine eye drops which must be applied each hour the patient is awake. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Solution </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-04 to potentially provide a functional cure to patients with cystinosis with a single dose of the patient&#8217;s own hematopoietic stem cells modified in an <span style="font-style:italic;">ex vivo</span> procedure. AVR-RD-04 is a lentiviral-based gene therapy containing a human gene for cystinosin designed to maximize the likelihood of sustained cystinosin production in hematopoietic stem cells and their progeny. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ongoing Phase 1/2 Investigator-Sponsored Clinical Trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Phase 1/2 clinical trial of AVR-RD-04 that is being conducted by our collaborators at UCSD, six patients with cystinosis who are currently being treated with cysteamine will be enrolled. <span style="Background-color:#FFFFFF;color:#000000;">The clinical trial&#8217;s primary endpoints are safety and tolerability, assessed for up to two years after treatment. Secondary endpoints to assess preliminary efficacy include change from baseline in cystine levels in rectal mucosa and granulocytes, as well as cystine crystal counts in the cornea and skin. These secondary efficacy endpoints will also be evaluated through clinical tests of kidney function, ophthalmologic measures, muscle</span> <span style="Background-color:#FFFFFF;color:#000000;">strength, pulmonary function and neurological and psychometric function, as well as through patient-reported outcomes and assessments of health-related quality of life. Mixed leukocyte and granulocyte cystine concentration measures have been part of cystinosis standard of care treatment for the past two decades, and changes in the average level of cystine in granulocytes from baseline was originally a primary endpoint of the clinical trial of AVR-RD-04. However, we and our collaborators at UCSD determined that cystine concentration in leukocytes and granulocytes, which is used to monitor small molecule therapies, is not appropriate to represent the mechanism of action of a gene therapy. As a result, the protocol for this clinical trial was amended in 2020 to retain safety and tolerability as the primary endpoint, as is appropriate for this stage of development, and shift measurement of cystine in granulocytes to a secondary endpoint.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because this is an investigator-sponsored clinical, the study drug will not be manufactured using our plato platform, and neither the automated, closed manufacturing system nor LV2 will be used in connection with this clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Kidney Function</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Assessment of kidney function includes measurements of eGFR and serum creatinine, or sCR. eGFR is determined using the&#160;CKD-EPI&#160;formula and sCR is measured as part of the comprehensive metabolic panel. The first patient in the Phase 1/2 clinical trial exhibited an eGFR value of 42 mL/min/1.73m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&#160;16 months post-treatment as compared to a baseline value of 55 mL/min/1.73m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>. This patient&#8217;s eGFR values had been trending downward in the three years prior to administration of </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">AVR-RD-04. However, at three and 16 months post-treatment the patient&#8217;s eGFR values were 43</span><span style="Background-color:#FFFFFF;"> mL/min/1.73m</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></span><span style="Background-color:#FFFFFF;"> and 42</span><span style="Background-color:#FFFFFF;"> mL/min/1.73m</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></span><span style="Background-color:#FFFFFF;">, respectively</span><span style="Background-color:#FFFFFF;">. </span><span style="Background-color:#FFFFFF;">While these data suggest potential kidney function stabilization after years of pathological decline, this patient&#8217;s eGFR levels could resume declining at an accelerated rate due to the irreversible nature of end-stage renal disease. </span><span style="Background-color:#FFFFFF;">A</span><span style="Background-color:#FFFFFF;">t six months post-treatment the second patient in the clinical trial</span><span style="Background-color:#FFFFFF;">, who has received two kidney transplants,</span><span style="Background-color:#FFFFFF;"> exhibited an eGFR value of 81 mL/min/1.73m</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></span><span style="Background-color:#FFFFFF;"> as compared to a baseline value of </span><span style="Background-color:#FFFFFF;">71</span><span style="Background-color:#FFFFFF;"> mL/min/1.73m</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></span><span style="Background-color:#FFFFFF;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cystine Crystals in Skin and Rectal Biopsy Tissues</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Skin and rectal biopsies were performed on the first patient at baseline and 12-months post-treatment with AVR-RD-04. The data from the biopsies are intended to show the average skin intracytoplasmic crystals per cell, which is a measurement of the number of toxic crystals in each cell, as well as the occupancy of cytoplasmic volume with crystals. In November 2020, we announced that at 12-months post-treatment the first patient&#8217;s skin and rectal biopsies exhibited a 44% and 76% reduction, respectively, in average intracytoplasmic crystals per cell, and a 72% and 87% reduction, respectively, in occupancy of cytoplasmic volume, in each case as compared to the patient&#8217;s baseline levels. We believe these data suggest that the patient is now producing an endogenous supply of functional cystinosin that is reducing the accumulation of toxic cystine crystals.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Levels of Cystine in Skin</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Levels of cystine in the skin are measured with&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">in vivo&#160;</span><span style="Background-color:#FFFFFF;">confocal microscopy, or IVCM, on two separate areas of the skin: behind the ear and in a location determined by the treating physician. The two measurements are analyzed and quantified with 3D&#160;Image-Pro&#160;software and averaged. The first patient in the Phase 1/2 clinical trial exhibited a 56% reduction from baseline in skin cystine levels measured 12 months post-treatment with&#160;AVR-RD-04.&#160;These skin measurements are considered experimental methodologies and will require additional study to determine their validity and significance.</span><span style="font-style:italic;Background-color:#FFFFFF;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Levels of Cystine in Cornea</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Levels of corneal cystine crystals are being assessed in this clinical trial using IVCM. In November 2020, we presented one set of images of the first patient&#8217;s cornea measured at baseline and&#160;12-months&#160;post-administration of&#160;AVR-RD-04,&#160;and another set of images measured at baseline, seven-, nine- and 12-months post-administration. The baseline IVCM images were taken using a Nidek ConfoScan microscope and the&#160;subsequent images were taken using a Heidelberg (HRT3) with Rostock Cornea Module microscope. Each of the post-treatment images showed a noticeable decline in the presence of corneal crystals. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Granulocyte Cystine Levels</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The first patient in the Phase 1/2 clinical trial exhibited granulocyte cystine levels of 4.2 nmol half cystine per milligram 12 months post-treatment with&#160;AVR-RD-04&#160;as compared to the baseline value of 7.8. This patient&#8217;s baseline value was measured two weeks after discontinuation of cysteamine treatment and prior to initiating mobilization. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Vector Copy Number </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021 we presented interim VCN data for the first three patients dosed in the Phase 1/2 clinical trial. At 12 months post-treatment with AVR-RD-04 the first patient exhibited VCN level of 0.9&#59; at six months post-treatment the second patient exhibited VCN level of 1.7&#59; and at one month post-treatment the third patient exhibited VCN level of 2.55. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Photophobia</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Photophobia, or light intolerance, is a symptom of cystinosis that is caused by the buildup of cystine crystals in the cornea, inflammatory cell infiltration and corneal nerve damage. In the Phase 1/2 clinical trial, photophobia is being assessed on a grade of zero to five. The first patient in the clinical trial scored a three at baseline and a one at 12-months post-treatment. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Exploratory Measurement &#8211; Skin and Hair Melanin</span><span style="Background-color:#FFFFFF;color:#32406B;font-style:normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Photographs of the first patient in this clinical trial taken at four-,&#160;six-&#160;and nine-months post-treatment suggest that the patient&#8217;s complexion, eyebrows and hair color have darkened following administration of&#160;AVR-RD-04.&#160;As is typical of many </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">people with cystinosis, this patient had fair hair color and skin tone prior to dosing. Cystinosin has been demonstrated to impact the regulation of melanin synthesis, and the protocol for this trial has been amended to prospectively assess changes in melanin.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Safety Data</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of the safety cut-off date of January 27, 2021, preliminary interim clinical data for the first three patients dosed in the Phase 1/2 clinical trial appear to indicate that the&#160;AVR-RD-04&#160;investigational gene therapy has been generally well tolerated with no unexpected safety events identified. There have been no reports of safety events attributed to the&#160;AVR-RD-04&#160;drug product.  As of the safety data&#160;cut-off&#160;date of January&#160;27, 2021 one SAE of appendicitis was reported, which occurred post-treatment and was</span><span style="color:#000000;"> deemed by the investigator to be</span><span style="Background-color:#FFFFFF;"> unrelated to AVR-RD-04 or the treatment procedures. A total of 48 AEs were reported as of the safety&#160;cut-off&#160;date of January&#160;27, 2021, a majority of which were reported by the investigator to be moderate or mild. All reported AEs were consistent with expectations for the underlying disease and conditioning regimen prescribed by the study protocol. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because this clinical trial is ongoing, safety and efficacy data are preliminary and subject to change. As is typical in open-label studies in which interim reports are provided, the data are regularly reviewed and validated. As a result, certain data may change over time, including reductions or increases in the number of reported safety events, until the database is locked at the end of the study.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVR-RD-02, Our Gene Therapy for Gaucher Disease type 1</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-02 for the treatment of Gaucher disease type 1. We plan to manufacture AVR-RD-02 from hematopoietic stem cells that are first harvested from the patient, modified to add the gene that encodes for glucocerebrosidase, or GCase, and then infused into the patient. Patient enrollment has commenced for the Phase 1/2 Guard1 clinical trial of AVR-RD-02 in patients with Gaucher disease type 1, and we dosed the first patient in the second quarter of 2020. <span style="Background-color:#FFFFFF;color:#000000;">The Guard1 trial&#160;is actively recruiting in Australia and Canada, with additional sites planned in the </span>United States, Israel and Europe<span style="Background-color:#FFFFFF;color:#000000;">. As of March 1, 2021 one patient has been dosed. </span> </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disease Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gaucher disease type 1 is the non-neuronopathic form of Gaucher disease, a rare, autosomal recessive, lysosomal disorder caused by a hereditary deficiency of functional GCase, an enzyme responsible for degrading glucocerebroside, a cell membrane building block, into glucose and lipids within lysosomes of cells. In patients with Gaucher disease type 1, the recycling of glucocerebroside from the breakdown of old red and white blood cells is inhibited, leading to its accumulation in macrophages. These abnormal macrophages, known as Gaucher cells, accumulate in multiple organs, particularly the liver, spleen and bone marrow. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gaucher disease type 1 is one of the most common lysosomal disorders. It is diagnosed in approximately one in 44,000&#160;births worldwide and is more prevalent in certain ethnic groups, such as people of Ashkenazi Jewish heritage. Approximately 90% of patients suffering from Gaucher disease in western countries have Gaucher disease type 1, which manifests as multiple morbidities including enlargement of the spleen and liver, low red blood cells, or anemia, low platelet count, or thrombocytopenia, and bone abnormalities including bone pain, fractures and arthritis. Bruising, risk of bleeding and fatigue are common due to the thrombocytopenia and anemia. Compared with the general population, patients with Gaucher disease type 1 have an approximately 20-fold increased risk of developing Parkinson&#8217;s disease. Gaucher disease type 1 does not have manifestations of central nervous system symptoms. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gaucher disease type 1 is currently treated with bi-weekly infusions of ERT consisting of recombinant GCase over a patient&#8217;s lifetime. The most commonly prescribed ERTs for Gaucher disease are Cerezyme, marketed by Sanofi Genzyme, and VPRIV, marketed by Shire. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although long-term ERT for Gaucher disease type 1 results in some therapeutic benefit, ERTs leave patients with significant unmet needs. Twenty-five percent of patients with Gaucher disease continue to experience physical limitations following two years of ERT, and a clinically significant percentage of patients continue to experience bone pain, thrombocytopenia and enlargement of spleen following ten years of ERT. In a published study of ERT therapy for Gaucher disease type 1, six target goals were evaluated, including parameters for hemoglobin and platelet levels, spleen and liver </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">volumes, and general bone pain and severe disabling bone pain known as bone crisis. Following at least four years of ERT in this study, approximately 60% of patients failed to achieve one or more of these six target goals. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to ERTs, the FDA has approved several oral therapies for the treatment of Gaucher disease, including Zavesca (miglustat) marketed by Actelion and Cerdelga (eliglustat) marketed by Sanofi Genzyme. We believe these oral therapies also provide suboptimal treatment. Zavesca is approved as a second line therapy and is associated with significant toxicities, including diarrhea, weight loss and tremors. Cerdelga is not approved for use in children, has highly variable metabolism due to patient-to-patient genetic variations and is highly susceptible to interactions with other drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both ERTs and oral therapies for Gaucher type 1 impose significant costs on the healthcare system. We estimate that the average five-year cost to the healthcare system per Gaucher patient (all types) prescribed standard of care treatment in the United States is approximately $2.3 million. In 2020, Sanofi Genzyme&#8217;s Cerezyme and Cerdelga together generated worldwide net sales of approximately &#8364;924 million euros and Takeda&#8217;s VPRIV generated worldwide net sales of approximately &#165;38.5 billion Japanese yen.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Solution </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-02 to potentially provide a functional cure to patients with Gaucher disease type 1 with a single dose of the patient&#8217;s own hematopoietic stem cells modified in an <span style="font-style:italic;">ex vivo</span> procedure. AVR-RD-02 is a lentiviral-based gene therapy that contains a codon-optimized human gene and is designed to maximize the likelihood of sustained GCase production in hematopoietic stem cells and their progeny. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ongoing Phase 1/2 Clinical Trial (Guard1)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated our Guard1 Phase 1/2 clinical trial of AVR-RD-02 in patients with Gaucher disease type 1. Patient enrollment has commenced, and as of March 1, 2021 one patient has been dosed. <span style="Background-color:#FFFFFF;color:#000000;">This clinical trial is actively recruiting in Australia and Canada, with additional sites planned in the </span>United States, Israel and Europe<span style="Background-color:#FFFFFF;color:#000000;">.</span> Our initial clinical trial will be an adaptive trial that will include both treatment-na&#239;ve patients and patients that are currently stable on ERT. We intend to enroll eight to 16&#160;patients, between the ages of 16 and 35, with Gaucher disease type 1. Patients currently prescribed ERT will cease treatment throughout the clinical trial. All enrolled patients will receive a single treatment with AVR-RD-02 and will be followed for 52 weeks to measure safety and efficacy. <span style="Background-color:#FFFFFF;color:#000000;">We intend to utilize our plato platform for all patients enrolling in our&#160;Phase 1/2&#160;clinical trial of AVR-RD-02. </span>Our efficacy endpoints for this clinical trial will include measures of clinical efficacy, such as liver and spleen volumes, hemoglobin, platelet counts, bone pain and bone density measures along with other blood markers used in Gaucher disease type 1. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021 we presented data on the first patient in the Guard1 clinical trial, who discontinued ERT one month prior to dosing of AVR-RD-02 and remains off ERT as of February 8, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plasma Lyso-Gb1 Reductions</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Glucosylsphingosine, or&#160;lyso-Gb1,&#160;is considered a surrogate marker for disease activity and treatment response for Gaucher disease type 1. In the case of&#160;ERT-na&#239;ve&#160;patients and patients who have discontinued ERT, we believe that reductions in&#160;lyso-Gb1&#160;levels following treatment with gene therapy are likely driven by the therapeutic effect of gene therapy. In February 2021, we announced that the first patient in our Guard1 clinical trial exhibited a 44% reduction in plasma&#160;lyso-Gb1&#160;levels six months post-administration of&#160;AVR-RD-02&#160;as compared to baseline while on ERT. In this study baseline ERT is the measurement of a single plasma lyso-Gb1&#160;value&#160;observed prior to initiating mobilization.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plasma Chitotriosidase Reductions<span style="font-style:normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chitotriosidase is a biomarker of macrophage activation that is found in high levels in Gaucher patients where the macrophages have accumulated an excess lipid burden. In February 2021, we announced that at six months post-treatment with&#160;AVR-RD-02&#160;the first patient in the Guard1 clinical trial exhibited a 49% reduction in chitotriosidase levels as compared to baseline while on ERT. In this study baseline ERT is the measurement of a single chitotriosidase&#160;value&#160;observed prior to initiating mobilization.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hemoglobin Concentration and Platelet Counts<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gaucher disease type 1 typically causes patients to have low levels of hemoglobin and platelets. In February 2021, we presented data on the hemoglobin and platelet levels of the first patient dosed in the Guard1 clinical trial at screening, baseline and six months post-administration of AVR-RD-02. The baseline measurement was taken one month prior to discontinuation of ERT. At screening, baseline and six months post-treatment, the patient&#8217;s platelet counts were 455x10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>/L, 432x10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>/L and 351 x10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>/L, respectively, and the patient&#8217;s hemoglobin concentration was 12.5 g/dL, 11.2 g/dL and 12.2 g/dL, respectively. Both six-month measurements are within the normal range for a healthy individual. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Vector Copy Number </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021 we presented VCN data for the first patient dosed in the Guard1 trial. At six months post-treatment, the patient exhibited a VCN </span><span style="Background-color:#FFFFFF;">of 0.6. In addition, at three months post-treatment an exploratory assessment of VCN in specific cell populations showed a VCN&#160;</span><span style="Background-color:#FFFFFF;font-family:'Times New Roman';"><span style="font-size:10pt;font-family:'Times New Roman'">&#8805;</span></span><span style="Background-color:#FFFFFF;">&#160;0.7 in the myeloid cell lines, which we believe could be indicative of transgene presence in the macrophages, the essential cell impacted in Gaucher patients. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Safety</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of the safety&#160;cut-off&#160;date of January 4, 2021, preliminary interim clinical data for the first patient dosed in the Guard1 clinical trial appear to indicate that the&#160;AVR-RD-02&#160;investigational gene therapy has been generally well tolerated with no unexpected safety events identified. There have been no reports of safety events attributed to the&#160;AVR-RD-02&#160;drug product, and no SAEs were reported as of the safety data&#160;cut-off&#160;date. A total of 29 AEs were reported as of the safety&#160;cut-off&#160;date, two of which were Grade 4 and seven of which were Grade 3. The remainder of the AEs were Grade 2 or Grade 1. All reported AEs were consistent with expectations for the underlying disease and conditioning regimen prescribed by the study protocol and have resolved. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because this clinical trial is ongoing, safety and efficacy data are preliminary and subject to change. As is typical in open-label studies in which interim reports are provided, the data are regularly reviewed and validated. As a result, certain data may change over time, including reductions or increases in the number of reported safety events, until the database is locked at the end of the study.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVR-RD-05, Our Gene Therapy for Hunter Syndrome </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-05 for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome. AVR-RD-05&#160;involves&#160;<span style="font-style:italic;">ex vivo</span>&#160;transduction of the patient&#8217;s own hematopoietic stem cells with a therapeutic transgene,&#160;in-licensed&#160;from the University of Manchester, or UoM, designed to express functional iduronate&#160;2-sulfatase,&#160;or IDS, which is the enzyme the patient needs to maintain cellular health, coupled to a proprietary ApoE2 protein tag that is designed to improve stability of the enzyme in the bloodstream and facilitate uptake by tissues.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVR-RD-05&#160;will be studied by our collaborators at UoM and a Phase 1/2 investigator-sponsored clinical trial of&#160;AVR-RD-05&#160;is expected to commence in the first half of 2022.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disease Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hunter syndrome disease is a rare, recessive lysosomal disorder caused by a mutation in the gene that encodes for IDS that results in accumulation of the glycosaminoglycans heparan and dermatan sulfate. Hunter syndrome affects a multitude of organs and is a chronic and progressive multi&#8208;system disorder. Clinical manifestations in Hunter syndrome include skeletal abnormalities, known as dysostosis multiplex, short stature, joint stiffness, and hepatosplenomegaly, accompanied by cardiorespiratory symptoms. Severe cases of Hunter syndrome, which are most common, also feature progressive neurodegeneration, typically followed by death in teenage years due to obstructive airway disease and cardiac failure.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hunter syndrome is an X-linked disorder, meaning the gene that is responsible is located on the X chromosome. Because males have only one X chromosome, an abnormal copy of the gene that causes Hunter syndrome disease is sufficient to cause the disease.&#160;The overall diagnosed incidence of Hunter syndrome is estimated to be approximately one in 100,000 to one in 170,000 males worldwide. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hunter syndrome is currently treated with ERT delivered by weekly intravenous infusion. The only approved therapy for Hunter syndrome is Elaprase, marketed by Shire, which generated worldwide net sales of&#160;approximately &#165;67 billion Japanese yen in 2020. We estimate that the average five-year cost to the healthcare system per Hunter patient prescribed standard of care treatment in the United States is approximately $2.4 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two-thirds of patients experience developmental and neurological decline, which is often noted by approximately age two. Due to lack of newborn screening, diagnosis usually occurs much later in patient&#8217;s lives, around five years of age and can be as late as eight years. Although patients typically begin ERT treatment almost immediately after diagnosis, often the disease symptoms are far advanced and ERT is insufficient to halt the disease progression. ERT does not treat the neurological symptoms of the disease, and therefore a significant unmet need remains in a majority of patients with Hunter syndrome. Furthermore, anti-ERT antibodies are a limitation for a significant part of the entire patient population. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Solution </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, together with our collaborators at UoM, are developing AVR-RD-05 to potentially provide a functional cure to patients with Hunter syndrome. AVR-RD-05 is intended to be a gene therapy product containing a codon-optimized human gene for IDS attached to a ApoE2 protein tag designed to increase the cells&#8217; secretion of IDS to potentially restore healthy cellular function, stabilize the secreted IDS so it has a longer half-life, and facilitate uptake of IDS into the brain. In addition, we believe that the utilization of busulfan in our conditioning regimen may have the potential to allow AVR-RD-05 to cross the blood-brain barrier, a feature which may yield therapeutic benefit. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Data</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we presented previously published preclinical data on AVR-RD-05. The study presented data from normal study mice, mice affected with the equivalent of Hunter syndrome, mice treated with&#160;AVR-RD-05&#160;modified to not incorporate the ApoE2 protein tag, and mice treated with&#160;AVR-RD-05&#160;incorporating the proprietary ApoE2 tag. These data demonstrated the effect of AVR-RD-05 on levels and composition of heparan sulfate in the brain, neuro-inflammatory pathologies, facial and skeletal abnormalities, as well as cognitive performance and sensorimotor coordination and balance. We believe these data support the potential of AVR-RD-05 to treat this progressive disease, and potentially prevent the onset of severe symptoms if treated early.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Planned Phase 1/2 Investigator-Sponsored Clinical Trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaborators at UoM plan to initiate a Phase 1/2 clinical trial in the first half of 2022. The Phase 1/2 clinical trial is expected to enroll five male patients, age three months to 24 months, with an early progressive form of the disease. The clinical trial is expected to be open to treatment-na&#239;ve patients as well as patients currently on ERT. <span style="Background-color:#FFFFFF;color:#000000;">The clinical trial&#8217;s primary endpoints are expected to be safety and tolerability. Secondary endpoints to assess preliminary efficacy are expected to include measurements of IDS levels and its activity as well as levels of </span>glycosaminoglycans<span style="Background-color:#FFFFFF;color:#000000;">. Neurocognitive evaluations will also be conducted to evaluate therapeutic activity in the brain.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because this is an investigator-sponsored clinical, the study drug will not be manufactured using our plato platform, and neither the automated, closed manufacturing system nor LV2 will be used in connection with this clinical trial.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVR-RD-06, Our Gene Therapy for Gaucher disease type 3</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we announced an expansion of our lysosomal disorder pipeline with a new preclinical product candidate,&#160;AVR-RD-06,&#160;our investigational gene therapy for Gaucher disease type 3. Gaucher disease type 3 is the subacute neurological form of Gaucher disease characterized by progressive encephalopathy and associated with the systemic manifestations of Gaucher type 1. As with Gaucher type 1, Gaucher type 3 disease is caused by a gene that codes for the enzyme glucocerebrosidase. The deficiency in glucocerebrosidase leads to the accumulation of Gb1 and its toxic metabolite,&#160;lyso-Gb1.&#160;AVR-RD-06&#160;is expected to use the same vector and drug product that we use in&#160;AVR-RD-02,&#160;our investigational gene therapy for Gaucher disease type 1. We currently expect to request a meeting with the FDA this year to discuss a potential path to the clinic for AVR-RD-06.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disease Overview</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gaucher disease type 3 is the subacute, chronic neurological form of Gaucher disease, a rare, autosomal recessive, lysosomal disorder caused by a hereditary deficiency of functional GCase, an enzyme responsible for degrading glucocerebroside, a cell membrane building block, into glucose and lipids within lysosomes of cells. In patients with Gaucher type 3 disease, the recycling of glucocerebroside from the breakdown of old red and white blood cells is inhibited, leading to its accumulation in macrophages. These abnormal macrophages, known as Gaucher cells, accumulate in multiple organs, particularly the liver, spleen and bone marrow. In addition, glucosylceramide accumulates in perivascular macrophages and brain glial cells and neurons leading to neuronal death. Clinically, central nervous system manifestations of Gaucher disease type 3 appear in childhood or adolescence, typically within the latter part of the first decade for the majority of patients, although the course of disease is markedly heterogenous. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gaucher disease type 3 is estimated to occur in one in 100,000-300,00 births and is more prevalent in certain ethnic groups, such as people of Swedish Norrbottnian descent. Systemic manifestations of Gaucher disease type 3 may include enlargement of the spleen and liver, low red blood cells, or anemia, low platelet count, or thrombocytopenia, and bone abnormalities including bone pain, fractures and arthritis. Bruising, risk of bleeding and fatigue are common due to the thrombocytopenia and anemia. Variable other features of Gaucher disease type 3 include pulmonary infiltrates and esophageal varices associated with liver cirrhosis. Presentation of diverse neurologic features may begin at any time during infancy and early childhood with the most prevalent finding of horizontal supranuclear gaze palsy. Other manifestations of neurological disease include generalized seizures, myoclonus, ataxia, and/or dementia.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current therapies used to treat Gaucher disease type 1, namely, ERT and substrate reduction therapy, or SRT, do not penetrate the brain and therefore have no effect on the neurological aspects of Gaucher disease type 3. The most commonly prescribed ERTs for Gaucher disease are Cerezyme, marketed by Sanofi Genzyme, and VPRIV, marketed by Shire. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with Gaucher disease type 3 may exhibit wide variation of disease progression with the severity of systemic disease and neurological deficits differing considerably between patients. In a published study of SRT therapy for Gaucher disease type 3, no significant benefits were demonstrated on the neurological manifestations of Gaucher disease type 3. Although long-term ERT for Gaucher disease type 3 results in some therapeutic benefit on visceral, hematological and bone manifestations, ERTs leave patients with significant unmet needs owing to persisting accumulation of substrate within the central nervous system. Following 10 years of ERT, two patients&#8217; epilepsy had worsened while a third patient developed epilepsy around eight years after treatment initiation. Another published study on ERT showed that enzyme infusions had no effect on patients with myoclonus and approximately 40% of patients deteriorated neurologically during a median 3.5 year follow-up period.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Solution </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-06 to potentially provide a functional cure to patients with Gaucher disease type 3 with a single dose of the patient&#8217;s own hematopoietic stem cells modified in an <span style="font-style:italic;">ex vivo</span> procedure. AVR-RD-06 is a lentiviral-based gene therapy that contains a codon-optimized human gene and is designed to maximize the likelihood of sustained GCase production in hematopoietic stem cells and their progeny. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Data</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we presented preclinical data from a mouse study which we believe demonstrate the potential of lentiviral gene therapy to repopulate the microglia compartment of the brain with microglia cells carrying the therapeutic gene. We also presented preclinical data demonstrating a technique that potentially allows us to examine individual cells in the brain to determine which cell types contain the therapeutic gene. Finally, we presented data comparing the genetically modified microglia and endogenous microglia, which we believe suggest that even though the modified cells are not native to the brain, they do not act as &#8220;invaders&#8221; and thus could be expected to carry out normal physiological functions.&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVR-RD-03, Our Gene Therapy for Pompe Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing AVR-RD-03 for the treatment of Pompe disease. We will manufacture AVR-RD-03 from hematopoietic stem cells that are first harvested from the patient, modified to add the gene that encodes for acid alpha glucosidase A, or GAA, attached to a peptide sequence known as a glycosylation-independent lysosomal targeting, or GILT, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tag and then infused into the patient. AVR-RD-03 will incorporate a GILT tag because the GILT tag has been found to increase the uptake of GAA into cells, especially in muscle cells by a multiple of 25, which is a particularly important target tissue for patients with Pompe disease and a target tissue that is considered difficult to access for ERT. AVR-RD-03 is designed to incorporate a potent promoter to increase volume of system enzyme in circulation. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disease Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pompe disease is a rare, autosomal recessive lysosomal disorder caused by a mutation in the gene that encodes for GAA that results in the buildup of glycogen, a complex sugar, in the body&#8217;s cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs normal tissue and organ function. Patients with Pompe disease experience serious muscle related problems, including progressive muscle weakness, especially in the legs and trunk, and the muscles that control breathing. As the disorder progresses, breathing problems can lead to respiratory failure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The overall diagnosed incidence of Pompe disease is estimated to be approximately one in 58,000 people although frequency and disease progression varies with age of onset, ethnicity and geography. Overall diagnosed incidence of Pompe disease is projected to increase to one in 22,000 people as it is increasingly included in newborn screening panels. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The severity of Pompe disease symptoms and rate of progression is highly variable and correlated with age of symptom onset and the degree of enzyme deficiency. Infantile or early onset disease, the most severe form of Pompe disease, accounts for approximately 25% of all affected patients. Those with early-onset disease are usually diagnosed in the first few months of life and is associated with cardiomyopathy. Left untreated, these patients can die due to heart failure, respiratory distress or malnutrition resulting from feeding difficulties within the first year of life. Patients with late-onset disease typically have higher enzyme levels and usually have symptoms such as reduced mobility and respiratory problems but are not at increased risk of developing cardiomyopathy. Late-onset patients experience progressive difficulty walking and respiratory decline. While life expectancy can vary, Pompe disease is a life-limiting disease that can result in death due to complications from respiratory failure. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pompe disease is currently treated with ERT delivered by bi-weekly intravenous infusion. The only approved therapy for Pompe disease is Lumizyme (known as Myozyme outside of the United States), marketed by Sanofi Genzyme, which generated worldwide net sales of approximately &#8364;948&#160;million euros in 2020. We estimate that the average five-year cost to the healthcare system per Pompe patient prescribed standard of care treatment in the United States is approximately $3.2 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Though patients treated with ERT for Pompe disease have improved survival and respiratory function, ERT is not curative, and patients in long-term observational studies continue to have increased risk of heart failure and have residual muscle weakness including difficulties swallowing with risk of aspiration. One challenge with ERT treatment for Pompe disease is that a standard dose requires approximately twenty-fold more enzyme compared to standard doses for Fabry or Gaucher diseases. Large doses of Lumizyme that are delivered systemically in order to achieve potentially therapeutic levels in the target tissues result in approximately 90% of patients developing antibodies against the therapy. These antibody responses may impact both the efficacy and safety of Lumizyme. The FDA approval of Lumizyme carries a black box warning related to the risk of severe allergic and immune mediated reactions, including life-threatening anaphylaxis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Solution </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our AVR-RD-03 program for Pompe disease is currently in preclinical development, and in 2020 we completed IND-enabling proof-of-concept preclinical studies, with toxicology studies expected to be completed in 2021.We are developing AVR-RD-03 to be a gene therapy product containing a codon-optimized human gene for GAA attached to a GILT tag designed to increase uptake of GAA in muscle cells. AVR-RD-03 will target patients with late onset Pompe disease, which represent the majority of patients with this disease. In addition, we believe that the utilization of busulfan in our conditioning regimen may have the potential to allow AVR-RD-03 to cross the blood-brain barrier, a feature which may yield therapeutic benefit. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Data</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020 we presented data from a study in which mice with the equivalent of classic infantile-onset Pompe disease were treated with&#160;AVR-RD-03. We these data believe support the potential of lentiviral-based gene expression of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAA to prevent some of the symptoms of GAA deficiency. These results also demonstrated the need to further increase the uptake of GAA into muscle cells to treat patients, which is a known challenge for ERTs and leads to the use of large quantities of enzyme to attempt to deliver effective treatment levels. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we can use a GILT tag to address the known challenges of skeletal muscle uptake in patients with Pompe disease. Attachment of a GILT tag to a particular protein can increase the effective uptake of that protein into target tissues. We are designing AVR-RD-03 to use a GILT tag to facilitate GAA uptake into cells and thereby reduce the therapeutically required amount of GAA produced by a patient&#8217;s cells following gene therapy treatment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In mouse models of Pompe, administration of recombinant GAA with the GILT tag demonstrated significant reduction in glycogen in cardiac and skeletal muscles as compared to the administration of recombinant GAA alone. We licensed GILT tag technology from BioMarin and are incorporating a GILT tag into our lentiviral vector with the goal of the patient producing GILT-tagged GAA following treatment with AVR-RD-03. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">GAA Enzyme Production</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our preclinical study measured the levels of GAA observed in normal mice, mice with the equivalent of infantile-onset Pompe disease, mice treated with AVR-RD-03 modified to not incorporate our proprietary GILT tag, and mice treated with AVR-RD-03 including our GILT tag, in each case measured 16 weeks post-treatment. These data showed significant overexpression of GAA in bone marrow, white blood cells and plasma in mice treated with AVR-RD-03 without our GILT tag as well as AVR-RD-03 incorporating our GILT tag. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Glycogen Reduction</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our preclinical study also measured glycogen levels in the heart and brain at four months post-treatment with our GILT-tagged version of&#160;AVR-RD-03,&#160;which showed a 99% and 100% reduction, respectively, in glycogen levels. In addition, our study measured glycogen levels in various organs of the study mice at eight months post-treatment. The data showed an average of greater than 99% reduction in glycogen levels in the heart, greater than 97% reduction in the diaphragm, greater than 85% reduction in skeletal muscle, greater than 95% reduction in the brain, and greater than 99% reduction in the spinal cord.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Industrializing Our Gene Therapies Through Our Outsourced Manufacture and Supply Network </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are establishing global manufacturing relationships that we believe will provide us with drug product manufacturing capabilities to support all aspects of the development and eventual commercialization of our gene therapies. Our team has leveraged their broad expertise in the manufacturing of gene and cellular therapies to build a global network of CMO partners for the development and manufacture of drug products and outsourced suppliers for the supply of vectors and plasmids. We believe that our third-party CMO partners and suppliers have capacity to accommodate current and future clinical trials and we are continuing to build a global network that we expect will have capacity to generate sufficient quantities to meet our expected commercial needs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To optimize production of our gene therapies, we have moved our cell processing to an automated, closed system using disposable supplies. We believe this industrialized manufacturing process will enable a repeatable approach through which we can design and manufacture commercially viable lentiviral gene therapies to potentially treat a large variety of genetic disorders. We expect that our automation of the manufacturing processes will further increase our CMO partners&#8217; manufacturing capacity. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Producing a Patient&#8217;s Gene Therapy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We start the process to produce a patient&#8217;s gene therapy with the mobilization of a patient&#8217;s stem cells from the bone marrow to the blood stream and isolate them using a standard procedure used in stem cell transplants. We then treat these cells with a lentiviral vector to insert the equivalent of a functional copy of the gene that is defective in the target disease in a 48-hour process. We preserve patients&#8217; modified cells at a very low temperature, using cryopreservation to maintain the cellular material in optimal condition until it is thawed prior to being infused into the patient. The cryopreservation allows us to conduct a number of tests to validate the modified cells prior to introducing them into the patient. We believe cryopreservation will also enable us to supply our products globally, as well as significantly increase the convenience of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infusion scheduling for clinicians and patients, compared to fresh </span><span style="font-style:italic;">ex vivo</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> gene therapy products that may have shelf-lives of only </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> hours. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to infusion of the gene therapy-modified cells into the patient, the patients undergo a conditioning regimen to remove some of the patient&#8217;s unmodified cells from the bone marrow to create sufficient space for the modified hematopoietic stem cells to engraft and produce their progeny. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the conditioning regimen is complete, the lentivirally-modified stem cells are infused into the patient by intravenous administration in an outpatient setting. After infusion, these cells engraft into the bone marrow, replicate and differentiate into all the various types of blood cells that will distribute throughout the body. These widely distributed cells lead to sustained expression of the desired therapeutic enzyme or other protein. The sustained expression of the functional enzyme is a direct substitute for the protein currently delivered by ERTs, which require periodic infusions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property and Other Barriers to Entry </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proprietary nature of, or protection for, our gene therapy technology, our product candidates, our production methods and supply chain are an important part of our strategy to develop and commercialize novel therapies. To maximize the commercial opportunity for our gene therapies, if approved, we and our partners have been building and continue to build barriers to entry by our competitors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We in-license and develop know-how, including data, relating to certain of our product candidates. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We rely on trade secret protection to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our management team has significant experience in cell processing and commercial-scale cellular therapy manufacturing. Leveraging this experience, we are building our global network of suppliers and CMO partners which combines their expertise in vector manufacturing with a closed, automated manufacturing system, all utilizing cGMP.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our gene therapies are designed to potentially provide a curative benefit. If our gene therapies are approved before any other potentially curative treatments, we believe the benefits of our approach and the resulting first mover advantage may provide meaningful disincentive for companies seeking to develop potentially curative therapies that may compete with our own. See &#8220;&#8212;Competition.&#8221; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We are developing therapies to treat rare diseases and expect to pursue orphan-drug designation in the United States and similar protection outside of the United States. To date, the FDA and the European Commission have each granted orphan drug designation to AVR-RD-01 for the treatment of Fabry disease, AVR-RD-04 for the treatment of cystinosis, and AVR-RD-02 for the treatment of Gaucher disease type 1. These and other regulatory exclusivities, if granted or applicable, can prevent competitors, during the exclusivity period, from obtaining regulatory approval of the same drug or biological product for the same indication. See &#8220;&#8212;Government Regulation.&#8221; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We currently in-license, and we expect to file our own, patents and patent applications relating to certain of our product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have in-licensed patents and patent applications from BioMarin Pharmaceutical Inc., GenStem Therapeutics, Inc. and The University of Manchester directed to compositions and methods related to the manufacture and use of certain of our gene therapies. In addition, we have in-licensed certain intellectual property rights and know-how from the University Health Network and affiliates of Lund University. For example, we have in-licensed know-how and data related to AVR-RD-01, including certain information about the vector and its use, from University Health Network, and we have in-licensed know-how and data related to AVR-RD-02, including certain information about the vector and its use, from certain academic scientists affiliated with Lund University. Each of our licenses are limited to particular fields, such as Fabry disease, Gaucher disease type 1, Pompe disease, cystinosis, or Hunter syndrome, and are subject to certain retained rights. We do not control the prosecution and maintenance of all of our in-licensed patents and patent applications, and our rights to enforce the patents are limited in certain ways. For additional detail regarding the risks associated with our license agreements see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;March </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our in-licensed patent portfolio relating to certain of our gene therapies included the following: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">AVR-RD-03 (Pompe program)</span><span style="font-size:10pt;color:#000000;">:&#160;two U.S. patents, projected to expire in 2022 and 2023, and two U.S. patent applications, which if granted, would be projected to expire in 2022 and 2029, as well as corresponding patents and patent applications in certain foreign jurisdictions, as they pertain to compositions and methods for promoting lysosomal uptake of acid alpha-glucosidase and the treatment of Pompe disease. These patents and patent applications are licensed to us by BioMarin and relate to the GILT tag.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">AVR-RD-04 (cystinosis program)</span><span style="font-size:10pt;color:#000000;">:&#160;one U.S. patent application, which, if granted, would be projected to expire in 2038, as well as corresponding patents and patent applications in certain foreign jurisdictions, containing claims directed to hematopoietic stem cells expressing cystinosin and methods of using the same for the treatment of cystinosis. These patent applications are licensed to us by GenStem Therapeutics, and GenStem obtained its rights from the University of California, San Diego. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">AVR-RD-05 (Hunter program)</span><span style="font-size:10pt;color:#000000;">: one U.S. patent application, which, if granted, would be projected to expire in 2038, as well as corresponding patents and patent applications in certain foreign jurisdictions, containing claims directed to gene therapy vectors encoding iduronate-2-sulfatase and methods of using the same for the treatment of Hunter syndrome. These patent applications are licensed to us by the University of Manchester.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of any given patent depends upon the legal term of patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&#160;years from the date of filing the application, subject to the timely payment of maintenance fees, among other considerations. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed commonly owned patent. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of FDA regulatory review period. However, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14&#160;years following FDA approval. In certain foreign jurisdictions similar extensions as compensation for regulatory delays are also available. The actual protection afforded by a patent varies on a claim by claim and country by country basis for each applicable product and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Currently, we do not own or license patents or patent applications related to our AVR-RD-01, AVR-RD-02 or AVR-RD-06 product candidates. We rely, in some circumstances, on trade secrets and unpatented know-how that is either owned by or licensed to us to protect our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with The University of Manchester</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we entered into an agreement, or the MPSII License Agreement, with The University of Manchester, England, or UoM, whereby UoM granted us <span style="Background-color:#FFFFFF;color:#000000;">an exclusive worldwide license under certain patent and other intellectual property rights, subject to certain retained rights, to develop, commercialize and sell an&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">ex vivo</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;lentiviral gene therapy for use in the treatment of Hunter syndrome, or mucopolysaccharidosis type II</span>. As consideration for the MPSII License Agreement, we agreed to pay UoM an upfront, one-time fee of $8.0 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the agreement, we are obligated to make milestone payments of up to an aggregate of $80.0 million upon the achievement of specified development and regulatory milestones, to pay royalties, on a product-by-product and country-by-country basis, of a mid-single digit percentage based on net sales of products licensed under the agreement and to pay a low double-digit percentage of any sublicense fees received by us. The next anticipated payment milestones under the MPSII License Agreement include $2.0 million, which would become due following the date of regulatory approval of the clinical trial application for the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM, and $4.0 million, upon the dosing of the first patient in the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the agreement <span style="Background-color:#FFFFFF;color:#000000;">expires upon the later of 15 years from the effective date or the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations.&#160;We and UoM can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. UoM has the right to terminate the agreement in the event of certain actions relating to challenge or opposition to the licensed intellectual property brought us or its affiliates or sublicensees.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the MPSII License Agreement, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> entered into a collaborative research funding agreement with UoM</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRFA. Under the CRFA, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agreed to fund the budgeted costs of an investigator-sponsored Phase 1/2 clinical trial to be sponsored by UoM in connection with the development activities under the MPSII License Agreement,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which are currently estimated to equal approximately</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#163;9.1 million in the aggregate</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusive License Agreement with University Health Network </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, we entered into a license agreement with University Health Network, or UHN, pursuant to which UHN granted us an exclusive worldwide license under certain intellectual property rights and a non-exclusive worldwide license under certain know-how, including certain rights to data, in each case subject to certain retained rights, to develop, commercialize and sell products for use in the treatment of Fabry disease. Intellectual property licensed to us under this agreement relates to our Fabry program. In addition, for three years following the execution of the agreement, UHN granted us an exclusive option to obtain an exclusive license under certain improvements to the licensed intellectual property rights as well as an exclusive option to negotiate a license under certain other improvements. Under the terms of the agreement, we are required to meet certain performance milestones within specified timeframes. UHN may terminate the agreement if we fail to meet these performance milestones despite using commercially reasonable efforts and we are unable to reach agreement with UHN on revised timeframes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licenses, we paid to UHN a one-time upfront fee in the amount of C$75,000 and are obligated to pay an additional annual fee until the first sale of a licensed product in certain markets. We are also required to make payments to UHN in connection with the achievement of certain development and regulatory milestones, in an aggregate amount of C$2.45&#160;million, as well as royalties on a country-by-country basis of a low to mid-single digit percentages on annual sales of licensed products and a lower single digit royalty in certain circumstances. Additionally, we will pay a low double-digit percentage of all sublicensing revenue. Our royalty obligation expires on a licensed product-by-licensed product and country-by-country basis upon the latest to occur of the expiration or termination of the last valid claim under the licensed patent rights in such country (if and when any such patent rights come into existence under the license agreement in the future), the tenth anniversary of the first commercial sale of such licensed product in such country and the expiration of any applicable regulatory exclusivity in such country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under this agreement we made a philanthropic commitment to donate funds to organizations for the benefit of the Canadian Fabry community in an amount equal to a low double-digit percentage of our royalty payments and regulatory milestone payments, up to a maximum amount of C$0.5 million in any calendar year. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, this exclusive license agreement with UHN will expire upon the expiration of our royalty obligation for all licensed products. Either we or UHN may terminate the license agreement if the other party commits a material breach and fails to cure such breach within a certain period of time. UHN may terminate this agreement if we enter into bankruptcy or insolvency. We may terminate this agreement for any reason upon notice to UHN. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with Lund University Rights Holders </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, we entered into an exclusive license agreement with Prof.&#160;Stefan Karlsson and Dr.&#160;Maria Dahl, affiliates of Lund University, pursuant to which Prof.&#160;Karlsson and Dr.&#160;Dahl, and certain other relevant rights holders that may have an interest in intellectual property generated under a research project we are funding with Lund University, granted to us an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights to develop, commercialize and sell products in any and all uses relevant to Gaucher disease. Intellectual property licensed to us under this agreement relates to our Gaucher program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the license, we are required to make payments in connection with the achievement of certain milestones up to an aggregate of $0.55 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license agreement with the rights holders expires on the latest of (i)&#160;the twentieth anniversary of the end of a certain research project we are funding pursuant to an agreement with Lund University, (ii)&#160;the expiration of the term of any patent filed on the licensed rights that covers a licensed product, (iii)&#160;the expiration of any applicable marketing exclusivity right and (iv)&#160;such time that neither we nor any of our sublicensees or partners or contractors are commercializing a licensed product. Either we or the rights holders acting together may terminate the license agreement if the other such party commits a material breach and fails to cure such breach within a certain period of time, or if the other party enters into liquidation, becomes insolvent, or enters into composition or statutory reorganization proceedings. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with BioMarin Pharmaceutical Inc. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, we entered into a license agreement with BioMarin Pharmaceutical Inc., or BioMarin, pursuant to which BioMarin granted us an exclusive worldwide license under certain intellectual property rights related to GILT tags owned or controlled by BioMarin to develop, commercialize and sell retroviridae-based gene therapy products for use in the treatment of Pompe disease. This agreement was amended in February 2018 and again in January 2020 to, among things, provide that BioMarin would supply us with certain materials related to the GILT tags technology. Under the terms of the agreement, we must use commercially reasonable efforts to develop and commercialize one or more licensed products in the United States and certain European countries. In addition, we are required to initiate an IND-enabling pharmacology/toxicology study of a licensed product within a specified period of time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the license, we paid an initial license fee in the amount of $0.5 million and issued 233,765 shares of our Series B preferred stock to BioMarin at the time of our Series B financing. We are also obligated to make payments to BioMarin upon achievement of certain milestones up to an aggregate of $13.0&#160;million and pay to BioMarin a low single digit royalty percentage on net sales of licensed products covered by patent rights in a relevant country. Our royalty obligation expires on a licensed product-by-licensed product and country-by-country basis upon the latest to occur of the expiration or termination of the last valid claim under the licensed patent rights in such country, which is currently projected to occur in 2029, the tenth anniversary of the first commercial sale of such licensed product in such country and the expiration of any applicable regulatory exclusivity in such country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, our license agreement with BioMarin will expire upon the expiration of our royalty obligation for all licensed products throughout the world. Either we or BioMarin may terminate the license agreement if the other party commits a material breach and fails to cure such breach within a certain period of time. BioMarin may also terminate the agreement in the event of any challenge or opposition to the licensed patent rights or related actions brought by us or our affiliates or sublicensees, or if we, our affiliates or sublicensees knowingly assist a third party in challenging or otherwise opposing the licensed patent rights, except as required under a court order or subpoena. In addition, BioMarin may terminate the agreement upon our bankruptcy or insolvency. We may terminate the agreement for any reason upon notice to BioMarin. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with GenStem Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, we entered into a license agreement with GenStem Therapeutics, Inc., or GenStem, pursuant to which GenStem granted us an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights owned or controlled by GenStem related to our cystinosis program, including certain rights licensed to GenStem from the University of California, San&#160;Diego, to develop, commercialize and sell products for use in the treatment of cystinosis. Under the terms of the agreement, we must use commercially reasonable efforts to develop and commercialize one or more licensed products in the United States and in at least one country from other specified markets. We also agreed to comply with certain access requirements consistent with the California Institute for Regenerative Medicine regulations and to manufacture certain licensed products substantially in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the license, we paid an initial license fee in the amount of $1.0&#160;million and are required to make payments upon completion of certain development milestones up to an aggregate of $16.0&#160;million. For example, i<span style="color:#000000;">n November 2019 we made a $2.0 million payment in connection with the dosing of the first patient in the investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis in the United States. </span>Additionally, we will pay to GenStem a tiered mid to high-single digit royalty percentage on annual net sales of licensed products as well as a low double-digit percentage of sublicense income received from certain third party sublicensees. Our royalty obligation expires on a licensed product-by-licensed product and country-by-country basis on the eleventh anniversary of the first commercial sale of such licensed product in such country or the expiration of the last valid claim under the licensed patent rights covering such licensed product in such country, which is currently projected to occur in 2038, whichever is later. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, our license agreement with GenStem will terminate upon the expiration of our royalty obligation for all licensed products throughout the world. Either we or GenStem may terminate the license agreement if the other party commits a material breach and fails to cure such breach within a certain period of time. In addition, we may terminate the agreement for any reason upon notice to GenStem. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include larger pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as academic institutions, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government agencies and private and public research institutions. Key competitive factors affecting the commercial success of our gene therapies are likely to be efficacy, safety and tolerability profile, reliability, convenience, price and reimbursement. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market for treatment of lysosomal disorders is especially large and competitive. The gene therapies we are currently developing, if approved, will face competition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a small number of our competitors. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval for drugs and achieving widespread market acceptance. Our competitors&#8217; products may be more effective, or more effectively marketed and sold, than any product we may commercialize and may render our gene therapies obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our gene therapies. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Finally, the development of new treatment methods for the diseases we are targeting could render our gene therapies non-competitive or obsolete. See &#8220;Risk Factors&#8212;Risks related to the discovery and development of our product candidates&#8212;We face significant competition and our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our ability to successfully market or commercialize any of our product candidates,&#8221; and elsewhere in this Annual Report on Form 10-K for more information regarding competitors and competitive products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&#38;C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&#38;C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. Each clinical study protocol for a gene therapy product must be reviewed by the FDA and, in some instances, the National Institute of Health, or NIH, through its Recombinant DNA Advisory Committee, or RAC. FDA approval must be obtained before the marketing of biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. The CBER works closely with the NIH and its RAC, which makes recommendations to the NIH on gene therapy issues and engages in a public discussion of scientific, safety, ethical and societal issues related to proposed and ongoing gene therapy protocols. The FDA and the NIH have published guidance documents with respect to the development and submission of gene therapy protocols. The FDA also has published guidance documents related to, among other things, gene therapy products in general, their preclinical assessment, observing subjects involved in gene therapy studies for delayed adverse events, potency testing, and chemistry, manufacturing and control information in INDs for gene therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed interest in further regulating biotechnology. More restrictive regulations or claims that our products are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Biological Products Development Process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of an application for an IND, which must become effective before human clinical studies may begin&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">approval by an independent institutional review board, or IRB, or ethics committee at each clinical study site before each study may be initiated&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical studies according to the FDA&#8217;s regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of a Biologics License Application, or BLA, for marketing approval that includes substantive evidence of safety, purity, and potency from results of nonclinical testing and clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with CGMPs, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices, or GTPs, for the use of human cellular and tissue products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential FDA audit of the nonclinical and clinical study sites that generated the data in support of the BLA&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">payment of user fees for FDA review of the BLA (unless a fee waiver applies)&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA review and approval, or licensure, of the BLA. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate, including a gene therapy product, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical study sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. An IND is a request for authorization from the FDA to ship an unapproved, investigational product in interstate commerce and to administer it to humans, and must become effective before clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical study on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules had historically been subject to review by the Recombinant DNA Advisory Committee, or RAC, of the National Institutes of Health, or NIH, Office of Biotechnology Activities, or the OBA, pursuant to the NIH Guidelines for Research Involving Recombinant DNA Molecules, or NIH Guidelines. On August 17, 2018, the NIH issued a notice in the Federal Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH Guidelines to modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products, and requesting public comment on its proposed modifications. During the public comment period, which closed October 16, 2018, the NIH announced that it will no longer accept new human gene transfer protocols for review as a part of the protocol registration process or convene the RAC to review individual clinical protocols. In April 2019, NIH announced the updated guidelines, which reflect these proposed changes, and clarified that these trials will remain subject to the FDA&#8217;s oversight and other clinical trial regulations, and oversight at the local level will continue as set forth in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution.&#160;&#160;The FDA also may impose clinical holds on a biological product candidate at any time before or during clinical studies due to safety concerns or non-compliance. If the FDA imposes a clinical hold, studies may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such studies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical studies involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical study will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical studies must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent. Further, each clinical study must be reviewed and approved by an </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional Review Board, or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRB</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at or servicing each institution at which the clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers such items as whether the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical study subject or his or her legal representative and must monitor the clinical study until completed. Clinical research involving recombinant DNA that is subject to NIH guidelines also must be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical studies typically are conducted in three sequential phases that may overlap or be combined: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;1</span><span style="font-size:10pt;color:#000000;">. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;2</span><span style="font-size:10pt;color:#000000;">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;3</span><span style="font-size:10pt;color:#000000;">. Clinical studies are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for approval and product labeling. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval clinical studies, sometimes referred to as Phase&#160;4 clinical studies, may be conducted after initial marketing approval. These clinical studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. The FDA recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by ten years of annual queries, either in person or by questionnaire, of study subjects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. Annual progress reports detailing the results of the clinical studies must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or <span style="font-style:italic;">in vitro</span> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor, acting on its own or based on a recommendation from the sponsor&#8217;s data safety monitoring board may suspend a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human gene therapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the study period, the number of patients the FDA will require to be enrolled in the studies in order to establish the safety, efficacy, purity and potency of human gene therapy products, or that the data generated in these studies will be acceptable to the FDA to support marketing approval. The NIH has a publicly accessible database, the Genetic Modification Clinical Research Information System which includes information on gene transfer studies and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these studies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical studies, companies usually complete additional animal studies and also must develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with CGMP requirements. To help </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">educe the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical studies of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. In most cases, the submission of a BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification. This review typically takes twelve months from the date the BLA is submitted to the FDA because the FDA has approximately two months to make a &#8216;&#8216;filing&#8217;&#8217; decision. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with CGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS&#59; the FDA will not approve the BLA without a REMS, if required. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with CGMP requirements and adequate to assure consistent production of the product within required specifications. For a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with GTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical studies were conducted in compliance with IND study requirements and GCP requirements. To assure CGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a novel product (e.g., new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical studies are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical studies. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical studies, sometimes referred to as Phase&#160;4 clinical studies, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the European Union has similar, but not identical, benefits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including Fast Track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are intended for the treatment of serious or life-threatening diseases or conditions. These programs do not change the standards for approval but may expedite the development or approval process. To be eligible for fast track designation, new drugs and biological products must be intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. One benefit of fast track designation, for example, is that the FDA may consider for review sections of the marketing application for a product that has received Fast Track designation on a rolling basis before the complete application is submitted. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the breakthrough therapy program, products intended to treat a serious or life-threatening disease or condition may be eligible for the benefits of the Fast Track program when preliminary clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies. Additionally, FDA will seek to ensure the sponsor of a breakthrough therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#8217;s goal is to review an application in six months, compared to ten months for a standard review. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Regenerative Medicine Advanced Therapies Designation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the 21st Century Cures Act, enacted in December 2016, Congress amended the FD&#38;C Act to facilitate an efficient development program for, and expedite review of regenerative medicine advanced therapies, which include cell and gene therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products.&#160;Regenerative medicine advanced therapies do not include those human cells, tissues, and cellular and tissue based products regulated solely under section 361 of the Public Health Service Act and 21 CFR Part 1271.&#160;This program is intended to facilitate efficient development and expedite review of regenerative medicine therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and qualify for RMAT designation.&#160;A drug sponsor may request that the FDA designate a drug as a RMAT concurrently with or at any time after submission of an IND.&#160;The FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious or life-threatening disease or condition.&#160;A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites.&#160;Benefits of RMAT designation also include early interactions with the FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval.&#160;A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence from clinical studies, patient registries, or other sources of real world evidence, such as electronic health records&#59; the collection of larger confirmatory data sets&#59; or post-approval monitoring of all patients treated with such therapy prior to its approval. Like the FDA&#8217;s other expedited development programs, RMAT designation does not change the standards for approval but may expedite the development or approval process. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to CGMP. We will rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the CGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products, include reporting of CGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors or other stakeholders, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with CGMPs and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain CGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Patent Term Restoration and Marketing Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant BLA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods, including some regulatory exclusivity periods tied to patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA, signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHS Act attempts to minimize </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reference biological product is granted four and 12 year exclusivity periods from the time of first licensure of the product. FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Foreign Corrupt Practices Act </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Regulation outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a Clinical Trial Application, or CTA, must be submitted for each clinical trial to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and an IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, the corresponding clinical study may proceed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements and process governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical studies must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of an investigational product under European Union regulatory systems, we must submit a marketing authorization application. The application used to file the BLA in the United States is similar to that required in the European Union, with the exception of, among other things, region-specific document requirements. The European Union also provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic or biosimilar application. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be an innovative medicinal product, and products may not qualify for data exclusivity. Products receiving orphan designation in the European Union can receive ten years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. An orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the European Union are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment&#59; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The applicant consents to a second orphan medicinal product application&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The applicant cannot supply enough orphan medicinal product. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to FDA restrictions on the marketing of pharmaceutical products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our&#160;business or financial arrangements and relationships through which we market, sell and distribute the gene therapies for which we obtain approval. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act, or FCA. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. On December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to an order entered by the U.S. District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has been delayed to January 1, 2023. Further, implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters&#59; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services information related to payments or other transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April&#160;2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and&#160;foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines, imprisonment and/or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the federal False Claims Act as well as under the false claims laws of several states. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our arrangements with physicians and other healthcare providers, some of whom receive stock options as compensation for services provided, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our gene therapies outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may also adversely affect our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulators globally are also imposing greater monetary fines for privacy violations. For example, in 2016, the European Union adopted a new regulation governing data practices and privacy called the General Data Protection Regulation, or GDPR, which became effective on May&#160;25, 2018. Non-compliance with the GDPR may result in monetary penalties of up to &#8364;20&#160;million or 4% of worldwide revenue, whichever is higher. Notably, on January&#160;21, 2019, Google was fined almost $57&#160;million by French regulators for violating GDPR. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Data Collection </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection and use of personal health data in the European Union is governed by the provisions of the Data Protection Directive, and as of May&#160;25, 2018 the GDPR. The GDPR applies to any company established in the European Union as well as to those outside the European Union if they collect and use personal data in connection with the offering of goods or services to individuals in the European Union or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data breach notification requirements and onerous new obligations on services providers. Non-compliance with the GDPR may result in monetary penalties of up to &#8364;20&#160;million or 4% of worldwide revenue, whichever is higher. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of personal data, such as healthcare data or other sensitive information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions that we may operate in. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program&#59; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans&#59; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part D&#59; subjects drug manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs&#59; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research&#59; and established the Center for Medicare Innovation at Centers for Medicare &#38; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court and members of Congress have introduced several pieces of legislation aimed at significantly revising or repealing the ACA. The United States Supreme Court is expected to rule on a legal challenge to the constitutionality of the ACA in early 2021. The implementation of the ACA is ongoing, the law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Litigation and legislation related to the ACA are likely to continue, with unpredictable and uncertain results. In addition, the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015 led to aggregate reductions of Medicare payments to providers of up to 2%&#160;per fiscal year that will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic. Further, on January&#160;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in proposing and passing legislation and implementing regulations designed to control pharmaceutical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, on May&#160;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA -approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional foreign, federal and state healthcare reform measures will be adopted in the future, any of which could limit the amounts that foreign federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, if approved, or additional pricing pressures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any gene therapies for which we obtain regulatory approval. In the United States and markets in other countries, sales of any gene therapies for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a third-party payor not to cover our gene therapies could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, coverage and reimbursement for products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain and maintain coverage and reimbursement for any product, we may need to conduct expensive clinical trials in order to demonstrate the medical necessity and cost-effectiveness of such product, in addition to the costs required to obtain regulatory approvals. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Factors payors consider in determining reimbursement are based on whether the product is:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a covered benefit under its health plan&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">safe, effective and medically necessary&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">appropriate for the specific patient&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">cost-effective&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">neither experimental nor investigational.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had 121 full-time employees, 34 of whom have Ph.D. or M.D. degrees. Of these full-time employees, 88 employees are engaged in research and development activities and 33 employees are engaged in finance, legal, human resources, facilities and general management. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages. We consider our relationship with our employees to be good. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Website Access to Reports </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings at the SEC&#8217;s website at www.sec.gov. We also maintain a website at www.avrobio.com. You may access, free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item&#160;1A.<span style="font-weight:normal;"> </span>Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as our other filings with the Securities and Exchange Commission, or the SEC, before investing in our common stock. Any of the risk factors we describe below could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties were to occur, which may cause you to lose all or part of the money you paid to buy our common stock. Additional risks that are currently unknown to us or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See &#8220;Forward-Looking Information&#8221; in this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our business, financial position and need for additional capital </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred net losses. We incurred net losses of $119.7&#160;million and $73.0&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. We historically financed our operations primarily through private placements of our preferred stock and, more recently, our initial public offering and follow-on public offerings of our common stock, as well as sales of our common stock under our &#8220;at-the-market&#8221; facility. We have devoted substantially all of our efforts to research and development, including clinical and preclinical development of our product candidates, as well as assembling our team. We expect that it will be several years, if ever, before we have commercialized any product candidates. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if, and as, we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">continue our development of our product candidates, including continuing enrollment in our ongoing clinical trials, particularly if and as we commence and continue clinical-stage activities for our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiate additional clinical trials, including the planned investigator-sponsored clinical trial of AVR-RD-05, and preclinical studies for our current and future product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">experience delays or interruptions in preclinical studies, clinical trials, or our supply chain due to the COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek to identify and develop or in-license additional product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek marketing approvals for our product candidates that successfully complete clinical trials, if any&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">continue our implementation of our plato platform as we seek to industrialize our <span style="font-style:italic;">ex vivo</span> lentiviral gene therapy approach into a robust, scalable and, if approved, commercially viable process&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">hire and retain additional personnel, such as clinical, quality control, commercial and scientific personnel&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expand our office space, infrastructure and facilities to accommodate our growing employee base, including adding equipment and physical infrastructure to support our research and development&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">continue to incur additional public company-related costs. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential. This will require us to be successful in a range of challenging activities, and our expenses will increase substantially as we seek to complete preclinical and clinical trials of our product candidates, and manufacture, market and sell these or any future product candidates for which we may obtain marketing approval, if any, and satisfy any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our Company also could cause you to lose all or part of your investment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never generated revenue from product sales and do not expect to do so for the next several years, if ever. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenues from product sales for the next several years, if ever. Our ability to generate future revenues from product sales depends heavily on our, or our collaborators&#8217;, success in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">completing research and preclinical and clinical development of our product candidates and identifying new lentiviral-based gene therapy product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seeking and obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">launching and commercializing product candidates for which we obtain regulatory and marketing approval by establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">qualifying for adequate coverage and reimbursement by government and third-party payors for our product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing and maintaining supply and manufacturing processes and relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for our product candidates, if approved&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining market acceptance of our product candidates, if approved, as a viable treatment option&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">addressing any competing technological and market developments&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">attracting, hiring and retaining qualified personnel. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or other foreign regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash and cash equivalents of $259.7&#160;million. We believe that our existing cash and cash equivalents as of December&#160;31, 2020 will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2023. <span style="Background-color:#FFFFFF;color:#000000;">This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses could prove to be significantly higher than we currently anticipate.&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate further clinical trials of and seek marketing approval for, our product candidates and continue to enhance and optimize our vector technology and manufacturing processes. For example, <span style="Background-color:#FFFFFF;color:#000000;">as part of our registration strategy for AVR-RD-01, we are evaluating expanding our clinical development program in support of optimizing the potential for a broad label. Such expansion, if implemented, could require significant additional development costs for AVR-RD-01.</span> Furthermore, we have expanded the number of programs in our pipeline to a total of six investigational gene therapies, three of which are in clinical development. As a result, further development of these programs will require us to expend significant resources to advance these candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital when needed or on reasonable terms, we would be forced to delay, reduce or eliminate certain of our research and development programs.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of drug discovery, laboratory testing, preclinical development and clinical trials for our other product candidates, including the extent of any impacts from the COVID-19 pandemic on these activities&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs, timing and outcome of regulatory review of our product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs associated with our manufacturing process development and evaluation of third-party manufacturers&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms of our current and any future license agreements and collaborations&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we acquire or in-license other product candidates, technologies and intellectual property. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, will be derived from or based on sales of products that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or cause us to relinquish valuable rights. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity, convertible debt securities or other equity-based derivative securities, your ownership interest will be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Any additional indebtedness we incur would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline and existing stockholders may not agree with our financing plans or the terms of such financings. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, or our product candidates, or grant licenses on terms unfavorable to us. Adequate additional financing may not be available to us on acceptable terms, or at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage company founded in November 2015. Our operations to date have been limited to corporate organization, recruiting key personnel, business planning, raising capital, acquiring rights to our technology, identifying potential product candidates, undertaking preclinical studies and planning and supporting clinical trials of certain of our product candidates and establishing research and development and manufacturing capabilities. We have not yet demonstrated the ability to complete clinical trials of our product candidates, obtain marketing approvals, manufacture products on a clinical or commercial scale or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. In addition, as an early-stage company, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the discovery and development of our product candidates </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business interruptions resulting from the coronavirus disease (COVID-19) pandemic or similar public health crises have caused and may continue to cause a disruption of the development of our product candidates and adversely impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease, or COVID-19, was reported to have surfaced in Wuhan, China and subsequently spread across the world. The COVID-19 pandemic has led to the implementation of various responses, including government-imposed quarantines and stay-at-home orders, business closures, border closures and travel restrictions, cancellations of public gatherings, and other public health safety measures. These measures continue to disrupt normal business operations both in and outside of affected areas and have had significant negative impacts on businesses and financial markets worldwide.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to monitor our operations and applicable government recommendations and have implemented a work-from-home policy for most employees, excluding our laboratory staff and a limited number of non-laboratory employees. Notwithstanding these measures, the COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties on which we rely. If members of our management and other key personnel are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. We may experience limitations in employee resources, including because of sickness of employees or their families or the desire of employees to avoid contact with individuals or large groups of people.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, clinical trial activities, including patient enrollment and data collection, are dependent upon global clinical trial sites which have been and continue to be adversely affected by the COVID-19 pandemic. For example, as the global healthcare community responded to the fluctuations in COVID-19 cases and hospitalizations, many hospitals, including our clinical sites, temporarily paused elective procedures, which included dosing of new patients with our investigational gene therapies. <span style="Background-color:#FFFFFF;color:#000000;">While dosing of new patients has begun to resume, our ability to continue clinical activities without further delay or interruption will depend on future developments that are highly uncertain and cannot be accurately predicted</span>. Additionally, while ongoing data collection has continued for our patients that have been dosed, certain data collection has been delayed and additional delays could result from COVID-19-related interruptions. We are currently conducting clinical trials for our product candidates in the United States, Canada and Australia, and plan to expand to other geographies including Japan, Europe and Israel, and each of these regions are currently being affected by COVID-19. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional factors from the COVID-19 pandemic that have delayed and may continue to delay or otherwise adversely affect enrollment in or the progress of the clinical trials of our product candidates, as well as our business generally, include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">limitations on travel that could interrupt key trial activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that may impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, any of which could delay or adversely impact the conduct or progress of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or those of third party service providers, contractors, or suppliers on whom we rely,</span><span style="color:#000000;"> </span><span style="font-size:10pt;color:#000000;">impair the productivity of our personnel, subject us to additional cybersecurity risks, create data accessibility problems, cause us to become more susceptible to communication disruptions, or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">business disruptions involving our third parties on whom we rely, including CROs and other collaborators for the conduct of our clinical trials or our third party suppliers or manufacturers, which could impact their ability to perform adequately or disrupt our supply chain&#59; and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in hospital or research institution policies or government regulations, which could delay or adversely impact our ability to conduct our clinical trials.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, three vaccines for COVID-19 were granted Emergency Use Authorization by the FDA in late 2020 and early 2021, and more are likely to be authorized in the coming months.&#160;The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other factors arising from the COVID-19 pandemic could worsen and further adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results. The extent to which the COVID-19 pandemic impacts our operations or those of our third party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, the efficacy and safety of vaccines, the ability of third parties to manufacture and distribute vaccines, new information that may emerge concerning mutations of the coronavirus, and the actions to contain or mitigate the coronavirus or treat its impact, among others.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our lentiviral-based gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our research and development efforts on our lentiviral-based gene therapy approach, and our future success depends on our successful development of viable gene therapy product candidates. There can be no assurance that we will not experience problems or delays in developing new product candidates and that such problems or delays will not cause unanticipated costs, or that any such development problems can be solved. For example, timely enrollment in our clinical trials is dependent upon global clinical trial sites which have been and may continue to be adversely affected by the COVID-19 pandemic. In addition, the implementation of our plato platform and upgrades, including our transition to TCI conditioning using busulfan for our single-agent conditioning regimen, may result in delays or setbacks in our research and development activities, and we may not realize the intended benefits of these efforts. In addition, we may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. For example, as of March 1, 2021 we have only dosed three patients using our plato platform, which we plan to utilize for the majority of patients in our ongoing FAB-GT clinical trial for AVR-RD-01 and all patients in the Guard1 clinical trial of AVR-RD-02. Our implementation of the LV2 lentiviral vector or of our cell processing to an industrialized, automated closed system using disposable supplies may not be successful or may experience unforeseen delays, which may cause shortages or delays in the supply of our products available for clinical trials and future commercial sales, if any, or impair our research and development efforts, including those in our ongoing and future clinical trials. In addition, there is no assurance that products using our proprietary LV2 lentiviral vector or manufactured using this automated system will ultimately achieve the same favorable preliminary results observed to date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the clinical trial requirements of the FDA and other foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied product candidates. To date, only a limited number of gene therapies have received marketing authorization from the FDA or foreign regulatory authorities. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, Canada or other major markets or how long it will take to commercialize our product candidates, if any are approved. Approvals by foreign regulatory authorities may not be indicative of what the FDA may require for approval, and vice versa. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise the CBER in its review. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the United States National Institutes of Health, or NIH, also are subject to the NIH Guidelines, under which supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before initiation of a clinical trial.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If we were to engage an NIH-funded institution to conduct a clinical trial, that institution&#8217;s IBC as well as its institutional review board, or IRB, would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. Similarly, foreign </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory authorities may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA, NIH and the European Medicines Agency, or EMA, have each expressed interest in further regulating biotechnology, including gene therapy and genetic testing. For example, the EMA advocates a risk-based approach to the development of a gene therapy product. Agencies at both the federal and state level in the United States, as well as the U.S. congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of certain of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be materially and adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA continues to develop its approach to assessing gene and cell therapy products. For example, the agency has released a series of draft and final guidance documents relating to, among other topics, various aspects of gene therapy product development, review, and approval, including aspects relating to clinical and manufacturing issues related to gene therapy products. In January 2020, the FDA released a final guidance with recommendations for long-term follow-up studies of patients following human gene therapy administration due to the increased risk of undesirable and unpredictable outcomes with gene therapies that may present as delayed adverse events. We cannot be certain whether such guidance, or other guidance that the FDA may issue, will be relevant to or have an adversely impact on our gene therapy candidates or the duration or expense of any applicable regulatory development and review processes. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates and the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the conduct of clinical trials, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. It is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of our product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by patients. Gene therapies are also subject to the potential risk that occurrence of adverse events will be delayed following administration of the gene therapy due to persistent biological activity of the genetic material or other components of the vectors used to carry the genetic material. Many times, side effects are only detectable after investigational products are tested in larger scale, pivotal clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. FDA guidance advises that patients treated with gene therapies undergo long-term follow-up observation for potential adverse events for as long as 15 years. If additional clinical or long-term follow-up experience indicates that any of our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked or limited. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been several significant adverse side effects in gene therapy treatments in the past, including multiple reported cases of leukemia, myelodysplastic syndrome and death seen in other clinical trials. For example, in February 2021 a case of potential myelodysplastic syndrome and a separate case of acute myeloid leukemia were reported in a third party&#8217;s clinical trials of lentiviral gene therapy for the treatment of sickle cell disease. These safety events are currently under investigation, and while several factors have been posited as potential direct or contributing causes, including the use of busulfan in the conditioning process, no definitive conclusion has been made as of the date of this Annual Report on Form 10-K. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Possible adverse side effects that may occur with treatment with gene therapy products include an immunologic reaction early after administration that could substantially limit the effectiveness of the treatment or represent safety risks for patients. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Another traditional safety concern for gene therapies using viral vectors has been the possibility of insertional </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oncogenesis</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by the vectors, leading to malignant transformation of transduced cells. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, d</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ominant clonal expansion due to vector integration has been observed in third-part</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-style:italic;">ex vivo</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> lentiviral gene therapy clinical trials, including one case of thalassemia </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and two cases of cerebral adrenoleukodystrophy. Although to date there have been no reports of malignant transformation in these patients, these cases and any similar cases will require further monitoring and follow-up.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our lentiviral gene therapy approach is designed to avoid immunogenicity against the vector after administration, there can be no assurance that patients would not create antibodies that may impair treatment. In addition, although w</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e are investigating a plan to potentially </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">implement</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> molecular</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cytogenetic screening</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, there can be no assurance that we will successfully implement such screening procedures or that, if implemented, they will enhance the safety </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profile </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our gene therapy product candidates. If any of our gene therapy product candidates demonstrates adverse side effects at unacceptable rates or degrees of severity, we may decide or be required to halt or delay clinical development of such product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to side effects caused by our product candidates, the conditioning, administration process or related procedures, which we evaluate from time to time as part of our process improvement and optimization efforts, also can cause adverse side effects. A gene therapy patient is generally administered one or more myeloablative drugs to remove stem cells from the bone marrow to create sufficient space in the bone marrow for the modified gene-corrected stem cells to engraft and produce their progeny. This procedure causes adverse side effects and transiently compromises the patient&#8217;s immune system, known as neutropenia, and ability to form blood clots, known as thrombocytopenia. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019 we began transitioning, in connection with our Company-sponsored clinical trials, towards a new conditioning regimen for our product candidates utilizing busulfan as the myeloablative conditioning agent instead of the melphalan that we previously used. The use of this conditioning regimen is designed to utilize a precision dosing program, TCI, to achieve a balance between the removal of a sufficient amount of bone marrow cells from a patient against potential risks such as toxicity or graft failure. While we believe that the conditioning regimen could be performed during a limited hospital stay, we cannot guarantee that the conditioning will not require a lengthier hospitalization. Our conditioning regimens may not be successful or may nevertheless result in adverse side effects. For example, in each of our ongoing clinical trials several adverse events, including suppression of neutrophils and platelet counts following the conditioning process, were observed. While such adverse events in connection with conditioning is expected, if in the future any such adverse events caused by the conditioning process or related procedures continue at unacceptable rates or degrees of severity, the FDA or other foreign regulatory authorities could order us to cease development of, or deny approval of, our product candidates for any or all targeted indications. There have been cases of therapy-related myelodysplastic syndrome, a type of blood disorder that is a potential precursor to acute myeloid leukemia, in patients with preexisting cancer where busulfan treatment was posited to be a contributing factor to this secondary malignancy. Although we are investigating a plan to potentially implement molecular cytogenetic screening as an additional risk reduction measure, there can be no guarantees that these procedures, if implemented, would be successful. Even if we are able to demonstrate that adverse events are not product-related, such occurrences could adversely affect patient recruitment or the ability of enrolled patients to complete the clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, and restrictions on how or where the product can be distributed, dispensed or used. Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several potentially significant negative consequences could result, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may suspend or withdraw approvals of such product candidate&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may require additional or boxed warnings on the label&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be required to change the way a product candidate is distributed, dispensed, or administered or conduct additional clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we could be sued and held liable for harm caused to patients&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our reputation may suffer. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates, lead to a drop in our stock price, and significantly harm our business, prospects, financial condition and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never completed a pivotal clinical trial, and may be unable to do so for any product candidates we may develop. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are at an early stage of development for all of our product candidates. As of March&#160;1, 2021, we have dosed only 14 patients across four ongoing clinical trials. These ongoing clinical trials, as well as potentially additional pivotal clinical trials, must be completed in order to obtain FDA approval to market these product candidates. We have limited experience in preparing, submitting and prosecuting regulatory filings, and have not previously submitted a biologics license application, or BLA, for any product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying out later-stage clinical trials is a complicated and lengthy process, and we do not expect that all data from patients participating in the clinical trials will be relevant or meaningful. For example, the primary efficacy endpoint of our Phase 2 clinical trial of AVR-RD-01, which we refer to as the FAB-GT clinical trial, is the change, from baseline to one year post-treatment with AVR-RD-01, in the average number of Gb3 inclusions per PTC, as measured in a patient kidney biopsy. The second patient in the FAB-GT trial has an N215S genotype, which is associated with a late-onset cardiac variant phenotype and lower plasma lyso-Gb3 levels. This patient&#8217;s cardiac variant phenotype does not typically result in Gb3 accumulation in the kidney and skin, and accordingly we do not expect that data obtained from this patient will have a meaningful impact on certain efficacy endpoints in our FAB-GT clinical trial, including kidney and skin biopsies. Nonetheless, there may be other important insights derived from data collected from this patient in the FAB-GT clinical trial. In addition, although a kidney biopsy was performed on the third patient in the FAB-GT clinical trial, as a result of human error in processing the biopsy sample at the external laboratory vendor, the kidney Gb3 inclusions could not be evaluated and will not be available. However, we expect to continue collecting other data from the third patient, including measures of kidney function such as estimated glomerular filtration rate and measured glomerular filtration rate.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have not yet conducted any company-sponsored clinical trials of any of our product candidates in the United States, and our interactions with the FDA have generally been limited. We cannot be certain how many additional clinical trials of AVR-RD-01, AVR-RD-04, AVR-RD-02 or any other product candidates will be required or how such trials should be designed. In order to commence a clinical trial in the United States, we are required to seek FDA acceptance of an IND for each of our product candidates. We cannot be sure any IND we submit to the FDA, or any similar clinical trial application we submit in other countries, will be accepted. While we have received clearance from the FDA to commence clinical testing in the United States for AVR-RD-01 and AVR-RD-02, and the sponsor of the investigator-led clinical trial for AVR-RD-04 has received the same, there can be no assurance that we will be able to submit and secure similar clearances for any of our other product candidates. We may also be required to conduct additional preclinical testing prior to filing an IND for any of our product candidates, and the results of any such testing may not be positive. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to a BLA submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing Phase 1 clinical trial of AVR-RD-01 is an investigator-sponsored trial being conducted by University Health Network, and the ongoing Phase 1/2 clinical trial of AVR-RD-04 is also an investigator-sponsored clinical trial, which is being conducted by our collaborators at the University of California, San Diego. In addition, the planned Phase 1/2 clinical trial of AVR-RD-05 will be an investigator-sponsored trial conducted by our collaborators at The University of Manchester. We do not control the design or administration of investigator-sponsored trials, nor the submission or approval of any IND or foreign equivalent required to conduct these trials, and the investigator-sponsored trials could, depending on the actions of such third parties, jeopardize the validity of the clinical data generated, identify significant concerns with respect to our product candidates that could impact our findings or clinical trials, and adversely affect our ability to obtain marketing approval from the FDA or other applicable regulatory authorities. To the extent the results of this or other investigator-sponsored trials are inconsistent with, or different from, the results of our planned Company-sponsored trials or raise concerns regarding our product candidates, the FDA or a foreign regulatory authority may question the results of the Company-sponsored trial, or subject such results to greater scrutiny than it otherwise would. In these circumstances, the FDA or such foreign regulatory authorities may require us to obtain and submit additional clinical data, which could delay clinical development or marketing approval of our product candidates. In addition, while investigator-sponsored trials could be useful to inform our own clinical development efforts, there is no guarantee that we will be able to use the data from these trials to form the basis for regulatory approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from preclinical studies or early clinical trials are not necessarily predictive of future clinical trial results and are not necessarily indicative of final results. For example, there can be no assurance that prior results, such as signals of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety, activity or durability of effect, observed from preclinical studies or clinical trials will be replicated or will continue in ongoing or future studies or trials. Furthermore, preliminary results may not be indicative of the final results of a trial after all data have been collected and analyzed. There is a high failure rate for gene therapy and biologic product candidates proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and clinical activities are subject to varying interpretations, which may delay, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit or prevent regulatory approval. In addition, the design of a pivotal clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanc</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed. Our </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompany has limited experience in designing and conducting clinical trials and we may be unable to design and execute a clinical trial to support regulatory approval. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we plan to meet with the FDA in the first quarter of 2021 to discuss our regulatory strategy</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and a potential accelerated approval pathway</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for AVR-RD-01, to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">date we have not received definitive guidance from the FDA or other foreign regulatory bodies regarding the necessary endpoints for approval of any of our product candidates. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we are aware that the FDA utilized an efficacy endpoint based on patients&#8217; kidney biopsy in the recent approval of Migalastat for Fabry disease, for which we are also measuring as our primary efficacy endpoint in our ongoing Phase 2 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FAB-GT </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical trial of AVR-RD-01, there can be no guarantees that regulatory agencies will permit us to use the same endpoint in connection with further development of AVR-RD-01. Therefore, there</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are no assurances that the FDA or other foreign regulatory bodies will find the efficacy endpoints we propose in future pivotal trials to be sufficiently validated and clinically meaningful, or that our product candidates will achieve the pre-specified endpoints in future pivotal trials to a degree of statistical significance. We also may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any of our </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current or future</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies. Any such failure would cause us to abandon the product candidate.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the clinical trials performed to date have been open-label studies and have been conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware that patients have received treatment and may interpret the information more favorably given this knowledge. Because our clinical trials are ongoing, the data that we report are preliminary and subject to change. As is typical in open-label studies in which interim reports are provided, the safety and efficacy data are regularly reviewed and validated. As a result, certain data may change over time, including reductions or increases in the number of reported safety events, until the database is locked at the end of the study.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we hope to have dosed an aggregate of 30 patients across all our clinical programs by the end of 2021, there can be no assurance we will achieve that goal. The timing and success of our patient enrollment and clinical trial activities depend on our ability to recruit patients to participate as well as the completion of required follow-up periods. Patients may be unwilling to participate in our gene therapy clinical trials because of negative publicity from adverse events related to the biotechnology or gene therapy fields, such as the recent announcement from a lentiviral gene therapy company regarding potential cases of myelodysplastic syndrome and acute myeloid leukemia in its clinical trials for sickle cell disease, competitive clinical trials for similar patient populations, clinical trials in product candidates employing our vectors, the existence of current treatments or for other reasons. In addition, the indications that we are currently targeting and may in the future target are rare diseases, which may limit the pool of patients that may be enrolled in our ongoing or planned clinical trials. The timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed, including as a result of the ongoing COVID-19 pandemic, which could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether. For example, as a result of the COVID-19 pandemic, patient enrollment and dosing was temporarily paused in our ongoing clinical trials and certain data collection has been delayed. While patient enrollment and dosing activities have begun to resume, there could be additional pauses in the future as a result of the COVID-19 pandemic or other factors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in 2017, the ongoing investigator-sponsored Phase 1 clinical trial of AVR-RD-01 encountered delays in the enrollment of patients due to delays in identifying patients for enrollment and the evaluation of information from screened potential trial participants. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we encountered delays in the enrollment of patients in the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompany-sponsored Phase 1/2 clinical trial of AVR-RD-02 for Gaucher disease</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which we refer to as the Guard1 clinical trial</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. While a number of patients had been identified</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guard1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trial</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we encountered patient pre-screening failures that impacted the commencement of enrollment. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment and trial completion is affected by factors including the: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ability to enroll patients and conduct studies as a result of the ongoing COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">size of the patient population and process for identifying patients&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">design of the trial protocol&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">eligibility and exclusion criteria&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">perceived risks and benefits of the product candidate under study&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">perceived risks and benefits of gene therapy-based approaches to treatment of diseases, including any required pretreatment conditioning regimens&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">availability of competing therapies and clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">severity of the disease under investigation&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">availability of genetic testing for potential patients&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">proximity and availability of clinical trial sites for prospective patients&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ability to obtain and maintain subject consent&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">risk that enrolled patients will drop out before completion of the trial&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">patient referral practices of physicians&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ability to monitor patients adequately during and after treatment. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are expanding our patient enrollment activities to include patients who reside in a country other than the country where the applicable clinical site is located, and who are required to travel for some or all of the clinical testing and procedures required for patients in the applicable clinical trial. We have encountered and in the future may continue to encounter logistical and regulatory challenges that could delay or prevent any such international patients from successfully enrolling and completing clinical trial procedures, including delays in processing or obtaining patient travel visas or denials of entry at borders, potential travel disruptions, or de-prioritization or unavailability of resources at clinical sites for non-resident international clinical trial participants, any of which could delay our progress and completion of planned clinical trials and which would have an adverse effect on our business. In addition, once these international patients return to their home country they may need to travel back to the country where the applicable clinical site is located. If these patients are unwilling or unable to return to the clinical site for testing and procedures, progress and completion of the clinical trial could be delayed or prevented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current product candidates are being developed to treat rare conditions. We plan to seek initial marketing approvals in the United States, Europe and certain other major markets, including Japan. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by FDA or other foreign regulatory authorities. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">difficulty in establishing or managing relationships with contract research organizations, or CROs, and physicians&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">different standards for the conduct of clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the absence in some countries of established groups with sufficient regulatory expertise for review of gene therapy protocols&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our inability to locate qualified local consultants, physicians and partners&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays as a result of the ongoing COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in reaching a consensus with regulatory agencies on study design&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in reaching agreement on acceptable terms with prospective CROs and clinical study sites&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical study site&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in recruiting suitable patients to participate in our clinical studies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">imposition of a clinical hold by regulatory agencies, after an inspection of our clinical study operations or study sites&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure by our CROs, other third parties or us to adhere to clinical study requirements&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure to perform in accordance with the FDA&#8217;s good clinical practices, or GCP, or applicable regulatory guidelines in other countries&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in having patients complete participation in a study or return for post-treatment follow-up&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinical study sites or patients dropping out of a study&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits&#59; or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues. In addition, if we make changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions, which could delay our clinical development plan or marketing approval for our product candidates. For example, for our FAB-GT clinical trial of AVR-RD-01, we have transitioned our lentiviral vectors to an LV2 version in connection with our plato platform implementation. In addition, the transition from LV1 to LV2 has required (and is anticipated to continue to require) submission of relevant data to the applicable regulatory authorities in connection with certain of our regulatory filings, including our INDs and clinical trial applications, to demonstrate analytic comparability between LV1 and LV2. Our IND application for our FAB-GT clinical study of AVR-RD-01 for Fabry disease in the United States, which was cleared by the FDA in April 2019, included data to demonstrate comparability between LV1 and LV2 and a transition to an automated manufacturing platform. In addition, our CTA (including amendments) and IND for our Guard1 clinical study of AVR-RD-02 for Gaucher disease in Canada and the United States, for which Health Canada has issued no objection letters and the FDA has cleared, respectively, included data utilizing LV2 and our automated manufacturing platform. While these applications included data relating to our LV2 lentiviral vector and our automated manufacturing process, which are elements of our plato platform, and allow us to commence clinical trials incorporating such elements, there can be no assurance that the FDA, Health Canada or other regulatory authorities will not require us to undertake additional actions in connection with our transition to our plato platform, including submission of additional comparability studies in connection with future regulatory filings, which may result in delays, suspension or termination of ongoing or future clinical trials, or our inability to conduct our trials according </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the plans or the timelines that we have envisioned. For example, the Phase 1/2 investigator-sponsored clinical study of AVR-RD-04 for cystinosis in the United States, which has been cleared by the FDA, does not include our LV2 lentiviral vector or our automated manufacturing platform, and we anticipate that we will be required to submit comparability data in future regulatory filings relating to our transition to LV2 and the automated manufacturing platform. Any such filings may result in delay, suspension or termination of ongoing or future clinical trials pending our submission, and the applicable </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory agency&#8217;s review, of such updates. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the results of our clinical studies are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be delayed in obtaining marketing approval for our product candidates, if at all&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain approval for indications or patient populations that are not as broad as intended or desired&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be subject to changes with the way the product is administered&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be required to perform additional clinical studies to support approval or be subject to additional post-marketing testing requirements&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a REMS&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be subject to the addition of labeling statements, such as warnings or contraindications&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be sued&#59;&#160;or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">experience damage to our reputation. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we complete the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical studies, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. If we are unable to obtain necessary regulatory approvals, our business, prospects, financial condition and results of operations may suffer. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Only certain of our clinical trials, including&#160;the Phase 2 FAB-GT&#160;clinical trial of AVR-RD-01&#160;for Fabry disease and the Phase 1/2 Guard1 clinical trial of AVR-RD-02 for Gaucher disease type 1, utilize our commercial-scale plato platform. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have submitted and intend to continue to submit comparability studies to the FDA and other regulatory agencies, as needed, with respect to our implementation of our commercial-scale plato platform in these and future clinical trials sponsored by us, there can be no assurance that the FDA or other regulatory agencies will not in the future require us to conduct additional preclinical studies or clinical trials that could result in delays and additional costs in our development or commercialization programs for our product candidates, which could adversely affect our business. We intend to continue implementing our commercial-scale plato platform, including heightened vector efficiency, our closed, automated manufacturing system and utilization of a TCI conditioning regimen with busulfan, in connection with each of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigational product candidates. We </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have developed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the plato platform to form the backbone of our commercial programs, with the intent of replacing our original academic platform with improved solutions for delivering our gene therapy candidates to patients in multiple disease indications. We believe improvements from our plato platform may lead to better patient outcomes with our gene therapy candidates. In order to implement this transition, we have been and will be required to conduct additional studies to bridge our modified product candidates to earlier versions, which could delay our clinical </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development plans or marketing approvals, if any. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face significant competition in our industry and there can be no assurance that our product candidates, if approved, will achieve acceptance in the market over existing established therapies. In addition, our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our ability to successfully market or commercialize any of our product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate in a highly competitive segment of the biopharmaceutical market. We face competition from many different sources, including larger pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies, some of which are being marketed by large and international companies. In addition, we expect to compete with new treatments that are under development or may be advanced into the clinic by our competitors. There are a variety of product candidates, including gene therapies, in development for the indications that we are targeting. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate competing with the largest pharmaceutical companies in the world. For example, Sanofi Genzyme and Shire, acquired by Takeda Pharmaceutical Company Ltd., market the enzyme replacement therapies, or ERTs, that represent the standard of care for Fabry patients. Amicus has secured regulatory approval in the United States and Europe for Migalastat, its oral chaperone therapy for Fabry disease. In addition, in August 2020, Protalix BioTherapeutics, together with Chiesi Global Rare Diseases, announced that the FDA had accepted a BLA and granted priority review designation for pegunigalsidase alfa, their investigational product candidate for Fabry disease. For Gaucher disease, we expect to compete with existing enzyme replacement therapies marketed by Sanofi Genzyme, Shire, Protalix and Pfizer, as well as oral therapies marketed by Actelion and Sanofi. Sanofi also markets an enzyme replacement therapy for Pompe disease, and Shire markets an enzyme replacement therapy for Hunter syndrome. Cystinosis is currently treated by therapies marketed by Horizon Orphan, Mylan, Chiesi, Recordati and Sigma Tau Pharmaceuticals, and Eloxx Pharmaceuticals has been advancing a new treatment in clinical trials, though in March 2020 it announced that its Phase 2 study of the new treatment has been discontinued. In addition, we may compete with other gene therapy companies in our industry such as bluebird bio and Spark Therapeutics (which was acquired by Roche in 2019). In particular, a number of gene therapy companies have announced preclinical or clinical non-viral and adeno-associated viral based gene therapy programs that, if successful in obtaining regulatory approval, could compete with our gene therapies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial, product candidate development, manufacturing and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and mergers and acquisitions within these industries may result in even more resources being concentrated among a smaller number of larger competitors. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our business would be materially and adversely affected if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, have broader market acceptance, are more convenient or are less expensive than any product candidate that we may develop. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">While we intend to seek designations for our product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for any of our product candidates. In addition, while such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for one or more of our product candidates, there can be no assurance that we will realize their intended benefits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we have submitted a briefing book to the FDA outlining our proposal for a potential accelerated approval strategy for&#160;AVR-RD-01, and we currently expect to meet with the FDA in the first quarter of 2021 to discuss our proposed strategy. The outcome of our meeting with the FDA is highly uncertain at this time, and there can be no assurances that the FDA will agree to our proposals or provide any accelerated regulatory pathway for AVR-RD-01.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy Designation for some of our product candidates. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA are also eligible for accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may seek Fast Track Designation for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track Designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may seek a regenerative medicine advanced therapy, or RMAT, designation for some of our product candidates. An RMAT is defined as cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a regenerative medicine therapy. The RMAT program is intended to facilitate efficient development and expedite review of RMATs, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A new drug application or a BLA for an RMAT may be eligible for priority review or accelerated approval through (1)&#160;surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2)&#160;reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence, such as electronic health records&#59; the collection of larger confirmatory data sets&#59; or post-approval monitoring of all patients treated with such therapy prior to its approval. RMAT designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a regenerative medicine advanced therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of RMAT designation for a product candidate may not result in a faster development process, review or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify for RMAT designation, the FDA may later decide that the biological products no longer meet the conditions for qualification. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside of the United States, we intend to develop AVR-RD-01 in Japan under the purview of the Japanese Pharmaceutical and Medical Device Agency, or PMDA. Pursuant to Japan&#8217;s regenerative medicine law, an expedited path to conditional approval may exist for regenerative medicine products that show sufficient safety evidence and signals of efficacy in a Phase 2 clinical trial. However, there can be no assurance that the results of our ongoing Phase 2 FAB-GT clinical trial will demonstrate the safety evidence and efficacy signals required for such conditional approval. In addition, this conditional approval is time-limited, and there must be an agreement as to follow-up collection of information to confirm efficacy and safety, similar to a post-marketing commitment in the United States.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to obtain orphan drug designation for our product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the United States and other major markets, may designate drugs intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than 5 in 10,000 persons in the European Union. Additionally, orphan designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biologic product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, October 2019 and March 2020, the FDA granted our requests for orphan drug designation for AVR-RD-01 for the treatment of Fabry disease, AVR-RD-02 for the treatment of Gaucher disease and AVR-RD-04 for the treatment of cystinosis, respectively. <span style="Background-color:#FFFFFF;color:#000000;">In September 2020, October 2020 and March 2021 we announced that the European Commission granted our request for orphan drug designation for AVR-RD-02 for the treatment of Gaucher disease, AVR-RD-01 for the treatment of Fabry disease, and AVR-RD-04 for the treatment of cystinosis, respectively. If we request orphan drug designation (or the foreign equivalent) for any other product candidates, there can be no assurances that the FDA or foreign regulatory authorities will grant any of our product candidates such designation. Additionally, the designation of any of our product candidates as an orphan product does not mean that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or foreign regulatory authorities from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and 10 years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition in the United States. Even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">makes a major contribution to patient care. In the European Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application&#59; or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain any regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our product candidates also may be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. FDA guidance advises that patients treated with gene therapies undergo long-term follow-up observation for potential adverse events for as long as 15 years. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or CGMP, requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory authority may: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">issue a warning letter asserting that we are in violation of the law&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek an injunction or impose administrative, civil or criminal penalties or monetary fines&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">suspend or withdraw regulatory approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">suspend any ongoing clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrict the marketing or manufacturing of the product&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seize or detain the product or otherwise require the withdrawal of the product from the market&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refuse to permit the import or export of products&#59; or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refuse to allow us to enter into supply contracts, including government contracts. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition, results of operations and prospects. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our focus on developing our current product candidates may not yield any commercially viable products, and our failure to successfully identify and develop additional product candidates could impair our ability to grow. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our growth strategy, we intend to identify, develop and market additional product candidates beyond our existing product candidates. We may spend several years completing our development of any particular current or future product candidates, and failure can occur at any stage. The product candidates to which we allocate our resources may not end up being successful. Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential than our product candidates. Our spending on current and future research and development programs may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaborations, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. If any of these events occur, we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our internal research capabilities are limited, we may be dependent upon biotechnology companies, academic scientists and other researchers to sell or license product candidates, approved products or the underlying technology to us. The success of this strategy depends partly upon our ability to identify, select, discover and acquire promising product candidates and products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain of our current or future product candidates may not demonstrate in patients any or all of the pharmacological benefits we believe they may possess or compare favorably to existing, approved therapies, such as ERT. We have not yet succeeded and may never succeed in demonstrating efficacy and safety of our product candidates or any future product candidates in clinical trials or in obtaining marketing approval thereafter. Accordingly, our focus on treating these diseases may not result in the development of commercially viable products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in our development efforts, we may not be able to advance the development of our product candidates, commercialize products, raise capital, expand our business or continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to manufacturing</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs or otherwise adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process we use to produce our product candidates is complex, novel and has not been validated for commercial use. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we and our manufacturing suppliers employ multiple steps to control the manufacturing process with the goal of ensuring that the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, including even minor deviations from the intended process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA or other applicable regulatory standards or specifications with consistent and acceptable production yields and costs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA and other foreign regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other foreign regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Even slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. There is no assurance we will not experience lot failures in the future. Lot failures or product recalls could cause us to delay clinical trials, or, if approved, commercial product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our reliance on third parties</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to rely on third parties to conduct some or all aspects of our vector production, product manufacturing, protocol development, research and preclinical and clinical testing, and these third parties may not perform satisfactorily. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect to independently conduct all aspects of our vector production, product manufacturing, protocol development, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to these items. For example, we have moved our cell processing to an automated, closed system with a single third-party supplier. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our preclinical and clinical studies are conducted in accordance with the study plan, protocols and regulatory requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our contract counterparties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical and clinical studies required to support approval of our product candidates or the FDA or other regulatory agencies may refuse to accept our clinical or preclinical data. For example, in 2017, the ongoing investigator-sponsored Phase 1 clinical trial of AVR-RD-01 encountered delays in the enrollment of patients due to delays in identifying patients for enrollment and the evaluation of information from screened potential trial participants. In 2019, we encountered delays in the enrollment of patients in the Company-sponsored Guard1 clinical trial of AVR-RD-02 for Gaucher disease. While a number of interested patients had been identified for the Guard1 clinical trial, we encountered patient pre-screening failures that impacted the commencement of enrollment in these studies. In 2020, a kidney biopsy was conducted on the third patient in the FAB-GT clinical trial of AVR-RD-01, but due to human error in processing the biopsy sample at the external laboratory vendor, the kidney Gb3 inclusions could not be evaluated and will not be available. Although our quality assurance personnel have worked closely with the external vendor to identify the cause of the vendor error and to identify additional protocols for implementation by the vendor that are designed to prevent similar errors in the future, there can be no assurances that such protocols will be successfully implemented by the vendor.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the impact of the ongoing COVID-19 pandemic or the bankruptcy of the manufacturer or supplier. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could lead to delays of our preclinical and clinical studies or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are dependent on a limited number of suppliers for some of our components and materials used in our product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently depend on a limited number of suppliers for some of the components necessary for our product candidates. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. Our use of a limited number of suppliers of raw materials, components and finished goods exposes us to several risks, including disruptions in supply, price increases, late deliveries and an inability to meet customer demand. There are, in general, relatively few alternative sources of supply for these components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any supplier or manufacturing location could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to switch to a replacement supplier or manufacture materials ourselves, the manufacture and delivery of our product candidates could be interrupted for an extended period, adversely affecting our business. Establishing additional or replacement suppliers may not be accomplished quickly, and we may not be able to enter agreements with replacement suppliers on reasonable terms, if at all. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay.&#160;For example, the FDA could require additional supplemental bridging data if we rely upon a new supplier. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. While we seek to maintain adequate inventory of the components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to conduct our clinical trials and, if our product candidates are approved, to meet the demand of our customers and cause them to cancel orders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as part of the FDA&#8217;s approval of our product candidates, the FDA must review and approve the individual components of our production process, which includes the manufacturing processes and facilities of our suppliers. Our current suppliers have not undergone this process, nor have they had any components included in any product approved by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these suppliers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in production, supply, shipment or delivery as a result of the ongoing COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a lack of long-term supply arrangements for key components with our suppliers&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a delay in delivery due to our suppliers prioritizing other customer orders over ours&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">damage to our reputation caused by defective components produced by our suppliers&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">increased cost of our warranty program due to product repair or replacement based upon defects in components produced by our suppliers&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these risks materialize, costs could significantly increase and our ability to conduct our clinical trials and, if our product candidates are approved, to meet demand for our products could be impacted. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have relationships with a limited number of suppliers for the manufacturing of our viral vectors and product candidates. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical studies must be manufactured in accordance with CGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s good laboratory practices, or GLP, and CGMP regulations enforced by the FDA through its facilities inspection program. Some of our contract manufacturers have not produced a commercially-approved product and have never been inspected by the FDA before. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, or if the FDA is unable to conduct such an inspection due to the COVID-19 pandemic, the FDA may issue a complete response letter or defer action on our applications, and approval of the products may be delayed or may not be granted.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our preclinical and clinical studies may be delayed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we rely on third parties to manufacture our vectors and our product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our gene therapy approach, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to commercialization of our product candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales, distribution and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we will be unable to generate any product revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in the preliminary stages of building our commercial organization. To successfully commercialize any of our current or future product candidates, if approved, we will need to develop these capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may enter into collaborations regarding any approved product candidates with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded sales, distribution and marketing operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates, if approved. Without an internal team or the support of a third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the market opportunities for our product candidates are smaller than we believe they are, our product revenues may be adversely affected and our business may suffer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our research and product development on treatments for serious lysosomal disorders. Our understanding of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain any regulatory approval for our product candidates, the commercial success of our product candidates will depend in part on the medical community, patients, and third-party payors accepting gene therapy products in general, and our product candidates in particular, as effective, safe and cost-effective. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of these product candidates, if approved for commercial sale, will depend on a number of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential efficacy and potential advantages over alternative treatments, including any similar generic treatments&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the efficacy and safety as demonstrated in pivotal clinical trials and published in peer-reviewed journals&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the prevalence and severity of any adverse events or side effects, including any limitations or warnings contained in a product&#8217;s approved labeling or that are later found to be associated with a product, including in findings from long-term follow-up studies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the prevalence and severity of any side effects resulting from the conditioning regimen for the administration of our product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ability to offer the products for sale at competitive prices&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the clinical indications for which the products are approved by the FDA or comparable regulatory agencies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the relative convenience and ease of dosing and administration compared to alternative treatments&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the strength of marketing and distribution support and timing of market introduction of competitive products&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on how the product is distributed&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">publicity concerning our products or competing products and treatments&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">favorable third-party insurance coverage and sufficient reimbursement. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost effective as compared with competing treatments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product candidate displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the product, if approved for commercial sale, will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently conducting clinical trials for our product candidates in the United States, Canada and Australia, and plan to expand to other geographies including Japan, Europe and Israel. If any of our product candidates are approved for commercialization, we may enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">different regulatory requirements for approval of drugs and biologics in foreign countries&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reduced protection for intellectual property rights&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the United States&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly-approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our or their commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to successfully commercialize our product candidates or any other products that we or they may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&#160;&#38; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs and commercial payors are critical to new product acceptance. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a covered benefit under its health plan&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">safe, effective and medically necessary&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">appropriate for the specific patient&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">cost-effective&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">neither experimental nor investigational. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and certain other major markets where we plan to commercialize may put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems, and pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, efforts by governmental and other third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our target patient populations are relatively small, as a result of which the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare legislative reform measures and constraints on national budget social security systems may have a material adverse effect on our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements&#59; (ii)&#160;additions or modifications to product labeling&#59; (iii)&#160;the recall or discontinuation of our products&#59; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, was enacted, which, substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjects biologic products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extends the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">managed care organizations, subjects manufacturers to new annual fees and taxes for certain branded prescription drugs, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70% </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(as of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, and provides incentives to programs that increase the federal government&#8217;s comparative effectiveness research. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court and members of Congress have introduced several pieces of legislation aimed at significantly revising or repealing the ACA. The United States Supreme Court is expected to rule on a legal challenge to the constitutionality of the ACA in early 2021. The implementation of the ACA is ongoing, the law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Litigation and legislation related to the ACA are likely to continue, with unpredictable and uncertain results.In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2%&#160;per fiscal year, which went into effect in April 2013, and will remain in effect through 2030 unless additional Congressional action is taken&#59; however, pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, these reductions have been suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic. In January 2013, the American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the former President signed four Executive Orders aimed at lowering drug prices. In response, the FDA released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.&#160;&#160;The MFN Model regulations mandate participation by identified Part B providers and would have applied to all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. However, in response to a lawsuit filed by several industry groups, on December 28, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction enjoining government defendants from implementing the MFN Rule pending completion of notice-and-comment procedures under the Administrative Procedure Act. On January 13, 2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not appeal the preliminary injunction granted in the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN Interim Final Rule shall not commence earlier than 60 days after publication of that regulation in the Federal Register. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada and the MFN Model may materially and adversely affect the price we receive for any of our product candidates. Additionally, on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to an order entered by the U.S. District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has been delayed to January 1, 2023. Further, implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fees are currently under review by the Biden administration and may be amended or repealed.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory and market implications of the Executive Orders are unknown at this time, but could decrease the price we receive for any products that </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may develop and commercialize and could adversely affect our future revenues and prospects for profitability. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, HHS, has already implemented certain measures. For example, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the demand for our drug product candidates, if we obtain regulatory approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to set a price that we believe is fair for our products&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to generate revenue and achieve or maintain profitability&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of taxes that we are required to pay&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of capital. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any denial in coverage or reduction in reimbursement from Medicare or other government programs may result in a similar denial or reduction in payments from private payors, which may adversely affect our future profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals&#59; however, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. Since March 2020, foreign and domestic inspections by the FDA have largely been on hold with the FDA announcing plans in July 2020 to resume prioritized domestic inspections. However, the FDA&#8217;s inspection activities will depend on data about the virus&#8217; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, the FDA has stated that it generally intends to issue a complete response letter.&#160;&#160;Further, if there is inadequate information to make a determination on the acceptability of a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facility, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA may defer action on the application until an inspection can be completed. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, several companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any contamination in our manufacturing process, shortages of materials or failure of any of our key suppliers to deliver necessary components could result in interruption in the supply of our product candidates and delays in our clinical development or commercialization schedules. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the nature of biologics manufacturing, there is a risk of contamination in our manufacturing processes. Any contamination could materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the materials required in our manufacturing process are derived from biologic sources. Such materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development timelines and our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our business operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our gene therapy approach utilizes lentiviral vectors derived from viruses, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gene therapy remains a novel technology, with only a limited number of gene therapy products approved to date. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia, myelodysplastic syndromes and deaths seen in other trials using other vectors. In addition, in February 2021 a lentiviral gene therapy company reported a potential case of myelodysplastic syndrome and another case of acute myeloid leukemia in their clinical trials for sickle cell disease, and these cases remain under investigation. Adverse events in our clinical studies or discovered in long-term follow-up, even if not ultimately attributable to our product candidates (such as the many adverse events that typically arise from the conditioning process), or adverse events in other lentiviral gene therapy trials, and the resulting publicity could result in a decline in our stock price, increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on principal members of our executive team and key employees, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. The loss of the services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives. Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or the loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to expand our operations and we may experience difficulties in managing this growth, which could disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had 121&#160;full-time employees. As we mature, we expect to rapidly expand our full-time employee base and to hire more consultants and contractors. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are successful in executing our business strategy, we will need to expand our managerial, operational, financial and other systems and resources to manage our operations, continue our research and development activities and, in the longer term, build a commercial infrastructure to support commercialization of any of our product candidates that are approved for sale. Future growth would impose significant added responsibilities on members of management. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and product candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas and to attract and retain sufficient numbers of talented employees. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA or of other foreign regulatory authorities, provide accurate information to the FDA and other foreign regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the United States Foreign Corrupt Practices Act&#8217;s accounting provisions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws health information privacy and security laws, and other health care laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act and Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act, or FCA. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. On December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to an order entered by the U.S. District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has been delayed to January 1, 2023. Further, implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters&#59; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services information related to payments or other transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members.  </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with any of these laws or regulatory requirements subjects entities to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in federal and state funded healthcare programs (such as Medicare and Medicaid), contractual damages and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial patients, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently plan to conduct clinical trials in the European Union, or EU, and as a result will be subject to additional privacy restrictions. The collection and use of personal health data in the EU is governed by the provisions of the General Data Protection Regulation, or GDPR. This directive imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national data protection laws of the European Union Member States may result in fines and other administrative penalties. The GDPR introduces new data protection requirements in the European Union and substantial fines for breaches of the data protection rules. The GDPR regulations may impose additional responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with these and/or new data protection rules. This may be onerous and adversely affect our business, financial condition, prospects and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates in clinical studies and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impairment of our business reputation&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the withdrawal of clinical study participants&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">costs due to related litigation&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the distraction of management&#8217;s attention from our primary business&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">substantial monetary awards to patients or other claimants&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability to commercialize our product candidates&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">decreased demand for our product candidates, if approved for commercial sale. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We carry master product liability insurance of $5.0&#160;million per occurrence and $5.0&#160;million in the aggregate in the United States. For studies conducted in Australia and Canada, we maintain local admitted policies with varying limits.&#160;We believe our product liability insurance coverage is sufficient in light of our current clinical programs&#59; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products&#59; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with the diseases targeted by certain of our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life- threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had federal and state net operating loss carryforwards of $214.0&#160;million and $201.6&#160;million, respectively, and federal and state research and development tax credit carryforwards of approximately $3.7 million and $0.7&#160;million, respectively. If not utilized, the net operating loss carryforwards and research and development credits will generally expire at various dates through 2038 (other than federal net operating loss carryforwards generated in taxable years ending after December 31, 2017, which are not subject to expiration and generally may not be carried back to prior taxable years except that net operating losses generated in 2018, 2019 and 2020 may be carried back five taxable years). These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We may have experienced ownership changes in the past. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurred or occurs and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, or if our research and development carryforwards are adjusted, it would harm our future operating results by effectively increasing our future tax obligations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our intellectual property </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and <span style="font-style:italic;">inter partes</span> reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we or our licensors are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. In particular, we are aware of issued patents in the United States that cover the lentiviral vectors used in the manufacture of our product candidates. While we believe that we have reasonable defenses against a claim of infringement, potentially including that certain of these patents are expected to expire prior to commercializing our product candidates, if approved, in the United States, there can be no assurance that we will prevail in any such action by the holder of these patents. In the event that the holder of these patents seeks to enforce its patent rights and our defenses against a claim of infringement are unsuccessful, we may not be able to commercialize our product candidates in the United States, if approved, without first obtaining a license to some or all of these patents, which may not be available on commercially reasonable terms or at all. In addition, the defense of any claim of infringement, even if successful, is time-consuming, expensive and diverts the attention of our management from our ongoing business operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe or be alleged to infringe. In addition, third parties may obtain patents in the future and claim that use of our or our licensors&#8217; technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Even in the absence of a finding of infringement, we may choose to obtain a license, if such a license is available. A successful claim of patent or other intellectual property infringement against us could materially adversely affect our business, results of operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of licenses granted to us by others. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend upon the intellectual property rights granted to us under licenses from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. In particular, we have in-licensed certain intellectual property rights and know-how from the University Health Network (relevant to AVR-RD-01 and our Fabry program) and affiliates of Lund University (relevant to AVR-RD-02 and our Gaucher type 1 program). In addition, we have in-licensed patents and patent applications from BioMarin Pharmaceutical Inc., or BioMarin (relevant to AVR-RD-03 and our Pompe program), GenStem Therapeutics, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc., or GenStem (relevant to AVR-RD-04 and our cystinosis program)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="Background-color:#FFFFFF;color:#000000;">and The University of Manchester (relevant to AVR-</span><span style="Background-color:#FFFFFF;color:#000000;">RD-05 and our Hunter program)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, directed to compositions and methods related to the manufacture and use of AVR-RD-03</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> AVR-RD-04</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and AVR-RD-05</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively. Any termination of these licenses could result in the loss of significant rights and could harm or prevent our ability to commercialize our product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of our existing licenses are exclusive but are limited to particular fields, such as Fabry disease, cystinosis, Gaucher disease type 1, Hunter syndrome, or Pompe disease, and are subject to certain retained rights. Absent an amendment or additional agreement, we may not have the right to use intellectual property in-licensed for one of our programs for another program. In addition, licenses that we may enter into in the future may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. For example, pursuant to each of our intellectual property licenses with GenStem, BioMarin, the rights holders associated with Lund University, and The University of Manchester, our licensors retain control of such activities. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our licensors fail to maintain such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current license agreements impose, and we expect that future license agreements that we may enter into will impose, various obligations, including diligence and certain payment obligations. If we fail to satisfy our obligations, the licensor may have the right to terminate the agreement. Disputes may arise between us and any of our licensors regarding intellectual property subject to such agreements and other issues. Such disputes over intellectual property that we have licensed or the terms of our license agreements may prevent or impair our ability to maintain our current arrangements on acceptable terms, or at all, or may impair the value of the arrangement to us. Any such dispute could have a material adverse effect on our business. If we cannot maintain a necessary license agreement or if the agreement is terminated, we may be unable to successfully develop and commercialize the affected product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete effectively will depend, in part, on our ability to maintain the proprietary nature of our technology and manufacturing processes. We rely on manufacturing and other know-how, patents, trade secrets, trademarks, license agreements and contractual provisions to establish our intellectual property rights and protect our products. These legal means, however, afford only limited protection and may not adequately protect our rights. The failure to obtain, maintain, enforce or defend such intellectual property rights, for any reason, could allow third parties to make competing products or impact our ability to develop, manufacture and market our products, if approved, on a commercially viable basis, or at all, which could have a material adverse effect on our financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, we rely primarily on trade secrets, know-how and other unpatented technology, which are difficult to protect. Although we seek such protection in part by entering into confidentiality agreements with our vendors, employees, consultants and others who may have access to proprietary information, we cannot be certain that these agreements will not be breached, adequate remedies for any breach would be available or our trade secrets, know-how and other unpatented proprietary technology will not otherwise become known to or be independently developed by our competitors. If we are unsuccessful in protecting our intellectual property rights, sales of our products may suffer and our ability to generate revenue could be severely impacted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our licensors and we have sought, and we intend to continue to seek to protect our proprietary position by filing patent applications in the United States and, in at least some cases, one or more countries outside the United States related to current and future product candidates that are important to our business. However, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents, whether the claims of any issued patents will provide us </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a competitive advantage, or whether we will be able to successfully pursue patent applications in the future related to our current or future product candidates. While we have in-licensed patents and patent applications relevant to AVR-RD-03, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we currently have no owned or in-licensed patents or patent applications covering AVR-RD-01</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> AVR-RD-02</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or AVR-RD-06</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the patent application</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that we in-licensed related to AVR-RD-04</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and AVR-RD-05</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at a very early stage. Many of our product candidates are in-licensed from third parties. Accordingly, in some cases, the availability and scope of potential patent protection is limited based on prior decisions by our licensors or the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> inventors, such as decisions on when to file patent applications or whether to file patent applications at all. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Although our license agreements grant us worldwide rights, and our currently in-licensed U.S. patent rights have certain corresponding foreign patents or patent applications, there can be no assurance that we will obtain or maintain such corresponding patents or patent applications with respect to any future license agreements. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States even in jurisdictions where we and our licensors pursue patent protection. Consequently, we and our licensors may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we and our licensors pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights, even if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If one of our licensing partners or we initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, should such a patent issue, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <span style="font-style:italic;">inter partes</span> review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Our licensors may face similar risks, which could have an adverse impact on intellectual property that is licensed to us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an ownership interest in the patents and intellectual property that we own or license or that we may own or license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own&#59; our licensors may face similar obstacles. We could be subject to ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against any claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Some intellectual property which we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the intellectual property rights we have licensed, including rights licensed to us by GenStem, may have been generated through the use of U.S. government and California state funding and may therefore be subject to certain federal and state laws and regulations. For example, with respect to the AVR-RD-04 program for cystinosis, the NIH previously granted funding to UCSD for certain research in connection with the development of UCSD&#8217;s gene therapy program for cystinosis, which we have licensed from GenStem. As a result, the U.S. government may have certain rights to intellectual property </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">embodied in our AVR-RD-04 program, or in other product candidates to the extent funded by the U.S. government pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taken to commercialize the invention&#59; (ii)&#160;government action is necessary to meet public health or safety needs&#59; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. Any exercise by the government of certain of its rights could harm our competitive position, business, financial condition, results of operations and prospects. With respect to state funding, specifically funding via the California Institute of Regenerative Medicine, or CIRM,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which has granted funds for the study of AVR-RD-04 for cystinosis,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the grantee has certain obligations and the state or CIRM has certain rights. For example, the grantee has an obligation to share intellectual property, including research results, generated by CIRM-funded research, for research use in California. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or the interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes several significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Two cases involving diagnostic method claims and &#8220;gene patents&#8221; have recently been decided by the Supreme Court of the United States, or Supreme Court. On March&#160;20, 2012, the Supreme Court issued a decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., or Prometheus, a case involving patent claims directed to a process of measuring a metabolic product in a patient to optimize a drug dosage for the patient. According to the Supreme Court, the addition of well-understood, routine or conventional activity such as &#8220;administering&#8221; or &#8220;determining&#8221; steps was not enough to transform an otherwise patent-ineligible natural phenomenon into patent-eligible subject matter. On July&#160;3, 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to not patent-eligible subject matter. On June&#160;13, 2013, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">susceptibility genes BRCA1 and BRCA2. Myriad held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent-eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent-eligible. On March&#160;4, 2014, the USPTO issued a guidance memorandum to patent examiners entitled 2014 Procedure For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products. These </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guidelines instruct USPTO examiners on the ramifications of the Prometheus and Myriad rulings and apply the Myriad ruling to natural products and principles including all naturally occurring nucleic acids. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain claims of our licensed patents and patent applications contain, and any future patents we may obtain may contain, claims that relate to specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties. In addition, the 2014 USPTO guidance could impact our ability to pursue similar patent claims in patent applications we may prosecute in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that our efforts to seek patent protection for our product candidates will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions in Prometheus and Myriad may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, although the Supreme Court has held in Myriad that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity positions, or paying to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter. Such outcomes could harm our business, financial condition, results of operations or prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension and data exclusivity for our product candidates, our business may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of any FDA marketing approval of our product candidates, one or more U.S. patents that we license or may own or license in the future, if any, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. A patent may only be extended once and only based on a single approved product. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. In addition, we do not control the efforts of our licensors to obtain a patent term extension, and there can be no assurance that they will pursue or obtain such extensions to the patents that we license from them. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have registered the marks &#8220;AVROBIO&#8221; and &#8220;plato&#8221; with the USPTO </span><span style="color:#000000;">but do not have trademarks or trademark applications with the USPTO for the marks &#8220;AVRO&#8221; or the AVROBIO logo. In the future, even if we apply for registration of these marks, there can be no assurance that such registration will be approved. Once registered, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">others may be able to make gene therapy products that are similar to our product candidates but that are not covered by the claims of the patents that we license or may own or license in the future&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we, our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patents or pending patent applications that we license or may own or license in the future&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we, our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">it is possible that our pending licensed patent applications or those that we may own or license in the future will not lead to issued patents&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">issued patents that we hold rights to or may hold rights to in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">one or more of our product candidates may never be protected by patents&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may not develop additional proprietary technologies that are patentable&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patents of others may have an adverse effect on our business&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may choose not to file a patent application for certain trade secrets or know-how, and a third party may subsequently file a patent application or obtain a patent covering such intellectual property. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to ownership of our common stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the price at which you purchased our shares. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is likely to be volatile. Since our initial public offering, or IPO, in June 2018, through March 1, 2021, the trading price of our common stock has ranged from $9.76 to $53.70. The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price at which you purchased shares. The market price for our common stock may be influenced by many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ongoing COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">adverse results or delays in preclinical studies or clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reports of adverse events in other gene therapy products or clinical studies of such products&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an inability to obtain additional funding&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure by us to successfully develop and commercialize our product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure by us to maintain our existing strategic collaborations or enter into new collaborations&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure by us or our licensors and strategic partners to prosecute, maintain or enforce our intellectual property rights&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in laws or regulations applicable to future products&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">adverse regulatory decisions&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the introduction of new products, services or technologies by our competitors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure by us to meet or exceed financial projections we may provide to the public&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure by us to meet or exceed the financial projections of the investment community&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic partner or our competitors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">additions or departures of key scientific or management personnel&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">significant lawsuits, including patent or stockholder litigation&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in the market valuations of similar companies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sales of our common stock by us or our stockholders in the future&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the trading volume of our common stock. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companies trading in the stock market in general, and The Nasdaq Global Select Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be sustained. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO in June 2018, there had been no public market for our common stock. Although our common stock is listed on The Nasdaq Global Select Market, an active trading market for our shares may never be sustained. If an active market for our common stock is not sustained, it may be difficult for you to sell shares you purchased without depressing the market price for the shares, or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling additional shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will likely depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. Although we have obtained research coverage from certain analysts, there can be no assurance that analysts will continue to cover us or provide </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">favorable coverage. If one or more analysts downgrade our stock or change their opinion of our stock, our share price would likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on shares outstanding as of March 9, 2021, our executive officers, directors, five percent stockholders and their affiliates beneficially owned approximately 27% of our voting stock. As a result, if these stockholders were to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, acting together, may be able to influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the current trading price of our stock and have held their shares for a longer period, they may be more interested in selling our Company to an acquirer than other investors or they may want us to pursue strategies that deviate from the interests of other stockholders. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; or EGC, as defined in the JOBS Act. We will remain an EGC until the earliest of: (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more&#59; (ii)&#160;the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO&#59; (iii)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous three years&#59; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the first day of the year following the first year in which the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of June&#160;30 in any given year. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reduced disclosure obligations regarding executive compensation&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an exemption from the requirement to seek nonbinding advisory votes on executive compensation or golden parachute arrangements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in this Annual Report on Form 10-K. In particular, we have not included in this Annual Report, and do not intend to include in our 2021 Proxy Statement, all of the executive compensation information that would be required if we were not an EGC. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act provides that an EGC may take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; if the market value of our common stock held by non-affiliates is below $250&#160;million (or $700&#160;million if our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annual revenue is less than $100 million) as of June&#160;30 in any given year, which would allow us to take advantage of many of the same exemptions from disclosure requirements. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we are no longer an EGC, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and will continue to make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and increasingly more expensive for us to obtain and maintain director and officer liability insurance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting, and, once we are no longer an EGC or a &#8220;smaller reporting company&#8221;, we will be required to furnish an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404, we continue to be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially continue to engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements, or may identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an EGC or a &#8220;smaller reporting company&#8221;, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&#160;404. We could be an EGC for up to five years following the completion of our IPO and will qualify as a &#8220;smaller reporting company&#8221; if the market value of our common stock held by non-affiliates is below $250&#160;million (or $700&#160;million if our annual revenue is less than $100 million) as of June&#160;30 in any given year. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We and our independent registered public accounting firm previously identified material weaknesses in our internal control over financial reporting, which have now been remediated. Nevertheless, if we experience additional material weaknesses or deficiencies in the future or otherwise fail to <span style="color:#000000;">establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our investors&#8217; confidence and our stock price. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Annual Report on Form 10-K for the year ended December 31, 2018, we reported material weaknesses in our internal control over financial reporting related to deficiencies in our controls over the financial statement close process, including over complex accounting issues, expense classification and accrued research and development expenses, as well as the cash disbursement process. During 2018 and 2019, we took a number of actions to improve our internal control over financial reporting to remediate these material weaknesses. As a result of these efforts, management has concluded that the previously disclosed material weaknesses have been remediated as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue our efforts to improve our control processes, though there can be no assurance that our efforts will ultimately be successful or avoid potential future material weaknesses, and we expect to continue incurring additional costs as a result of these efforts. If we are unable to successfully remediate any future material weaknesses in our internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to certain restrictions described below. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. As of March 1, 2021, holders of an aggregate of approximately 4.5&#160;million shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. In addition, shares reserved for issuance upon the exercise of stock options outstanding under our equity incentive plans will become eligible for sale in the public market in the future. We have registered all shares of common stock that we may issue under our equity compensation plans, which can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. For example, our prior loan facility with Silicon Valley Bank restricted our ability to pay any dividends or making any distributions on account of our capital stock, and we may enter into agreements in the future with similar restrictions. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and by-laws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and by-laws, include provisions that: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">create a classified board of directors whose members serve staggered three-year terms&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer or our president&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">prohibit stockholder action by written consent&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide that our directors may be removed only for cause&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">specify that no stockholder is permitted to cumulate votes at any election of directors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expressly authorize our board of directors to modify, alter or repeal our amended and restated by-laws&#59; and require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our amended and restated certificate of incorporation or amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our bylaws contain exclusive forum provisions, which may limit a stockholder&#8217;s ability to bring a claim in a judicial forum it finds favorable and may discourage lawsuits with respect to such claims.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for (1)&#160;any derivative action or proceeding brought on our behalf&#59; (2)&#160;any action asserting a claim of breach of or based on a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders&#59; (3)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws&#59; or (4)&#160;any action asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision, as our principal executive offices are located in Cambridge, Massachusetts. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and the Federal Forum Provision&#59; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize that the Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders who assert the provision is not enforceable and may impose more general additional litigation costs in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, these forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. W</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hile the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Federal Forum Provision may also impose additional litigation costs on stockholders who assert the provision is unenforceable, and if the Federal Forum Provision is found to be unenforceable, we may incur additional costs with resolving such matters. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The COVID-19 pandemic has caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite our security measures, our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. For example, in 2017 we were subjected to a cyberattack by a third party, which led to the theft of a portion of our funds. We implemented remedial measures promptly following this breach and do not believe that this breach had a material adverse effect on our business. In addition, in February 2019, one of our vendors was subject to a cyberattack by a third party, which resulted in the payment by us of a fraudulent invoice. We have implemented remedial measures following this breach and do not believe that this breach had a material effect on our business.<span style="font-weight:bold;"> </span>However, if any cyberattack or data breach were to occur in the future and cause interruptions in our or our collaborators&#8217;, contractors&#8217; or consultants&#8217; operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our business data, trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in tax law could adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item&#160;1B. Unresolved Staff Comments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item&#160;2. Properties </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located in Cambridge, Massachusetts. Our current leased facility for our corporate headquarters encompasses approximately 11,218 square feet of office space. The lease for this facility expires in January 2023. In August 2018, we entered into a sub-lease for 13,643 square feet of laboratory space located in Cambridge Massachusetts, which expires in April 2022. In June 2020, we entered into a&#160;lease&#160;agreement for 3,885 square feet office space located in Toronto, Ontario, Canada, which expires in June 2025. We believe that our office and laboratory space is sufficient to meet our current needs and that suitable additional space or alternative space will be available as needed on commercially reasonable terms.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item&#160;3. Legal Proceedings </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report on Form 10-K, we <span style="Background-color:#FFFFFF;color:#000000;">are not presently subject to any pending or threatened litigation that we believe</span>, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item&#160;4.<span style="font-weight:normal;"> </span>Mine Safety Disclosures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item&#160;5. Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;AVRO&#8221;. Trading of our common stock commenced on June&#160;21, 2018, following the completion of our initial public offering. Prior to that time, there was no established public trading market for our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Holders of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;5, 2021, the number of holders of record of our common stock was eight. The number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in &#8220;street name&#8221; or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend on, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Compensation Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Issuer Purchases of Equity Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not sell any unregistered equity securities during the period covered by this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_RESERVED">Item&#160;6. Reserved </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included in this Annual Report on Form 10-K, which have been prepared by us in accordance with United States generally accepted accounting principles, or GAAP, and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with the consolidated financial statements and the notes thereto included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part I, Item&#160;1A. Risk Factors of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease.&#160;&#160;Our company is focused on developing potentially curative <span style="font-style:italic;">ex vivo</span> lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Our gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is defective in the target disease. We believe that our approach, which is designed to transform stem cells from patients into therapeutic products, has the potential to provide curative benefit for a range of diseases. Our initial focus is on a group of rare genetic diseases referred to as lysosomal disorders, some of which today are primarily managed with enzyme replacement therapies, or ERTs. These lysosomal disorders have well-understood biologies, identified patient populations, established standards of care yet with significant unmet needs, and represent large market opportunities with approximately $4.8&#160;billion in worldwide net sales in 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial pipeline is comprised of six lentiviral-based gene therapy programs: AVR-RD-01 for the treatment of Fabry disease&#59; AVR-RD-04 for the treatment of cystinosis&#59; AVR-RD-02 for the treatment of Gaucher disease type 1&#59; AVR-RD-05 for the treatment of Hunter syndrome&#59; AVR-RD-06 for the treatment of Gaucher disease type 3&#59; and AVR-RD-03 for the treatment of Pompe disease. AVR-RD-01 is currently being evaluated for the treatment of Fabry disease in an investigator-sponsored Phase&#160;1 clinical trial and a Company-sponsored Phase 2 clinical trial. Five patients have been dosed in the investigator-sponsored Phase 1 clinical trial of AVR-RD-01, and enrollment is complete. Five patients have been dosed in our Company-sponsored Phase 2 clinical trial of AVR-RD-01, which we refer to as the FAB-GT clinical trial, and we are actively recruiting additional potential patients for our currently active sites in Australia, Canada and the United States. AVR-RD-04 is currently being studied <span style="Background-color:#FFFFFF;color:#000000;">for the treatment of cystinosis</span> <span style="Background-color:#FFFFFF;color:#000000;">by our collaborators at the University of California, San Diego, or UCSD, in a Phase 1/2 investigator-sponsored clinical trial, and three patients have been dosed.</span> One patient has been dosed in our Company-sponsored Phase 1/2 clinical trial of AVR-RD-02 for the treatment of Gaucher disease, which we refer to as the Guard1 clinical trial, and we are actively recruiting in Australia and Canada, with additional sites planned in the United States, Israel and Europe. AVR-RD-05 is being studied for the treatment of Hunter syndrome by our collaborators at The University of Manchester, and a Phase 1/2 investigator-sponsored clinical trial is expected to commence in the first half of 2022. In November 2020, we announced a new preclinical program, AVR-RD-06 for the treatment of Gaucher disease type 3, and we expect to request a meeting with the Food and Drug Administration, or FDA, this year to discuss a potential path to the clinic. Our AVR-RD-03 program for Pompe disease is currently in preclinical development, and in 2020 we completed IND-enabling proof-of-concept preclinical studies, with toxicology studies expected to be completed in 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, acquiring or discovering product candidates and securing related intellectual property rights, conducting discovery, research and development activities for our programs and planning for potential commercialization. To date, we have not generated any product revenue and have financed our operations primarily through the private placement of our securities and through public offerings of our common stock. Through December&#160;31, 2020, we had received gross cash proceeds of $87.5&#160;million from sales of our preferred stock&#59; gross cash proceeds, before deducting underwriting discounts and commissions and expenses, of $428.1&#160;million from sales of our common stock through our initial public offering and follow-on offerings&#59; and gross cash proceeds, before deducting commissions and expenses, of $8.5 million from sales of our common stock through our &#8220;at-the-market&#8221; (ATM) facility.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates and programs. Our net losses were $119.7&#160;million and $73.0&#160;million for the years </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million. We expect to continue to incur significant expenses for at least the next several years as we advance our current and future product candidates from discovery through preclinical development and clinical trials and seek regulatory approval of our product candidates. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have expanded the number of programs in our pipeline to a total of six investigational gene therapies, three of which are currently in clinical development. As a result, further development of these programs will require us to expend significant resources to advance these candidates. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection with the in-licensing or acquisition of additional product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations with proceeds from outside sources, with a majority of such proceeds to be derived from sales of equity, including the net proceeds from our follow-on offerings. We also plan to pursue additional funding from outside sources, including our expansion of, or our entry into, new borrowing arrangements&#59; research and development incentive payments from the Australian government&#59; and our entry into potential future collaboration agreements for one or more of our programs. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash and cash equivalents of $259.7&#160;million. We believe that our existing cash and cash equivalents as of December&#160;31, 2020 will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;<span style="font-style:italic;">Liquidity and Capital Resources.</span>&#8221; To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Our Consolidated Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses consist of costs incurred in connection with the development of our product candidates, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">license maintenance fees and milestone fees incurred in connection with various license agreements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials and commercial materials, including manufacturing validation batches&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">costs of purchasing lab supplies and non&#8209;capital equipment used in our preclinical activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">employee-related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">costs related to compliance with regulatory requirements&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">allocated facilities costs, depreciation and other expenses, which include rent and utilities. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs, and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under license agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee the research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes our research and development expenses related to our product candidates (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fabry</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,483</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,833</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gaucher</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,546</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pompe</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,593</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,722</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cystinosis</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,225</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,177</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hunter</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,728</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,138</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,451</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,523</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,236</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,974</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years, particularly as we increase personnel costs, including stock-based compensation, contractor costs and facilities costs, as we continue to advance the development of our product candidates. We also expect to incur additional expenses related to milestone and royalty payments payable to third parties with whom we have entered into license agreements to acquire the rights to our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establishing an appropriate safety profile with IND-enabling studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">successful patient enrollment in, and the design, initiation and completion of, clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">significant and changing government regulation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">maintaining a continued acceptable safety profile of the product candidates following approval&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the risks disclosed in the section entitled &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries, related benefits, travel and stock-based compensation expense for personnel in executive, finance and administrative functions. General and administrative expenses also include professional fees for legal, consulting, accounting and audit services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will continue to incur increased accounting, audit, legal, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company. We anticipate the additional costs for these services will substantially increase our general and administrative expenses. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other commercialization-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense), net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net primarily consists of interest income earned on our cash and cash equivalents and changes in foreign currency.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Results of Operations</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31, 2020 and 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our consolidated results of operations (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,236</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,974</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,262</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,992</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,835</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,157</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,228</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,809</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,419</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120,228</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,809</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,419</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,934</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,215</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,844</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,328</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,712</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,965</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,747</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by $32.3&#160;million to $87.2&#160;million for the year ended December&#160;31, 2020, from approximately $55.0&#160;million for the year ended December&#160;31, 2019. This increase was attributable to increased program development activities related to the advancement of our pipeline programs, including a $11.7&#160;million increase in personnel-related costs, $9.1 million in one-time, upfront licensing fees, including payment to The University of Manchester <span style="color:#000000;">as consideration for the MPSII License Agreement,</span> <span style="color:#000000;">a $4.6 million increase in noncash stock-based compensation, </span>a $5.7 million increase in <span style="color:#000000;">clinical costs, </span>a $2.1 million increase in facility costs, a $1.9 million increase in consulting fees, a $0.8 million increase in lab supplies expense, and a $1.1 million increase in other expenses. These increases were partially off-set by a $2.0 million one-time licensing fee paid in 2019, a $2.1 million decrease in preclinical costs, and a $0.6 million decrease in manufacturing costs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by $12.2&#160;million to $33.0&#160;million for the year ended December&#160;31, 2020, from $20.8&#160;million for the year ended December&#160;31, 2019. This increase was attributable to <span style="color:#000000;">a $4.3 million increase in non-cash stock-based compensation,</span> a $3.6&#160;million increase in personnel-related costs, a $2.1 million increase in professional fees, a $1.0 million increase in facility costs, a $0.6 million increase in insurance costs, and $0.6 million in other expenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Income (Expense), net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net decreased by $2.3 million to $0.5 million in other income, net during the fiscal year ended December 31, 2020, from $2.8 million other income, net for the year ended December 31, 2019. The decrease was primarily due to a $2.2 million decrease in interest income and an approximate increase in foreign currency losses of $0.1 million.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not generated any revenue and have incurred significant operating losses and negative cash flows from our operations. We have funded our operations to date primarily with proceeds from the sale of preferred stock and our common stock through our initial public offering, or IPO, and we have raised additional capital through subsequent follow-on offerings and our &#8220;at-the-market&#8221; facility, or ATM facility. Through December&#160;31, 2020, we had received gross cash proceeds of $87.5&#160;million from sales of our preferred stock&#59; gross cash proceeds, before deducting underwriting discounts and commissions and expenses, of $428.1&#160;million from sales of our common stock through our IPO and follow-on public offerings&#59; and $8.5 million in gross proceeds from the sale of our common stock under our ATM Facility. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2019, we filed a shelf registration statement on Form S-3 with the SEC, or the July 2019 Shelf, which covers the offering, issuance and sale by us of up to an aggregate of $200.0 million of our common stock, preferred stock, debt securities, warrants and/or units. We simultaneously entered into a Sales Agreement with Cowen and Company, LLC, as sales agent, to provide for the offering, issuance and sale by us of up to $50.0 million of our common stock from time to time in ATM offerings under the July 2019 Shelf. The July 2019 Shelf was declared effective by the SEC on July 10, 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 20, 2019, we filed a shelf registration statement on Form S-3 with the SEC, or the December 2019 Shelf, which covers the offering, issuance and sale by us of up to an aggregate of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units. The December 2019 Shelf was declared effective by the SEC on January 14, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we closed an underwritten public offering, or the July 2019 Follow-On Offering, under the July 2019 Shelf of 7,475,000 shares of our common stock at a public offering price of $18.50 per share, which included 975,000 shares of our common stock resulting from the full exercise of the underwriters&#8217; option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The net proceeds to us from this offering, after deducting underwriting discounts and commissions and other offering expenses payable by us, were $129.5 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, we closed an underwritten public offering, or the February 2020 Follow-On Offering, under the December 2019 Shelf of 4,350,000 shares of our common stock at a public offering price of $23.00 per share, less underwriting discounts and commissions. The net proceeds to us from this offering, after deducting underwriting discounts and commissions and other offering expenses payable by us, were $93.6 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sold an aggregate of 384</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,140</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock under the&#160;ATM&#160;Facility</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for net proceeds, after deducting commissions and other offering expenses payable by </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, of $8</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020, approximately $41</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.5 million</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of common stock remained available for future issuance under the ATM Facility. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we closed an underwritten public offering, or the November 2020 Follow-On Offering, of 5,000,000 shares of our common stock at a public offering price of $15.00 per share, less underwriting discounts and commissions. The net proceeds to us from the November 2020 Follow-On Offering, after deducting underwriting discounts and commissions and other offering expenses payable by us, were $70.2 million. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash and cash equivalents of $259.7&#160;million. Cash in excess of immediate requirements is invested primarily with a view to liquidity and capital preservation. We believe that our existing cash and cash equivalents as of December&#160;31, 2020 will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2023.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for each of the periods presented (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.68%;width:75.06%;">
<tr style="height:18.9pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:8.8pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98,803</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,668</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,177</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,585</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.95pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,619</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,994</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:22.65pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash, cash equivalents and restricted</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,639</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,741</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, operating activities used $98.8&#160;million of cash and cash equivalents, resulting from our net loss of $119.7 million, partially off-set by net cash provided by changes in our operating assets and liabilities of $4.2 million and non-cash charges of $16.7&#160;million. Net cash provided by changes in our operating assets and liabilities for the year ended December&#160;31, 2020 consists primarily of a $3.9 million increase in accrued expenses and other current liabilities, a $1.1&#160;million decrease in prepaid expenses and other current assets and a $0.1 million decrease in other assets, partially offset by a $0.9&#160;million decrease in accounts payable. The increase in accrued expenses and other current liabilities was primarily due to a $3.4 million increase in accrued compensation and benefit costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2019, operating activities used $67.7 million of cash and cash equivalents, resulting from our net loss of $73.0 million and net cash used by changes in our operating assets and liabilities of $2.2 million, offset in part by non-cash charges of $7.5 million. Net cash used by changes in our operating assets and liabilities for the year ended December 31, 2019 consisted primarily of a $4.9 million increase in prepaid expenses and other current assets and a $0.2 million increase in other assets, partially offset by a $1.0 million increase in accounts payable and a $1.9 million increase in accrued expenses and other current liabilities. The increase in prepaid expenses and other current assets was primarily due to a $3.9 million increase in prepaid development costs, $0.6 million increase in prepaid insurance and a $0.6 million increase in a tax incentive refund receivable from the Australian government.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.57%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities was $1.2&#160;million for the year ended December&#160;31, 2020 compared to $1.6&#160;million for the year ended December&#160;31, 2019. The decrease in cash used in investing activities was primarily due to a reduction in purchases of property and equipment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.57%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $172.6&#160;million for the year ended December&#160;31, 2020 compared to $130.0 million for the year ended December&#160;31, 2019. The increase in cash provided by financing activities was primarily due to the proceeds of $164.1 million raised from the February Follow-On Offering and November 2020 Follow-On Offering </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and proceeds of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million raised from our ATM facility, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as compared to the $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129.5</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in proceeds raised from the July 2019 </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ollow-</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ffering in the comparative period</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. Our expenses will also increase as we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continue our development of our product candidates, including continuing enrollment in our ongoing FAB-GT clinical trial for AVR-RD-01, the ongoing investigator-sponsored clinical trial of AVR-RD-04 and our ongoing clinical trial of AVR-RD-02&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">initiate additional clinical trials, including the planned investigator-sponsored clinical trial of AVR-RD-05, and preclinical studies for our other current and future product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek to identify and develop or in-license or acquire additional product candidates and technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek to industrialize our </span><span style="font-style:italic;font-size:10pt;color:#000000;">ex vivo</span><span style="font-size:10pt;color:#000000;"> lentiviral gene therapy approach into a robust, scalable and, if approved, commercially viable process&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek marketing approvals for our product candidates that successfully complete clinical trials, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">hire and retain additional personnel, such as clinical, quality control, commercial and scientific personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expand our infrastructure, office space and facilities to accommodate our growing employee base, including adding equipment and physical infrastructure to support our research and development&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continue to incur additional public company-related costs. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our $259.7 million of existing cash and cash equivalents as of December&#160;31, 2020, will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2023. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration agreements, government and other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government and other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our contractual obligations as of December&#160;31, 2020 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due by Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 to 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4 to 5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease commitments (1)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,078</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,078</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents future minimum lease payments under our non-cancelable operating leases for office and laboratory space, which are located in Cambridge, Massachusetts and Toronto, Canada. Those leases will expire from April 2022 to June 2025. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manufacturing services. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the preceding table as the amount and timing of such payments are not known. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to our license agreements with UHN, BioMarin, The University of Manchester, GenStem and the Lund University rights holders, we are required to make certain milestone and royalty payments to our licensors. See &#8220;Business&#8212;License Agreements&#8221; for additional details regarding our payment obligations to these licensors. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in Note&#160;2 <span style="font-style:italic;">&#8220;Summary of Significant Accounting Policies&#8221;</span> to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met&#59; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">vendors, including central laboratories, in connection with preclinical development activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">CROs and investigative sites in connection with preclinical and clinical studies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">CMOs in connection with drug substance and drug product formulation of preclinical and clinical trial materials. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure stock options and other stock-based awards granted to employees and members of our board of directors for their services as directors based on the fair value on the date of the grant and recognize the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. We have issued stock options, restricted stock and restricted stock units with service-based vesting conditions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of Accounting Standards Update (ASU) No.&#160;2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (ASU 2018-07)</span>, as discussed in Note 2 <span style="font-style:italic;">&#8220;Summary of Significant Accounting Policies&#8221;</span> to our consolidated financial statements appearing elsewhere in this Annual Report, the measurement date for non-employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the later of the adoption date of ASU 2018-07, or the date of grant, without change in the fair value of the award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model, which uses as inputs the estimated fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined the assumptions for the Black-Scholes option-pricing model as discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Determination of the Fair Value of Common Stock.</span><span style="font-size:10pt;color:#000000;"> The fair value of our common stock is determined based on the quoted market price of our common stock. Prior to our IPO, there was no public market for our common stock, and consequently, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering third-party valuations of our common stock as well as our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. After a public trading market for our common stock was established following the closing of our IPO, it was no longer necessary for our board of directors to estimate the fair market value of our common stock in connection with our accounting for granted equity awards.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Expected Term.</span><span style="font-size:10pt;color:#000000;">&#160;The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term of stock options granted has been determined using the simplified method, which uses the midpoint between the vesting date and the contractual term. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Risk-Free Interest Rate.</span><span style="font-size:10pt;color:#000000;">&#160;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based award&#8217;s expected term. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Expected Volatility.</span><span style="font-size:10pt;color:#000000;">&#160;Because we do not have long-term trading history of our common stock, the expected volatility was derived from the average historical stock volatilities of several public companies within our industry that we consider to be comparable to our business over a period equivalent to the expected term of the stock-based awards. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Dividend Rate.</span><span style="font-size:10pt;color:#000000;">&#160;The expected dividend is zero as we have not paid and do not anticipate paying any dividends in the foreseeable future. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation for future awards may differ materially compared with the awards granted previously. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We may take advantage of these exemptions until we are no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards and, as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our IPO or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.07&#160;billion in annual revenue, we have more than $700.0&#160;million in market value of our stock held by non-affiliates (and we have been a public company for at least 12&#160;months and have filed one annual report on Form&#160;10-K) or we issue more than $1.0&#160;billion of non-convertible debt securities over a three-year period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 <span style="font-style:italic;">&#8220;Summary of Significant Accounting Policies&#8221;</span> to our audited financial statements appearing elsewhere in this Annual Report. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Rate Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash and cash equivalents of $259.7&#160;million, which consisted of cash and money market funds. Interest income is sensitive to changes in the general level of interest rates&#59; however, due to the nature of these investments, an immediate 10%&#160;change in interest rates would not have a material impact on our cash and cash equivalents, financial position or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Exchange Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to foreign exchange rate risk. Our headquarters are located in the United States, where the majority of our general and administrative expenses and research and development costs are incurred in U.S. dollars. A portion of our research and development costs are incurred by our subsidiaries in Australia and Canada, whose functional currencies are the U.S. dollar but engage in transactions in Australian dollars and Canadian dollars, respectively. During each of the years ended December&#160;31, 2020 and 2019, we recognized immaterial foreign currency transaction losses. These losses primarily related to unrealized and realized foreign currency gains and losses as a result of transactions entered into by our Australian and Canadian subsidiaries in currencies other than the U.S. dollar. These foreign currency transaction gains and losses were recorded in other expense, net in our consolidated statements of operations. We believe that a 10% change in the exchange rate between the U.S. dollar, Australian dollar and Canadian dollar would not have a material impact on our financial position or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to grow our business, our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could adversely impact our results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign currency exchange risk. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item&#160;8. Financial Statements and Supplementary Data </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statements and supplementary data required to be filed hereunder are filed as listed under Item&#160;15(a) of this Annual Report on Form 10-K and are incorporated herein by this reference. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item&#160;9A. Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2020, our Chief Executive Officer and Chief Financial Officer <span style="color:#000000;">concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this Annual Report on Form 10-K.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the Company. Our internal control over financial reporting is designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, and includes those policies and procedures that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of its Chief Executive Officer and Chief Financial Officer, assessed our internal control over financial reporting as of December 31, 2020. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for &#8220;emerging growth companies&#8221;.</span><span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Remediation of Previously Reported Material Weaknesses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2018, we reported material weaknesses in our internal control over financial reporting related to deficiencies in our controls over the financial statement close process, including over complex accounting issues, expense classification and accrued research and development expenses, as well as the cash disbursement process. We took a number of actions in 2018 and 2019 to improve our internal control over financial reporting to remediate these material weaknesses.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, we completed our testing of the operating effectiveness of the implemented controls and determined they were effective. As a result, we have concluded the material weaknesses identified in fiscal year 2018 have been remediated as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that material weaknesses or significant deficiencies will not occur in the future or that we will be able to remediate such weaknesses or deficiencies in a timely manner, which could impair our ability to accurately and timely report our financial position, results of operations or cash flows. For additional information see the related risks in<span style="Background-color:#FFFFFF;">&#160;the section titled &#8220;Risk Factors&#8221; in Part I, Section 1.A of this Annual Report.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item&#160;9B. Other Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information required by Part III is omitted from this Annual Report on Form 10-K and is incorporated by reference from our definitive proxy statement relating to our 2021 annual meeting of stockholders, pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, also referred to in this Annual Report on Form 10-K as our 2021 Proxy Statement, which we expect to file with the SEC no later than April&#160;30, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item&#160;10. Directors, Executive Officers and Corporate Governance </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item with respect to our directors and executive officers and compliance with Section&#160;16(a) of the Exchange Act will be included in our 2021 Proxy Statement and is incorporated herein by reference. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item&#160;11. Executive Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding executive compensation will be included in our 2021 Proxy Statement and is incorporated herein by reference. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding security ownership of certain beneficial owners and management and securities authorized for issuance under equity compensation plans will be included in our 2021 Proxy Statement and is incorporated herein by reference. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding certain relationships and related transactions and director independence will be included in our 2021 Proxy Statement and is incorporated herein by reference. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item&#160;14. Principal Accounting Fees and Services </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding principal accounting fees and services will be included in our 2021 Proxy Statement and is incorporated herein by reference. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item&#160;15. Exhibits, Financial Statement Schedules </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following documents are included in this Annual Report on Form 10-K: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The following Report and Consolidated Financial Statements of the Company are included in this Annual Report: </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheets </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations and Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Stockholders&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All financial schedules have been omitted because the required information is either presented in the consolidated financial statements or the notes thereto or is not applicable or required. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The exhibits required by Item&#160;601 of Regulation S-K and Item&#160;15(b) of this Annual Report on Form&#160;10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item&#160;16. Form 10-K Summary </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.79%;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report of Independent Registered Public Accounting Firm </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of AVROBIO, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of AVROBIO, Inc. (the Company) as of December&#160;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst&#160;&#38; Young LLP </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2018. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;18, 2021 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands, except per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">259,682</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">187,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AssetsCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">267,242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AssetsCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:Assets" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">271,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Assets" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">200,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,682</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">214</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">484</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:Liabilities" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:Liabilities" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,501</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 6)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000062">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000063">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000076" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001681087_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000077" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001681087_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></ix:nonFraction> shares authorized and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001681087_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001681087_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001681087_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001681087_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of December 31, 2020 and 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000064">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000065">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000084" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001681087_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000085" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001681087_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">150,000</ix:nonFraction></ix:nonFraction> shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">41,569</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">31,673</ix:nonFraction> shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; as of December 31, 2020 and 2019, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">41,569</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">31,643</ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares outstanding as of December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:CommonStockValue" contextRef="C_0001681087_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:CommonStockValue" contextRef="C_0001681087_20191231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">518,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">330,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001681087_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">264,416</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001681087_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">144,704</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">254,344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,013</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">271,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">200,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands, except per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">87,236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:OperatingExpenses" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OperatingExpenses" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">120,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">75,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">719</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OtherNonoperatingExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OtherNonoperatingExpense" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">516</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:NetIncomeLoss" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:NetIncomeLoss" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">72,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">72,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share &#8212;basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000110" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001681087_20200101_20201231" decimals="2" sign="-">3.31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000111" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001681087_20190101_20191231" decimals="2" sign="-">2.66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000112" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000114" name="us-gaap:SharesOutstanding" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,807</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,921</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">71,739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">122,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted stock awards and units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000119" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000120" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering, net of offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" scale="3">525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000123" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under 2018 employee stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000127" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:NetIncomeLoss" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">72,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:NetIncomeLoss" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">72,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000134" name="us-gaap:SharesOutstanding" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">330,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">144,704</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,013</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted stock awards and units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000139" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000140" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offerings, net of offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" scale="3">697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000143" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;ATM facility, net of offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231" decimals="-3" scale="3">67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000147" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231" decimals="-3" scale="3">384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under 2018 employee stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:NetIncomeLoss" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:NetIncomeLoss" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000157" name="us-gaap:SharesOutstanding" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">518,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">264,416</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockholdersEquity" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">254,344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:ProfitLoss" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:ProfitLoss" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">72,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:ShareBasedCompensation" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:ShareBasedCompensation" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="avro:DeferredRentExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="avro:DeferredRentExpense" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" scale="3">172</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="avro:OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,098</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" scale="3">881</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">98,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">67,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001681087_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001681087_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon completion of public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offerings, net of offering costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">164,053</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock under ATM facility, net of offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock under 2018 employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-3" scale="3">166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="-3" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">172,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,639</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,741</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">187,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001681087_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">260,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">187,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment included in accounts payable and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock offering costs incurred but unpaid at period end</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="avro:CommonStockOfferingCostsIncurredButNotYetPaid" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="avro:CommonStockOfferingCostsIncurredButNotYetPaid" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">259,682</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">187,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:RestrictedCash" contextRef="C_0001681087_20201231" decimals="-3" scale="3">492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:RestrictedCash" contextRef="C_0001681087_20191231" decimals="-3" scale="3">492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">260,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">187,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands, except share and per share data) </p><ix:nonNumeric id="F_000213" name="us-gaap:NatureOfOperations" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, Inc. (the &#8220;Company&#8221; or &#8220;AVROBIO&#8221;) is a clinical-stage gene therapy company focused on developing potentially curative <span style="font-style:italic;">ex vivo</span> lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. <span style="font-size:12pt;">&#160;</span> <span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;</span> <span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;</span> <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has devoted substantially all of its efforts to research and development, business planning, acquiring operating assets, seeking protection for its technology and product candidates, and raising capital. Since inception, the Company has funded its operations through sales of preferred stock and common stock. As of December 31, 2020, the Company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001681087_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">264,416</ix:nonFraction>. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash and cash equivalents on hand as of December&#160;31, 2020 of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">259,682</ix:nonFraction> will be sufficient to fund current planned operations and capital expenditure requirements for at least the next twelve months from the filing date of this Annual Report on Form&#160;10-K with the SEC. However, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.  </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000214" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000214_dcnt_fe2ad930-fa25-4dcf-8f45-b384882de784">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p><ix:nonNumeric id="F_000225" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p></ix:nonNumeric><ix:nonNumeric id="F_000226" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of AVROBIO, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </p></ix:nonNumeric><ix:nonNumeric id="F_000227" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker is the chief executive officer (&#8220;CEO&#8221;). The Company and the CEO view the Company&#8217;s operations and manage its business as <ix:nonFraction unitRef="U_avroSegment" id="F_000264" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment. All material long-lived assets of the Company reside in the United States.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000228" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000228_dcnt_d0ee3a1f-294d-4fcd-91d6-18b00f4c2ea2">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">492</ix:nonFraction> as of December 31, 2019 has been reclassified from &#8220;Other assets&#8221; to &#8220;Restricted cash&#8221; in order to conform to the current period presentation. Additionally, the Company has reclassified $<ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:DeferredRentCredit" contextRef="C_0001681087_20191231" decimals="-3" scale="3">214</ix:nonFraction> which was previously classified as &#8220;Accrued expenses and other current liabilities&#8221; as of December 31, 20219 to &#8220;Deferred rent&#8221; in order to </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_fe2ad930-fa25-4dcf-8f45-b384882de784" continuedAt="F_000214_dcnt_537b6f65-d14d-42a8-9040-6d7ec9dc8313"><ix:continuation id="F_000228_dcnt_d0ee3a1f-294d-4fcd-91d6-18b00f4c2ea2">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conform to the current period presentation. These reclassifications had no effect on the consolidated results of operation or cash flows for the year ended December 31, 2019. </span></p></ix:continuation><ix:nonNumeric id="F_000229" name="us-gaap:UseOfEstimates" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities<span style="color:#000000;"> at the date of the financial statements and the reported amounts of expenses during the reporting periods</span>. On an on&#8209;going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p></ix:nonNumeric><ix:nonNumeric id="F_000230" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less at acquisition to be cash equivalents. As of December 31, 2020 and 2019,<span style="font-size:12pt;"> </span>cash and cash equivalents were primarily held in interest-bearing money market funds. </p></ix:nonNumeric><ix:nonNumeric id="F_000231" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p></ix:nonNumeric><ix:nonNumeric id="F_000232" name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Issuance Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. <span style="font-size:12pt;">&#160;</span> As of December&#160;31, 2019, the Company recorded deferred issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">133</ix:nonFraction> within other assets on the consolidated balance sheet related to a follow-on offering of common stock completed in February 2020. There were<span style="font-size:12pt;"> </span><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> amounts deferred as of December 31, 2020.</p></ix:nonNumeric><ix:nonNumeric id="F_000233" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000233_dcnt_5a8429aa-9a30-4621-acbc-28ca0cdee7eb">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level 1&#8212;</span><span style="color:#000000;"> </span><span style="font-size:10pt;color:#000000;">Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.64%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_537b6f65-d14d-42a8-9040-6d7ec9dc8313" continuedAt="F_000214_dcnt_c0b780f6-e2af-4a6f-a4db-3a551111d6bb"><ix:continuation id="F_000233_dcnt_5a8429aa-9a30-4621-acbc-28ca0cdee7eb">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s financial instruments, which include cash equivalents, accounts payable, and accrued expenses, approximated their fair values as of December&#160;31, 2020 and 2019 due to the short</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;term nature of these instruments.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the estimated fair value of financial instruments using available market information. The use of different market assumptions, estimation methodologies, or both, could have a significant effect on the estimated fair value amounts. See Note 4<span style="font-style:italic;"> &#8220;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Fair Value of Financial Assets and Liabilities&#8221;</span><span style="font-style:italic;"> </span>for further discussion.</p></ix:continuation><ix:nonNumeric id="F_000234" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p><ix:nonNumeric id="F_000247" name="avro:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Depreciation and amortization is calculated using the straight-line method over the following estimated useful lives of the assets: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000269" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000270" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231" format="ixt-sec:duryear">2</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000271">Lesser of lease term or 10 years</span></p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000235" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. <span style="color:#000000;">The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001681087_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t record any impairment loss during the years ended December 31, 2020 and 2019.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000236" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company categorizes leases at their inception as either operating or capital leases. On certain lease arrangements, the Company may receive rent holidays or other incentives. The Company recognizes lease costs on a straight-line basis once control of the space is achieved, without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments or escalating payment amounts. The difference between required lease payments and rent expense has been recorded as deferred rent and accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Additionally, incentives received are treated as a reduction of costs over the term of the agreement, as they are considered an inseparable part of the lease agreement.</p></ix:nonNumeric><ix:nonNumeric id="F_000237" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as the change in stockholders&#8217; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) as well as other changes in stockholders&#8217; equity (deficit) which includes certain changes in equity that are excluded from net income (loss). Comprehensive loss has been disclosed in the accompanying consolidated statements of operations and comprehensive loss and equals the Company&#8217;s net loss for all periods presented. </p></ix:nonNumeric><ix:nonNumeric id="F_000238" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000238_dcnt_d92b02ea-0584-4d7e-a36f-844c426e2ba3">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Translation </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_c0b780f6-e2af-4a6f-a4db-3a551111d6bb" continuedAt="F_000214_dcnt_c7d4abad-e182-4b1d-9526-76daffda281f"><ix:continuation id="F_000238_dcnt_d92b02ea-0584-4d7e-a36f-844c426e2ba3">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s international operations in Canada and Australia is the U.S. dollar. Accordingly, all operating assets and liabilities of these international subsidiaries are remeasured into U.S. dollars using the exchange rates in effect at the balance sheet date or historical rates, as appropriate, while expenses are remeasured into U.S. dollars at the average rates in effect during the period. Any differences resulting from the remeasurement of assets, liabilities, and operations of the Canadian and Australian subsidiaries are recorded within other income (expense), net in the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated statements of operations and comprehensive loss. During the years ended December&#160;31, 2020 and 2019, the Company recorded foreign exchange losses of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="avro:ForeignExchangeLoss" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">203</ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="avro:ForeignExchangeLoss" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">90</ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, in other expense.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></ix:continuation><ix:nonNumeric id="F_000239" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development related contracts with parties both inside and outside of the United States. The payments related to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. <span style="color:#000000;">Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span> </p></ix:nonNumeric><ix:nonNumeric id="F_000240" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000240_dcnt_be0b9909-206a-49d9-b08d-5d1bbaba3f1e">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock-based awards issued to employees and members of the Company&#8217;s board of directors (the &#8220;Board&#8221;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions. The Company accounts for forfeitures as they occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2018-07,&#160;<span style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span>, the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the Company&#8217;s adoption of ASU 2018-07 in 2018, the measurement date for non-employee awards is the later of the adoption date of ASU 2018-07, or the date of grant, without change in the fair value of the award. For stock-based awards granted to nonemployees subject to graded vesting that only contain service conditions, the Company has elected to recognize stock-based compensation expense using the straight-line recognition method.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s cash compensation costs are classified. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the absence of an active market for the Company&#8217;s common stock prior to its initial public offering (&#8220;IPO&#8221;), the Company and the Board, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#8217;s common stock at the time of each grant of a stock-based award. The Company and the Board determined the estimated fair value of the Company&#8217;s equity instruments based on a number of factors, including external market conditions affecting the biotechnology industry sector. The Company and the Board utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, <span style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span>, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors in determining the value of the Company&#8217;s common stock at each grant date, including: (1)&#160;prices paid for the Company&#8217;s redeemable convertible preferred stock, which the Company had sold to outside investors in arm&#8217;s-length transactions, and the rights, preferences, and privileges of the Company&#8217;s redeemable convertible preferred stock and common stock&#59; (2)&#160;valuations performed by an independent valuation specialist&#59; (3)&#160;the Company&#8217;s stage of development&#59; (4)&#160;the fact that the grants of stock-based awards involved illiquid securities in a private company&#59; and (5)&#160;the likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as an IPO or sale of the Company, given prevailing market conditions. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_c7d4abad-e182-4b1d-9526-76daffda281f" continuedAt="F_000214_dcnt_812ee17a-3691-4aed-867d-5500c535ddeb"><ix:continuation id="F_000240_dcnt_be0b9909-206a-49d9-b08d-5d1bbaba3f1e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. As there was no public market for its common stock prior to June&#160;21, 2018, which was the first day of trading, and as the trading history of the Company&#8217;s common stock was limited through December&#160;31, 2020, the Company determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common stock&#59; therefore, the expected dividend yield is assumed to be <ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="C_0001681087_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20201231" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction>. </p></ix:continuation><ix:nonNumeric id="F_000241" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p></ix:nonNumeric><ix:nonNumeric id="F_000242" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by adjusting the weighted-average shares outstanding for the potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For purposes of the diluted net loss per share calculation, stock options and restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000243" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subsequent Event Considerations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure.</p></ix:nonNumeric><ix:nonNumeric id="F_000244" name="avro:EmergingGrowthCompanyStatusPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000244_dcnt_cf17524d-3baf-4a13-9902-60e3e67c0d26">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#8220;emerging growth company.&#8221; Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an &#8220;emerging growth company.&#8221; </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_812ee17a-3691-4aed-867d-5500c535ddeb" continuedAt="F_000214_dcnt_c32b3f91-56ad-4138-bb24-7bc6a349c58c"><ix:continuation id="F_000244_dcnt_cf17524d-3baf-4a13-9902-60e3e67c0d26">
</ix:continuation><ix:nonNumeric id="F_000245" name="avro:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No.&#160;2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and Topic 606</span>, or ASU 2018-18. The amendments in ASU 2018-18 clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU 2018-18 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606. The Company adopted ASU 2018-18 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <span style="font-style:italic;">Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), </span>or ASU 2018-15.&#160;ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span>, or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure requirements for fair value measurements. The amendments are effective for interim and annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted for either the entire ASU or only the provisions that eliminate or modify requirements. The amendments with respect to changes in unrealized gains and losses, the range and weighted-average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively. All other amendments are to be applied retrospectively to all periods presented. The Company adopted ASU 2018-13 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p></ix:nonNumeric><ix:nonNumeric id="F_000246" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000246_dcnt_dff181a5-c2c1-46e8-b4eb-c8c68b760c94">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02, <span style="font-style:italic;">(Topic 842) Leases, </span>or ASU 2016-02.&#160;ASU 2016-02&#160;requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. For public entities,&#160;ASU 2016-02&#160;is effective for fiscal years beginning after December&#160;15, 2018. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;ASU 2016-02&#160;is effective for the Company for the year ended December 31, 2022, and all interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. Based on this evaluation t<span style="color:#000000;">he Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the Company&#8217;s total assets and total liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, or ASU 2016-13. ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity's current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.<span style="color:#000000;"> </span>ASU 2016-13 is effective for non-emerging growth companies (&#8220;EGCs&#8221;) for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2016-13 may have on its financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="font-size:8pt;">&#160;</span>November 2019, the FASB issued ASU 2019-11, &#8220;<span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span>&#8221;, or ASU 2019-11. ASU 2019-11 is an accounting pronouncement that amends ASU 2016-13, &#8220;<span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>.&#8221; The amendments update guidance on reporting credit losses for financial assets. These amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in both ASU 2016-13 and ASU 2019-11 are </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_c32b3f91-56ad-4138-bb24-7bc6a349c58c"><ix:continuation id="F_000246_dcnt_dff181a5-c2c1-46e8-b4eb-c8c68b760c94">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. </span><span style="color:#000000;">As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;2016-13 and ASU 2019-11&#160;are effective for the Company for fiscal years beginning after December 15, 202</span><span style="color:#000000;">2</span><span style="color:#000000;">, and interim periods within </span><span style="color:#000000;">those </span><span style="color:#000000;">fiscal years. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is currently evaluating ASU 2016-13 and ASU 2019-11 and their impact on its consolidated financial statements and financial statement disclosures.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span>, or ASU 2019-12. ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for non-EGCs for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years and will be effective for the Company for fiscal years beginning after December 15, 2021 and interim periods beginning after December 15, 2022, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2019-12 may have on its financial statements.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000215" name="avro:LicenseAgreementDisclosureTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000215_dcnt_c438f958-2b62-4be0-9db7-121628ed77f2">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. License Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with The University of Manchester</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2020, the Company entered into an agreement (&#8220;MPSII License Agreement&#8221;) with The University of Manchester, England (&#8220;UoM&#8221;), whereby UoM granted to the Company <span style="Background-color:#FFFFFF;color:#000000;">an exclusive worldwide license under certain patent and other intellectual property rights, subject to certain retained rights, to develop, commercialize and sell an&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">ex vivo</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;lentiviral gene therapy for use in the treatment of Hunter syndrome, or mucopolysaccharidosis type II (&#8220;MPSII&#8221;)</span>.&#160;&#160;As consideration for the MPSII License Agreement, the Company agreed to pay UoM an upfront, one-time fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="avro:UpfrontLicenseFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,000</ix:nonFraction>, which was recognized as research and development expense during the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the agreement, the Company is obligated to make milestone payments of up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="avro:MilestonePayments" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">80,000</ix:nonFraction> upon the achievement of specified development and regulatory milestones, to pay royalties, on a product-by-product and country-by-country basis, of a mid-single digit percentage based on net sales of products licensed under the agreement and to pay a low double digit percentage of any sublicense fees received by the Company. The next anticipated payment milestones under the MPSII License Agreement include $<ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="avro:MilestonePaymentPaid" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction>, which would become due following the date of regulatory approval of the clinical trial application for the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="avro:MilestonePaymentDue" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,000</ix:nonFraction>, upon the dosing of the first patient in the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the agreement <span style="Background-color:#FFFFFF;color:#000000;">expires <ix:nonNumeric id="F_000292" name="avro:AgreementExpirationDescription" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231">upon the later of <ix:nonNumeric id="F_000291" name="avro:AgreementExpirationPeriod" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231" format="ixt-sec:duryear">15</ix:nonNumeric> years from the effective date or the expiration of the last valid claim of the licensed patents</ix:nonNumeric>, subject to certain surviving rights and obligations.</span><span style="font-size:12pt;">&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">UoM and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. UoM has the right to terminate the agreement in the event of certain actions relating to challenge or opposition to the licensed intellectual property brought by the Company or its affiliates or sublicensees.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the MPSII License Agreement, the Company entered into a collaborative research funding agreement with UoM (&#8220;CRFA&#8221;). Under the CRFA, the Company has agreed to fund the budgeted costs of an investigator-sponsored Phase 1/2 clinical trial to be sponsored by UoM in connection with the development activities under the MPSII License Agreement, which are currently estimated to equal approximately<span style="Background-color:#FFFFFF;color:#000000;"> &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000293" name="avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,100</ix:nonFraction> in the aggregate</span>.<span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="avro:CostOfMilestonePayment" contextRef="C_0001681087_20201231" decimals="-3" scale="3">565</ix:nonFraction> of costs related to the CRFA.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreements with University Health Network (&#8220;UHN&#8221;) </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fabry License Agreement&#8212; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;27, 2016, the Company entered into an agreement with UHN, pursuant to which UHN granted the Company an option to enter into an exclusive license under the UHN intellectual property related to Fabry disease in accordance with the pre-negotiated licensing terms. On November&#160;4, 2016, the Company exercised its option and entered into a license agreement with UHN, pursuant to which UHN granted the Company an exclusive worldwide license under certain intellectual property rights and a non-exclusive worldwide license under certain know-how, in each case subject to certain retained rights, to develop, commercialize and sell products for use in the treatment of Fabry disease. In addition, for three years following the execution of the agreement, UHN granted the Company an exclusive option to obtain a license under </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000215_dcnt_c438f958-2b62-4be0-9db7-121628ed77f2" continuedAt="F_000215_dcnt_cefe7a4e-7ccb-4440-92d0-885917de2a97">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain improvements to the licensed intellectual property rights as well as an option to negotiate a license under certain other improvements. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this agreement, the Company paid an option fee of CAD $<ix:nonFraction unitRef="U_iso4217CAD" id="F_000295" name="avro:OptionFee" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127" decimals="-3" scale="3">20</ix:nonFraction>, an upfront license fee of CAD $<ix:nonFraction unitRef="U_iso4217CAD" id="F_000296" name="avro:UpfrontLicenseFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127_20160127" decimals="-3" scale="3">75</ix:nonFraction>, plus the annual license maintenance fee for the first year. Thereafter, the Company is also required to pay UHN future annual license maintenance fees until the first sale of a licensed product in certain markets. The Company is also obligated to make future milestone payments in an aggregate amount of up to CAD $<ix:nonFraction unitRef="U_iso4217CAD" id="F_000297" name="avro:MilestonePayments" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127_20160127" decimals="-3" format="ixt:numdotdecimal" scale="3">2,450</ix:nonFraction> upon the achievement of specified milestones as well as royalties on a country-by-country basis of a low to mid-single-digit percentage of annual net sales of licensed products and a lower single-digit royalty percentage in certain circumstances. Additionally, the Company has agreed to pay a low double-digit royalty percentage of all sublicensing revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires the Company to meet certain performance milestones within specified timeframes. UHN may terminate the agreement if the Company fails to meet these performance milestones despite using commercially reasonable efforts and the Company is unable to reach agreement with UHN on revised timeframes. The Company&#8217;s royalty obligation expires on a licensed product-by-licensed product and country-by-country basis upon the latest to occur of the expiration or termination of the last valid claim under the licensed intellectual property rights in such country, the tenth anniversary of the first commercial sale of such licensed product in such country and the expiration of any applicable regulatory exclusivity in such country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the agreement expires upon the expiration of the Company&#8217;s royalty obligation for all licensed products. UHN can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event that the Company fails to obtain or maintain insurance. Either the Company or UHN may terminate the license agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company can voluntarily terminate the agreement with prior notice to UHN. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company recorded research and development expense related to this agreement with UHN of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20200101_20201231" decimals="-3" scale="3">344</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20190101_20191231" decimals="-3" scale="3">783</ix:nonFraction>, respectively, which consists of reimbursable funded study trial costs and license maintenance fees. <ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="avro:MilestoneFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="avro:MilestoneFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction></ix:nonFraction> milestone fees were incurred related to the Fabry license agreement in the years ended December 31, 2020 and 2019.<span style="font-size:12pt;">&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interleukin 12 License Agreement&#8212; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;27, 2016, the Company entered into an exclusive license agreement with UHN, pursuant to which UHN granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights related to Interleukin 12. Upon execution of this agreement, the Company paid an upfront license fee of CAD&#160;$<ix:nonFraction unitRef="U_iso4217CAD" id="F_000302" name="avro:UpfrontLicenseFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127" decimals="-3" scale="3">264</ix:nonFraction>. In addition, as part of the initial consideration for the license, the Company issued to UHN <ix:nonFraction unitRef="U_xbrlishares" id="F_000305" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127" decimals="INF" format="ixt:numdotdecimal">1,161,665</ix:nonFraction> shares of the Company&#8217;s common stock and<span style="color:#000000;"> agreed to pay UHN up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="avro:PaymentsUponClosingOfInitialPublicOffering" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127" decimals="INF" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction> upon the closing of an IPO if certain criteria are met</span>. The fair value of the shares issued to UHN of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127" decimals="-3" scale="3">480</ix:nonFraction> and the upfront fee was expensed upon the execution of the agreement. Upon the closing of the IPO in 2018, as the criteria were met, the Company paid UHN $<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="avro:PaymentsUponClosingOfInitialPublicOffering" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction>.<span style="font-size:12pt;">&#160;</span>The Company is also required to pay UHN future annual license maintenance fees of CAD $<ix:nonFraction unitRef="U_iso4217CAD" id="F_000304" name="avro:LicenseMaintenanceFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127" decimals="-3" scale="3">50</ix:nonFraction> on each anniversary of the effective date of the license agreement prior to expiration or termination and potential future milestone payments of up to CAD $<ix:nonFraction unitRef="U_iso4217CAD" id="F_000303" name="avro:MilestonePayments" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127" decimals="-3" format="ixt:numdotdecimal" scale="3">19,275</ix:nonFraction> upon the achievement of specified clinical and regulatory milestones. The Company also agreed to pay UHN royalties of a low single-digit percentage of net sales of licensed products sold by the Company. If the Company grants any sublicense rights under the license agreement, the Company has agreed to pay UHN a low double-digit royalty percentage of any sublicense income received by the Company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires the Company to meet certain diligence requirements based upon specified milestones. The agreement expires on the later of the date the last patent rights expire in the last country or ten years from the date of first sale. UHN can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event that the Company fails to obtain or maintain insurance. The Company can voluntarily terminate the agreement with prior notice to UHN. Either the Company or UHN may terminate the license agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company recorded research and development expense related to this agreement with UHN of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20200101_20201231" decimals="-3" scale="3">37</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20190101_20191231" decimals="-3" scale="3">38</ix:nonFraction>, respectively, which consists of license maintenance fees. <ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="avro:MilestoneFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="avro:MilestoneFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction></ix:nonFraction> milestone fees were incurred related to the Interleukin 12 license agreement in the years ended December 31, 2020 and 2019.<span style="font-size:12pt;">&#160;&#160;</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000215_dcnt_cefe7a4e-7ccb-4440-92d0-885917de2a97" continuedAt="F_000215_dcnt_21d96b40-532a-4738-afd6-4bc328d1c5fc">

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with BioMarin Pharmaceutical Inc. (&#8220;BioMarin&#8221;) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;31, 2017, the Company entered into a license agreement with BioMarin, pursuant to which BioMarin granted the Company an exclusive worldwide license under certain intellectual property rights owned or controlled by BioMarin to develop, commercialize and sell products for use in the treatment of Pompe disease. The license agreement was amended in February 2018 and again in January 2020 to, among things, provide that BioMarin would supply the Company with certain technology materials. As consideration for this agreement, the Company paid an upfront license fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="avro:UpfrontLicenseFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170801_20170831" decimals="-3" scale="3">500</ix:nonFraction> in cash and issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000314" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170831" decimals="INF" format="ixt:numdotdecimal">233,765</ix:nonFraction> shares of Series B Preferred Stock to BioMarin at the time of the Company&#8217;s Series B Preferred Stock financing in January 2018. The Company is also obligated to make future milestone payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="avro:MilestonePayment" contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,000</ix:nonFraction> upon the achievement of certain specified milestones and agreed to pay BioMarin royalties of a low single-digit percentage of net sales of licensed products sold by the Company or its affiliates covered by patent rights in a relevant country. <ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="avro:LicenseAgreementExpenses" contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="avro:LicenseAgreementExpenses" contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction></ix:nonFraction> expenses related to the license were recorded for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the agreement expires upon the expiration of the Company&#8217;s royalty obligation for all licensed products throughout the world. BioMarin and the Company can terminate the agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company may terminate the agreement at will upon written notice to BioMarin. BioMarin has the right to terminate the agreement upon the Company&#8217;s bankruptcy or insolvency, or in the event of any challenge or opposition to the licensed patent rights or related actions brought by the Company or its affiliates or sublicensees, or if the Company, its affiliates or sublicensees knowingly assist a third-party in challenging or otherwise opposing the licensed patent rights, except as required under a court order or subpoena. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with GenStem Therapeutics, Inc. (&#8220;GenStem&#8221;) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;2, 2017, the Company entered into a license agreement with GenStem, pursuant to which GenStem granted the Company an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights owned or controlled by GenStem to develop, commercialize and sell products for use in the treatment of cystinosis. Under this agreement, the Company paid an upfront license fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="avro:UpfrontLicenseFees" contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20171002_20171002" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction> and is required to make payments upon completion of certain milestones up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="avro:MilestonePayments" contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20171002_20171002" decimals="-3" format="ixt:numdotdecimal" scale="3">16,000</ix:nonFraction>. The Company also agreed to pay GenStem a tiered mid to high single-digit royalty percentage on annual net sales of licensed products as well as a low double-digit percentage of sublicense income received from certain third-party licensees. The Company&#8217;s royalty obligation expires on a licensed product-by-licensed product and country-by-country basis on the eleventh anniversary of the first commercial sale of such licensed product in such country or the expiration of the last valid claim under the licensed patent rights covering such licensed product in such country, whichever is later. Unless terminated earlier, the agreement expires upon the expiration of the Company&#8217;s royalty obligation for all licensed products throughout the world. GenStem and the Company can terminate the agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company may terminate the agreement at will upon the specified prior written notice to GenStem. &#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020 the Company recorded<span style="font-size:12pt;"> </span><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> research and development expense related to milestone payments. For the year ended December&#160;31, 2019 the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="avro:MilestonePayments" contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction> related to milestone payments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Lund University Rights Holders </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;17, 2016, the Company entered into a license agreement with affiliates of Lund University, along with certain other relevant rights holders that may be added from time to time, pursuant to which such rights holders granted to the Company an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights to develop, commercialize and sell products in any and all uses relevant to Gaucher disease. As consideration for the license, the Company is required to make payments in connection with the achievement of certain milestones up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="avro:MilestonePayments" contextRef="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20161117_20161117" decimals="-3" scale="3">550</ix:nonFraction>. The agreement expires on the latest of (i)&#160;the twentieth anniversary of the end of a certain research project the Company is funding pursuant to an agreement with Lund University, (ii)&#160;the expiration of the term of any patent filed on the licensed rights that covers a licensed product, (iii)&#160;the expiration of any applicable marketing exclusivity right and (iv)&#160;such time that neither the Company nor any sublicensees, partners or contractors are commercializing a licensed product. Either the Company or the rights holders acting together may terminate the license agreement if the other such party commits a material breach and fails to cure such breach within a certain period of time, or if the other party enters into liquidation, becomes insolvent, or enters into composition or statutory reorganization proceedings. <ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="avro:LicenseAgreementExpenses" contextRef="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="avro:LicenseAgreementExpenses" contextRef="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction></ix:nonFraction> expenses related to the license were recorded for the years ended December&#160;31, 2020 and 2019. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000215_dcnt_21d96b40-532a-4738-afd6-4bc328d1c5fc">
</ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000216" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Fair Value of Financial Assets and Liabilities </p><ix:nonNumeric id="F_000248" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents&#8212;money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,416</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,416</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,416</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,416</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents&#8212;money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="avro:FairValueInputAmountTransferBetweenLevels" contextRef="C_0001681087_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="avro:FairValueInputAmountTransferBetweenLevels" contextRef="C_0001681087_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> transfers between levels.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000217" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000217_dcnt_c7269e9a-f954-4042-98c2-402c37aa22d5">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Supplemental Balance Sheet Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prepaid expenses and Other Current Assets</p><ix:nonNumeric id="F_000249" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax incentive refund</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="avro:TaxIncentiveRefundCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,558</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="avro:TaxIncentiveRefundCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="avro:PrepaidResearchAndDevelopmentCostsCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="avro:PrepaidResearchAndDevelopmentCostsCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:PrepaidInsurance" contextRef="C_0001681087_20201231" decimals="-3" scale="3">973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:PrepaidInsurance" contextRef="C_0001681087_20191231" decimals="-3" scale="3">897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid compensation benefits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="avro:PrepaidCompensationBenefits" contextRef="C_0001681087_20201231" decimals="-3" scale="3">609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="avro:PrepaidCompensationBenefits" contextRef="C_0001681087_20191231" decimals="-3" scale="3">362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment, net </p><ix:nonNumeric id="F_000250" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,377</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" scale="3">134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,207</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">850</ix:nonFraction>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000217_dcnt_c7269e9a-f954-4042-98c2-402c37aa22d5">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p><ix:nonNumeric id="F_000251" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company had restricted cash as presented in the table below, which consists of cash used to secure letters of credit for the benefit of the landlord in connection with the Company&#8217;s lease agreements. The cash will be restricted until the termination or modification of the lease arrangement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p><ix:nonNumeric id="F_000252" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and benefit costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="avro:AccruedResearchAndDevelopmentExpenseCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="avro:AccruedResearchAndDevelopmentExpenseCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting and professional fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001681087_20201231" decimals="-3" scale="3">348</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001681087_20191231" decimals="-3" scale="3">115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000218" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000218_dcnt_1f7b272a-8e44-4a55-a90a-22c7eb2e6fd0">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;12, 2018, the Company entered into a lease agreement for office space located in Cambridge, Massachusetts. The lease agreement expires in <ix:nonNumeric id="F_000375" name="avro:LeaseExpirationMonthAndYear" contextRef="C_0001681087_20180112_20180112" format="ixt:datemonthyearen">January 2023</ix:nonNumeric>. The annual lease payments are subject to a <ix:nonFraction unitRef="U_xbrlipure" id="F_000376" name="avro:OperatingLeaseAnnualIncreaseInRentalPercentage" contextRef="C_0001681087_20180112" decimals="2" scale="-2">3</ix:nonFraction>% increase each year. The Company recognizes rent expense on a straight-line basis over the lease period and has recorded deferred rent for rent expense incurred but not yet paid. The Company received a tenant incentive allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:PaymentsForProceedsFromTenantAllowance" contextRef="C_0001681087_20180112_20180112" decimals="-3" scale="3">842</ix:nonFraction> in 2018. Such incentive allowance is being amortized as a reduction of rent expense on a straight-line basis over the lease period. In accordance with the lease agreement, the Company is required to maintain a security deposit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:SecurityDeposit" contextRef="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231" decimals="-3" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:SecurityDeposit" contextRef="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231" decimals="-3" scale="3">209</ix:nonFraction></ix:nonFraction>, which was recorded in restricted cash as of December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;31, 2018, the Company entered into a sub-lease agreement for lab space located in Cambridge Massachusetts, United States, which was set to expire in <ix:nonNumeric id="F_000381" name="avro:LeaseExpirationMonthAndYear" contextRef="C_0001681087_20180831_20180831" format="ixt:datemonthyearen">October 2020</ix:nonNumeric>. On June 9, 2020, the Company amended the terms of the sublease, which is now set to expire in <ix:nonNumeric id="F_000380" name="avro:LeaseExpirationMonthAndYear" contextRef="C_0001681087_20200609_20200609" format="ixt:datemonthyearen">April 2022</ix:nonNumeric>. The annual lease payments are subject to a <ix:nonFraction unitRef="U_xbrlipure" id="F_000382" name="avro:OperatingLeaseAnnualIncreaseInRentalPercentage" contextRef="C_0001681087_20200609" decimals="2" scale="-2">5</ix:nonFraction>% increase each year. In accordance with the lease agreement, the Company is required to maintain a security deposit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:SecurityDeposit" contextRef="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231" decimals="-3" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:SecurityDeposit" contextRef="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231" decimals="-3" scale="3">283</ix:nonFraction></ix:nonFraction>, which was recorded in restricted cash as of December&#160;31, 2020 and 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 1, 2020, the Company entered into a&#160;lease&#160;agreement for office space located in Toronto, Ontario, Canada, which is set to expire in <ix:nonNumeric id="F_000385" name="avro:LeaseExpirationMonthAndYear" contextRef="C_0001681087_20200601_20200601" format="ixt:datemonthyearen">June 2025</ix:nonNumeric>. <ix:nonNumeric id="F_000386" name="avro:AnnualLeasePaymentsDescription" contextRef="C_0001681087_20200101_20201231">The annual lease payments are fixed for years 1 and 2, and then subject to a <ix:nonFraction unitRef="U_xbrlipure" id="F_000387" name="avro:OperatingLeaseAnnualIncreaseInRentalPercentage" contextRef="C_0001681087_20200601" decimals="4" scale="-2">6.67</ix:nonFraction>% increase for years 3 through 5</ix:nonNumeric>. In accordance with the lease agreement, the Company is required to maintain a security deposit of CAD $<ix:nonFraction unitRef="U_iso4217CAD" id="F_000388" name="us-gaap:SecurityDeposit" contextRef="C_0001681087_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20201231" decimals="-3" scale="3">27</ix:nonFraction>, which was recorded in other long-term assets as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded rent expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,352</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,257</ix:nonFraction> during the years ended December&#160;31, 2020 and 2019, respectively. </p><ix:nonNumeric id="F_000253" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000253_dcnt_66afe9a1-4ca5-4944-81dd-68e30b798be8">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the future minimum lease payments due under operating leases as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,297</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="C_0001681087_20201231" decimals="-3" scale="3">207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="C_0001681087_20201231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="avro:OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" contextRef="C_0001681087_20201231" decimals="-3" scale="3">73</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000218_dcnt_1f7b272a-8e44-4a55-a90a-22c7eb2e6fd0"><ix:continuation id="F_000253_dcnt_66afe9a1-4ca5-4944-81dd-68e30b798be8">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Funding Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had several ongoing clinical and non-clinical studies for its various pipeline programs. The Company enters into contracts in the normal course of business with contract research organizations and clinical sites for the conduct of clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have significant cancellation penalties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Guarantees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December&#160;31, 2020 and 2019, and to the best of its knowledge, no material legal proceedings are currently pending or threatened. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December&#160;31, 2020 and 2019, or royalties on future sales of specified products. No milestone or royalty payments under these agreements are expected to be payable in the immediate future. See Note&#160;3 <span style="font-style:italic;">&#8220;Licenses Agreements&#8221;</span> for discussion of these arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. </p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000219" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000219_dcnt_bb2626b3-2c83-41e2-a354-cedd543143fd">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the authorized capital stock of the Company included <ix:nonFraction unitRef="U_xbrlishares" id="F_000397" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000398" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000399" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001681087_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000400" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001681087_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000401" name="avro:UndesignatedPreferredStock" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000402" name="avro:UndesignatedPreferredStock" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock. As of December&#160;31, 2020 and 2019, <ix:nonFraction unitRef="U_xbrlishares" id="F_000403" name="avro:UndesignatedSharesOfPreferredStockOutstanding" contextRef="C_0001681087_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000404" name="avro:UndesignatedSharesOfPreferredStockOutstanding" contextRef="C_0001681087_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> undesignated shares of preferred stock were outstanding.&#160;&#160;&#160;&#160; </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000219_dcnt_bb2626b3-2c83-41e2-a354-cedd543143fd">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance to the Fourth Amended and Restated Certificate of Incorporation, the holders of the common stock shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote&#59;&#160;provided,&#160;however, that, except as otherwise required by law, holders of common stock, as such, shall not be entitled to vote on any amendment to any amendment to a certificate of designations of any series of undesignated preferred stock that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of undesignated preferred stock if the holders of such affected series of undesignated preferred stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to a certificate of designations of any series of undesignated preferred stock.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through December&#160;31, 2020, <ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:DividendsCash" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> cash dividends have been declared or paid. <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offerings </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company closed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000406" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731" decimals="INF" format="ixt:numdotdecimal">7,475,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000407" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190731" decimals="INF">18.50</ix:nonFraction> per share (the &#8220;July 2019 Follow-on Offering&#8221;), which included <ix:nonFraction unitRef="U_xbrlishares" id="F_000408" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20190701_20190731" decimals="INF" format="ixt:numdotdecimal">975,000</ix:nonFraction> shares of the Company&#8217;s common stock resulting from the full exercise of the underwriters&#8217; option to purchase additional shares at the public offering price, less underwriting discounts and commissions.&#160;&#160;The net proceeds to the Company from the July 2019 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731" decimals="-3" format="ixt:numdotdecimal" scale="3">129,464</ix:nonFraction>. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company closed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000410" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229" decimals="INF" format="ixt:numdotdecimal">4,350,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000411" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200229" decimals="INF">23.00</ix:nonFraction> per share (the &#8220;February 2020 Follow-on Offering&#8221;). The net proceeds to the Company from the February 2020 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229" decimals="-3" format="ixt:numdotdecimal" scale="3">93,627</ix:nonFraction>. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company sold an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000413" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200601_20200630" decimals="INF" format="ixt:numdotdecimal">384,140</ix:nonFraction> shares of common stock under its &#8220;at-the-market&#8221; facility&#160;(the &#8220;ATM&#160;Facility&#8221;) for net proceeds, after deducting commissions and other offering expenses payable by the Company, of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200601_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,130</ix:nonFraction>. As of December 31, 2020, approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="avro:CommonStockCapitalSharesAmountAvailableForFutureIssuance" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,549</ix:nonFraction> of common stock remained available for future issuance under the ATM Facility. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company closed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000416" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000417" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201130" decimals="INF">15.00</ix:nonFraction> per share (the &#8220;November 2020 Follow-on Offering&#8221;). The net proceeds to the Company from the November 2020 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130" decimals="-3" format="ixt:numdotdecimal" scale="3">70,221</ix:nonFraction>. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance </p><ix:nonNumeric id="F_000254" name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company has reserved the following shares of common stock for future issuance:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for vesting of restricted stock awards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000419" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">30,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for exercise of outstanding stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000420" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" format="ixt:numdotdecimal">5,559,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000421" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" format="ixt:numdotdecimal">3,414,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for vesting of restricted stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000422" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000423" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="INF" format="ixt:numdotdecimal">2,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2018 Stock Option</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and Incentive Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000424" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">3,877,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000425" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">332,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2018 Employee</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Stock Purchase Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000426" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">762,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000427" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">459,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2019 Inducement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000428" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">365,050</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000429" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,800,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2020 Inducement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000430" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandTwentyInducementPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,700,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of authorized common stock reserved for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; future issuance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000431" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal">12,266,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000432" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal">6,039,105</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000220" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000220_dcnt_0a1fbc7a-cba8-4056-b13b-84e0c247d588">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended and Restated 2015 Stock Option and Grant Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Amended and Restated 2015 Stock Option and Grant Plan, (the &#8220;2015 Plan&#8221;) provides for the Company to issue restricted stock awards and restricted stock units, or to grant incentive stock options or non-statutory stock options. Incentive stock options may be granted only to the Company&#8217;s employees including officers and members of the Board who are also employees. Restricted stock awards and restricted stock units and non- statutory stock options may be granted to employees, members of the Board, outside advisors, and consultants of the Company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total number of common shares that may be issued under the 2015 Plan was <ix:nonFraction unitRef="U_xbrlishares" id="F_000433" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,008,564</ix:nonFraction>&#160;shares. Following the IPO, <ix:nonFraction unitRef="U_xbrlishares" id="F_000434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> further grants have been made under 2015 plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares that expire, are terminated, surrendered or cancelled under the 2015 Plan without having been fully exercised will be available for future awards under the 2018 Plan (as defined below). In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future awards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2015 Plan is administered by the Board. Equity awards granted to employees and members of the Board typically vest over <ix:nonNumeric id="F_000435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20200101_20201231" format="ixt-sec:durwordsen">four years</ix:nonNumeric>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Stock Option and Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2018 Stock Option and Incentive Plan (the &#8220;2018 Plan&#8221;) was adopted by the Board on June&#160;1, 2018 and approved by stockholders on June&#160;7, 2018 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form S-1. The 2018 Plan replaced the 2015 Plan as the Board determined not to make additional awards under the 2015 Plan following the pricing of the Company&#8217;s IPO. The 2018 Plan allows the Board, compensation committee or other designated committee to make equity-based and cash-based incentive awards to its officers, employees, directors and other key persons (including consultants). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000436" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">616,300</ix:nonFraction> shares of its common stock for the issuance of awards under the 2018 Plan. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January&#160;1, beginning on January&#160;1, 2019, by <ix:nonFraction unitRef="U_xbrlipure" id="F_000437" name="avro:NumberOfSharesOfCommonStockOutstandingIncreasePercentage" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" scale="-2">4</ix:nonFraction>% of the outstanding number of shares of our common stock on the immediately preceding December&#160;31, or such lesser number of shares as determined by its Board or compensation committee (the &#8220;Plan Evergreen&#8221;). This number is subject to adjustment in the event of a stock split, stock dividend or other change in its capitalization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 16, 2020, the Board adopted an amendment to the 2018 Plan (the &#8220;Amendment&#8221;), to (i) increase the number of shares of common stock currently reserved for issuance under the 2018 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000438" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200416" decimals="INF" format="ixt:numdotdecimal">3,300,000</ix:nonFraction> shares and (ii) automatically terminate the 2018 Plan&#8217;s annual increase (or &#8220;evergreen&#8221;) provision after January 2022. The Amendment was approved by the Board on June 4, 2020 and the Company&#8217;s stockholders on June 4, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock available for future grant under the 2018 Plan was <ix:nonFraction unitRef="U_xbrlishares" id="F_000439" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">3,877,478</ix:nonFraction> as of December&#160;31, 2020, which does not include the shares added to the 2018 Plan reserve on January 1, 2021 as a result of the Plan Evergreen for the year ended December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, the Company granted options to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,019,663</ix:nonFraction> and, <ix:nonFraction unitRef="U_xbrlishares" id="F_000441" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,677,967</ix:nonFraction> shares, respectively, of common stock to employees, nonemployees and members of the Board. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Board on June&#160;1, 2018 and approved by stockholders on June&#160;7, 2018 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form S-1. The ESPP is intended to qualify as an &#8220;employee sto</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000220_dcnt_0a1fbc7a-cba8-4056-b13b-84e0c247d588" continuedAt="F_000220_dcnt_8babe0ed-bec2-4e1a-8034-cbc88ea09835">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ck</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purchase plan&#8221; within the meaning of Section&#160;423(b) of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000442" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">223,200</ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock to participating employees. </span><ix:nonNumeric id="F_000445" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January&#160;1, beginning on January&#160;1, 2019 and each January&#160;1 thereafter through January&#160;1, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028, by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000443" name="avro:NumberOfSharesOfCommonStockOutstandingIncreasePercentage" contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" scale="-2">1</ix:nonFraction>%</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the outstanding number of shares of our common stock on the immediately preceding December 31&#59; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000444" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,115,700</ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares or (iii)&#160;such number of shares as determined by the ESPP administrator</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the &#8220;ESPP Evergreen&#8221;)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></ix:nonNumeric><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000446" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">13,425</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000447" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,671</ix:nonFraction> shares, respectively of common stock. The total number of shares of common stock that may be issued under the ESPP was <ix:nonFraction unitRef="U_xbrlishares" id="F_000448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">762,900</ix:nonFraction>&#160;shares as of December&#160;31, 2020, of which <ix:nonFraction unitRef="U_xbrlishares" id="F_000449" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">762,900</ix:nonFraction> shares remained available for future grant, and which does not include the shares added to the ESPP reserve on January 1, 2021 as a result of the ESPP Evergreen for the year ended December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Inducement Plan </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.85%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2019 Inducement Plan (the &#8220;2019 Plan&#8221;) was adopted by the Board on December 11, 2019. The purpose of the 2019 Plan is to allow the Company to grant equity awards to new employees as inducements material to such new employee&#8217;s acceptance of employment with the Company. The Company intends that the shares underlying the 2019 Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Nasdaq marketplace rules.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000450" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandNineteenInducementPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,800,000</ix:nonFraction> shares of its common stock for the issuance of awards under the 2019 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock available for future grant under the 2019 Plan was <ix:nonFraction unitRef="U_xbrlishares" id="F_000451" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandNineteenInducementPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">365,050</ix:nonFraction> as of December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Inducement Plan </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.85%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2020 Inducement Plan (the &#8220;2020 Plan&#8221;) was adopted by the Board on December 9, 2020. The purpose of the 2020 Plan is to allow the Company to grant equity awards to new employees as inducements material to such new employee&#8217;s acceptance of employment with the Company. The Company intends that the shares underlying the 2020 Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Nasdaq marketplace rules.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandTwentyInducementPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,700,000</ix:nonFraction> shares of its common stock for the issuance of awards under the 2020 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock available for future grant under the 2020 Plan was <ix:nonFraction unitRef="U_xbrlishares" id="F_000453" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandTwentyInducementPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,700,000</ix:nonFraction> as of December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Option Valuation </p><ix:nonNumeric id="F_000255" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000255_dcnt_ac25aada-cc6e-4f68-a815-80b5fc663a86">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and members of the Board were as follows, presented on a weighted-average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option life (years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">6.00</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">5.62</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000456" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001681087_20200101_20201231" decimals="4" scale="-2">0.76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001681087_20190101_20191231" decimals="4" scale="-2">2.09</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000458" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001681087_20200101_20201231" decimals="4" scale="-2">76.02</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000459" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001681087_20190101_20191231" decimals="4" scale="-2">76.83</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000220_dcnt_8babe0ed-bec2-4e1a-8034-cbc88ea09835" continuedAt="F_000220_dcnt_01d96cf4-5b23-4598-a7dd-a31f142b03ab"><ix:continuation id="F_000255_dcnt_ac25aada-cc6e-4f68-a815-80b5fc663a86">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000256" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s stock option activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal">3,414,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000466" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001681087_20191231" decimals="2">12.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000472">8.43</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,019,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000467" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001681087_20200101_20201231" decimals="2">18.74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000462" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">147,335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000468" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001681087_20200101_20201231" decimals="2">1.83</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled or forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000463" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">727,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000469" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001681087_20200101_20201231" decimals="2">19.70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal">5,559,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001681087_20201231" decimals="2">14.97</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000473">7.65</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,511</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000465" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal">1,934,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000471" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001681087_20201231" decimals="2">10.37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000474">5.40</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,077</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,514</ix:nonFraction>, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant-date fair value of the Company&#8217;s stock options granted during the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000480" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001681087_20200101_20201231" decimals="2">12.28</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000481" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001681087_20190101_20191231" decimals="2">11.61</ix:nonFraction>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted restricted common stock (or restricted stock awards) with time-based vesting conditions to certain employees of the Company.<span style="font-weight:bold;font-style:italic;"> </span>The purchase price of the restricted stock awards are determined by the Board. Unvested shares of restricted stock awards may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. The Company has the option to repurchase the restricted stock awards at the original purchase price if the grantee terminates its working relationship with the Company prior to the vesting date. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000482" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> unvested restricted stock awards as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted stock units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units represent an unsecured promise to grant at no cost a set number of shares of common stock upon vesting. With respect to restricted stock units, recipients are not entitled to cash dividends and have no voting rights during the vesting period.</p><ix:nonNumeric id="F_000257" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s restricted stock award and restricted stock unit activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000483" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001681087_20191231" decimals="INF" format="ixt:numdotdecimal">32,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000486" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001681087_20191231" decimals="2">1.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000484" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">31,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000487" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001681087_20200101_20201231" decimals="2">0.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited, cancelled or expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001681087_20201231" decimals="INF" format="ixt:numdotdecimal">1,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000488" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001681087_20201231" decimals="2">15.65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair value of restricted stock awards and restricted stock units vested during the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">29</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="C_0001681087_20180101_20181231" decimals="-3" scale="3">50</ix:nonFraction>, respectively. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000220_dcnt_01d96cf4-5b23-4598-a7dd-a31f142b03ab">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </span></p><ix:nonNumeric id="F_000258" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was allocated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, total unrecognized compensation cost related to unvested stock-based awards was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,045</ix:nonFraction>, which is expected to be recognized over a weighted-average period of <ix:nonNumeric id="F_000498" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001681087_20190101_20191231" format="ixt-sec:duryear">3.01</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company modified certain awards in conjunction with employee terminations. The&#160;modification&#160;provided for the extension of the post-employment exercise period. The&#160;modifications&#160;resulted in approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="avro:AdditionalResearchAndDevelopmentExpense" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">417</ix:nonFraction> of additional research and development expenses for the year ended December 31, 2020. </p></ix:continuation><ix:nonNumeric id="F_000221" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. 401(k) Savings Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. At the election of the Board, the Company may elect to match employee contributions. <ix:nonNumeric id="F_000500" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" contextRef="C_0001681087_20200101_20201231">Currently, the Company makes matching contributions at a rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000501" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0001681087_20200101_20201231" decimals="2" scale="-2">50</ix:nonFraction>% of the first <ix:nonFraction unitRef="U_xbrlipure" id="F_000502" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0001681087_20200101_20201231" decimals="2" scale="-2">6</ix:nonFraction>% of employee contributions.</ix:nonNumeric> The Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">468</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001681087_20190101_20191231" decimals="-3" scale="3">224</ix:nonFraction>&#160;of expenses related to its 401(k) match for the years ended December&#160;31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000222" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true" continuedAt="F_000222_dcnt_f6f8c67c-a22b-497b-add4-58a74d3d2fdb">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020 and 2019, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001681087_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001681087_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t record a current or deferred income tax expense or (benefit) due to current and historical losses incurred by the Company. The Company&#8217;s operations are predominantly based in the United States and the Company&#8217;s foreign subsidiaries generated <span style="font-style:italic;">de minimis</span> losses for the years ended December&#160;31, 2020 and 2019. </p><ix:nonNumeric id="F_000259" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company&#8217;s effective tax rate as reflected in the consolidated financial statements is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax expense at statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000507" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001681087_20200101_20201231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000508" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001681087_20190101_20191231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000509" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001681087_20200101_20201231" decimals="3" scale="-2">5.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000510" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001681087_20190101_20191231" decimals="3" scale="-2">5.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000511" name="avro:EffectiveIncomeTaxRateReconciliationPermanentDifference" contextRef="C_0001681087_20200101_20201231" decimals="3" sign="-" scale="-2">0.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000512" name="avro:EffectiveIncomeTaxRateReconciliationPermanentDifference" contextRef="C_0001681087_20190101_20191231" decimals="3" sign="-" scale="-2">0.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000513" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0001681087_20200101_20201231" decimals="3" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000514" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0001681087_20190101_20191231" decimals="3" scale="-2">0.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000515" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001681087_20200101_20201231" decimals="3" scale="-2">2.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000516" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001681087_20190101_20191231" decimals="3" scale="-2">2.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000517" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001681087_20200101_20201231" decimals="3" sign="-" scale="-2">28.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000518" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001681087_20190101_20191231" decimals="3" sign="-" scale="-2">27.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision to Return</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000519" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="C_0001681087_20200101_20201231" decimals="3" sign="-" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000520" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="C_0001681087_20190101_20191231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000521" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001681087_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000522" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001681087_20190101_20191231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000222_dcnt_f6f8c67c-a22b-497b-add4-58a74d3d2fdb" continuedAt="F_000222_dcnt_325738f5-2b04-49f2-84b8-8e898718e164">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000260" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets and liabilities are comprised of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S., foreign and state net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,716</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized start up and organizational costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="avro:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" contextRef="C_0001681087_20201231" decimals="-3" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="avro:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" contextRef="C_0001681087_20191231" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001681087_20191231" decimals="-3" scale="3">543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensing agreements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="avro:DeferredTaxAssetsLicenseAgreement" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="avro:DeferredTaxAssetsLicenseAgreement" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="C_0001681087_20191231" decimals="-3" scale="3">993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001681087_20201231" decimals="-3" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001681087_20191231" decimals="-3" scale="3">209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001681087_20201231" decimals="-3" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001681087_20191231" decimals="-3" scale="3">209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December&#160;31, 2020 and 2019, based on the Company&#8217;s history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2020 and 2019. The valuation allowance increased $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001681087_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,066</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001681087_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,968</ix:nonFraction> during the years ended December&#160;31, 2020 and 2019, respectively, due primarily to net operating losses generated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">213,991</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="C_0001681087_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,836</ix:nonFraction>, respectively, that may be available to offset future income tax liabilities. The U.S. federal tax operating loss carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2037Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,743</ix:nonFraction> will expire at various dates through 2037. Approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="C_0001681087_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">196,248</ix:nonFraction> of the U.S. federal tax operating losses can be carried forward indefinitely. As of December&#160;31, 2020 and 2019, the Company also had U.S. state net operating loss carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">201,642</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">115,129</ix:nonFraction>, respectively, which may be available to offset future taxable income. These losses expire at various dates through 2040.<span style="font-size:12pt;">&#160;&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company has federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,677</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,547</ix:nonFraction>, respectively. Included in the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,677</ix:nonFraction> of federal tax credit carryforwards are $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_avroOrphanDrugCreditMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,351</ix:nonFraction> of orphan drug credits. The Company qualifies for, and has elected to, apply part of its federal research credits against its payroll tax liability in accordance with certain provisions of the Internal Revenue Code. The amount applied towards the Company&#8217;s payroll tax liability is capped at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="avro:PayrollTaxLiabilityCappedPerYear" contextRef="C_0001681087_20201231" decimals="-3" scale="3">250</ix:nonFraction> per year. The federal research credits generated in excess of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001681087_20200101_20201231" decimals="-3" scale="3">250</ix:nonFraction> cap are able to be carried forward for <ix:nonNumeric id="F_000558" name="avro:TaxCreditCarryforwardsExpirationPeriod" contextRef="C_0001681087_20200101_20201231" format="ixt-sec:duryear">20</ix:nonNumeric> years. As of December&#160;31, 2020 and 2019, the Company had state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20201231" decimals="-3" scale="3">894</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20191231" decimals="-3" scale="3">214</ix:nonFraction>, respectively, available to reduce future tax liabilities which expire at various dates through 2034. For all years through December&#160;31, 2020, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company carries out extensive research and development activities, it seeks to benefit from the Australian research and development tax credit cash rebate regime. Under this regime, the Company&#8217;s Australian subsidiary may be eligible to surrender the trading losses that arise from its research and development activities for a payable tax credit of up to approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000561" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231" decimals="INF" scale="-2">43.5</ix:nonFraction>% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs for research staff, consumables, certain internal overhead costs and subcontracted expenditures as part of research projects for which the Company does not receive income. For the year ended December&#160;31, 2020, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231" decimals="-3" scale="3">589</ix:nonFraction> in research and development tax credits as an offset to research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a <span style="-sec-ix-hidden:F_000564">three-year</span> period in excess of <ix:nonFraction unitRef="U_xbrlipure" id="F_000563" name="avro:OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" contextRef="C_0001681087_20200101_20201231" decimals="2" scale="-2">50</ix:nonFraction>&#160;percentage points, as defined under Sections&#160;382 </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000222_dcnt_325738f5-2b04-49f2-84b8-8e898718e164">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed numerous financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States, Australia and Canada, and in several states. The foreign, federal and state income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2019. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by foreign tax authorities, the Internal Revenue Service, or state tax authorities to the extent utilized in a future period. <span style="font-size:12pt;">&#160;&#160;&#160;</span></p></ix:continuation><ix:nonNumeric id="F_000223" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock awards and unvested restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </p><ix:nonNumeric id="F_000261" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000565" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">5,559,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000566" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">3,414,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards and units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000567" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000568" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">32,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000224" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001681087_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Related Party Transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">UHN <span style="font-size:12pt;font-weight:normal;font-style:normal;">&#160;&#160;</span><span style="font-weight:normal;font-style:normal;">  </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entry into a license agreement with UHN on January 27, 2016, the Company issued UHN <ix:nonFraction unitRef="U_xbrlishares" id="F_000569" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001681087_us-gaapAwardTypeAxis_avroStockPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20160127_20160127" decimals="INF" format="ixt:numdotdecimal">1,161,665</ix:nonFraction> shares of its common stock. Upon the closing of the IPO in 2018, as UHN&#8217;s fully-diluted percentage ownership of the Company was reduced within a range of specified percentages, the Company was obligated to pay UHN an amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="avro:ProvisionForMaximumCashPayment" contextRef="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20180701_20180731" decimals="INF" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction>, which was paid in July 2018. For the years ended&#160;December&#160;31, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20200101_20201231" decimals="-3" scale="3">381</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20190101_20191231" decimals="-3" scale="3">821</ix:nonFraction>, respectively, of research and development expense related to the license agreements with UHN. Refer to Note&#160;3 <span style="font-style:italic;">&#8220;License Agreements&#8221;</span> for additional information regarding the UHN license agreements. <span style="font-size:12pt;">&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Others </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020 and 2019, the Company recorded expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,488</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,451</ix:nonFraction>, respectively, related to a sublease to rent lab space, provided by an entity affiliated with a member of the board. </p></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NO.<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12.15pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT&#160;INDEX<span style="font-weight:normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518202460/d153924dex31.htm"><span style="text-decoration:underline;">Fourth Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on June&#160;25, 2018 (File No.&#160;001-38537) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001681087/000156459020051456/avro-ex32_90.htm"><span style="text-decoration:underline;">Certificate of Change of Registered Agent and/or Registered Office of the Registrant (filed as Exhibit 3.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2020 (File No. 001-38537) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.3</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518202460/d153924dex32.htm"><span style="text-decoration:underline;">Amended and Restated By-laws (filed as Exhibit 3.2 to the Registrant&#8217;s Current Report on Form&#160;8-K filed on June&#160;25, 2018 (File No.&#160;001-38537) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518188630/d562006dex41.htm"><span style="text-decoration:underline;">Form of Specimen Common Stock Certificate (filed as Exhibit 4.1 to the Registrant&#8217;s Second Amendment to the Registration Statement on Form S-1 filed on June&#160;11, 2018 (File No.&#160;333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518175024/d562006dex42.htm"><span style="text-decoration:underline;">Second Amended and Restated Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, dated January&#160;9, 2018 (filed as Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1 filed on May&#160;25, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001681087/000156459020011144/avro-ex43_591.htm"><span style="text-decoration:underline;">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (filed as Exhibit 4.3 to the to the Registrant&#8217;s Annual Report on Form 10-K filed on March 16, 2020 (File No. 001-38537) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518175024/d562006dex101.htm"><span style="text-decoration:underline;">2015 Amended and Restated Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (filed as Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 filed on May&#160;25, 2018 (File No.&#160;333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518188630/d562006dex102.htm"><span style="text-decoration:underline;">2018 Stock Option and Incentive Plan and forms of award agreements thereunder (filed as Exhibit 10.2 to the Registrant&#8217;s Second Amendment to the Registration Statement on Form S-1 filed on June&#160;11, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001681087/000156459020028774/avro-ex101_30.htm"><span style="text-decoration:underline;">First Amendment to the AVROBIO, Inc. 2018 Stock Option and Incentive Plan (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on June 9, 2020 (File No. 333-225213) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.4#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518188630/d562006dex103.htm"><span style="text-decoration:underline;">Senior Executive Cash Incentive Bonus Plan (filed as Exhibit 10.3 to the Registrant&#8217;s Second Amendment to the Registration Statement on Form S-1 filed on June&#160;11, 2018 (File No.&#160;333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.5#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518188630/d562006dex104.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement (filed as Exhibit 10.4 to the Registrant&#8217;s Second Amendment to the Registration Statement on Form S-1 filed on June&#160;11, 2018 (File No.&#160;333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.6&#8224;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518181102/d562006dex105.htm"><span style="text-decoration:underline;">Exclusive License Agreement, by and between the Registrant and University Health Network, dated November&#160;4, 2016, as amended (filed as Exhibit 10.5 to the Registrant&#8217;s First Amendment to the Registration Statement on Form S-1 filed on June&#160;1, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.7&#8224;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518188630/d562006dex106.htm"><span style="text-decoration:underline;">License Agreement, by and between the Registrant and BioMarin Pharmaceutical Inc., dated August&#160;31, 2017 (filed as Exhibit 10.6 to the Registrant&#8217;s Second Amendment to the Registration Statement on Form S-1 filed on June&#160;11, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.8&#8224;&#8224;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001681087/000156459020011144/avro-ex107_544.htm"><span style="text-decoration:underline;">Amendment No. 1 to License Agreement, by and between the Registrant and BioMarin Pharmaceutical Inc., dated February 21, 2018 (filed as Exhibit 10.7 to the to the Registrant&#8217;s Annual Report on Form 10-K filed on March 16, 2020 (File No. 001-38537) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.9&#8224;&#8224;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001681087/000156459020011144/avro-ex108_543.htm"><span style="text-decoration:underline;">Amendment No. 2 to License Agreement, by and between the Registrant and BioMarin Pharmaceutical Inc., dated January 7, 2020 (filed as Exhibit 10.8 to the to the Registrant&#8217;s Annual Report on Form 10-K filed on March 16, 2020 (File No. 001-38537) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.10&#8224;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518175024/d562006dex107.htm"><span style="text-decoration:underline;">Exclusive License Agreement, by and among the Registrant, Stefan Karlsson and Maria Dahl, dated January&#160;30, 2017 (filed as Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1 filed on May&#160;25, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NO.<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12.15pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT&#160;INDEX<span style="font-weight:normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518175024/d562006dex108.htm"><span style="text-decoration:underline;">License Agreement, by and between the Registrant and GenStem Therapeutics, Inc., dated October&#160;2, 2017 (filed as Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1 filed on May&#160;25, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.12#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518188630/d562006dex109.htm"><span style="text-decoration:underline;">Amended and Restated Employment Agreement, by and between the Registrant and Geoff MacKay, effective as of June&#160;25, 2018 (filed as Exhibit 10.9 to the Registrant&#8217;s Second Amendment to the Registration Statement on Form S-1 filed on June&#160;11, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.13#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518356370/d676576dex101.htm"><span style="text-decoration:underline;">Employment Agreement, by and between the Registrant and Erik Ostrowski, dated December&#160;17, 2018 (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December&#160;21, 2018 (File No.&#160;001-38537) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.14#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312519085321/d677215dex1013.htm"><span style="text-decoration:underline;">Employment Agreement, by and between the Registrant and Steven Avruch, dated December&#160;17, 2018 (filed as Exhibit 10.13 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 25, 2019 (File No. 001-38537) and incorporated herein by reference)</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.15#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312519085321/d677215dex1014.htm"><span style="text-decoration:underline;">Consulting Agreement, by and between the Registrant and Birgitte Volck, M.D., Ph.D., dated December&#160;17, 2018 (filed as Exhibit 10.14 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 25, 2019 (File No. 001-38537) and incorporated herein by reference) </span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.16#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312519085321/d677215dex1015.htm"><span style="text-decoration:underline;">Employment Agreement, by and between the Registrant and Birgitte Volck, M.D., Ph.D., dated December&#160;17, 2018 (filed as Exhibit 10.15 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 25, 2019 (File No. 001-38537) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.17#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001681087/000156459020037237/avro-ex102_230.htm"><span style="text-decoration:underline;">Separation Agreement and Release, by and between the Registrant and Birgitte Volck, M.D., Ph.D., dated July 16, 2020 (filed as Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on August 6, 2020 (File No. 001-38537) and incorporated herein by reference).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.18#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001681087/000156459020011144/avro-ex1016_545.htm"><span style="text-decoration:underline;">Employment Agreement, by and between the Registrant and Deanna Petersen, dated September 1, 2018 (filed as Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 16, 2020 (File No. 001-38537) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.19#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex1019_283.htm"><span style="text-decoration:underline;">Employment Agreement, by and between the Registrant and Chris Mason, dated September 1, 2018</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.20#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex1020_284.htm"><span style="text-decoration:underline;">Employment Agreement, by and between the Registrant and Diana Escolar, dated December 4, 2020</span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.21#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518188630/d562006dex1014.htm"><span style="text-decoration:underline;">2018 Employee Stock Purchase Plan (filed as Exhibit 10.14 to the Registrant&#8217;s Second Amendment to the Registration Statement on Form S-1 filed on June&#160;11, 2018 (File No.&#160;333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.22</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312518175024/d562006dex1012.htm"><span style="text-decoration:underline;">Lease Agreement, dated as of January&#160;12, 2018, by and between the Registrant and ARE-MA Region No. 59, LLC (filed as Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1 filed on May&#160;25, 2018 (File No.&#160; 333-225213) and incorporated herein by reference) </span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.23#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312519320938/d842233dex991.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">2019 Inducement Plan and form of award agreement thereunder (filed as Exhibit 99.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed on December 20, 2019 (File No.&#160;&#160;333-235643) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.24#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1681087/000119312519085335/d724212dex991.htm"><span style="text-decoration:underline;">Form of 2019 Inducement Stock Option Award (filed as Exhibit 99.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed on March 25, 2019 (File No. 333-230493)) and incorporated herein by reference)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.25#</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex1025_465.htm"><span style="text-decoration:underline;">2020 Inducement Plan and form of award agreement thereunder</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;21.1</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex211_12.htm"><span style="text-decoration:underline;">Subsidiaries of the Registrant</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;23.1</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex231_8.htm"><span style="text-decoration:underline;">Consent of Ernst&#160;&#38; Young LLP, Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex311_9.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex312_10.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1*</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="avro-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NO.<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12.15pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT&#160;INDEX<span style="font-weight:normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language (&#8220;Inline XBRL&#8221;).</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*).</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 406 promulgated under the Securities Act of 1933, as amended.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit have been omitted because they are both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or any compensatory plan, contract or arrangement. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates the exhibit is being furnished, not filed, with this report. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 18<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of March, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:right;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;text-align:left;">&#160;</p></td>
<td colspan="3" valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="middle" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoff Mackay</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geoff MacKay</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-weight:bold;color:#000000;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">KNOW&#160;ALL&#160;PERSONS&#160;BY&#160;THESE&#160;PRESENTS<span style="font-weight:normal;">, that each person whose signature appears below constitutes and appoints Geoff MacKay and Erik Ostrowski, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:35%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoff MacKay</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geoff MacKay</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Erik Ostrowski</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Erik Ostrowski</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Officer)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Bruce Booth</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce Booth, D.Phil.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ian T. Clark</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ian T. Clark</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Gail Farfel, Ph.D.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gail Farfel</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Phillip B. Donenberg</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phillip B. Donenberg</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Annalisa Jenkins</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annalisa Jenkins, M.B.B.S., F.R.C.P</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christopher Paige</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Paige, Ph.D.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Philip J. Vickers</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philip J. Vickers, Ph.D.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>avro-ex1019_283.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex1019_283.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.19</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">AvroBio, Inc. </p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">EMPLOYMENT AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Employment Agreement (&#8220;Agreement&#8221;) is made as of the 1st day of September, 2018, between AVROBIO, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Chris Mason (the &#8220;Executive&#8221;) and is effective as of the closing of the Company&#8217;s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#8220;Effective Date&#8221;).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company and the Executive are parties to an existing employment agreement, dated November 1, 2016 (the &#8220;Prior Agreement&#8221;); and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the parties intend to replace the Prior Agreement with this Agreement, effective as of the Effective Date.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-right:1.07%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE,<font style="font-style:italic;"> </font>in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to restate the Prior Agreement as follows:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Employment</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Term</font><font style="color:#000000;">.&nbsp;&nbsp;The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the provisions hereof (the &#8220;Term&#8221;).&nbsp;&nbsp;The Executive&#8217;s employment with the Company will continue to be &#8220;at will,&#8221; meaning that the Executive&#8217;s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Position and Duties</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall serve as the Chief Science Officer of the Company, and shall have supervision and control over and responsibility for the day&#8209;to&#8209;day business and affairs of the Company and shall have such other powers and duties as may from time to time be prescribed by the Board of Directors of the Company (the &#8220;Board&#8221;), the Chief Executive Officer of the Company (the &#8220;CEO&#8221;) or other authorized executive. The Executive shall devote his full working time and efforts to the business and affairs of the Company.&nbsp;&nbsp;Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not materially interfere with the Executive&#8217;s performance of his duties to the Company as provided in this Agreement.&nbsp;&nbsp;For the avoidance of doubt, the Executive may continue to serve in the roles set forth on Schedule 1 hereto without the necessity of further approval from the Board, provided that no conflicts result in the future from the Executive&#8217;s service in such role.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation and Related Matters</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Base Salary</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive&#8217;s annual base salary shall be $303,850.&nbsp;&nbsp;The Executive&#8217;s base salary shall be reviewed annually by the Board or the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;).&nbsp;&nbsp;The base salary in </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">effect at any given time is referred to herein as &#8220;Base Salary.&#8221;&nbsp;&nbsp;The Base Salary shall be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for executive officers.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Incentive Compensation</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall be eligible to receive cash incentive compensation as determined by</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">the Board or the Compensation Committee from time to time.&nbsp;&nbsp;The Executive&#8217;s initial target annual incentive compensation shall be thirty-five percent</font><font style="font-style:italic;color:#000000;"> </font><font style="color:#000000;">of his Base Salary effective July 1, 2018 (resulting in a 30 percent effective rate for the 2018 target annual incentive compensation) (as in effect at any time, the &#8220;Target Annual Incentive Compensation&#8221;). Except as otherwise provided herein, to earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by his during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior officers.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Other Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall be eligible to participate in or receive benefits under the Company&#8217;s employee benefit plans in effect from time to time, subject to the terms of such plans.&nbsp;&nbsp;Additionally, during the Term, the Executive shall be eligible to receive such benefits and perquisites as those made available to the other employees of the Company generally. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Vacations</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall be entitled to paid vacation in accordance with the Company&#8217;s policies and procedures, which shall be a minimum of 20 days in addition to the Company&#8217;s paid holidays.&nbsp;&nbsp;The Executive shall also be entitled to all paid holidays given by the Company to its executive officers.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive&#8217;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Death</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive&#8217;s employment hereunder shall terminate upon his death.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disability</font><font style="color:#000000;">.&nbsp;&nbsp;The Company may terminate the Executive&#8217;s employment if he is disabled and unable to perform the essential functions of the Executive&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period.&nbsp;&nbsp;If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#8217;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive&#8217;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue.&nbsp;&nbsp;The Executive shall cooperate with any reasonable request of the physician in connection with such certification.&nbsp;&nbsp;If such question shall arise and the Executive shall fail to submit such certification, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the Company&#8217;s determination of such issue shall be binding on the Executive.&nbsp;&nbsp;Nothing in this Section 3(b) shall be construed to waive the Executive&#8217;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 </font><font style="font-style:italic;color:#000000;">et seq</font><font style="color:#000000;">. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 </font><font style="font-style:italic;color:#000000;">et seq.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination by Company for Cause</font><font style="color:#000000;">.&nbsp;&nbsp;The Company may terminate the Executive&#8217;s employment hereunder for Cause.&nbsp;&nbsp;For purposes of this Agreement, &#8220;Cause&#8221; shall mean:&nbsp;&nbsp;(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of his duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by the Executive of any felony or a misdemeanor involving moral turpitude, material deceit or dishonesty, or fraud, or any conduct by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if he were retained in his position; (iii) continued non-performance by the Executive of his duties hereunder (other than by reason of the Executive&#8217;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice (with a reasonably detailed summary of such alleged non-performance specified) of such non-performance from the Company&#8217;s CEO or the Executive&#8217;s direct supervisor; (iv) a breach by the Executive of any of the provisions incorporated into or contained in Section 7 of this Agreement; (v) a material violation by the Executive of the Company&#8217;s written employment policies; or (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Without Cause</font><font style="color:#000000;">.&nbsp;&nbsp;The Company may terminate the Executive&#8217;s employment hereunder at any time without Cause.&nbsp;&nbsp;Any termination by the Company of the Executive&#8217;s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination by the Executive</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason.&nbsp;&nbsp;For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean that the Executive has complied with the &#8220;Good Reason Process&#8221; (hereinafter defined) following the occurrence of any of the following events:&nbsp;&nbsp;(i) a material diminution in the Executive&#8217;s responsibilities, authority or duties; (ii) a material diminution in the Executive&#8217;s Base Salary except for across-the-board salary reductions based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (iii) a material change in the geographic location at which the Executive provides services to the Company; or (iv) a material breach of this Agreement by the Company.&nbsp;&nbsp;&#8220;Good Reason Process&#8221; shall mean that (i) the Executive reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">(the &#8220;Cure Period&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates h</font><font style="color:#000000;">is</font><font style="color:#000000;"> employment within 60 days after the end of the Cure Period.&nbsp;&nbsp;If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice of Termination</font><font style="color:#000000;">.&nbsp;&nbsp;Except for termination as specified in Section 3(a), any termination of the Executive&#8217;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto.&nbsp;&nbsp;For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Date of Termination</font><font style="color:#000000;">.&nbsp;&nbsp;&#8220;Date of Termination&#8221; shall mean:&nbsp;&nbsp;(i) if the Executive&#8217;s employment is terminated by his death, the date of his death; (ii) if the Executive&#8217;s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive&#8217;s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period.&nbsp;&nbsp;Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation Upon Termination</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Generally</font><font style="color:#000000;">.&nbsp;&nbsp;If the Executive&#8217;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement) and unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Executive&#8217;s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#8220;Accrued Benefit&#8221;).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination by the Company Without Cause or by the Executive with Good Reason</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, if the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive his Accrued Benefit.&nbsp;&nbsp;In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the company (the &#8220;Separation Agreement and Release&#8221;) and the Separation Agreement and Release becoming irrevocable and fully effective and, if applicable, the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Executive resigning as a member of the Board of Directors, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release):</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company shall pay the Executive an amount equal to 0.75 times the sum of the Executive&#8217;s Base Salary (the &#8220;Severance Amount&#8221;).  Notwithstanding the foregoing, if the Executive breaches any of the provisions incorporated into or contained in Section 7 of this Agreement, all payments of the Severance Amount shall immediately cease; </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all time-based stock options and other time-based stock-based awards held by the Executive in which such stock option or other stock-based award would have vested if the Executive had remained employed for an additional nine months following the Date of Termination shall vest and become exercisable or nonforfeitable as of the Date of Termination;&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for nine months or the Executive&#8217;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the amounts payable under Section 4(b)(i) and (iii) shall be paid out in substantially equal installments in accordance with the Company&#8217;s payroll practice over nine</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">months commencing within 60</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.&nbsp;&nbsp;Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Change in Control Payment</font><font style="color:#000000;">.&nbsp;&nbsp;The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive&#8217;s rights and obligations upon the occurrence of a Change in Control of the Company.&nbsp;&nbsp;In the event of a Change in Control during the Term, all time-based stock options and other time&#173; based stock-based awards held by the Executive as of the Effective Date that were granted to the Executive at least 12 months prior to the Effective Date shall immediately accelerate and become fully exercisable or nonforfeitable as of immediately prior to such Change in Control. These provisions are intended to assure and encourage in advance the Executive&#8217;s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event.&nbsp;&nbsp;These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within three months prior to or 18 </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">months after the occurrence of the first event constituting a Change in Control.&nbsp;&nbsp;These provisions shall terminate and be of no further force or effect beginning </font><font style="color:#000000;">18</font><font style="color:#000000;"> months after the occurrence of a Change in Control.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Change in Control</font><font style="color:#000000;">.  During the Term, if within three months prior to or 18 months after a Change in Control, the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates his employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable and fully effective and, if applicable, the Executive resigning as a member of the Board of Directors, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive&#8217;s current Base Salary (or the Executive&#8217;s Base Salary in effect immediately prior to the Change in Control, if higher) and (B) the Executive&#8217;s Target Annual Incentive Compensation then in effect;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all time-based stock options and other time-based stock-based awards held by the Executive shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination; </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for twelve</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">months or the Executive&#8217;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The amounts payable under Section 5(a)(i) and (iii) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Additional Limitation.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the applicable regulations thereunder (the &#8220;Aggregate Payments&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">$1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction.&nbsp;&nbsp;In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code:&nbsp;&nbsp;(1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For purposes of this Section 5(b), the &#8220;After Tax Amount&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#8217;s receipt of the Aggregate Payments.&nbsp;&nbsp;For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 5(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#8220;Accounting Firm&#8221;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive.&nbsp;&nbsp;Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Definitions</font><font style="color:#000000;">.&nbsp;&nbsp;For purposes of this Section 5, the following terms shall have the following meanings:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Change in Control&#8221; shall mean any of the following:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any &#8220;person,&#8221; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Act&#8221;) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all &#8220;affiliates&#8221; and &#8220;associates&#8221; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &#8220;beneficial owner&#8221; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 50 percent or more of the combined voting power of the Company&#8217;s then outstanding securities having the right to vote in an election of the Board (&#8220;Voting </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Securities&#8221;) (in such case other than as a result of an acquisition of securities directly from the Company); or</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than 50 percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, a &#8220;Change in Control&#8221; shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to 50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns 50 percent or more of the combined voting power of all of the then outstanding Voting Securities, then a &#8220;Change in Control&#8221; shall be deemed to have occurred for purposes of the foregoing clause (i).</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Section 409A</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#8217;s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#8217;s separation from service, or (B) the Executive&#8217;s death.&nbsp;&nbsp;If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement.&nbsp;&nbsp;All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.&nbsp;&nbsp;The amount of in-kind benefits </font><font style="color:#000000;">provided</font><font style="color:#000000;"> or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).&nbsp;&nbsp;Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#8217;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#8217;s &#8220;separation from service.&#8221;&nbsp;&nbsp;The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A&#8209;1(h).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.&nbsp;&nbsp;To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.&nbsp;&nbsp;Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A&#8209;2(b)(2).&nbsp;&nbsp;The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Confidential Information, Noncompetition and Cooperation</font><font style="color:#000000;">. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The terms of the Confidentiality and IP Assignment Agreement (the &#8220;Restricted Covenants Agreement&#8221;), between the Company and the Executive, attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;">, shall continue to be in full force and effect and are incorporated by reference in this Agreement. The Executive hereby reaffirms the terms of the Restrictive Covenant Agreement as material terms of this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Third-Party Agreements and Rights</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#8217;s use or disclosure of information or the Executive&#8217;s engagement in any business.&nbsp;&nbsp;The Executive represents to the Company that the Executive&#8217;s execution of this Agreement, the Executive&#8217;s employment with the Company and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the performance of the Executive&#8217;s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party.&nbsp;&nbsp;In the Executive&#8217;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Litigation and Regulatory Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;During and after the Executive&#8217;s employment, the Executive shall reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company.&nbsp;&nbsp;The Executive&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times, taking into consideration Executive&#8217;s then current business and personal commitments.&nbsp;&nbsp;During and after the Executive&#8217;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company.&nbsp;&nbsp;The Company shall reimburse the Executive for any reasonable out&#8209;of&#8209;pocket expenses incurred in connection with the Executive&#8217;s performance of obligations pursuant to this Section 7(c).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relief</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the promises incorporated into or set forth in this Section 7, and that in any event money damages would be an inadequate remedy for any such breach.&nbsp;&nbsp;Accordingly, subject to Section 8 of this Agreement, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. In addition, in the event the Executive breaches this Section 7 or the provisions incorporated herein during a period when he is receiving severance payments pursuant to Section 4 or Section 5 hereof, the Company shall have the right to suspend or terminate such severance payments.&nbsp;&nbsp;Such suspension or termination shall not limit the Company&#8217;s other options with respect to relief for such breach and shall not relieve the Executive of his duties under this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Protected Disclosures and Other Protected Action</font><font style="color:#000000;">.&nbsp;&nbsp;Nothing contained in this Agreement limits the Executive&#8217;s ability to communicate with any federal, state or local governmental agency or commission, including to provide documents or other information, without notice to the Company.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Arbitration of Disputes</font><font style="color:#000000;">.&nbsp;&nbsp;Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executive&#8217;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">in the absence of such an agreement, under the auspices of the American Arbitration Association (&#8220;AAA&#8221;) in Boston, Massachusetts in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators.&nbsp;&nbsp;</font><font style="color:#000000;">In the event that</font><font style="color:#000000;"> any person or entity other than the Executive or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity&#8217;s agreement.&nbsp;&nbsp;Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.&nbsp;&nbsp;This Section 8 shall be specifically enforceable. Notwithstanding the foregoing, this Section 8 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; </font><font style="color:#000000;">provided that</font><font style="color:#000000;"> any other relief shall be pursued through an arbitration proceeding pursuant to this Section 8.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Consent to Jurisdiction</font><font style="color:#000000;">.&nbsp;&nbsp;To the extent that any court action is permitted consistent with or to enforce Section 8 of this Agreement, the parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts.&nbsp;&nbsp;Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Integration</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement and the Restrictive Covenant Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements between the parties concerning such subject matter, including the Prior Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Withholding</font><font style="color:#000000;">.&nbsp;&nbsp;All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successor to the Executive</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall inure to the benefit of and be enforceable by the Executive&#8217;s personal representatives, executors, administrators, heirs, distributees, devisees and legatees.&nbsp;&nbsp;In the event of the Executive&#8217;s death after his termination of employment but prior to the completion by the Company of all payments due to his under this Agreement, the Company shall continue such payments to the Executive&#8217;s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Enforceability</font><font style="color:#000000;">.&nbsp;&nbsp;If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Survival</font><font style="color:#000000;">.&nbsp;&nbsp;The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#8217;s employment to the extent necessary to effectuate the terms contained herein.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party.&nbsp;&nbsp;The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendment</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">19.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Counterparts</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successor to Company</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place.&nbsp;&nbsp;Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">21.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Gender Neutral</font><font style="color:#000000;">.&nbsp;&nbsp;Wherever used herein, a pronoun in the masculine or feminine gender shall be considered as including the opposite gender as well unless the context clearly indicates otherwise.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the parties have executed this Agreement effective on the date and year first above written.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:86.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoff MacKay</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:86.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geoff MacKay</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:86.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christopher Mason</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:100%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chris Mason</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approved Activities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">University College London, London, UK: Professor of Cell and Gene Therapy - De minimis GSK: Gene Therapy Advisory Board - 1 meeting p.a.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UCB: Gene Therapy Advisory Board - I meeting p.a. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OriBiotech, London, UK:&nbsp;&nbsp;Advisory Board - 1 meeting p.a.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cell and Gene Therapy Catapult, London, UK:&nbsp;&nbsp;SAB- 1 meeting p.a.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality and IP Assignment Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>avro-ex1020_284.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex1020_284.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.20</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">AvroBio, Inc. </p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">EMPLOYMENT AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Employment Agreement (&#8220;Agreement&#8221;) is made as of the 4<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of December 2020, between AVROBIO, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Diana Escolar, MD (the &#8220;Executive&#8221;).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company commencing on January 18, 2021, unless another date is agreed to by the parties.&nbsp;&nbsp;The Executive&#8217;s first day of employment shall be the &#8220;Effective Date&#8221; of this Agreement; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, to protect the Company&#8217;s proprietary information and goodwill, as a condition of Executive&#8217;s employment, the Executive and the Company will become parties to the Employee Confidentiality, Assignment and Noncompetition Agreement (the &#8220;Restrictive Covenants Agreement&#8221;), which is being provided to the Executive along with this Agreement.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE,<font style="font-style:italic;"> </font>in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Employment</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Term</font><font style="color:#000000;">.&nbsp;&nbsp;The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the provisions hereof (the &#8220;Term&#8221;).&nbsp;&nbsp;The Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that the Executive&#8217;s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Position and Duties</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall serve as the Chief Medical Officer of the Company, reporting to Geoff MacKay, the Company&#8217;s President and CEO (&#8220;CEO&#8221;).&nbsp;&nbsp;In such role, the Executive shall have supervision and control over and responsibility for all clinical, medical, and regulatory affairs of the Company and shall have such other powers and duties as may from time to time be prescribed by the Board of Directors of the Company (the &#8220;Board&#8221;), the Chief Executive Officer of the Company (the &#8220;CEO&#8221;), or other authorized executive. The Executive shall devote her full working time and efforts to the business and affairs of the Company.&nbsp;&nbsp;Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not materially interfere with the Executive&#8217;s performance of her duties to the Company as provided in this Agreement.&nbsp;&nbsp;For the avoidance of doubt, the Executive may continue to serve in the roles set forth on Schedule 1 hereto without the necessity of further approval from the Board, provided that no conflicts result in the future from the Executive&#8217;s service in such role.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation and Related Matters</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Base Salary</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive&#8217;s annual base salary shall be $450,000.&nbsp;&nbsp;The Executive&#8217;s base salary shall be reviewed annually by the Board or the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;).&nbsp;&nbsp;The base salary in effect at any given time is referred to herein as &#8220;Base Salary.&#8221;&nbsp;&nbsp;The Base Salary shall be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for executive officers.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Incentive Compensation</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall be eligible to receive cash incentive compensation as determined by</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">the Board or the Compensation Committee from time to time.&nbsp;&nbsp;The Executive&#8217;s initial target annual incentive compensation shall be forty percent (40%) of her Base Salary (as in effect at any time, the &#8220;Target Annual Incentive Compensation&#8221;).&nbsp;&nbsp;To earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior officers.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Other Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall be eligible to participate in or receive benefits under the Company&#8217;s employee benefit plans in effect from time to time, subject to the terms of such plans.&nbsp;&nbsp;Additionally, during the Term, the Executive shall be eligible to receive such benefits and perquisites as those made available to the other employees of the Company generally. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Vacations</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive shall be entitled to paid vacation in accordance with the Company&#8217;s policies and procedures, which shall be a minimum of 20 days in addition to the Company&#8217;s paid holidays.&nbsp;&nbsp;The Executive shall also be entitled to all paid holidays given by the Company to its executive officers.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Equity</font><font style="color:#000000;">.&#160; The Executive shall also be eligible to participate in the Company&#8217;s equity incentive plan, subject to approval by the Board or Compensation Committee. As a material inducement to the Executive entering into this Agreement and becoming an employee of the Company, and subject to approval by the Board or Compensation Committee, the Company will grant the Executive an option to purchase 130,000 shares of the Company&#8217;s common stock (&#8220;New Hire Award&#8221;). The New Hire Award shall vest over four years, with twenty-five percent of the New Hire Award vesting on the one-year anniversary of the Effective Date and the remaining shares vesting in thirty-six equal monthly installments following the one-year anniversary of the Effective Date, subject to the Executive&#8217;s continued service relationship with the Company. The New Hire Award shall be granted under the Company&#8217;s 2019 Inducement Plan in the form of a non-qualified stock option as an inducement grant consistent with the requirements of NASDAQ Stock Market Rule 5635(c)(4).&nbsp;&nbsp;The New Hire Award will be governed by the terms and conditions of an award agreement (such documents, together with any other equity awards held by the Executive and the applicable award agreements and the Company&#8217;s applicable equity incentive plan(s), the &#8220;Equity Documents&#8221;); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section 4(b)(ii) or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Section 5(a)(ii) of this Agreement (as applicable) shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason (as such terms are defined below).&nbsp;&nbsp; </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Signing Bonus</font><font style="color:#000000;">.&#160; The Company will pay the Executive a one-time signing bonus of $100,000 payable in a lump sum on the date of the first payroll after the Effective Date, subject to applicable deductions and withholdings (the &#8220;Signing Bonus&#8221;).&nbsp;&nbsp;The Signing Bonus will be subject to repayments in full if the Executive voluntarily chooses to resign from the Company within the first twelve (12) months of the Effective Date.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relocation Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;Provided that the Executive executes and delivers a Relocation Repayment Agreement prior to the Effective Date, the Executive will be eligible for the Company&#8217;s relocation benefits (&#8220;Relocation Benefits&#8221;), covering relocation expenses from Colorado to the Boston, Massachusetts area, as described in further detail in the Company&#8217;s Executive Relocation Policy and Benefits Summary, a copy of which is attached as </font><font style="text-decoration:underline;color:#000000;">Exhibit B</font><font style="color:#000000;"> (the &#8220;Relocation Policy&#8221;). Notwithstanding anything to the contrary in the Relocation Policy regarding the number of months for which executives are eligible for temporary housing, the Executive shall be entitled to six (6) months of temporary housing, subject to the terms and conditions of the Relocation Policy. In addition, and notwithstanding anything to the contrary in the Relocation Policy, to the extent that any of the Relocation Benefits result in taxable income to the Executive (after taking into account any and all offsetting deductions), the Company will pay the Executive an additional amount (the &#8220;Relocation Gross-Up&#8221;) such that the net after-tax amount of the reimbursement of the Relocation Benefits and the Relocation Gross-Up (at the Executive&#8217;s then-current combined state and federal marginal income tax rates, taking into account the deductibility of state and local income taxes for federal income tax purposes and all other applicable deductions) is equal to the Relocation Benefits. [Notwithstanding the foregoing, the Relocation Gross-Up shall not exceed $50,000. Any tax gross-up payment will be paid to the Executive no later than sixty (60) days after which the Executive remits the related taxes.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, the Executive&#8217;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Death</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive&#8217;s employment hereunder shall terminate upon her death.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disability</font><font style="color:#000000;">.&nbsp;&nbsp;The Company may terminate the Executive&#8217;s employment if he is disabled and unable to perform the essential functions of the Executive&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period.&nbsp;&nbsp;If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#8217;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive&#8217;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue.&nbsp;&nbsp;The Executive shall cooperate with any reasonable request of the physician in connection with such certification.&nbsp;&nbsp;If such question shall arise and the Executive shall fail to submit such certification, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the Company&#8217;s determination of such issue shall be binding on the Executive.&nbsp;&nbsp;Nothing in this Section 3(b) shall be construed to waive the Executive&#8217;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 </font><font style="font-style:italic;color:#000000;">et seq</font><font style="color:#000000;">. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 </font><font style="font-style:italic;color:#000000;">et seq.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination by Company for Cause</font><font style="color:#000000;">.&nbsp;&nbsp;The Company may terminate the Executive&#8217;s employment hereunder for Cause.&nbsp;&nbsp;For purposes of this Agreement, &#8220;Cause&#8221; shall mean:&nbsp;&nbsp;(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of her duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by the Executive of any felony or a misdemeanor involving moral turpitude, material deceit or dishonesty, or fraud, or any conduct by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if he were retained in her position; (iii) continued non-performance by the Executive of her duties hereunder (other than by reason of the Executive&#8217;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice (with a reasonably detailed summary of such alleged non-performance specified) of such non-performance from the Company&#8217;s CEO; (iv) a breach by the Executive of any of the provisions incorporated into or contained in Section 7 of this Agreement; (v) a material violation by the Executive of the Company&#8217;s written employment policies; or (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Without Cause</font><font style="color:#000000;">.&nbsp;&nbsp;The Company may terminate the Executive&#8217;s employment hereunder at any time without Cause.&nbsp;&nbsp;Any termination by the Company of the Executive&#8217;s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination by the Executive</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive may terminate her employment hereunder at any time for any reason, including but not limited to Good Reason.&nbsp;&nbsp;For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean that the Executive has complied with the &#8220;Good Reason Process&#8221; (hereinafter defined) following the occurrence of any of the following events:&nbsp;&nbsp;(i) a material diminution in the Executive&#8217;s responsibilities, authority or duties or reporting relationship; (ii) a material diminution in the Executive&#8217;s Base Salary except for across-the-board salary reductions based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (iii) a material change in the geographic location at which the Executive provides services to the Company; or (iv) a material breach of this Agreement by the Company.&nbsp;&nbsp;&#8220;Good Reason Process&#8221; shall mean that (i) the Executive reasonably determines in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company&#8217;s efforts, for a period not less than 30 days following </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">such notice (the &#8220;Cure Period&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates</font><font style="color:#000000;"> her </font><font style="color:#000000;">employment within 60 days after the end of the Cure Period.&nbsp;&nbsp;If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice of Termination</font><font style="color:#000000;">.&nbsp;&nbsp;Except for termination as specified in Section 3(a), any termination of the Executive&#8217;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto.&nbsp;&nbsp;For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Date of Termination</font><font style="color:#000000;">.&nbsp;&nbsp;&#8220;Date of Termination&#8221; shall mean:&nbsp;&nbsp;(i) if the Executive&#8217;s employment is terminated by her death, the date of her death; (ii) if the Executive&#8217;s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive&#8217;s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period.&nbsp;&nbsp;Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation Upon Termination</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Generally</font><font style="color:#000000;">.&nbsp;&nbsp;If the Executive&#8217;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to her authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement) and unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Executive&#8217;s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#8220;Accrued Benefit&#8221;).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination by the Company Without Cause or by the Executive with Good Reason</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, if the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates her employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive her Accrued Benefit.&nbsp;&nbsp;In addition, subject to the Executive signing a separation agreement in a form satisfactory to the Company containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement provisions, a reaffirmation of all of the Executive&#8217;s Continuing Obligations, a twelve-month post-employment noncompetition provision and a seven business-day revocation </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">period, and which&nbsp;&nbsp;provides that if the Executive breaches any of the Executive&#8217;s Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#8220;Separation Agreement and Release&#8221;) and the Separation Agreement and Release becoming irrevocable and fully effective and, if applicable, the Executive resigning as a member of the Board of Directors, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release):</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company shall pay the Executive an amount equal to 0.75 times the sum of the Executive&#8217;s Base Salary (the &#8220;Severance Amount&#8221;); </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all time-based stock options and other time-based stock-based awards held by the Executive in which such stock option or other stock-based award would have vested if the Executive had remained employed for an additional nine months following the Date of Termination shall vest and become exercisable or nonforfeitable as of the Date of Termination;&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for nine months or the Executive&#8217;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the amounts payable under Section 4(b)(i) and (iii) shall be paid out in substantially equal installments in accordance with the Company&#8217;s payroll practice over nine</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">months commencing within 60</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.&nbsp;&nbsp;Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2); and</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Severance Amount which Executive is paid or for which Executive is eligible in any calendar year shall be reduced by the amount of Garden Leave Pay (as defined in the Restrictive Covenants Agreement) paid to Executive in such calendar year. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Change in Control Payment</font><font style="color:#000000;">.&nbsp;&nbsp;The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive&#8217;s rights and obligations upon the occurrence of a Change in Control of the Company.&nbsp;&nbsp;These provisions are intended to assure and encourage in advance the Executive&#8217;s continued attention and dedication to her assigned duties and her objectivity during the pendency and after the occurrence of any such event.&nbsp;&nbsp;These provisions shall apply in lieu of, and expressly </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within three months prior to or </font><font style="color:#000000;">18</font><font style="color:#000000;"> months after the occurrence of the first event constituting a Change in Control.&nbsp;&nbsp;These provisions shall terminate and be of no further force or effect beginning </font><font style="color:#000000;">18</font><font style="color:#000000;"> months after the occurrence of a Change in Control.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Change in Control</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term, if within three months prior to or 18 months after a Change in Control, the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates her employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable and fully effective and, if applicable, the Executive resigning as a member of the Board of Directors, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive&#8217;s current Base Salary (or the Executive&#8217;s Base Salary in effect immediately prior to the Change in Control, if higher) and (B) the Executive&#8217;s Target Annual Incentive Compensation then in effect (together the &#8220;Change in Control Payment&#8221;);</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all time-based stock options and other time-based stock-based awards held by the Executive shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination; </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for twelve</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">months or the Executive&#8217;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The amounts payable under Section 5(a)(i) and (iii) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period; and </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Change in Control Payment which Executive is paid or for which Executive is eligible in any calendar year shall be reduced by the amount of Garden Leave Pay (as defined in the Restrictive Covenants Agreement) paid to Executive in such calendar year.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Additional Limitation.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the applicable regulations thereunder (the &#8220;Aggregate Payments&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction.&nbsp;&nbsp;In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code:&nbsp;&nbsp;(1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For purposes of this Section 5(b), the &#8220;After Tax Amount&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#8217;s receipt of the Aggregate Payments.&nbsp;&nbsp;For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 5(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#8220;Accounting Firm&#8221;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive.&nbsp;&nbsp;Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Definitions</font><font style="color:#000000;">.&nbsp;&nbsp;For purposes of this Section 5, the following terms shall have the following meanings:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Change in Control&#8221; shall mean any of the following:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any &#8220;person,&#8221; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Act&#8221;) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all &#8220;affiliates&#8221; and &#8220;associates&#8221; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &#8220;beneficial owner&#8221; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 50 percent or more of the combined voting power of the Company&#8217;s then outstanding securities having the right to vote in an election of the Board (&#8220;Voting Securities&#8221;) (in such case other than as a result of an acquisition of securities directly from the Company); or</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than 50 percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, a &#8220;Change in Control&#8221; shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to 50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns 50 percent or more of the combined voting power of all of the then outstanding Voting Securities, then a &#8220;Change in Control&#8221; shall be deemed to have occurred for purposes of the foregoing clause (i).</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Section 409A</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#8217;s separation from service within the meaning of Section 409A of the Code, the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement or the Restrictive Covenants Agreement on account of the Executive&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#8217;s separation from service, or (B) the Executive&#8217;s death.&nbsp;&nbsp;If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement.&nbsp;&nbsp;All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.&nbsp;&nbsp;The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).&nbsp;&nbsp;Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent that any payment or benefit described in this Agreement or the Restrictive Covenants Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#8217;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#8217;s &#8220;separation from service.&#8221;&nbsp;&nbsp;The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A&#8209;1(h).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.&nbsp;&nbsp;To the extent that any provision of this Agreement or the Restrictive Covenants Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.&nbsp;&nbsp;Each payment pursuant to this Agreement or and the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A&#8209;2(b)(2).&nbsp;&nbsp;The parties agree that this Agreement and the Restrictive Covenants Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Confidential Information, Nonsolicitation and Cooperation</font><font style="color:#000000;">. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Restrictive Covenants Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive acknowledges and agrees that in consideration and as a condition of the Executive&#8217;s employment by the Company and in exchange for, among other things, the benefits contained in this Agreement, the Executive will enter into the Restrictive Covenants Agreement attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;">, the terms of which are incorporated by reference as material terms of this Agreement.&nbsp;&nbsp;For purposes of this Agreement, the obligations in this Section 7 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;Continuing Obligations.&#8221;&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Third-Party Agreements and Rights</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#8217;s use or disclosure of information or the Executive&#8217;s engagement in any business.&nbsp;&nbsp;The Executive represents to the Company that the Executive&#8217;s execution of this Agreement, the Executive&#8217;s employment with the Company and the performance of the Executive&#8217;s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party.&nbsp;&nbsp;In the Executive&#8217;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Litigation and Regulatory Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;During and after the Executive&#8217;s employment, the Executive shall reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company.&nbsp;&nbsp;The Executive&#8217;s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times, taking into consideration Executive&#8217;s then current business and personal commitments.&nbsp;&nbsp;During and after the Executive&#8217;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company.&nbsp;&nbsp;The Company shall reimburse the Executive for any reasonable out&#8209;of&#8209;pocket expenses incurred in connection with the Executive&#8217;s performance of obligations pursuant to this Section 7(c).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relief</font><font style="color:#000000;">.&nbsp;&nbsp;The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the promises incorporated into or set forth in this Section 7, and that in any event money damages would be an inadequate remedy for any such breach.&nbsp;&nbsp;Accordingly, subject to Section 8 of this Agreement, the Executive agrees that if the Executive breaches, or proposes to breach, any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. In addition, in the event the Executive breaches this Section 7 or the provisions incorporated herein during a period when he is receiving severance payments pursuant to Section 4 or Section 5 hereof, the Company shall have the right to suspend or terminate such severance payments.&nbsp;&nbsp;Such suspension or termination shall not limit the Company&#8217;s other options with respect to relief for such breach and shall not relieve the Executive of</font><font style="color:#000000;"> her </font><font style="color:#000000;">duties under this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Protected Disclosures and Other Protected Action</font><font style="color:#000000;">.&nbsp;&nbsp;Nothing contained in this Agreement limits the Executive&#8217;s ability to communicate with any federal, state or local governmental agency or commission, including to provide documents or other information, without notice to the Company.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Arbitration of Disputes</font><font style="color:#000000;">.&nbsp;&nbsp;Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executive&#8217;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (&#8220;AAA&#8221;) in Boston, Massachusetts in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators.&nbsp;&nbsp;In the event that any person or entity other than the Executive or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity&#8217;s agreement.&nbsp;&nbsp;Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.&nbsp;&nbsp;This Section 8 shall be specifically enforceable. Notwithstanding the foregoing, this Section 8 shall not preclude either party from pursuing a court action for the sole purpose of enforcing the Restrictive Covenants Agreement or obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 8.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Consent to Jurisdiction</font><font style="color:#000000;">.&nbsp;&nbsp;To the extent that any court action is permitted consistent with or to enforce Section 8 of this Agreement, the parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts.&nbsp;&nbsp;Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Integration</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement and the Restrictive Covenants Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements between the parties concerning such subject matter, including without the limitation the Offer Letter.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Withholding</font><font style="color:#000000;">.&nbsp;&nbsp;All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successor to the Executive</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall inure to the benefit of and be enforceable by the Executive&#8217;s personal representatives, executors, administrators, heirs, distributees, devisees and legatees.&nbsp;&nbsp;In the event of the Executive&#8217;s death after her termination of employment but prior to the completion by the Company of all payments due to him under this Agreement, the Company shall continue such payments to the Executive&#8217;s beneficiary designated in writing to the Company prior to her death (or to her estate, if the Executive fails to make such designation).</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Enforceability</font><font style="color:#000000;">.&nbsp;&nbsp;If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Survival</font><font style="color:#000000;">.&nbsp;&nbsp;The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#8217;s employment to the extent necessary to effectuate the terms contained herein.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party.&nbsp;&nbsp;The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendment</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">19.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Counterparts</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">20.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successor to Company</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place.&nbsp;&nbsp;Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">21.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conditions</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding anything to the contrary herein, the effectiveness of this Agreement is conditioned on (i) successful reference and background verifications of the Executive, and (ii) the Executive&#8217;s submission of satisfactory proof of identity and legal authorization to work in the United States, as is required for all employees.&nbsp;&nbsp;This Agreement shall be void ab initio and of no further force or effect if the conditions set forth in this Section are not satisfied.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Gender Neutral</font><font style="color:#000000;">.&nbsp;&nbsp;Wherever used herein, a pronoun in the masculine or feminine gender shall be considered as including the opposite gender as well unless the context clearly indicates otherwise.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC.</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:50.42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoff MacKay</p></td>
<td valign="top"  style="width:35.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04-Dec-2020</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:50.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geoff MacKay</p></td>
<td valign="top"  style="width:35.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:50.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td valign="top"  style="width:35.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:50.42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Diana Escolar</p></td>
<td valign="top"  style="width:35.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:50.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:35.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:64.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diana Escolar, MD</p></td>
<td valign="top"  style="width:35.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approved Activities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restrictive Covenants Agreement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>avro-ex1025_465.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex1025_465.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.25</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk26523396"></a>AVROBIO, INC.</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">2020 INDUCEMENT PLAN</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 1.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">GENERAL PURPOSE OF THE PLAN; DEFINITIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The name of the plan is the AVROBIO, Inc. 2020 Inducement Plan (the &#8220;Plan&#8221;).&nbsp;&nbsp;The purpose of the Plan is to enable AVROBIO, Inc., a Delaware corporation (the &#8220;Company&#8221;) and its Subsidiaries to grant equity awards to induce highly-qualified prospective officers and employees who are Eligible Employees to accept employment and to provide them with a proprietary interest in the Company.&nbsp;&nbsp;It is anticipated that providing such persons with a direct stake in the Company&#8217;s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#8217;s behalf and strengthening their desire to remain with the Company.&nbsp;&nbsp;The Company intends that the Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, Inc.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following terms shall be defined as set forth below:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> &#8220;Administrator&#8221;<font style="font-style:normal;"> means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non&#8209;Employee Directors who are independent.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Award&#8221;<font style="font-style:normal;"> or </font>&#8220;Awards,&#8221;<font style="font-style:normal;"> except where referring to a particular category of grant under the Plan, shall include Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, and Dividend Equivalent Rights.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Award Certificate&#8221;<font style="font-style:normal;"> means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan.&nbsp;&nbsp;Each Award Certificate is subject to the terms and conditions of the Plan.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Board&#8221;<font style="font-style:normal;"> means the Board of Directors of the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> &#8220;Code&#8221;<font style="font-style:normal;"> means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Consultant&#8221; <font style="font-style:normal;">means any natural person that provides bona fide services to the Company, and such services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company&#8217;s securities.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Dividend Equivalent Right&#8221;<font style="font-style:normal;"> means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Effective Date&#8221;</font><font style="font-style:normal;"> means the date on which the Plan becomes effective as set forth in Section&#160;18.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_31"></a><a name="_cp_text_4_32"></a><a name="_cp_text_1_33"></a>&#8220;Eligible Employee&#8221;<font style="font-style:normal;"><a name="_cp_text_1_31"></a><a name="_cp_text_4_32"></a> means any individual who was not previously an employee or a non-employee director of the Company or any of its Subsidiaries (or who has had a bona fide period of non-employment with<a name="_cp_text_1_33"></a> the Company and its Subsidiaries) who is hired as a full or part-time employee by the Company or one of its Subsidiaries, and for whom the Award is being made as an inducement material to the individual&#8217;s entering into such employment.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Exchange Act&#8221;<font style="font-style:normal;"> means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Fair Market Value&#8221;<font style="font-style:normal;"> of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System, Nasdaq Global Market, The New York Stock Exchange or another national securities exchange, the determination shall be made by reference to the Stock&#8217;s closing price on such exchange.&nbsp;&nbsp;If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Non-Employee Director&#8221;<font style="font-style:normal;"> means a member of the Board who is not also an employee of the Company or any Subsidiary.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Option&#8221;<font style="font-style:normal;"> or </font>&#8220;Stock Option&#8221;<font style="font-style:normal;"> means any option to purchase shares of Stock granted pursuant to Section&#160;5.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Restricted Shares&#8221;<font style="font-style:normal;"> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company&#8217;s right of repurchase.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Restricted Stock Award&#8221;<font style="font-style:normal;"> means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Restricted Stock Units&#8221;<font style="font-style:normal;"> means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Sale Event&#8221;<font style="font-style:normal;"> shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-style:italic;">Sale Price</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Section 409A&#8221;<font style="font-style:normal;"> means Section 409A of the Code and the regulations and other guidance promulgated thereunder.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Service Relationship&#8221; <font style="font-style:normal;">means </font><font style="color:#000000;font-style:normal;">a</font><font style="font-style:normal;">ny relationship as a full-time employee, part-time employee, director or other advisor (including Consultants) of the Company or any Subsidiary or any successor entity (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual&#8217;s status changes from full-time employee to part-time employee or Consultant).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Stock&#8221;<font style="font-style:normal;"> means the Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to Section&#160;3.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Stock Appreciation Right&#8221;<font style="font-style:normal;"> means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Subsidiary&#8221;<font style="font-style:normal;"> means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Unrestricted Stock Award&#8221;<font style="font-style:normal;"> means an Award of shares of Stock free of any restrictions.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 2.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Administration of Plan</font>.&nbsp;&nbsp;The Plan shall be administered by the Administrator.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Powers of Administrator</font>.&nbsp;&nbsp;The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>to select the individuals to whom Awards may from time to time be granted; <font style="font-style:italic;">provided</font>, such individuals are Eligible Employees;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>to determine the time or times of grant, and the extent, if any, of Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>to determine the number of shares of Stock to be covered by any Award;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to accelerate at any time the exercisability or vesting of all or any portion of any </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Award;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font>subject to the provisions of Section&#160;5(c), to extend at any time the period in which Stock Options may be exercised; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font>at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Award Certificate</font>.&nbsp;&nbsp;Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service of the grantee terminates.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification</font>.&nbsp;&nbsp;Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#8217; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#8217;s articles or bylaws or any directors&#8217; and officers&#8217; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Foreign Award Recipients</font>.&nbsp;&nbsp;Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to:&nbsp;&nbsp;(i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which Eligible Employees outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices) and subject to the Nasdaq Listing Rule 5635(c)(4) and related guidelines and interpretations; provided, however, that no such subplans and/or modifications shall increase the share limitation contained in Section 3(a) hereof; and (v) take any action, before or after<font style="font-weight:bold;"> </font>an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals.&nbsp;&nbsp;Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law, or NASDAQ Listing Rule 5635(c).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 3.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Stock Issuable</font>.&nbsp;&nbsp;The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 1,700,000 shares, subject to adjustment as provided in Section 3(b).&nbsp;&nbsp;For purposes of this limitation, the shares of Stock underlying any Awards under the Plan that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise or settlement) shall be added back to the shares of Stock available for issuance under the Plan.&nbsp;&nbsp;In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan.&nbsp;&nbsp;Subject to such overall limitation, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award.&nbsp;&nbsp;The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Changes in Stock</font>.&nbsp;&nbsp;Subject to Section&#160;3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company&#8217;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv)&#160;the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable.&nbsp;&nbsp;The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event.&nbsp;&nbsp;The adjustment by the Administrator shall be final, binding and conclusive.&nbsp;&nbsp;No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Mergers and Other Transactions</font>.&nbsp;&nbsp;In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree.&nbsp;&nbsp;To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate.&nbsp;&nbsp;In such case, except as may be otherwise provided in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the relevant Award Certificate, all Options and Stock Appreciation Rights that are not exercisable immediately prior to the effective time of the Sale Event shall become fully exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator&#8217;s discretion or to the extent specified in the relevant Award Certificate.&nbsp;&nbsp;In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable after taking into account any acceleration thereunder at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or less than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee.&nbsp;&nbsp;The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 4.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">ELIGIBILITY</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grantees under the Plan will be such Eligible Employees to whom the Company may issue securities without stockholder approval in accordance with Rules 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, Inc., as are selected from time to time by the Administrator in its sole discretion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 5.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">STOCK OPTIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Award of Stock Options</font>.&nbsp;&nbsp;The Administrator may grant Stock Options under the Plan.&nbsp;&nbsp;Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve.&nbsp;&nbsp;All Stock Options granted under the Plan shall be non-qualified stock options.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options granted pursuant to this Section&#160;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exercise Price</font>.&nbsp;&nbsp;The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section&#160;5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Option Term</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exercisability; Rights of a Stockholder</font>.&nbsp;&nbsp;Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date.&nbsp;&nbsp;The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option.&nbsp;&nbsp;An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Method of Exercise</font>.&nbsp;&nbsp;Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased.&nbsp;&nbsp;Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Option Award Certificate:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>In cash, by certified or bank check or other instrument acceptable to the Administrator;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan.&nbsp;&nbsp;Such surrendered shares shall be valued at Fair Market Value on the exercise date; </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; or </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>By a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment instruments will be received subject to collection.&nbsp;&nbsp;The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in the optionee&#8217;s stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Option Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee).&nbsp;&nbsp;In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares.&nbsp;&nbsp;In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 6.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">STOCK APPRECIATION RIGHTS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Award of Stock Appreciation Rights</font>.&nbsp;&nbsp;The Administrator may grant Stock Appreciation Rights under the Plan.&nbsp;&nbsp;A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exercise Price of Stock Appreciation Rights</font>.&nbsp;&nbsp;The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Grant and Exercise of Stock Appreciation Rights</font>.&nbsp;&nbsp;Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section&#160;5 of the Plan.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Terms and Conditions of Stock Appreciation Rights</font>.&nbsp;&nbsp;Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator.&nbsp;&nbsp;The term of a Stock Appreciation Right may not exceed ten years.&nbsp;&nbsp;The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 7.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">RESTRICTED STOCK AWARDS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Nature of Restricted Stock Awards</font>.&nbsp;&nbsp;The Administrator may grant Restricted Stock Awards under the Plan.&nbsp;&nbsp;A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.&nbsp;&nbsp;Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.&nbsp;&nbsp;The terms and conditions of each such Award Certificate shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Rights as a Stockholder</font>.&nbsp;&nbsp;Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are met with respect to the Restricted Stock Award.&nbsp;&nbsp;Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section&#160;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Restrictions</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Restricted Shares may not be sold, assigned, transferred, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pledged</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate.&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 14 below, in writing after the Award is issued, if a grantee&#8217;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#8217;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder.&nbsp;&nbsp;Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Vesting of Restricted Shares</font>.&nbsp;&nbsp;The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&#8217;s right of repurchase or forfeiture shall lapse.&nbsp;&nbsp;Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#8220;vested.&#8221;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 8.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">RESTRICTED STOCK UNITS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Nature of Restricted Stock Units</font>.&nbsp;&nbsp;The Administrator may grant Restricted Stock Units under the Plan.&nbsp;&nbsp;A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant.&nbsp;&nbsp;Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.&nbsp;&nbsp;The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.&nbsp;&nbsp;Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock.&nbsp;&nbsp;Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Election to Receive Restricted Stock Units in Lieu of Compensation</font>.&nbsp;&nbsp;The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units.&nbsp;&nbsp;Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures established by the Administrator.&nbsp;&nbsp;Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein.&nbsp;&nbsp;The Administrator shall </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate.&nbsp;&nbsp;Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Rights as a Stockholder</font>.&nbsp;&nbsp;A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying the grantee&#8217;s Restricted Stock Units, subject to the provisions of Section 10 and such terms and conditions as the Administrator may determine.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination</font>.&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&#160;14 below, in writing after the Award is issued, a grantee&#8217;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 9.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">UNRESTRICTED STOCK AWARDS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Grant or Sale of Unrestricted Stock</font>.&nbsp;&nbsp;The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan.&nbsp;&nbsp;An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan.&nbsp;&nbsp;Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 10.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">DIVIDEND EQUIVALENT RIGHTS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Dividend Equivalent Rights</font>.&nbsp;&nbsp;The Administrator may grant Dividend Equivalent Rights under the Plan.&nbsp;&nbsp;A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee.&nbsp;&nbsp;A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award under the Plan.&nbsp;&nbsp;The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate.&nbsp;&nbsp;Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents.&nbsp;&nbsp;Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any.&nbsp;&nbsp;Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments.&nbsp;&nbsp;A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&#160;14 below, in writing after the Award is issued, a grantee&#8217;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 11.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">Transferability of Awards</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Transferability</font>.&nbsp;&nbsp;Except as provided in Section&#160;11(b) below, during a grantee&#8217;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#8217;s legal representative or guardian in the event of the grantee&#8217;s incapacity.&nbsp;&nbsp;No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order.&nbsp;&nbsp;No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Administrator Action</font>.&nbsp;&nbsp;Notwithstanding Section&#160;11(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee) may transfer his or her Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award.&nbsp;&nbsp;In no event may an Award be transferred by a grantee for value.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Family Member</font>.&nbsp;&nbsp;For purposes of Section&#160;11(b), &#8220;family member&#8221; shall mean a grantee&#8217;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee&#8217;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Designation of Beneficiary</font>.&nbsp;&nbsp;To the extent permitted by the Administrator, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#8217;s death.&nbsp;&nbsp;Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator.&nbsp;&nbsp;If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#8217;s estate.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 12.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">TAX WITHHOLDING</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payment by Grantee</font>.&nbsp;&nbsp;Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income.&nbsp;&nbsp;The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee.&nbsp;&nbsp;The Company&#8217;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payment in Stock</font>.&nbsp;&nbsp;Subject to approval by the Administrator, a grantee may elect to have the Company&#8217;s required tax withholding obligation satisfied, in whole or in part, by authorizing the Company to withhold from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment.&nbsp;&nbsp;The Administrator may also require Awards to be subject to mandatory share withholding up to the required withholding amount.&nbsp;&nbsp;For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the participants.&nbsp;&nbsp;The required tax withholding obligation may also be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 13.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">Section 409A awards</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that any Award is determined to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A (a &#8220;409A Award&#8221;), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A.&nbsp;&nbsp;In this regard, if any amount under a 409A Award is payable upon a &#8220;separation from service&#8221; (within the meaning of Section 409A) to a grantee who is then considered a &#8220;specified employee&#8221; (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee&#8217;s separation from service, or (ii) the grantee&#8217;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A.&nbsp;&nbsp;Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section 409A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:16.35%;text-indent:-16.35%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 14.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">TERMINATION OF EMPLOYMENT, TRANSFER, LEAVE OF ABSENCE, ETC.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination of Employment</font>.&nbsp;&nbsp;If the grantee&#8217;s Service Relationship is with a Subsidiary and such Subsidiary ceases to be a Subsidiary, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>For purposes of the Plan, the following events shall not be deemed a termination of employment:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another; or</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&#8217;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 15.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">AMENDMENTS AND TERMINATION</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the holder&#8217;s consent.&nbsp;&nbsp;Except as provided in Section 3(b) or 3(c), without prior stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect repricing through cancellation and re-grants or cancellation of Stock Options or Stock Appreciation Rights in exchange for cash or other Awards.&nbsp;&nbsp;Nothing in this Section&#160;15 shall limit the Administrator&#8217;s authority to take any action permitted pursuant to Section&#160;3(b) or 3(c).</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 16.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">STATUS OF PLAN</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the portion of any Award that has not been settled or exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards.&nbsp;&nbsp;In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#8217;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 17.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">GENERAL PROVISIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Distribution</font>.&nbsp;&nbsp;The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Issuance of Stock</font>.&nbsp;&nbsp;To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company.&nbsp;&nbsp;Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#8220;book entry&#8221; records).&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded.&nbsp;&nbsp;Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded.&nbsp;&nbsp;The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock.&nbsp;&nbsp;In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements.&nbsp;&nbsp;The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Stockholder Rights</font>.&nbsp;&nbsp;<font style="color:#000000;">Until Stock is deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Other Compensation Arrangements; No Employment Rights</font>.&nbsp;&nbsp;Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases.&nbsp;&nbsp;The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Trading Policy Restrictions</font>.&nbsp;&nbsp;Option exercises and other Awards under the Plan shall be subject to the Company&#8217;s insider trading policies and procedures, as in effect from time to time.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Clawback Policy</font>.&nbsp;&nbsp;Awards under the Plan shall be subject to the Company&#8217;s clawback policy, as in effect from time to time.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 18.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">EFFECTIVE DATE OF PLAN</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Plan shall become effective immediately upon approval by the Board.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">SECTION 19.&nbsp;&nbsp;</font><font style="text-decoration:underline;text-transform:uppercase;">GOVERNING LAW</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware, applied without regard to conflict of law principles.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DATE APPROVED BY BOARD OF DIRECTORS: December 9, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">NON-QUALIFIED STOCK OPTION AGREEMENT<br />FOR COMPANY EMPLOYEES<br />UNDER THE AVROBIO, INC.<br />2020 Inducement PLAN</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of Optionee:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:65.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No. of Option Shares:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:65.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:65.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option Exercise Price per Share:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:29.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:65.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant Date:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:65.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiration Date:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the AVROBIO, Inc. 2020 Inducement Plan as amended through the date hereof (the &#8220;Plan&#8221;), AVROBIO, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named above an option (the &#8220;Stock Option&#8221;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.&nbsp;&nbsp;For the avoidance of doubt, this Stock Option is not issued under the Company&#8217;s 2018 Stock Option and Incentive Plan, as amended from time to time, and does not reduce the share reserve under such equity plan.&nbsp;&nbsp;This Stock Option has been granted as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, Inc.&nbsp;&nbsp;This Stock Option is not intended to be an &#8220;incentive stock option&#8221; under Section 422 of the Internal Revenue Code of 1986, as amended.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 1.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exercisability Schedule</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;No portion of this Stock Option may be exercised until such portion shall have become exercisable.&nbsp;&nbsp;Except as set forth below, and subject to the discretion of the Administrator to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.85%;width:71.15%;">
<tr>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incremental Number of<font style="text-decoration:underline;"><br />Option Shares Exercisable</font></p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exercisability Date</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ (___%)</p></td>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ (___%)</p></td>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ (___%)</p></td>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ (___%)</p></td>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ (___%)</p></td>
<td valign="top"  style="width:40%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 2.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Manner of Exercise.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Optionee may exercise this Stock Option only in the following manner:&nbsp;&nbsp;from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice.&nbsp;&nbsp;This notice shall specify the number of Option Shares to be purchased.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of the purchase price for the Option Shares may be made by one or more of the following methods:&nbsp;&nbsp;(i)&#160;in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii)&#160;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&#160;by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv)&#160;by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v)&#160;a combination of (i), (ii), (iii) and (iv) above.&nbsp;&nbsp;Payment instruments will be received subject to collection.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#8217;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations.&nbsp;&nbsp;In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan.&nbsp;&nbsp;The determination of the Administrator as to such compliance shall be final and binding on the Optionee.&nbsp;&nbsp;The Optionee shall not be deemed to be the holder of, or to have any of the rights of a </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#8217;s name shall have been entered as the stockholder of record on the books of the Company.&nbsp;&nbsp;Thereupon, the Optionee shall have full voting, </font><font style="color:#000000;">dividend</font><font style="color:#000000;"> and other ownership rights with respect to such shares of Stock.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 3.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination of Service Relationship.</font><font style="text-decoration:none;color:#000000;">&nbsp;&nbsp;If the Optionee&#8217;s Service Relationship by the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Due to Death</font><font style="color:#000000;">.&nbsp;&nbsp;If the Optionee&#8217;s Service Relationship terminates by reason of the Optionee&#8217;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#8217;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier.&nbsp;&nbsp;Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Due to Disability</font><font style="color:#000000;">.&nbsp;&nbsp;If the Optionee&#8217;s Service Relationship terminates by reason of the Optionee&#8217;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination of Service Relationship, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier.&nbsp;&nbsp;Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Cause</font><font style="color:#000000;">.&nbsp;&nbsp;If the Optionee&#8217;s Service Relationship terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect.&nbsp;&nbsp;For purposes hereof, &#8220;Cause&#8221; shall mean, unless otherwise provided in an employment agreement (or similar services agreements) between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee&#8217;s duties to the Company.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Other Termination</font><font style="color:#000000;">.&nbsp;&nbsp;If the Optionee&#8217;s Service Relationship terminates for any reason other than the Optionee&#8217;s death, the Optionee&#8217;s disability or Cause, and unless otherwise </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier.&nbsp;&nbsp;Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Administrator&#8217;s determination of the reason for termination of the Optionee&#8217;s Service Relationship shall be conclusive and binding on the Optionee and his or her representatives or legatees.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 4.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Incorporation of Plan</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in&nbsp;&nbsp;Section 2(b) of the Plan.&nbsp;&nbsp;Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 5.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transferability</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution.&nbsp;&nbsp;This Stock Option is exercisable, during the Optionee&#8217;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#8217;s legal representative or legatee.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 6.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tax Withholding</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.&nbsp;&nbsp;The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid adverse accounting treatment or as determined by the Administrator. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 7.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Obligation to Continue Service Relationship</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee&#8217;s Service Relationship and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Service Relationship of the Optionee at any time.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 8.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Integration</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 9.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Data Privacy Consent</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;color:#000000;">process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#8220;Relevant Information&#8221;).&nbsp;&nbsp;By entering into this Agreement, the Optionee (</font><font style="text-decoration:none;color:#000000;">i</font><font style="text-decoration:none;color:#000000;">) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.&nbsp;&nbsp;The Optionee shall have access to, and the right to change, the Relevant Information.&nbsp;&nbsp;Relevant Information will only be used in accordance with applicable law.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">SECTION 10.&nbsp;&nbsp;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;text-transform:none;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">[</font><font style="font-style:italic;text-decoration:none;">Remainder of page intentionally blank</font><font style="text-decoration:none;">]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:30pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.&nbsp;&nbsp;Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Optionee (including through an online acceptance process) is acceptable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optionee&#8217;s Signature</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optionee&#8217;s name and address:</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>avro-ex211_12.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex211_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">List of Subsidiaries </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Subsidiary</font><font style="text-decoration:underline;font-weight:normal;">&#160;</font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Jurisdiction of incorporation or organization</font><font style="text-decoration:underline;font-weight:normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO Inc.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ontario, Canada</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO Australia Pty Ltd</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO Securities Corporation</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>avro-ex231_8.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex231_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_Hlk66795652"></a>Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the following Registration Statements:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-8 No. 333-225788) pertaining to the Amended and Restated 2015 Stock Option and Grant Plan, the 2018 Stock Option and Incentive Plan, and the 2018 Employee Stock Purchase Plan of AVROBIO, Inc.,</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-8 No. 333-230493) pertaining to the Inducement Stock Option Agreement of AVROBIO, Inc.,</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-8 No. 333-230494) pertaining to the 2018 Stock Option and Incentive Plan and the 2018 Employee Stock Purchase Plan of AVROBIO, Inc.,</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-3 No. 333-232489) of AVROBIO, Inc.,</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-8 No. 333-234641) pertaining to the Inducement Stock Option Agreement of AVROBIO, Inc.,</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-3 No. 333-235641) of AVROBIO, Inc.,</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(7)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-8 No. 333-235643) pertaining to the 2019 Inducement Plan and the Inducement Stock Option Agreement of AVROBIO, Inc.,</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(8)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-8 No. 333-237203) pertaining to the 2018 Stock Option and Incentive Plan and the 2018 Employee Stock Purchase Plan of AVROBIO, Inc., and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(9)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Registration Statement (Form S-8 No. 333-241400) pertaining to the 2018 Stock Option and Incentive Plan of AVROBIO, Inc.;</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our report dated March 18, 2021, with respect to the consolidated financial statements of AVROBIO, Inc. included in this Annual Report (Form 10-K) of AVROBIO, Inc. for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst&#160;<font style="font-size:11pt;">&amp; Young LLP</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>avro-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-size:10pt;">Exhibit 31.1 </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Geoff MacKay, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of AVROBIO, Inc.; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;18, 2021</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoff MacKay&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geoff MacKay</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>avro-ex312_10.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex312_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Erik Ostrowski, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of AVROBIO, Inc.; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;18, 2021</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Erik Ostrowski&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Erik Ostrowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>avro-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
avro-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of AVROBIO, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to the best of his or her knowledge that: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;18, 2021</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoff MacKay&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geoff MacKay</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;18, 2021</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Erik Ostrowski&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Erik Ostrowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gan5qj4us5ce000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gan5qj4us5ce000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /,!CH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\\^,G_(FP?\ 7ZG_ *"]>AUYY\9/^1-@_P"OU/\ T%Z .;^"
M?_(6U7_K@G_H1KV>O&/@G_R%M5_ZX)_Z$:]GH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .(^*W_(DO_P!?,7\Z[5/]6OT%
M<5\5O^1)?_KYB_G7:I_JU^@H =1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Q&F_\E@UK_L'1?S6NWKB--_Y+!K7_8.B_FM
M';T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?*T/_ ",4?_7V/_0Z^J:^5H?^1BC_ .OL?^AU]4T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4HHXYA*5 1"HQ]"3744 %%%% !1110 45YM;>/-7F^)3>'V2U^QBX>/(C._
M!(YSCMZ5Z30 455U*X>TTN[N8\;XH7=<CC(!(KB?AWXTU3Q5=7\6H);*MNJE
M/)0KU)ZY)]* /0**XNTU?Q?)XT>RN-+1=%$KJMQY1SM .TYW=^.U=I0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q&F_P#)8-:_[!T7
M\UKMZXC3?^2P:U_V#HOYK0!V]%%% !115/5;J2RTB]NH@IDA@>1=PXR%)&:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ KB--_Y+!K7_8.B_FM=O7$:;_R6#6O^P=%_-:
M.WHHHH *JZG:M?:5=VB,%:>%XPQZ D$?UJU10!Q/@+P3=>$7OFN;N&?[1MV^
M6",8SZ_6NVHHH R_$6ER:UX?O-.BD6-YTVAVZ#FL;P'X2N?".GW5M<W,4[32
M[P8P0!P!WKK:* //_%GP_O/$/BFWU:&]@BCB" HX.3M.>U:7C7P/#XMMH668
M07< VI(1D$>AKKJ* /++7X47TUN8=7UV2YBC4B&%78HIQQP>GX5N>#? ]QX?
MTR_T[49[>[M;LY*H".HP<Y]J[>B@#RRX^$]]9W;RZ!KLEFC]0793CTRM7O#W
MPQ-EJZ:KK6H-J%TC!ER202.A)/)KT6B@#G/%G@^Q\5V2Q7!,4\?,4R]5]OI7
M$K\+/$#(MK-XE8V(X$0D? 'T/%>LT4 97A_1%T'3$LUNI[DCDR3.6)^F>E:M
M%% !7G^D_#^\T_QQ)KSWL#PNS,(E!W<_I7H%% '(^-/"5UXIET\1W445O;RA
MY$<'+?3'M6[J=A/<:#-864RPS-#Y:2-G"\8K1HH \5_X4KJO_06L_P#OEO\
M"K.G_!W4[/4+>Y;5+1EB<,0%;)Q7L-% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\K0_\ (Q1_]?8_]#KZ
MIKY6A_Y&*/\ Z^Q_Z'7U30 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GGQD_Y$V#_K]3_P!!
M>O0Z\\^,G_(FP?\ 7ZG_ *"] '-_!/\ Y"VJ_P#7!/\ T(U[/7C'P3_Y"VJ_
M]<$_]"->ST %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '$?%;_D27_Z^8OYUVJ?ZM?H*XKXK?\B2_P#U\Q?SKM4_U:_04 .H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XC3
M?^2P:U_V#HOYK7;UQ&F_\E@UK_L'1?S6@#MZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG/Z_I3** '^<_K^E'G/Z_I3** '^<_K^E'G/Z_I3** '^<_K^E'G/Z_I3**
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MY_7]*910 _SG]?TH\Y_7]*910 _SG]?TH\Y_7]*910 _SG]?TH\Y_7]*910
M_P Y_7]*/.?U_2F44 /\Y_7]*/.?U_2F44 /\Y_7]*/.?U_2F44 /\Y_7]*/
M.?U_2F44 /\ .?U_2CSG]?TIE% #_.?U_2CSG]?TIE% #_.?U_2CSG]?TIE%
M #_.?U_2CSG]?TIE% #_ #G]?TH\Y_7]*910 _SG]?TH\Y_7]*910 _SG]?T
MH\Y_7]*910 _SG]?TH\Y_7]*910 _P Y_7]*/.?U_2F44 /\Y_7]*/.?U_2F
M44 <=\4I&;P8X)_Y>(OYUV:2OY:\]AVKBOBA_P B:_\ U\1?SKL4_P!6OT%
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M_A:OA7_GZG_\!VH_X6KX5_Y^I_\ P':O :*/J%+S#ZS,]^_X6KX5_P"?J?\
M\!VH_P"%J^%?^?J?_P !VKP&BCZA2\P^LS/?O^%J^%?^?J?_ ,!VH_X6KX5_
MY^I__ =J\!HH^H4O,/K,SW[_ (6KX5_Y^I__  ':C_A:OA7_ )^I_P#P':O
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M%% !1110 4444 %%%% !1110 4444 %%%% 'S'!_R,,?_7V/_0Z^J:^5H/\
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M5@?H: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K@?B[_P BA#_U^)_Z"U=]7 _%W_D4(?\
MK\3_ -!:@#PZ3H*CJ23H*CKV\%_!1P5_XC"BBBNHQ"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ')]ZFTY/O4VLH_Q9>B_4M_ OF%%
M%%:D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3C_
M *L?6FTX_P"K'UK*KO'U_P RX;/T&T445J0%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7NOP@_Y$R3_ *_'_P#05KPJO=?A!_R)
MDG_7X_\ Z"M<>._A&^'^,[ZBBBO&.X**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ^8X/\ D88_^OL?^AU]4U\K0?\
M(PQ_]?8_]#KZIH P=/\ ]<W^[6C6=I_^N;_=K1K2K\1$-@HHHK,L**** "BB
MB@#YPUN[^P?$"YO-F_R+XR;<]<-G%=N/C. /^00W_?RN/OHTF^)S1R*&1]2"
MLI'!!?I7N0\,:'@?\2JT_P"_0KU,1*E%1YXWT..FIMOE=BCX-\5CQ9I]Q="U
M-OY,OE[2V<\ Y_6N-\7Z=XQU[Q)]EMXY[?3M^R-XR0N/[S$5Z;9Z?9Z=&T=G
M;10(QW,L:X!->2:EXPU_Q-XJ_L;1KH6<1<HC!L$XZDFN>AK4<J:LO/H:U-(I
M29D^)_"6K^$+2&^_MIYMS;3Y;,I4_G7HOA/6;C6_AW<7%V^^=(I8V8_Q87K7
M!>-?!D^B:,NH7^KR7ET[A=K=/?!/-=5\.?\ DFM]_P!M_P#T&MZS4Z*E>[ON
M9PNJC6VAYGX1CU:YUC['HTOE7%PA1I/[J]S70>)/"'B'PG;)JBZO+<*&&]T9
M@4/;.3R*@^%5S#;^,465E4R1LJ$^N.E>G_$BXAA\#:@LK -*%5 3U.X'^0-:
M5JLHUU%+1DP@G3;9'X!\42>)/#SFY.;NWS'(W][C(/ZUXYHVIZY+J;V5A=3/
M<78,*[I"<<Y)'IP*[OX.1.++59>?+)"CZXKE_AK&K^/+9CU3>1^1%*$8TY5;
M+8<FY*%SIM*^'FNV\6I&_O9-S6Y$!2<G+G/7GM57X4Z[<1:]<:7>S2/YZDH)
M&)(=?K[9KV2O"O%ELWA/XD1W\(VPR2B=2/0GYA^M8TJCKJ4);M:%SBJ=I(Z;
MXNZY):V]GIEM,\<LA,C[&(..@Z>^:Z?P!I\UAX3M3<R2//.OFL9&)(SR!S7E
M]Y*?'/Q)B6/+6Q95'M&.3^I->[JJHH50 H& !VJ*_P"[I1I]=V53]Z;D+111
M7$;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<#\7?^10A_P"OQ/\ T%J[ZN!^+O\ R*$/_7XG_H+4
M >'2=!4=22=!4=>W@OX*."O_ !&%%%%=1B%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 .3[U-IR?>IM91_BR]%^I;^!?,****U("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G'_5CZTVG'
M_5CZUE5WCZ_YEPV?H-HHHK4@**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O=?A!_R)DG_7X__H*UX57NOP@_Y$R3_K\?_P!!6N/'
M?PC?#_&=]1117C'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?,<'_(PQ_P#7V/\ T.OJFOE:#_D88_\ K['_ *'7
MU30!@Z?_ *YO]VM&L[3_ /7-_NUHUI5^(B&P4445F6%%%% !1110!Y'/\/=>
MD\<_VLL=O]E^VB;/FC.W=GI]*]<'0445K4K2J6YNA$8*.P5Y#KOPVUJUU]M2
M\/RIM+ETRVUHR?YUZ]112K2I.\0G!3W/)+WP!XLUVP>;6-36:[C'[B'<-OXD
M#%='X+\.:OHOA?4-+OXX5>0-Y)23=DLI'/IVKN**N6)G*/*[6$J44[GBNE?"
M?6AY[74T=K,JAK>2*3=AO>G77@#QIJ]S'!J5XLEO&>':7( ]<=S7M%%7]=J7
MOH3["%K&/X?T"W\.Z(FGVWS$ EW/5V/<UP/@KP#KFA>*([^]C@$"ALE)03S[
M5ZM164:\TI>>Y;IQ=O(*\T^,5I;/HMG=LX6X278@[L"#D5Z#J,4\VG7$=LYC
MG9"$8'!![<UX]<> _&FOWD8U:X)13P\TVX*/8#-:8514^=RM8BLVX\J5[FA\
M'=&RUWK$B\#]S$??J?YBO6ZS= T:#0-'@T^#E8Q\S?WCW-:59UZGM*CD73CR
MQ2"BBBL2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N!^+O_(H0_\ 7XG_ *"U=]7 _%W_ )%"'_K\
M3_T%J /#I.@J.I).@J.O;P7\%'!7_B,****ZC$**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH <GWJ;3D^]3:RC_ !9>B_4M_ OF%%%%
M:D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3C_JQ
M]:;3C_JQ]:RJ[Q]?\RX;/T&T445J0%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7NOP@_P"1,D_Z_'_]!6O"J]U^$'_(F2?]?C_^
M@K7'COX1OA_C.^HHHKQCN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /F.#_D88_\ K['_ *'7U37RM!_R,,?_ %]C
M_P!#KZIH P=/_P!<W^[6C6=I_P#KF_W:T:TJ_$1#8****S+"BBB@ HHHH Q?
M$NM/HM@LL*HTSMA0XR/>JGAGQ)/J\T]O>1QQS( 5" C([]3]*R]??^UO%]GI
MZ_-'$1O'ZG]*BO5_L+QO#.HVPS]?QZ_TKTH4(.ER->\U<Y)5)<_-T3L:DOB2
M]M/%"Z;=1PBW=P%<*0<'IWKIY9!%"\C'Y54L:XSQY:%1:ZC%]Y#M+#MW%6=;
MUL-X.BFC;$ER G'4>M9RH*I&G*"WT9:J.+DI="?P]K]]K-]<!XX5M8B<,JG)
M].]9,/BW7[R>6.SL89MAYVQL<#\ZW/".G?8="C9AB2;]XW]/TKC-%U:[TJ^N
MGM;(W)8D, #QS[5O"G3G.IR13M:QG*4E&/,]S;D\6:YI[*^I:8L<3' ^4J3^
M))KL;.[COK.*YB^Y(NX5Y_=ZQJ7BT#3X;2./#;F&_G]:[?3;>/1](@@FF11&
MH#.S8&?QK'%4XQ@M$I=D71DVWK=%]CA2?05P=OXM\07LLB6EA#-L/.V-CC]:
M[5;RUG#)#<PR-@\(X)_2O--"U>[TFYNFM;(W.[[V ?E_*C"4E*,VXW:MN%>=
MG&SLC;?Q;K>GNC:GIBQQ,<#"E2?S)KH=0U@Q>'7U2T"M\BL@<<<D=?SKC[K5
MM2\7;;"&UCCVMN8!^?UKH=7LO[.\#R6I;<8XU!([G(K2K2@I04DE)O5+L3"<
MFI-.ZL9=MXF\37D(FM],BEC/1EC8C^=7](\7//?"QU.W%O<$X!' SZ8-6?!7
M_(NQ_P"^:Q?'4:Q:E8W*#$AZGUP>*=J52JZ/*EO9H+SC!5+G>55U&_BTVQDN
MIC\B#IZGL*$O((K:$W%Q%&S(#\[@9X]ZYKQQ>1RZ)&()HY$:4!BC CIGM7%1
MI.=11>QO4GRQ;15_X3#6-GVS^S5^P;OO[3T^N?Z5UVFZA%J=A'=P_=<<CT/<
M5E+ G_"$>5@;?L_I6=X*\V?P]=P(^QLE4;/W21UKHJPISIN45;E=C*$I1DDW
M>Z+OB3Q0ND*L-J8Y+HGE6Y"CWQ6WI]P]UIUO<. 'DC5R!TR17 >(_#L.CZ9'
M,96FN))/G<UW6C?\@6R_ZX)_(5->G2C1BX:Z[CIRFZC4B]1117$= 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 _%W_D4
M(?\ K\3_ -!:N^K@?B[_ ,BA#_U^)_Z"U 'ATG05'4DG05'7MX+^"C@K_P 1
MA111748A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #
MD^]3:<GWJ;64?XLO1?J6_@7S"BBBM2 HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ IQ_U8^M-IQ_U8^M95=X^O^9<-GZ#:***U("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW7X0?\B9
M)_U^/_Z"M>%5[K\(/^1,D_Z_'_\ 05KCQW\(WP_QG?4445XQW!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S'!_R,
M,?\ U]C_ -#KZIKY6@_Y&&/_ *^Q_P"AU]4T 8.G_P"N;_=K1K.T_P#US?[M
M:-:5?B(AL%%%%9EA1110 5'<3+!;R2L<!%)J2FR1I-&T<B*Z,,%6&0::M?4&
M>9Z5I%SXEO[N[2[-N0Y.[!)Y[=1VJ77/"MWIEE]M>_-SL8#!4Y7WY)KT*VL[
M:S4K;6\<*L<D1J%S^522PQ3Q-%-&LD;=589!KO>83]I>/P]CF^K1Y;/<YZ C
MQ#X-VGYI#$5_X$.!_*N%TV*XU"_M--))CCD)V^GK_*O6+>UM[2,QV\$<2$Y*
MHH J.+3K*"<S0VD,<IZNJ '\Z5+&*GS)+?;R'.@Y6;?J6%18XE11A5& *X;P
M-_R$[_Z?UKNZKV]C:6KL]O;11,WWBB $USTZJC3G%]324+R3['#^*M-ET;5(
M]5L<HKG+;>BM_A731_9?%.@IYC,$DQO"'D$=JUIH(;F(Q3Q))&>JN,@TVWM+
M>T0I;01PJ3DA% %7+$<T(I_%'J2J5I/LS)TWPO8Z/.UQ;/.7*%?G8$?RK!\!
M\WM_GT_K7==15>WL;2T9FM[:*(M]XH@&:%B6X24]6[?@-TES)QZ'#>*-.FT3
M5H]5L<I&YR=O\+?X5M:MJ,>J>"9[J/\ B5=P]#N&171SV\-S$8IXDDC/577(
MJ)=.LDMVMUM(5A?[T80;3^%5]94E#F6L7OY$^R:;MLSC/#GBG3=+TA+:Y,OF
M!B3M3(JO>3R>+M?MEM8G%M$>68=NI-=I_8>E?] VU_[]+5N"V@MH_+@B2)/[
MJ+@5;Q5*,G4A%\S[DJC-I1D]#,U3PW9:N(?M+S+Y2[5\M@/Z5DZQX7BM?#<T
M%CYCE7$N'()]^@]*ZZBN>&)J0MKHC65*,KZ'GP\4P#PO_9QCD^V;/+QMXKH?
M!UA)8Z&AE7:\IWX]NU:O]F6'G^?]C@\W.=_EC/YU;K2KB(R@XP5KN[)A3DI7
MD]CD?'__ ""H/^NE=!HW_(%LO^N"?R%6+BTMKM ES!',H.0)%! J1$2*-4C4
M*BC 4#  K.55.BJ?8I0:FY#J***P- HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N!^+O\ R*$/_7XG_H+5WU<#\7?^10A_
MZ_$_]!:@#PZ3H*CJ23H*CKV\%_!1P5_XC"BBBNHQ"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ')]ZFTY/O4VLH_Q9>B_4M_ OF%%%
M%:D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3C_J
MQ]:;3C_JQ]:RJ[Q]?\RX;/T&T445J0%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7NOP@_Y$R3_K\?\ ]!6O"J]U^$'_ ")DG_7X
M_P#Z"M<>._A&^'^,[ZBBBO&.X**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^8X/^1AC_Z^Q_Z'7U37RM!_R,,?_7V/
M_0Z^J: ,'3_]<W^[6C6=I_\ KF_W:T:TJ_$1#8****S+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!^+O\
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MOF?*7V.Z_P"?:;_O@T?8[K_GVF_[X-?5M%']HO\ E_$/JOF?*7V.Z_Y]IO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 _%W_
M )%"'_K\3_T%J[ZN!^+O_(H0_P#7XG_H+4 <[\&_^0IJG_7%/_0C7L%>/_!O
M_D*:I_UQ3_T(U[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 <9\4/^1-?_ *^(OYUV*?ZM?H*X[XH?\B:__7Q%_.NQ3_5K
M]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KC-._Y*SK'_7A'_-:[.N,T[_DK.L?]>$?\UH [.BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YC@_Y&
M&/\ Z^Q_Z'7U37RM!_R,,?\ U]C_ -#KZIH 8T2L<G-)Y">]244 1^0GO1Y"
M>]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]24
M4 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^
M0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1
MY">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]
M244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244
M1^0GO1Y">]244 1^0GO1Y">]244 1^0GO1Y">]244 1^0GO7GWQAC5/!T!&?
M^/Q/_07KT6O//C)_R)L'_7ZG_H+T <S\%D#ZKJN>T"?^A&O9?(3WKQSX)_\
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MI** (_(3WH\A/>I** (_(3WH\A/>I** (_(3WH\A/>I** (_(3WH\A/>I**
M(_(3WH\A/>I** (_(3WH\A/>I** (_(3WH\A/>I** (_(3WH\A/>I** (_(3
MWH\A/>I** (_(3WH\A/>I** (_(3WH\A/>I** (_(3WH\A/>I** (_(3WH\A
M/>I** /E:'_D8H_^OL?^AU]4U\K0_P#(Q1_]?8_]#KZIH K6][%<N5C#9 SR
M*LUC:/\ \?$G^Y_6MFKJ14961,7=!1114%!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"-']IV'_/];?\ ?U?\:^2:*/[.7\P?67V/K;^T[#_G^MO^_J_XT?VG8?\
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M<)+\9[<RM]DT>XFA!Y<G''X9K8^*.BW>H^$!'I\;/]G8,8D[J/\ "O-?"OQ
M3PY8#3KS1;:XB5CEM@$A^I-%"C"<'-*[[7'4J2C*U['JOA7XB:3XHN/LD:R6
M]V!D1R@?-]#7G?Q;\2KJ&I#2$B=&LY#N;/#5T'@VY\!ZEKPN;*V:VU1GWQI(
M[  ^B\X/TJE\:;*V@CL;B*"-)I9#O<+RW!ZU5*,(8A))KU)FY2IWN7?A?XUA
MGMM/\,BU<2Q1.3+G@_,3_6F7VN>&D^(+6DN@A[_[7M^TY'WL]:Z+X::78)X,
MTJ_6TB%VT;YF"_,?G8=:\PU;_DL;?]A ?^A41C"=6=M-P;E&$;GK_C'Q?%X0
MM+>XEMGG$S%0%.,8Q_C6%>?%K2+73;6=8)9KF=-Y@3!V<?Q&L[XV_P#(&TW_
M *ZO_(59^%'AW3O^$474)[.&:XN';+2H&P <#&:SC3I*BJDD6Y3=1Q1=\,?%
M+3/$&H)82P26EQ(<1[B"K'TSZUV]W=V]C:R7-U*L4,8RSL> *^>?$ME#I7Q/
MDALU$4:W",JKT7..E=O\:M3FATZQT^-BL<SEY,'[P';\Z<\-%S@H:*0HU6HO
MFZ$VI?&C2[>X:.RLIKA5."[$*#]*W/#/Q*T;Q'<"U^>UNCPJ2XPY]C6=\-?"
M.E1^%+:_N;.&XN;L%RTJ!L#H  >.WZUPWQ0T*V\->);6[TM?LXF7S0J=$<'J
M/YU2IT)S=**L^XG*I&/.SVW6=9LM!TV2^OI=D*?FQ]!7G<GQGA:0FVT:XDA!
MY<G''X4OCBVO_$WPXTS4+97E9%$DJ*.2,8SC\/UKD/"_Q$BT'3DTZ]T2UN(4
M)!<( [9]<]:5'#Q<&[7=^X3J-2M>R/5O"GQ TKQ5(UO")(+M1DQ2@?,/8UC?
M$G5M"TV[LUU?2!?,\9*'(^49-5/ \O@2^UD7&FP-;ZH261)788]0O.#6/\;O
M^0CIG_7(_P S1"G'ZPHI-#E-^SNST[2]3T^W\)VVH!1:6*P!PI_@7TKB+KXR
MVGGNFGZ5<7,:G&X\9]^,U>O]+N]7^#UM:V0+3?9U<(/X@,\5YKX4\:MX2CEL
MKG1[>X4OEC(F) ?3)HI4(R4G:[3VN*=1JRV/5?#7Q.TGQ!?+8O'+:73?<$@&
MUCZ ^M=Q7D7A_4? &N>(%NWLVM-0D<,B.Y5 WMC _"O7:Y\1",9:)KU-:<FU
MJ[A1116!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YY\9/\
MD38/^OU/_07KT.O//C)_R)L'_7ZG_H+T >#2=!4=22=!4=>W@OX*."O_ !&%
M%%%=1B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .3
M[U-IR?>IM91_BR]%^I;^!?,****U("BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTZM-+WD[]T5*$KZ;'BGANQ74/B%#_844JVB3[T+<E$]S74_&[_D(Z9_UR/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\K0_\C%'_P!?8_\
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M#=11"X#-EEP>"?6G5Q%*I0>FK?<4*4XU%VL;M%%%>8=84444 %%%% !1110
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MI7@5>^_!G_D2)/\ K]D_]!2N/'?PC?#_ !GH=%%%>,=P4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\K0_\C%'_P!?
M8_\ 0Z^J:^5H?^1BC_Z^Q_Z'7U30!C:/_P ?$G^Y_6MFL;1_^/B3_<_K6S6E
M7XB(;!1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%=>$?^@)!_WTW^-'_"NO"/\ T!(/^^F_QH_M"GV8?5I=SYGHKZ8_X5UX1_Z
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M_P#0$@_[Z;_&C^T*?9A]6EW/F>BOIC_A77A'_H"0?]]-_C1_PKKPC_T!(/\
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M]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@#B?BM_R)+_\
M7S%_.NU3_5K]!7%?%8_\42__ %\Q?SKM4(\M>>PH =129'K1D>M "T4F1ZT9
M'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5P/Q=_Y%"'_K\3_T%J[ZN!^+O_(H
M0_\ 7XG_ *"U '._!O\ Y"FJ?]<4_P#0C7L%>/\ P;_Y"FJ?]<4_]"->P4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&?%
M#_D37_Z^(OYUV*?ZM?H*X[XH?\B:_P#U\1?SKL4_U:_04 .HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XS3O^2LZQ_UX1_S
M6NSKC-._Y*SK'_7A'_-: .SHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@#QCXE^$KJPU5]>T]'-NY#R%!_JW]?ZU=T?XPI%8QPZG8N\R#'F1,
M&_#UKUEE5U*LH93U!%8%WX(\.7LC22Z7!O;JRK@FNR.(A*"C55[&#IR4KP9Y
M/XR^(4GBFT&GV]GY-N6#'<<N2*[?X:Z5J&G>$KS[1 \,D^6B5A@G@XXKJ=/\
M*Z'I;^9::;!')_?"\UL=!@4JF(@X>SIJR'"G+FYI/4^=?#]]9:3XTDG\0VYE
M19'$@==VULGG'?FM?X@^*-/UZW@MM'M_]$MWW/*(]HW8X'\Z]9U/PGH>KW'V
MB]T^*2;N^.34R^&]%73S8#3;?[*3N,6S@GUK5XJFY*;3NON(]C*SC?0Y/P9%
M_:7PJ:RAPTC12Q8]R3_C7GG@7Q'#X2\07#7\;B)T,3X'*'(/3\*]WT[2K#28
M&@T^UBMHF;<5C7 )]:HW_A'0=3N/M%WID$DI.2^WD_6LXXB%YJ2TD4Z4M&MT
M>2_$+Q9'XJAM_L%O+]AMG.9F4C+'M^6*[;P38_VE\+_L6<&99%!/KVKJG\-Z
M+)8I9/IMLUJARL13Y0:N65A:Z;:K;64"00+R$08 I3Q$734(*UF.--\W-)GA
M'A;6I? /B6ZAU"W?8W[N5<8/'0C\ZV?$_P 3;K4[FVM_#K30$/\ >V@F0G@#
M!'O7J>I^'])UD@ZA8PSLHPK.O(J#3/">AZ1*);/3X8Y1T?;S5O$TI/GE'WOP
M)5*:7*GH<IXQ74!\+%_M67S+TE3*=H'//8>U1_!S_D 7O_78?R->@7UA::E;
M&VO;>.>%CDHXR#3-.TG3](B:+3[2*VC8Y98UP":R]LO9.%MW<OV;YU(\A^,'
M_(R67_7 ?^A&NI\3:%-KGPTL%MD+SV\$<J(!DM\HS^F:Z_4/#^D:M,LVH:?!
M<R*-JM(N2!5^*&."%(8D"1HH55 X ':F\1:,$MXB]EK)OJ>*>!_%VBZ+I\NG
M:Y8H61RRRF .W^Z>/:M+3O&KZUXH6QTKP]I\EK(X +P?,J]V./SKT"_\'Z!J
M<K376F0-*W5PN":N:9H>F:,A73[.* -U*+R:N5>D[RY7=_<)4YJROH>;?&D8
MBT48 QYO Z?P5V7P^X\$Z?C^Z?YUL:EHFF:QY?\ :-C#=>5G9YJYVYZX_(58
MM+.WL+9+:UA2&%.%1!@"LI5DZ*I]BE!J;D3T445SFIXS\98775]/F(.QXF /
MT(_QKLO WC&QUNUMM+@1UGMK5%?=T^48X_*NGU/2+#6+?R-0M8YXP<@.,X/M
M5"R\/Z)X9BGO+.Q2)D0L[*/F('.*ZG6A*BH-:HQ4)*;DMCS[XO:0T%Y9:Y"N
M,GRY&']X<K_(UB^ ;6?Q-XY34+S]Y]G ED8^H&%_E6AX^^(%CK^E+ING12G,
M@:1Y% QC/ Y]ZZOX6: ^E>'VO+A"L]VVX CD+T'\L_C74Y2IX;WM]D964JNF
MQV6I_P#()O/^N#_^@FOG7PKK<OA[Q"NI)"TL<>1*J_W3UKZ*U/\ Y!5Y_P!<
M'_\ 037BOPKACG\57$4J*\;0L"K#(/6LL*TJ4VU<JLFYQL:?C3XE6.LZ!)IN
MFQR;KC E9QC !SC\P*UOA[X5F7P;?"[!C.I*0H(Y"8P*ZR+P3X<@NOM$>DVX
MD!R/EX!]JW@ H  P!T K.=>"AR4E8N--N7-,^?\ PY?1^"O$]Q;ZYIX>)E,;
MB2/<5YR& /TKH=9^(NF_;8(M T:SN%/WC-;8W'T ZUZ=J>@:5K&/[0L8;@KT
M+KDBJVF^$M"TF<36>G0I*.C[>15O$TI/GE%W_ E4IK1/0N:-YW]DV[7%K%:S
M.@9X8EP$)[8J_117$W=W.A!7@>C_ /)6XO\ K]->^5E1^&M$BU 7\>F6RW8;
M>)@GS9]<UO0K*FI)]49U(.37D:M%%%<YH%%%% !1110 4444 %<#\7?^10A_
MZ_$_]!:N^K@?B[_R*$/_ %^)_P"@M0!X=)T%1U))T%1U[>"_@HX*_P#$8444
M5U&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Y/O4
MVG)]ZFUE'^++T7ZEOX%\PHHHK4@**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *<?\ 5CZTVG'_ %8^M95=X^O^9<-GZ#:***U("BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW7X0?\B9)
M_P!?C_\ H*UX57NOP@_Y$R3_ *_'_P#05KCQW\(WP_QG?4445XQW!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S'!
M_P C#'_U]C_T.OJFOE:#_D88_P#K['_H=?5- &#I_P#KF_W:T:SM/_US?[M:
M-:5?B(AL%%%%9EA1110 4444 17%S!:1&6XE2*,=6<X%,M;ZUO59K6XCF5>"
M4;.*Y7QO<-/)9Z7$?FE<$C\<"J?ATOHGBF;39"1'*,#/<]OZUVQPJ='GOKO;
MR,'6:J<O0[--3L9+K[*EW"TX./+#C=^56Z\_\31'1_%%MJ,8(1R&;'J.HKKM
M4U%+31);S/'E_+CN36=2A90<->;\RHU+N2ET+$.I65Q.T$-U#)*N<HK@D8J
MZ_I"D@ZE; CJ/,%<]X%LCY%SJ,J_/*Q"D^G?]<UA>'],T[4K^[74)-BJ<K^\
MV]ZW^JTU*:;=HV,_;3M&RW/08=8TVYD$<-];R.>BJX)J]7F_B71]'TVS273[
MG,Q;&T2;\C^E=KX?FFGT*TDGR9"@R3U-8UJ$8P52#=GW+IU&Y.,C3Z#-9QU_
M2 <'4K8$?]-!5]_]6WTKS+PYIFFZE=W0U"38$Y7]YM[T8>C"<92FWIV"I4E%
MI1ZGH4&L:;<R>7!?02.?X5<$U9GGBMH6FGD6.->K,< 5YWXETC2--M8Y=/N<
MS%L;1)NR/Z5NWLTL_P /C)/DR-$F2>IY%7+#0M&46[-VU)566J:U1L_\)!H_
M_02M?^_@JY;W=O=Q^9;S)*G]Y&R*XKPWX7TW4](2YN5E,A8@[7P*JWMM)X1\
M06[VLK&VE/W2>W0@U3PU*4G3A)\R[B56:2E):'HM%-1Q)&KCHP!K"\7W\EAH
M;^4VUY3L!'Z_I7'3IN<U!=3>4E&/,:7]KZ=]H^S_ &V#SLXV;QG-7:\_'A:V
M/A;^T"[_ &O9YF=W'TQ6GH5_?7WA&1;<[[N,&-3GGV_2NFIAH<O-"6SL[F4:
MLKVDO,Z";5].MI?+GO8(W_NLX!JVCI(@=&#*1D$'@UQ.G^#8WTV6?5?,2Z.2
M/G^[]:=X#GFWW=J7+P1G*GMG-$\/3Y)2A*_+O_P C5ES)26YVU%%%<9N%-DC
M66-HW&Y&&"/44ZB@#GH/ OAJVN?M$6E1"7.[+,S#/T)Q70 !5"J  !@ =J6B
MJE.4OB=Q));#719$9'&588(/<5GV.@:5ILYGLK&*&4C!91S6E123:5D%D%%%
M%(84444 %%%% !1110 4444 %%%% !1110 4444 %<#\7?\ D4(?^OQ/_06K
MOJX'XN_\BA#_ -?B?^@M0!X=)T%1U))T%1U[>"_@HX*_\1A111748A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #D^]3:<GWJ;64?X
MLO1?J6_@7S"BBBM2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ IQ_U8^M-IQ_U8^M95=X^O\ F7#9^@VBBBM2 HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]U^$'_(F2?]?C_P#H*UX5
M7NOP@_Y$R3_K\?\ ]!6N/'?PC?#_ !G?4445XQW!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S'!_R,,?_7V/_0Z^
MJ:^5H/\ D88_^OL?^AU]4T 8.G_ZYO\ =K1K.T__ %S?[M:-:5?B(AL%%%%9
MEA1110 4$X&3VHJ&[266TECA*K(RD*6Z"FM6#/-[W6D/B][Z2)IHH'VJBG'3
MC^8J'5]>2_UBWU"&V>!X\!MQSG_/-=EX9\/2Z,)WNI(I993P4R>/Q%7=>TC^
MU]+>V0HDF0R,W0&O5^M48U$DM$K7OT]#B]C4<6[^=C,\46ZZOX92\BY**)1]
M,<URMUK+ZCH-AI:D^8'PWX<#^==WHVESV6B_V?>O'+@%04)(P?K6%I?@J>SU
MA+J>:%X48LJJ3GV[5-"M2@G&3^%W152$Y--==SJ--LUL-+@ME'W$ /U[_K7G
M>@:%!KE]=I/+(GEY(*8]?<5Z@>E<WX<\/7.CWES-/+$ZR] A.1S[BL*%?DA4
M=[2=C2I3YG%6T1R,5G;:%XA^S:K;B:#/RL<CCL>.M>@ZE<W-II?FZ;;K/(,;
M(PI(Q]!5/Q)X?&N6Z>6R)<)]UVZ8]#5O0[.\L--2VO)8Y&CX5D)Z?B*JM6C5
MC&HWJMT*G3<&XK;N9VD:KK=Y<O'J&FBWAV$[]C#G\37)>'M!M]<N;M9Y9(_+
MY79C]<BO3V&5(]17.^&_#USHUQ<R3RQ.)>FPGC\Q13Q"C";C[KTL*=)MQ3U1
MR%O:6VA^(3;:K;B:'(VL<C ['WKMO%&P>%KKRP FU<8Z8W"F^)/#PUN!#$R1
MW*?==NA'H:8-%U"3PM)I4\\+38"HX)Q@$'GCVJIUH57"HWJFKK]11IRAS12T
M$\%?\B['_OFL7QU(LVI6-LG,G<?4T^W\*^([2(16^KQQ1C^%)' _E6CI/A(V
M]\M]J-S]IN%.1U(SZ\U7-2IU76YK[Z"M.4%3M8L:K?ZOI\-JFG6 N08QO)1C
M@X]C6!XAN-2U#PXLVH6GV:2.<?+M(R,>]=_574+&+4;*2UF'R.,9]#ZUST<1
M&$HMQV>_4UG2<D]3(6=/^$(\W(V_9_6J?@)"FCS2-PK29!^E5?\ A#=4V_9!
MJ@^PY_U>YOY8Q6[/HLD/ATZ9ITB1L5V[WR,^O3UYK6<J:@X1E?F=_1$14W)2
M:V1AZOK%WK]V=)T@'RLXEE'^>E=%H6C1:+8B!#ND;F1_4UR]KX0U^Q#"UU2*
M$-][8[#/Z5T&A:;J]C+*VI7XN59<*-['!_$45^14^2G)673JPI\W-S26IN44
M45YYTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<#\7?\ D4(?^OQ/_06KOJX'XN_\BA#_ -?B?^@M0!X=)T%1U))T%1U[
M>"_@HX*_\1A111748A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@Q<?]^5_QH_X4M9?]!BX_P"_*_XT?7:/</85.QXY17L?_"EK+_H,7'_?E?\
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MI:R_Z#%Q_P!^5_QH_P"%+67_ $&+C_ORO^-'UVCW#V%3L>.45['_ ,*6LO\
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MI:R_Z#%Q_P!^5_QH_P"%+67_ $&+C_ORO^-'UVCW#V%3L>.45['_ ,*6LO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK@?B[_R*$/\ U^)_Z"U=]7 _%W_D4(?^OQ/_ $%J .=^#?\ R%-4_P"N*?\
MH1KV"O'_ (-_\A35/^N*?^A&O8* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#C/BA_R)K_]?$7\Z[%/]6OT%<=\4/\ D37_
M .OB+^==BG^K7Z"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_A=^J?\ 0(L_^^VH_P"%WZI_T"+/_OMJ/J5;L'MX=SVVBO$O^%WZI_T"+/\
M[[:C_A=^J?\ 0(L_^^VH^I5NP>WAW/;:*\2_X7?JG_0(L_\ OMJ/^%WZI_T"
M+/\ [[:CZE6[![>'<]MHKQ+_ (7?JG_0(L_^^VH_X7?JG_0(L_\ OMJ/J5;L
M'MX=SVVBO$O^%WZI_P! BS_[[:C_ (7?JG_0(L_^^VH^I5NP>WAW/;:*\2_X
M7?JG_0(L_P#OMJ/^%WZI_P! BS_[[:CZE6[![>'<]MHKQ+_A=^J?] BS_P"^
MVH_X7?JG_0(L_P#OMJ/J5;L'MX=SVVBO$O\ A=^J?] BS_[[:C_A=^J?] BS
M_P"^VH^I5NP>WAW/;:*\2_X7?JG_ $"+/_OMJ/\ A=^J?] BS_[[:CZE6[![
M>'<]MHKQ+_A=^J?] BS_ .^VH_X7?JG_ $"+/_OMJ/J5;L'MX=SVVBO$O^%W
MZI_T"+/_ +[:C_A=^J?] BS_ .^VH^I5NP>WAW/;:XC3?^2P:U_V#HOYK7$_
M\+OU3_H$6?\ WVU:WPY\0S>)_'FJ:I/ D,DEDJE$)(&&4=ZSJ8>I37-)%1JQ
MD[(]7HHHK T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /E:'_ )&*/_K['_H=?5-?*T/_ ",4?_7V/_0Z^J:
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M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ')]ZFTY/O4VLH_Q9>B_4M_ OF%%%%:D!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J/P2_Y&'4/^O3_V=:\N
MKU'X)?\ (PZA_P!>G_LZUQ8_^%\S?#?&>WT445XYW!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RM#_R,4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+?P+YA1116I 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5ZC\$O\ D8=0_P"O3_V=:\NKU'X)?\C#J'_7I_[.M<6/_A?,WPWQGM]%
M%%>.=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\K0_\ (Q1_]?8_]#KZIKY6A_Y&*/\ Z^Q_Z'7U30!C:/\
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MG_/"U_\  @4?\*A\6?\ /"U_\"!73]8I?S(R]G/L<)17=_\ "H?%G_/"U_\
M @4?\*A\6?\ /"U_\"!1]8I?S(/9S['"45W?_"H?%G_/"U_\"!1_PJ'Q9_SP
MM?\ P(%'UBE_,@]G/L<)17=_\*A\6?\ /"U_\"!1_P *A\6?\\+7_P "!1]8
MI?S(/9S['"45W?\ PJ'Q9_SPM?\ P(%'_"H?%G_/"U_\"!1]8I?S(/9S['"4
M5W?_  J'Q9_SPM?_  (%'_"H?%G_ #PM?_ @4?6*7\R#V<^QPE%=W_PJ'Q9_
MSPM?_ @4?\*A\6?\\+7_ ,"!1]8I?S(/9S['"45W?_"H?%G_ #PM?_ @4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(^*W_(DO_U\
MQ?SKM4_U:_05Q7Q6_P"1)?\ Z^8OYUVJ?ZM?H* '4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<1IO\ R6#6O^P=%_-:[>N(
MTW_DL&M?]@Z+^:T =O1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\O,7\Z[-)SY:_*.@KB/BA_R)K_\ 7Q%_.NQ3_5K]!0!8^T'^Z*/M!_NBH:*
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M&/6\_P"_/_UZ/^%M^&/6\_[\_P#UZ/J]7^5A[6'<[JBN%_X6WX8];S_OS_\
M7H_X6WX8];S_ +\__7H^KU?Y6'M8=SNJ*X7_ (6WX8];S_OS_P#7H_X6WX8]
M;S_OS_\ 7H^KU?Y6'M8=SNJ*X7_A;?ACUO/^_/\ ]>C_ (6WX8];S_OS_P#7
MH^KU?Y6'M8=SNJ*X7_A;?ACUO/\ OS_]>C_A;?ACUO/^_/\ ]>CZO5_E8>UA
MW.ZHKA?^%M^&/6\_[\__ %Z/^%M^&/6\_P"_/_UZ/J]7^5A[6'<[JBN%_P"%
MM^&/6\_[\_\ UZ/^%M^&/6\_[\__ %Z/J]7^5A[6'<[JBN%_X6WX8];S_OS_
M /7H_P"%M^&/6\_[\_\ UZ/J]7^5A[6'<[JBN%_X6WX8];S_ +\__7H_X6WX
M8];S_OS_ /7H^KU?Y6'M8=SNJ*X7_A;?ACUO/^_/_P!>C_A;?ACUO/\ OS_]
M>CZO5_E8>UAW.ZHKA?\ A;?ACUO/^_/_ ->C_A;?ACUO/^_/_P!>CZO5_E8>
MUAW.ZHKA?^%M^&/6\_[\_P#UZ/\ A;?ACUO/^_/_ ->CZO5_E8>UAW.ZHKA?
M^%M^&/6\_P"_/_UZ/^%M^&/6\_[\_P#UZ/J]7^5A[6'<[JBN%_X6WX8];S_O
MS_\ 7H_X6WX8];S_ +\__7H^KU?Y6'M8=SNJ*X7_ (6WX8];S_OS_P#7H_X6
MWX8];S_OS_\ 7H^KU?Y6'M8=SNJ*X7_A;?ACUO/^_/\ ]>C_ (6WX8];S_OS
M_P#7H^KU?Y6'M8=SNJ*X7_A;?ACUO/\ OS_]>C_A;?ACUO/^_/\ ]>CZO5_E
M8>UAW.ZHKA?^%M^&/6\_[\__ %Z/^%M^&/6\_P"_/_UZ/J]7^5A[6'<[JBN%
M_P"%M^&/6\_[\_\ UZ/^%M^&/6\_[\__ %Z/J]7^5A[6'<[JBN%_X6WX8];S
M_OS_ /7H_P"%M^&/6\_[\_\ UZ/J]7^5A[6'<[JN,T[_ )*SK'_7A'_-:@_X
M6WX8];S_ +\__7JKX3UNT\0?$;5=0L?,\A[%%'F+@Y!4'BIE2G!7DK#4XRT3
M/1****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 Y/O4VG)]ZFUE'^++T7ZEOX%\PHHHK4@**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]+^#7_ "'K_P#Z]?\
MV=:\TKTOX-?\AZ__ .O7_P!G6N+'_P +YF^&^,]HHHHKQSN"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F.#_
M )&&/_K['_H=?5-?*T'_ ",,?_7V/_0Z^J: ,'3_ /7-_NUHUG:?_KF_W:T:
MTJ_$1#8****S+"BBB@ HHIDI(A<CJ%.* /%_B1XIN]5ULZ%8.WV>-A&RH?\
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MAZ__ .O7_P!G6O-*]+^#7_(>O_\ KU_]G6N+'_POF;X;XSVBBBBO'.X****
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MW@OX*."O_$84445U&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM>%M GTOSKJ\8&YFZ@'.!U_.KQ,X2A)MIWVMN32C)25D_,Z2BBBO).T****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@?B[_
M ,BA#_U^)_Z"U=]7 _%W_D4(?^OQ/_06H \.DZ"HZDDZ"HZ]O!?P4<%?^(PH
MHHKJ,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!R?
M>IM.3[U-K*/\67HOU+?P+YA1116I 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Z7\&O^0]?_ /7K_P"SK7FE>E_!K_D/7_\ UZ_^
MSK7%C_X7S-\-\9[11117CG<%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?,<'_ ",,?_7V/_0Z^J:^5H/^1AC_
M .OL?^AU]4T 8.G_ .N;_=K1K.T__7-_NUHUI5^(B&P4445F6%%%% !1110
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MRW^%']DZE_T#[O\ [\M_A1S+N%F4Z*N?V3J7_0/N_P#ORW^%']DZE_T#[O\
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M!^^O8UQ8YITOF=&'3YSV2BBBO(.T**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^8X/^1AC_P"OL?\ H=?5-?*T
M'_(PQ_\ 7V/_ $.OJF@#$LH9(IFWHR_+W%7JDF_UAJ.JE+F=Q)65@HHHJ1A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7 _%W_D4(?^OQ/_06KOJX'XN_\BA#_P!?B?\ H+4 <[\&_P#D*:I_
MUQ3_ -"->P5X_P#!O_D*:I_UQ3_T(U[!0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <9\4/^1-?_KXB_G78I_JU^@KCOBA_
MR)K_ /7Q%_.NQ3_5K]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KC-._Y*SK'_7A'_-:[.N,T[_DK.L?]>$?\UH [.BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#YC@_Y&&/_ *^Q_P"AU]4U\K0?\C#'_P!?8_\ 0Z^J: (9(V9\
MBF>2_M^=6:* *WDO[?G1Y+^WYU9HH K>2_M^='DO[?G5FB@"MY+^WYT>2_M^
M=6:* *WDO[?G1Y+^WYU9HH K>2_M^='DO[?G5FB@"MY+^WYT>2_M^=6:* *W
MDO[?G1Y+^WYU9HH K>2_M^='DO[?G5FB@"MY+^WYT>2_M^=6:* *WDO[?G1Y
M+^WYU9HH K>2_M^='DO[?G5FB@"MY+^WYT>2_M^=6:* *WDO[?G1Y+^WYU9H
MH K>2_M^='DO[?G5FB@"MY+^WYT>2_M^=6:* *WDO[?G1Y+^WYU9HH K>2_M
M^='DO[?G5FB@"MY+^WYT>2_M^=6:* *WDO[?G1Y+^WYU9HH K>2_M^='DO[?
MG5FB@"MY+^WYT>2_M^=6:* *WDO[?G1Y+^WYU9HH K>2_M^='DO[?G5FB@"M
MY+^WYT>2_M^=6:* *WDO[?G1Y+^WYU9HH K>2_M^=<!\7XV3P?"3_P _B?\
MH+UZ17GGQD_Y$V#_ *_4_P#07H Y?X,(7U75,?\ /!/_ $(U[%Y+^WYUY#\$
M_P#D+:K_ -<$_P#0C7L] %;R7]OSH\E_;\ZLT4 5O)?V_.CR7]OSJS10!6\E
M_;\Z/)?V_.K-% %;R7]OSH\E_;\ZLT4 5O)?V_.CR7]OSJS10!6\E_;\Z/)?
MV_.K-% %;R7]OSH\E_;\ZLT4 5O)?V_.CR7]OSJS10!6\E_;\Z/)?V_.K-%
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M;\ZLT4 5O)?V_.CR7]OSJS10!6\E_;\Z/)?V_.K-% %;R7]OSH\E_;\ZLT4
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M_C1RR[!=&A16?_;VC_\ 06L?_ E/\:/[>T?_ *"UC_X$I_C1RR[!=&A16?\
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M+L%T:%%9_P#;VC_]!:Q_\"4_QH_M[1_^@M8_^!*?XT<LNP71S'Q6_P"1)?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'RM#_P C%'_U]C_T.OJFOE:'_D8H_P#K['_H=?5- &-H_P#Q\2?[G]:V
M:QM'_P"/B3_<_K6S6E7XB(;!1116984444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ>N/8W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KSSXR?\ (FP?]?J?^@O7H=>>?&3_ )$V#_K]3_T%Z /!
MI.@J.I).@J.O;P7\%'!7_B,****ZC$**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH <GWJ;3D^]3:RC_ !9>B_4M_ OF%%%%:D!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\K0_\C%'_ -?8_P#0Z^J:^5H?^1BC_P"O
ML?\ H=?5- &-H_\ Q\2?[G]:V:QM'_X^)/\ <_K6S6E7XB(;!1116984444
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MINGAW&6G;S",E*HFO^&.RHHHKS#K"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\\^,G_(FP?\ 7ZG_ *"]>AUYY\9/^1-@
M_P"OU/\ T%Z /!I.@J.I).@J.O;P7\%'!7_B,****ZC$**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH <GWJ;3D^]3:RC_%EZ+]2W\"^
M84445J0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'N/P1_Y%S4?^OO\ ]D6O3Z\P^"/_
M "+FH_\ 7W_[(M>GUX6*_C2/1H_ @HHHKG- HHHH **** "BBB@ KB--_P"2
MP:U_V#HOYK7;UQ&F_P#)8-:_[!T7\UH [>BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ')]ZFTY/O4VLH_Q9>B_4M_ OF%%%%:D!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110![C\$?\ D7-1_P"OO_V1:]/KS#X(_P#(N:C_ -??_LBUZ?7A
M8K^-(]&C\""BBBN<T"BBB@ HHHH **** "N(TW_DL&M?]@Z+^:UV]<1IO_)8
M-:_[!T7\UH [>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_"!^%?^@%9?]^ZZ*BCVL^[#DCV.=_X0/PK_ - *R_[]T?\ "!^%?^@%9?\
M?NNBHH]K/NPY(]CG?^$#\*_] *R_[]T?\('X5_Z 5E_W[KHJ*/:S[L.2/8YW
M_A _"O\ T K+_OW1_P ('X5_Z 5E_P!^ZZ*BCVL^[#DCV.=_X0/PK_T K+_O
MW1_P@?A7_H!67_?NNBHH]K/NPY(]CG?^$#\*_P#0"LO^_='_  @?A7_H!67_
M '[KHJ*/:S[L.2/8YW_A _"O_0"LO^_='_"!^%?^@%9?]^ZZ*BCVL^[#DCV.
M=_X0/PK_ - *R_[]T?\ "!^%?^@%9?\ ?NNBHH]K/NPY(]CG?^$#\*_] *R_
M[]T?\('X5_Z 5E_W[KHJ*/:S[L.2/8\P^(WA70M*\)M<V&E6UO.)XUWQI@X)
MY%=8G@3PL44G0K+I_P \ZR_BM_R)+_\ 7S%_.NU3_5K]!1[2>]PY8]CG_P#A
M _"O_0"LO^_='_"!^%?^@%9?]^ZZ*BCVL^[#DCV.=_X0/PK_ - *R_[]T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O//C)_P B;!_U^I_Z
M"]>AUYY\9/\ D38/^OU/_07H YOX)_\ (6U7_K@G_H1KV>O&/@G_ ,A;5?\
MK@G_ *$:]GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .(^*W_(DO\ ]?,7\Z[5/]6OT%<5\5O^1)?_ *^8OYUVJ?ZM?H*
M'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M1IO_ "6#6O\ L'1?S6NWKB--_P"2P:U_V#HOYK0!V]%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RM#_R
M,4?_ %]C_P!#KZIKY6A_Y&*/_K['_H=?5- !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-\5=
M.O-3\*0P65N\\HNT8J@YQM;G]:[FB@#R?X1Z+J6E:EJ3WUG+ KPH%+CJ<FO6
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#D/B38W6H^$6@M(7FE^T1ML7K@'FNM3A%'M3J* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD+"QND^*6K7K0N+:2QC1)
M3T+ KQ77T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
L44 %%%% !1110 4444 %%%% 'S?%X4UX:ZDITNXV"Y#;L=MW6OI"BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gan5qj4us5ce000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gan5qj4us5ce000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,!!VP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)I[NL:[G8*HZDG H =14:3PRG$<L;G_98&I* "BHC=6X;:9XMW3&\9J7MF@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ"JLDD7\(. Q'^->=^,O#>A^%8(M4\/:R\=UYHV01S!_Q!'/YUZ#J?BJ32/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\*9+$D\3Q2J'C<%64]"#3Z*1CL>?-X U32[J63PYK1M(I3EHY,\?D#FM#0/
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MQ/$ !@#G_P")KT"BA5&E8=/'U:=-4TDTNZ3,GP]9:I8Z<8M7OEO+GS"1(O\
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M_P#] FV_[YH_X1'P_P#] FV_[YHYL/\ R!:KW.(_X7>__0(7_OY1_P +O?\
MZ!"_]_*[?_A$?#__ $";;_OFC_A$?#__ $";;_OFCFP_\@6J]SB/^%WO_P!
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M Z?X4<]#^0.6I_,>8_\ "[]4_P"@19_]]M1_PN_5/^@19_\ ?;5Z=_8FD_\
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MQ3_(B_YY)_WR*/:TOY$')/\ F/&O^%J^,/\ GA'_ . ]'_"U?&'_ #PC_P#
M>O9?(B_YY)_WR*/(B_YY)_WR*/;4OY$')/\ F/&O^%J^,/\ GA'_ . ]'_"U
M?&'_ #PC_P# >O9?(B_YY)_WR*/(B_YY)_WR*/;4OY$')/\ F/&O^%J^,/\
MGA'_ . ]-;XI>,W&(XD4^HM<_P!*]G\B+_GDG_?(IRQHARJ*#Z@4>VI?R(.2
M?\QXG_PLWQSZ#_P#'^%'_"S?'/H/_ ,?X5[=13]M3_Y]H/9R_F/$?^%F^.?0
M?^ 8_P */^%F^.?0?^ 8_P *]NHH]M3_ .?:#V<OYCQ'_A9OCGT'_@&/\*/^
M%F^.?0?^ 8_PKVZBCVU/_GV@]G+^8\1_X6%X\N/F7?QQ\MKC^E'_  G7C_\
MZ;?^ W_UJ]NHH]O#^1![.7\QXC_PG7C_ /Z;?^ W_P!:C_A.O'__ $V_\!O_
M *U>W44>WA_(@]G+^8\1_P"$Z\?_ /3;_P !O_K4?\)UX_\ ^FW_ (#?_6KV
MZBCV\/Y$'LY?S'B/_"=>/_\ IM_X#?\ UJ3_ (2SXAR_.IN\'^[#@5[?11[>
M'\B#V<OYF>(?\)/\1/6\_P"_5'_"3_$3UO/^_5>WT4?6(_R(/9O^9GB'_"3_
M !$];S_OU1_PD_Q$];S_ +]5[?11]8C_ "(/9O\ F9XA_P )/\1/6\_[]4?\
M)/\ $0\9O?\ OU7M]%'UB/\ (@]F_P"9GB']J_$H\[M2_P"^:/[5^)7][4_R
MKV^BCZPOY$'LG_,SQ#^U?B5_>U/\J/[5^)7][4_RKV^BCZPOY$'LG_,SQ#^U
M?B5_>U/\J/[5^)7][4_RKV^BCZPOY$'LG_,SRWP;?^.IO%EA'JIOS8EF\WS!
M\N-IQG\<5['52V_UI^E6ZY:\U.5TK&U./*MPKGO$OBZT\,R0)=12/YP)&T>E
M=#6%K_AW3M=DA-]&SF($+AL=:SC:^IUX7V7M5[;X?(YW_A:^D_\ /O/^51GX
MM::"0+*<CUR*N?\ "O?#W_/M)_W\J0> ?#H 'V'/N7-:_NNQZM\K7V9?U\S.
M_P"%M:=_SXS_ )BC_A;6G?\ /C/^8K2_X0+PY_SX?^/FC_A O#G_ #X?^/FC
M]UV#FRO^27]?,S?^%M:=_P ^,_YBC_A;6G?\^,_YBM+_ (0+PY_SX?\ CYH_
MX0+PY_SX?^/FC]UV#FRO^27]?,S?^%M:=_SXS_F*/^%M:?C_ (\)_P#OH5I?
M\(%X<_Y\/_'S2_\ "!^',_\ '@/^^S_C1^Z[!S97_)+^OF8__"W;/_H%S_\
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MI<61_M-_C3_^$0\/_P#0+A_7_&B]+L'M<L7_ "Z?W_\ !.:_X6[%_P! M_\
MOX*/^%NQ?] M_P#OX*Z7_A$/#_\ T"X?U_QH_P"$0\/_ /0+A_7_ !HO2[![
M7+/^?3^__@G-?\+=B_Z!;_\ ?P4?\+=B_P"@6_\ W\%=+_PB'A__ *!</Z_X
MT?\ "(>'_P#H%P_K_C1>EV#VN6?\^G]__!.:_P"%NQ?] M_^_@IC_%T?P:6?
M^!/74?\ "(>'_P#H%P_K_C3D\*:$GW=,@Y]031>GV#VV6?\ /I_?_P $Y/\
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MZSEZVH?B>>_\+=U'_H&6O_?;4?\ "W=1_P"@9:_]]M7H?]D:9_T#K3_OPO\
MA1_9&F?] ZT_[\+_ (4<U/\ E#ZU@/\ GQ^)YY_PMW4?^@9:_P#?;4?\+=U'
M_H&6O_?;5Z'_ &1IG_0.M/\ OPO^%']D:9_T#K3_ +\+_A1S4_Y0^M8#_GQ^
M)YY_PMW4?^@9:_\ ?;4'XN:D1A=-M03T^9J]#_LC3/\ H'6G_?A?\*!I.F@Y
M&GV@/_7%?\*.:G_*'UK ?\^/Q/.?^%K:S_SX6_Y&C_A:VL_\^%O^1KTG^SK'
M_GSM_P#OTO\ A1_9UC_SYV__ 'Z7_"CGA_*'UO _\^/Q/-O^%K:S_P ^%O\
MD:/^%K:S_P ^%O\ D:])_LZQ_P"?.W_[]+_A1_9UC_SYV_\ WZ7_  HYX?RA
M];P/_/C\3S;_ (6MK/\ SX6_Y&C_ (6MK/\ SX6_Y&O2?[.L?^?.W_[]+_A1
M_9UC_P ^=O\ ]^E_PHYX?RA];P/_ #X_$\T;XIZXXPEE #[*33?^%G^(/^?6
M'_OV:].6PLU.5M( ?:,4[[);?\^\/_? HYX?RA]<P72@OO/+_P#A9_B#_GUA
M_P"_9H_X6?X@_P"?6'_OV:]0^R6W_/O#_P!\"C[);?\ /O#_ -\"CGA_*'UW
M!_\ /A?>>7_\+/\ $'_/K#_W[-'_  L_Q!_SZP_]^S7J'V2V_P"?>'_O@4?9
M+;_GWA_[X%'/#^4/KN#_ .?"^\\O_P"%G^(/^?6'_OV::WQ*\2N<I!&![0YK
MU+[);?\ /O#_ -\"G+;P+]V&,?111SP_E#Z[@^E!?>>5?\+'\4?\\4_[\4?\
M+'\4?\\4_P"_%>K>3%_SS3_OD4>3%_SS3_OD4<\/Y0^O87_H'7]?(\I_X6/X
MH_YXI_WXH_X6/XH_YXI_WXKU;R8O^>:?]\BCR8O^>:?]\BCGA_*'U["_] Z_
MKY'E/_"Q_%'_ #Q3_OQ1_P +'\4?\\4_[\5ZMY,7_/-/^^11Y,7_ #S3_OD4
M<\/Y0^O87_H'7]?(\F/Q"\7,<JH /0?9<_TI/^%@>,/0?^ O_P!:O7  !@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M,D_U3?2J-7I/]4WTJC6D"9!1115$A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!-;?ZT_2K=5+;_6GZ5;K.6Y:V"J\_WQ]*L57G^^/I21
M<-R*BBBF:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M;C_U:_2JE6X_]6OTI,B>PZBBBD9A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,D_P!4WTJC5Z3_
M %3?2J-:0)D%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% $UM_K3]*MU4MO]:?I5NLY;EK8*KS_?'TJQ5>?[X^E)%PW(J***9J%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5N/_ %:_2JE6
MX_\ 5K]*3(GL.HHHI&84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #)/]4WTJC5Z3_5-]*HUI F0
M44451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 36W^M
M/TJW52V_UI^E6ZSEN6M@JO/]\?2K%5Y_OCZ4D7#<BHHHIFH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %6X_]6OTJI5N/_5K]*3(GL.H
MHHI&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% #)/\ 5-]*HU>D_P!4WTJC6D"9!1115$A1110
M4444 %%%% !1110 4444 5-3GDM=)O+B(@210.ZDC/(4D5Y/8>,_'FJQO)86
MPN(T;:S1VP(!KU37/^0!J/\ U[2?^@FO%?"GB#Q+I-E/%HNF&ZA:3<["V>3!
M],J:F6Y2.V\.:OXYN==MHM6L7CL6)\QS;A<<''/UQ7H'FQB3RS(F_KMW#/Y5
MPWA+Q)XJU36A;ZQI)MK7RV/F&UDCY[<L<5S_ (FM+B_^*R6=O<O;M.B(TB=0
MNW)Q^5%[(#UA)X9&*I*C,.H# FB2>&(XDEC0GLS 5X]XAT0>"?$VESZ7=7)$
M[ N9'R2<\YQU!KNO%GA71-7']JZQ<7$*6T."T<@4!>O<'FG<5CI1=VQ.!<1$
MGH XIZS1.Q5)$9AU 8$BO#?"?AQ->\4F73TFBTNVD#F24@M@=!D#&373A3X8
M^+"_P6NIC ],G_Z^*7,%CTMYHHV"O(BEN@9@,T>=$)/+,B;_ .[N&?RKS:^
M\3_%B*U^]:Z8@+8Z9')_\>('X5F^);*;4/BJEG!</;F545I(_O*N.<4[A8]:
M6>%WV)*C,.H# F@SPB3RS*@?^[N&:\:\6Z$W@K6--N-&O;I9;@G+2N"=P(Z^
MH.>]6_&'@]= T2'68]1NY=1$BB25WZD]QW'YTKA8]>J,7$+/L$T9?^Z&&:\^
M\2>)KRT^'.GW$4Q%U>JL9E'!'')^O%<5/'X<M=&2^L/$%TVOJ%=OD< MW&=O
M;U)YQ0Y!8]ZKSOQOXKU[2?$5MIVD;&,T8*H8@S,Q..*Z?P?J\FM^&;2\F(,Q
M7;(1W8<$UP'Q%N+JT\=Z;<647FW4:*T4>TMN8-P,#DT-Z MQTGB;XBVL;3W&
MFLL*#+DVH  KMO!GBC_A*-+>:2(17$+;)%'3ZBO.[SQ_XMN';2Y[2VM)IQLQ
M)$8FY]W; _&NL\.://X)\'ZA?73*UVR&9E5@0N!P,]Z$]1L[A[B&-MLDT:MZ
M,P!J3(QG/'K7@^G-X?UF&XO?$VO7,>HR.?+5(W8)Z'A3QGL,=*Z_X?:[<:AH
M>J:?<W!G-K&QCD8G)0@^O-"D*QZ)]H@V%_.CV@X)W#%/1TD7<C*R^JG(KQGP
M/X77Q-'?)>WES'90R<0PMMW,<\G\JU?"[7?A;XA3>&_M+SV,@)C#'IQN!]CC
M(-',%C<L_$^I3?$F?1'>/[$BL0H0;N!ZUVDDL<0S)(J ]V.*\RT[_DM-U_N/
M_*K?B/P]#J'B*6Y\3:];6VG;/]'MH[C:_'?##'KTS0F!Z&DB2+NC=77U4YI)
M)8XAF214'JQQ7DOP[NA;>-;S3K&]DGTS8YCW$X(!&#CMUIUM:R?$'QA?Q7]Y
M-'8VA.R&,XXSCZ?CBCF"QZRDB2KNC=7'JIS2231Q#,DB)GIN8"N/\-^#+SPU
MK4\T&JLVED86V?+$_7H 0>XK@9-4TOQ+XAO9_$VJSVMHC$00Q*S=_8$"G<+'
MN"LKJ&5@RGH0<TP3PDL!*A*_> 8<?6O+? &M+;>*9]$M+][S3)%8V[2 @@@9
MZ$9]:S-$T1M>\>:W9M=SV]KYTKS>2V"_SG S^)I<P6/9DFBE!,<B/CKM8&D6
M>%WV)*C,.H# FO&9M%N=%\=_V!I.HW$%O=!59BV3M;K^/O4GBG0U\#ZWI5WI
M=[<[IG)D,CY)((SG'4'/2CF'8]E) &20 .YIB3PRDB.5'(ZA6!KSCXFZ[-#-
MI^DQW36T$ZB2>5<YVYQVY]:Y2\N=$\/RVE[X6URYFN5<><DB.H8>O*@8]J'(
M5CW-Y8XL>9(J9Z;CC-(;B%7V&:,,?X2PS7F7Q/NS=Z-X?O(?E:4F5,=B0I%4
MO%7@T:5X<BUL:A=3:BI0R2._'/IW&/K0V%CTKQ#K*:#HMQJ#()#$N53=C<<X
MJKX0UU]?T&&]G,:SR,^8T/W0&('Z5R/B&V76_A9::G>22-<V\8=2#]XYV\\<
M\5:^%V@6<&CQ:VC2_:IU>-P6&S 8C@8]O6B[N'0V/&=_XDLH[8^'[9IF8GS<
M1;\"N#N?''CFSOHK&XA6*ZEQY<36P#-DX&*]FKROQG_R5/0_I#_Z,-$AHV?#
M.K>+YYKLZY:-##' SQLT 3YA5CP'XFO==M;^74Y8OW$H5"%" #FNKOO^0?<_
M]<F_D:\?\#>%U\2QZBEW>7$5G')_JH6"[V.>3]*-4P/9DD21=R.K+ZJ<TDDL
M<0S)(B _WF KS#X>-<:7XOU?1//>2UA#;0QZ;6P#CMD&L&?5-,\2>);V7Q+J
ML]K91L5@AB5FZ''8$"CF%8]O5U=0R,&4]"#D4PW$(9E,T8*_>&X<5Y9X"UI+
M3Q=-HEG?O>:5,K&W:0$%2!GH1GL16<-(.N_$_5-/:XDA@>21IO+."R@]/UHY
M@L>RK+&Z;TD5E_O Y%(EQ!(VU)HV;T5@37&:UX4EL?"\>E:/J,5C9+)ON)[J
M8JQ7Z@8_E7GWB.VT?PY=V4OAO69)[H$F8I)N&1C!RO&#SQS3;L%CW5Y8X@#(
MZH#TW'%(;B%6"F:,,>@+#->=_%.1V\.Z7)GYS(#GWP*J7OP_#>%CJYU*Z?5$
M@\_>S_+P,[1W''O1<+'J$DL<0!DD1,]-S8S3MP"[B1CKFO)7>Z\6?"PW$Y:6
M\TZ4XD/5E'_UB/RK3OO%/F?"N.X5_P#29D%MQUW=#1S!8]&CECE7=&ZN/53F
MN;\:^(Y/#^EQ_9=IOKEQ'"&&1]<4_P #:2-'\*6D1&)9E\Z3ZMT_3%<IXM8W
MWQ/T:Q?F*/:=IZ9Y-#>@&OXR\0ZQX>\,Z?<PRQ?;)7"RL8P0?E)Z5S<7B/XC
MSPI+%IS/&ZAE86HP0>AK8^+O_(OV7_7S_P"RFL&Q\8>.8+"WAM]"9X$B58V^
MPRG<H'!R#SQ4O<:V.U\*:CXCN=.OI=>MS!-'S$&BV9&*XFT\:>.=3>?^SH%N
M4B?:QCM@<>E=YX;U/5]5\.W,^LV9M;@;P$,+1\8]&YKROPYX@\0:(+_^Q[#[
M3$TFZ5S;O($QG'*GCOUH8'0IX^\5:+>P#Q!8;8)#_%%L..Y%=9XMU3Q##:64
MWARV:?S?F?$6_ QQ7 13^(/B9>06\[6D=O;ME]A"E0>IVDEC_*O9[:!;:UB@
M0DK&@4$^U-:@SQZY\<>.;.^BLKF%8KJ7'EQ-; ,V3@8_&NJ\-ZEXTO9;M-5M
MC;J(287:W"C?V^M8_C7_ )*EH?TB_P#1AKU2A+4&<QX+\1RZ]I\T=YM%_:R&
M.8*, ^AQ73UYAX98V'Q6U:R3(CF#94=.@:O3Z:>@F%%%%,04444 %%%% !11
M10 4444 %%%% $UM_K3]*MU4MO\ 6GZ5;K.6Y:V"J\_WQ]*L57G^^/I21<-R
M*BBBF:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/1=0DT:?1TO8)(@7WS;<@]L;346C^+X!X"U74-/TJ+3_ +(VQ(XWW L0 &/
M]1^5 D[/<]":XA1]C31JW]TL :>2 I8D #DDUX'9+X<U#3);W6O$%TFLOED
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZBBBD9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU"#Q5I;F.28R6][L=D<'M\O>MWPW)HEK<7^KZ=H?V'3+> [;Z1F4S=R%5NW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)/]4WTJC5Z3_5-]*H
MUI F044451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 36W^M/TJW52V_UI^E6ZSEN6M@JO/]\?2K%5Y_OCZ4D7#<BHHHIFH4444
M%%%% !1110 4444 %%%4;O6=-L)O*N[V&&0C.UVP<4 7J*RO^$FT3_H*6O\
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M/_(NW/U3_P!"%(3V-=?NCZ4M(OW1]*6F,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *MQ_P"K7Z54JW'_ *M?I29$]AU%%%(S
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 9)_JF^E4:O2?ZIOI5&M($R"BBBJ)"BBB@#C?%VA:I
M<:@-4TA8I96M'M)89&Q\C=P3WK/T#0M>N+G2!JL,%K::6O[I5<,\C8QS4OC#
M-UXKL-/N]<?3-/>W9P8I0C-)GHW/ QT)XX-+I'A_1[;5;::#Q=/=2H^5@:]5
M@Y], \U/4H[RBBBJ)"BBB@ HHHH Q]3_ .0]H_\ O2_^@BMBL?4_^0]H_P#O
M2_\ H(K8I(84444Q!1110 4444 >:Z6VWXWZM[VV/_'8Z]*KR[3G/_"\-1R.
ML6/_ !Q*]1K>OO'T1G3V?J%%%%8&@4444 %%%% !1110 4444 %%%% !39"5
MC8CJ 33JCN&VVTK=<(3^E,#S;X.-_P 2W4D])P?T%>FUY9\&V_<ZJGHZG^=>
MIUMB?XK,Z7P(****P- HHHH **** "BBB@ HHHH **** "O-/B2VWQ7X3;TN
M,_\ C\=>EUY;\4&*^*/#;9QMDS]/G2M\-_$^_P#(SJ_">I#H**1?N+]*6L#0
M**** "BBB@ HHHH **** "BBB@ HHHH **** /+]9D_XO1IRYQA4'YBO4*\C
MU>3/QOL_9XEZ_P"S7KE=%=:1]#.GN_4****YS0**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@":V_UI^E6ZJ6W^M/TJW6<MRUL%5Y_OCZ58JO/]\?
M2DBX;D5%%%,U"BBB@ JAK<]Q;:+>3V@!N$B)0'UJ_7/^)-4L(89=-OK>[ECG
M@9V,"Y^4=1G/6@&<IINB:MJVG07S^,)%:9=Q52,*?2NYT*RFL-*CMY[YKV12
M<S-U/->2[/ W_0)\0?\ ?(_QKTWP<-/'AR'^S(;F*UW-M2Y'SCDYS2)B;]%%
M%,H*QO%6GW6J^&[NQLUB:>90JB7IU&3]<5LUS_C>[N[+PAJ%Q8NR3*@^=>J@
MD D?AF@3V,""+XBP0)$)].8(H7<X!)^O-=II9O3ID']H&,W>W]Z8_NY]J\?>
MRBC_ +4CG\67\4D4:S6C/.VV=&4$=^3VKU'PFR-X5TYHQ*%,(.)6RWXFD*)M
M4444R@HHHH *Q_%/_(NW/U3_ -"%;%8_BG_D7;GZI_Z$*0GL:Z_='TI:1?NC
MZ4M,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5;C_P!6OTJI5N/_ %:_2DR)[#J***1F%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3_5-]*HU
M>D_U3?2J-:0)D%%%%42%-=MJ,V,X&<>M.HH \UU^_L-3EM;N^\)7MS-)#V?&
MP!V&#Q[9_&H=!_LC^W;/R/"%Y:R>9\L[OPA]373>)-<U/P[J"7XM3=Z,8PLP
MBQOB?)^;Z'(%5-&U;Q!XHO+>_A6&QT=7W;2P:28>G'2IZE':T4451(4444 %
M%%% &/J?_(>T?_>E_P#016Q6/J?_ "'M'_WI?_016Q20PHHHIB"BBB@ HHHH
M \HLFV_'*[]P1_XXM>KUY' VWXZRC/WGQ_Y"%>N5T8C[/HC.EU]0HHHKG- H
MHHH **** "BBB@ HHHH **** "H+PA;*=CT$;$_E4]5M1(&F71/00O\ R--;
M@SR_X,O^_P!83T$9_5J]9KQ_X-MC4]57UC0_JU>P5OBOXK,Z/P(****YS0**
M** "BBB@ HHHH **** "BBB@ KR;XKN5\1Z%Z+D_^/+7K->/_%Y\:_I/'W8R
M?_'A71A?XJ,ZWP'KT?\ JU^@IU,B_P!2G^Z*?7.:!1110 4444 %%%% !111
M0 4444 %%%% !1110!XSJ<A/QJMV'5;A!^E>S5X;J$@/QBW$_=O0*]RKJQ*T
MAZ&5+=^H4445RFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UM
M_K3]*MU4MO\ 6GZ5;K.6Y:V"J\_WQ]*L57G^^/I21<-R*BBBF:A1110 53U6
M\BT[3;B^E0,L,98C'6KE8OB?5=,TW1YQJ;KY<D9 BW -)[#/>@&<QHOB#7+_
M %:X@N;2UC#Z>UW:Q*H]<+DUU7AK5AK>A6]Z(A$SY#H.@8'!_6O-8-,T@LES
M!XU6VC>#R_+=E\Q$/.S.:]!\%RV$OABV.FQR);+N4>9]XD'DGZFD2CH*:9(P
M<%U'U-4=<DEBT.]D@E6*586*.YP%..M>9Z5I?AN_TR"YOO%DR73KF56N@I5N
MXP30-L];#!AE2"/4&D=%D1D=0RL,$$<$5D^&K6QM-'2+3[XWMN&.)C('R<^M
M5_&UW=67A#4)[-F694 #+U4$@$_@,TPOH6;SP[H5U]G6ZT^U;R5"1!D' '0#
MVK51$CC5$4*BC  ' %>.S21:_>W3+J=S_9>CV"K'<*Y&^0 8)]R<UZ=X8GN+
MGPSI\UT6,[P@L6ZFD"99U>XO+32YI]/MA<W2 %(2?O<C/Z9KF[;XA6*2^1K%
MG=:9,#@^<F4_[ZKH]8?4$TJ=M*CCDO<#RED.%ZC)/X9KBY?"MYK;@^*/$,3H
M&S]EML*J_B>: =^AW5I?6E_$)+2XCF0C.4;-6*X_2O!D&C>(+74-&F\NQ\IE
MN(S(3YAQP1VKL*8T%8_BG_D7;GZI_P"A"MBL?Q3_ ,B[<_5/_0A2$]C77[H^
ME+2+]T?2EIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "K<?^K7Z54JW'_JU^E)D3V'4444C,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DG^J;
MZ51J])_JF^E4:T@3(****HD*:ZAT9#T88.*=10!Y5XC\+>'M"\N%I=6N[RXR
M8[:&0$L.Y/' IGA'3=$CU^W22VU73KY&WQ17$@*2$>^T9KJ/$UGJMCK]KX@T
MFV2\D2 V\MNQY*YR"OO52S&N>)O$%A=:EIHTVVL6,BJY^=ST_*IMJ4=W1115
M$A1110 4444 8^I_\A[1_P#>E_\ 016Q6/J?_(>T?_>E_P#016Q20PHHHIB"
MBBB@ HHHH \;A;;\=#SUN&'_ )#->R5XJS;?C?G_ *>O_:=>U5TXG[/HC*EU
M]0HHHKF-0HHHH **** "BBB@ HHHH **** "JFJ_\@B]_P"N#_\ H)JW5'6O
M^0%J'_7M)_Z":<=P>QY/\'FQKU^OK"/YU[-7B7PA;'BBY7UMR?U%>VUTXO\
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M9@TPRSXZ DY('YTB4,U^_DBS9?V3)?030.9-K8' ^[T[UY_BP_Z)U-_W]/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JW'_ *M?I52K<?\ JU^E)D3V
M'4444C,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!DG^J;Z51J])_JF^E4:T@3(****HD**** .
M$\57D5GXUTF75;V>TTN.(O$\8.UI@W1L \8J"?5K#5?'NEW&AWTMS,05N57/
MEK&!].M:7C/Q/9Z65T^?2O[29HC-)&P&U$SC)R/6LW0O$?E:M::?:>%4TT71
MW%Q@ KW(P!FIZE'H5%-D_P!6WT->/^!_%%WHVG7<$6C75^'N"_F1MPO &.A]
M*;=A6/8J*X_3_&M[?:A!:OX;O8%E<*97?A?<\5V%.X!1110(Q]3_ .0]H_\
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M,*Q_%/\ R+MS]4_]"%;%8_BG_D7;GZI_Z$* >QKK]T?2EI%^Z/I2TQA1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5;C_ -6OTJI5
MN/\ U:_2DR)[#J***1F%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_D7;GZI_Z$*V*Q_%/_(NW/U3_P!"%(3V-=?NCZ4M(OW1]*6F,**** "BBB@
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MA6/XI_Y%VY^J?^A"MBL?Q3_R+MS]4_\ 0A2$]C77[H^E+2+]T?2EIC"BBB@
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M% !5N/\ U:_2JE6X_P#5K]*3(GL.HHHI&84444 %%%% !1110 4444 %%%%
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M/M_(ZVBBBL2PJ 7MN;XV0E7[0$\PQ]POK4]<G-K\T2>(KT)'Y=BWDPMY?)8
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MM#:RB:5 D"1YCG_UB <;O7BNIL[:"SLXK:V4+#&H5 .PI$I,GHHHIE!1110
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M^X?^ G"_9OB)_P _UC_WRO\ \31]F^(G_/\ 6/\ WRO_ ,37=44<_D@^O/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P" <T^QZ9D49%>9_P#"O8O^ANN?^_P_QH_X5[%_T-US_P!_A_C1R4_Y_P
MYI]CTS(K@_BT?^*/7G_EX3^M9_\ PKV+_H;KG_O\/\:CF^&MI<)LG\4S2+G.
MUY 1_.KIJG"2ES;>1,G-JUCMKA ?!DJ#I]A/_H%8?PK?/@F+)Z3R#^5=*39'
M2S8F\BVF'RBWF#.,8S7!+\,-'083Q#<*,YPLJ"IA*#BXR=M1M2332/3<CU%&
M1ZBO-/\ A6>D_P#0R77_ '^2C_A6>D_]#)=?]_DI<E+^;\!\T^QZ7D>HHR/4
M5YI_PK/2?^ADNO\ O\E'_"L])_Z&2Z_[_)1R4OYOP#FGV/2\CU%&1ZBO-/\
MA6>D_P#0R77_ '^2C_A6>D_]#)=?]_DHY*7\WX!S3['I>1ZBC(]17FG_  K/
M2?\ H9+K_O\ )1_PK/2?^ADNO^_R4<E+^;\ YI]CTO(]11D>HKS3_A6>D_\
M0R77_?Y*/^%9Z3_T,EU_W^2CDI?S?@'-/L>EY'J*,CU%>:?\*STG_H9+K_O\
ME'_"L])_Z&2Z_P"_R4<E+^;\ YI]CTO(]17G7@0[O'7BEAT\P#_QXU#_ ,*S
MTG_H9+K_ +_)6]X4\-:7X5ENI(-4\]KD*&\V1>,9]/K57IQA)*5[B]YR5T9.
M@_)\6M<7/WH\UZ)D5Y_K7@>RU;7;C5(]?:UDFQE8G4=O7-4_^%>Q?]#=<_\
M?X?XTY^SG9\UM.PES1TL>F9%&17F?_"O8O\ H;KG_O\ #_&C_A7L7_0W7/\
MW^'^-1R4_P"?\"N:?8],R*,BO,_^%>Q?]#=<_P#?X?XT?\*]B_Z&ZY_[_#_&
MCDI_S_@'-/L>F9%&17F?_"O8O^ANN?\ O\/\:/\ A7L7_0W7/_?X?XT<E/\
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M?I52K<?^K7Z4F1/8=1112,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2?ZIOI5&KTG^J;Z51K
M2!,@HHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\:^)D
M\*^'9K[Y6N"=D"'^)C_AUKHJ^>?BQXE_MKQ)]A@?-K8Y08/#/W/]/SI2=D-(
M]WT35H-<T:UU*V.8[B,-C^Z>X_ Y%7Z\7^"_B7RYY_#]P_ROF:WR>_\ $O\
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M[0[BOJK3K^'4]-M[ZW8-%.@=2/>IB[C:+5%%%42%%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5;C_ -6OTJI5N/\ U:_2DR)[#J***1F%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5;C_U:_2JE6X_]6OTI,B>PZBBBD9A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH I7.CZ=>6:6EQ9Q26\9!2,C@$=*6YTJQO)[::XMHY)+4[H&8<H>.GY"KE%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "K<?\ JU^E5*MQ_P"K7Z4F1/8=1112,PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&2?ZIOI5&KTG^J;Z51K2!,@HHHJB0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH FMO]:?I5NJEM_K3]*MUG+<M;!5>?[X^E6*KS_?'TI(
MN&Y%1113-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_$T?\)A=_P#0 N_S/_Q-=710!RG_  F%W_T +O\ ,_\ Q-'_  F%W_T +O\
M,_\ Q-=710!RG_"87?\ T +O\S_\31_PF%W_ - "[_,__$UU=% '*?\ "87?
M_0 N_P S_P#$T?\ "87?_0 N_P S_P#$UU=% '*?\)A=_P#0 N_S/_Q-'_"8
M7?\ T +O\S_\375T4 <I_P )A=_] "[_ #/_ ,31_P )A=_] "[_ #/_ ,37
M5T4 <I_PF%W_ - "[_,__$T?\)A=_P#0 N_S/_Q-=710!RG_  F%W_T +O\
M,_\ Q-'_  F%W_T +O\ ,_\ Q-=710!RG_"87?\ T +O\S_\31_PF%W_ - "
M[_,__$UU=% '*?\ "87?_0 N_P S_P#$T?\ "87?_0 N_P S_P#$UU=% '*?
M\)A=_P#0 N_S/_Q-'_"87?\ T +O\S_\375T4 <I_P )A=_] "[_ #/_ ,31
M_P )A=_] "[_ #/_ ,375T4 <I_PF%W_ - "[_,__$T?\)A=_P#0 N_S/_Q-
M=710!RG_  F%W_T +O\ ,_\ Q-'_  F%W_T +O\ ,_\ Q-=710!RG_"87?\
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M56?<1S7_  E-S_T!;G\S_P#$T?\ "4W/_0%N?S/_ ,372T46?<#FO^$IN?\
MH"W/YG_XFC_A*;G_ * MS^9_^)KI:*+/N!S7_"4W/_0%N?S/_P 31_PE-S_T
M!;G\S_\ $UTM%%GW YK_ (2FY_Z MS^9_P#B:/\ A*;G_H"W/YG_ .)KI:*+
M/N!S7_"4W/\ T!;G\S_\31_PE-S_ - 6Y_,__$UTM%%GW YK_A*;G_H"W/YG
M_P")H_X2FY_Z MS^9_\ B:Z6BBS[@<U_PE-S_P! 6Y_,_P#Q-'_"4W/_ $!;
MG\S_ /$UTM%%GW YK_A*;G_H"W/YG_XFC_A*;G_H"W/YG_XFNEHHL^X'-?\
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M2FY_Z MS^9_^)H_X2FY_Z MS^9_^)KI:*+/N!S7_  E-S_T!;G\S_P#$T?\
M"4W/_0%N?S/_ ,372T46?<#FO^$IN?\ H"W/YG_XFC_A*;G_ * MS^9_^)KI
M:*+/N!S7_"4W/_0%N?S/_P 31_PE-S_T!;G\S_\ $UTM%%GW YK_ (2FY_Z
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MG\S_ /$UTU% 6?<YG_A*[K_H"7/YG_XFC_A*[K_H"7/YG_XFNFHH"S[G,_\
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M\S_\37344!9]SF?^$KNO^@)<_F?_ (FC_A*[K_H"7/YG_P")KIJ* L^YS/\
MPE=U_P! 2Y_,_P#Q-'_"5W7_ $!+G\S_ /$UTU% 6?<YG_A*[K_H"7/YG_XF
MC_A*[K_H"7/YG_XFNFHH"S[G,_\ "5W7_0$N?S/_ ,31_P )7=?] 2Y_,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNYZ^_3%<GHOF_P#"F=:W[O+^U#R\],?+G'XYH [S3OB;IFJZK:6%G97DCW&
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M* "BBB@ HHHH **** "BBB@ JW'_ *M?I52K<?\ JU^E)D3V'4444C,****
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MY2"4C:/RK<\4>#[3Q/;6D$MQ);I:ON01 >F,<UT=% #479&J#G: *YGXA_\
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M9' W#=70T4 8?A;PS!X5TUK*WN))T9R^Z0 'GZ5J7UJM]I]S:.Q59XFC+#J
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M."W:FZ7HT6EW-]/'*[F\G,S!@/E)["M.BB[)=:;O=[[A1112,PHHHH ****
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M645R?_"<P?\ 0.N_R%'_  G,'_0.N_R% '645R?_  G,'_0.N_R%'_"<P?\
M0.N_R% '645R?_"<P?\ 0.N_R%'_  G,'_0.N_R% '645R?_  G,'_0.N_R%
M'_"<P?\ 0.N_R% '645R?_"<P?\ 0.N_R%'_  G,'_0.N_R% '645R?_  G,
M'_0.N_R%'_"<P?\ 0.N_R% '645R?_"<P?\ 0.N_R%'_  G,'_0.N_R% '64
M5R?_  G,'_0.N_R%'_"<P?\ 0.N_R% '645R?_"<P?\ 0.N_R%'_  G,'_0.
MN_R% '645R?_  G,'_0.N_R%'_"<P?\ 0.N_R% '645R?_"<P?\ 0.N_R%'_
M  G,'_0.N_R% '645R?_  G,'_0.N_R%'_"<P?\ 0.N_R% '645R?_"<P?\
M0.N_R%'_  G,'_0.N_R% '645R?_  G,'_0.N_R%'_"<P?\ 0.N_R% '645R
M?_"<P?\ 0.N_R%'_  G,'_0.N_R% '4R?ZIOI5&L-_'$#(P_LZZY'H*K?\)A
M#_SX7/Y"KBTB6=+17-?\)A#_ ,^%S^0H_P"$PA_Y\+G\A5<R%9G2T5S7_"80
M_P#/A<_D*/\ A,(?^?"Y_(4<R"S.EHKFO^$PA_Y\+G\A1_PF$/\ SX7/Y"CF
M069TM%<U_P )A#_SX7/Y"C_A,(?^?"Y_(4<R"S.EHKFO^$PA_P"?"Y_(4?\
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M17-?\)A#_P ^%S^0H_X3"'_GPN?R%',@LSI:*YK_ (3"'_GPN?R%'_"80_\
M/A<_D*.9!9G2T5S7_"80_P#/A<_D*/\ A,(?^?"Y_(4<R"S.EHKFO^$PA_Y\
M+G\A1_PF$/\ SX7/Y"CF069TM%<U_P )A#_SX7/Y"C_A,(?^?"Y_(4<R"S.E
MHKFO^$PA_P"?"Y_(4?\ "80_\^%S^0HYD%F=+17-?\)A#_SX7/Y"C_A,(?\
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M3.'_ )\+G\A0',CIJ*YG_A,X?^?"Y_(4?\)G#_SX7/Y"@.9'345S/_"9P_\
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M ,)G#_SX7/Y"C_A,X?\ GPN?R% <R.FHKF?^$SA_Y\+G\A1_PF</_/A<_D*
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M']G77'L*&1)IHZVBN3_X3F#_ *!UW^0H_P"$Y@_Z!UW^0I$'645R?_"<P?\
M0.N_R%'_  G,'_0.N_R% '645R?_  G,'_0.N_R%'_"<P?\ 0.N_R% '645S
M-KXRANKJ. 6%RID;;N8# KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 9)_JF^E4:O2?ZIOI5&M($R"BBBJ)"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":V_P!:?I5NJEM_
MK3]*MUG+<M;!5>?[X^E6*KS_ 'Q]*2+AN14444S4**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG^J;Z51K2!,@HHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU:+>FY$[[]QCV;>,>II/!W@]?"4%U$MZ;K[1)OR8]FWCIU- '34444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% #)/]4WTJC5Z3_5-]*HUI F044451
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5D^*/\ D5-6_P"O27_T$UK54U.R&I:5=V)D\L7$31;\9VY&,XJHNS3!
M['"^%_"^H7GAC3YX_$^IVT<D*D0QD;4'H*M>%H6\/>*[S0IG%S).GVA;IOOM
M[-4]GX-UZPM(K2U\8SQP1+M1!9(<#\36MHGAB+2;N:_GNYK[4)EVO<38''H
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MHHHKG- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 9)_JF^E4:O2?ZIOI5&M($R"BBBJ)
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K>:;8ZAY?VRT@N/+;<
MGFQAMI]1GI5JBBG< HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% $UM_K3]*MU4MO]:?I5NLY;EK8*KS_ 'Q]*L57G^^/
MI21<-R*BBBF:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFA_\_P"O_?M_\*/^$LT/_G_7_OV_^%6/[ TC_H'6W_?L4?V!I'_0.MO^_8H
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MFA_\_P"O_?M_\*/^$LT/_G_7_OV_^%6/[ TC_H'6W_?L4?V!I'_0.MO^_8H
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M_P"^&_PH_P"$GT;_ )_1_P!\-_A4_P#8>E_\^%O_ -\"C^P]+_Y\+?\ [X%
M:D'_  D^C?\ /Z/^^&_PH_X2?1O^?T?]\-_A4_\ 8>E_\^%O_P!\"C^P]+_Y
M\+?_ +X% :D'_"3Z-_S^C_OAO\*/^$GT;_G]'_?#?X5/_8>E_P#/A;_]\"C^
MP]+_ .?"W_[X% :D'_"3Z-_S^C_OAO\ "C_A)]&_Y_1_WPW^%3_V'I?_ #X6
M_P#WP*/[#TO_ )\+?_O@4!J0?\)/HW_/Z/\ OAO\*/\ A)]&_P"?T?\ ?#?X
M5/\ V'I?_/A;_P#? H_L/2_^?"W_ .^!0&I!_P )/HW_ #^C_OAO\*/^$GT;
M_G]'_?#?X5/_ &'I?_/A;_\ ? H_L/2_^?"W_P"^!0&I!_PD^C?\_H_[X;_"
MC_A)]&_Y_1_WPW^%3_V'I?\ SX6__? H_L/2_P#GPM_^^!0&I!_PD^C?\_H_
M[X;_  H_X2?1O^?T?]\-_A4_]AZ7_P ^%O\ ]\"C^P]+_P"?"W_[X% :D'_"
M3Z-_S^C_ +X;_"C_ (2?1O\ G]'_ 'PW^%3_ -AZ7_SX6_\ WP*/[#TO_GPM
M_P#O@4!J0?\ "3Z-_P _H_[X;_"C_A)]&_Y_1_WPW^%3_P!AZ7_SX6__ 'P*
M/[#TO_GPM_\ O@4!J0?\)/HW_/Z/^^&_PH_X2?1O^?T?]\-_A4_]AZ7_ ,^%
MO_WP*/[#TO\ Y\+?_O@4!J0?\)/HW_/Z/^^&_P */^$GT;_G]'_?#?X5/_8>
ME_\ /A;_ /? H_L/2_\ GPM_^^!0&I!_PD^C?\_H_P"^&_PH_P"$GT;_ )_1
M_P!\-_A4_P#8>E_\^%O_ -\"C^P]+_Y\+?\ [X% :D'_  D^C?\ /Z/^^&_P
MH_X2?1O^?T?]\-_A4_\ 8>E_\^%O_P!\"C^P]+_Y\+?_ +X% :D'_"3Z-_S^
MC_OAO\*/^$GT;_G]'_?#?X5/_8>E_P#/A;_]\"C^P]+_ .?"W_[X% :D'_"3
MZ-_S^C_OAO\ "C_A)]&_Y_1_WPW^%3_V'I?_ #X6_P#WP*/[#TO_ )\+?_O@
M4!J0?\)/HW_/Z/\ OAO\*/\ A)]&_P"?T?\ ?#?X5/\ V'I?_/A;_P#? H_L
M/2_^?"W_ .^!0&I!_P )/HW_ #^C_OAO\*/^$GT;_G]'_?#?X5/_ &'I?_/A
M;_\ ? H_L/2_^?"W_P"^!0&I!_PD^C?\_H_[X;_"C_A)]&_Y_1_WPW^%3_V'
MI?\ SX6__? H_L/2_P#GPM_^^!0&I!_PD^C?\_H_[X;_  H_X2?1O^?T?]\-
M_A4_]AZ7_P ^%O\ ]\"C^P]+_P"?"W_[X% :D'_"3Z-_S^C_ +X;_"C_ (2?
M1O\ G]'_ 'PW^%3_ -AZ7_SX6_\ WP*/[#TO_GPM_P#O@4!J0?\ "3Z-_P _
MH_[X;_"C_A)]&_Y_1_WPW^%3_P!AZ7_SX6__ 'P*/[#TO_GPM_\ O@4!J0?\
M)/HW_/Z/^^&_PH_X2?1O^?T?]\-_A4_]AZ7_ ,^%O_WP*/[#TO\ Y\+?_O@4
M!J0?\)/HW_/Z/^^&_P */^$GT;_G]'_?#?X5/_8>E_\ /A;_ /? H_L/2_\
MGPM_^^!0&I!_PD^C?\_H_P"^&_PH_P"$GT;_ )_1_P!\-_A4_P#8>E_\^%O_
M -\"C^P]+_Y\+?\ [X% :D'_  D^C?\ /Z/^^&_PH_X2?1O^?T?]\-_A4_\
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M_P"^&_PH_P"$GT;_ )_1_P!\-_A4_P#8>E_\^%O_ -\"C^P]+_Y\+?\ [X%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 445F:YJLFC6'VQ;1KF-6 D"O@JOKTYH2N[%0A*
M<E&.[-.BH+6[AO+..ZA<-#(NX-[5G:+KO]MW%YY%JRVD$GEI<%^)2.N!CI^-
M.S*5*;3=MMS8HHHI&84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8[?AUH T?B!J.DV]AILNH17<\4LW[HVLWE\XZGU%8'Q)N9(]1\*^1++'&[=
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M7K:]RQ1116184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPC9^)K6TMYYI8$M7WIY./RY%1Z]X+L]?ETR2>YGC.G_ZL1X^;IUR/]FNEHH
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M)[[78KF=Y[L$/&V-JY(/'&>U&C>#[31==O\ 5H;B>26])+H^-JY.>,"NBHH
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M]*HU>D_U3?2J-:0)D%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4$=E:Q7<MW';QK<3 "24* S@=,GOBIZ*8$-W9VU];M;W<$<\+=4D4,#
M^!IPMX5MQ;B)!"%V"/;\H'ICTJ2BB[ H6>B:5I\S2V>G6UO(W5HX@I/Y5?HH
MH;;W"U@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-
M;?ZT_2K=5+;_ %I^E6ZSEN6M@JO/]\?2K%5Y_OCZ4D7#<BHHHIFH4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P 0_P#0?;_QZ@#K**Y/_A'_ !#_ -!]O_'J/^$?\0_]!]O_ !Z@#K**Y/\
MX1_Q#_T'V_\ 'J/^$?\ $/\ T'V_\>H ZRBN3_X1_P 0_P#0?;_QZC_A'_$/
M_0?;_P >H ZRBN3_ .$?\0_]!]O_ !ZC_A'_ !#_ -!]O_'J .LHKD_^$?\
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M\0?]!A_UH_X1_P 0?]!A_P!:.8+'145SO_"/^(/^@P_ZT?\ "/\ B#_H,/\
MK1S!8Z*BN=_X1_Q!_P!!A_UH_P"$?\0?]!A_UHY@L=%17._\(_X@_P"@P_ZT
M?\(_X@_Z##_K1S!8Z*BN=_X1_P 0?]!A_P!:/^$?\0?]!A_UHY@L=%17._\
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M8?\ 6CF"QT5%<[_PC_B#_H,/^M'_  C_ (@_Z##_ *T<P6.BHKG?^$?\0?\
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M^(?^@T_ZT!S'245S?_"/^(?^@T_ZT?\ "/\ B'_H-/\ K0',=)17-_\ "/\
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M^(?^@T_ZT!S'245S?_"/^(?^@T_ZT?\ "/\ B'_H-/\ K0',=)17-_\ "/\
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M^(?^@T_ZT!S'245S?_"/^(?^@T_ZT?\ "/\ B'_H-/\ K0',=)17-_\ "/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gan5qj4us5ce000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gan5qj4us5ce000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -K" @# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!UOZUTW@KX?3>%-7N+V2_2X$J;=H3&.<U8\>>!I?&)M3'>K;>0"#N3=G-
M%+Q/_P D;_[=8OYBH/@S_P BO<_]?!KK+GP['>^$?[!N)3M-N(3(H[@<'%<5
MX;^&NN:#K,$ZZW']BCEWO"F[]Y]1C% 'J-%%% 'A?CO_ )*S:?[\/_H1KW-?
MN+]*X'Q!\.YM:\80ZXNH)$L90^44R3M.>M=\!@ >E "T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D*"2< <DF
ML[3=>TS5YIXK"Z69X#B0*#Q0!I445BZCXLT32;LVM[?+%, "5*D\&@#:HK(T
MOQ/I&M7#0:?>+-(B[F4*1@?C6O0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'I?Y+71USFM_P#(TZ!_O2_R6@#HZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .<\:Z]=>'=$%Y9QI)(90F'!(P?I7GW_  M77?\
MGSM?^_;?XU[#+#%.FR:))%ZX=01^M0?V;8?\^5M_WZ7_  H \E_X6KKO_/G:
M_P#?MO\ &C_A:VNCK9VH^J-_C7K7]FV'_/E;?]^E_P *Y'XDV=K!X/E>*VAC
M;S4^9(P#WH Y,?%;73TM+4_1&_QH_P"%JZ[_ ,^=K_W[;_&NB^%MI;3^&YFF
MMX9&%P1ET!/0>M=Q_9MA_P ^5M_WZ7_"@#R7_A:NN_\ /G:_]^V_QKN? WB2
M]\2Z?<SWL4<;12[%"*1D8![_ %KH?[-L/^?*V_[]+_A4T-O#;J5AACC!.2$4
M#/Y4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7-:)_R-OB'_ 'HO_0:Z6N:T3_D;
M?$/^]%_Z#0!TM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%<GXX\47'A^UMX+"(27UVVV+(SC\/Q%<WXI\5:[]HTW1K!C#?S1*T^T#=N/
M0>W0T >H45PW@?Q%JEUJ%YH>M#-[:@,'QR1WS^GYUW- !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8^B>*--\03W,5@[N;<_.2I _"@#:HHKGM:\::)H-R+:\NOW_ %*(I8CZXZ4
M=#15#2=8L=;LQ=6$ZRQYP<=0?0CM5^@ KG-;_P"1IT#_ 'I?Y+71USFM_P#(
MTZ!_O2_R6@#HZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KCOB;_P B9-_UU3^M=C7'?$W_ )$R;_KJG]: *GPH_P"19G_Z
M^#_(5WE<'\*/^19G_P"O@_R%=Y0 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&F:[?-8D-;W&\K&'Z28/8UT\EE;2SQSO!&TL9RCE>5H GHHHH ***0YP<=:
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M_)Z4!9$@E?S%@1BS*?G;K5RJ,>=PBB'[I3S(>]7J3,YA1112,PHHHH ****
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MT/\ 2NL\F/S?-V+YF,;L<UY7XGM[:Q^)FE'3 JSN5:98^QR?Z8KU>@ HHHH
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M/Q=NX=2 :./E(VZ-A1@?K7JZQHD0C50$ P% XQ7!^-O!U[>7Z:YHC[;Y -Z
MX+8Z$'UKGAXI\?0+Y#V$K..-QMR3^8H L?$C2[+2=1TV_L$6"ZDD^94XSCO7
MJ<#,\$;,,,R@GZUY?H7A77?$.M1:MXD+)%$05C<\MCMCL*]4H **** "BBB@
M JA8:-I^F332V5K'"\QS(RC[U7Z* ,^#1--MM2DU"&TC2[D!#R@<G_.*34-"
MTO565KZRAG9>C.O-:-% $%K:6]C L%K"D42]%08%3T44 %<YK?\ R-.@?[TO
M\EKHZYS6_P#D:= _WI?Y+0!T=%%% !1110 4V3_5M]#3J;)_JV^AH ^1[O\
MX_KC_KHW\ZAJ:[_X_KC_ *Z-_.H:^E6QY04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M*OWU_P!X?SI*5?OK_O#^= 'UGI7_ "!['_KWC_\ 015RJ>E?\@>Q_P"O>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(KRD?"K4PP/]M#@YZ-_C7J<*&*".,G)50"?7% #Z*** "BBB@ HHHH ****
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M-]3O=:O+ZVU.*(32%@%R"/8D&JC?"O678,^JQLPZ,VXD?K0!ZR)HB<"1"?\
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M_NC\J-J_W1^5']GP[L/K,NQ]2?\ "9^&_P#H,6O_ 'W1_P )GX;_ .@Q:_\
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M/^$S\-_]!BU_[[KY;VK_ '1^5&U?[H_*C^SX=V'UF78^I/\ A,_#?_08M?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %*OWU_WA_.DI5^^O^\/YT ?6>E?\@>Q_P"O>/\
M]!%7*IZ5_P @>Q_Z]X__ $$5<KYN6YZBV"BBBD,**** "BBB@ HHHH ****
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M^_)ZT#$JD1_NX4^_ZM00LBB,';;KU?U-!_>X9_DMT^[_ +5 "?*R;C\MJO\
M#W)I3EE\V3B ?=C'>@E21-)Q /N+Z_A1_%YTW7_EFE ?U_7F!( $\@S&>$B]
M/\\T'Y"'F^:1O]6O9:,E7\YQFX;[L?I0/W9.[YKA^@Z[: #E'PWS73=#V HY
MC;R_OW#_ ,9_A_SS0-R Q)\URWWF]!]:!\BF*'YF;_6/Z?YYH#^OZ\@ (8P1
MG,W5I3_GZ4Z+_6!(.Q_>L>]-QE/)A/[H?>DIT?SNJP<1(?F/3)H$]B]1114G
M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\EKHZYS6_P#D:= _WI?Y+0!T=%%% !1110 4V3_5M]#3J;)_JV^AH ^1[O\
MX_KC_KHW\ZAJ:[_X_KC_ *Z-_.H:^E6QY04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M*OWU_P!X?SI*5?OK_O#^= 'UGI7_ "!['_KWC_\ 015RJ>E?\@>Q_P"O>/\
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M2/B!#][^]5ZDS*IN%%%%(S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBO?/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVBPV$;;ROS.^/O,>M:U%% !7-:)_R-OB'_>B_P#0:Z6N:T3_ )&WQ#_O1?\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2K]]?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2K]]?\ >'\Z2E7[Z_[P_G0!]9Z5_P @>Q_Z]X__ $$5
M<JGI7_('L?\ KWC_ /015ROFY;GJ+8****0PHHHH **** "BBB@ HHHH *XO
MXCZ]>:+H\"63&.2Y<J9!U4#'^-=I7-^,1H,^FBUURY$ ?YHF_B!]JN'Q*YUX
M%Q6(@YQYE?;<\_TWPO=ZQI:7T'BC-TZ[O(+D$'TSN_I78^!H?$UI');ZVA,&
M,Q,[9<'T^E<@_P -[MK=;_1-5BN(67>C<H<?45<^'?B+5#KQT:\F:>+:WWSD
MH5]ZWG[T79W/>QB=>A4=.:DEK9JS7]>95UV]NT^**0K=3+%]HB&P2$+V[5WO
MC.80>&[]XRRS^0VUU."O%><>*&%O\4/,<A0LT39/88%>@>.KZ&#PO>*Q7,T)
M56SZ\<5,EK$PQ$+SPMENE^ARWPQO;F47P:6261B &=BV*Y,/?P^-YAIA'VMI
MWCC8]MV1G]:ZCX5F3;J"1C[Q 9O05S]A/!:?$3S)9-D7VEE+GMGC^M:+XI'H
MQM'%8BRZ;?(T-:\,Z]H]K)J*ZK+.T>#-M8C;DXXYYZUU/A+Q'/J_ABZ>;'F6
M*%I<?Q\$C^5:'BV]MX_"MZ/,58O+VJV>9">!_.N4^&D,::?JEW>2^79KM#YZ
M-UJ+\T+LX74>(P4JE5:Q:MIZ:&-IK7?B_49Q>Z]]A5!E%.<'V R!^M:VG:-X
MHTG5(Y+:X-[8*PW,\GR,.XQG@U!+X1T;7KJZET/5D0H<^2Z[@<^AXK)N&U_P
M5J<"2W)Y^94W[E8?0]*TWT7W'>VJUZ=)I:?#)6_K\3?^)FFW[B'5WF"V9"0K
M!O/#?,<XZ?C4'@+1=1$EKK"7(^R)(5\C><DX].E;/Q!9KKP5:W<AQ)++&_EC
M^'*G/]*L_#F2./PNA0A[@S, F>G K/F:IG'[><<MT[V^7]=3B=7U35+;QO=&
MUN)?.\[")O.,D#M74>'?#'B#3-?2ZO[OS"T98JLI;YCV-<W*CO\ %#;C+&Z'
M'X5Z[-(MK!($.XA2SR>E.I*R208^NZ5.%."7O15]#S>[T;Q9K_B&:&9Y+.#)
M(8/A0O;H>36+JD>J>#M8CBAU9IPP#$JV0?4$9-7]-OM:\;:S+:IJ9LK8 MA.
M,+^&"3^-97B_1;?1+^""*\DNI&3=([G/.?TJX[\K.VA=550JM;?"E^+9T?CZ
MWNM0T>TU6&3991PH'CW'YF8]<=#UJK\/-!U*[NK?4H+O99P3CS(MY&['MTK;
M\4^9+\,K?"A8TC@Q_M=*L_"F1/\ A'IU++N\[IFL^9JFSBE7G3RZ7+TE;Y&3
MXO\ $6J:OXE_X1[2)3$HD$3%3@LW?)[ 52U?0O$?@VWBU2+5GF56 <;CA2?4
M$\CM61<V<S_$&XM6O392O=,HN,="3P>HZUTNL^#I[2R']K^,2MM(P&)8203U
M'\55I&R-U[+#JE332BUJN5MR^Y'>>&-:77]"M[[ $C#;(!T##K6Q7,>!M+AT
MK1&BMM12^A:0LLB)M'TZFNGKFE;F=CYC%1A&M)4]KZ!1114G.%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 54U+3K35+&2TOHQ);M@LI)'0Y[5;KE/B)J4VF^$+EX&*/*1%N'4 GG],
MT 4[/PUX(OYKF*TMHI7MA^\"R,<?K6 UW\-4=E-G)E20>&_^*K<\ >&8]*T)
MM1,CO<WL&67/R@=A]:Y[PEX+AU6#5_[5LI8Y@^+=VRN,YY'KVH [WPK::%%I
MQNM"B"07!!;!))(]<GWK>KS;X5SRP2:MI3MN6"0,OMU!_I7I- &9XAMXKKP_
M?0SR>7&T1W/Z5P7@_P =Z+HVB)IMWF-H&($L:Y649Z_6O2[J&&>UEBN #"ZD
M."<#%>=3+\-;>5HF2$LIP=KN1_.@#*\3^+='\1:SIJJ6BM+63?)<,GS-TX _
M"O0-%\8:/KUVUK83.\JKN(9<<5R*'X;RSQ00VZR22L$559^I_&NUTOPOHVC7
M+7%A9+#*R[2P9CQ^)H V**** "BBB@ HIK.B_>91]33J "BBF>=$#@R)_P!]
M"@!]%(K*XRK CV-+0 5S6B?\C;XA_P!Z+_T&NEKFM$_Y&WQ#_O1?^@T =+11
M10 4444 %<!\8?\ D1G_ .N\?_H0KOZX#XP_\B,__7>/_P!"%;8?^+'U,ZOP
M,^?J***]\\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OH'X._\B*O_ %\O_2OGZOH'
MX._\B*O_ %\O_2N/'?POF;X?XSOZ***\8[@HHHH **** "BBB@ HHHH ****
M *.L7_\ 9FD75[MW&&,L!ZFO)]);7_&ES<3'7OLFP\('V_D 17KFH_93I\RW
MK*MLRE7+' P:\GD^'ZWDLT_AS6(;E8VQLW89/;-;TFDG<]O*IT8TY\WNRZ2:
MND:^@IXST?Q +6X6:^L-V'=CE<>H/6K7Q3U"\T^TTUK2YE@+R.&,;8SP*Y2U
MUWQ+X0UJ*ROII)%)&Z*5MX*DXX)YKH/BTWFZ9I$@!VL[G\PM5R_O$V=GL7]?
MHRFHM.^JV>G5'4>&KB>Y\-Z>Q=GN)(@6D8Y)%<!I.H:@_P 19K$WTQM_M<B%
M"WRX#'M7<^$Y!-X2T](V"J(OGD],$\5YQH9BG^)4C))^Y:ZD(;U7<:(+61&$
M@N;$76R?ZEOXH,G]MV:QKA5@Q]>:LKIOB[7])6_2[%O D8,-NC%<@#BJWQ0<
M-K=GA-J"# ]^:]%T6ZAN]"L[HLJPI$NQ >#@=*;DXP3-:E>5#!T91BF_/7^K
MG%^!_%EU<7XTC6)&E4 ^66'S CL:J^+/$FIW_B7^RK6Z^R0HX0'..?<UFZ/*
MEQ\2O/@7,9N7< =-O)KH?%7AW2M:U/S8=4AAU.5MI@/.X^F/6FU%3N:SA0I8
MM3E&UXWVND_0SKG1/%FD+;WMCJLM\SM]U'W$?@2>*Z#7H-;U'PE$YS;:CNWS
MKNV_(%.>GKD<5QE[I'B;P@!=BZ=(T(YCDR!Z9!XKN/#FNS:UX3NY9H]]WY<B
M.W_ 3S2E?22U,\3SJ,*\>623W2M\GY'G'AC3M8U#4Y(=(G\F<+EV\PKD9]:Z
MSXA7M[I(TN&WO)8Y3$WG&-R-Q&W_ .O5+X9;CX@O8E.UFA.6] &%3_%38+C3
M43G:LF6]?NU3=ZB1T5)\^91IR2LE^G4JV5OXM\0"WNX)Y8[4%0-LA7@<$^_X
MUT'BZ]U]!!IFC03BW" 37*KR[=.O;IG\:Z+PTN[PS8P@>7 L0+/ZG_)KDO%W
MC"__ +871-(*P;"%:3C+$_IZ5";E*R6QPPJ3Q&*Y8PC:-_3U?<Q=3T?Q-HFF
M?VE)JLC1A@&02DX/T/%=#9WFL>+? K-;SK'>6\GEL^[9N &3^A%8WB#PSJ=K
MX>DU'5=:DF(8!("3M)_/'Z5L?#*-#X;OG=\$7#;5]3L6JDURW.C$3B\-[9-2
ME&6Z7X>9PWAW3M6U#6'M]*G\JZ )9O,*\#KS7IOBKQ-=>%O#UC:JROJ<D*JS
M'YL$#!;WYS7)?#8[?&TRGKLDJQ\6DD_MNQD/^K,&%/8'<:)>]4467B5'$9A"
MC42Y4K^HEOH?C6\TL:PNIR[G3S$B\PY9>O3I74> /%L^O02V=^5-Y ,[P,;U
M]3[UDV/ASQ--I4%S#XF"6S1!E^7A5Q4O@7PVNFZR][%J]M>*R$,L0Y_G4R<7
M%W.3%2HU:%13<6UM9-6\GH>CT445S'S84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;K^J+HNAW>H$
M!C"F5![D\#]36E7-^/+22\\&W\<0)95#X'< @F@#GOAY+K^IZC<ZS?S,]G.A
M50QXSD?='I7'V6A:CXEUW5XK2^>-K>1FPSMSDG@<^U=_\.]>L;GPW;V)E2.Y
MMQM:-C@GWK96W\/^&_M6HH(+9I>97#DEN_K0!RGPPU:Z\R_T.\=VDMVW)O.2
M.Q'\OSKTBO+OA[NU/QGK&L1H5MV!4'ZG_P"M^M>HT ,E4O$Z X+*0#Z5Y7)\
M+M5:ZDG_ +:42.Q.[:V[\\UZC=S?9[.:;&?+0M^0KP^>7Q)JVD7?B,ZE.MLD
MQ78DI7 ]@.PH VV^%FI;Q*^M1[QT=@<C\=U;'A_P%JFDZW;7T^L&>*,Y,?S?
M-^M<?>Z/KEKIUCJ%YK$[Z==%-TBRL=F?49KVZV"BUA"-O4(,-ZC'6@"6BBB@
M HHHH **X+6/&^I/KTFC>'K!+J>+/F.^2..O2K'A?QK<ZEK$FC:O9K:WZ E=
MN<''4<T =K117G7B#QIKMOXIFTC1K.&X,2 E2A+>_?Z4 >BT5Q_A36?$VHZC
M+%K6FK;0+'E7"$9;/3K784 %<YK?_(TZ!_O2_P EKHZYS6_^1IT#_>E_DM '
M1T444 %%%% !39/]6WT-.ILG^K;Z&@#Y'N_^/ZX_ZZ-_.H:FN_\ C^N/^NC?
MSJ&OI5L>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2K]]?]X?SI*5?OK_O#^= 'UGI
M7_('L?\ KWC_ /015RJ>E?\ ('L?^O>/_P!!%7*^;EN>HM@HHHI#"BBB@ HH
MHH **** "BBB@ K&\2>&[3Q+8"WN<HZ',<B]5-;-%--IW1=.I.G)3@[-'ET?
MPY\06JFWM==9+8\84L!CZ9KIO"7@FV\-%KAYC<7CC!D(P%'L*ZNBK=235F=E
M;,L16@X2>CWLDKG&>+_ 2>([M;VWN1;W(7:V5R'QT_&L2'X<W;HT6HZI)<.8
MR(E+-LC..#R>WX5Z=5:YWNWE_=C(RS^E"J22L51S+$P@J:EHOP.0\(>%KGP^
M;N'[6DHE(W,%Q@5D+\.!>ZS<W=Q=J;1RYPJX920<8Y[&N_ $JF-#LA3J_P#>
MHXG7>W[N%/X1_%3]I*]S18_$*<JB=G+?0\V/PWO[J39+K+-9QG*^8"3CV!.*
M[;3-$LM/T<6@3_1%!#(W60G@DUIDB51)*-D:?<7^]0QZ3SCYA]V+UHE.4MQ5
ML;7K)1F]%V_K_ACSN]^'5Q;7!O-)U%K9'/R(<[A^(QQ4UI\/9_ML=]KNHO=L
M""(ADEO8D]J[XDQD32#>[\+'_=_SQ1S ^?\ 6SMT![4_:R-'F>)<;<WSLK_?
M^IDZ]H<6K:,]D[;9)<>60/\ 5XZ5RV@^!M5T37+>4:BA2-MQ10<-V]:[\9B8
MB/YYG^__ +-  4F"$[F;EI/2DIM*QE2QM:G3=.+T9Q(\#W1\9_VJM[&<2^:R
M[.G'KFNT9$DC:S0?*PQ(Y[^M. WY@C.T+R\OK_GF@8D0Q+\L"_>D]:3DWN16
MQ%2MR\[V5D><R_#>[CU2672=2,$(/!.05]L@\TMS\-9+NU68:F\EP"3+-*,[
MO8#/]:]%XE0!OD@3[I_O4%O,7SV&R).D?]ZJ]K(Z?[4Q6GO;>2,3_A'Y-0\*
M1:3>W V+$(D=5[@8!Q7/Z'\.M5TC6;:Y_M-/L\4JR,B@C> >F,UWJ@,Z3R':
M"?DC]*O5/M)+1'.L?7IQE"+TEOH<AXL\"6WB*87<$WV6\& 9-N0P'J/6N=7X
M8ZK>3(NI:TTENAX&2QQ[9/%>HT4*K)*R%2S/$TH*$9:+;1:%33--MM)T^*RM
M$V0QC 'K[U;HHK,X)2<GS/=A1110(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \9:*^O>&KFSB&9
M@ \8]2#G'XUOT4 >4^&/B%'HEBNDZU;RJ]O\BN!R!Z$5HZM\5=/%I)'ID,LM
MPZX5G& I]:Z_4_#.CZP^^^L(I9/[^,-^8YJ"Q\&^'].F$UOIL(D'1G&['YT
M87PUT6YL=/NM2O4*SWKA@&'.WG^>:[JCH,"B@#&\6/(GA34FB)#B$XQ7D<F@
MZ9_P@-IK%NQDNEF NANZ D\8[<#]:]KOKBRBA\J]EB1)OD"R'&[/:L"V\%:/
MIFF:G:Y86EY\SAS]P#T- '$:A8:%H.J:!J>G*DJW!!DMV<MCI\P]#S7L%><>
M'OASI2WT6HIJ7VVWC;=&JD8SVR17H] !1110 4R9WC@D=$WNJDA1W/I3Z* /
M++3PEK_B26[OM;U"\L9 Q\J,,0!^'I6G\,]7O[R.^L+R9KA;5L1RL<GZ9J/Q
M1XGO-8U!O#?A[YI7^2><'A1W&>WUKI_"OAZV\-Z4+:)Q),QW32?WC0!LW$H@
MMI9CTC0L?P&:\,TNPAUV6[NKWQ$U@6G(1&E/S=?>O:-8DMET:\-S,T=OY3"1
MTY*@C!K@M+\'>$K_ ,-W5W;227.%8B>1B&0@9Z4 =;X1T0Z'I!@^WM>K(_F+
M*3G@UOUY]\*+J>32;ZV=V>&"8"(GL#G('Y"NSU2#4+B%%TZ\6UD#99FC#Y'I
MS0!>KFM$_P"1M\0_[T7_ *#3O[-\3_\ 0>A_\!E_PJKX5CNH?$.O)>3B></%
MND50H/R^@H ZVBBB@ HHHH *X#XP_P#(C/\ ]=X__0A7?UP'QA_Y$9_^N\?_
M *$*VP_\6/J9U?@9\_4445[YYP4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?0/P=_Y$
M5?\ KY?^E?/U?0/P=_Y$5?\ KY?^E<>._A?,WP_QG?T445XQW!1110 4444
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M%=/11*I*2L%?,J]:#A*R3WLK7]0HHHK,X HHHH **** "BBB@ HHHH ****
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M^)K"0S1K'<PD!PO0^XKJ*S::=F<-:C.C4=.:U04444C(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L3Q=I$
MNM^&KNQ@(\YP"@)X)!!Q^E;=% '@>M#Q+;1:9::K R+;R 6FY!RW89[UTJZK
M\2=HQ928QQ^X'^%=EXRUG3=$TV.ZO;6*YGWXMXW4$[O7VKBQXP\<RI]LBTMO
MLO4 6Y(Q]<4 =/X.O/%=S>W*^((&CA" QDQA<GG-=E7,^#_%T7B>UD5X_)O(
M,"6+^HKIJ /)_M,/A_XMW,^HX2&<?)(W09  /Z&O4DN[:2,2)/&R$9#!ABL?
MQ-X3L/$UNJW(*3Q_ZN9>H]OI7"M\)+]6VQ:K'Y?N#0 [XD:E::MJ>FZ=8.L]
MTDGS-'SC/:O4X4,<$:,<LJ@&N0\+_#ZQ\/W O)9#<W:_=8CA/H*[*@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH X#X@ZGJ$M]I_A[39#%)>GYV!QQZ9]/\
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M "(S_P#7>/\ ]"%;8?\ BQ]3.K\#/GZBBBO?/."BBB@ HHHH **** "BBB@
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M8QUVXQ^F!^=4/ TGB6"=-/N;5H[".-EW,F"ISGD_G4[TS"2C5R^,8R5XMO\
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M]#FS><9XN3B[K3\@HHHK(\P**** "BBB@ HHHH **** "BBB@ HHHH ****
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MDM='7.:W_P C3H'^]+_): .CHHHH **** "FR?ZMOH:=39/]6WT- 'R/=_\
M']<?]=&_G4-37?\ Q_7'_71OYU#7TJV/*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M5^^O^\/YTE*OWU_WA_.@#ZSTK_D#V/\ U[Q_^@BKE4]*_P"0/8_]>\?_ *"*
MN5\W+<]1;!1112&%%%% !1110 4444 %%%% !1110 4444 %5;DQK(I(S+C"
M"K55KEE5P%7,Q&%]J:+AN0',; R_/._W!V6CYHW\L?/<M_&>P_\ U4#=%\J?
MO)W^\?[M&"@\F [B>6D':F;?U_7D #!C'"<SG_6.:%!;,=J=H_C<T8R/*@/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN4''IQ7C&HZGH;^$=*NK,11ZU"R JB\\<'/UKV.PF:YTZVG==KR1*[+Z$C-
M%BBBB@ HHHH **\ZU7Q7KVJ>))]%\.0QC[/G?+)[=?PJQX6\6ZI)XAD\/Z["
MBW:@E'3N1V/X4 =[117FU_XL\0ZUX@NM-\-11".U!WN_\6* /2:*X_P3XLN-
M=-U8ZC&L=_:G#[>C#I_2NPH *YS6_P#D:= _WI?Y+71USFM_\C3H'^]+_):
M.CHHHH **** "FR?ZMOH:=39/]6WT- 'R/=_\?UQ_P!=&_G4-37?_']<?]=&
M_G4-?2K8\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "E7[Z_P"\/YTE*OWU_P!X?SH
M^L]*_P"0/8_]>\?_ *"*N53TK_D#V/\ U[Q_^@BKE?-RW/46P4444AA1110
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M%DLY UH?[V.>#^-2:KXC\;P:M=16>FA[9)"(V\K.1^=4_P#A*/B!_P! L?\
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M-'$HW-^[B3[H_O\ ^>* _K^O,/E=-[_+:C[J]R?\YIT?SNCS?*H/[I::</\
MOI?D X6/UIR?/(LD_P K9_=I0)[?U_7J7J***DYPHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .<\8>*5\-6$;1Q>==SMLAC]3ZFN6\/^)O$USXG^QZJ@B#VKS)
M$P3TQWJ[\2=/O=VF:S:0F<6,A9XP,\'!S^E<JWCRW;QE%KKV<@V6GD&'<,[L
MY_*@#NO!OBZ;7)[O3]0@\F^MFSC&-RY]/6NOKS?P#%>ZKXEU+Q)<VY@BG78B
MXQGZ?D/SKTB@#$O_ !=H6F7DEG>7Z13IC<A5CC//85AV^O>!K6_N;R&ZA2:Y
M7;+A&PWX8K1U;P-H>K:A-J%['*9G WD/@<#'I7.GPS\/P2#>KD'!_??_ %J
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MCW?_ !_7'_71OYU#4UW_ ,?UQ_UT;^=0U]*MCR@HHHH **** "BBB@ HHHH
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M/RQ^E7J3,J@4444C,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 5] _!W_ )$5?^OE_P"E?/U?0/P=_P"1%7_KY?\
MI7'COX7S-\/\9W]%%%>,=P4444 %%%% !1110 4444 %%%% !1110 4444 5
M;A?,?;(=L(&3[FH,K(N^8;84_P!6H[U-=*KN/-;;&H_,U$3NQ+.-NW_5QCO5
M(WCL!.5\VY'[O^!!02RXEG^:4_ZM1VH)*GSY1ECPL7I1\T3;S^\F?HO]V@H"
M6C_>GYKEN@[ ?_JH_P!6<)\UP_WCV% W1MN3Y[ANJ]EH \LF.([W?[[G^&@/
MZ_KR##*WEQ'_ $@_??M0,9\F#A3_ *US_GZT =;>,^[S4#YE\E!MA'WY/6@/
MZ_K_ "  -F%#BW'+-W/^>*!^\!"_+;)U]31A77R\[;9?X^[&C_6C<W[N).B_
MWZ _K^O,/E==[\6J_=7N31]]?-GX5?\ 5J._^>*"=W[^0;5'"Q>O^>:"<D33
M##C_ %<= ?U_7^8$\>=.,S'A%':G)\LB-<?-,Q^0#L*;DHWFN-UPW2/L*='^
MZE4M^\DD//\ L4">Q>HHHJ3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*YN8;.W
M>XN)%CA099VZ"@#)\3>([+PWIOVB[4R,YVQPCJY_PKS-O&AEG^TCPG:F/.=V
MP_SQBM7Q]J.DZC=:3?0WL-U!;3?OH5/)4XY_2NMB\6>%18JZWEJL6W_5[>1[
M8Q0 [PEXJL/$=HRVT7V>:'&^#^[[CVKHZ\W\"Q6M[XOU?5[$I%:.-D<(/)]6
MQV'%>D4 -D021LAZ,"#7!-\)M&9V8W5WEF)/*]_PKO)0S0N$.&*D#ZUY6_AG
MQ^9'*ZE\I8D?ONV?I0!6\3^ ].\-0V^HB>6>U$JK+$Q 8@GJ#_\ 6KUJT>.2
MS@>$DQ-&I0GTQQ7E0\!>*]5GB35]14VZMDYD+?D,"O5K>!+:VB@C^Y$@1?H!
MB@"6BBB@ HHHH **** "BBB@ HHHH *YS6_^1IT#_>E_DM='7.:W_P C3H'^
M]+_): .CHHHH **** "FR?ZMOH:=39/]6WT- 'R/=_\ ']<?]=&_G4-37?\
MQ_7'_71OYU#7TJV/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I5^^O^\/YTE*OWU_W
MA_.@#ZSTK_D#V/\ U[Q_^@BKE4]*_P"0/8_]>\?_ *"*N5\W+<]1;!1112&%
M%%% !1110 4444 %%%% !1110 4444 %5KE26S(W[@#YAZFK-5;E%WB1W^51
M]S^\::+AN0_+(NZ7Y8$^XOK02&'G7(^8<(@H)#XEF&T+_JXQWH)(;SIAF;HL
M=,V_K^OU DJ!+<#<Y_U:CM028B&?Y[D_=] *,M$WF,/,F?HG]V@9@.$_>S-W
M_NT 'S1']W\UP_WCV'^>*,;&\NV.9&^\Y[4 &,E(3OD?_6,?X: !@P0'Y3]Z
M4]J  #),4!P1_K7/?_/- VOF*+Y;<??;N?\ /%& X\E#LC3[TG][_/-&1*NP
MCR[=>K>M  -L@V-\MLG3U)_SFC.]=\@Q;+T7N:#B11YOR0I]S_:H)+8GE&U5
M^[%ZT!_7]>8'!42S_P"K_P"6:"@EL>=-S-_RS2@G:?/D&6/W8O2CYE;S7^:X
M/W8^PH#^OZ_4<FU9%>3F=ST]*O51CQ'*#]^9S\P_NU>I,RJ!1112,PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q_$]]?Z;H4]UIL FND*[$*YSD@'CZ5L44 >):QJ?
MBK69K6>;2&BN+5]\4T41##VY/2M!_%WCIK7R1IQ5B,>8(#N_GBNP\9>,_P#A
M&3!;V]L+B[GY52> /PKE_P#A8_B<\C08\?\ 7-_\: -KX:1WD=G?B^L6@F,B
MLTK@[I2<YS]/ZUW=<OX-\0ZGK\5VVI6*VIA90@52-V<YZGVKJ* (KB**>WDB
MG4-"RD.#T(KS/4=2^'FGW#6ZZ8L[(<,8MV!^.:[KQ(9)/#NH1VL@^T&$A0&Y
M_P XKCO 7AWP[=>'X[BYBAN+QF(F$K<H<],4 :/A34?!MW>8TFUBM[S'"R+\
MWX9)KMZ\K\4:'IMIXGT== 58[YY<R1Q-D!1_%[=Z]4H **** "BBB@ HHHH
M**** "BBB@ KFM$_Y&WQ#_O1?^@UTM<UHG_(V^(?]Z+_ -!H Z6BBB@ HHHH
M *X#XP_\B,__ %WC_P#0A7?UP'QA_P"1&?\ Z[Q_^A"ML/\ Q8^IG5^!GS]1
M117OGG!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5] _!W_D15_Z^7_I7S]7T#\'?^1%
M7_KY?^E<>._A?,WP_P 9W]%%%>,=P4444 %%%% !1110 4444 %%%% !1110
M 4444 5;H('$DW* <*/6H2Q7$TXW2'_5J.U2W.V.02M\YQ@)_6HLM$V]AYDS
M]%_N52-X[ 2T/[YOGG;H/0?_ *J,-"V$.ZXD^\?2@9A;*?O9VZC^[0!Y9,41
MWN_WW_NT%!AD;RX3_I#<NQH&,F"#@?\ +1C0!UMXVYZM+0,2*8D^2)?O2>M
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MYK?/.WW8_2@/Z_K_ # DQ8F/S3OT'I1AHVQG==/_ !=A0,Q.67]Y._WA_=H
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M)_R-OB'_ 'HO_0:Z6N:T3_D;?$/^]%_Z#0!TM%%% !1110 5P'QA_P"1&?\
MZ[Q_^A"N_K@/C#_R(S_]=X__ $(5MA_XL?4SJ_ SY^HHHKWSS@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>&_OU>I,RJ;A1112,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]<OT/84<PMA?WDTG7_8H V'R83ND;DR>E   58QQ<W!^^3T'^<T#!S;P??\
MXW- &[,,)PPYDD]:!B0>5'\D0^])ZT  'F#R8OE"??8]_P#/-&5D3"?+;+]X
M]S1Q*NW_ %<,?\7]^C/F+YK#9;IT3^]0']?UY@<.H=N+5?NCN:"=P%PXQ"/N
MIZT$C FE'[O^".@DY$\@^?\ @BH#^OZ_S'*!YBS2]'/[M1VJ]5%,)*LDGS2R
M'A/[M7J3,J@4444C,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %<UHG_(V^(?\ >B_]!KI:YK1/^1M\0_[T7_H- '2T444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 (SJBEG8*HZDG %5(-6T^ZEDB@O()'C7<X1P=H]37#?$&YNK[7-*\/17
M!MX;ILR.#C-5/#7A^'3?&.M:/#.^QM/*^:PY&XC)H ].1TD0/&RLIZ%3D&G5
MY[\-KFX@NM6T:2<SPVD@\M\Y]<UZ%0!2UBP&J:1=6);;YT97/H:\9U*7Q'IF
MB?\ "-WNGN]O#*'CE5"> <\$=JZCQ5XYU9=>?1M!@#21\,^W<S-Z >E,\->-
M]4.NQZ/XBME#2G",R893[CN* *%FGB#QOJNG"[LS:Z?9$')4@<?7J>*]=I
MHP  /04M !1110 4444 %%<AXO\ '-KX=@\NU,=S?$\1;N%'<DUT6CWKZCH]
MI>2($>:,.5!X&: +M%1S31V\$DTK;8XU+,?0"O.9OB9J$CS75AHC3:; V'F+
MX./RH ]*HK/T36+?7=*AO[7.R0<J>JGN*T* "N:T3_D;?$/^]%_Z#72US6B?
M\C;XA_WHO_0: .EHHHH **** "N ^,/_ "(S_P#7>/\ ]"%=_7 ?&'_D1G_Z
M[Q_^A"ML/_%CZF=7X&?/U%%%>^><%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7T#\'?
M^1%7_KY?^E?/U?0/P=_Y$5?^OE_Z5QX[^%\S?#_&=_1117C'<%%%% !1110
M4444 %%%% !1110 4444 %(RJXPPR*6B@"E.H1S).=Z]$4#I3#N1@9AON&^X
M!_#5\@$8(S5.1&@SL!DDD/#'^&FF;1E?09\T;\?/='J.P'_ZJ "K%(3NG/\
MK&/:C!0;(3OG/WF]*"!_JH#_ -=)*9?]?UY  =QB@/[[_EHYH&&!2#Y8A_K&
M/>C ?]Q&=J#[TOK1_K3@?NX$ZG^]0 85DV@[;1>K=R:.73<WRVJ]!W:CY7.6
M^6U7H/[U'+'S9?E1?N1^M ?U_7F!*E1+*,6X^XG?_/6@]I)_O?\ +)!_GZ49
MQ^_D&6/"1?Y_&C[HWR?-,WW$]* _K^OU8$E6#R#-R?NKV _SF@Y1AO\ GN6^
M[Z+1R@_OW3?^.BCF,;$^>5_O-_=_SS0']?UY!\R/Y:?-='[S]@/\XH4$,8[<
MY<_ZUCVHP0?(A.XG[TO^?PJY%$L*X4?4^M!,I6"*%(4VH.*DHHJ3%N^K"BBB
M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M RQRWK3Z**DQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\'?^1%7_ *^7_I7S]7T#\'?^1%7_ *^7_I7'COX7S-\/\9W]%%%>,=P4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!SWBWPK!XHT]8FD,5Q$=T4H&<'T/M7"_\(-XQ5?LPU<?9
M^G^O;&/I6_\ $;5M1MVTW2M,F:&:]D(+J<'C'&>W6N+CTCQ,_B230SK,R72Q
M>:"9VVL/;F@#L(/A^;3PM=Z9;7B-?W;*9IFZ;1V KJO#>A1>'=%BT^)RY4EG
M<_Q,>IKC/AU!=6^NZK#J5[+)?0A4:&1BW'/S FO2: (KIWCM97B7=(J$J/4X
MKCO _BV]UR2\M]4$$,UNV !E6/U!-=G*I>%U4X8J0#Z5Y--\,M:-U)<MJT2R
M.Q._)!Z^N: /6O,C_OK^=.KRA/AUXCRI&O$C(/$C\_K7JD*&."-&.650"?6@
M!]%%% !1110 4444 %%%% !1110 5SFM_P#(TZ!_O2_R6NCKG-;_ .1IT#_>
ME_DM '1T444 %%%% !39/]6WT-.ILG^K;Z&@#Y'N_P#C^N/^NC?SJ&IKO_C^
MN/\ KHW\ZAKZ5;'E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4J_?7_ 'A_.DI5^^O^
M\/YT ?6>E?\ ('L?^O>/_P!!%7*IZ5_R!['_ *]X_P#T$5<KYN6YZBV"BBBD
M,**** "BBB@ HHHH **** "BBB@ HHHH IO&\)Q""SR'YG/:HP  8H#^[/\
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M0 8$H\H_+;IT/<_YYHSYBY<;;5>@[F@XE0!_W<"?=/\ >H)WJ)I!MB7[L?\
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MV^(?]Z+_ -!H Z6BBB@ HHHH *X#XP_\B,__ %WC_P#0A7?UP'QA_P"1&?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M37?_ !_7'_71OYU#7TJV/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"TMS-XBUZ2[M_L\Y>+='N#8^7U%=;7-:)_R-OB'_ 'HO_0: .EHHHH ****
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M^@C:_P#?Y?\ &OFS%&*/JZ[A_JY#_GX_N/I/^V=+_P"@C:_]_E_QH_MG2_\
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M_?Y?\:^;,48H^KKN'^KD/^?C^X^D_P"V=+_Z"-K_ -_E_P :/[9TO_H(VO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2K]]?\ >'\Z2E7[Z_[P_G0!]9Z5_P @>Q_Z]X__ $$5
M<JGI7_('L?\ KWC_ /015ROFY;GJ+8****0PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "FN@="K#(-.HH IRP%@L?W84&2?6HR1<+O?Y;=./<U
M?95==K#(/:JD\85O-E(\I>B#O33-H2OH1DAU$TW$*\1@=_\ .*<B.[K/(,MT
M110JEF65UW!ON1^GO5N./;R3ECU- 2E8$C"EF/WFZFGT44C%NX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '(>-/$FJZ-+:6FDV1N)[D,<A
M2VW'L*YN+PAXK\3,LNNZ@;> \^5G)_(<"NXU?Q1HFC M>7D7FJ.$3YG_ $Z5
MP6J?%2\O)?LVBV6PN=JO)RQ/L!0!WWASPQ8^&;:2*S+LTI!D=SRQ'3^=;5<A
MX$M]?2&]N=>,GF3LIC5V!( SG@=.HKKZ "BBB@ HHHH **** "BBB@ HHHH
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MC/:R'_>_DSB:***[3[0**** "BBB@ HHHH **** "BBB@ HHI55G8*JEF)P
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MN\?_ *$*[^N ^,/_ "(S_P#7>/\ ]"%;8?\ BQ]3.K\#/GZBBBO?/."BBB@
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MR_-&A2(GM@9/ZXI>ZZ:9#>'G@(5)14FDDO4=\3?$PE":#%M<IA[AQT#=@/\
M/I7FM375S)>7<US*27E<N2?>H:UA%15CU\'AHX:BJ<?GZA1115G2%%%% !11
M10 4444 %%%% !1110!+;?\ 'W!_UU7^8KZ7M_\ CVB_W!_*OFBV_P"/N#_K
MJO\ ,5]+V_\ Q[1?[@_E7+B.A\QQ'_R[^?Z$M%%%<Q\P%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6;X@TQ]9T&[T])!&TZ;0Q'
M Y!_I6E10!X>/#_B+P;>_:O[,AO8U_C"[UQ].H_*H?$'BU/$-WI+26GV1[23
M]X,\8)7I^5>ZD C!&0:P]6\'Z)K()N;-5D/_ "TC^5J -#3=2LM1ME>SNHIE
M"C.QLD?45=KDO"_@I?"^JW4\%VTUO,@4(RX*D$_G76T %%%% !1110 4444
M%%%% !1110 4444 %%%% !7.:W_R-.@?[TO\EKHZYS6_^1IT#_>E_DM '1T4
M44 %%%% !39/]6WT-.ILG^K;Z&@#Y'N_^/ZX_P"NC?SJ&IKO_C^N/^NC?SJ&
MOI5L>4%%%% !1110 4444 %%%% !1110 4444 =1X&\*/XHUM1+\FGVW[RYD
M/3 _A_'^5>Q7.L66K^ M<_LZ,+:6T<D$9'1@HZBN9\'ZUX1MO 2:5?:DMI-<
M+_I(3<')/7G!KJM#LO"D7@N]@TVZ9]';?Y\A8Y'KV_I7EXB;E*\D]'H==**2
MLGN?. Z5Z7\%K..;Q/>7+J"T%OA?8D__ %JY>Y\/?VMXCO;3PK"][:1?-&0P
MSM]><=ZZOX/RG3O&%_IUT/+G>'&TG^)2./UKKQ$KT96WL8TE::N.T37K^3XS
M2![F0Q2S/"8RWR[0../PJ#QU>-X6^*?]J6L$<DAA64(_3<<C/Z5<T7PSJ</Q
MBDEDM)1;1S/-YV/E((XY_&LOX@Q2^)/B<=.L ))0B0 CH#R3^6:RCRNJK;<N
MI;OR>=RI!KGB'QKXWM9[9I8I=R_NXG.R-1U)K=^--_;3:II]E&RO<6\9,I'\
M.>@/\_QKJSH-WX&\,K:^&M+:^U6X&);DD#:?7D]/05XWX@T;7=.N?M6NV\L<
MUTQ;?(P)<]^AITG"I44HZ);=Q3YHQ:>[,:BBBNTP"BBB@ HHHH **** "BBB
M@ HHHH *5?OK_O#^=)2K]]?]X?SH ^L]*_Y ]C_U[Q_^@BKE4]*_Y ]C_P!>
M\?\ Z"*N5\W+<]1;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!YG\7KF06FG6@8A))"Q'K@?_ %ZE\8Z+90?#F!HX$1X!&RL!SSP?YU'\
M7K:0V6GW:J2D<A5CZ9'%)XO\0V%U\/((H;A'FG"+Y8/(QR<C\* .E\ 73W?@
MZR:0DL@*9/M4GCJZ>T\'7[H<,RA 1[D55\'F+0O EK/?N(8@OF.S \9/%+XI
MGMO$/@2^FTZ43Q[<JR@\X(S0!B>!]&LKCX?73S0(\DWF%F(YX'%9OPXOY+;1
M]>@W$K N]!Z$@C^@J[X*U_3[3P!=0SW*1S0[QL8\G(XQ53X;Z=)<Z+KMQM(6
MX'EH?4@$_P!10 [X5V-O?G5;NZB661F"Y<9ZY)_G47@<_P!G_$;4["+B%BX"
M]N#Q_.E^&&IVNE-JMI>S) ZL& <XSC(/\J3P(O\ :7Q"U348@3 I<AOJ>/Y4
M >M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%,EE6&%Y7.%12Q^@H ?17D.GPZYX[N-1U!-6EM(X"1
M#''G&>PZUU'PY\076K:=<6E_)YES:/MWGJP]Z .VHJEJ]^-+TB[O2,^3$7 ]
M3V_6O*;.Q\0:_H5YXE.M3Q21,S1PKP"!R: /8Z*YGP+KLVO>'(Y[D@W$3&.0
MCOCO734 %<UHG_(V^(?]Z+_T&NEKFM$_Y&WQ#_O1?^@T =+1110 4444 %<!
M\8?^1&?_ *[Q_P#H0KOZX#XP_P#(C/\ ]=X__0A6V'_BQ]3.K\#/GZBBBO?/
M."BBB@ HHHH **** "BBB@ HHHH *EMKF:SNHKFWD,<T3!T8=B.E144 >LV_
MQ8T>\MX)-<T'S[Z ?+(@# GUYZ?K7&>-/&5WXPO4=XQ!:PY\F$'./<GUKF:*
MQAAZ<)<R1<JDI*S.Q\5>,[3Q#X?L=-ATS[,]LP9I<@[\*1V'O6QX=^)UO;:(
MNC^(--^W6\8PCC!.!T!!_G7FU%-T*;CRV!5))W.^\7?$?^VM*&CZ19?8=/\
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M!_UU7^8KZ7M_^/:+_<'\J^:+;_C[@_ZZK_,5]+V__'M%_N#^5<N(Z'S'$?\
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M .@K;_F: ,2\^%^A75ZUPK7$*L<M&C#;_*NKT[3;72K&.SLXA'"@X']36?\
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M/_ K_P"M1_P@5I_T%]8_\"O_ *U=;10!S0\(   :YJ^!_P!-E_\ B:7_ (1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<K\1O\
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M[=]/U'.G.390UX^'9?AOHEMK\\L >!#!+&A)5@M<M>^&-=\):2=:T;Q'OL%
M<;)2N0?]G.#7K,W@[2[KPQ#H-VCW%K"H6-G/SKCH0?6N53X+Z,) 'U"]> '/
MDEN*5*O"*LWU[7"=.3Z&+K^KZAXJ^#:ZA<)F:*X7S648# $#/ZU#X9T2]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>,M!U/Q%</K%\L%K8.4MK9HW;>XX+G (Z]* .P\+^)/[?T ZI- +90[@KG.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *KWUL]W:/ EQ);LW22,X8?2K%174)N;66 2/'YBE=Z'#
M+GN/>@#"/AJ[[>(M2'_ A2?\(S>?]#'J7_?0KFM?TB[TJ_TF"'7M49;RY\IR
MT[<#!/'/M72P6]OX4'GWNJWMPEPZPK]H<N%8]/I0 ?\ ",WG_0QZE_WT*/\
MA&;S_H8]2_[Z%:=]K=AIUW:6MS.$FNV*PKC.XBGR:K:1ZI'IK2?Z4\9E"XZ*
M,9)/;K0!D_\ ",WG_0QZE_WT*/\ A&;S_H8]2_[Z%.D\;:#%<M"UZ/E;8SA2
M44^A;I6_'(DL:R1L&1AE6!X(H Y[_A&;S_H8]2_[Z%'_  C-Y_T,>I?]]"M7
M5-8L=&@6:^G$:N=JCJ6/L.]0Z5XATS66D2SN-TD?WXV!5E_ \T 4/^$9O/\
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M'US8'5;RTMX[5)%6&4J,DFGQ?;-!\5:=8P:O<:A!=[A+#.^]HP/XO84 :O\
MPC-Y_P!#'J7_ 'T*/^$9O/\ H8]2_P"^A5S4_$NE:3<"WNKC]^1N\M%+,!ZX
M%2V6OZ9J&GR7UO=HUO%GS&)QLQUSZ4 9W_",WG_0QZE_WT*/^$9O/^ACU+_O
MH5+:>,M#O;J.WBN\/*<1EU*AS[$]:MZKX@TW1FC6\N-LDGW(U&YF^@'- &?_
M ,(S>?\ 0QZE_P!]"C_A&;S_ *&/4O\ OH5.^N6>J>']0N=-NMS10ODKPR,%
M/4=0:R=/O(Y/#_AV6^U*YBFED3:58GSFQ]UO:@"__P (S>?]#'J7_?0H_P"$
M9O/^ACU+_OH59O/%>CV%S-;W%SMFA(#1A26.?0=ZMZ9K6GZO:-<V5PLD2'#G
MH5^H[4 9?_",WG_0QZE_WT*/^$9O/^ACU+_OH4\>-=!-R(?MHY;8)-IV9]-W
M2M\$,H8'((R"* .=_P"$9O/^ACU+_OH4?\(S>?\ 0QZE_P!]"M:QU6TU":ZA
MMY"TEL_ERJ1@J<9J ^(M+7[:6N55;)@L[,,!21G&>YH H?\ ",WG_0QZE_WT
M*/\ A&;S_H8]2_[Z%6-/\6:/J=VMK;W)$SC*)(A4N/;/6MN@#G/^$9O/^ACU
M+_OH4?\ ",WG_0QZE_WT*Z/H,FN"U/Q!>WOBO3$LI633$O/(=E.!,X^\/<#I
M^% &U_PC-Y_T,>I?]]"C_A&;S_H8]2_[Z%5O$UW=/KNF:2MZ]C:W(9I)T.UF
M(Z*#VS3-#N;JR\67.C"^EO[181)OE;<T3>A- %S_ (1F\_Z&/4O^^A1_PC-Y
M_P!#'J7_ 'T*U]2U2TTFW6>\D*1LZQAL9Y)P/UJ._P!;L--N+2"ZGV27;A(1
MC[Q- &9_PC-Y_P!#'J7_ 'T*/^$9O/\ H8]2_P"^A6O)J=K%J<.G-)_I,R%T
M0#L.I]JS+CQIH5M<O!)>@E&VNZJ2BGW;H* (_P#A&;S_ *&/4O\ OH4?\(S>
M?]#'J7_?0K7NM5L;+3_M]Q<QI;8!$A;@YZ8]:IZ;XHTG5;G[-:W/[_&X1NI4
ML/4 ]: *G_",WG_0QZE_WT*/^$9O/^ACU+_OH57T#4G74?$<E[=-]GMK@;3(
MW"+M'3TK6_X2/3!I U1YS':,<*[J5W?0'K0!1_X1F\_Z&/4O^^A1_P (S>?]
M#'J7_?0JYIGB;2M6N6MK6X/G@;O+=2K$>H!JS9ZM:7UY=6L#LTMJP64%2,$C
M/XT 97_",WG_ $,>I?\ ?0I?^$9O/^ACU+_OH5T5% &?IFFRZ>)!+J%S=[SD
M&8YV_2M"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;J%[
MBUDBCF>%V&!(G5?I4U,E0R0R1JY0LI 9>JY[B@# /A[4NWB2^'_ 4_PI/^$=
MU/\ Z&6^_P"^$_PKGO$FFZKHL-G)%XDU)S<720D-)T#9YKH+>T/AH/?ZEKMY
M<VY 3;<-E5)(P: %_P"$=U/_ *&6^_[X3_"C_A'=3_Z&6^_[X3_"M6^UBPTV
M.WDN[A8UN'"1$_Q$]*DN-1M;6ZMK::4+-<DB)>[8Z_SH QO^$=U/_H9;[_OA
M/\*/^$=U/_H9;[_OA/\ "K-[XMT/3[LVMSJ$*3+]Y<YV_7TK7AFBN(4FAD62
M-QE64Y!% '/_ /".ZG_T,M]_WPG^%'_".ZG_ -#+??\ ?"?X5N7E[;:?:O<W
M<R0PI]YW. *H:9XETC5YS!97L<DH&=F<$CUQ0!2_X1W4_P#H9;[_ +X3_"C_
M (1W4_\ H9;[_OA/\*N:EXFT?2)_(O+V..7&2F<D#W%2C7]+;26U1;N-K-1E
MI5.0* ,[_A'=3_Z&6^_[X3_"C_A'=3_Z&6^_[X3_  JRGBS0WOULEU&$S,<
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M RO^$=U/_H9;[_OA/\*/^$=U/_H9;[_OA/\ "M*/7=-DL9KT7<8MH79'D8X
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M4G\/Z_;VK7-MXANIKQ!N\J3!C<^F*V+;6/(T&._UE18N!B59#C#?_7H I?\
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M1MYH#+NDY>(CU/O6SJ7BC1M)N/(O+V-)@,E <D?44 5/^$=U/_H9;[_OA/\
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M=:Z2^I2ZA;W4+.?..7B*C.<^AKJ;Z^M].LY+NZD\N",9=CVYQ0!B?\([J?\
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M*Z^QT#3M.M+FUMH D-RS-*N>I/6IM,TJSTBP6RLXA' I)"]>O6@#"T3^S/\
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M;E0C[HVC KN>U9FIZ!IVKP0PW< *PG,>TX*?2M&.-8HEC7.U0 ,T ></Y_\
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M1T\<:C]E7;*^FY&WN><5UO\ 9=I_:HU+R_\ 2A'Y0;/\/I1_9=I_:IU+R_\
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M1_R-=K9>'=,T^SGM;:V").I64Y^9P>.32_\ "/:=]GL8/)/EV+AX!N^Z1TH
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M_K$5L ?3TH P/%>G6D7@&SCC@155X0,#D98 U;\6VL%M'X=:")(RE_"JE1C
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M^SO7MHYX9#(5]!Z>]-L?MNC>,8M*;4)KJTNK=Y!YQRR,OH: .QHK@Y-OFO\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0]#0
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MUF./:.@4N,BNO\=1)_PA-RP !A"/&?[I##&* .CN+B"TMY+FXD2.)%W,['
MJKHVKV^N:<M]:AA"S$+N&"<5GWNB6VN6-G/?-(R0Q;O)#85CCJ?6JW@  >%(
MU' $K@>W- '4UE:_KL'A^Q2ZGAEE#R"-4B&6).<?RJQIEK=VD$B7=X;IVD+*
MY7&T=A7.?$5VBT:QD5#(RWT9"+U;KQ0!+_PFSXS_ ,([K/\ WX_^O71V5T;R
MRBN##)#Y@SY<HPR_45S \6ZL%'_%*:A_WTG_ ,52^)]4U2(:&M@QM9KR4HZ.
M,[>!U^E '745Q&NR:WHT.EVL.J&>XNKHH973'RD#C'MS4^HW.KZ0EGI,-_\
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MI+Z1?[6M]4TXQ[DF5@)$;/0CTH Z.>:.V@DGF8+'&I9F/8"LR\\16=IIEKJ
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M6NKGPY'83BW;4$?S>,@8 .?YU/?W6KVEYI_AVVU#S+RYWR27DB<I&,=!ZY-
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M?$@URPLH[Y)(A%/;.0&XZ%<\5UU% ',:8NLWE[--+I]OI=J(RL:85I"WJ2.
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M+Y-9TSQM=:G9Z/)>P36RQ K(JX.<]S27-OKWBF_L$O-,73K&UF$[L\H9W(Z
M8KN** .#DTS4M.\2ZA=OHBZLETRM!+YBCRP!]TAN@^E.TC2->AO=>D>**UN+
MR.-H'3!C4C/R_P"1WKNJ* /.+[2=4UF".VD\.1VM^&7??K*H48ZL,<\^F*U-
M1T74--UY=7LK2/4DE@6*XA<@-E1@,,\5V=% '+Z:FL7=Q<SW&F6]A:^45BA
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M9CGC3#J2#@_A6[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCC)]#0 [3[6PA\<2:;I+F739K5OM<*N613VYIGB?PUH]EJ.AQV]DL:3WBQR
M,?F7TZUVVGZ1I^E(R6-I' &Z[1R?QKG_ !C_ ,A7PY_V$$H GU*VT[P=H6H:
MGIUFD4JQ'&"3D]NOOBJ^C>$;&YTV.[U=7O;VX7?(\CG@GL #Q6QXETMM9\.7
MMA&<22Q'9_O=1^M9.A>+M.32XK?4IOL=Y;J$EBE!!R/3U% %K2-+G\-OJ#27
MF_257S(D<DM%CDC/IBJP\:-Y27CZ->#378!;D8/!. =O7%+9:]<:V=4D2Q\W
M2(H2L>00\[8Y ]L5RCS6]AI)O-#UV>)ATTNY3S,G/W,8R* .O\5DV]E:Z[;$
MB2SD5C_M1-PP/Y@_A7102K/!',GW74,/QKG/$EP[^ +F2XC$<TMNH*>C$CBM
M#3KNWT_3M+LKJ=4N)80L:'JQ &: ->BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>avro-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:42.5344307+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6fb2e3cb4db74b44b876e8a9aa22350a -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:avro="http://www.avrobio.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.avrobio.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.avrobio.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avro-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avro-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avro-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avro-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100070 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100090 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilities">
        <link:definition>100100 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformation" id="Role_DisclosureSupplementalBalanceSheetInformation">
        <link:definition>100110 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100130 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100140 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan" id="Role_Disclosure401KSavingsPlan">
        <link:definition>100150 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100170 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100180 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
        <link:definition>100210 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" id="Role_DisclosureSupplementalBalanceSheetInformationTables">
        <link:definition>100220 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100230 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100240 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100250 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100270 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Nature of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100320 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100340 - Disclosure - Supplemental Balance Sheet Information - Summary of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" id="Role_DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail">
        <link:definition>100350 - Disclosure - Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" id="Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail" id="Role_DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail">
        <link:definition>100370 - Disclosure - Supplemental Balance Sheet Information - Summary of Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail" id="Role_DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail">
        <link:definition>100380 - Disclosure - Supplemental Balance Sheet Information - Summary of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail">
        <link:definition>100400 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Due Under Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" id="Role_DisclosureCommonStockAdditionalInformationDetail">
        <link:definition>100410 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail" id="Role_DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>100420 - Disclosure - Common Stock - Summary of Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail">
        <link:definition>100440 - Disclosure - Stock-Based Compensation - Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail">
        <link:definition>100460 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award and Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
        <link:definition>100470 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail" id="Role_Disclosure401KSavingsPlanAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - 401(k) Savings Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail">
        <link:definition>100500 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100510 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail">
        <link:definition>100520 - Disclosure - Net Loss per Share - Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100530 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="avro_AtTheMarketFacilityMember" name="AtTheMarketFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_DeferredRentExpense" name="DeferredRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" name="OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_CommonStockOfferingCostsIncurredButNotYetPaid" name="CommonStockOfferingCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_SignificantOfAccountingPoliciesLineItems" name="SignificantOfAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_SignificantOfAccountingPoliciesTable" name="SignificantOfAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_ForeignExchangeLoss" name="ForeignExchangeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_UpfrontLicenseFees" name="UpfrontLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_LicenseAgreementLineItems" name="LicenseAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_LicenseAgreementTable" name="LicenseAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_UniversityOfManchesterAgreementMember" name="UniversityOfManchesterAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_MPSIILicenseAgreementMember" name="MPSIILicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_UHNagreementMember" name="UHNagreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_FabrylicenseagreementMember" name="FabrylicenseagreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_Interleukin12LicenseAgreementMember" name="Interleukin12LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_BioMarinPharmaceuticalIncMember" name="BioMarinPharmaceuticalIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_GenstemTherapeuticsIncMember" name="GenstemTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_LundUniversityRightsHoldersAgreementMember" name="LundUniversityRightsHoldersAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_MilestonePaymentPaid" name="MilestonePaymentPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_MilestonePaymentDue" name="MilestonePaymentDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_AgreementExpirationPeriod" name="AgreementExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_AgreementExpirationDescription" name="AgreementExpirationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" name="ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_CostOfMilestonePayment" name="CostOfMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_OptionFee" name="OptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_MilestoneFees" name="MilestoneFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_LicenseMaintenanceFees" name="LicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_PaymentsUponClosingOfInitialPublicOffering" name="PaymentsUponClosingOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_LicenseAgreementExpenses" name="LicenseAgreementExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_FairValueInputAmountTransferBetweenLevels" name="FairValueInputAmountTransferBetweenLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_TaxIncentiveRefundCurrent" name="TaxIncentiveRefundCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_PrepaidCompensationBenefits" name="PrepaidCompensationBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" name="SupplementalBalanceSheetInformationDisclosuresAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_OperatingLeaseAnnualIncreaseInRentalPercentage" name="OperatingLeaseAnnualIncreaseInRentalPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="avro_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_RestrictedCashMember" name="RestrictedCashMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_AnnualLeasePaymentsDescription" name="AnnualLeasePaymentsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" name="OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_UndesignatedPreferredStock" name="UndesignatedPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="avro_UndesignatedSharesOfPreferredStockOutstanding" name="UndesignatedSharesOfPreferredStockOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="avro_JulyTwoThousandNineteenFollowOnOfferingMember" name="JulyTwoThousandNineteenFollowOnOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" name="FebruaryTwoThousandTwentyFollowOnOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_NovemberTwoThousandTwentyFollowOnOfferingMember" name="NovemberTwoThousandTwentyFollowOnOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" name="CommonStockCapitalSharesAmountAvailableForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" name="TwoThousandEighteenStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_TwoThousandNineteenInducementPlanMember" name="TwoThousandNineteenInducementPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_TwoThousandTwentyInducementPlanMember" name="TwoThousandTwentyInducementPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_TwoThousandFifteenStockOptionAndGrantPlanMember" name="TwoThousandFifteenStockOptionAndGrantPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" name="NumberOfSharesOfCommonStockOutstandingIncreasePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_AdditionalResearchAndDevelopmentExpense" name="AdditionalResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_ExpirationThrough2037Member" name="ExpirationThrough2037Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_ExpirationThrough2039Member" name="ExpirationThrough2039Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_OrphanDrugCreditMember" name="OrphanDrugCreditMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_ExpirationThrough2033Member" name="ExpirationThrough2033Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" name="EffectiveIncomeTaxRateReconciliationPermanentDifference" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" name="DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_DeferredTaxAssetsLicenseAgreement" name="DeferredTaxAssetsLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_PayrollTaxLiabilityCappedPerYear" name="PayrollTaxLiabilityCappedPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="avro_TaxCreditCarryforwardsExpirationPeriod" name="TaxCreditCarryforwardsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" name="OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" name="OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="avro_RestrictedStockAwardsAndUnitsMember" name="RestrictedStockAwardsAndUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_ProvisionForMaximumCashPayment" name="ProvisionForMaximumCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="avro_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_OfficersAndBoardMembersMember" name="OfficersAndBoardMembersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="avro_SubleaseAgreementMember" name="SubleaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>avro-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:42.5344307+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6fb2e3cb4db74b44b876e8a9aa22350a -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="avro-20201231.xsd#TemplateLink" roleURI="http://www.avrobio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredRentExpense" xlink:type="locator" xlink:label="avro_DeferredRentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avro_DeferredRentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PrepaidCompensationBenefits" xlink:type="locator" xlink:label="avro_PrepaidCompensationBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PrepaidResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="avro_PrepaidResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TaxIncentiveRefundCurrent" xlink:type="locator" xlink:label="avro_TaxIncentiveRefundCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="avro_TaxIncentiveRefundCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="avro_PrepaidResearchAndDevelopmentCostsCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="avro_PrepaidCompensationBenefits" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="avro_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="avro_AccruedResearchAndDevelopmentExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="avro-20201231.xsd#avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:type="locator" xlink:label="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredTaxAssetsLicenseAgreement" xlink:type="locator" xlink:label="avro_DeferredTaxAssetsLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:type="locator" xlink:label="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="avro_DeferredTaxAssetsLicenseAgreement" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>avro-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:42.5344307+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6fb2e3cb4db74b44b876e8a9aa22350a -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="avro-20201231.xsd#TemplateLink" roleURI="http://www.avrobio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommonStockOfferingCostsIncurredButNotYetPaid" xlink:type="locator" xlink:label="avro_CommonStockOfferingCostsIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredRentExpense" xlink:type="locator" xlink:label="avro_DeferredRentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10180.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="avro_DeferredRentExpense" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="avro_CommonStockOfferingCostsIncurredButNotYetPaid" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="us-gaap_RestrictedCash" order="11850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ForeignExchangeLoss" xlink:type="locator" xlink:label="avro_ForeignExchangeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantOfAccountingPoliciesTable" xlink:type="locator" xlink:label="avro_SignificantOfAccountingPoliciesTable" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantOfAccountingPoliciesLineItems" xlink:type="locator" xlink:label="avro_SignificantOfAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="avro_SignificantOfAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_SignificantOfAccountingPoliciesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_SignificantOfAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="avro_ForeignExchangeLoss" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementExpenses" xlink:type="locator" xlink:label="avro_LicenseAgreementExpenses" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePayment" xlink:type="locator" xlink:label="avro_MilestonePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PaymentsUponClosingOfInitialPublicOffering" xlink:type="locator" xlink:label="avro_PaymentsUponClosingOfInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseMaintenanceFees" xlink:type="locator" xlink:label="avro_LicenseMaintenanceFees" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestoneFees" xlink:type="locator" xlink:label="avro_MilestoneFees" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OptionFee" xlink:type="locator" xlink:label="avro_OptionFee" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CostOfMilestonePayment" xlink:type="locator" xlink:label="avro_CostOfMilestonePayment" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AgreementExpirationDescription" xlink:type="locator" xlink:label="avro_AgreementExpirationDescription" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AgreementExpirationPeriod" xlink:type="locator" xlink:label="avro_AgreementExpirationPeriod" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePaymentDue" xlink:type="locator" xlink:label="avro_MilestonePaymentDue" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePaymentPaid" xlink:type="locator" xlink:label="avro_MilestonePaymentPaid" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePayments" xlink:type="locator" xlink:label="avro_MilestonePayments" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UpfrontLicenseFees" xlink:type="locator" xlink:label="avro_UpfrontLicenseFees" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LundUniversityRightsHoldersAgreementMember" xlink:type="locator" xlink:label="avro_LundUniversityRightsHoldersAgreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_GenstemTherapeuticsIncMember" xlink:type="locator" xlink:label="avro_GenstemTherapeuticsIncMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_BioMarinPharmaceuticalIncMember" xlink:type="locator" xlink:label="avro_BioMarinPharmaceuticalIncMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_Interleukin12LicenseAgreementMember" xlink:type="locator" xlink:label="avro_Interleukin12LicenseAgreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_FabrylicenseagreementMember" xlink:type="locator" xlink:label="avro_FabrylicenseagreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UHNagreementMember" xlink:type="locator" xlink:label="avro_UHNagreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MPSIILicenseAgreementMember" xlink:type="locator" xlink:label="avro_MPSIILicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UniversityOfManchesterAgreementMember" xlink:type="locator" xlink:label="avro_UniversityOfManchesterAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementTable" xlink:type="locator" xlink:label="avro_LicenseAgreementTable" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementLineItems" xlink:type="locator" xlink:label="avro_LicenseAgreementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_LicenseAgreementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_UniversityOfManchesterAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_MPSIILicenseAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_UHNagreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_FabrylicenseagreementMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_Interleukin12LicenseAgreementMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_BioMarinPharmaceuticalIncMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_GenstemTherapeuticsIncMember" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_LundUniversityRightsHoldersAgreementMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_UpfrontLicenseFees" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePayments" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePaymentPaid" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePaymentDue" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_AgreementExpirationPeriod" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_AgreementExpirationDescription" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_CostOfMilestonePayment" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_OptionFee" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestoneFees" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_LicenseMaintenanceFees" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_PaymentsUponClosingOfInitialPublicOffering" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePayment" order="12250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_LicenseAgreementExpenses" order="12290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="avro-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10780.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AnnualLeasePaymentsDescription" xlink:type="locator" xlink:label="avro_AnnualLeasePaymentsDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLeaseAnnualIncreaseInRentalPercentage" xlink:type="locator" xlink:label="avro_OperatingLeaseAnnualIncreaseInRentalPercentage" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="avro_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_RestrictedCashMember" xlink:type="locator" xlink:label="avro_RestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="avro_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="avro_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_CommitmentsAndContingenciesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="avro_RestrictedCashMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_LeaseExpirationMonthAndYear" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_OperatingLeaseAnnualIncreaseInRentalPercentage" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SecurityDeposit" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_AnnualLeasePaymentsDescription" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10810.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" xlink:type="locator" xlink:label="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCash" xlink:type="locator" xlink:label="us-gaap_DividendsCash" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UndesignatedSharesOfPreferredStockOutstanding" xlink:type="locator" xlink:label="avro_UndesignatedSharesOfPreferredStockOutstanding" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UndesignatedPreferredStock" xlink:type="locator" xlink:label="avro_UndesignatedPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="avro-20201231.xsd#avro_NovemberTwoThousandTwentyFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_NovemberTwoThousandTwentyFollowOnOfferingMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_JulyTwoThousandNineteenFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_JulyTwoThousandNineteenFollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_JulyTwoThousandNineteenFollowOnOfferingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_NovemberTwoThousandTwentyFollowOnOfferingMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avro_UndesignatedPreferredStock" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avro_UndesignatedSharesOfPreferredStockOutstanding" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCash" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" order="11220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandTwentyInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandTwentyInducementPlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandNineteenInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandNineteenInducementPlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandNineteenInducementPlanMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandTwentyInducementPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_AdditionalResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="avro_AdditionalResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="avro-20201231.xsd#avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" xlink:type="locator" xlink:label="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandTwentyInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandTwentyInducementPlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandNineteenInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandNineteenInducementPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandFifteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandFifteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandFifteenStockOptionAndGrantPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandNineteenInducementPlanMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandTwentyInducementPlanMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avro_AdditionalResearchAndDevelopmentExpense" order="11910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:type="locator" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:type="locator" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TaxCreditCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="avro_TaxCreditCarryforwardsExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PayrollTaxLiabilityCappedPerYear" xlink:type="locator" xlink:label="avro_PayrollTaxLiabilityCappedPerYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2033Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2033Member" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OrphanDrugCreditMember" xlink:type="locator" xlink:label="avro_OrphanDrugCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2039Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2039Member" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2037Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2037Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_IncomeTaxesTable" xlink:type="locator" xlink:label="avro_IncomeTaxesTable" />
    <link:loc xlink:href="avro-20201231.xsd#avro_IncomeTaxesLineItems" xlink:type="locator" xlink:label="avro_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="avro_ExpirationThrough2037Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="avro_ExpirationThrough2039Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="avro_OrphanDrugCreditMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="avro_ExpirationThrough2033Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avro_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_PayrollTaxLiabilityCappedPerYear" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_TaxCreditCarryforwardsExpirationPeriod" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" order="11270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:href="avro-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="avro-20201231.xsd#avro_RestrictedStockAwardsAndUnitsMember" xlink:type="locator" xlink:label="avro_RestrictedStockAwardsAndUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="avro_RestrictedStockAwardsAndUnitsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ProvisionForMaximumCashPayment" xlink:type="locator" xlink:label="avro_ProvisionForMaximumCashPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SubleaseAgreementMember" xlink:type="locator" xlink:label="avro_SubleaseAgreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OfficersAndBoardMembersMember" xlink:type="locator" xlink:label="avro_OfficersAndBoardMembersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_StockPurchaseAgreementMember" xlink:type="locator" xlink:label="avro_StockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementMember" xlink:type="locator" xlink:label="avro_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_LicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avro_StockPurchaseAgreementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avro_OfficersAndBoardMembersMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_SubleaseAgreementMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avro_ProvisionForMaximumCashPayment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10550.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>avro-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:42.5344307+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6fb2e3cb4db74b44b876e8a9aa22350a -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line3</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000 shares authorized and no shares issued or outstanding as of December 31, 2020 and 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 150,000 shares authorized as of December 31, 2020 and 2019; 41,569 and 31,673 shares issued as of December 31, 2020 and 2019, respectively; 41,569 and 31,643 shares outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share &#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares outstanding&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="avro_AtTheMarketFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market Facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_AtTheMarketFacilityMember" xlink:to="avro_AtTheMarketFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_AtTheMarketFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AtTheMarketFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock awards and units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock awards and units, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, net of offering costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under 2018 employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under 2018 employee stock purchase plan, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredRentExpense" xlink:type="locator" xlink:label="avro_DeferredRentExpense" />
    <link:label xml:lang="en-US" xlink:label="avro_DeferredRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred rent expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_DeferredRentExpense" xlink:to="avro_DeferredRentExpense_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other adjustments noncash items to reconcile net income loss to cash provided by used in operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommonStockOfferingCostsIncurredButNotYetPaid" xlink:type="locator" xlink:label="avro_CommonStockOfferingCostsIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="avro_CommonStockOfferingCostsIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock offering costs incurred but not yet paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_CommonStockOfferingCostsIncurredButNotYetPaid" xlink:to="avro_CommonStockOfferingCostsIncurredButNotYetPaid_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_DeferredRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent expense</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_DeferredRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_CommonStockOfferingCostsIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock offering costs incurred but unpaid at period end</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_CommonStockOfferingCostsIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="avro_LicenseAgreementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LicenseAgreementDisclosureTextBlock" xlink:to="avro_LicenseAgreementDisclosureTextBlock_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="avro_LicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LicenseAgreementsAbstract" xlink:to="avro_LicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Balance Sheet Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Savings Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prior Period Reclassification Adjustment Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Considerations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="avro_EmergingGrowthCompanyStatusPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="avro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="avro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="locator" xlink:label="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently Adopted Accounting Pronouncements Policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Estimated Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments Due Under Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Award and Restricted Stock Unit Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="avro_SignificantAccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="avro_SignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_SignificantAccountingPoliciesAbstract" xlink:to="avro_SignificantAccountingPoliciesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_SignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantOfAccountingPoliciesLineItems" xlink:type="locator" xlink:label="avro_SignificantOfAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="avro_SignificantOfAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant of accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="avro_SignificantOfAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantOfAccountingPoliciesTable" xlink:type="locator" xlink:label="avro_SignificantOfAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="avro_SignificantOfAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant Of Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_SignificantOfAccountingPoliciesTable" xlink:to="avro_SignificantOfAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_SignificantOfAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Of Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_SignificantOfAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Of Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Dividend Yield [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2018-18 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201818 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2018-15 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201815Member" xlink:to="us-gaap_AccountingStandardsUpdate201815Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201815 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2018-13 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201813 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_SignificantOfAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Of Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_SignificantOfAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Of Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Financing And Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ForeignExchangeLoss" xlink:type="locator" xlink:label="avro_ForeignExchangeLoss" />
    <link:label xml:lang="en-US" xlink:label="avro_ForeignExchangeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign Exchange Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ForeignExchangeLoss" xlink:to="avro_ForeignExchangeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_ForeignExchangeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange losses</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ForeignExchangeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Exchange Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected cash dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_UpfrontLicenseFees" xlink:type="locator" xlink:label="avro_UpfrontLicenseFees" />
    <link:label xml:lang="en-US" xlink:label="avro_UpfrontLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of the upfront license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_UpfrontLicenseFees" xlink:to="avro_UpfrontLicenseFees_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementLineItems" xlink:type="locator" xlink:label="avro_LicenseAgreementLineItems" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_LicenseAgreementLineItems_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementTable" xlink:type="locator" xlink:label="avro_LicenseAgreementTable" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LicenseAgreementTable" xlink:to="avro_LicenseAgreementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_UniversityOfManchesterAgreementMember" xlink:type="locator" xlink:label="avro_UniversityOfManchesterAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_UniversityOfManchesterAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Manchester agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_UniversityOfManchesterAgreementMember" xlink:to="avro_UniversityOfManchesterAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_UniversityOfManchesterAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of Manchester Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UniversityOfManchesterAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of Manchester Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_MPSIILicenseAgreementMember" xlink:type="locator" xlink:label="avro_MPSIILicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_MPSIILicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MPSII license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_MPSIILicenseAgreementMember" xlink:to="avro_MPSIILicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_MPSIILicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MPSII License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MPSIILicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M P S I I License Agreement [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_UHNagreementMember" xlink:type="locator" xlink:label="avro_UHNagreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_UHNagreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UHN agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_UHNagreementMember" xlink:to="avro_UHNagreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_UHNagreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UHN Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UHNagreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U H Nagreement [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_FabrylicenseagreementMember" xlink:type="locator" xlink:label="avro_FabrylicenseagreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_FabrylicenseagreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fabry license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_FabrylicenseagreementMember" xlink:to="avro_FabrylicenseagreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_FabrylicenseagreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fabry License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_FabrylicenseagreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fabrylicenseagreement [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_Interleukin12LicenseAgreementMember" xlink:type="locator" xlink:label="avro_Interleukin12LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_Interleukin12LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interleukin 12 license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_Interleukin12LicenseAgreementMember" xlink:to="avro_Interleukin12LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_Interleukin12LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interleukin 12 License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_Interleukin12LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interleukin12 License Agreement [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_BioMarinPharmaceuticalIncMember" xlink:type="locator" xlink:label="avro_BioMarinPharmaceuticalIncMember" />
    <link:label xml:lang="en-US" xlink:label="avro_BioMarinPharmaceuticalIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioMarin Pharmaceutical Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_BioMarinPharmaceuticalIncMember" xlink:to="avro_BioMarinPharmaceuticalIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_BioMarinPharmaceuticalIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioMarin Pharmaceutical Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_BioMarinPharmaceuticalIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio Marin Pharmaceutical Inc [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_GenstemTherapeuticsIncMember" xlink:type="locator" xlink:label="avro_GenstemTherapeuticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="avro_GenstemTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GenStem Therapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_GenstemTherapeuticsIncMember" xlink:to="avro_GenstemTherapeuticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_GenstemTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GenStem Therapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_GenstemTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genstem Therapeutics Inc [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_LundUniversityRightsHoldersAgreementMember" xlink:type="locator" xlink:label="avro_LundUniversityRightsHoldersAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_LundUniversityRightsHoldersAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lund University Rights Holders Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LundUniversityRightsHoldersAgreementMember" xlink:to="avro_LundUniversityRightsHoldersAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_LundUniversityRightsHoldersAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lund University Rights Holders Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LundUniversityRightsHoldersAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lund University Rights Holders Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UpfrontLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UpfrontLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePayments" xlink:type="locator" xlink:label="avro_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_MilestonePayments" xlink:to="avro_MilestonePayments_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePaymentPaid" xlink:type="locator" xlink:label="avro_MilestonePaymentPaid" />
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePaymentPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_MilestonePaymentPaid" xlink:to="avro_MilestonePaymentPaid_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePaymentDue" xlink:type="locator" xlink:label="avro_MilestonePaymentDue" />
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePaymentDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payment Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_MilestonePaymentDue" xlink:to="avro_MilestonePaymentDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePaymentPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment paid</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePaymentPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePaymentDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePaymentDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_AgreementExpirationPeriod" xlink:type="locator" xlink:label="avro_AgreementExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="avro_AgreementExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_AgreementExpirationPeriod" xlink:to="avro_AgreementExpirationPeriod_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AgreementExpirationDescription" xlink:type="locator" xlink:label="avro_AgreementExpirationDescription" />
    <link:label xml:lang="en-US" xlink:label="avro_AgreementExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiration description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_AgreementExpirationDescription" xlink:to="avro_AgreementExpirationDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_AgreementExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AgreementExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AgreementExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement Expiration Description</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AgreementExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiration Description</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial cost related to research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" xlink:to="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Cost Related To Research And Development Expense</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_CostOfMilestonePayment" xlink:type="locator" xlink:label="avro_CostOfMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="avro_CostOfMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_CostOfMilestonePayment" xlink:to="avro_CostOfMilestonePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_CostOfMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued upfront license</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_CostOfMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Milestone Payment</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_OptionFee" xlink:type="locator" xlink:label="avro_OptionFee" />
    <link:label xml:lang="en-US" xlink:label="avro_OptionFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OptionFee" xlink:to="avro_OptionFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_OptionFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option fee</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OptionFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Fee</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestoneFees" xlink:type="locator" xlink:label="avro_MilestoneFees" />
    <link:label xml:lang="en-US" xlink:label="avro_MilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_MilestoneFees" xlink:to="avro_MilestoneFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_MilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone fees</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Fees</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseMaintenanceFees" xlink:type="locator" xlink:label="avro_LicenseMaintenanceFees" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License Maintenance Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LicenseMaintenanceFees" xlink:to="avro_LicenseMaintenanceFees_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PaymentsUponClosingOfInitialPublicOffering" xlink:type="locator" xlink:label="avro_PaymentsUponClosingOfInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="avro_PaymentsUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments upon closing of initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_PaymentsUponClosingOfInitialPublicOffering" xlink:to="avro_PaymentsUponClosingOfInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PaymentsUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments upon closing of an initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PaymentsUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Upon Closing Of Initial Public Offering</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementExpenses" xlink:type="locator" xlink:label="avro_LicenseAgreementExpenses" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LicenseAgreementExpenses" xlink:to="avro_LicenseAgreementExpenses_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePayment" xlink:type="locator" xlink:label="avro_MilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_MilestonePayment" xlink:to="avro_MilestonePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock issued</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to license</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value on Recurring Basis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_FairValueInputAmountTransferBetweenLevels" xlink:type="locator" xlink:label="avro_FairValueInputAmountTransferBetweenLevels" />
    <link:label xml:lang="en-US" xlink:label="avro_FairValueInputAmountTransferBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value input amount of assets and liabilities between levels.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_FairValueInputAmountTransferBetweenLevels" xlink:to="avro_FairValueInputAmountTransferBetweenLevels_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_FairValueInputAmountTransferBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value input transfer between levels</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_FairValueInputAmountTransferBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Input Amount Transfer Between Levels</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_TaxIncentiveRefundCurrent" xlink:type="locator" xlink:label="avro_TaxIncentiveRefundCurrent" />
    <link:label xml:lang="en-US" xlink:label="avro_TaxIncentiveRefundCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax incentive refund current .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_TaxIncentiveRefundCurrent" xlink:to="avro_TaxIncentiveRefundCurrent_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PrepaidResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="avro_PrepaidResearchAndDevelopmentCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="avro_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="avro_PrepaidResearchAndDevelopmentCostsCurrent_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PrepaidCompensationBenefits" xlink:type="locator" xlink:label="avro_PrepaidCompensationBenefits" />
    <link:label xml:lang="en-US" xlink:label="avro_PrepaidCompensationBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid compensation benefits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_PrepaidCompensationBenefits" xlink:to="avro_PrepaidCompensationBenefits_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:type="locator" xlink:label="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="avro_SupplementalBalanceSheetInformationDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental balance sheet information disclosures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="avro_SupplementalBalanceSheetInformationDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_SupplementalBalanceSheetInformationDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Information Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TaxIncentiveRefundCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax incentive refund</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TaxIncentiveRefundCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Incentive Refund Current</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Costs Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PrepaidCompensationBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid compensation benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PrepaidCompensationBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Compensation Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property plant and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="avro_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="avro_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="avro_AccruedResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation and benefit costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting and professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="avro_LeaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="avro_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LeaseExpirationMonthAndYear" xlink:to="avro_LeaseExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLeaseAnnualIncreaseInRentalPercentage" xlink:type="locator" xlink:label="avro_OperatingLeaseAnnualIncreaseInRentalPercentage" />
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLeaseAnnualIncreaseInRentalPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease annual increase in rental percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OperatingLeaseAnnualIncreaseInRentalPercentage" xlink:to="avro_OperatingLeaseAnnualIncreaseInRentalPercentage_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="avro_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="avro_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="avro_CommitmentsAndContingenciesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="avro_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_CommitmentsAndContingenciesDisclosureTable" xlink:to="avro_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:label xml:lang="en-US" xlink:label="country_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge, Massachusetts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MA" xlink:to="country_MA_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">MOROCCO</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_RestrictedCashMember" xlink:type="locator" xlink:label="avro_RestrictedCashMember" />
    <link:label xml:lang="en-US" xlink:label="avro_RestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_RestrictedCashMember" xlink:to="avro_RestrictedCashMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_RestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_RestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLeaseAnnualIncreaseInRentalPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in rent</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLeaseAnnualIncreaseInRentalPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Annual Increase In Rental Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant incentive allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Tenant Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit in connection with lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_AnnualLeasePaymentsDescription" xlink:type="locator" xlink:label="avro_AnnualLeasePaymentsDescription" />
    <link:label xml:lang="en-US" xlink:label="avro_AnnualLeasePaymentsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual lease payments, description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_AnnualLeasePaymentsDescription" xlink:to="avro_AnnualLeasePaymentsDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_AnnualLeasePaymentsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual lease payments, description</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AnnualLeasePaymentsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Lease Payments Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" />
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum payments due after year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:to="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due After Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_UndesignatedPreferredStock" xlink:type="locator" xlink:label="avro_UndesignatedPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="avro_UndesignatedPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_UndesignatedPreferredStock" xlink:to="avro_UndesignatedPreferredStock_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UndesignatedSharesOfPreferredStockOutstanding" xlink:type="locator" xlink:label="avro_UndesignatedSharesOfPreferredStockOutstanding" />
    <link:label xml:lang="en-US" xlink:label="avro_UndesignatedSharesOfPreferredStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated shares of preferred stock outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_UndesignatedSharesOfPreferredStockOutstanding" xlink:to="avro_UndesignatedSharesOfPreferredStockOutstanding_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_JulyTwoThousandNineteenFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_JulyTwoThousandNineteenFollowOnOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="avro_JulyTwoThousandNineteenFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">July two thousand nineteen follow-on offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_JulyTwoThousandNineteenFollowOnOfferingMember" xlink:to="avro_JulyTwoThousandNineteenFollowOnOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_JulyTwoThousandNineteenFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July 2019 Follow-on Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_JulyTwoThousandNineteenFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">July Two Thousand Nineteen Follow On Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">February two thousand twenty follow on offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" xlink:to="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2020 Follow-on Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">February Two Thousand Twenty Follow On Offering [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_NovemberTwoThousandTwentyFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_NovemberTwoThousandTwentyFollowOnOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="avro_NovemberTwoThousandTwentyFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">November two thousand twenty follow on offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_NovemberTwoThousandTwentyFollowOnOfferingMember" xlink:to="avro_NovemberTwoThousandTwentyFollowOnOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_NovemberTwoThousandTwentyFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2020 Follow-on Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_NovemberTwoThousandTwentyFollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">November Two Thousand Twenty Follow On Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UndesignatedPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UndesignatedPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UndesignatedSharesOfPreferredStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated shares of preferred stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_UndesignatedSharesOfPreferredStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Shares Of Preferred Stock Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCash" xlink:type="locator" xlink:label="us-gaap_DividendsCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCash" xlink:to="us-gaap_DividendsCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued and sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance price per shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" xlink:type="locator" xlink:label="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares amount available for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" xlink:to="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock remained available for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Amount Available For Future Issuance</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 stock option and incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" xlink:to="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Stock Option and Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Option And Incentive Plan [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandNineteenInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandNineteenInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandNineteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_TwoThousandNineteenInducementPlanMember" xlink:to="avro_TwoThousandNineteenInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandNineteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Inducement Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandNineteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Inducement Plan [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandTwentyInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandTwentyInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandTwentyInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_TwoThousandTwentyInducementPlanMember" xlink:to="avro_TwoThousandTwentyInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandTwentyInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Inducement Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandTwentyInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Inducement Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares of authorized common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandFifteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandFifteenStockOptionAndGrantPlanMember" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandFifteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen stock option and grant plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_TwoThousandFifteenStockOptionAndGrantPlanMember" xlink:to="avro_TwoThousandFifteenStockOptionAndGrantPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandFifteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Stock Option and Grant Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TwoThousandFifteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Option And Grant Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares that may be issued under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares available for future grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" xlink:type="locator" xlink:label="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" />
    <link:label xml:lang="en-US" xlink:label="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of common stock outstanding increase percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" xlink:to="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock outstanding, increase, percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Of Common Stock Outstanding Increase Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock reserved for issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares that may increase under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected option life (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, Outstanding beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Cancelled or forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, Outstanding ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Cancelled or forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Outstanding balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Granted, Weighted-average grant-date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" xlink:type="locator" xlink:label="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options forfeited and expirations in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" xlink:to="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Issued and unvested beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited, cancelled or expired</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Issued and unvested ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, Issued and unvested, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Forfeited, cancelled or expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, Issued and unvested, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of restricted stock awards and restricted stock units vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_AdditionalResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="avro_AdditionalResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="avro_AdditionalResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_AdditionalResearchAndDevelopmentExpense" xlink:to="avro_AdditionalResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense, period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AdditionalResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_AdditionalResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Defined Contribution Pension And Other Postretirement Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution, percent of match</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of employee contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_IncomeTaxesLineItems" xlink:type="locator" xlink:label="avro_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="avro_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_IncomeTaxesTable" xlink:type="locator" xlink:label="avro_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="avro_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_IncomeTaxesTable" xlink:to="avro_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2037Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2037Member" />
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2037Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration Through 2037.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ExpirationThrough2037Member" xlink:to="avro_ExpirationThrough2037Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2037Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Through 2037 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2037Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Through2037 [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2039Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2039Member" />
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2039Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration Through 2039.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ExpirationThrough2039Member" xlink:to="avro_ExpirationThrough2039Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2039Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Through 2039 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2039Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Through2039 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_OrphanDrugCreditMember" xlink:type="locator" xlink:label="avro_OrphanDrugCreditMember" />
    <link:label xml:lang="en-US" xlink:label="avro_OrphanDrugCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan drug credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OrphanDrugCreditMember" xlink:to="avro_OrphanDrugCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_OrphanDrugCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OrphanDrugCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Credit [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2033Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2033Member" />
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2033Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration Through 2033.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ExpirationThrough2033Member" xlink:to="avro_ExpirationThrough2033Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2033Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Through 2033 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ExpirationThrough2033Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Through2033 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australia [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:type="locator" xlink:label="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" />
    <link:label xml:lang="en-US" xlink:label="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent difference.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:to="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax expense at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Difference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision to Return</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Prior Year Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:type="locator" xlink:label="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" />
    <link:label xml:lang="en-US" xlink:label="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized start up and organizational costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:to="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredTaxAssetsLicenseAgreement" xlink:type="locator" xlink:label="avro_DeferredTaxAssetsLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="avro_DeferredTaxAssetsLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_DeferredTaxAssetsLicenseAgreement" xlink:to="avro_DeferredTaxAssetsLicenseAgreement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S., foreign and state net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized start up and organizational costs</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Start Up And Organizational Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_DeferredTaxAssetsLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_DeferredTaxAssetsLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets License Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, not subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, state</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_PayrollTaxLiabilityCappedPerYear" xlink:type="locator" xlink:label="avro_PayrollTaxLiabilityCappedPerYear" />
    <link:label xml:lang="en-US" xlink:label="avro_PayrollTaxLiabilityCappedPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll tax liability capped per year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_PayrollTaxLiabilityCappedPerYear" xlink:to="avro_PayrollTaxLiabilityCappedPerYear_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TaxCreditCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="avro_TaxCreditCarryforwardsExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="avro_TaxCreditCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Credit Carryforwards Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_TaxCreditCarryforwardsExpirationPeriod" xlink:to="avro_TaxCreditCarryforwardsExpirationPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PayrollTaxLiabilityCappedPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll tax liability capped per year</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_PayrollTaxLiabilityCappedPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payroll Tax Liability Capped Per Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax reconciliation tax credit research</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TaxCreditCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax credit carryforward expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_TaxCreditCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforwards Expiration Period</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:type="locator" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:to="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:type="locator" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:to="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cumulative changes in ownership interest subject to annual limitation</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of cumulative changes in ownership interest</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_RestrictedStockAwardsAndUnitsMember" xlink:type="locator" xlink:label="avro_RestrictedStockAwardsAndUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="avro_RestrictedStockAwardsAndUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock awards and units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_RestrictedStockAwardsAndUnitsMember" xlink:to="avro_RestrictedStockAwardsAndUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_RestrictedStockAwardsAndUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards and Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_RestrictedStockAwardsAndUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards And Units [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_ProvisionForMaximumCashPayment" xlink:type="locator" xlink:label="avro_ProvisionForMaximumCashPayment" />
    <link:label xml:lang="en-US" xlink:label="avro_ProvisionForMaximumCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Provision for maximum cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_ProvisionForMaximumCashPayment" xlink:to="avro_ProvisionForMaximumCashPayment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementMember" xlink:type="locator" xlink:label="avro_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_LicenseAgreementMember" xlink:to="avro_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_StockPurchaseAgreementMember" xlink:type="locator" xlink:label="avro_StockPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_StockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_StockPurchaseAgreementMember" xlink:to="avro_StockPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_StockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_StockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_OfficersAndBoardMembersMember" xlink:type="locator" xlink:label="avro_OfficersAndBoardMembersMember" />
    <link:label xml:lang="en-US" xlink:label="avro_OfficersAndBoardMembersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Officers and board members.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_OfficersAndBoardMembersMember" xlink:to="avro_OfficersAndBoardMembersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_OfficersAndBoardMembersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officers and Board Members [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_OfficersAndBoardMembersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Officers And Board Members [Member]</link:label>
    <link:loc xlink:href="avro-20201231.xsd#avro_SubleaseAgreementMember" xlink:type="locator" xlink:label="avro_SubleaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="avro_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sub-lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avro_SubleaseAgreementMember" xlink:to="avro_SubleaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="avro_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sub-lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for initial consideration for license</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ProvisionForMaximumCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for maximum cash payment</link:label>
    <link:label xml:lang="en-US" xlink:label="avro_ProvisionForMaximumCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Maximum Cash Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>avro-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:42.5354300+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6fb2e3cb4db74b44b876e8a9aa22350a -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.avrobio.com/20201231/role/TemplateLink" xlink:href="avro-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="avro-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="avro-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommonStockOfferingCostsIncurredButNotYetPaid" xlink:type="locator" xlink:label="avro_CommonStockOfferingCostsIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredRentExpense" xlink:type="locator" xlink:label="avro_DeferredRentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10200.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="avro_DeferredRentExpense" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="avro_CommonStockOfferingCostsIncurredButNotYetPaid" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="us-gaap_RestrictedCash" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="avro-20201231.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="avro-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreements" xlink:href="avro-20201231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreements">
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="avro_LicenseAgreementDisclosureTextBlock" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="avro_LicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementsAbstract" xlink:to="avro_LicenseAgreementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:href="avro-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformation" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="avro-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStock" xlink:href="avro-20201231.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan" xlink:href="avro-20201231.xsd#Role_Disclosure401KSavingsPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="avro-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="avro-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avro-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="avro-20201231.xsd#avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="locator" xlink:label="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
    <link:loc xlink:href="avro-20201231.xsd#avro_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="avro_EmergingGrowthCompanyStatusPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avro_EmergingGrowthCompanyStatusPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="avro-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="avro-20201231.xsd#avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="avro-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="avro-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockTables" xlink:href="avro-20201231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="avro-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ForeignExchangeLoss" xlink:type="locator" xlink:label="avro_ForeignExchangeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantOfAccountingPoliciesLineItems" xlink:type="locator" xlink:label="avro_SignificantOfAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantOfAccountingPoliciesTable" xlink:type="locator" xlink:label="avro_SignificantOfAccountingPoliciesTable" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="avro_SignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantAccountingPoliciesAbstract" xlink:to="avro_SignificantOfAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesTable" xlink:to="avro_SignificantOfAccountingPoliciesLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="avro_ForeignExchangeLoss" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SignificantOfAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementExpenses" xlink:type="locator" xlink:label="avro_LicenseAgreementExpenses" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePayment" xlink:type="locator" xlink:label="avro_MilestonePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PaymentsUponClosingOfInitialPublicOffering" xlink:type="locator" xlink:label="avro_PaymentsUponClosingOfInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseMaintenanceFees" xlink:type="locator" xlink:label="avro_LicenseMaintenanceFees" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestoneFees" xlink:type="locator" xlink:label="avro_MilestoneFees" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OptionFee" xlink:type="locator" xlink:label="avro_OptionFee" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CostOfMilestonePayment" xlink:type="locator" xlink:label="avro_CostOfMilestonePayment" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AgreementExpirationDescription" xlink:type="locator" xlink:label="avro_AgreementExpirationDescription" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AgreementExpirationPeriod" xlink:type="locator" xlink:label="avro_AgreementExpirationPeriod" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePaymentDue" xlink:type="locator" xlink:label="avro_MilestonePaymentDue" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePaymentPaid" xlink:type="locator" xlink:label="avro_MilestonePaymentPaid" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MilestonePayments" xlink:type="locator" xlink:label="avro_MilestonePayments" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UpfrontLicenseFees" xlink:type="locator" xlink:label="avro_UpfrontLicenseFees" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementLineItems" xlink:type="locator" xlink:label="avro_LicenseAgreementLineItems" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LundUniversityRightsHoldersAgreementMember" xlink:type="locator" xlink:label="avro_LundUniversityRightsHoldersAgreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_GenstemTherapeuticsIncMember" xlink:type="locator" xlink:label="avro_GenstemTherapeuticsIncMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_BioMarinPharmaceuticalIncMember" xlink:type="locator" xlink:label="avro_BioMarinPharmaceuticalIncMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_Interleukin12LicenseAgreementMember" xlink:type="locator" xlink:label="avro_Interleukin12LicenseAgreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_FabrylicenseagreementMember" xlink:type="locator" xlink:label="avro_FabrylicenseagreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UHNagreementMember" xlink:type="locator" xlink:label="avro_UHNagreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_MPSIILicenseAgreementMember" xlink:type="locator" xlink:label="avro_MPSIILicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UniversityOfManchesterAgreementMember" xlink:type="locator" xlink:label="avro_UniversityOfManchesterAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementTable" xlink:type="locator" xlink:label="avro_LicenseAgreementTable" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="avro_LicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementsAbstract" xlink:to="avro_LicenseAgreementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_UniversityOfManchesterAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_MPSIILicenseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_UHNagreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_FabrylicenseagreementMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_Interleukin12LicenseAgreementMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_BioMarinPharmaceuticalIncMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_GenstemTherapeuticsIncMember" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avro_LundUniversityRightsHoldersAgreementMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementTable" xlink:to="avro_LicenseAgreementLineItems" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_UpfrontLicenseFees" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePayments" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePaymentPaid" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePaymentDue" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_AgreementExpirationPeriod" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_AgreementExpirationDescription" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_CostOfMilestonePayment" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_OptionFee" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestoneFees" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_LicenseMaintenanceFees" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_PaymentsUponClosingOfInitialPublicOffering" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_MilestonePayment" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_LicenseAgreementLineItems" xlink:to="avro_LicenseAgreementExpenses" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="avro-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_FairValueInputAmountTransferBetweenLevels" xlink:type="locator" xlink:label="avro_FairValueInputAmountTransferBetweenLevels" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="avro_FairValueInputAmountTransferBetweenLevels" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PrepaidCompensationBenefits" xlink:type="locator" xlink:label="avro_PrepaidCompensationBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PrepaidResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="avro_PrepaidResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TaxIncentiveRefundCurrent" xlink:type="locator" xlink:label="avro_TaxIncentiveRefundCurrent" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:type="locator" xlink:label="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="avro_TaxIncentiveRefundCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="avro_PrepaidResearchAndDevelopmentCostsCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="avro_PrepaidCompensationBenefits" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:type="locator" xlink:label="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:type="locator" xlink:label="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_SupplementalBalanceSheetInformationDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail" xlink:href="avro-20201231.xsd#Role_DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="avro_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="avro_AccruedResearchAndDevelopmentExpenseCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AnnualLeasePaymentsDescription" xlink:type="locator" xlink:label="avro_AnnualLeasePaymentsDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLeaseAnnualIncreaseInRentalPercentage" xlink:type="locator" xlink:label="avro_OperatingLeaseAnnualIncreaseInRentalPercentage" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="avro_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="avro_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_RestrictedCashMember" xlink:type="locator" xlink:label="avro_RestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="avro_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="avro_CommitmentsAndContingenciesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="avro_RestrictedCashMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureTable" xlink:to="avro_CommitmentsAndContingenciesDisclosureLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_LeaseExpirationMonthAndYear" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_OperatingLeaseAnnualIncreaseInRentalPercentage" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SecurityDeposit" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="avro_AnnualLeasePaymentsDescription" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" xlink:type="locator" xlink:label="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCash" xlink:type="locator" xlink:label="us-gaap_DividendsCash" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UndesignatedSharesOfPreferredStockOutstanding" xlink:type="locator" xlink:label="avro_UndesignatedSharesOfPreferredStockOutstanding" />
    <link:loc xlink:href="avro-20201231.xsd#avro_UndesignatedPreferredStock" xlink:type="locator" xlink:label="avro_UndesignatedPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="avro-20201231.xsd#avro_NovemberTwoThousandTwentyFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_NovemberTwoThousandTwentyFollowOnOfferingMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="avro_AtTheMarketFacilityMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_JulyTwoThousandNineteenFollowOnOfferingMember" xlink:type="locator" xlink:label="avro_JulyTwoThousandNineteenFollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_JulyTwoThousandNineteenFollowOnOfferingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_FebruaryTwoThousandTwentyFollowOnOfferingMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_AtTheMarketFacilityMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avro_NovemberTwoThousandTwentyFollowOnOfferingMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avro_UndesignatedPreferredStock" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avro_UndesignatedSharesOfPreferredStockOutstanding" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCash" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:href="avro-20201231.xsd#Role_DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandTwentyInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandTwentyInducementPlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandNineteenInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandNineteenInducementPlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandNineteenInducementPlanMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandTwentyInducementPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_AdditionalResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="avro_AdditionalResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="avro-20201231.xsd#avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" xlink:type="locator" xlink:label="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandTwentyInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandTwentyInducementPlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandNineteenInducementPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandNineteenInducementPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TwoThousandFifteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="avro_TwoThousandFifteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandFifteenStockOptionAndGrantPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avro_TwoThousandEighteenStockOptionAndIncentivePlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandNineteenInducementPlanMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avro_TwoThousandTwentyInducementPlanMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avro_AdditionalResearchAndDevelopmentExpense" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" xlink:type="locator" xlink:label="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:href="avro-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_Disclosure401KSavingsPlanAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:type="locator" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:type="locator" xlink:label="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="avro-20201231.xsd#avro_TaxCreditCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="avro_TaxCreditCarryforwardsExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="avro-20201231.xsd#avro_PayrollTaxLiabilityCappedPerYear" xlink:type="locator" xlink:label="avro_PayrollTaxLiabilityCappedPerYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="avro-20201231.xsd#avro_IncomeTaxesLineItems" xlink:type="locator" xlink:label="avro_IncomeTaxesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2033Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2033Member" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OrphanDrugCreditMember" xlink:type="locator" xlink:label="avro_OrphanDrugCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2039Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2039Member" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ExpirationThrough2037Member" xlink:type="locator" xlink:label="avro_ExpirationThrough2037Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_IncomeTaxesTable" xlink:type="locator" xlink:label="avro_IncomeTaxesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="avro_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="avro_ExpirationThrough2037Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="avro_ExpirationThrough2039Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="avro_OrphanDrugCreditMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="avro_ExpirationThrough2033Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesTable" xlink:to="avro_IncomeTaxesLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_PayrollTaxLiabilityCappedPerYear" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_TaxCreditCarryforwardsExpirationPeriod" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avro_IncomeTaxesLineItems" xlink:to="avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="avro-20201231.xsd#avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" xlink:type="locator" xlink:label="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="avro_EffectiveIncomeTaxRateReconciliationPermanentDifference" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="avro-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredTaxAssetsLicenseAgreement" xlink:type="locator" xlink:label="avro_DeferredTaxAssetsLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="avro-20201231.xsd#avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" xlink:type="locator" xlink:label="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="avro_DeferredTaxAssetsLicenseAgreement" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:href="avro-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="avro-20201231.xsd#avro_RestrictedStockAwardsAndUnitsMember" xlink:type="locator" xlink:label="avro_RestrictedStockAwardsAndUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="avro_RestrictedStockAwardsAndUnitsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="avro-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="avro-20201231.xsd#avro_ProvisionForMaximumCashPayment" xlink:type="locator" xlink:label="avro_ProvisionForMaximumCashPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="avro-20201231.xsd#avro_SubleaseAgreementMember" xlink:type="locator" xlink:label="avro_SubleaseAgreementMember" />
    <link:loc xlink:href="avro-20201231.xsd#avro_OfficersAndBoardMembersMember" xlink:type="locator" xlink:label="avro_OfficersAndBoardMembersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_StockPurchaseAgreementMember" xlink:type="locator" xlink:label="avro_StockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="avro-20201231.xsd#avro_LicenseAgreementMember" xlink:type="locator" xlink:label="avro_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_LicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avro_StockPurchaseAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avro_OfficersAndBoardMembersMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avro_SubleaseAgreementMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avro_ProvisionForMaximumCashPayment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>avro-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avro="http://www.avrobio.com/20201231"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avro-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001681087_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="C_0001681087_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001681087_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UniversityOfManchesterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:MPSIILicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UniversityOfManchesterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:MPSIILicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-30</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:FabrylicenseagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-27</instant>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127_20160127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:FabrylicenseagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-27</startDate>
            <endDate>2016-01-27</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-27</startDate>
            <endDate>2016-01-27</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-27</instant>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:UHNagreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:Interleukin12LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170801_20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20171002_20171002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:GenstemTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-02</startDate>
            <endDate>2017-10-02</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:GenstemTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:GenstemTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20161117_20161117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:LundUniversityRightsHoldersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-17</startDate>
            <endDate>2016-11-17</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:LundUniversityRightsHoldersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avro:LundUniversityRightsHoldersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_20180112_20180112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2018-01-12</startDate>
            <endDate>2018-01-12</endDate>
        </period>
    </context>
    <context id="C_0001681087_20180112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2018-01-12</instant>
        </period>
    </context>
    <context id="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_20200609_20200609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2020-06-09</startDate>
            <endDate>2020-06-09</endDate>
        </period>
    </context>
    <context id="C_0001681087_20180831_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2018-08-31</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_20200609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2020-06-09</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">avro:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_20200601_20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="C_0001681087_20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:JulyTwoThousandNineteenFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:JulyTwoThousandNineteenFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:JulyTwoThousandNineteenFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:FebruaryTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:FebruaryTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:FebruaryTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200601_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:NovemberTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:NovemberTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avro:NovemberTwoThousandTwentyFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandNineteenInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandNineteenInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandTwentyInducementPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandTwentyInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandFifteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandFifteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-16</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avro:TwoThousandEighteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandNineteenInducementPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandNineteenInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandTwentyInducementPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avro:TwoThousandTwentyInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2037Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_avroOrphanDrugCreditMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">avro:OrphanDrugCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">avro:ExpirationThrough2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avro:RestrictedStockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avro:RestrictedStockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapAwardTypeAxis_avroStockPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20160127_20160127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avro:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-27</startDate>
            <endDate>2016-01-27</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20180701_20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avro:OfficersAndBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avro:OfficersAndBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avro:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_avroSegment">
        <measure>avro:Segment</measure>
    </unit>
    <unit id="U_iso4217GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U_iso4217CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001681087_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001681087_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001681087_20200101_20201231" id="F_000007">0001681087</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001681087_20200101_20201231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231"
      id="F_000278">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000279">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231"
      id="F_000280">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231"
      id="F_000281">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000282">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231"
      id="F_000283">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231"
      id="F_000284">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000285">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001681087_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231"
      id="F_000286">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <avro:OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered contextRef="C_0001681087_20200101_20201231" id="F_000564">P3Y</avro:OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001681087_20201231"
      id="F_000062"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001681087_20191231"
      id="F_000063"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001681087_20201231"
      id="F_000064"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001681087_20191231"
      id="F_000065"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000271">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000272">Lesser of lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001681087_20200101_20201231" id="F_000454">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001681087_20190101_20191231" id="F_000455">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001681087_20190101_20191231" id="F_000472">P8Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001681087_20200101_20201231" id="F_000473">P7Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001681087_20200101_20201231" id="F_000474">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dei:DocumentType contextRef="C_0001681087_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001681087_20200101_20201231" id="F_000029">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001681087_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001681087_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001681087_20200101_20201231" id="F_000030">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001681087_20200101_20201231" id="F_000019">001-38537</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001681087_20200101_20201231" id="F_000006">AVROBIO,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001681087_20200101_20201231" id="F_000031">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001681087_20200101_20201231" id="F_000020">81-0710585</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001681087_20200101_20201231" id="F_000021">One Kendall Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001681087_20200101_20201231" id="F_000022">Building 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="C_0001681087_20200101_20201231" id="F_000023">Suite 201</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="C_0001681087_20200101_20201231" id="F_000024">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001681087_20200101_20201231" id="F_000025">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001681087_20200101_20201231" id="F_000026">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001681087_20200101_20201231" id="F_000027">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001681087_20200101_20201231" id="F_000028">914-8420</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001681087_20200101_20201231" id="F_000033">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001681087_20200101_20201231" id="F_000005">AVRO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001681087_20200101_20201231" id="F_000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001681087_20200101_20201231" id="F_000015">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001681087_20200101_20201231" id="F_000017">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001681087_20200101_20201231" id="F_000016">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001681087_20200101_20201231" id="F_000032">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001681087_20200101_20201231" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001681087_20200101_20201231" id="F_000014">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001681087_20200101_20201231" id="F_000012">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001681087_20200101_20201231" id="F_000013">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001681087_20200101_20201231" id="F_000035">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001681087_20200101_20201231" id="F_000018">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001681087_20200630"
      decimals="0"
      id="F_000011"
      unitRef="U_iso4217USD">533953963</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001681087_20210309"
      decimals="INF"
      id="F_000010"
      unitRef="U_xbrlishares">41622060</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000212">
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#x2019;s definitive Proxy Statement for its 2021 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year end of December&#160;31, 2020. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K. &lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">259682000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">187043000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">7560000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">8658000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">267242000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">195701000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">3064000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">3696000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">492000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">492000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">436000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">625000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">271234000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">200514000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">2682000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">3949000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">13693000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">9854000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">239000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">214000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">16614000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">14017000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">276000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">484000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">16890000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">14501000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000076"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000077"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000084"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000085"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">41569000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">31673000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">41569000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">31643000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">518756000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">330714000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">-264416000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">-144704000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">254344000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">186013000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">271234000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">200514000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">87236000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">54974000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">32992000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">20835000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">120228000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">75809000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">-120228000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">-75809000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">719000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">2934000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">203000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">90000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">516000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">2844000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">-119712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-72965000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-119712000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">-72965000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000110"
      unitRef="U_iso4217USD_xbrlishares">-3.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001681087_20190101_20191231"
      decimals="2"
      id="F_000111"
      unitRef="U_iso4217USD_xbrlishares">-2.66</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_xbrlishares">36206000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000113"
      unitRef="U_xbrlishares">27432000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000114"
      unitRef="U_xbrlishares">23807000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">193921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-71739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_20181231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">122184000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000119"
      unitRef="U_xbrlishares">123000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000120"
      unitRef="U_xbrlishares">236000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">502000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">502000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">525000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231"
      decimals="-3"
      id="F_000123"
      unitRef="U_xbrlishares">7475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">129464000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">129465000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000127"
      unitRef="U_xbrlishares">2000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">27000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">27000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">6800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">6800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-72965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">-72965000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000134"
      unitRef="U_xbrlishares">31643000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">330714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">-144704000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">186013000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000139"
      unitRef="U_xbrlishares">31000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_xbrlishares">148000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">270000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">270000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">697000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000143"
      unitRef="U_xbrlishares">9350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">163848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">163849000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">67000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231"
      decimals="-3"
      id="F_000147"
      unitRef="U_xbrlishares">384000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">8130000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">8130000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000150"
      unitRef="U_xbrlishares">13000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">166000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">166000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">15628000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">15628000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">-119712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-119712000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_xbrlishares">41569000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">518756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">-264416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">254344000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">-119712000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">-72965000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">15628000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">6800000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">1207000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">850000</us-gaap:DepreciationDepletionAndAmortization>
    <avro:DeferredRentExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-183000</avro:DeferredRentExpense>
    <avro:DeferredRentExpense
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-172000</avro:DeferredRentExpense>
    <avro:OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">20000</avro:OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-1098000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">4888000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">-84000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">241000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-881000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">1028000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">3936000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">1920000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">-98803000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">-67668000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">1177000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">1585000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-1177000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-1585000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">164053000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">129465000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">8130000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">270000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">502000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">166000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">27000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">172619000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">129994000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">72639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">60741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">187535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001681087_20181231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">126794000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">260174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">187535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">582000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <avro:CommonStockOfferingCostsIncurredButNotYetPaid
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">205000</avro:CommonStockOfferingCostsIncurredButNotYetPaid>
    <avro:CommonStockOfferingCostsIncurredButNotYetPaid
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">104000</avro:CommonStockOfferingCostsIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">259682000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">187043000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">492000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">492000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">260174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">187535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="C_0001681087_20200101_20201231" id="F_000213">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of the Business &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AVROBIO, Inc. (the &#x201c;Company&#x201d; or &#x201c;AVROBIO&#x201d;) is a clinical-stage gene therapy company focused on developing potentially curative &lt;span style="font-style:italic;"&gt;ex vivo&lt;/span&gt; lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; &lt;span style="font-size:12pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt; &lt;span style="font-size:12pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt; &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has devoted substantially all of its efforts to research and development, business planning, acquiring operating assets, seeking protection for its technology and product candidates, and raising capital. Since inception, the Company has funded its operations through sales of preferred stock and common stock. As of December 31, 2020, the Company had an accumulated deficit of $264,416. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash and cash equivalents on hand as of December&#160;31, 2020 of $259,682 will be sufficient to fund current planned operations and capital expenditure requirements for at least the next twelve months from the filing date of this Annual Report on Form&#160;10-K with the SEC. However, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.  &lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">-264416000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">259682000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000214">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of AVROBIO, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#x2019;s chief operating decision maker is the chief executive officer (&#x201c;CEO&#x201d;). The Company and the CEO view the Company&#x2019;s operations and manage its business as one operating segment. All material long-lived assets of the Company reside in the United States.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash totaling $492 as of December 31, 2019 has been reclassified from &#x201c;Other assets&#x201d; to &#x201c;Restricted cash&#x201d; in order to conform to the current period presentation. Additionally, the Company has reclassified $214 which was previously classified as &#x201c;Accrued expenses and other current liabilities&#x201d; as of December 31, 20219 to &#x201c;Deferred rent&#x201d; in order to &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;conform to the current period presentation. These reclassifications had no effect on the consolidated results of operation or cash flows for the year ended December 31, 2019. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities&lt;span style="color:#000000;"&gt; at the date of the financial statements and the reported amounts of expenses during the reporting periods&lt;/span&gt;. On an on&#x2011;going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less at acquisition to be cash equivalents. As of December 31, 2020 and 2019,&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;cash and cash equivalents were primarily held in interest-bearing money market funds. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Issuance Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; As of December&#160;31, 2019, the Company recorded deferred issuance costs of $133 within other assets on the consolidated balance sheet related to a follow-on offering of common stock completed in February 2020. There were&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;no amounts deferred as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.64%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 1&#x2014;&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.64%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.64%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, which include cash equivalents, accounts payable, and accrued expenses, approximated their fair values as of December&#160;31, 2020 and 2019 due to the short&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2011;term nature of these instruments.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the estimated fair value of financial instruments using available market information. The use of different market assumptions, estimation methodologies, or both, could have a significant effect on the estimated fair value amounts. See Note 4&lt;span style="font-style:italic;"&gt; &#x201c;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;Fair Value of Financial Assets and Liabilities&#x201d;&lt;/span&gt;&lt;span style="font-style:italic;"&gt; &lt;/span&gt;for further discussion.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost. Depreciation and amortization is calculated using the straight-line method over the following estimated useful lives of the assets: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000271"&gt;Lesser of lease term or 10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. &lt;span style="color:#000000;"&gt;The Company did not record any impairment loss during the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company categorizes leases at their inception as either operating or capital leases. On certain lease arrangements, the Company may receive rent holidays or other incentives. The Company recognizes lease costs on a straight-line basis once control of the space is achieved, without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments or escalating payment amounts. The difference between required lease payments and rent expense has been recorded as deferred rent and accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Additionally, incentives received are treated as a reduction of costs over the term of the agreement, as they are considered an inseparable part of the lease agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) is defined as the change in stockholders&#x2019; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) as well as other changes in stockholders&#x2019; equity (deficit) which includes certain changes in equity that are excluded from net income (loss). Comprehensive loss has been disclosed in the accompanying consolidated statements of operations and comprehensive loss and equals the Company&#x2019;s net loss for all periods presented. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company&#x2019;s international operations in Canada and Australia is the U.S. dollar. Accordingly, all operating assets and liabilities of these international subsidiaries are remeasured into U.S. dollars using the exchange rates in effect at the balance sheet date or historical rates, as appropriate, while expenses are remeasured into U.S. dollars at the average rates in effect during the period. Any differences resulting from the remeasurement of assets, liabilities, and operations of the Canadian and Australian subsidiaries are recorded within other income (expense), net in the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated statements of operations and comprehensive loss. During the years ended December&#160;31, 2020 and 2019, the Company recorded foreign exchange losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively, in other expense.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development related contracts with parties both inside and outside of the United States. The payments related to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. &lt;span style="color:#000000;"&gt;Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For stock-based awards issued to employees and members of the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions. The Company accounts for forfeitures as they occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2018-07,&#160;&lt;span style="font-style:italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt;, the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the Company&#x2019;s adoption of ASU 2018-07 in 2018, the measurement date for non-employee awards is the later of the adoption date of ASU 2018-07, or the date of grant, without change in the fair value of the award. For stock-based awards granted to nonemployees subject to graded vesting that only contain service conditions, the Company has elected to recognize stock-based compensation expense using the straight-line recognition method.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s cash compensation costs are classified. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Given the absence of an active market for the Company&#x2019;s common stock prior to its initial public offering (&#x201c;IPO&#x201d;), the Company and the Board, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#x2019;s common stock at the time of each grant of a stock-based award. The Company and the Board determined the estimated fair value of the Company&#x2019;s equity instruments based on a number of factors, including external market conditions affecting the biotechnology industry sector. The Company and the Board utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, &lt;span style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/span&gt;, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors in determining the value of the Company&#x2019;s common stock at each grant date, including: (1)&#160;prices paid for the Company&#x2019;s redeemable convertible preferred stock, which the Company had sold to outside investors in arm&#x2019;s-length transactions, and the rights, preferences, and privileges of the Company&#x2019;s redeemable convertible preferred stock and common stock; (2)&#160;valuations performed by an independent valuation specialist; (3)&#160;the Company&#x2019;s stage of development; (4)&#160;the fact that the grants of stock-based awards involved illiquid securities in a private company; and (5)&#160;the likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as an IPO or sale of the Company, given prevailing market conditions. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. As there was no public market for its common stock prior to June&#160;21, 2018, which was the first day of trading, and as the trading history of the Company&#x2019;s common stock was limited through December&#160;31, 2020, the Company determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by adjusting the weighted-average shares outstanding for the potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For purposes of the diluted net loss per share calculation, stock options and restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Subsequent Event Considerations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#x201c;emerging growth company.&#x201d; Section&#160;107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an &#x201c;emerging growth company.&#x201d; &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No.&#160;2018-18, &lt;span style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;, or ASU 2018-18. The amendments in ASU 2018-18 clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU 2018-18 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606. The Company adopted ASU 2018-18 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-15, &lt;span style="font-style:italic;"&gt;Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), &lt;/span&gt;or ASU 2018-15.&#160;ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;, or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure requirements for fair value measurements. The amendments are effective for interim and annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted for either the entire ASU or only the provisions that eliminate or modify requirements. The amendments with respect to changes in unrealized gains and losses, the range and weighted-average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively. All other amendments are to be applied retrospectively to all periods presented. The Company adopted ASU 2018-13 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&#160;2016-02, &lt;span style="font-style:italic;"&gt;(Topic 842) Leases, &lt;/span&gt;or ASU 2016-02.&#160;ASU 2016-02&#160;requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. For public entities,&#160;ASU 2016-02&#160;is effective for fiscal years beginning after December&#160;15, 2018. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;ASU 2016-02&#160;is effective for the Company for the year ended December 31, 2022, and all interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. Based on this evaluation t&lt;span style="color:#000000;"&gt;he Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the Company&#x2019;s total assets and total liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;, or ASU 2016-13. ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity's current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.&lt;span style="color:#000000;"&gt; &lt;/span&gt;ASU 2016-13 is effective for non-emerging growth companies (&#x201c;EGCs&#x201d;) for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2016-13 may have on its financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;span style="font-size:8pt;"&gt;&#160;&lt;/span&gt;November 2019, the FASB issued ASU 2019-11, &#x201c;&lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&#x201d;, or ASU 2019-11. ASU 2019-11 is an accounting pronouncement that amends ASU 2016-13, &#x201c;&lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;.&#x201d; The amendments update guidance on reporting credit losses for financial assets. These amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in both ASU 2016-13 and ASU 2019-11 are &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. &lt;/span&gt;&lt;span style="color:#000000;"&gt;As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;2016-13 and ASU 2019-11&#160;are effective for the Company for fiscal years beginning after December 15, 202&lt;/span&gt;&lt;span style="color:#000000;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;"&gt;, and interim periods within &lt;/span&gt;&lt;span style="color:#000000;"&gt;those &lt;/span&gt;&lt;span style="color:#000000;"&gt;fiscal years. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is currently evaluating ASU 2016-13 and ASU 2019-11 and their impact on its consolidated financial statements and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;, or ASU 2019-12. ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for non-EGCs for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years and will be effective for the Company for fiscal years beginning after December 15, 2021 and interim periods beginning after December 15, 2022, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2019-12 may have on its financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000225">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000226">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of AVROBIO, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000227">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#x2019;s chief operating decision maker is the chief executive officer (&#x201c;CEO&#x201d;). The Company and the CEO view the Company&#x2019;s operations and manage its business as one operating segment. All material long-lived assets of the Company reside in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000264"
      unitRef="U_avroSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="C_0001681087_20200101_20201231" id="F_000228">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash totaling $492 as of December 31, 2019 has been reclassified from &#x201c;Other assets&#x201d; to &#x201c;Restricted cash&#x201d; in order to conform to the current period presentation. Additionally, the Company has reclassified $214 which was previously classified as &#x201c;Accrued expenses and other current liabilities&#x201d; as of December 31, 20219 to &#x201c;Deferred rent&#x201d; in order to &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;conform to the current period presentation. These reclassifications had no effect on the consolidated results of operation or cash flows for the year ended December 31, 2019. &lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">492000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredRentCredit
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">214000</us-gaap:DeferredRentCredit>
    <us-gaap:UseOfEstimates contextRef="C_0001681087_20200101_20201231" id="F_000229">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities&lt;span style="color:#000000;"&gt; at the date of the financial statements and the reported amounts of expenses during the reporting periods&lt;/span&gt;. On an on&#x2011;going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000230">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less at acquisition to be cash equivalents. As of December 31, 2020 and 2019,&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;cash and cash equivalents were primarily held in interest-bearing money market funds. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001681087_20200101_20201231" id="F_000231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000232">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Issuance Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; As of December&#160;31, 2019, the Company recorded deferred issuance costs of $133 within other assets on the consolidated balance sheet related to a follow-on offering of common stock completed in February 2020. There were&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;no amounts deferred as of December 31, 2020.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">133000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000267"
      unitRef="U_iso4217USD">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000233">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.64%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 1&#x2014;&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.64%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.64%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, which include cash equivalents, accounts payable, and accrued expenses, approximated their fair values as of December&#160;31, 2020 and 2019 due to the short&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2011;term nature of these instruments.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the estimated fair value of financial instruments using available market information. The use of different market assumptions, estimation methodologies, or both, could have a significant effect on the estimated fair value amounts. See Note 4&lt;span style="font-style:italic;"&gt; &#x201c;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;Fair Value of Financial Assets and Liabilities&#x201d;&lt;/span&gt;&lt;span style="font-style:italic;"&gt; &lt;/span&gt;for further discussion.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000234">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost. Depreciation and amortization is calculated using the straight-line method over the following estimated useful lives of the assets: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000271"&gt;Lesser of lease term or 10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <avro:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000247">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost. Depreciation and amortization is calculated using the straight-line method over the following estimated useful lives of the assets: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000271"&gt;Lesser of lease term or 10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</avro:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231"
      id="F_000269">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231"
      id="F_000270">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000235">
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. &lt;span style="color:#000000;"&gt;The Company did not record any impairment loss during the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000273"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001681087_20190101_20191231"
      decimals="INF"
      id="F_000274"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000236">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company categorizes leases at their inception as either operating or capital leases. On certain lease arrangements, the Company may receive rent holidays or other incentives. The Company recognizes lease costs on a straight-line basis once control of the space is achieved, without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments or escalating payment amounts. The difference between required lease payments and rent expense has been recorded as deferred rent and accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Additionally, incentives received are treated as a reduction of costs over the term of the agreement, as they are considered an inseparable part of the lease agreement.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000237">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) is defined as the change in stockholders&#x2019; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) as well as other changes in stockholders&#x2019; equity (deficit) which includes certain changes in equity that are excluded from net income (loss). Comprehensive loss has been disclosed in the accompanying consolidated statements of operations and comprehensive loss and equals the Company&#x2019;s net loss for all periods presented. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000238">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company&#x2019;s international operations in Canada and Australia is the U.S. dollar. Accordingly, all operating assets and liabilities of these international subsidiaries are remeasured into U.S. dollars using the exchange rates in effect at the balance sheet date or historical rates, as appropriate, while expenses are remeasured into U.S. dollars at the average rates in effect during the period. Any differences resulting from the remeasurement of assets, liabilities, and operations of the Canadian and Australian subsidiaries are recorded within other income (expense), net in the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated statements of operations and comprehensive loss. During the years ended December&#160;31, 2020 and 2019, the Company recorded foreign exchange losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively, in other expense.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <avro:ForeignExchangeLoss
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">203000</avro:ForeignExchangeLoss>
    <avro:ForeignExchangeLoss
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">90000</avro:ForeignExchangeLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001681087_20200101_20201231" id="F_000239">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development related contracts with parties both inside and outside of the United States. The payments related to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. &lt;span style="color:#000000;"&gt;Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt; &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000240">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For stock-based awards issued to employees and members of the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions. The Company accounts for forfeitures as they occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2018-07,&#160;&lt;span style="font-style:italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt;, the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the Company&#x2019;s adoption of ASU 2018-07 in 2018, the measurement date for non-employee awards is the later of the adoption date of ASU 2018-07, or the date of grant, without change in the fair value of the award. For stock-based awards granted to nonemployees subject to graded vesting that only contain service conditions, the Company has elected to recognize stock-based compensation expense using the straight-line recognition method.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s cash compensation costs are classified. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Given the absence of an active market for the Company&#x2019;s common stock prior to its initial public offering (&#x201c;IPO&#x201d;), the Company and the Board, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#x2019;s common stock at the time of each grant of a stock-based award. The Company and the Board determined the estimated fair value of the Company&#x2019;s equity instruments based on a number of factors, including external market conditions affecting the biotechnology industry sector. The Company and the Board utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, &lt;span style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/span&gt;, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors in determining the value of the Company&#x2019;s common stock at each grant date, including: (1)&#160;prices paid for the Company&#x2019;s redeemable convertible preferred stock, which the Company had sold to outside investors in arm&#x2019;s-length transactions, and the rights, preferences, and privileges of the Company&#x2019;s redeemable convertible preferred stock and common stock; (2)&#160;valuations performed by an independent valuation specialist; (3)&#160;the Company&#x2019;s stage of development; (4)&#160;the fact that the grants of stock-based awards involved illiquid securities in a private company; and (5)&#160;the likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as an IPO or sale of the Company, given prevailing market conditions. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. As there was no public market for its common stock prior to June&#160;21, 2018, which was the first day of trading, and as the trading history of the Company&#x2019;s common stock was limited through December&#160;31, 2020, the Company determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_0001681087_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20201231"
      decimals="INF"
      id="F_000277"
      unitRef="U_iso4217USD">0</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000241">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000242">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by adjusting the weighted-average shares outstanding for the potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For purposes of the diluted net loss per share calculation, stock options and restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000243">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Subsequent Event Considerations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <avro:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000244">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#x201c;emerging growth company.&#x201d; Section&#160;107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an &#x201c;emerging growth company.&#x201d; &lt;/p&gt;
</avro:EmergingGrowthCompanyStatusPolicyTextBlock>
    <avro:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000245">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No.&#160;2018-18, &lt;span style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;, or ASU 2018-18. The amendments in ASU 2018-18 clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU 2018-18 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606. The Company adopted ASU 2018-18 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-15, &lt;span style="font-style:italic;"&gt;Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), &lt;/span&gt;or ASU 2018-15.&#160;ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;, or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure requirements for fair value measurements. The amendments are effective for interim and annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted for either the entire ASU or only the provisions that eliminate or modify requirements. The amendments with respect to changes in unrealized gains and losses, the range and weighted-average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively. All other amendments are to be applied retrospectively to all periods presented. The Company adopted ASU 2018-13 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. &lt;/p&gt;</avro:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000246">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&#160;2016-02, &lt;span style="font-style:italic;"&gt;(Topic 842) Leases, &lt;/span&gt;or ASU 2016-02.&#160;ASU 2016-02&#160;requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. For public entities,&#160;ASU 2016-02&#160;is effective for fiscal years beginning after December&#160;15, 2018. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;ASU 2016-02&#160;is effective for the Company for the year ended December 31, 2022, and all interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. Based on this evaluation t&lt;span style="color:#000000;"&gt;he Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the Company&#x2019;s total assets and total liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;, or ASU 2016-13. ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity's current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.&lt;span style="color:#000000;"&gt; &lt;/span&gt;ASU 2016-13 is effective for non-emerging growth companies (&#x201c;EGCs&#x201d;) for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2016-13 may have on its financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;span style="font-size:8pt;"&gt;&#160;&lt;/span&gt;November 2019, the FASB issued ASU 2019-11, &#x201c;&lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&#x201d;, or ASU 2019-11. ASU 2019-11 is an accounting pronouncement that amends ASU 2016-13, &#x201c;&lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;.&#x201d; The amendments update guidance on reporting credit losses for financial assets. These amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in both ASU 2016-13 and ASU 2019-11 are &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. &lt;/span&gt;&lt;span style="color:#000000;"&gt;As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;2016-13 and ASU 2019-11&#160;are effective for the Company for fiscal years beginning after December 15, 202&lt;/span&gt;&lt;span style="color:#000000;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;"&gt;, and interim periods within &lt;/span&gt;&lt;span style="color:#000000;"&gt;those &lt;/span&gt;&lt;span style="color:#000000;"&gt;fiscal years. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is currently evaluating ASU 2016-13 and ASU 2019-11 and their impact on its consolidated financial statements and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;, or ASU 2019-12. ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for non-EGCs for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years and will be effective for the Company for fiscal years beginning after December 15, 2021 and interim periods beginning after December 15, 2022, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2019-12 may have on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avro:LicenseAgreementDisclosureTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000215">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. License Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreement with The University of Manchester&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 30, 2020, the Company entered into an agreement (&#x201c;MPSII License Agreement&#x201d;) with The University of Manchester, England (&#x201c;UoM&#x201d;), whereby UoM granted to the Company &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;an exclusive worldwide license under certain patent and other intellectual property rights, subject to certain retained rights, to develop, commercialize and sell an&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;ex vivo&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;&#160;lentiviral gene therapy for use in the treatment of Hunter syndrome, or mucopolysaccharidosis type II (&#x201c;MPSII&#x201d;)&lt;/span&gt;.&#160;&#160;As consideration for the MPSII License Agreement, the Company agreed to pay UoM an upfront, one-time fee of $8,000, which was recognized as research and development expense during the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the agreement, the Company is obligated to make milestone payments of up to an aggregate of $80,000 upon the achievement of specified development and regulatory milestones, to pay royalties, on a product-by-product and country-by-country basis, of a mid-single digit percentage based on net sales of products licensed under the agreement and to pay a low double digit percentage of any sublicense fees received by the Company. The next anticipated payment milestones under the MPSII License Agreement include $2,000, which would become due following the date of regulatory approval of the clinical trial application for the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM, and $4,000, upon the dosing of the first patient in the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless terminated earlier, the agreement &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;expires upon the later of 15 years from the effective date or the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations.&lt;/span&gt;&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;UoM and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. UoM has the right to terminate the agreement in the event of certain actions relating to challenge or opposition to the licensed intellectual property brought by the Company or its affiliates or sublicensees.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concurrently with the MPSII License Agreement, the Company entered into a collaborative research funding agreement with UoM (&#x201c;CRFA&#x201d;). Under the CRFA, the Company has agreed to fund the budgeted costs of an investigator-sponsored Phase 1/2 clinical trial to be sponsored by UoM in connection with the development activities under the MPSII License Agreement, which are currently estimated to equal approximately&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; &#xa3;9,100 in the aggregate&lt;/span&gt;.&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020, the Company recognized $565 of costs related to the CRFA.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreements with University Health Network (&#x201c;UHN&#x201d;) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fabry License Agreement&#x2014; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&#160;27, 2016, the Company entered into an agreement with UHN, pursuant to which UHN granted the Company an option to enter into an exclusive license under the UHN intellectual property related to Fabry disease in accordance with the pre-negotiated licensing terms. On November&#160;4, 2016, the Company exercised its option and entered into a license agreement with UHN, pursuant to which UHN granted the Company an exclusive worldwide license under certain intellectual property rights and a non-exclusive worldwide license under certain know-how, in each case subject to certain retained rights, to develop, commercialize and sell products for use in the treatment of Fabry disease. In addition, for three years following the execution of the agreement, UHN granted the Company an exclusive option to obtain a license under &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;certain improvements to the licensed intellectual property rights as well as an option to negotiate a license under certain other improvements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under this agreement, the Company paid an option fee of CAD $20, an upfront license fee of CAD $75, plus the annual license maintenance fee for the first year. Thereafter, the Company is also required to pay UHN future annual license maintenance fees until the first sale of a licensed product in certain markets. The Company is also obligated to make future milestone payments in an aggregate amount of up to CAD $2,450 upon the achievement of specified milestones as well as royalties on a country-by-country basis of a low to mid-single-digit percentage of annual net sales of licensed products and a lower single-digit royalty percentage in certain circumstances. Additionally, the Company has agreed to pay a low double-digit royalty percentage of all sublicensing revenue. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The agreement requires the Company to meet certain performance milestones within specified timeframes. UHN may terminate the agreement if the Company fails to meet these performance milestones despite using commercially reasonable efforts and the Company is unable to reach agreement with UHN on revised timeframes. The Company&#x2019;s royalty obligation expires on a licensed product-by-licensed product and country-by-country basis upon the latest to occur of the expiration or termination of the last valid claim under the licensed intellectual property rights in such country, the tenth anniversary of the first commercial sale of such licensed product in such country and the expiration of any applicable regulatory exclusivity in such country. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless terminated earlier, the agreement expires upon the expiration of the Company&#x2019;s royalty obligation for all licensed products. UHN can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event that the Company fails to obtain or maintain insurance. Either the Company or UHN may terminate the license agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company can voluntarily terminate the agreement with prior notice to UHN. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2020 and 2019, the Company recorded research and development expense related to this agreement with UHN of $344 and $783, respectively, which consists of reimbursable funded study trial costs and license maintenance fees. No milestone fees were incurred related to the Fabry license agreement in the years ended December 31, 2020 and 2019.&lt;span style="font-size:12pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Interleukin 12 License Agreement&#x2014; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&#160;27, 2016, the Company entered into an exclusive license agreement with UHN, pursuant to which UHN granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights related to Interleukin 12. Upon execution of this agreement, the Company paid an upfront license fee of CAD&#160;$264. In addition, as part of the initial consideration for the license, the Company issued to UHN 1,161,665 shares of the Company&#x2019;s common stock and&lt;span style="color:#000000;"&gt; agreed to pay UHN up to $2,000 upon the closing of an IPO if certain criteria are met&lt;/span&gt;. The fair value of the shares issued to UHN of $480 and the upfront fee was expensed upon the execution of the agreement. Upon the closing of the IPO in 2018, as the criteria were met, the Company paid UHN $2,000.&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;The Company is also required to pay UHN future annual license maintenance fees of CAD $50 on each anniversary of the effective date of the license agreement prior to expiration or termination and potential future milestone payments of up to CAD $19,275 upon the achievement of specified clinical and regulatory milestones. The Company also agreed to pay UHN royalties of a low single-digit percentage of net sales of licensed products sold by the Company. If the Company grants any sublicense rights under the license agreement, the Company has agreed to pay UHN a low double-digit royalty percentage of any sublicense income received by the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The agreement requires the Company to meet certain diligence requirements based upon specified milestones. The agreement expires on the later of the date the last patent rights expire in the last country or ten years from the date of first sale. UHN can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event that the Company fails to obtain or maintain insurance. The Company can voluntarily terminate the agreement with prior notice to UHN. Either the Company or UHN may terminate the license agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2020 and 2019, the Company recorded research and development expense related to this agreement with UHN of $37 and $38, respectively, which consists of license maintenance fees. No milestone fees were incurred related to the Interleukin 12 license agreement in the years ended December 31, 2020 and 2019.&lt;span style="font-size:12pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreement with BioMarin Pharmaceutical Inc. (&#x201c;BioMarin&#x201d;) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&#160;31, 2017, the Company entered into a license agreement with BioMarin, pursuant to which BioMarin granted the Company an exclusive worldwide license under certain intellectual property rights owned or controlled by BioMarin to develop, commercialize and sell products for use in the treatment of Pompe disease. The license agreement was amended in February 2018 and again in January 2020 to, among things, provide that BioMarin would supply the Company with certain technology materials. As consideration for this agreement, the Company paid an upfront license fee of $500 in cash and issued 233,765 shares of Series B Preferred Stock to BioMarin at the time of the Company&#x2019;s Series B Preferred Stock financing in January 2018. The Company is also obligated to make future milestone payments of up to $13,000 upon the achievement of certain specified milestones and agreed to pay BioMarin royalties of a low single-digit percentage of net sales of licensed products sold by the Company or its affiliates covered by patent rights in a relevant country. No expenses related to the license were recorded for the years ended December&#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless terminated earlier, the agreement expires upon the expiration of the Company&#x2019;s royalty obligation for all licensed products throughout the world. BioMarin and the Company can terminate the agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company may terminate the agreement at will upon written notice to BioMarin. BioMarin has the right to terminate the agreement upon the Company&#x2019;s bankruptcy or insolvency, or in the event of any challenge or opposition to the licensed patent rights or related actions brought by the Company or its affiliates or sublicensees, or if the Company, its affiliates or sublicensees knowingly assist a third-party in challenging or otherwise opposing the licensed patent rights, except as required under a court order or subpoena. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreement with GenStem Therapeutics, Inc. (&#x201c;GenStem&#x201d;) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&#160;2, 2017, the Company entered into a license agreement with GenStem, pursuant to which GenStem granted the Company an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights owned or controlled by GenStem to develop, commercialize and sell products for use in the treatment of cystinosis. Under this agreement, the Company paid an upfront license fee of $1,000 and is required to make payments upon completion of certain milestones up to an aggregate of $16,000. The Company also agreed to pay GenStem a tiered mid to high single-digit royalty percentage on annual net sales of licensed products as well as a low double-digit percentage of sublicense income received from certain third-party licensees. The Company&#x2019;s royalty obligation expires on a licensed product-by-licensed product and country-by-country basis on the eleventh anniversary of the first commercial sale of such licensed product in such country or the expiration of the last valid claim under the licensed patent rights covering such licensed product in such country, whichever is later. Unless terminated earlier, the agreement expires upon the expiration of the Company&#x2019;s royalty obligation for all licensed products throughout the world. GenStem and the Company can terminate the agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company may terminate the agreement at will upon the specified prior written notice to GenStem. &#160;&#160;&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December&#160;31, 2020 the Company recorded&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;no research and development expense related to milestone payments. For the year ended December&#160;31, 2019 the Company recorded $2,000 related to milestone payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreement with Lund University Rights Holders &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November&#160;17, 2016, the Company entered into a license agreement with affiliates of Lund University, along with certain other relevant rights holders that may be added from time to time, pursuant to which such rights holders granted to the Company an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights to develop, commercialize and sell products in any and all uses relevant to Gaucher disease. As consideration for the license, the Company is required to make payments in connection with the achievement of certain milestones up to an aggregate of $550. The agreement expires on the latest of (i)&#160;the twentieth anniversary of the end of a certain research project the Company is funding pursuant to an agreement with Lund University, (ii)&#160;the expiration of the term of any patent filed on the licensed rights that covers a licensed product, (iii)&#160;the expiration of any applicable marketing exclusivity right and (iv)&#160;such time that neither the Company nor any sublicensees, partners or contractors are commercializing a licensed product. Either the Company or the rights holders acting together may terminate the license agreement if the other such party commits a material breach and fails to cure such breach within a certain period of time, or if the other party enters into liquidation, becomes insolvent, or enters into composition or statutory reorganization proceedings. No expenses related to the license were recorded for the years ended December&#160;31, 2020 and 2019. &lt;/p&gt;
</avro:LicenseAgreementDisclosureTextBlock>
    <avro:UpfrontLicenseFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">8000000</avro:UpfrontLicenseFees>
    <avro:MilestonePayments
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">80000000</avro:MilestonePayments>
    <avro:MilestonePaymentPaid
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">2000000</avro:MilestonePaymentPaid>
    <avro:MilestonePaymentDue
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">4000000</avro:MilestonePaymentDue>
    <avro:AgreementExpirationDescription
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231"
      id="F_000292">upon the later of 15 years from the effective date or the expiration of the last valid claim of the licensed patents</avro:AgreementExpirationDescription>
    <avro:AgreementExpirationPeriod
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200101_20201231"
      id="F_000291">P15Y</avro:AgreementExpirationPeriod>
    <avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUniversityOfManchesterAgreementMember_us-gaapTypeOfArrangementAxis_avroMPSIILicenseAgreementMember_20200930_20200930"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217GBP">9100000</avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense>
    <avro:CostOfMilestonePayment
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">565000</avro:CostOfMilestonePayment>
    <avro:OptionFee
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217CAD">20000</avro:OptionFee>
    <avro:UpfrontLicenseFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127_20160127"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217CAD">75000</avro:UpfrontLicenseFees>
    <avro:MilestonePayments
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroFabrylicenseagreementMember_20160127_20160127"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217CAD">2450000</avro:MilestonePayments>
    <avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20200101_20201231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">344000</avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense>
    <avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20190101_20191231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">783000</avro:ClinicalTrialCostRelatedToResearchAndDevelopmentExpense>
    <avro:MilestoneFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20200101_20201231"
      decimals="INF"
      id="F_000298"
      unitRef="U_iso4217USD">0</avro:MilestoneFees>
    <avro:MilestoneFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_20190101_20191231"
      decimals="INF"
      id="F_000299"
      unitRef="U_iso4217USD">0</avro:MilestoneFees>
    <avro:UpfrontLicenseFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217CAD">264000</avro:UpfrontLicenseFees>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127"
      decimals="INF"
      id="F_000305"
      unitRef="U_xbrlishares">1161665</us-gaap:CommonStockSharesIssued>
    <avro:PaymentsUponClosingOfInitialPublicOffering
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127"
      decimals="INF"
      id="F_000307"
      unitRef="U_iso4217USD">2000000</avro:PaymentsUponClosingOfInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">480000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avro:PaymentsUponClosingOfInitialPublicOffering
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">2000000</avro:PaymentsUponClosingOfInitialPublicOffering>
    <avro:LicenseMaintenanceFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217CAD">50000</avro:LicenseMaintenanceFees>
    <avro:MilestonePayments
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20160127_20160127"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217CAD">19275000</avro:MilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">37000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">38000</us-gaap:ResearchAndDevelopmentExpense>
    <avro:MilestoneFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000311"
      unitRef="U_iso4217USD">0</avro:MilestoneFees>
    <avro:MilestoneFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroUHNagreementMember_us-gaapTypeOfArrangementAxis_avroInterleukin12LicenseAgreementMember_20190101_20191231"
      decimals="INF"
      id="F_000312"
      unitRef="U_iso4217USD">0</avro:MilestoneFees>
    <avro:UpfrontLicenseFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170801_20170831"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">500000</avro:UpfrontLicenseFees>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20170831"
      decimals="INF"
      id="F_000314"
      unitRef="U_xbrlishares">233765</us-gaap:PreferredStockSharesIssued>
    <avro:MilestonePayment
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20200101_20201231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">13000000</avro:MilestonePayment>
    <avro:LicenseAgreementExpenses
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20200101_20201231"
      decimals="INF"
      id="F_000316"
      unitRef="U_iso4217USD">0</avro:LicenseAgreementExpenses>
    <avro:LicenseAgreementExpenses
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroBioMarinPharmaceuticalIncMember_20190101_20191231"
      decimals="INF"
      id="F_000317"
      unitRef="U_iso4217USD">0</avro:LicenseAgreementExpenses>
    <avro:UpfrontLicenseFees
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20171002_20171002"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">1000000</avro:UpfrontLicenseFees>
    <avro:MilestonePayments
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20171002_20171002"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">16000000</avro:MilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20200101_20201231"
      decimals="INF"
      id="F_000320"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <avro:MilestonePayments
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroGenstemTherapeuticsIncMember_20190101_20191231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">2000000</avro:MilestonePayments>
    <avro:MilestonePayments
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20161117_20161117"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">550000</avro:MilestonePayments>
    <avro:LicenseAgreementExpenses
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000323"
      unitRef="U_iso4217USD">0</avro:LicenseAgreementExpenses>
    <avro:LicenseAgreementExpenses
      contextRef="C_0001681087_srtCounterpartyNameAxis_avroLundUniversityRightsHoldersAgreementMember_20190101_20191231"
      decimals="INF"
      id="F_000324"
      unitRef="U_iso4217USD">0</avro:LicenseAgreementExpenses>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000216">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Fair Value of Financial Assets and Liabilities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 and 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&#x2014;money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&#x2014;money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2020 and 2019, there were no transfers between levels.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000248">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 and 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&#x2014;money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&#x2014;money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">44416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">44416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">44416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">44416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">186797000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">186797000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">186797000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">186797000</us-gaap:AssetsFairValueDisclosure>
    <avro:FairValueInputAmountTransferBetweenLevels
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000333"
      unitRef="U_iso4217USD">0</avro:FairValueInputAmountTransferBetweenLevels>
    <avro:FairValueInputAmountTransferBetweenLevels
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000334"
      unitRef="U_iso4217USD">0</avro:FairValueInputAmountTransferBetweenLevels>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000217">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Supplemental Balance Sheet Information&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and Other Current Assets&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax incentive refund&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,558&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;973&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid compensation benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and equipment, net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,340&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,485&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019 was $1,207 and $850, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, the Company had restricted cash as presented in the table below, which consists of cash used to secure letters of credit for the benefit of the landlord in connection with the Company&#x2019;s lease agreements. The cash will be restricted until the termination or modification of the lease arrangement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accrued Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation and benefit costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,794&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting and professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000249">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax incentive refund&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,558&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;973&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid compensation benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <avro:TaxIncentiveRefundCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">2558000</avro:TaxIncentiveRefundCurrent>
    <avro:TaxIncentiveRefundCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">1916000</avro:TaxIncentiveRefundCurrent>
    <avro:PrepaidResearchAndDevelopmentCostsCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">3145000</avro:PrepaidResearchAndDevelopmentCostsCurrent>
    <avro:PrepaidResearchAndDevelopmentCostsCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">4915000</avro:PrepaidResearchAndDevelopmentCostsCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">973000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">897000</us-gaap:PrepaidInsurance>
    <avro:PrepaidCompensationBenefits
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">609000</avro:PrepaidCompensationBenefits>
    <avro:PrepaidCompensationBenefits
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">362000</avro:PrepaidCompensationBenefits>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">4000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">224000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">271000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">344000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">7560000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">8658000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000250">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,340&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,485&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">3965000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">3456000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">1377000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">1340000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">143000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">134000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">5485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">4930000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">2421000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">1234000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">3064000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">3696000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">1207000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">850000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000251">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, the Company had restricted cash as presented in the table below, which consists of cash used to secure letters of credit for the benefit of the landlord in connection with the Company&#x2019;s lease agreements. The cash will be restricted until the termination or modification of the lease arrangement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">492000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">492000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000252">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation and benefit costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,794&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting and professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">6402000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">3028000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <avro:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">5847000</avro:AccruedResearchAndDevelopmentExpenseCurrent>
    <avro:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">5794000</avro:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">1096000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">917000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">348000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">115000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">13693000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">9854000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000218">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Lease Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&#160;12, 2018, the Company entered into a lease agreement for office space located in Cambridge, Massachusetts. The lease agreement expires in January 2023. The annual lease payments are subject to a 3% increase each year. The Company recognizes rent expense on a straight-line basis over the lease period and has recorded deferred rent for rent expense incurred but not yet paid. The Company received a tenant incentive allowance of $842 in 2018. Such incentive allowance is being amortized as a reduction of rent expense on a straight-line basis over the lease period. In accordance with the lease agreement, the Company is required to maintain a security deposit of $209, which was recorded in restricted cash as of December&#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&#160;31, 2018, the Company entered into a sub-lease agreement for lab space located in Cambridge Massachusetts, United States, which was set to expire in October 2020. On June 9, 2020, the Company amended the terms of the sublease, which is now set to expire in April 2022. The annual lease payments are subject to a 5% increase each year. In accordance with the lease agreement, the Company is required to maintain a security deposit of $283, which was recorded in restricted cash as of December&#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 1, 2020, the Company entered into a&#160;lease&#160;agreement for office space located in Toronto, Ontario, Canada, which is set to expire in June 2025. The annual lease payments are fixed for years 1 and 2, and then subject to a 6.67% increase for years 3 through 5. In accordance with the lease agreement, the Company is required to maintain a security deposit of CAD $27, which was recorded in other long-term assets as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded rent expense of $2,352 and $2,257 during the years ended December&#160;31, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the future minimum lease payments due under operating leases as of December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,078&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,297&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Other Funding Commitments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had several ongoing clinical and non-clinical studies for its various pipeline programs. The Company enters into contracts in the normal course of business with contract research organizations and clinical sites for the conduct of clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company&#x2019;s option and do not have significant cancellation penalties.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Guarantees&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#x2019;s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Litigation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December&#160;31, 2020 and 2019, and to the best of its knowledge, no material legal proceedings are currently pending or threatened. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Other &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December&#160;31, 2020 and 2019, or royalties on future sales of specified products. No milestone or royalty payments under these agreements are expected to be payable in the immediate future. See Note&#160;3 &lt;span style="font-style:italic;"&gt;&#x201c;Licenses Agreements&#x201d;&lt;/span&gt; for discussion of these arrangements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#x2019;s business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company&#x2019;s products. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <avro:LeaseExpirationMonthAndYear contextRef="C_0001681087_20180112_20180112" id="F_000375">2023-01</avro:LeaseExpirationMonthAndYear>
    <avro:OperatingLeaseAnnualIncreaseInRentalPercentage
      contextRef="C_0001681087_20180112"
      decimals="2"
      id="F_000376"
      unitRef="U_xbrlipure">0.03</avro:OperatingLeaseAnnualIncreaseInRentalPercentage>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_0001681087_20180112_20180112"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">842000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:SecurityDeposit
      contextRef="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">209000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_0001681087_srtStatementGeographicalAxis_countryMA_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">209000</us-gaap:SecurityDeposit>
    <avro:LeaseExpirationMonthAndYear contextRef="C_0001681087_20180831_20180831" id="F_000381">2020-10</avro:LeaseExpirationMonthAndYear>
    <avro:LeaseExpirationMonthAndYear contextRef="C_0001681087_20200609_20200609" id="F_000380">2022-04</avro:LeaseExpirationMonthAndYear>
    <avro:OperatingLeaseAnnualIncreaseInRentalPercentage
      contextRef="C_0001681087_20200609"
      decimals="2"
      id="F_000382"
      unitRef="U_xbrlipure">0.05</avro:OperatingLeaseAnnualIncreaseInRentalPercentage>
    <us-gaap:SecurityDeposit
      contextRef="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20201231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">283000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_0001681087_us-gaapBalanceSheetLocationAxis_avroRestrictedCashMember_20191231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">283000</us-gaap:SecurityDeposit>
    <avro:LeaseExpirationMonthAndYear contextRef="C_0001681087_20200601_20200601" id="F_000385">2025-06</avro:LeaseExpirationMonthAndYear>
    <avro:AnnualLeasePaymentsDescription contextRef="C_0001681087_20200101_20201231" id="F_000386">The annual lease payments are fixed for years 1 and 2, and then subject to a 6.67% increase for years 3 through 5</avro:AnnualLeasePaymentsDescription>
    <avro:OperatingLeaseAnnualIncreaseInRentalPercentage
      contextRef="C_0001681087_20200601"
      decimals="4"
      id="F_000387"
      unitRef="U_xbrlipure">0.0667</avro:OperatingLeaseAnnualIncreaseInRentalPercentage>
    <us-gaap:SecurityDeposit
      contextRef="C_0001681087_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217CAD">27000</us-gaap:SecurityDeposit>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">2352000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">2257000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000253">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the future minimum lease payments due under operating leases as of December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,078&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,297&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">2078000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">1297000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">207000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">146000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <avro:OperatingLeasesFutureMinimumPaymentsDueAfterYearFour
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">73000</avro:OperatingLeasesFutureMinimumPaymentsDueAfterYearFour>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">3801000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000219">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value, and 10,000,000 shares of undesignated preferred stock. As of December&#160;31, 2020 and 2019, no undesignated shares of preferred stock were outstanding.&#160;&#160;&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance to the Fourth Amended and Restated Certificate of Incorporation, the holders of the common stock shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote;&#160;provided,&#160;however, that, except as otherwise required by law, holders of common stock, as such, shall not be entitled to vote on any amendment to any amendment to a certificate of designations of any series of undesignated preferred stock that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of undesignated preferred stock if the holders of such affected series of undesignated preferred stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to a certificate of designations of any series of undesignated preferred stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through December&#160;31, 2020, no cash dividends have been declared or paid. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Public Offerings &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company closed an underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $18.50 per share (the &#x201c;July 2019 Follow-on Offering&#x201d;), which included 975,000 shares of the Company&#x2019;s common stock resulting from the full exercise of the underwriters&#x2019; option to purchase additional shares at the public offering price, less underwriting discounts and commissions.&#160;&#160;The net proceeds to the Company from the July 2019 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $129,464. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company closed an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share (the &#x201c;February 2020 Follow-on Offering&#x201d;). The net proceeds to the Company from the February 2020 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $93,627. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2020, the Company sold an aggregate of 384,140 shares of common stock under its &#x201c;at-the-market&#x201d; facility&#160;(the &#x201c;ATM&#160;Facility&#x201d;) for net proceeds, after deducting commissions and other offering expenses payable by the Company, of $8,130. As of December 31, 2020, approximately $41,549 of common stock remained available for future issuance under the ATM Facility. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, the Company closed an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share (the &#x201c;November 2020 Follow-on Offering&#x201d;). The net proceeds to the Company from the November 2020 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $70,221. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common Stock Reserved for Future Issuance &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, the Company has reserved the following shares of common stock for future issuance:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for vesting of restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for exercise of outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,559,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,414,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for vesting of restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2018 Stock Option&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; and Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,877,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;332,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2018 Employee&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;762,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2019 Inducement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;365,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2020 Inducement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of authorized common stock reserved for&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,266,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,039,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000397"
      unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000398"
      unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000399"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000400"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <avro:UndesignatedPreferredStock
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000401"
      unitRef="U_xbrlishares">10000000</avro:UndesignatedPreferredStock>
    <avro:UndesignatedPreferredStock
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000402"
      unitRef="U_xbrlishares">10000000</avro:UndesignatedPreferredStock>
    <avro:UndesignatedSharesOfPreferredStockOutstanding
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000403"
      unitRef="U_xbrlishares">0</avro:UndesignatedSharesOfPreferredStockOutstanding>
    <avro:UndesignatedSharesOfPreferredStockOutstanding
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000404"
      unitRef="U_xbrlishares">0</avro:UndesignatedSharesOfPreferredStockOutstanding>
    <us-gaap:DividendsCash
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000405"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731"
      decimals="INF"
      id="F_000406"
      unitRef="U_xbrlishares">7475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190731"
      decimals="INF"
      id="F_000407"
      unitRef="U_iso4217USD_xbrlishares">18.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20190701_20190731"
      decimals="INF"
      id="F_000408"
      unitRef="U_xbrlishares">975000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroJulyTwoThousandNineteenFollowOnOfferingMember_20190701_20190731"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">129464000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229"
      decimals="INF"
      id="F_000410"
      unitRef="U_xbrlishares">4350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200229"
      decimals="INF"
      id="F_000411"
      unitRef="U_iso4217USD_xbrlishares">23.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroFebruaryTwoThousandTwentyFollowOnOfferingMember_20200201_20200229"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">93627000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200601_20200630"
      decimals="INF"
      id="F_000413"
      unitRef="U_xbrlishares">384140</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20200601_20200630"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">8130000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <avro:CommonStockCapitalSharesAmountAvailableForFutureIssuance
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroAtTheMarketFacilityMember_20201231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">41549000</avro:CommonStockCapitalSharesAmountAvailableForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130"
      decimals="INF"
      id="F_000416"
      unitRef="U_xbrlishares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001681087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201130"
      decimals="INF"
      id="F_000417"
      unitRef="U_iso4217USD_xbrlishares">15.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001681087_us-gaapSubsidiarySaleOfStockAxis_avroNovemberTwoThousandTwentyFollowOnOfferingMember_20201101_20201130"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">70221000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000254">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, the Company has reserved the following shares of common stock for future issuance:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for vesting of restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for exercise of outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,559,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,414,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for vesting of restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2018 Stock Option&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; and Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,877,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;332,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2018 Employee&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;762,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2019 Inducement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;365,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,800,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance under the 2020 Inducement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of authorized common stock reserved for&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,266,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,039,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231"
      decimals="INF"
      id="F_000419"
      unitRef="U_xbrlishares">30252</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="INF"
      id="F_000420"
      unitRef="U_xbrlishares">5559545</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231"
      decimals="INF"
      id="F_000421"
      unitRef="U_xbrlishares">3414445</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="INF"
      id="F_000422"
      unitRef="U_xbrlishares">1198</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231"
      decimals="INF"
      id="F_000423"
      unitRef="U_xbrlishares">2300</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000424"
      unitRef="U_xbrlishares">3877478</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000425"
      unitRef="U_xbrlishares">332513</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000426"
      unitRef="U_xbrlishares">762900</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20191231"
      decimals="INF"
      id="F_000427"
      unitRef="U_xbrlishares">459595</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20201231"
      decimals="INF"
      id="F_000428"
      unitRef="U_xbrlishares">365050</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandNineteenInducementPlanMember_20191231"
      decimals="INF"
      id="F_000429"
      unitRef="U_xbrlishares">1800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandTwentyInducementPlanMember_20201231"
      decimals="INF"
      id="F_000430"
      unitRef="U_xbrlishares">1700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000431"
      unitRef="U_xbrlishares">12266171</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000432"
      unitRef="U_xbrlishares">6039105</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000220">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Amended and Restated 2015 Stock Option and Grant Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Amended and Restated 2015 Stock Option and Grant Plan, (the &#x201c;2015 Plan&#x201d;) provides for the Company to issue restricted stock awards and restricted stock units, or to grant incentive stock options or non-statutory stock options. Incentive stock options may be granted only to the Company&#x2019;s employees including officers and members of the Board who are also employees. Restricted stock awards and restricted stock units and non- statutory stock options may be granted to employees, members of the Board, outside advisors, and consultants of the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total number of common shares that may be issued under the 2015 Plan was 2,008,564&#160;shares. Following the IPO, no further grants have been made under 2015 plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares that expire, are terminated, surrendered or cancelled under the 2015 Plan without having been fully exercised will be available for future awards under the 2018 Plan (as defined below). In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future awards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2015 Plan is administered by the Board. Equity awards granted to employees and members of the Board typically vest over four years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2018 Stock Option and Incentive Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s 2018 Stock Option and Incentive Plan (the &#x201c;2018 Plan&#x201d;) was adopted by the Board on June&#160;1, 2018 and approved by stockholders on June&#160;7, 2018 and became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form S-1. The 2018 Plan replaced the 2015 Plan as the Board determined not to make additional awards under the 2015 Plan following the pricing of the Company&#x2019;s IPO. The 2018 Plan allows the Board, compensation committee or other designated committee to make equity-based and cash-based incentive awards to its officers, employees, directors and other key persons (including consultants). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company initially reserved 616,300 shares of its common stock for the issuance of awards under the 2018 Plan. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January&#160;1, beginning on January&#160;1, 2019, by 4% of the outstanding number of shares of our common stock on the immediately preceding December&#160;31, or such lesser number of shares as determined by its Board or compensation committee (the &#x201c;Plan Evergreen&#x201d;). This number is subject to adjustment in the event of a stock split, stock dividend or other change in its capitalization. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 16, 2020, the Board adopted an amendment to the 2018 Plan (the &#x201c;Amendment&#x201d;), to (i) increase the number of shares of common stock currently reserved for issuance under the 2018 Plan by 3,300,000 shares and (ii) automatically terminate the 2018 Plan&#x2019;s annual increase (or &#x201c;evergreen&#x201d;) provision after January 2022. The Amendment was approved by the Board on June 4, 2020 and the Company&#x2019;s stockholders on June 4, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of shares of common stock available for future grant under the 2018 Plan was 3,877,478 as of December&#160;31, 2020, which does not include the shares added to the 2018 Plan reserve on January 1, 2021 as a result of the Plan Evergreen for the year ended December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2020 and 2019, the Company granted options to purchase 3,019,663 and, 1,677,967 shares, respectively, of common stock to employees, nonemployees and members of the Board. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2018 Employee Stock Purchase Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was adopted by the Board on June&#160;1, 2018 and approved by stockholders on June&#160;7, 2018 and became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form S-1. The ESPP is intended to qualify as an &#x201c;employee sto&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ck&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;purchase plan&#x201d; within the meaning of Section&#160;423(b) of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,200&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of common stock to participating employees. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January&#160;1, beginning on January&#160;1, 2019 and each January&#160;1 thereafter through January&#160;1, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2028, by the least of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1%&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; of the outstanding number of shares of our common stock on the immediately preceding December 31; (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,115,700&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares or (iii)&#160;such number of shares as determined by the ESPP administrator&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; (the &#x201c;ESPP Evergreen&#x201d;)&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2020 and 2019, the Company issued 13,425 and 1,671 shares, respectively of common stock. The total number of shares of common stock that may be issued under the ESPP was 762,900&#160;shares as of December&#160;31, 2020, of which 762,900 shares remained available for future grant, and which does not include the shares added to the ESPP reserve on January 1, 2021 as a result of the ESPP Evergreen for the year ended December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2019 Inducement Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.85%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s 2019 Inducement Plan (the &#x201c;2019 Plan&#x201d;) was adopted by the Board on December 11, 2019. The purpose of the 2019 Plan is to allow the Company to grant equity awards to new employees as inducements material to such new employee&#x2019;s acceptance of employment with the Company. The Company intends that the shares underlying the 2019 Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Nasdaq marketplace rules.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company initially reserved 1,800,000 shares of its common stock for the issuance of awards under the 2019 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of shares of common stock available for future grant under the 2019 Plan was 365,050 as of December&#160;31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2020 Inducement Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.85%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s 2020 Inducement Plan (the &#x201c;2020 Plan&#x201d;) was adopted by the Board on December 9, 2020. The purpose of the 2020 Plan is to allow the Company to grant equity awards to new employees as inducements material to such new employee&#x2019;s acceptance of employment with the Company. The Company intends that the shares underlying the 2020 Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Nasdaq marketplace rules.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company initially reserved 1,700,000 shares of its common stock for the issuance of awards under the 2020 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of shares of common stock available for future grant under the 2020 Plan was 1,700,000 as of December&#160;31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock Option Valuation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and members of the Board were as follows, presented on a weighted-average basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected option life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000454"&gt;6.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000455"&gt;5.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.02&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&#160;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,414,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000472"&gt;8.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,019,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(147,335&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled or forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(727,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,559,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000473"&gt;7.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,511&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,934,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000474"&gt;5.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#x2019;s common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $2,077 and $3,514, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant-date fair value of the Company&#x2019;s stock options granted during the years ended December&#160;31, 2020 and 2019 was $12.28 and $11.61, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Common Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has granted restricted common stock (or restricted stock awards) with time-based vesting conditions to certain employees of the Company.&lt;span style="font-weight:bold;font-style:italic;"&gt; &lt;/span&gt;The purchase price of the restricted stock awards are determined by the Board. Unvested shares of restricted stock awards may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. The Company has the option to repurchase the restricted stock awards at the original purchase price if the grantee terminates its working relationship with the Company prior to the vesting date. There were no unvested restricted stock awards as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units represent an unsecured promise to grant at no cost a set number of shares of common stock upon vesting. With respect to restricted stock units, recipients are not entitled to cash dividends and have no voting rights during the vesting period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s restricted stock award and restricted stock unit activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&#160;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited, cancelled or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total fair value of restricted stock awards and restricted stock units vested during the years ended December&#160;31, 2020 and 2019 was $29 and $50, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was allocated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,646&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, total unrecognized compensation cost related to unvested stock-based awards was $36,045, which is expected to be recognized over a weighted-average period of 3.01 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company modified certain awards in conjunction with employee terminations. The&#160;modification&#160;provided for the extension of the post-employment exercise period. The&#160;modifications&#160;resulted in approximately $417 of additional research and development expenses for the year ended December 31, 2020. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20201231"
      decimals="INF"
      id="F_000433"
      unitRef="U_xbrlishares">2008564</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20201231"
      decimals="INF"
      id="F_000434"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandFifteenStockOptionAndGrantPlanMember_20200101_20201231"
      id="F_000435">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlishares">616300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <avro:NumberOfSharesOfCommonStockOutstandingIncreasePercentage
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000437"
      unitRef="U_xbrlipure">0.04</avro:NumberOfSharesOfCommonStockOutstandingIncreasePercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200416"
      decimals="INF"
      id="F_000438"
      unitRef="U_xbrlishares">3300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000439"
      unitRef="U_xbrlishares">3877478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlishares">3019663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001681087_us-gaapStatementClassOfStockAxis_avroTwoThousandEighteenStockOptionAndIncentivePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000441"
      unitRef="U_xbrlishares">1677967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000442"
      unitRef="U_xbrlishares">223200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      id="F_000445">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January&#160;1, beginning on January&#160;1, 2019 and each January&#160;1 thereafter through January&#160;1, 2028, by the least of (i) 1% of the outstanding number of shares of our common stock on the immediately preceding December 31; (ii) 1,115,700 shares or (iii)&#160;such number of shares as determined by the ESPP administrator (the &#x201c;ESPP Evergreen&#x201d;).</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <avro:NumberOfSharesOfCommonStockOutstandingIncreasePercentage
      contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="2"
      id="F_000443"
      unitRef="U_xbrlipure">0.01</avro:NumberOfSharesOfCommonStockOutstandingIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000444"
      unitRef="U_xbrlishares">1115700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000446"
      unitRef="U_xbrlishares">13425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000447"
      unitRef="U_xbrlishares">1671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000448"
      unitRef="U_xbrlishares">762900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandEighteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000449"
      unitRef="U_xbrlishares">762900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandNineteenInducementPlanMember_20201231"
      decimals="INF"
      id="F_000450"
      unitRef="U_xbrlishares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandNineteenInducementPlanMember_20201231"
      decimals="INF"
      id="F_000451"
      unitRef="U_xbrlishares">365050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandTwentyInducementPlanMember_20201231"
      decimals="INF"
      id="F_000452"
      unitRef="U_xbrlishares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001681087_us-gaapPlanNameAxis_avroTwoThousandTwentyInducementPlanMember_20201231"
      decimals="INF"
      id="F_000453"
      unitRef="U_xbrlishares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000255">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and members of the Board were as follows, presented on a weighted-average basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected option life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000454"&gt;6.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000455"&gt;5.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.02&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001681087_20200101_20201231"
      decimals="4"
      id="F_000456"
      unitRef="U_xbrlipure">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001681087_20190101_20191231"
      decimals="4"
      id="F_000457"
      unitRef="U_xbrlipure">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001681087_20200101_20201231"
      decimals="4"
      id="F_000458"
      unitRef="U_xbrlipure">0.7602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001681087_20190101_20191231"
      decimals="4"
      id="F_000459"
      unitRef="U_xbrlipure">0.7683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000256">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&#160;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,414,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000472"&gt;8.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,019,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(147,335&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled or forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(727,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,559,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000473"&gt;7.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,511&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,934,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000474"&gt;5.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000460"
      unitRef="U_xbrlishares">3414445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001681087_20191231"
      decimals="2"
      id="F_000466"
      unitRef="U_iso4217USD_xbrlishares">12.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">29353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000461"
      unitRef="U_xbrlishares">3019663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000467"
      unitRef="U_iso4217USD_xbrlishares">18.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000462"
      unitRef="U_xbrlishares">147335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000468"
      unitRef="U_iso4217USD_xbrlishares">1.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000463"
      unitRef="U_xbrlishares">727228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000469"
      unitRef="U_iso4217USD_xbrlishares">19.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000464"
      unitRef="U_xbrlishares">5559545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001681087_20201231"
      decimals="2"
      id="F_000470"
      unitRef="U_iso4217USD_xbrlishares">14.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">13511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000465"
      unitRef="U_xbrlishares">1934685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001681087_20201231"
      decimals="2"
      id="F_000471"
      unitRef="U_iso4217USD_xbrlishares">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">11188000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">2077000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">3514000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000480"
      unitRef="U_iso4217USD_xbrlishares">12.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001681087_20190101_20191231"
      decimals="2"
      id="F_000481"
      unitRef="U_iso4217USD_xbrlishares">11.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001681087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231"
      decimals="INF"
      id="F_000482"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000257">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s restricted stock award and restricted stock unit activity for the year ended December&#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&#160;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited, cancelled or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001681087_20191231"
      decimals="INF"
      id="F_000483"
      unitRef="U_xbrlishares">32552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001681087_20191231"
      decimals="2"
      id="F_000486"
      unitRef="U_iso4217USD_xbrlishares">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000484"
      unitRef="U_xbrlishares">31354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000487"
      unitRef="U_iso4217USD_xbrlishares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001681087_20201231"
      decimals="INF"
      id="F_000485"
      unitRef="U_xbrlishares">1198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001681087_20201231"
      decimals="2"
      id="F_000488"
      unitRef="U_iso4217USD_xbrlishares">15.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_0001681087_20180101_20181231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000258">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was allocated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,646&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">8207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">3646000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">7421000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001681087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">3154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">15628000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">6800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">36045000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001681087_20190101_20191231" id="F_000498">P3Y3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <avro:AdditionalResearchAndDevelopmentExpense
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">417000</avro:AdditionalResearchAndDevelopmentExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000221">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. 401(k) Savings Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. At the election of the Board, the Company may elect to match employee contributions. Currently, the Company makes matching contributions at a rate of 50% of the first 6% of employee contributions. The Company recorded $468 and $224&#160;of expenses related to its 401(k) match for the years ended December&#160;31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="C_0001681087_20200101_20201231" id="F_000500">Currently, the Company makes matching contributions at a rate of 50% of the first 6% of employee contributions.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000501"
      unitRef="U_xbrlipure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000502"
      unitRef="U_xbrlipure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">468000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">224000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000222">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&#160;31, 2020 and 2019, the Company did not record a current or deferred income tax expense or (benefit) due to current and historical losses incurred by the Company. The Company&#x2019;s operations are predominantly based in the United States and the Company&#x2019;s foreign subsidiaries generated &lt;span style="font-style:italic;"&gt;de minimis&lt;/span&gt; losses for the years ended December&#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company&#x2019;s effective tax rate as reflected in the consolidated financial statements is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-28.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-27.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision to Return&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities are comprised of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S., foreign and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized start up and organizational costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Licensing agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December&#160;31, 2020 and 2019, based on the Company&#x2019;s history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2020 and 2019. The valuation allowance increased $32,066 and $19,968 during the years ended December&#160;31, 2020 and 2019, respectively, due primarily to net operating losses generated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of $213,991 and $121,836, respectively, that may be available to offset future income tax liabilities. The U.S. federal tax operating loss carryforwards of approximately $17,743 will expire at various dates through 2037. Approximately $196,248 of the U.S. federal tax operating losses can be carried forward indefinitely. As of December&#160;31, 2020 and 2019, the Company also had U.S. state net operating loss carryforwards of $201,642 and $115,129, respectively, which may be available to offset future taxable income. These losses expire at various dates through 2040.&lt;span style="font-size:12pt;"&gt;&#160;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, the Company has federal research and development tax credit carryforwards of $3,677 and $1,547, respectively. Included in the $3,677 of federal tax credit carryforwards are $1,351 of orphan drug credits. The Company qualifies for, and has elected to, apply part of its federal research credits against its payroll tax liability in accordance with certain provisions of the Internal Revenue Code. The amount applied towards the Company&#x2019;s payroll tax liability is capped at $250 per year. The federal research credits generated in excess of the $250 cap are able to be carried forward for 20 years. As of December&#160;31, 2020 and 2019, the Company had state research and development tax credit carryforwards of approximately $894 and $214, respectively, available to reduce future tax liabilities which expire at various dates through 2034. For all years through December&#160;31, 2020, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As the Company carries out extensive research and development activities, it seeks to benefit from the Australian research and development tax credit cash rebate regime. Under this regime, the Company&#x2019;s Australian subsidiary may be eligible to surrender the trading losses that arise from its research and development activities for a payable tax credit of up to approximately 43.5% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs for research staff, consumables, certain internal overhead costs and subcontracted expenditures as part of research projects for which the Company does not receive income. For the year ended December&#160;31, 2020, the Company recorded $589 in research and development tax credits as an offset to research and development expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a &lt;span style="-sec-ix-hidden:F_000564"&gt;three-year&lt;/span&gt; period in excess of 50&#160;percentage points, as defined under Sections&#160;382 &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed numerous financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the United States, Australia and Canada, and in several states. The foreign, federal and state income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2019. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by foreign tax authorities, the Internal Revenue Service, or state tax authorities to the extent utilized in a future period. &lt;span style="font-size:12pt;"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000505"
      unitRef="U_iso4217USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001681087_20190101_20191231"
      decimals="INF"
      id="F_000506"
      unitRef="U_iso4217USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000259">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company&#x2019;s effective tax rate as reflected in the consolidated financial statements is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-28.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-27.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision to Return&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001681087_20200101_20201231"
      decimals="INF"
      id="F_000507"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001681087_20190101_20191231"
      decimals="INF"
      id="F_000508"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001681087_20200101_20201231"
      decimals="3"
      id="F_000509"
      unitRef="U_xbrlipure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001681087_20190101_20191231"
      decimals="3"
      id="F_000510"
      unitRef="U_xbrlipure">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <avro:EffectiveIncomeTaxRateReconciliationPermanentDifference
      contextRef="C_0001681087_20200101_20201231"
      decimals="3"
      id="F_000511"
      unitRef="U_xbrlipure">-0.006</avro:EffectiveIncomeTaxRateReconciliationPermanentDifference>
    <avro:EffectiveIncomeTaxRateReconciliationPermanentDifference
      contextRef="C_0001681087_20190101_20191231"
      decimals="3"
      id="F_000512"
      unitRef="U_xbrlipure">-0.009</avro:EffectiveIncomeTaxRateReconciliationPermanentDifference>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0001681087_20200101_20201231"
      decimals="3"
      id="F_000513"
      unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0001681087_20190101_20191231"
      decimals="3"
      id="F_000514"
      unitRef="U_xbrlipure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001681087_20200101_20201231"
      decimals="3"
      id="F_000515"
      unitRef="U_xbrlipure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001681087_20190101_20191231"
      decimals="3"
      id="F_000516"
      unitRef="U_xbrlipure">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001681087_20200101_20201231"
      decimals="3"
      id="F_000517"
      unitRef="U_xbrlipure">-0.283</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001681087_20190101_20191231"
      decimals="3"
      id="F_000518"
      unitRef="U_xbrlipure">-0.276</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_0001681087_20200101_20201231"
      decimals="3"
      id="F_000519"
      unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_0001681087_20190101_20191231"
      decimals="3"
      id="F_000520"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001681087_20200101_20201231"
      decimals="3"
      id="F_000521"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001681087_20190101_20191231"
      decimals="3"
      id="F_000522"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000260">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities are comprised of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S., foreign and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized start up and organizational costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Licensing agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">57705000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">33594000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">4383000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">1716000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <avro:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000527"
      unitRef="U_iso4217USD">29000</avro:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts>
    <avro:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">32000</avro:DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">2944000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">543000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <avro:DeferredTaxAssetsLicenseAgreement
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">4004000</avro:DeferredTaxAssetsLicenseAgreement>
    <avro:DeferredTaxAssetsLicenseAgreement
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">1756000</avro:DeferredTaxAssetsLicenseAgreement>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">1587000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">993000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">70652000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">38634000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">70492000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">38425000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">160000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">209000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">160000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">209000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">32066000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001681087_20190101_20191231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">19968000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">213991000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_0001681087_20191231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">121836000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2037Member_20201231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">17743000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000549"
      unitRef="U_iso4217USD">196248000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20201231"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">201642000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_0001681087_us-gaapTaxPeriodAxis_avroExpirationThrough2039Member_20191231"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">115129000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">3677000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">1547000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">3677000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_avroOrphanDrugCreditMember_20201231"
      decimals="-3"
      id="F_000555"
      unitRef="U_iso4217USD">1351000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <avro:PayrollTaxLiabilityCappedPerYear
      contextRef="C_0001681087_20201231"
      decimals="-3"
      id="F_000556"
      unitRef="U_iso4217USD">250000</avro:PayrollTaxLiabilityCappedPerYear>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001681087_20200101_20201231"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">250000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <avro:TaxCreditCarryforwardsExpirationPeriod contextRef="C_0001681087_20200101_20201231" id="F_000558">P20Y</avro:TaxCreditCarryforwardsExpirationPeriod>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20201231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">894000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxPeriodAxis_avroExpirationThrough2033Member_20191231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">214000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001681087_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231"
      decimals="INF"
      id="F_000561"
      unitRef="U_xbrlipure">0.435</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001681087_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">589000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <avro:OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered
      contextRef="C_0001681087_20200101_20201231"
      decimals="2"
      id="F_000563"
      unitRef="U_xbrlipure">0.50</avro:OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000223">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Net Loss per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock awards and unvested restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,559,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,414,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000261">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,559,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,414,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock awards and units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="0"
      id="F_000565"
      unitRef="U_xbrlishares">5559545</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="0"
      id="F_000566"
      unitRef="U_xbrlishares">3414445</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20200101_20201231"
      decimals="0"
      id="F_000567"
      unitRef="U_xbrlishares">1198</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_avroRestrictedStockAwardsAndUnitsMember_20190101_20191231"
      decimals="0"
      id="F_000568"
      unitRef="U_xbrlishares">32552</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001681087_20200101_20201231" id="F_000224">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Related Party Transactions &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;UHN &lt;span style="font-size:12pt;font-weight:normal;font-style:normal;"&gt;&#160;&#160;&lt;/span&gt;&lt;span style="font-weight:normal;font-style:normal;"&gt;  &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&#x2019;s entry into a license agreement with UHN on January 27, 2016, the Company issued UHN 1,161,665 shares of its common stock. Upon the closing of the IPO in 2018, as UHN&#x2019;s fully-diluted percentage ownership of the Company was reduced within a range of specified percentages, the Company was obligated to pay UHN an amount of $2,000, which was paid in July 2018. For the years ended&#160;December&#160;31, 2020 and 2019, the Company recognized $381&#160;and $821, respectively, of research and development expense related to the license agreements with UHN. Refer to Note&#160;3 &lt;span style="font-style:italic;"&gt;&#x201c;License Agreements&#x201d;&lt;/span&gt; for additional information regarding the UHN license agreements. &lt;span style="font-size:12pt;"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Others &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&#160;31, 2020 and 2019, the Company recorded expenses of $1,488 and $1,451, respectively, related to a sublease to rent lab space, provided by an entity affiliated with a member of the board. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001681087_us-gaapAwardTypeAxis_avroStockPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20160127_20160127"
      decimals="INF"
      id="F_000569"
      unitRef="U_xbrlishares">1161665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <avro:ProvisionForMaximumCashPayment
      contextRef="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20180701_20180731"
      decimals="INF"
      id="F_000570"
      unitRef="U_iso4217USD">2000000</avro:ProvisionForMaximumCashPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">821000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000573"
      unitRef="U_iso4217USD">1488000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001681087_srtTitleOfIndividualAxis_avroOfficersAndBoardMembersMember_us-gaapTypeOfArrangementAxis_avroSubleaseAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000574"
      unitRef="U_iso4217USD">1451000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517529752952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVRO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVROBIO,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001681087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,622,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533,953,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-0710585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Kendall Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">914-8420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive Proxy Statement for its 2021 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of December&#160;31, 2020. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K. </p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517609752504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 259,682<span></span>
</td>
<td class="nump">$ 187,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,560<span></span>
</td>
<td class="nump">8,658<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">267,242<span></span>
</td>
<td class="nump">195,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">271,234<span></span>
</td>
<td class="nump">200,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">3,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">13,693<span></span>
</td>
<td class="nump">9,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,614<span></span>
</td>
<td class="nump">14,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,890<span></span>
</td>
<td class="nump">14,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized and no shares issued or outstanding as of December 31, 2020 and 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000 shares authorized as of December 31, 2020 and 2019; 41,569 and 31,673 shares issued as of December 31, 2020 and 2019, respectively; 41,569 and 31,643 shares outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">518,756<span></span>
</td>
<td class="nump">330,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(264,416)<span></span>
</td>
<td class="num">(144,704)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">254,344<span></span>
</td>
<td class="nump">186,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 271,234<span></span>
</td>
<td class="nump">$ 200,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517529890872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">41,569,000<span></span>
</td>
<td class="nump">31,673,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">41,569,000<span></span>
</td>
<td class="nump">31,643,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517603235752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 87,236<span></span>
</td>
<td class="nump">$ 54,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">32,992<span></span>
</td>
<td class="nump">20,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">120,228<span></span>
</td>
<td class="nump">75,809<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(120,228)<span></span>
</td>
<td class="num">(75,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">2,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,712)<span></span>
</td>
<td class="num">(72,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (119,712)<span></span>
</td>
<td class="num">$ (72,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share &#8212;basic and diluted</a></td>
<td class="num">$ (3.31)<span></span>
</td>
<td class="num">$ (2.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">36,206<span></span>
</td>
<td class="nump">27,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517530005848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Public Offering [Member]</div></th>
<th class="th"><div>ATM Facility [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Public Offering [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>ATM Facility [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Public Offering [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>ATM Facility [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 122,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71,739)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,807,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock awards and units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under 2018 employee stock purchase plan</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under 2018 employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(72,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">186,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,704)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock awards and units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">147,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,849<span></span>
</td>
<td class="nump">$ 8,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,848<span></span>
</td>
<td class="nump">$ 8,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,350,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under 2018 employee stock purchase plan</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under 2018 employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">15,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,712)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 254,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 518,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (264,416)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,569,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517530411128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock upon public offering, offering costs</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember', window );">ATM Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock upon public offering, offering costs</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517529778216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (119,712)<span></span>
</td>
<td class="num">$ (72,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">15,628<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_DeferredRentExpense', window );">Deferred rent expense</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Other</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="num">(4,888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(881)<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,936<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(98,803)<span></span>
</td>
<td class="num">(67,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(1,585)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(1,585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">172,619<span></span>
</td>
<td class="nump">129,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">72,639<span></span>
</td>
<td class="nump">60,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">187,535<span></span>
</td>
<td class="nump">126,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">260,174<span></span>
</td>
<td class="nump">187,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_CommonStockOfferingCostsIncurredButNotYetPaid', window );">Common stock offering costs incurred but unpaid at period end</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">259,682<span></span>
</td>
<td class="nump">187,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">260,174<span></span>
</td>
<td class="nump">187,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">164,053<span></span>
</td>
<td class="nump">$ 129,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember', window );">ATM Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 8,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_CommonStockOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock offering costs incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_CommonStockOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_DeferredRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_DeferredRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other adjustments noncash items to reconcile net income loss to cash provided by used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524188600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, Inc. (the &#8220;Company&#8221; or &#8220;AVROBIO&#8221;) is a clinical-stage gene therapy company focused on developing potentially curative <span style="font-style:italic;">ex vivo</span> lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. <span style="font-size:12pt;">&#160;</span> <span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;</span> <span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;</span> <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has devoted substantially all of its efforts to research and development, business planning, acquiring operating assets, seeking protection for its technology and product candidates, and raising capital. Since inception, the Company has funded its operations through sales of preferred stock and common stock. As of December 31, 2020, the Company had an accumulated deficit of $264,416. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash and cash equivalents on hand as of December&#160;31, 2020 of $259,682 will be sufficient to fund current planned operations and capital expenditure requirements for at least the next twelve months from the filing date of this Annual Report on Form&#160;10-K with the SEC. However, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.  </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525458344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of AVROBIO, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker is the chief executive officer (&#8220;CEO&#8221;). The Company and the CEO view the Company&#8217;s operations and manage its business as one operating segment. All material long-lived assets of the Company reside in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash totaling $492 as of December 31, 2019 has been reclassified from &#8220;Other assets&#8221; to &#8220;Restricted cash&#8221; in order to conform to the current period presentation. Additionally, the Company has reclassified $214 which was previously classified as &#8220;Accrued expenses and other current liabilities&#8221; as of December 31, 20219 to &#8220;Deferred rent&#8221; in order to </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conform to the current period presentation. These reclassifications had no effect on the consolidated results of operation or cash flows for the year ended December 31, 2019. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities<span style="color:#000000;"> at the date of the financial statements and the reported amounts of expenses during the reporting periods</span>. On an on&#8209;going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less at acquisition to be cash equivalents. As of December 31, 2020 and 2019,<span style="font-size:12pt;"> </span>cash and cash equivalents were primarily held in interest-bearing money market funds. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Issuance Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. <span style="font-size:12pt;">&#160;</span> As of December&#160;31, 2019, the Company recorded deferred issuance costs of $133 within other assets on the consolidated balance sheet related to a follow-on offering of common stock completed in February 2020. There were<span style="font-size:12pt;"> </span>no amounts deferred as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.64%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 1&#8212;</span><span style="color:#000000;"> </span><span style="font-size:10pt;color:#000000;">Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.64%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.64%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s financial instruments, which include cash equivalents, accounts payable, and accrued expenses, approximated their fair values as of December&#160;31, 2020 and 2019 due to the short</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;term nature of these instruments.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the estimated fair value of financial instruments using available market information. The use of different market assumptions, estimation methodologies, or both, could have a significant effect on the estimated fair value amounts. See Note 4<span style="font-style:italic;"> &#8220;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Fair Value of Financial Assets and Liabilities&#8221;</span><span style="font-style:italic;"> </span>for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Depreciation and amortization is calculated using the straight-line method over the following estimated useful lives of the assets: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000271">Lesser of lease term or 10 years</span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. <span style="color:#000000;">The Company did not record any impairment loss during the years ended December 31, 2020 and 2019.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company categorizes leases at their inception as either operating or capital leases. On certain lease arrangements, the Company may receive rent holidays or other incentives. The Company recognizes lease costs on a straight-line basis once control of the space is achieved, without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments or escalating payment amounts. The difference between required lease payments and rent expense has been recorded as deferred rent and accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Additionally, incentives received are treated as a reduction of costs over the term of the agreement, as they are considered an inseparable part of the lease agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as the change in stockholders&#8217; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) as well as other changes in stockholders&#8217; equity (deficit) which includes certain changes in equity that are excluded from net income (loss). Comprehensive loss has been disclosed in the accompanying consolidated statements of operations and comprehensive loss and equals the Company&#8217;s net loss for all periods presented. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Translation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s international operations in Canada and Australia is the U.S. dollar. Accordingly, all operating assets and liabilities of these international subsidiaries are remeasured into U.S. dollars using the exchange rates in effect at the balance sheet date or historical rates, as appropriate, while expenses are remeasured into U.S. dollars at the average rates in effect during the period. Any differences resulting from the remeasurement of assets, liabilities, and operations of the Canadian and Australian subsidiaries are recorded within other income (expense), net in the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated statements of operations and comprehensive loss. During the years ended December&#160;31, 2020 and 2019, the Company recorded foreign exchange losses of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, in other expense.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development related contracts with parties both inside and outside of the United States. The payments related to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. <span style="color:#000000;">Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span> </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock-based awards issued to employees and members of the Company&#8217;s board of directors (the &#8220;Board&#8221;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions. The Company accounts for forfeitures as they occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2018-07,&#160;<span style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span>, the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the Company&#8217;s adoption of ASU 2018-07 in 2018, the measurement date for non-employee awards is the later of the adoption date of ASU 2018-07, or the date of grant, without change in the fair value of the award. For stock-based awards granted to nonemployees subject to graded vesting that only contain service conditions, the Company has elected to recognize stock-based compensation expense using the straight-line recognition method.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s cash compensation costs are classified. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the absence of an active market for the Company&#8217;s common stock prior to its initial public offering (&#8220;IPO&#8221;), the Company and the Board, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#8217;s common stock at the time of each grant of a stock-based award. The Company and the Board determined the estimated fair value of the Company&#8217;s equity instruments based on a number of factors, including external market conditions affecting the biotechnology industry sector. The Company and the Board utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, <span style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span>, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors in determining the value of the Company&#8217;s common stock at each grant date, including: (1)&#160;prices paid for the Company&#8217;s redeemable convertible preferred stock, which the Company had sold to outside investors in arm&#8217;s-length transactions, and the rights, preferences, and privileges of the Company&#8217;s redeemable convertible preferred stock and common stock; (2)&#160;valuations performed by an independent valuation specialist; (3)&#160;the Company&#8217;s stage of development; (4)&#160;the fact that the grants of stock-based awards involved illiquid securities in a private company; and (5)&#160;the likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as an IPO or sale of the Company, given prevailing market conditions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. As there was no public market for its common stock prior to June&#160;21, 2018, which was the first day of trading, and as the trading history of the Company&#8217;s common stock was limited through December&#160;31, 2020, the Company determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by adjusting the weighted-average shares outstanding for the potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For purposes of the diluted net loss per share calculation, stock options and restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subsequent Event Considerations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#8220;emerging growth company.&#8221; Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an &#8220;emerging growth company.&#8221; </p>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No.&#160;2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and Topic 606</span>, or ASU 2018-18. The amendments in ASU 2018-18 clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU 2018-18 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606. The Company adopted ASU 2018-18 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <span style="font-style:italic;">Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), </span>or ASU 2018-15.&#160;ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span>, or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure requirements for fair value measurements. The amendments are effective for interim and annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted for either the entire ASU or only the provisions that eliminate or modify requirements. The amendments with respect to changes in unrealized gains and losses, the range and weighted-average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively. All other amendments are to be applied retrospectively to all periods presented. The Company adopted ASU 2018-13 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02, <span style="font-style:italic;">(Topic 842) Leases, </span>or ASU 2016-02.&#160;ASU 2016-02&#160;requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. For public entities,&#160;ASU 2016-02&#160;is effective for fiscal years beginning after December&#160;15, 2018. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;ASU 2016-02&#160;is effective for the Company for the year ended December 31, 2022, and all interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. Based on this evaluation t<span style="color:#000000;">he Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the Company&#8217;s total assets and total liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, or ASU 2016-13. ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity's current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.<span style="color:#000000;"> </span>ASU 2016-13 is effective for non-emerging growth companies (&#8220;EGCs&#8221;) for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2016-13 may have on its financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="font-size:8pt;">&#160;</span>November 2019, the FASB issued ASU 2019-11, &#8220;<span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span>&#8221;, or ASU 2019-11. ASU 2019-11 is an accounting pronouncement that amends ASU 2016-13, &#8220;<span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>.&#8221; The amendments update guidance on reporting credit losses for financial assets. These amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in both ASU 2016-13 and ASU 2019-11 are </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. </span><span style="color:#000000;">As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;2016-13 and ASU 2019-11&#160;are effective for the Company for fiscal years beginning after December 15, 202</span><span style="color:#000000;">2</span><span style="color:#000000;">, and interim periods within </span><span style="color:#000000;">those </span><span style="color:#000000;">fiscal years. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is currently evaluating ASU 2016-13 and ASU 2019-11 and their impact on its consolidated financial statements and financial statement disclosures.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span>, or ASU 2019-12. ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for non-EGCs for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years and will be effective for the Company for fiscal years beginning after December 15, 2021 and interim periods beginning after December 15, 2022, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2019-12 may have on its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525723928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. License Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with The University of Manchester</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2020, the Company entered into an agreement (&#8220;MPSII License Agreement&#8221;) with The University of Manchester, England (&#8220;UoM&#8221;), whereby UoM granted to the Company <span style="Background-color:#FFFFFF;color:#000000;">an exclusive worldwide license under certain patent and other intellectual property rights, subject to certain retained rights, to develop, commercialize and sell an&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">ex vivo</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;lentiviral gene therapy for use in the treatment of Hunter syndrome, or mucopolysaccharidosis type II (&#8220;MPSII&#8221;)</span>.&#160;&#160;As consideration for the MPSII License Agreement, the Company agreed to pay UoM an upfront, one-time fee of $8,000, which was recognized as research and development expense during the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the agreement, the Company is obligated to make milestone payments of up to an aggregate of $80,000 upon the achievement of specified development and regulatory milestones, to pay royalties, on a product-by-product and country-by-country basis, of a mid-single digit percentage based on net sales of products licensed under the agreement and to pay a low double digit percentage of any sublicense fees received by the Company. The next anticipated payment milestones under the MPSII License Agreement include $2,000, which would become due following the date of regulatory approval of the clinical trial application for the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM, and $4,000, upon the dosing of the first patient in the investigator-sponsored Phase 1/2 clinical trial sponsored by UoM.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the agreement <span style="Background-color:#FFFFFF;color:#000000;">expires upon the later of 15 years from the effective date or the expiration of the last valid claim of the licensed patents, subject to certain surviving rights and obligations.</span><span style="font-size:12pt;">&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">UoM and the Company can each terminate the agreement in the event of the bankruptcy or insolvency of the other party, or a material breach by the other party and failure to cure such breach within a certain period of time. UoM has the right to terminate the agreement in the event of certain actions relating to challenge or opposition to the licensed intellectual property brought by the Company or its affiliates or sublicensees.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the MPSII License Agreement, the Company entered into a collaborative research funding agreement with UoM (&#8220;CRFA&#8221;). Under the CRFA, the Company has agreed to fund the budgeted costs of an investigator-sponsored Phase 1/2 clinical trial to be sponsored by UoM in connection with the development activities under the MPSII License Agreement, which are currently estimated to equal approximately<span style="Background-color:#FFFFFF;color:#000000;"> &#163;9,100 in the aggregate</span>.<span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company recognized $565 of costs related to the CRFA.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreements with University Health Network (&#8220;UHN&#8221;) </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fabry License Agreement&#8212; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;27, 2016, the Company entered into an agreement with UHN, pursuant to which UHN granted the Company an option to enter into an exclusive license under the UHN intellectual property related to Fabry disease in accordance with the pre-negotiated licensing terms. On November&#160;4, 2016, the Company exercised its option and entered into a license agreement with UHN, pursuant to which UHN granted the Company an exclusive worldwide license under certain intellectual property rights and a non-exclusive worldwide license under certain know-how, in each case subject to certain retained rights, to develop, commercialize and sell products for use in the treatment of Fabry disease. In addition, for three years following the execution of the agreement, UHN granted the Company an exclusive option to obtain a license under </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain improvements to the licensed intellectual property rights as well as an option to negotiate a license under certain other improvements. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this agreement, the Company paid an option fee of CAD $20, an upfront license fee of CAD $75, plus the annual license maintenance fee for the first year. Thereafter, the Company is also required to pay UHN future annual license maintenance fees until the first sale of a licensed product in certain markets. The Company is also obligated to make future milestone payments in an aggregate amount of up to CAD $2,450 upon the achievement of specified milestones as well as royalties on a country-by-country basis of a low to mid-single-digit percentage of annual net sales of licensed products and a lower single-digit royalty percentage in certain circumstances. Additionally, the Company has agreed to pay a low double-digit royalty percentage of all sublicensing revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires the Company to meet certain performance milestones within specified timeframes. UHN may terminate the agreement if the Company fails to meet these performance milestones despite using commercially reasonable efforts and the Company is unable to reach agreement with UHN on revised timeframes. The Company&#8217;s royalty obligation expires on a licensed product-by-licensed product and country-by-country basis upon the latest to occur of the expiration or termination of the last valid claim under the licensed intellectual property rights in such country, the tenth anniversary of the first commercial sale of such licensed product in such country and the expiration of any applicable regulatory exclusivity in such country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the agreement expires upon the expiration of the Company&#8217;s royalty obligation for all licensed products. UHN can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event that the Company fails to obtain or maintain insurance. Either the Company or UHN may terminate the license agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company can voluntarily terminate the agreement with prior notice to UHN. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company recorded research and development expense related to this agreement with UHN of $344 and $783, respectively, which consists of reimbursable funded study trial costs and license maintenance fees. No milestone fees were incurred related to the Fabry license agreement in the years ended December 31, 2020 and 2019.<span style="font-size:12pt;">&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interleukin 12 License Agreement&#8212; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;27, 2016, the Company entered into an exclusive license agreement with UHN, pursuant to which UHN granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights related to Interleukin 12. Upon execution of this agreement, the Company paid an upfront license fee of CAD&#160;$264. In addition, as part of the initial consideration for the license, the Company issued to UHN 1,161,665 shares of the Company&#8217;s common stock and<span style="color:#000000;"> agreed to pay UHN up to $2,000 upon the closing of an IPO if certain criteria are met</span>. The fair value of the shares issued to UHN of $480 and the upfront fee was expensed upon the execution of the agreement. Upon the closing of the IPO in 2018, as the criteria were met, the Company paid UHN $2,000.<span style="font-size:12pt;">&#160;</span>The Company is also required to pay UHN future annual license maintenance fees of CAD $50 on each anniversary of the effective date of the license agreement prior to expiration or termination and potential future milestone payments of up to CAD $19,275 upon the achievement of specified clinical and regulatory milestones. The Company also agreed to pay UHN royalties of a low single-digit percentage of net sales of licensed products sold by the Company. If the Company grants any sublicense rights under the license agreement, the Company has agreed to pay UHN a low double-digit royalty percentage of any sublicense income received by the Company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement requires the Company to meet certain diligence requirements based upon specified milestones. The agreement expires on the later of the date the last patent rights expire in the last country or ten years from the date of first sale. UHN can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event that the Company fails to obtain or maintain insurance. The Company can voluntarily terminate the agreement with prior notice to UHN. Either the Company or UHN may terminate the license agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company recorded research and development expense related to this agreement with UHN of $37 and $38, respectively, which consists of license maintenance fees. No milestone fees were incurred related to the Interleukin 12 license agreement in the years ended December 31, 2020 and 2019.<span style="font-size:12pt;">&#160;&#160;</span></p>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with BioMarin Pharmaceutical Inc. (&#8220;BioMarin&#8221;) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;31, 2017, the Company entered into a license agreement with BioMarin, pursuant to which BioMarin granted the Company an exclusive worldwide license under certain intellectual property rights owned or controlled by BioMarin to develop, commercialize and sell products for use in the treatment of Pompe disease. The license agreement was amended in February 2018 and again in January 2020 to, among things, provide that BioMarin would supply the Company with certain technology materials. As consideration for this agreement, the Company paid an upfront license fee of $500 in cash and issued 233,765 shares of Series B Preferred Stock to BioMarin at the time of the Company&#8217;s Series B Preferred Stock financing in January 2018. The Company is also obligated to make future milestone payments of up to $13,000 upon the achievement of certain specified milestones and agreed to pay BioMarin royalties of a low single-digit percentage of net sales of licensed products sold by the Company or its affiliates covered by patent rights in a relevant country. No expenses related to the license were recorded for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the agreement expires upon the expiration of the Company&#8217;s royalty obligation for all licensed products throughout the world. BioMarin and the Company can terminate the agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company may terminate the agreement at will upon written notice to BioMarin. BioMarin has the right to terminate the agreement upon the Company&#8217;s bankruptcy or insolvency, or in the event of any challenge or opposition to the licensed patent rights or related actions brought by the Company or its affiliates or sublicensees, or if the Company, its affiliates or sublicensees knowingly assist a third-party in challenging or otherwise opposing the licensed patent rights, except as required under a court order or subpoena. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with GenStem Therapeutics, Inc. (&#8220;GenStem&#8221;) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;2, 2017, the Company entered into a license agreement with GenStem, pursuant to which GenStem granted the Company an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights owned or controlled by GenStem to develop, commercialize and sell products for use in the treatment of cystinosis. Under this agreement, the Company paid an upfront license fee of $1,000 and is required to make payments upon completion of certain milestones up to an aggregate of $16,000. The Company also agreed to pay GenStem a tiered mid to high single-digit royalty percentage on annual net sales of licensed products as well as a low double-digit percentage of sublicense income received from certain third-party licensees. The Company&#8217;s royalty obligation expires on a licensed product-by-licensed product and country-by-country basis on the eleventh anniversary of the first commercial sale of such licensed product in such country or the expiration of the last valid claim under the licensed patent rights covering such licensed product in such country, whichever is later. Unless terminated earlier, the agreement expires upon the expiration of the Company&#8217;s royalty obligation for all licensed products throughout the world. GenStem and the Company can terminate the agreement in the event of a material breach by the other party and failure to cure such breach within a certain period of time. The Company may terminate the agreement at will upon the specified prior written notice to GenStem. &#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020 the Company recorded<span style="font-size:12pt;"> </span>no research and development expense related to milestone payments. For the year ended December&#160;31, 2019 the Company recorded $2,000 related to milestone payments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Lund University Rights Holders </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;17, 2016, the Company entered into a license agreement with affiliates of Lund University, along with certain other relevant rights holders that may be added from time to time, pursuant to which such rights holders granted to the Company an exclusive worldwide license, subject to certain retained rights, under certain intellectual property rights to develop, commercialize and sell products in any and all uses relevant to Gaucher disease. As consideration for the license, the Company is required to make payments in connection with the achievement of certain milestones up to an aggregate of $550. The agreement expires on the latest of (i)&#160;the twentieth anniversary of the end of a certain research project the Company is funding pursuant to an agreement with Lund University, (ii)&#160;the expiration of the term of any patent filed on the licensed rights that covers a licensed product, (iii)&#160;the expiration of any applicable marketing exclusivity right and (iv)&#160;such time that neither the Company nor any sublicensees, partners or contractors are commercializing a licensed product. Either the Company or the rights holders acting together may terminate the license agreement if the other such party commits a material breach and fails to cure such breach within a certain period of time, or if the other party enters into liquidation, becomes insolvent, or enters into composition or statutory reorganization proceedings. No expenses related to the license were recorded for the years ended December&#160;31, 2020 and 2019. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517523907416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Fair Value of Financial Assets and Liabilities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents&#8212;money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents&#8212;money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, there were no transfers between levels.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524228520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Supplemental Balance Sheet Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prepaid expenses and Other Current Assets</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax incentive refund</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,558</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,915</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">973</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid compensation benefits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,560</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,658</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,965</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,456</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,377</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,234</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,064</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,696</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019 was $1,207 and $850, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company had restricted cash as presented in the table below, which consists of cash used to secure letters of credit for the benefit of the landlord in connection with the Company&#8217;s lease agreements. The cash will be restricted until the termination or modification of the lease arrangement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and benefit costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,402</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,028</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,847</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,794</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting and professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,096</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524241768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;12, 2018, the Company entered into a lease agreement for office space located in Cambridge, Massachusetts. The lease agreement expires in January 2023. The annual lease payments are subject to a 3% increase each year. The Company recognizes rent expense on a straight-line basis over the lease period and has recorded deferred rent for rent expense incurred but not yet paid. The Company received a tenant incentive allowance of $842 in 2018. Such incentive allowance is being amortized as a reduction of rent expense on a straight-line basis over the lease period. In accordance with the lease agreement, the Company is required to maintain a security deposit of $209, which was recorded in restricted cash as of December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;31, 2018, the Company entered into a sub-lease agreement for lab space located in Cambridge Massachusetts, United States, which was set to expire in October 2020. On June 9, 2020, the Company amended the terms of the sublease, which is now set to expire in April 2022. The annual lease payments are subject to a 5% increase each year. In accordance with the lease agreement, the Company is required to maintain a security deposit of $283, which was recorded in restricted cash as of December&#160;31, 2020 and 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 1, 2020, the Company entered into a&#160;lease&#160;agreement for office space located in Toronto, Ontario, Canada, which is set to expire in June 2025. The annual lease payments are fixed for years 1 and 2, and then subject to a 6.67% increase for years 3 through 5. In accordance with the lease agreement, the Company is required to maintain a security deposit of CAD $27, which was recorded in other long-term assets as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded rent expense of $2,352 and $2,257 during the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the future minimum lease payments due under operating leases as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,078</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,297</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Funding Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had several ongoing clinical and non-clinical studies for its various pipeline programs. The Company enters into contracts in the normal course of business with contract research organizations and clinical sites for the conduct of clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have significant cancellation penalties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Guarantees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December&#160;31, 2020 and 2019, and to the best of its knowledge, no material legal proceedings are currently pending or threatened. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December&#160;31, 2020 and 2019, or royalties on future sales of specified products. No milestone or royalty payments under these agreements are expected to be payable in the immediate future. See Note&#160;3 <span style="font-style:italic;">&#8220;Licenses Agreements&#8221;</span> for discussion of these arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517603395400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value, and 10,000,000 shares of undesignated preferred stock. As of December&#160;31, 2020 and 2019, no undesignated shares of preferred stock were outstanding.&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance to the Fourth Amended and Restated Certificate of Incorporation, the holders of the common stock shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote;&#160;provided,&#160;however, that, except as otherwise required by law, holders of common stock, as such, shall not be entitled to vote on any amendment to any amendment to a certificate of designations of any series of undesignated preferred stock that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of undesignated preferred stock if the holders of such affected series of undesignated preferred stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to a certificate of designations of any series of undesignated preferred stock.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through December&#160;31, 2020, no cash dividends have been declared or paid. <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offerings </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company closed an underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $18.50 per share (the &#8220;July 2019 Follow-on Offering&#8221;), which included 975,000 shares of the Company&#8217;s common stock resulting from the full exercise of the underwriters&#8217; option to purchase additional shares at the public offering price, less underwriting discounts and commissions.&#160;&#160;The net proceeds to the Company from the July 2019 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $129,464. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company closed an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share (the &#8220;February 2020 Follow-on Offering&#8221;). The net proceeds to the Company from the February 2020 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $93,627. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company sold an aggregate of 384,140 shares of common stock under its &#8220;at-the-market&#8221; facility&#160;(the &#8220;ATM&#160;Facility&#8221;) for net proceeds, after deducting commissions and other offering expenses payable by the Company, of $8,130. As of December 31, 2020, approximately $41,549 of common stock remained available for future issuance under the ATM Facility. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company closed an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share (the &#8220;November 2020 Follow-on Offering&#8221;). The net proceeds to the Company from the November 2020 Follow-on Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $70,221. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company has reserved the following shares of common stock for future issuance:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for vesting of restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for exercise of outstanding stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,559,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,414,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for vesting of restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2018 Stock Option</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and Incentive Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,877,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,513</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2018 Employee</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Stock Purchase Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762,900</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,595</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2019 Inducement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365,050</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2020 Inducement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of authorized common stock reserved for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; future issuance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,266,171</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,039,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525665608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended and Restated 2015 Stock Option and Grant Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Amended and Restated 2015 Stock Option and Grant Plan, (the &#8220;2015 Plan&#8221;) provides for the Company to issue restricted stock awards and restricted stock units, or to grant incentive stock options or non-statutory stock options. Incentive stock options may be granted only to the Company&#8217;s employees including officers and members of the Board who are also employees. Restricted stock awards and restricted stock units and non- statutory stock options may be granted to employees, members of the Board, outside advisors, and consultants of the Company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total number of common shares that may be issued under the 2015 Plan was 2,008,564&#160;shares. Following the IPO, no further grants have been made under 2015 plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares that expire, are terminated, surrendered or cancelled under the 2015 Plan without having been fully exercised will be available for future awards under the 2018 Plan (as defined below). In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future awards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2015 Plan is administered by the Board. Equity awards granted to employees and members of the Board typically vest over four years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Stock Option and Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2018 Stock Option and Incentive Plan (the &#8220;2018 Plan&#8221;) was adopted by the Board on June&#160;1, 2018 and approved by stockholders on June&#160;7, 2018 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form S-1. The 2018 Plan replaced the 2015 Plan as the Board determined not to make additional awards under the 2015 Plan following the pricing of the Company&#8217;s IPO. The 2018 Plan allows the Board, compensation committee or other designated committee to make equity-based and cash-based incentive awards to its officers, employees, directors and other key persons (including consultants). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved 616,300 shares of its common stock for the issuance of awards under the 2018 Plan. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January&#160;1, beginning on January&#160;1, 2019, by 4% of the outstanding number of shares of our common stock on the immediately preceding December&#160;31, or such lesser number of shares as determined by its Board or compensation committee (the &#8220;Plan Evergreen&#8221;). This number is subject to adjustment in the event of a stock split, stock dividend or other change in its capitalization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 16, 2020, the Board adopted an amendment to the 2018 Plan (the &#8220;Amendment&#8221;), to (i) increase the number of shares of common stock currently reserved for issuance under the 2018 Plan by 3,300,000 shares and (ii) automatically terminate the 2018 Plan&#8217;s annual increase (or &#8220;evergreen&#8221;) provision after January 2022. The Amendment was approved by the Board on June 4, 2020 and the Company&#8217;s stockholders on June 4, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock available for future grant under the 2018 Plan was 3,877,478 as of December&#160;31, 2020, which does not include the shares added to the 2018 Plan reserve on January 1, 2021 as a result of the Plan Evergreen for the year ended December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, the Company granted options to purchase 3,019,663 and, 1,677,967 shares, respectively, of common stock to employees, nonemployees and members of the Board. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Board on June&#160;1, 2018 and approved by stockholders on June&#160;7, 2018 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form S-1. The ESPP is intended to qualify as an &#8220;employee sto</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ck</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purchase plan&#8221; within the meaning of Section&#160;423(b) of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,200</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock to participating employees. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January&#160;1, beginning on January&#160;1, 2019 and each January&#160;1 thereafter through January&#160;1, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028, by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1%</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the outstanding number of shares of our common stock on the immediately preceding December 31; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115,700</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares or (iii)&#160;such number of shares as determined by the ESPP administrator</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the &#8220;ESPP Evergreen&#8221;)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company issued 13,425 and 1,671 shares, respectively of common stock. The total number of shares of common stock that may be issued under the ESPP was 762,900&#160;shares as of December&#160;31, 2020, of which 762,900 shares remained available for future grant, and which does not include the shares added to the ESPP reserve on January 1, 2021 as a result of the ESPP Evergreen for the year ended December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Inducement Plan </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.85%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2019 Inducement Plan (the &#8220;2019 Plan&#8221;) was adopted by the Board on December 11, 2019. The purpose of the 2019 Plan is to allow the Company to grant equity awards to new employees as inducements material to such new employee&#8217;s acceptance of employment with the Company. The Company intends that the shares underlying the 2019 Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Nasdaq marketplace rules.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved 1,800,000 shares of its common stock for the issuance of awards under the 2019 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock available for future grant under the 2019 Plan was 365,050 as of December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Inducement Plan </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.85%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2020 Inducement Plan (the &#8220;2020 Plan&#8221;) was adopted by the Board on December 9, 2020. The purpose of the 2020 Plan is to allow the Company to grant equity awards to new employees as inducements material to such new employee&#8217;s acceptance of employment with the Company. The Company intends that the shares underlying the 2020 Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Nasdaq marketplace rules.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved 1,700,000 shares of its common stock for the issuance of awards under the 2020 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock available for future grant under the 2020 Plan was 1,700,000 as of December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Option Valuation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and members of the Board were as follows, presented on a weighted-average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option life (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">6.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">5.62</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.09</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.02</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s stock option activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,414,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000472">8.43</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,019,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(147,335</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled or forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(727,228</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,559,545</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000473">7.65</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,511</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,934,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000474">5.40</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,188</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $2,077 and $3,514, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant-date fair value of the Company&#8217;s stock options granted during the years ended December&#160;31, 2020 and 2019 was $12.28 and $11.61, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted restricted common stock (or restricted stock awards) with time-based vesting conditions to certain employees of the Company.<span style="font-weight:bold;font-style:italic;"> </span>The purchase price of the restricted stock awards are determined by the Board. Unvested shares of restricted stock awards may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. The Company has the option to repurchase the restricted stock awards at the original purchase price if the grantee terminates its working relationship with the Company prior to the vesting date. There were no unvested restricted stock awards as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted stock units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units represent an unsecured promise to grant at no cost a set number of shares of common stock upon vesting. With respect to restricted stock units, recipients are not entitled to cash dividends and have no voting rights during the vesting period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s restricted stock award and restricted stock unit activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,354</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited, cancelled or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair value of restricted stock awards and restricted stock units vested during the years ended December&#160;31, 2020 and 2019 was $29 and $50, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was allocated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,646</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,154</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,628</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, total unrecognized compensation cost related to unvested stock-based awards was $36,045, which is expected to be recognized over a weighted-average period of 3.01 years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company modified certain awards in conjunction with employee terminations. The&#160;modification&#160;provided for the extension of the post-employment exercise period. The&#160;modifications&#160;resulted in approximately $417 of additional research and development expenses for the year ended December 31, 2020. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517531125880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. 401(k) Savings Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. At the election of the Board, the Company may elect to match employee contributions. Currently, the Company makes matching contributions at a rate of 50% of the first 6% of employee contributions. The Company recorded $468 and $224&#160;of expenses related to its 401(k) match for the years ended December&#160;31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524001048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020 and 2019, the Company did not record a current or deferred income tax expense or (benefit) due to current and historical losses incurred by the Company. The Company&#8217;s operations are predominantly based in the United States and the Company&#8217;s foreign subsidiaries generated <span style="font-style:italic;">de minimis</span> losses for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company&#8217;s effective tax rate as reflected in the consolidated financial statements is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax expense at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-28.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-27.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision to Return</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets and liabilities are comprised of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S., foreign and state net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,705</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,383</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,716</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized start up and organizational costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">543</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensing agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,587</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">993</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,652</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,634</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,425</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(209</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December&#160;31, 2020 and 2019, based on the Company&#8217;s history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2020 and 2019. The valuation allowance increased $32,066 and $19,968 during the years ended December&#160;31, 2020 and 2019, respectively, due primarily to net operating losses generated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of $213,991 and $121,836, respectively, that may be available to offset future income tax liabilities. The U.S. federal tax operating loss carryforwards of approximately $17,743 will expire at various dates through 2037. Approximately $196,248 of the U.S. federal tax operating losses can be carried forward indefinitely. As of December&#160;31, 2020 and 2019, the Company also had U.S. state net operating loss carryforwards of $201,642 and $115,129, respectively, which may be available to offset future taxable income. These losses expire at various dates through 2040.<span style="font-size:12pt;">&#160;&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company has federal research and development tax credit carryforwards of $3,677 and $1,547, respectively. Included in the $3,677 of federal tax credit carryforwards are $1,351 of orphan drug credits. The Company qualifies for, and has elected to, apply part of its federal research credits against its payroll tax liability in accordance with certain provisions of the Internal Revenue Code. The amount applied towards the Company&#8217;s payroll tax liability is capped at $250 per year. The federal research credits generated in excess of the $250 cap are able to be carried forward for 20 years. As of December&#160;31, 2020 and 2019, the Company had state research and development tax credit carryforwards of approximately $894 and $214, respectively, available to reduce future tax liabilities which expire at various dates through 2034. For all years through December&#160;31, 2020, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company carries out extensive research and development activities, it seeks to benefit from the Australian research and development tax credit cash rebate regime. Under this regime, the Company&#8217;s Australian subsidiary may be eligible to surrender the trading losses that arise from its research and development activities for a payable tax credit of up to approximately 43.5% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs for research staff, consumables, certain internal overhead costs and subcontracted expenditures as part of research projects for which the Company does not receive income. For the year ended December&#160;31, 2020, the Company recorded $589 in research and development tax credits as an offset to research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a <span style="-sec-ix-hidden:F_000564">three-year</span> period in excess of 50&#160;percentage points, as defined under Sections&#160;382 </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed numerous financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States, Australia and Canada, and in several states. The foreign, federal and state income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2019. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by foreign tax authorities, the Internal Revenue Service, or state tax authorities to the extent utilized in a future period. <span style="font-size:12pt;">&#160;&#160;&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525768024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock awards and unvested restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,559,545</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,414,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards and units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,552</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525533816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Related Party Transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">UHN <span style="font-size:12pt;font-weight:normal;font-style:normal;">&#160;&#160;</span><span style="font-weight:normal;font-style:normal;">  </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entry into a license agreement with UHN on January 27, 2016, the Company issued UHN 1,161,665 shares of its common stock. Upon the closing of the IPO in 2018, as UHN&#8217;s fully-diluted percentage ownership of the Company was reduced within a range of specified percentages, the Company was obligated to pay UHN an amount of $2,000, which was paid in July 2018. For the years ended&#160;December&#160;31, 2020 and 2019, the Company recognized $381&#160;and $821, respectively, of research and development expense related to the license agreements with UHN. Refer to Note&#160;3 <span style="font-style:italic;">&#8220;License Agreements&#8221;</span> for additional information regarding the UHN license agreements. <span style="font-size:12pt;">&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Others </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020 and 2019, the Company recorded expenses of $1,488 and $1,451, respectively, related to a sublease to rent lab space, provided by an entity affiliated with a member of the board. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517529822600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of AVROBIO, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker is the chief executive officer (&#8220;CEO&#8221;). The Company and the CEO view the Company&#8217;s operations and manage its business as one operating segment. All material long-lived assets of the Company reside in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash totaling $492 as of December 31, 2019 has been reclassified from &#8220;Other assets&#8221; to &#8220;Restricted cash&#8221; in order to conform to the current period presentation. Additionally, the Company has reclassified $214 which was previously classified as &#8220;Accrued expenses and other current liabilities&#8221; as of December 31, 20219 to &#8220;Deferred rent&#8221; in order to </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conform to the current period presentation. These reclassifications had no effect on the consolidated results of operation or cash flows for the year ended December 31, 2019. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities<span style="color:#000000;"> at the date of the financial statements and the reported amounts of expenses during the reporting periods</span>. On an on&#8209;going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less at acquisition to be cash equivalents. As of December 31, 2020 and 2019,<span style="font-size:12pt;"> </span>cash and cash equivalents were primarily held in interest-bearing money market funds. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Issuance Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Issuance Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred issuance costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. <span style="font-size:12pt;">&#160;</span> As of December&#160;31, 2019, the Company recorded deferred issuance costs of $133 within other assets on the consolidated balance sheet related to a follow-on offering of common stock completed in February 2020. There were<span style="font-size:12pt;"> </span>no amounts deferred as of December 31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.64%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 1&#8212;</span><span style="color:#000000;"> </span><span style="font-size:10pt;color:#000000;">Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.64%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.64%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s financial instruments, which include cash equivalents, accounts payable, and accrued expenses, approximated their fair values as of December&#160;31, 2020 and 2019 due to the short</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;term nature of these instruments.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the estimated fair value of financial instruments using available market information. The use of different market assumptions, estimation methodologies, or both, could have a significant effect on the estimated fair value amounts. See Note 4<span style="font-style:italic;"> &#8220;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Fair Value of Financial Assets and Liabilities&#8221;</span><span style="font-style:italic;"> </span>for further discussion.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Depreciation and amortization is calculated using the straight-line method over the following estimated useful lives of the assets: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000271">Lesser of lease term or 10 years</span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. <span style="color:#000000;">The Company did not record any impairment loss during the years ended December 31, 2020 and 2019.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company categorizes leases at their inception as either operating or capital leases. On certain lease arrangements, the Company may receive rent holidays or other incentives. The Company recognizes lease costs on a straight-line basis once control of the space is achieved, without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments or escalating payment amounts. The difference between required lease payments and rent expense has been recorded as deferred rent and accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Additionally, incentives received are treated as a reduction of costs over the term of the agreement, as they are considered an inseparable part of the lease agreement.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as the change in stockholders&#8217; equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) as well as other changes in stockholders&#8217; equity (deficit) which includes certain changes in equity that are excluded from net income (loss). Comprehensive loss has been disclosed in the accompanying consolidated statements of operations and comprehensive loss and equals the Company&#8217;s net loss for all periods presented. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Translation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s international operations in Canada and Australia is the U.S. dollar. Accordingly, all operating assets and liabilities of these international subsidiaries are remeasured into U.S. dollars using the exchange rates in effect at the balance sheet date or historical rates, as appropriate, while expenses are remeasured into U.S. dollars at the average rates in effect during the period. Any differences resulting from the remeasurement of assets, liabilities, and operations of the Canadian and Australian subsidiaries are recorded within other income (expense), net in the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated statements of operations and comprehensive loss. During the years ended December&#160;31, 2020 and 2019, the Company recorded foreign exchange losses of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, in other expense.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development related contracts with parties both inside and outside of the United States. The payments related to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. <span style="color:#000000;">Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span> </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock-based awards issued to employees and members of the Company&#8217;s board of directors (the &#8220;Board&#8221;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance- or market-based vesting conditions. The Company accounts for forfeitures as they occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2018-07,&#160;<span style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span>, the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the Company&#8217;s adoption of ASU 2018-07 in 2018, the measurement date for non-employee awards is the later of the adoption date of ASU 2018-07, or the date of grant, without change in the fair value of the award. For stock-based awards granted to nonemployees subject to graded vesting that only contain service conditions, the Company has elected to recognize stock-based compensation expense using the straight-line recognition method.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s cash compensation costs are classified. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the absence of an active market for the Company&#8217;s common stock prior to its initial public offering (&#8220;IPO&#8221;), the Company and the Board, the members of which the Company believes have extensive business, finance, and venture capital experience, were required to estimate the fair value of the Company&#8217;s common stock at the time of each grant of a stock-based award. The Company and the Board determined the estimated fair value of the Company&#8217;s equity instruments based on a number of factors, including external market conditions affecting the biotechnology industry sector. The Company and the Board utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, <span style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span>, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors in determining the value of the Company&#8217;s common stock at each grant date, including: (1)&#160;prices paid for the Company&#8217;s redeemable convertible preferred stock, which the Company had sold to outside investors in arm&#8217;s-length transactions, and the rights, preferences, and privileges of the Company&#8217;s redeemable convertible preferred stock and common stock; (2)&#160;valuations performed by an independent valuation specialist; (3)&#160;the Company&#8217;s stage of development; (4)&#160;the fact that the grants of stock-based awards involved illiquid securities in a private company; and (5)&#160;the likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as an IPO or sale of the Company, given prevailing market conditions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. As there was no public market for its common stock prior to June&#160;21, 2018, which was the first day of trading, and as the trading history of the Company&#8217;s common stock was limited through December&#160;31, 2020, the Company determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by adjusting the weighted-average shares outstanding for the potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For purposes of the diluted net loss per share calculation, stock options and restricted stock units are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Event Considerations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subsequent Event Considerations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#8220;emerging growth company.&#8221; Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an &#8220;emerging growth company.&#8221; </p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No.&#160;2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and Topic 606</span>, or ASU 2018-18. The amendments in ASU 2018-18 clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU 2018-18 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606. The Company adopted ASU 2018-18 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <span style="font-style:italic;">Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), </span>or ASU 2018-15.&#160;ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span>, or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure requirements for fair value measurements. The amendments are effective for interim and annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted for either the entire ASU or only the provisions that eliminate or modify requirements. The amendments with respect to changes in unrealized gains and losses, the range and weighted-average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively. All other amendments are to be applied retrospectively to all periods presented. The Company adopted ASU 2018-13 during the quarter ended March&#160;31, 2020. The adoption did not have a material impact on the consolidated financial statements. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02, <span style="font-style:italic;">(Topic 842) Leases, </span>or ASU 2016-02.&#160;ASU 2016-02&#160;requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. For public entities,&#160;ASU 2016-02&#160;is effective for fiscal years beginning after December&#160;15, 2018. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;ASU 2016-02&#160;is effective for the Company for the year ended December 31, 2022, and all interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. Based on this evaluation t<span style="color:#000000;">he Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the Company&#8217;s total assets and total liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, or ASU 2016-13. ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity's current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.<span style="color:#000000;"> </span>ASU 2016-13 is effective for non-emerging growth companies (&#8220;EGCs&#8221;) for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2016-13 may have on its financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="font-size:8pt;">&#160;</span>November 2019, the FASB issued ASU 2019-11, &#8220;<span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span>&#8221;, or ASU 2019-11. ASU 2019-11 is an accounting pronouncement that amends ASU 2016-13, &#8220;<span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>.&#8221; The amendments update guidance on reporting credit losses for financial assets. These amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in both ASU 2016-13 and ASU 2019-11 are </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. </span><span style="color:#000000;">As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section&#160;107(b) of the JOBS Act,&#160;2016-13 and ASU 2019-11&#160;are effective for the Company for fiscal years beginning after December 15, 202</span><span style="color:#000000;">2</span><span style="color:#000000;">, and interim periods within </span><span style="color:#000000;">those </span><span style="color:#000000;">fiscal years. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is currently evaluating ASU 2016-13 and ASU 2019-11 and their impact on its consolidated financial statements and financial statement disclosures.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span>, or ASU 2019-12. ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for non-EGCs for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years and will be effective for the Company for fiscal years beginning after December 15, 2021 and interim periods beginning after December 15, 2022, assuming the Company remains an EGC. Early adoption is permitted. The Company is currently evaluating the effects the adoption of ASU 2019-12 may have on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Pronouncements Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525500328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Property and Equipment Estimated Useful Life</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Depreciation and amortization is calculated using the straight-line method over the following estimated useful lives of the assets: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000271">Lesser of lease term or 10 years</span></p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517602699560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents&#8212;money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,416</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents&#8212;money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,797</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524185496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax incentive refund</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,558</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,915</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">973</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid compensation benefits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,560</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,658</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,965</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,456</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,377</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,234</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,064</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,696</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Summary of Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company had restricted cash as presented in the table below, which consists of cash used to secure letters of credit for the benefit of the landlord in connection with the Company&#8217;s lease agreements. The cash will be restricted until the termination or modification of the lease arrangement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and benefit costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,402</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,028</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,847</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,794</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting and professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,096</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517523898648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments Due Under Operating Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the future minimum lease payments due under operating leases as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,078</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,297</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517602835064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock Reserved for Future Issuance</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company has reserved the following shares of common stock for future issuance:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for vesting of restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for exercise of outstanding stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,559,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,414,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for vesting of restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2018 Stock Option</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and Incentive Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,877,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,513</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2018 Employee</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Stock Purchase Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762,900</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,595</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2019 Inducement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365,050</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,800,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance under the 2020 Inducement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of authorized common stock reserved for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; future issuance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,266,171</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,039,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517523967752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and members of the Board were as follows, presented on a weighted-average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option life (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">6.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">5.62</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.09</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.02</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s stock option activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,414,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000472">8.43</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,019,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(147,335</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled or forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(727,228</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,559,545</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000473">7.65</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,511</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,934,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000474">5.40</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,188</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Award and Restricted Stock Unit Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s restricted stock award and restricted stock unit activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,354</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited, cancelled or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was allocated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,646</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,154</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,628</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517530416472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense (Benefit)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company&#8217;s effective tax rate as reflected in the consolidated financial statements is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax expense at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-28.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-27.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision to Return</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets and liabilities are comprised of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S., foreign and state net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,705</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,383</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,716</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized start up and organizational costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">543</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensing agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,587</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">993</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,652</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,634</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,425</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(209</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524228520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,559,545</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,414,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards and units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,552</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517603387768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (264,416)<span></span>
</td>
<td class="num">$ (144,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 259,682<span></span>
</td>
<td class="nump">$ 187,043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517530334520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_SignificantOfAccountingPoliciesLineItems', window );"><strong>Significant Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 492,000<span></span>
</td>
<td class="nump">$ 492,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Deferred issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_ForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member', window );">ASU No. 2018-18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_SignificantOfAccountingPoliciesLineItems', window );"><strong>Significant Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member', window );">ASU No. 2018-15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_SignificantOfAccountingPoliciesLineItems', window );"><strong>Significant Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member', window );">ASU No. 2018-13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_SignificantOfAccountingPoliciesLineItems', window );"><strong>Significant Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_SignificantOfAccountingPoliciesLineItems', window );"><strong>Significant Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Expected cash dividend yield</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_SignificantOfAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant of accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_SignificantOfAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524131032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment estimated useful life</a></td>
<td class="text">Lesser of lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517518803112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Detail)<br> &#163; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Oct. 02, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 17, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 27, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 27, 2016 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_CostOfMilestonePayment', window );">Accrued upfront license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,569,000<span></span>
</td>
<td class="nump">31,673,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,236,000<span></span>
</td>
<td class="nump">$ 54,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avro_UniversityOfManchesterAgreementMember', window );">University of Manchester Agreement [Member] | MPSII License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_UpfrontLicenseFees', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePaymentPaid', window );">Milestone payment paid</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePaymentDue', window );">Milestone payment due</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_AgreementExpirationPeriod', window );">Agreement Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_AgreementExpirationDescription', window );">Agreement Expiration Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">upon the later of 15 years from the effective date or the expiration of the last valid claim of the licensed patents<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense', window );">Research and development expense | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avro_UHNagreementMember', window );">UHN Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="nump">$ 783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestoneFees', window );">Milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avro_UHNagreementMember', window );">UHN Agreement [Member] | Fabry License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_UpfrontLicenseFees', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_OptionFee', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avro_UHNagreementMember', window );">UHN Agreement [Member] | Interleukin 12 License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_UpfrontLicenseFees', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestoneFees', window );">Milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseMaintenanceFees', window );">Annual maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_PaymentsUponClosingOfInitialPublicOffering', window );">Payments upon closing of an initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avro_BioMarinPharmaceuticalIncMember', window );">BioMarin Pharmaceutical Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_UpfrontLicenseFees', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementExpenses', window );">Expenses related to license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avro_GenstemTherapeuticsIncMember', window );">GenStem Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_UpfrontLicenseFees', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avro_LundUniversityRightsHoldersAgreementMember', window );">Lund University Rights Holders Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LicenseAgreementExpenses', window );">Expenses related to license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_AgreementExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_AgreementExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_AgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_AgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical trial cost related to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_CostOfMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_CostOfMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_LicenseAgreementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_LicenseAgreementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_MilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_MilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_MilestonePaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_MilestonePaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_MilestonePaymentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_MilestonePaymentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_OptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_OptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_PaymentsUponClosingOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments upon closing of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_PaymentsUponClosingOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_UpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_UpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avro_UniversityOfManchesterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avro_UniversityOfManchesterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avro_MPSIILicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avro_MPSIILicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avro_UHNagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avro_UHNagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avro_FabrylicenseagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avro_FabrylicenseagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avro_Interleukin12LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avro_Interleukin12LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avro_BioMarinPharmaceuticalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avro_BioMarinPharmaceuticalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avro_GenstemTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avro_GenstemTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avro_LundUniversityRightsHoldersAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avro_LundUniversityRightsHoldersAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517602782536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value on Recurring Basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets Fair Value Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets Fair Value Disclosure</a></td>
<td class="nump">$ 44,416<span></span>
</td>
<td class="nump">$ 186,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets Fair Value Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets Fair Value Disclosure</a></td>
<td class="nump">44,416<span></span>
</td>
<td class="nump">186,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets Fair Value Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets Fair Value Disclosure</a></td>
<td class="nump">44,416<span></span>
</td>
<td class="nump">186,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member] | Money Market Funds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets Fair Value Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets Fair Value Disclosure</a></td>
<td class="nump">$ 44,416<span></span>
</td>
<td class="nump">$ 186,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525486824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_FairValueInputAmountTransferBetweenLevels', window );">Fair value input transfer between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_FairValueInputAmountTransferBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value input amount of assets and liabilities between levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_FairValueInputAmountTransferBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517602742200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_SupplementalBalanceSheetInformationDisclosuresAbstract', window );"><strong>Supplemental Balance Sheet Information Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_TaxIncentiveRefundCurrent', window );">Tax incentive refund</a></td>
<td class="nump">$ 2,558<span></span>
</td>
<td class="nump">$ 1,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development expenses</a></td>
<td class="nump">3,145<span></span>
</td>
<td class="nump">4,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_PrepaidCompensationBenefits', window );">Prepaid compensation benefits</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest income receivable</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 7,560<span></span>
</td>
<td class="nump">$ 8,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_PrepaidCompensationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid compensation benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_PrepaidCompensationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_SupplementalBalanceSheetInformationDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental balance sheet information disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_SupplementalBalanceSheetInformationDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_TaxIncentiveRefundCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax incentive refund current .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_TaxIncentiveRefundCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517530045960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 5,485<span></span>
</td>
<td class="nump">$ 4,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(2,421)<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">3,965<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524212808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_SupplementalBalanceSheetInformationDisclosuresAbstract', window );"><strong>Supplemental Balance Sheet Information Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1,207<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_SupplementalBalanceSheetInformationDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental balance sheet information disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_SupplementalBalanceSheetInformationDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517523048328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Summary of Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted Cash And Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524040248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Summary of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefit costs</a></td>
<td class="nump">$ 6,402<span></span>
</td>
<td class="nump">$ 3,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">5,847<span></span>
</td>
<td class="nump">5,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and professional fees</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 13,693<span></span>
</td>
<td class="nump">$ 9,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517518715704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 09, 2020</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th">
<div>Jan. 12, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_LeaseExpirationMonthAndYear', window );">Lease agreement expiration month and year</a></td>
<td class="text">2022-04<span></span>
</td>
<td class="text">2025-06<span></span>
</td>
<td class="text">2020-10<span></span>
</td>
<td class="text">2023-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_OperatingLeaseAnnualIncreaseInRentalPercentage', window );">Percentage of annual increase in rent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant incentive allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_AnnualLeasePaymentsDescription', window );">Annual lease payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The annual lease payments are fixed for years 1 and 2, and then subject to a 6.67% increase for years 3 through 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,352<span></span>
</td>
<td class="nump">$ 2,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=avro_RestrictedCashMember', window );">Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit in connection with lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-term Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit in connection with lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Cambridge, Massachusetts | Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit in connection with lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_AnnualLeasePaymentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual lease payments, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_AnnualLeasePaymentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_OperatingLeaseAnnualIncreaseInRentalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease annual increase in rental percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_OperatingLeaseAnnualIncreaseInRentalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=avro_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=avro_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517529810696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments Due Under Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 2,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 3,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases future minimum payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517520240088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_UndesignatedPreferredStock', window );">Undesignated preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_UndesignatedSharesOfPreferredStockOutstanding', window );">Undesignated shares of preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Cash dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_JulyTwoThousandNineteenFollowOnOfferingMember', window );">July 2019 Follow-on Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_JulyTwoThousandNineteenFollowOnOfferingMember', window );">July 2019 Follow-on Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_FebruaryTwoThousandTwentyFollowOnOfferingMember', window );">February 2020 Follow-on Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_FebruaryTwoThousandTwentyFollowOnOfferingMember', window );">February 2020 Follow-on Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember', window );">ATM Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance', window );">Common stock remained available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_NovemberTwoThousandTwentyFollowOnOfferingMember', window );">November 2020 Follow-on Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 70,221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avro_NovemberTwoThousandTwentyFollowOnOfferingMember', window );">November 2020 Follow-on Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance price per shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares amount available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_UndesignatedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undesignated preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_UndesignatedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_UndesignatedSharesOfPreferredStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undesignated shares of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_UndesignatedSharesOfPreferredStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avro_JulyTwoThousandNineteenFollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avro_JulyTwoThousandNineteenFollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avro_FebruaryTwoThousandTwentyFollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avro_FebruaryTwoThousandTwentyFollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avro_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avro_NovemberTwoThousandTwentyFollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avro_NovemberTwoThousandTwentyFollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517529970440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Summary of Common Stock Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">12,266,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,039,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">5,559,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,414,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenStockOptionAndIncentivePlanMember', window );">2018 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">3,877,478<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">332,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">762,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandNineteenInducementPlanMember', window );">2019 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">365,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandTwentyInducementPlanMember', window );">2020 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandNineteenInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avro_TwoThousandNineteenInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandTwentyInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avro_TwoThousandTwentyInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517520396184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">12,266,171<span></span>
</td>
<td class="nump">6,039,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">3,019,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 2,077<span></span>
</td>
<td class="nump">$ 3,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options Granted, Weighted-average grant-date fair value</a></td>
<td class="nump">$ 12.28<span></span>
</td>
<td class="nump">$ 11.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">32,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock awards and restricted stock units vested</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses</a></td>
<td class="nump">36,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_AdditionalResearchAndDevelopmentExpense', window );">Additional research and development expenses</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenStockOptionAndIncentivePlanMember', window );">2018 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares that may be issued under the plan</a></td>
<td class="nump">616,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for future grant</a></td>
<td class="nump">3,877,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage', window );">Number of shares of common stock outstanding, increase, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">3,877,478<span></span>
</td>
<td class="nump">332,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">3,019,663<span></span>
</td>
<td class="nump">1,677,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avro_TwoThousandFifteenStockOptionAndGrantPlanMember', window );">2015 Stock Option and Grant Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares that may be issued under the plan</a></td>
<td class="nump">2,008,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for future grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares that may be issued under the plan</a></td>
<td class="nump">762,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for future grant</a></td>
<td class="nump">762,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Employee Stock Purchase Plan, description</a></td>
<td class="text">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January&#160;1, beginning on January&#160;1, 2019 and each January&#160;1 thereafter through January&#160;1, 2028, by the least of (i) 1% of the outstanding number of shares of our common stock on the immediately preceding December 31; (ii) 1,115,700 shares or (iii)&#160;such number of shares as determined by the ESPP administrator (the &#8220;ESPP Evergreen&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common shares issued</a></td>
<td class="nump">13,425<span></span>
</td>
<td class="nump">1,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares that may be issued under the plan</a></td>
<td class="nump">223,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage', window );">Number of shares of common stock outstanding, increase, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of common shares that may increase under the plan</a></td>
<td class="nump">1,115,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avro_TwoThousandNineteenInducementPlanMember', window );">2019 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares that may be issued under the plan</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for future grant</a></td>
<td class="nump">365,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avro_TwoThousandTwentyInducementPlanMember', window );">2020 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares that may be issued under the plan</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for future grant</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_AdditionalResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_AdditionalResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding increase percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avro_TwoThousandEighteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avro_TwoThousandFifteenStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avro_TwoThousandFifteenStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avro_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avro_TwoThousandNineteenInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avro_TwoThousandNineteenInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avro_TwoThousandTwentyInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avro_TwoThousandTwentyInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524025912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.76%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.02%<span></span>
</td>
<td class="nump">76.83%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517530030504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding beginning balance</a></td>
<td class="nump">3,414,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">3,019,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="num">(147,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Cancelled or forfeited</a></td>
<td class="num">(727,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding ending balance</a></td>
<td class="nump">5,559,545<span></span>
</td>
<td class="nump">3,414,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable</a></td>
<td class="nump">1,934,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding beginning balance</a></td>
<td class="nump">$ 12.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">18.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Cancelled or forfeited</a></td>
<td class="nump">19.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding ending balance</a></td>
<td class="nump">14.97<span></span>
</td>
<td class="nump">$ 12.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 10.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, Outstanding balance</a></td>
<td class="text">7 years 7 months 24 days<span></span>
</td>
<td class="text">8 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding balance</a></td>
<td class="nump">$ 13,511<span></span>
</td>
<td class="nump">$ 29,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">$ 11,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517525689960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Award and Restricted Stock Unit Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Issued and unvested beginning balance | shares</a></td>
<td class="nump">32,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(31,354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Issued and unvested ending balance | shares</a></td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Issued and unvested, beginning balance | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested | $ / shares</a></td>
<td class="nump">0.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Issued and unvested, ending balance | $ / shares</a></td>
<td class="nump">$ 15.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517524115432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,628<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">8,207<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,421<span></span>
</td>
<td class="nump">$ 3,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517602744856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Defined contribution plan, description</a></td>
<td class="text">Currently, the Company makes matching contributions at a rate of 50% of the first 6% of employee contributions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percent of employee contributions</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, expense</a></td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517602582744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Deferred tax assets change in valuation allowance</a></td>
<td class="nump">32,066,000<span></span>
</td>
<td class="nump">19,968,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred tax assets, operating loss carryforwards, domestic</a></td>
<td class="nump">213,991,000<span></span>
</td>
<td class="nump">$ 121,836,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">196,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_PayrollTaxLiabilityCappedPerYear', window );">Payroll tax liability capped per year</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax reconciliation tax credit research</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_TaxCreditCarryforwardsExpirationPeriod', window );">Income tax credit carryforward expiration period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered', window );">Percentage of cumulative changes in ownership interest subject to annual limitation</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered', window );">Period of cumulative changes in ownership interest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits carryforwards</a></td>
<td class="nump">$ 3,677,000<span></span>
</td>
<td class="nump">$ 1,547,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax reconciliation tax credit research</a></td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Australia [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=avro_OrphanDrugCreditMember', window );">Orphan Drug Credit [Member] | U.S. federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits carryforwards</a></td>
<td class="nump">$ 1,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=avro_ExpirationThrough2037Member', window );">Expiration Through 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, subject to expiration</a></td>
<td class="nump">17,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=avro_ExpirationThrough2039Member', window );">Expiration Through 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets, operating loss carryforwards, state</a></td>
<td class="nump">201,642,000<span></span>
</td>
<td class="nump">115,129,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=avro_ExpirationThrough2033Member', window );">Expiration Through 2033 [Member] | State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits carryforwards</a></td>
<td class="nump">$ 894,000<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_PayrollTaxLiabilityCappedPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll tax liability capped per year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_PayrollTaxLiabilityCappedPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_TaxCreditCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforwards Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_TaxCreditCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=avro_OrphanDrugCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=avro_OrphanDrugCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=avro_ExpirationThrough2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=avro_ExpirationThrough2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=avro_ExpirationThrough2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=avro_ExpirationThrough2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=avro_ExpirationThrough2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=avro_ExpirationThrough2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517602715192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_EffectiveIncomeTaxRateReconciliationPermanentDifference', window );">Permanent differences</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(28.30%)<span></span>
</td>
<td class="num">(27.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Provision to Return</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_EffectiveIncomeTaxRateReconciliationPermanentDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent difference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_EffectiveIncomeTaxRateReconciliationPermanentDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517529303768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">U.S., foreign and state net operating loss carryforwards</a></td>
<td class="nump">$ 57,705<span></span>
</td>
<td class="nump">$ 33,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">4,383<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts', window );">Capitalized start up and organizational costs</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity based compensation</a></td>
<td class="nump">2,944<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_DeferredTaxAssetsLicenseAgreement', window );">Licensing agreements</a></td>
<td class="nump">4,004<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">70,652<span></span>
</td>
<td class="nump">38,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(70,492)<span></span>
</td>
<td class="num">(38,425)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">$ (160)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized start up and organizational costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_DeferredTaxAssetsLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_DeferredTaxAssetsLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517531199704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">5,559,545<span></span>
</td>
<td class="nump">3,414,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avro_RestrictedStockAwardsAndUnitsMember', window );">Restricted Stock Awards and Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">32,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avro_RestrictedStockAwardsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avro_RestrictedStockAwardsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140517609730440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2016</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,236,000<span></span>
</td>
<td class="nump">$ 54,974,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avro_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avro_ProvisionForMaximumCashPayment', window );">Provision for maximum cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,000<span></span>
</td>
<td class="nump">821,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avro_LicenseAgreementMember', window );">License Agreement [Member] | Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock issued for initial consideration for license</a></td>
<td class="nump">1,161,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avro_SubleaseAgreementMember', window );">Sub-lease Agreement [Member] | Officers and Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,488,000<span></span>
</td>
<td class="nump">$ 1,451,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avro_ProvisionForMaximumCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision for maximum cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avro_ProvisionForMaximumCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avro_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avro_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avro_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avro_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avro_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avro_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avro_OfficersAndBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avro_OfficersAndBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MFV'3#T(;X/L-Y^HTT!]H_T8L_P-02P,$%     @ ;X9R4B0XO[%^!0  GAD
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M[=[Q8YV( P"T#0!4 U /(#.C!]@UP.X#D '@U #GJ0"W!K@]@.,9 %X-\/H
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MT"X SPNE[,9Q";H_C_%?4$L#!!0    ( &^&<E([LX>DBP8  )<;   8
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MHB66$R+.GG5$9MS3?R1@)%7>BCI2",3'C\(EH&7[02"T3#VP'%IM:HTX:<T
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M\*)E%R*5[UWU";$)>4P-^D,="[8L^;FL,ZS:788VDUC :1-;.*01 I=Q1^$
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M$;T),F'3D.]>=Z5FF%G6/G);P00*@)C)4:K$9(]S74]F(("N,A$[)/FL-5[
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M67"BO7N=^AM!*N0._QN9"5,F/#Q_3++TZSA]':]$RWUN6\ V^D&M:4,QGG
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MWQV)X0Q_D+_CW[U<NKYW&_ZX-B6EHEA SU?.]>$/'!!_"/7Y_P%02P,$%
M  @ ;X9R4B#;R^W<#@  /C@  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&ULW5MID]LV$OTKK(DKE51I#FG.Q$?5V(G7WHJ=J3C9_;"U'R 2DK!#$@P
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M2SQDLQD2F+^2LYEDWA$,[,W$$KSEPIY*@2W!U@J!70I5Q>M=+'I$VXQ5MC4
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MYG4[0S_/>0O2#]],V]AA48\00#*R$PC$9U ,RS-7VY8\TN&Y7!I<C&Z:ZNU
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M\ V%>%2(/>_!D&=YPRS;K+7:4^VD$<U]>%>]-I+CTB7EP6H\Y:AG-P]]UPG
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M@=<8/5QTAH55G;]<;)7%JXK_;/!N"-H)X'FME#TLG('IMKGY&U!+ P04
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M(,4Q[W>45IUXSP'V+*X>Y1_@8)]!CM-U&]*B=L)$QY7&"($QK@A#(#_)-8%
MZVO%M""7/+?E T$AUQOWV.0>)P]F-4)(FP3\-MS& #H18+1U8;OR)[%C.0Q$
MK#YMDD@+;<\&;9^$%4&#Y.2N.HC9-)CZH^&P%9O(0B<^J^2+V(NHAH/Z\6=?
MH74.)WPY"@@U,^2_'32HUVQ6RBV  CAR2%I0BKNX!05 (P)0)'BT83_RK(2^
M D-C"5Z:9>0&6?L]\+CP,4S&WU4.@ND+%$=J/(9;" @=W;AHD6DJ8@D^ 'Q
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MQN'H='G6<!R+-@_[Z=W:&>!IHPKYI] ':;S,*0^X!@Q>A.'(#SOEP+Y'U0V
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M>NTL$*YGR6)\N9P$^VCP3>/.'ZTA1+)R;ALVG\M9D@5!:+#@@*#D\8!7:$P
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MFAYCM&Q YY6A/ T;OF!\WE=_ 5!+ P04    " !OAG)2Z3Z#SI@=  "E80
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M8.CYXBGXCIK_)@#_ NZ8WL._MDUC]_3C3F>%KO$!^'YC;>-_P07"7V;X\?\
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MN[<J+NPT.P%ZX5NZ(9FJI*W[7KO:OAJSNEF^F-=/SC75"R8-7K8"7:/#X5%
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MY9I:.I]JM2?:>2.:$WRI/AK),>F:<F<U6AG&V?E*"<$LWK(UA,J"K)2T3.Y
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M*&*.$*A9:&PD.=/6$V#*DIC=?F^D>PD_VSPD !0/<BSN3H=#E@X3]DEF?C(
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MS)^M]&*F&BNXQ)4&TU05TT]+%*J=!W&P.[CEV]*Z@V@QJ]D6UVB_U2M-NVA
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MG9F,A^4<3D_.X 0HAQ^5:!3AA4I];619<C_O)$Q;"=$1"7/,!Q"'7R *HN
M?/9I>'CU&NX;,WI'HMZ1R/'%1_CNY)IP^J\M=R:X$HP6;33A!2PD*N2ZW;@K
MX89RPG-J;%J:330-KA7\GJR4EJ9%_WP@*.X%Q4Y0<D30),^;NF&&O+ -2G.J
M#YG<DHP<B9W=;78>C9(D'*7^=M_- WEADEP$29_W2F72JTP^5#DCJ@+3 )#;
M!3XU=$N8->.0UN2=AFAX-;J,WDA]GQ9>&J'Q&Z7^7OO;J^<;D6O*%3 L#3 8
M7 P]D.TXMX$6&S<1*Z'-?+EE96Y E#;!G)="Z)? #EE_IV;_ 5!+ P04
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M.3S!RT.W_;2=6%7['K94%CNB'U;X#P+:&>!^J93=3%R \%<S^0M02P,$%
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MH2.KK^C5C1)I^?'S6B@EXO)RS:B>^:*!?K\20CW>%-]3F__+</@_4$L#!!0
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M[OON[M-):6?LHZL D#W52KMY5"$VUYR[O():N(EI0--.:6PMD%R[YZZQ((H
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M3SY?1LSV-Z%WT#1AF'8&:32#6='C =8'T'YI#+XX?C['YRC["U!+ P04
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MK37A+213$(<:L%.%ZKQ_MW>K8-WWZ/;NKL2]]G:W-QB%K3UUZ%5\>Z]TN_Z
M+#B+T762";ZT<U2^17[L;>:S]_X%P+7/ 7Z/$I1>Z_+BH-/9JD&C5;AGY.#-
M0,;^0<XCGF2Y O%W)P!O9C ._D,)-B,4'YZA_UJ"<&>>XS#8KD"#T<[4=&O7
M"7.7NR5B3E.)&,PTRCOKZ **XGI4+!3/[ UCRI6^K]C'A;Y2@C &^OV,<[5>
MF$M+=4D=_@%02P,$%     @ ;X9R4C-/)*I4 @  9 4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&ULI53);MLP$/T50L@A 5IK\9(TD 5X:=$< AAQ
MTQZ*'FAI;!&A2)6D;+=?WR$IJVH:!P5ZD3C#>6\VSJ0'J9YT"6#(L>)"3X/2
MF/HV#'5>0D7U0-8@\&8K544-BFH7ZEH!+1RHXF$219.PHDP$6>IT*Y6ELC&<
M"5@IHINJHNK''+@\3(,X."D>V*XT5A%F:4UWL ;S6*\42F''4K *A&92$ 7;
M:3"+;Q<C:^\,/C,XZ-Z9V$PV4CY9X:Z8!I$-"#CDQC)0_.UA 9Q;(@SC>\L9
M="XML'\^L7]PN6,N&ZIA(?D75IAR&MP$I( M;;AYD(>/T.8SMGRYY-I]R:&U
MC0*2-]K(J@5C!!43_D^/;1UZ@'AR!I"T@.0Y8'0&,&P!0Y>HC\REM:2&9JF2
M!Z*L-;+9@ZN-0V,V3-@NKHW"6X8XDZV;NN: ;3&4DSGE5.1 UN[]W G_2&RU
MWY)943![1+/^Q>42#&7\"BT>UTMR>7%%+@@3Y%,I&TU%H=/08)C669BW(<U]
M2,F9D.*$W$MA2DW>BP**/PE"S*]+,CDE.4]>95Q"/B##^ U)HB1Z(:#%/\/C
M=Z^$,^QJ/G1\P_^K^9+IG$O=*-#DZVRCC<(W_^T5_Z/._\CY'YW-!P<^9]X+
M]HC02BK#?GH%''%#:'BI;YYVXFCM>MACKZ+K--SW:_FWT<TXZFQ\P&'OP5:@
M=FZ.-<EE(XQO:Z?M5L7,3<@S_1Q7B)_XWS1^_]Q3M6-"$PY;I(P&U^. *#_3
M7C"R=F.QD0:'S!U+7(.@K '>;Z4T)\$ZZ!9K]@M02P,$%     @ ;X9R4D5$
M4J\5 @  F00  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULC51-;]LP
M#/TKA-%#"VR18Z?=6C@&\H%A/0P(DG4[##LH-AT+E25/4N+NWX^2W2 ;FJX7
M6Z3X'LDG2EFGS:.M$1T\-5+9:50[U]XQ9HL:&VY'ND5%.Y4V#7=DFAVSK4%>
M!E C61+'-ZSA0D5Y%GPKDV=Z[Z10N#)@]TW#S>\Y2MU-HW'T[%B+7>V\@^59
MRW>X0??0K@Q9[,A2B@:5%5J!P6H:S<9WB]3'AX!O CM[L@;?R5;K1V_<E],H
M]@6AQ,)Y!DZ_ RY02D]$9?P:.*-C2@\\73^S?PJ]4R];;G&AY7=1NGH:?8R@
MQ(KOI5OK[C,._5Q[OD)+&[[0#;%Q!,7>.MT,8*J@$:K_\Z=!AQ/ >'(&D R
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M5WIVVF6I_VX@C(%^7W"N=ALS0/O_Y>PO4$L#!!0    ( &^&<E*:HR10* 0
M '0/   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+U746_B.!#^*Q;:
MDW:E0N*$!+H")!;::U>MKFJ[=P^K>S#!$-\F-F<[I97NQ]_8"8'28+A;J2\D
M#OZ^&<]\,[8':R%_J)12C9[SC*MA*]5Z]=GS5)+2G*B.6%$._RR$S(F&H5QZ
M:B4IF5M0GGF![\=>3AAOC0;VVYT<#42A,\;IG42JR',B7[[03*R'+=S:?+AG
MRU2;#]YHL")+^D#UM]6=A)%7L\Q93KEB@B-)%\/6&'^^PK$!V!F_,[I6.^_(
M+&4FQ \SN)X/6[[QB&8TT8:"P..)3FB6&2;PX^^*M%7;-,#=]PW[I5T\+&9&
M%)V([ \VU^FPU6^A.5V0(M/W8GU%JP5%AB\1F;*_:%W-]5LH*906>04&#W+&
MRR=YK@*Q \#= X"@ @2G L(*$)X*Z%: [AX@P < 406(]@ '%QU7@/A4"[T*
MT#L5T*\ ?9O=,ATVEU.BR6@@Q1I),QO8S(L5A$5#"ADWVGW0$OYE@-.CB<AS
MID&,6B'"YV@BN&9\27G"J$)M-)[/F1$9R= U+TO%2.[CE&K"LD_H V(</::B
M4(!69WOC@:?!1V/)2RI_OI3^! ?\^5KP#O+/SU#@!WX#?'(*'!^$3]WP<;'L
MH-#"<;\!?G'$.@'K."CAWQZFZ..'3PTLEVZ6*4TV3@3^899?3V;!YX=9KOZ#
M+Y-Q XL'@JM5%]2J"RQM>(+JQF]4-V4JR80J)$7?;P")KC7-U9\.NV%M-[1V
MNP?LWE!H<X@L):7&.*+/*R9+1>?@0FI+X(42V21<-S4$*&C[W2;)'@5&;3]N
M$NM1H-_&32J_. H,VSYVQ+-;Q[/K9+JC,H$XPB:'Q *"QPOH$XPGTL:9F=V-
MZZ98NFFCCN__TA1)-RSNQ+TFV(4;%KZU]BH841V,R,GS2#D!3<'R8=&P(2.2
MP<F P+#)IY(KMESF@/$TZG>#@??4X$!<.Q ['1B7\<]L\%?DQ=;7&>SD*I%L
M953>U(S<G(\IW>3U-2\B4)X+]DSG"+8%6S0*85M T #-0Z>4PYEH]A<<4Y 6
MB"";H*T^MK@0)DM1+%,4.1+1J^/0<_I\7Y4VG+":0G_9>Q/Z((RVL2^[:\.D
M(.HU)ZA?.]8_XIC2DB4:8C8A*D7?;VD^H]+5V<YKZO-W[:C8WQX@?.>B'FA2
M2*9?0&<KH9@I )0(SJO#Z9I!6[72:=P)2^YH-\S]<"\51R:]]GOGX(.=?O\&
M^I3H1O!E6U.9H[%2%()W0D[P=IO#[[O/X>U&A]T]_F>R<E5QOQ+_ >GC[5:!
MW6UV0O*99/,E/4.W1"F2I 4$' +S#_H?=8&W71E'[YN#;3O&[M[Y<Y41O\V!
M?[Y?&>Y)I=_>SNW W$=OB5PRKL#T E!^IP?QD^45KQQHL;(7AIG0</VPKRE<
MBZDT$^#_A1!Z,S!WD/JB/?H74$L#!!0    ( &^&<E+"+0O:< (  $ &   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;(V5;V^;,!#&O\H)]44K;>5?
M$EA%(K6)JDU:M:AIMQ?37CAP!*O&9K9IVF\_VU"4+;3=FV";>^YWSP&7;"_D
M@ZH0-3S5C*NY5VG=7/B^RBNLB3H7#7)SIQ2R)MILY<Y7C412.%'-_"@(9GY-
M*/<6F3M;RT4F6LTHQ[4$U=8UD<]7R,1^[H7>R\$MW57:'OB+K"$[W*"^;];2
M[/PA2T%KY(H*#A++N7<97ERE-MX%?*>X5P=KL$ZV0CS8S9=B[@6V(&28:YN!
MF,LC+I$QF\B4\;O/Z0U(*SQ<OV2_=MZ-ERU1N!3L!RUT-?=2#PHL2<OTK=A_
MQM[/U.;+!5/N%_9];.!!WBHMZEYL*J@I[Z[DJ>_#@2 *7Q%$O2!R=7<@5^6*
M:++(I-B#M-$FFUTXJTYMBJ/</I2-EN8N-3J]6(JZIMIT62L@O("EX)KR'?*<
MHH*/L.D>%H@2KEO=2H0;RFG=UO 533-@39X[\:I%N.<%2OC6H"0V21>BX'2%
MFE!V!B= .=Q5HE4&I3)?&P.V##_OB[WJBHU>*7:%^3G$X0>(@BBXWZS@].3L
M[RR^L3_T(!IZ$+FT\7_TX/*H!RNJ<B:4M?[S<JNT-"_2KS>H\4"-'77R"M5X
M",=:T*EF3F4_J4<3F:29_SC"F@RLR7NL:(S5J:8'K##ZE(RSI@-K^AXK'F--
MCUC&USAJ-J!F[Z$F8ZC9L:W);!R5#*CD3=1=A6;FE1KE&# Y B;Q."\=>.G;
M/*$)&T.E1Z]'G ;A/S#_8"#8V7I#Y(YR!0Q+(PO.$U.J[.95M]&B<3-B*[29
M.&Y9F1&/T@:8^Z40^F5CQ\[PI['X U!+ P04    " !OAG)24M5!4@P%   F
M&   &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6R]65MSVC@4_BL:9A_:
MF19;DLTE0Y@)D'2SLVDRS6;WH;,/ @OPQ+98289F9W_\2K:Q#-@*):4\@"_Z
MSOETSM&G"X,-X\]B2:D$W^(H$9>MI92K"\<1LR6-B6BS%4W4FSGC,9'JEB\<
ML>*4!!DHCASDNATG)F'2&@ZR9P]\.&"IC,*$/G @TC@F_&5$([:Y;,'6]L&7
M<+&4^H$S'*S(@CY2^;1ZX.K.*:T$84P3$;($<#J_;%W!BT^XJP%9BS]#NA&5
M:Z"[,F7L6=_<!I<M5S.B$9U);8*HGS4=TRC2EA2/?PJCK=*G!E:OM]9OLLZK
MSDR)H&,6_14&<GG9ZK5 0.<DC>07MOF5%AWRM;T9BT3V#39YVTZG!6:ID"PN
MP(I!'";Y+_E6!*("4';J :@ H'V UP# !0 ?"_ *@'<LP"\ _CZ@J=.= M Y
MUD.W &39=_+H9JF9$$F& \XV@.O6RIJ^R/*;H55&PD27XJ/DZFVH<'(X9G&L
M*N)1LMDS^ BN@B#4)4(B<)ODA:X+YMV$2A)&[U6+I\<)>/?+^X$CE7=MPYD5
MGD:Y)]3@"8([ELBE -=)0(,:_,TK>&0QX*ANEWU'V[Z/D-7B9[9N ^Q^ ,A%
M;@VAL1W^6YI8X1,[_(9.VP#U&^'7KWF/E'>HX;!?%TT[?$)G6WBM]T]'P_>]
M[Z0"EV6(,WNXJ0PC(@1@\Z(0O_ZNWH-;26/QM\6Z5UKW,NN>O<B%MOT!B"7A
M5 "2RB7CX;_UM9@;]#.#6L[70^B[^6?@K*N!.J;E#FN_9.U_!^L5X6!-HI36
ML<T-=2L<W+;R#_>HOMILAV>GY-FQ\GQ2PU&$BX1(&@ U'\XIY^HJXUU'MG,8
ML/K('M%PAW"W)-P]GG!1#:KT]J@#-7$+29(@3!9UW>@>L-OG;VNQ0[Q7$N_9
M*X*()0C"=1C0)!!UI')\YW67_=)EW^I2R<Q+-LC!#8O4NN6CJLC[N8J3B@KX
M>D?C*>6V(0I=,Q&Y9Y  6)GHH+4G#YS-* T$F',6@U"(E"0SJAW.=@9:HM9_
MZB';=G+&A*R+]77AKQILB/I>QVLL4(@,6?3VL(/_P,[T?4PZC"##<R@R-)(,
M3]!DG14U_M2@ X)%=<)\#0_UMNMU_>:8&[F%=KV]W9;$BH?ZF_*"5BV-W%:O
MFOQ>VV_@8*04VK7T?DWYQRN5<:F6^Q+<K[+EUUL2;D01=L^1<*-=\!7Q.C7A
MO8.$]VWY-LH&[=*F%F \5=NO; ETHKPA(V_H'/*&C+RAGRMO$W0H;WW<0=W&
MR".C;LBN;D='_H2"1T;AT#D4#AF%0V=1N DZ5#@/^\W+'F04#OTXA9L4MJKY
M1[B!@=$W9->WJS_NP V9A5$H7X[*II$O= [Y0D:^T%GD:XP.Y0OW/.@U)=/(
M%[++UX\>\./"7S7A/8@/U^4W14/?TG!W$VA$$KM'!QEPJH_2='C7)(S(-*)@
MSCB8IS+EM.QPW2JX\%+MB0=]K]_,T,@LMLOL9[;.BO8MDP8V0HG1&8H:5W;=
M^*?6T*CP5XU\UT4(-D?>R"FVR^G1D3]ATL!&0K%_CHP8@<1V@3Q19D;X<+/L
MV_;*V @KMN^6OV?2&!6V=O9$^XMBIW):&5.^R ZBA:JI-)'YX5WYM#SLOLJ.
M>/>>C^#%=7YD;<SD)^AWA"_"1("(SI5)M]U5<>'YH71^(]DJ.Q.=,BE9G%TN
M*0DHUPW4^SEC<GNC'91_#0S_!U!+ P04    " !OAG)2%EN1-)D#  !,$
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MTKR&;!1Z'$$W&2OV*@U+_'CZ1DK#LCMVT[OM2.*F2.K.7"V9@LEA@^ZX*1)
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M0JG5E>_+M,"*R Y?(=,K.1<547HHEKY<"229-:I*/PJ"KE\1RKS1P,Y-Q6C
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M.A<]=;9XU8ZKB60KT]'F3*K^:(:I^H1!K@/4\P5C<CO1&S0?1=%?4$L#!!0
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MKCF#(F,'P/NEE.;EQDY0'_+._P-02P,$%     @ ;X9R4O9W:C9/ P  %PL
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M +]OA-"O W/Q:B_:B_\ 4$L#!!0    ( &^&<E*PC<7/W@(  "((   9
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M"-DY.T=.JNY(]<3(TCWJ"VFP1;AACDT<E#7 _:649CNQ =J_!<,_4$L#!!0
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MU_BD!&4%\'PII7G<V"=%]TB=_ 102P,$%     @ ;X9R4I7Z HM. @  ?@L
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MT(K?M+,>;"&:69W]U6[/G]4)NQ=W] )02P,$%     @ ;X9R4I>*NQS
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MWO$_]<[EM$OYVO.]QN?_)]7E?&^Z/OZR_#XY>GLO. ?XD^#Q"U!+ P04
M" !OAG)2(5VG)LT!   D(   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VLEN
MPC 4!=!?0=E6Q'@('01LVFY;%OT!-WE 1!);MJ'P]W7"(+6BJ(A*O1LB8OO=
M%ULZFV3TMK7D>YNZ:OPX681@'QCS^8)J[5-CJ8DC,^-J'>)?-V=6YTL])R8&
M@R'+31.H"?W0UD@FHR>:Z545>L^;>-N7IADGCBJ?]!YW$]NL<:*MK<I<ASC.
MUDWQ+:6_3TCCRFZ.7Y36W\0)"3N9T([\'+!?][HFY\J">E/MPHNNXRRVJ9@/
MVXI\>K[$B1[-;%;F5)A\5<<EJ;>.=.$71*&NTEW1F_/)(>XP[7[YU?E=F7.!
M<>;4&>OCB3FZ/.YP).WJOHV%R(7R_",>$V/IJY^/VM,NJ/AE=MS>#^.6W7EX
MUEVNW^.O9WRL?V$? J0/"=*' NDC ^EC"-+'+4@?=R!]W(/TP0<HC:"(RE%(
MY2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%BJP"15:!(JM D56@R"I0
M9!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL"D56A2*K0I%5H<BJ
M4&15*+(J%%D5BJP*15:%(FN&(FN&(FN&(FN&(FOVG[*^&[/\Z_?6[36M==D<
M\EGW<<#D$U!+ 0(4 Q0    ( &^&<E('04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ;X9R4I\=+B'N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ ;X9R4IE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !OAG)2[2+=_UT'   *'0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ ;X9R4OX-#8$3!0  EA,  !@              ("!H \  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &^&<E*+SYGCN@(
M "$)   8              " @>D4  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !OAG)2N /T=LL#  !2#   &               @('9
M%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ;X9R4B0X
MO[%^!0  GAD  !@              ("!VAL  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( &^&<E)O>E*1@0(  $@&   8
M  " @8XA  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !O
MAG)2.[.'I(L&  "7&P  &               @(%%)   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ ;X9R4G+E,]I&!@  4PX  !@
M         ("!!BL  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( &^&<E)#@HOZ\QL  !15   8              " @8(Q  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !OAG)2(-O+[=P.   ^.
M&0              @(&K30  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( &^&<E(CP+BB&P,  ,H'   9              " @;Y<  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ;X9R4DFUH):7
M!   >0H  !D              ("!$&   'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !OAG)2ZA)W"L0(  "J&   &0
M@('>9   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &^&
M<E(E2EWCWP8  #T4   9              " @=EM  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ ;X9R4BS=?A"!#0  M2P  !D
M         ("![W0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !OAG)2O"M96@(#  ">!@  &0              @(&G@@  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &^&<E)0-5O,UPH  !P>
M   9              " @>"%  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ ;X9R4EX*WN=E P  TP<  !D              ("![I
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !OAG)2W*W^
MFXP#  #J!P  &0              @(&*E   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( &^&<E+I/H/.F!T  *5A   9
M  " @4V8  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M;X9R4B,\4C.R @  S 4  !D              ("!'+8  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !OAG)2)=KH"_L"  !7!P  &0
M            @($%N0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( &^&<E($3\F8J00  #X+   9              " @3>\  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ;X9R4@Z[].*& @
M:P4  !D              ("!%\$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !OAG)20[7^%#@#  !J!P  &0              @('4
MPP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &^&<E+
M@/8P-P4  !(-   9              " @4/'  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ ;X9R4M@C<MBN!   F H  !D
M     ("!L<P  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &^&<E+NCB2ZI08  -<@   9              "
M@;#>  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ;X9R
M4J--_<Z[ @  C0D  !D              ("!C.4  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !OAG)2ZV#.NQL"  ":!   &0
M        @(%^Z   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( &^&<E*+[U+" @,  )L(   9              " @=#J  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ;X9R4D9$!=DA P  L H
M !D              ("!">X  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !OAG)2,T\DJE0"  !D!0  &0              @(%A\0
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &^&<E)%1%*O
M%0(  )D$   9              " @>SS  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ ;X9R4HZH>8:^ @  .P<  !D
M ("!./8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !O
MAG)2FJ,D4"@$  !T#P  &0              @($M^0  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( &^&<E+"+0O:< (  $ &   9
M          " @8S]  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#
M%     @ ;X9R4E+505(,!0  )A@  !D              ("!,P ! 'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !OAG)2%EN1-)D#  !,
M$   &0              @(%V!0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;%!+ 0(4 Q0    ( &^&<E(RHZ1(<0<  #TB   9              " @48)
M 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ;X9R4ATP
MW$K? @  F@<  !D              ("![A ! 'AL+W=O<FMS:&5E=',O<VAE
M970T-2YX;6Q02P$"% ,4    " !OAG)2:=3,/RH$  ""#P  &0
M    @($$% $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M &^&<E(VN-NE[@(  $P(   9              " @648 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ ;X9R4A)9!'?L @  ( D  !D
M             ("!BAL! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !OAG)2D619&>4"  "1!P  &0              @(&M'@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( &^&<E)&\H& "@4
M / 5   9              " @<DA 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ ;X9R4O9W:C9/ P  %PL  !D              ("!
M"B<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !OAG)2
M(I,;5: #  !T"P  &0              @(&0*@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( &^&<E*PC<7/W@(  "((   9
M      " @6<N 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ ;X9R4F)E+[@Z P  L H  !D              ("!?#$! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !OAG)2E?H"BTX"  !^"P
M#0              @ 'M- $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &^&
M<E*7BKL<P    !,"   +              "  68W 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( &^&<E(U&6432 0  $ D   /              "  4\X 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !OAG)2#Y142-H!  !9(   &@
M            @ '$/ $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !OAG)2(5VG)LT!   D(   $P              @ '6/@$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     /@ ^ .D0  #40 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Nature of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Supplemental Balance Sheet Information - Summary of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Summary of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Supplemental Balance Sheet Information - Summary of Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Summary of Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Supplemental Balance Sheet Information - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Due Under Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments Due Under Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Common Stock - Summary of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Common Stock - Summary of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation - Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award and Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Award and Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - 401(k) Savings Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail</Role>
      <ShortName>401(k) Savings Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Net Loss per Share - Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="avro-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="avro-10k_20201231.htm">avro-10k_20201231.htm</File>
    <File>avro-20201231.xsd</File>
    <File>avro-20201231_cal.xml</File>
    <File>avro-20201231_def.xml</File>
    <File>avro-20201231_lab.xml</File>
    <File>avro-20201231_pre.xml</File>
    <File>avro-ex1019_283.htm</File>
    <File>avro-ex1020_284.htm</File>
    <File>avro-ex1025_465.htm</File>
    <File>avro-ex211_12.htm</File>
    <File>avro-ex231_8.htm</File>
    <File>avro-ex311_9.htm</File>
    <File>avro-ex312_10.htm</File>
    <File>avro-ex321_7.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gan5qj4us5ce000001.jpg</File>
    <File>gan5qj4us5ce000002.jpg</File>
    <File>gan5qj4us5ce000003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "avro-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 147,
   "dts": {
    "calculationLink": {
     "local": [
      "avro-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avro-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "avro-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avro-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avro-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "avro-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 457,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 20,
    "http://www.avrobio.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 25
   },
   "keyCustom": 44,
   "keyStandard": 300,
   "memberCustom": 27,
   "memberStandard": 27,
   "nsprefix": "avro",
   "nsuri": "http://www.avrobio.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avro:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - License Agreements",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avro:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Common Stock",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stock-Based Compensation",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - 401(k) Savings Plan",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan",
     "shortName": "401(k) Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Net Loss per Share",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Related Party Transactions",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avro:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avro:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Common Stock (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Nature of the Business - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
     "shortName": "Nature of the Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_avroSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_avroSegment",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "avro:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "avro:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "avro:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "avro:CostOfMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - License Agreements - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
     "shortName": "License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "avro:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "avro:CostOfMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value of Financial Assets and Liabilities - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "avro:FairValueInputAmountTransferBetweenLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
     "shortName": "Fair Value of Financial Assets and Liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "avro:FairValueInputAmountTransferBetweenLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "avro:TaxIncentiveRefundCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Supplemental Balance Sheet Information - Summary of Prepaid Expenses and Other Current Assets (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Supplemental Balance Sheet Information - Summary of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "avro:TaxIncentiveRefundCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail",
     "shortName": "Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
     "shortName": "Supplemental Balance Sheet Information - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Supplemental Balance Sheet Information - Summary of Restricted Cash (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail",
     "shortName": "Supplemental Balance Sheet Information - Summary of Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Supplemental Balance Sheet Information - Summary of Accrued Expenses (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail",
     "shortName": "Supplemental Balance Sheet Information - Summary of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200609_20200609",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avro:LeaseExpirationMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200609_20200609",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avro:LeaseExpirationMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Due Under Operating Leases (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments Due Under Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Common Stock - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
     "shortName": "Common Stock - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "avro:UndesignatedPreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Common Stock - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
     "shortName": "Common Stock - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stock-Based Compensation - Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail",
     "shortName": "Stock-Based Compensation - Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award and Restricted Stock Unit Activity (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Award and Restricted Stock Unit Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - 401(k) Savings Plan - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail",
     "shortName": "401(k) Savings Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Net Loss per Share - Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail",
     "shortName": "Net Loss per Share - Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapTypeOfArrangementAxis_avroLicenseAgreementMember_20180701_20180731",
      "decimals": "INF",
      "lang": null,
      "name": "avro:ProvisionForMaximumCashPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Nature of the Business",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "avro-10k_20201231.htm",
      "contextRef": "C_0001681087_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "avro_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_AdditionalResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional research and development expense.",
        "label": "Additional Research And Development Expense",
        "terseLabel": "Additional research and development expenses"
       }
      }
     },
     "localname": "AdditionalResearchAndDevelopmentExpense",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_AgreementExpirationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration description.",
        "label": "Agreement Expiration Description",
        "terseLabel": "Agreement Expiration Description"
       }
      }
     },
     "localname": "AgreementExpirationDescription",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_AgreementExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration period.",
        "label": "Agreement Expiration Period",
        "terseLabel": "Agreement Expiration Period"
       }
      }
     },
     "localname": "AgreementExpirationPeriod",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "avro_AnnualLeasePaymentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual lease payments, description.",
        "label": "Annual Lease Payments Description",
        "terseLabel": "Annual lease payments, description"
       }
      }
     },
     "localname": "AnnualLeasePaymentsDescription",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_AtTheMarketFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market Facility.",
        "label": "At The Market Facility [Member]",
        "terseLabel": "ATM Facility [Member]"
       }
      }
     },
     "localname": "AtTheMarketFacilityMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_BioMarinPharmaceuticalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioMarin Pharmaceutical Inc.",
        "label": "Bio Marin Pharmaceutical Inc [Member]",
        "terseLabel": "BioMarin Pharmaceutical Inc [Member]"
       }
      }
     },
     "localname": "BioMarinPharmaceuticalIncMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_ClinicalTrialCostRelatedToResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial cost related to research and development expense.",
        "label": "Clinical Trial Cost Related To Research And Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ClinicalTrialCostRelatedToResearchAndDevelopmentExpense",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies Disclosure [Table]",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_CommonStockCapitalSharesAmountAvailableForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital shares amount available for future issuance.",
        "label": "Common Stock Capital Shares Amount Available For Future Issuance",
        "terseLabel": "Common stock remained available for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesAmountAvailableForFutureIssuance",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_CommonStockOfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock offering costs incurred but not yet paid.",
        "label": "Common Stock Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Common stock offering costs incurred but unpaid at period end"
       }
      }
     },
     "localname": "CommonStockOfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_CostOfMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of milestone payment.",
        "label": "Cost Of Milestone Payment",
        "terseLabel": "Accrued upfront license"
       }
      }
     },
     "localname": "CostOfMilestonePayment",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_DeferredRentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred rent expense.",
        "label": "Deferred Rent Expense",
        "terseLabel": "Deferred rent expense"
       }
      }
     },
     "localname": "DeferredRentExpense",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized start up and organizational costs.",
        "label": "Deferred Tax Assets Capitalized Start Up And Organizational Costs",
        "terseLabel": "Capitalized start up and organizational costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedStartUpAndOrganizationalCosts",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_DeferredTaxAssetsLicenseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets License Agreement",
        "label": "Deferred Tax Assets License Agreement",
        "terseLabel": "Licensing agreements"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicenseAgreement",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_EffectiveIncomeTaxRateReconciliationPermanentDifference": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent difference.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Difference",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifference",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "avro_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avro_ExpirationThrough2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Through 2033.",
        "label": "Expiration Through2033 [Member]",
        "terseLabel": "Expiration Through 2033 [Member]"
       }
      }
     },
     "localname": "ExpirationThrough2033Member",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_ExpirationThrough2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Through 2037.",
        "label": "Expiration Through2037 [Member]",
        "terseLabel": "Expiration Through 2037 [Member]"
       }
      }
     },
     "localname": "ExpirationThrough2037Member",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_ExpirationThrough2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Through 2039.",
        "label": "Expiration Through2039 [Member]",
        "terseLabel": "Expiration Through 2039 [Member]"
       }
      }
     },
     "localname": "ExpirationThrough2039Member",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_FabrylicenseagreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fabry license agreement.",
        "label": "Fabrylicenseagreement [Member]",
        "terseLabel": "Fabry License Agreement [Member]"
       }
      }
     },
     "localname": "FabrylicenseagreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_FairValueInputAmountTransferBetweenLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value input amount of assets and liabilities between levels.",
        "label": "Fair Value Input Amount Transfer Between Levels",
        "terseLabel": "Fair value input transfer between levels"
       }
      }
     },
     "localname": "FairValueInputAmountTransferBetweenLevels",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_FebruaryTwoThousandTwentyFollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February two thousand twenty follow on offering.",
        "label": "February Two Thousand Twenty Follow On Offering [Member]",
        "terseLabel": "February 2020 Follow-on Offering [Member]"
       }
      }
     },
     "localname": "FebruaryTwoThousandTwentyFollowOnOfferingMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_ForeignExchangeLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Exchange Loss",
        "label": "Foreign Exchange Loss",
        "terseLabel": "Foreign exchange losses"
       }
      }
     },
     "localname": "ForeignExchangeLoss",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_GenstemTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GenStem Therapeutics Inc.",
        "label": "Genstem Therapeutics Inc [Member]",
        "terseLabel": "GenStem Therapeutics Inc [Member]"
       }
      }
     },
     "localname": "GenstemTherapeuticsIncMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_Interleukin12LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interleukin 12 license agreement.",
        "label": "Interleukin12 License Agreement [Member]",
        "terseLabel": "Interleukin 12 License Agreement [Member]"
       }
      }
     },
     "localname": "Interleukin12LicenseAgreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_JulyTwoThousandNineteenFollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July two thousand nineteen follow-on offering.",
        "label": "July Two Thousand Nineteen Follow On Offering [Member]",
        "terseLabel": "July 2019 Follow-on Offering [Member]"
       }
      }
     },
     "localname": "JulyTwoThousandNineteenFollowOnOfferingMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_LeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease agreement expiration month and year"
       }
      }
     },
     "localname": "LeaseExpirationMonthAndYear",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "avro_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement disclosure.",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avro_LicenseAgreementExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Expenses",
        "label": "License Agreement Expenses",
        "terseLabel": "Expenses related to license"
       }
      }
     },
     "localname": "LicenseAgreementExpenses",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_LicenseAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Line Items]",
        "terseLabel": "License Agreement [Line Items]"
       }
      }
     },
     "localname": "LicenseAgreementLineItems",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_LicenseAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Table]",
        "label": "License Agreement [Table]",
        "terseLabel": "License Agreement [Table]"
       }
      }
     },
     "localname": "LicenseAgreementTable",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://www.avrobio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "avro_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fees",
        "label": "License Maintenance Fees",
        "terseLabel": "Annual maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_LundUniversityRightsHoldersAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lund University Rights Holders Agreement.",
        "label": "Lund University Rights Holders Agreement [Member]",
        "terseLabel": "Lund University Rights Holders Agreement [Member]"
       }
      }
     },
     "localname": "LundUniversityRightsHoldersAgreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_MPSIILicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MPSII license agreement.",
        "label": "M P S I I License Agreement [Member]",
        "terseLabel": "MPSII License Agreement [Member]"
       }
      }
     },
     "localname": "MPSIILicenseAgreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_MilestoneFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone fees.",
        "label": "Milestone Fees",
        "terseLabel": "Milestone fees"
       }
      }
     },
     "localname": "MilestoneFees",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_MilestonePaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Due",
        "label": "Milestone Payment Due",
        "terseLabel": "Milestone payment due"
       }
      }
     },
     "localname": "MilestonePaymentDue",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_MilestonePaymentPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment paid.",
        "label": "Milestone Payment Paid",
        "terseLabel": "Milestone payment paid"
       }
      }
     },
     "localname": "MilestonePaymentPaid",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_NovemberTwoThousandTwentyFollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November two thousand twenty follow on offering.",
        "label": "November Two Thousand Twenty Follow On Offering [Member]",
        "terseLabel": "November 2020 Follow-on Offering [Member]"
       }
      }
     },
     "localname": "NovemberTwoThousandTwentyFollowOnOfferingMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_NumberOfSharesOfCommonStockOutstandingIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding increase percentage.",
        "label": "Number Of Shares Of Common Stock Outstanding Increase Percentage",
        "terseLabel": "Number of shares of common stock outstanding, increase, percentage"
       }
      }
     },
     "localname": "NumberOfSharesOfCommonStockOutstandingIncreasePercentage",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "avro_OfficersAndBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers and board members.",
        "label": "Officers And Board Members [Member]",
        "terseLabel": "Officers and Board Members [Member]"
       }
      }
     },
     "localname": "OfficersAndBoardMembersMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_OperatingLeaseAnnualIncreaseInRentalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease annual increase in rental percentage.",
        "label": "Operating Lease Annual Increase In Rental Percentage",
        "terseLabel": "Percentage of annual increase in rent"
       }
      }
     },
     "localname": "OperatingLeaseAnnualIncreaseInRentalPercentage",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "avro_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases future minimum payments due after year four.",
        "label": "Operating Leases Future Minimum Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAfterYearFour",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered",
        "label": "Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered",
        "terseLabel": "Period of cumulative changes in ownership interest"
       }
      }
     },
     "localname": "OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "avro_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered",
        "label": "Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered",
        "terseLabel": "Percentage of cumulative changes in ownership interest subject to annual limitation"
       }
      }
     },
     "localname": "OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "avro_OptionFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option fee.",
        "label": "Option Fee",
        "terseLabel": "Option fee"
       }
      }
     },
     "localname": "OptionFee",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_OrphanDrugCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan drug credit.",
        "label": "Orphan Drug Credit [Member]",
        "terseLabel": "Orphan Drug Credit [Member]"
       }
      }
     },
     "localname": "OrphanDrugCreditMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other adjustments noncash items to reconcile net income loss to cash provided by used in operating activities.",
        "label": "Other Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_PaymentsUponClosingOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments upon closing of initial public offering.",
        "label": "Payments Upon Closing Of Initial Public Offering",
        "terseLabel": "Payments upon closing of an initial public offering"
       }
      }
     },
     "localname": "PaymentsUponClosingOfInitialPublicOffering",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_PayrollTaxLiabilityCappedPerYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll tax liability capped per year.",
        "label": "Payroll Tax Liability Capped Per Year",
        "terseLabel": "Payroll tax liability capped per year"
       }
      }
     },
     "localname": "PayrollTaxLiabilityCappedPerYear",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_PrepaidCompensationBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid compensation benefits.",
        "label": "Prepaid Compensation Benefits",
        "terseLabel": "Prepaid compensation benefits"
       }
      }
     },
     "localname": "PrepaidCompensationBenefits",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_PrepaidResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development costs current.",
        "label": "Prepaid Research And Development Costs Current",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_ProvisionForMaximumCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for maximum cash payment.",
        "label": "Provision For Maximum Cash Payment",
        "terseLabel": "Provision for maximum cash payment"
       }
      }
     },
     "localname": "ProvisionForMaximumCashPayment",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Adopted Accounting Pronouncements Policy.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avro_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash.",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted Cash [Member]"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_RestrictedStockAwardsAndUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards and units.",
        "label": "Restricted Stock Awards And Units [Member]",
        "terseLabel": "Restricted Stock Awards and Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockAwardsAndUnitsMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block]",
        "terseLabel": "Schedule of Property and Equipment Estimated Useful Life"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avro_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited and expirations in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Expirations In Period",
        "negatedLabel": "Number of shares, Forfeited, cancelled or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "avro_SignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Abstract]",
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.avrobio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "avro_SignificantOfAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant of accounting policies.",
        "label": "Significant Of Accounting Policies [Line Items]",
        "terseLabel": "Significant Of Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantOfAccountingPoliciesLineItems",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_SignificantOfAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Of Accounting Policies [Table]",
        "label": "Significant Of Accounting Policies [Table]",
        "terseLabel": "Significant Of Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantOfAccountingPoliciesTable",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "avro_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement.",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sub-lease agreement.",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sub-lease Agreement [Member]"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_SupplementalBalanceSheetInformationDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental balance sheet information disclosures.",
        "label": "Supplemental Balance Sheet Information Disclosures [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationDisclosuresAbstract",
     "nsuri": "http://www.avrobio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "avro_TaxCreditCarryforwardsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforwards Expiration Period",
        "label": "Tax Credit Carryforwards Expiration Period",
        "terseLabel": "Income tax credit carryforward expiration period"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationPeriod",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "avro_TaxIncentiveRefundCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax incentive refund current .",
        "label": "Tax Incentive Refund Current",
        "terseLabel": "Tax incentive refund"
       }
      }
     },
     "localname": "TaxIncentiveRefundCurrent",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avro_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 employee stock purchase plan.",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_TwoThousandEighteenStockOptionAndIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 stock option and incentive plan.",
        "label": "Two Thousand Eighteen Stock Option And Incentive Plan [Member]",
        "terseLabel": "2018 Stock Option and Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenStockOptionAndIncentivePlanMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_TwoThousandFifteenStockOptionAndGrantPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen stock option and grant plan.",
        "label": "Two Thousand Fifteen Stock Option And Grant Plan [Member]",
        "terseLabel": "2015 Stock Option and Grant Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenStockOptionAndGrantPlanMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_TwoThousandNineteenInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen inducement plan.",
        "label": "Two Thousand Nineteen Inducement Plan [Member]",
        "terseLabel": "2019 Inducement Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenInducementPlanMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_TwoThousandTwentyInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty inducement plan.",
        "label": "Two Thousand Twenty Inducement Plan [Member]",
        "terseLabel": "2020 Inducement Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyInducementPlanMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_UHNagreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UHN agreement.",
        "label": "U H Nagreement [Member]",
        "terseLabel": "UHN Agreement [Member]"
       }
      }
     },
     "localname": "UHNagreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_UndesignatedPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated preferred stock.",
        "label": "Undesignated Preferred Stock",
        "terseLabel": "Undesignated preferred stock"
       }
      }
     },
     "localname": "UndesignatedPreferredStock",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "avro_UndesignatedSharesOfPreferredStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated shares of preferred stock outstanding.",
        "label": "Undesignated Shares Of Preferred Stock Outstanding",
        "terseLabel": "Undesignated shares of preferred stock outstanding"
       }
      }
     },
     "localname": "UndesignatedSharesOfPreferredStockOutstanding",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "avro_UniversityOfManchesterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Manchester agreement.",
        "label": "University Of Manchester Agreement [Member]",
        "terseLabel": "University of Manchester Agreement [Member]"
       }
      }
     },
     "localname": "UniversityOfManchesterAgreementMember",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "avro_UpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of the upfront license fees.",
        "label": "Upfront License Fees",
        "terseLabel": "Upfront license fee"
       }
      }
     },
     "localname": "UpfrontLicenseFees",
     "nsuri": "http://www.avrobio.com/20201231",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MOROCCO",
        "terseLabel": "Cambridge, Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address Address Line3",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r42",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r189",
      "r208",
      "r209",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r189",
      "r208",
      "r209",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r187",
      "r188",
      "r380",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r187",
      "r188",
      "r380",
      "r394",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r143",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201813Member": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.",
        "label": "Accounting Standards Update201813 [Member]",
        "terseLabel": "ASU No. 2018-13 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201813Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201815Member": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).",
        "label": "Accounting Standards Update201815 [Member]",
        "terseLabel": "ASU No. 2018-15 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201815Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update201818 [Member]",
        "terseLabel": "ASU No. 2018-18 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r32"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Consulting and professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r164"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r280",
      "r281",
      "r282",
      "r283",
      "r359",
      "r360",
      "r361",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r211",
      "r213",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r178",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance of common stock upon public offering, offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r213",
      "r243",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment Measurement Input",
        "terseLabel": "Expected cash dividend yield"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r127",
      "r135",
      "r139",
      "r145",
      "r298",
      "r303",
      "r322",
      "r363",
      "r371"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r41",
      "r78",
      "r145",
      "r298",
      "r303",
      "r322"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r214",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r68"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r69",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r68",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r324"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r86",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r247",
      "r248",
      "r249",
      "r280",
      "r309",
      "r323",
      "r337",
      "r359",
      "r360",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r93",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r247",
      "r248",
      "r249",
      "r280",
      "r309",
      "r323",
      "r337",
      "r359",
      "r360",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in CCYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r87",
      "r98",
      "r153",
      "r254",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r76",
      "r78",
      "r99",
      "r100",
      "r101",
      "r103",
      "r105",
      "r111",
      "r112",
      "r113",
      "r145",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r172",
      "r365",
      "r376"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Total shares of authorized common stock reserved for future issuance",
        "verboseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value; 150,000 shares authorized as of December 31, 2020 and 2019; 41,569 and 31,673 shares issued as of December 31, 2020 and 2019, respectively; 41,569 and 31,643 shares outstanding as of December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r51",
      "r367",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r117",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges Policy [Text Block]",
        "terseLabel": "Deferred Issuance Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r66",
      "r79",
      "r278",
      "r286",
      "r287",
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense Benefit",
        "terseLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r32",
      "r334"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r35",
      "r334"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "U.S., foreign and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Domestic",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, domestic"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards State And Local",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, state"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r274",
      "r276",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development tax credits carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Equity based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r263",
      "r271"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, expense"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Percent of employee contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Employer matching contribution, percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r126"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of defined contribution pension and other postretirement plans.",
        "label": "Description Of Defined Contribution Pension And Other Postretirement Plans",
        "terseLabel": "Defined contribution plan, description"
       }
      }
     },
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r185",
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends Cash",
        "terseLabel": "Cash dividends"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "U.S. federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share \u2014basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r264",
      "r289"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal income tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r264",
      "r289"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r264",
      "r289"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r264",
      "r289"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation Prior Year Income Taxes",
        "terseLabel": "Provision to Return"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r264",
      "r289"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r264",
      "r289"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Compensation and benefit costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized stock-based compensation expense, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized stock-based compensation expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option [Member]",
        "verboseLabel": "Options to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r88",
      "r95",
      "r97",
      "r110",
      "r152",
      "r178",
      "r185",
      "r251",
      "r252",
      "r253",
      "r282",
      "r283",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r310",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r204",
      "r311",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r310",
      "r311",
      "r314",
      "r315",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r190",
      "r192",
      "r197",
      "r204",
      "r311",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r190",
      "r192",
      "r197",
      "r204",
      "r311",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r204",
      "r311",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r204",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value on Recurring Basis [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Country [Member]",
        "terseLabel": "Australia [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r66",
      "r162",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment loss of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r160",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r265",
      "r267",
      "r273",
      "r285",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r75",
      "r261",
      "r262",
      "r267",
      "r268",
      "r272",
      "r279",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Deferred tax assets change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "terseLabel": "Income tax reconciliation tax credit research"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable Current",
        "terseLabel": "Interest income receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r54",
      "r125"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease And Rental Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r78",
      "r136",
      "r145",
      "r299",
      "r303",
      "r304",
      "r322"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r78",
      "r145",
      "r322",
      "r364",
      "r374"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r78",
      "r145",
      "r299",
      "r303",
      "r304",
      "r322"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input Expected Dividend Rate [Member]",
        "terseLabel": "Expected Dividend Yield [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r114",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r44",
      "r46",
      "r50",
      "r67",
      "r78",
      "r87",
      "r91",
      "r92",
      "r93",
      "r94",
      "r96",
      "r97",
      "r102",
      "r127",
      "r134",
      "r137",
      "r138",
      "r140",
      "r145",
      "r322",
      "r366",
      "r377"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Laboratory and Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r127",
      "r134",
      "r137",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r332",
      "r335"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r332",
      "r335"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Current",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r332",
      "r335"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r332",
      "r335"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r332",
      "r335"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r32"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Long-term Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment Of Financing And Stock Issuance Costs",
        "terseLabel": "Deferred issuance costs"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments For Proceeds From Tenant Allowance",
        "terseLabel": "Tenant incentive allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r191",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "401(k) Savings Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r214",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, issued",
        "verboseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized and no shares issued or outstanding as of December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r156",
      "r157"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Prior Period Reclassification Adjustment Description",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r60",
      "r246"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r44",
      "r46",
      "r62",
      "r78",
      "r87",
      "r96",
      "r97",
      "r127",
      "r134",
      "r137",
      "r138",
      "r140",
      "r145",
      "r297",
      "r301",
      "r302",
      "r305",
      "r306",
      "r322",
      "r368"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r75",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r163"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r165",
      "r375"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r75",
      "r165",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Expense related to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r339",
      "r340",
      "r342",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r260",
      "r408"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r75",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r73",
      "r362",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash And Investments [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r14",
      "r73",
      "r395"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfRestrictedCashDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r185",
      "r254",
      "r373",
      "r388",
      "r393"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r88",
      "r95",
      "r97",
      "r152",
      "r251",
      "r252",
      "r253",
      "r282",
      "r283",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r213",
      "r242",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r213",
      "r242",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments Due Under Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r80",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r73",
      "r362",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]",
        "terseLabel": "Summary of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r214",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r220",
      "r231",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Assumptions that Used to Determine Grant-Date Fair Value of Stock Options Granted to Employees and Members of Board"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]",
        "terseLabel": "Summary of Restricted Stock Award and Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r76",
      "r111",
      "r112",
      "r174",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule Of Stock By Class [Text Block]",
        "terseLabel": "Summary of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit in connection with lease"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r212",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "Employee Stock Purchase Plan, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Forfeited, cancelled or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Common stock issued for initial consideration for license",
        "verboseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of shares, Issued and unvested ending balance",
        "periodStartLabel": "Number of shares, Issued and unvested beginning balance",
        "terseLabel": "Unvested restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, Issued and unvested, ending balance",
        "periodStartLabel": "Weighted average grant date fair value, Issued and unvested, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value",
        "terseLabel": "Total fair value of restricted stock awards and restricted stock units vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Number of common shares that may increase under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of common shares that may be issued under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of options, Cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of options granted",
        "verboseLabel": "Number of options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Options Granted, Weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r222",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of options, Outstanding ending balance",
        "periodStartLabel": "Number of options, Outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding ending balance",
        "periodStartLabel": "Weighted average exercise price, Outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Number of common shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r212",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r237",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected option life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsThatUsedToDetermineGrantDateFairValueOfStockOptionsGrantedToEmployeesAndMembersOfBoardDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted average remaining contractual term, Outstanding balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Issuance price per shares"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r76",
      "r78",
      "r99",
      "r100",
      "r101",
      "r103",
      "r105",
      "r111",
      "r112",
      "r113",
      "r145",
      "r178",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r83",
      "r84",
      "r85",
      "r88",
      "r95",
      "r97",
      "r110",
      "r152",
      "r178",
      "r185",
      "r251",
      "r252",
      "r253",
      "r282",
      "r283",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r110",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under 2018 employee stock purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock upon public offering, net of offering costs, shares",
        "verboseLabel": "Common stock, shares issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r178",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted stock awards and units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r185",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of options, Exercised",
        "terseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under 2018 employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs",
        "verboseLabel": "Fair value of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted stock awards and units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r178",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r78",
      "r144",
      "r145",
      "r322"
     ],
     "calculation": {
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events Policy Policy [Text Block]",
        "terseLabel": "Subsequent Event Considerations"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r280",
      "r281",
      "r282",
      "r283",
      "r359",
      "r360",
      "r361",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average number of common shares outstanding\u2014basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.avrobio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39896-112707"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39927-112707"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r412": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r413": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r414": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r415": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r416": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r417": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r418": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001564590-21-014190-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-014190-xbrl.zip
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M / LSB=?A]+$Y5J(*(WSI2#WY'NU^D06=ZT^W:=OY&2$5=_I+T$FA:\'/H
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MH+U7:Q+=>"I_?)/HZZ!X:Q+=!.I_;71KJ67-) ),P>DDER/^C<4_>'+"7#^
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MKW)D3WZN[SNPIS]L]QW94Y/\O''-<^._$CB;[Q6=4]@D/@*^-HSBZ0-]5_1
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M&0B(:[4@P4*]CZ)\L*?'SPVG&\), "?&?JB#C,K;5]B2PJ[5Y!@JMJEZD_L
MBP,?,0^V+;H)Y: CU:RRYGA^#(.-8B$Q.">#$;OF,CB0WV*E ^XUG$L,DM)C
M5_4@!_E-*.LEJ= 1O2%W 9&!<.'-6" !"R8(C.LJ/F&05=4$N7 2 ;RO&'RQ
M=L>R(.YD#62JS@JUL)0;6C@L%65?90(CY2_VZ(:S-"'9&FAH\>EI-7?089.?
MGN[IR<+SL]NJ[;?;M>9^<_;XY-2W=$9ES8GRH:KS (?#5>KZ(9V_EMST>9C4
M;E4VVQ%Y%6/N?9K"]$'\"EU^"6OQ*8"!K0957+AL@GDI<<H?E)2V1H4\/I\=
M??]V?'K9<[JG1V<7YV<7'6R9^>E?SL7QR?'%\>G1\08?MW,&"D2WV\U".&5+
M,N<B4RU.X%('6PLZ>2%;&!(PP5A3BP.L,&%813Z4IX+8$O;WF,-A=;0;\+)S
M0,6I0T7/2"E!;H;B/)(TL%0:S)AST@$0!_! C&#[B?G*%/*RO!BB&BZR .Y"
MB&L6T>JT=CM2$2]%FR,;SR1'HV,%<F2XE>13$)9:@'@8O W<.YF16;.)EKIA
MX0QFFU#A^6G@._DDD4,"#C%1X>3FDJJ*_3+<U]@-K[@;L!&TE=G.U6AXY956
M*.-AJ^-B>#ZPF G2A::)[$&*QY1$S94,0L4$M>INO$:2VMR#LJ@A[_VM4D_S
MU-;=3Z4&Q.W\F<9;JAY[KP[*HSAW#PQYO1]S]J-.Y/N>!3= RV^<MX\UXXK7
MOV3/Z(?MW8L%GSY3)^;F4^*G;K@"8KL[*YAN\L3F(Z5.]9'] AUL&.@<DVFX
MFOMOT[)<4J0TR;<(Q #E+W?^UZCB^$%C_V!1S?&#_49SX05[C?;N,F7)%WF"
M32_O THD&]1)?2FK(1X_(J$XYC-+SK]9&EC#&A1=$)BTU:QQ#__[(ZWZ1GN;
M[QV\<._%>^65_<X9%J1>K:+6VE/M#(]?I4+\FDWH);#Y%^:,8C3D_.V\<W%Y
MU2TU1*4GS>EVB3<XW<SUQ)8,%'[<LSRW M(J)?6H>$GI:-_1+:+>6H8PGY.?
MMK;S;#^K%S*#]=8\5+<+N!PWZ5X>?[MJ77WZWNN>'O=Z*[ 5'1MM,I8E.W,_
M^?06MKU^$CYGV9AE8P]@8QW+QQZ#CW6N+KJ]WZ]..D>79Q>K,+,+7_QP3ABY
M@U](4GIU'&2W;5G(([*03Y:%/ 8+^73U_?3BN'?V]8_CSU>]R\[)R=71V3=R
M(Z_ 3[Z',0=UYYI[Z+8;R) !-*E:YO(\VWIP:)G+XS&7MN4MC\!;VE?G%V?G
MQQ>7W>-5>,EY'$UXC!$.EGE8YK$IM)\SCQW+/!Z!>>Q<?3W^TOF*+.3H^/AS
M]_3+*CSD*Q^R ..(7$X5_2PKL:QD8TY"SDIV+2MY!%:R>_6M>WI\U>N<'%_^
MZ^ISMW?T]:SW_6(EH>0;_./TV( G4^>S+S!K((VMA/+";*54+F1_<F>QD,TX
M+*O5S+!S6FY.=QR*IYJD!<%'#\/9E*5;A\B)U4,G7BIVXC%/Z_I!V&'3,H7'
MDXSWMD<R#GB2\+BNHGS?UYN-UM[+"LQ[5]\Z%[\?7UZ=G%U<71Q_Z?8N+SJG
MESWR#)R=7AW_S_=51&>9\:HCS2M:;JO\PN._4C^9UN"*@%*%*-]09E YW[!F
MA$I=E5U[G/,T=D=,R!1%>:^1'64E<\O6-H^M[6\/6WM!_K4/3*MW?/''\>=5
M0B*XX/$U-O>UC,,RCLV@^YQQO+.,XQ$8QSL0?$X[7XXI_($LA=][O2Y(//#M
MUW_UNKVKDY4$GYF:5F@Z3&66-DHRG9 %4^&3!'.25:PZBD)/UF3#:X OI4%"
MEYQ-N'S-.@:A.C8*]1F8I@U#?4RF:<-0'X5K=J[^YSOHA]W+SF7WCV/\\%7_
MK;PM*W#-_\$*&#[6J;OFQ #ABT!_-EPO#NM':59["0-:K>3V3*'P3<N%'I$+
M'5@F] A,Z.#JI'O:.3WJ=KYB&.NEDN%ZW\_/O]+?G8L5F% NC&55:*3MJ9=.
M)@%]9O&4VE9:KF.YSL8<FISK'%JN\PA<Y_#JZ+?.Z9?CWE7W%&6=SI>+8\5Y
M_NQ>_G;5.3I:@>L<42DO+&E,O :$'3:,N>(^5&ZK(\L,,_P"],-.7G48;\BY
M5BXGK:&F:!5%RRTWXK ;W-)JBH_"+CM71V>GEQ=G7WLRL/?SBF%X6*DIC@(I
MBU%XKV?#\"Q7V:@S87 5F\/X*%SET]79!0A@)V<7WSJ7W;/3%1C*&96C[N:E
M2RTK>2Y64IT.;4-Z[9QL2.]6LFT;TOM8(;WWB.FU0;U/@V([EB\\GD#<:EJ!
M^#&*>C2O/G<OCJDHT-7Q/X^/OI,O]J1[='R!0;P7YV<K,)#/NF],S3F^Y6Y*
MCM@SU5:&%/$C7=[?^8+-U] (R:T<;3G0QIP?@P/9"HN/PH%:!M\Y.OMV?GS:
M6U4USYD--J/CH;#ZN>4KFW4J#+YB2PH]"E]I7_6 K5QT+_]U=?;G*8@SOW7/
MKT"LN>QT3Z\^'9\>KQ*@J[*%IL[930BRS,B?4#<(U2+J4]9/3_U.LDX>U*NB
M<^?F*JVAY]7&Z%K.N1GGWN"<MI[2HW#.G8Q-7AQ_)5D,>6=/?CK^?'6Y2GR<
MYI'$_C A 7BG*#!$:K N6TF"XBC#6:0>Z73A01/L/V_51,N4-NE(&4S)5F9Z
M%*:T>W5^T3T]ZIYWOF*LW-GWT\ONZ9>KD^/CWA5F<'97"9\[C_W0]2<@KQEQ
M<2=<=<KL\?C:=VVLR$MS'.O@M7.R#MZMY.[6P?M(#MX_5O;O_F'=NT^"8;N6
M*SRBU+Q%59M>4FK>NSK^YV_=3]W+7E72VU7OZ+>5W"PCO^^K]+:*O#>GYXZX
MEP9\'0V:UIYIF>!&'&&#"=H:3X_"!/>Q.AW&NOQ^U?O^[5OGXE^KY/=&N@%Z
M+QW#M*?6*F"9R<8<A:W0LUZ:B_2Z7TX[EROFG_5@B5GR@BEGVZYO'51PA[<)
MZP<<OO7\Z]5(L3"WOR^AOU<:A>:L>+'S.KZRU9Y4;4'5*%YF?7TUG5&<4^60
MU_LQ9S_J; #3><^"&S85;YRW#U_IE5;SWZE(_,'T;@JN>I-ILW&C((K?ZW;;
MSV7!46($QH]@D=MOH#S%J$9A72+A=(2(0*M"ORBE\9^EL9/W$YY4+35.=_].
M<MIM'.S__8%3?D3ZPGGUU;P<7S@B[?^;NXF31$Z8CGD<I<*):450V4Q#5[J1
ML5XO+!M+G&F4.F(4I8'G]+G#;EC,<4G]T.' 5E-&+IW(>$O#N1QQP=53_= -
M4H_7X.?$P7O#*'$"?^SCRB=1C?9F$ 5!= ,/>O]4Y$B+OS]+]\"_]*OD6Y -
M*^\'LCC5//[7-\TWCLN#0)6$SCXK/*#/ZCFJW3Q00, F@K_7?WP 0O.2$9
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M9"')0M+K@B0>4M$\T$S0FX0]9M$F1O@R#XH0=VX4H#$_D/&%XR@4"76#$&S
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MC"QT3* ?^JX*MM48D.>Q5J%!PMV13MW"H"BT!F5=+BT8;#!)6S"P8&#!8#O
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M^\3+?W!J>3_@U(I1UXV&FU4?KFG- 3F=JX#1LAO@+Y#79:^NPC,L(&PP65M
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MD"]''*V8LR^$-8$I8UFQ.ADP1!)%GM/W0?D92DNHK#5 =01FNXO7\@)H6+\
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M3S!94(X>-)#,RH&MM61%?Z625;PI,PX++M5^4,%TY#P9AX(@ZQFF*5DZX+*
M7[PU 4HO&5NJS\[+!A29BI@?AM&U4OQA'A4(6J, D#1@<1':X/MX&DUDF51E
M/"_J:FB+DAE@JM*J6EHN,Y8 !Z,XP5@%--Z@4G1#80W,NY95W)1[@0?>W3J1
M!&NF:(F,O6D0%-4[&3S$%/ 7PTW^Y%DZB6X508:;F VEJQ+'E$?_9X$Q4GK
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M"6<F)\GFDDD+,"F2??4!)/^&[ AEK"]Q!0I.0#MVEM^+6X,!V?4@PO=*#XD
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M-:/VB+0">A3^1S6*1%8]QXTY"6P41.Q.$VDM42RFY!!'X]IPR+6N+<V;!3V
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M]2+;S@"$)6%09.DZY4:ILWI5<Q6L$->;>G]-R>CC!4Y6H13 4%YQL1+-SSQ
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MKQ,38*HV-@:C9(_BTAJC:T7::QEEW*"J PCC%1=KC$86SZ#+F#[1HE\K"4R
MD%SV;U9O1HB*(YV-C_U<7"6LOR=/ALKNRDI*!OS\?""[90*JI^<.8LN?^($K
M?<\PS_-]Y::$Z\3XC!,; L*;O&=.N%\'__/T;O+BX ['NVL]_CQ-CZY//"L/
M],77;(^]4@..N205NJ@DD5!HW]GMF9.F0?XV3^H-Z ?S-+)LUQU?F/"85M-B
MO<P24CLIG6#)[\\,VZL76!3JE/91#:.CS23+WY"GX=50!GD/$$EGO,BN5&B
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M#VR;G'\^'Y\-S*B/W.^QVQ><CA6Z?N,Z1^_I^A6"0$GXJITRF@&7D[R,LD6
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M5,F  *(0SNS&]X:6+O_V+/G1 +Y #(+"+;>[FZ6)HF8](*H5,8;)#7A;V'B
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M&;2%>2(0$;5\6NBSEHKJ/4G'XXX;1?_DAF900<G6V?TLQ,$IL$XCW%7]2LT
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MO=3)$"I6TS0'R ,+:*T!S^KVA)!?I>)JT+@\W$MA:^^2@+31)'F9I=%%*3B
M=^.HHJQ0\*OI'N8=*L!;Q9-A*^=O:?$:2%(MFDT&(>VE=QSYU#$[D4/U*HN,
M789%(7:)A^G10X:'X5$C>M0" Z)QNJ/E1!P_RC.(/DU'WH\[;K?4;M^)F']C
MD?M'?F'@KC==Y:WAV8L5NV#8\[  $H743+)R/#ANV!Z+>J<EW4$0ZXG27;2P
M3/KF\;B:X]W##.L#JVQ("<]PWT-%?@1<-U2#7873)]Q?HMDB/&"+U?HL7TH
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MQ2$=R&S8,OD?LAU0/PS4EJ6:E=M"'R9[P[P8J2N0MT8#9*OIZL'BFR>FZ7_
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M'WU]$X+*8Z @X0T,G^6@"/HH^J9>4)K]!SFRQL'(V&S^%+[A_M0#-[K ' O
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MF*:^VQ0+ 0/HG3901MCOB#-< >\1Z7EV=K(D.'M"JF+<>^#= YXB?J]H)8E
MH]:#JRA"]&*L!(%:;:X%,[';4\)^:8BQA.[B0+]ZPR/\4ED<![.O9RQ'%^*^
M&G_^Y+E2%*T?Z[./C$$IS WMOU>3)YN6$-L:!WU&?&F'*CZ,(&BJ;K$)\;_1
MUH@GHMZ$14<L(NMB.5N7A"=GVQNJ'-2/*\1Y-^^.K&9:?@C?UH[AM_U$I79(
MWSS/H'_/6;Z7DO"A)_[T_#QGT5*0J#]TY9+ \L2;5."M^&9=GO[X?]2%T(&X
M9YS.?C(J9R("(\;@N;U+R%,+Y4M09##1&F\)R86N@R-:-5@MW&%XP"RY</H$
M[D6F4X,6B^C\5DVQ#00#UL=:.LCN9]Q;^5-<^W1O?8@4J%Z6*][6IMX8;ASN
M37FI24C9Q;BC X2M\;,X JRE<)&B/47"RF(P5AF 1ZE\TF0YAB=E.'$O7K#B
M@*[)O\B"0!O8 )6V- ZW)]_T-ZZHJF@E+Q3NI]PSPDY5SS9U110'#+X,E%R>
M(4\'"I0Q$QDH#/NAUBX)?J]<#!"QP4$0*A)#!VP$9SW8XJ:K%HV!>.*7A,DZ
MT&?,LWR^:\H-2)/F@RD1!\H2P? KVVU=FVC;;;!WZW@SG-948!\.LT>K '1B
MFBIN@VXM%BJ:/D69B8A^VC:=W80TV1-R&881/I6^P_8%XQL2Y\^&WVO*.*YU
MRXCM*.4=N?U1K3,IVH(QD!,::?XYHM';$;A:FU40Y_MM(E9JO)*ER]:'0;59
MLXUOL(G6OABKBTQ"OGX>)60AL\R_DGINL -\*MJT2@'0>B+:XI<$^>I3)3_6
MN<@:@DXY%L/_FZ'@D54 Z*J0:V<A>;K-IZ$7D:J%TA852/!T?)\'U>7+#M4&
MMFBBDQVL.-<WQ(NP,LW*0VO[ML,\:U$EW$J%1I3Z"$)QX\23-]/$8H@G@HK7
MY?" (% _EP$E]5#C&>9<0#)3S<6H<2 72M'@S% 5@*3AZH#;(=H?H@L+P@>D
MR<1?=O&7 KPH HWPJ(F#5=[?4@N8YWH68B%Y]M!Y>>"(&=_=?\2,A^HGWA<:
MEHO^_1"@,39^Q"?**=UN%55DU, N/<SB<[IXYBF20BB S"C8.E724QTH<8+>
M]'2#@O_)*&B[]:$M%W$*+2YGB**L/K H(<+2]&3O>*=B*"[,.IT-)@UN$8YO
M&'-RLE*61 O+"-+'T*AKJ/+R.IE[N=\S5Y9%V"]1<K/J9 .@#1NI;4/'#)/6
M$L%D4X+7+&%Y1_LHFK(<G )'32>TL'%8!"*?'BGETLFNC0[*#M00#707@^US
M15O1=](4,!'?H?U(])8Y%FKTOX'U"(X]P;4VN\U:D A(EX,]8NK81Q0MVN(
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MO!%)H7G2&D)2C2]@'.>V)H@S+O[=#_&*,.[\#45V/?UP%+>54.,(1^&*9T8
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ME*V1/@DRXB@QEALM(R0>A;KEI(AB3*:[1.GTL+5NCZ98EK6@$J75R+D?HSE
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M1$@>Y9[[E!M[[,Y1:"HK_(5+\J?:5>-+*"PEPLDN<!D1BO)Q C/HD=1ZDC[
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M,!ZR&34:6K/E8;:L9UPA 0@*V7FS].-K7; \#@=,6BO^*FWJ,L0-@ $G+;@
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M5OJF H5F(D.T,0$100='9=!1*JZV\?92X@*2!3$4IGXL ./J+V+\>#0K*<Q
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M.*YNGGE-U\*5RF9#T? %&%G0T]EY$F1S.[6]FG[N]+4!CG1CL[;(EBO);IK
M\AIGE9_D&Z!>)Z-O+N;GT79FWD_F#SV6[+D9D@&.LGPYXL6LZVD^VX8E6]6K
M55$V'O-QWKM$_3J_T\&&WT8^YIDW1AV2I*&A;7((@E.BE*\;NBX;[G1.%F0R
M]5Q+^YAM?40L.AXB;[6]-N>@J]0]X*[D1];*^^S1M/(^G4)*-(XQ%X<<DRHQ
MW9OK=*,M^Y>!7:"E<X"BT]XM$+<(Y O! Q(+,RF_(_:!RD_5#O=E<6;W;#P
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M]_-=7M  27IU%5T%5JW+I(57&^(73 ?2WK$H5#'$^XW@CWC\''\XV*^S9<M
MN#!EJE?84B"J(3KX'5NO8</Y5,Z?+UE&\=I(PB4N=<T(VBOP/LM^M"G4?3N@
MU:_%%/QY75*R:?S=9,%<AJNNXHAUVVW#?"3UP+N9D%937(4&3V&0A)FU*0Y<
M^)%\B#Y8B<1+/,F 9)OB;PFW+ZYKJDA@/,9*99M$4#86E0E+<<4H]*T1;V3-
M,7-%M^L==$Q=I^;8E'1E,)YTK)=DG\TM'C?V,/X<S5^\F2R]A&#*PF>^X$WI
MZ;1JVLSW@KS%>3?T0E?_<0RU8<01 MYIF/VY@BYYM^>(W$745$LV@\\[4@J;
MLIA;B%(0S21ZS6KL*A!ZSV[-Z+IZ1_YOL2.C^F5'"3!\_W7;%!2 172RB)?
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MFT1^1N^L(*:$-@0/DJ-K"!'7]FOD,]7V'S3B?L/(!Y,%W!:EE& K(8'DPGY
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M3Q/9@IH3&4B164N@%,AX"604:WW$'AVR'O:3A>+6U'[-R 0;"X9UBH*+W.
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M48%O."KH7DQ(OV<!>4]<RI-?XDX,74;'^B@]E8B '_<53(2H'M9!?5+H9%#
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M;.%9\@J7L2X6$[.8F,<J3+!42V#=$P@\UQIAC2BN>A'QOL396PS!8@@>J^J
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M2%AL8VC7^# H";;6=@DR%[.T]!21TIH:FUM&T_3D !:'HRL:RBB96R-5%/6
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MKYTN^:F!B&LY-7#)26KWEQYA$W<4D9(I$\8S@Z=C/*PYOYO!C5OB2V I#N5
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MP] VR5%&[+9Z)2W2_/,SK?+\@7&SM&Z\V+PU;"0>76NZD;@['>'[F;3P>NT
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M#IC,<#*488D8?Z;@WR2/HGG/02ZWTVQFA\.#=NE\4O'^./(2MJQA'I*!1:]
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M1'SI$*>)B.(>A_DI'+]O33Q@0Q<N]L2XK,2J,6[0)M8_LPD3FM3!QWIT,8D
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M7S$5$KSM T0=F%'&C1T<J3/:$@S=-!>6J^)7R+*@2Y8W/8%OX>A!.[&)HT^
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MT1TW:V(="Z18SI:#T9]%L%IX G_6[DURY2QN]&KJ78K+C]B(<*%+/5O#QL;
MN95HR(DL.%^]JB&$^=O! 6KZ<@"YC\-0[QA%%SGO.G)<X*=T3)0GXUNBNX.!
M7@Y]\YAT%E[$U<0H)O23F5=D:A@[<U?7[<:A<X^<OL1"[:5EK)J,9@;,1#G
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M?=5DKXK_>&@0'>TD26 #PRMX0&KBB&ET-Q40& <C/:/I*\5F5XDC?%5U6M&
MO_NA9-K*,,S4Q>,R].$W1)],1,+"QY?2/8,&5!+VF$8F]Q7<!B.#$N &E]@
M60&;*&A =57=5$C@\XTV5Y3.MS?B1<*09]#S8YPBM=U2H-:HZD8&UH.\;+):
M"5[!G^8A:ZC=E,E=1PCT'@/9HS-XNI;01PC<%R(B+E^F,TV-EE0M$A97%KZF
M&Y1\J1%5:[<NA8\3N5M9RUP5RVY;EK8")5@CC7'I#MTID>ZVIR;?LE22-+11
MMMTN<ZE?8=;P( TJM8H)U'XV#+]4]+#RA"=T61.Q;BYU,FGFXS9JQ_V+=JO8
MT.[>7U^:UB VEBUK6ZRTS)R"2%R=7B:\[26=11<T @^\6N&Z?")Q939#HZVI
M9#!FN*X,TTIH!]T!Z+RF(BGP@.&=JT(:]UTK_X,O [^H^FXKG&8RU:D]M;DQ
M+H6>L$CT04AZF#BKT=][?A=>2@Q/H+*D@0'F3M9US&9;J]UA5%LT0PG$"PW
MS#O1;ZPMB9>G0<O='0E)UE]M-\ WV.=E\3LM&%\XL8<$4Z:TFH=QRWB#7#'G
M\7+;U>@$(% %EMC!HZH,S][NE$ZK#VLE?BFNWV&+!-,E_77;E+-G7V6N:Y+N
MT[38H!L6&[+:-5 W0&_(J<-3Y#F"I#5"=4 \W#N2 NVWO9,QJ,.,<#,=,<^H
M*4J:<\"<,.C]UV=6082YT_=0& )=4/"Y,PI?Q#::J:JAG<+GUKR4WGJA,!23
MP=(]E DOSYQ@#'"0.!0)L9+\8AG%8?J*^@)\>P8,S1$> $5&7:,KT"&MZ%4K
M3RXA'6:B0V$WB$^2C+R\-#?WG<^8Z8?Y"7@)*%4Q'E";&/W%!-!,SX$%6Q.!
M1KUC1!&)* 37+NI#\*IMVN!3 &L&S&&8[+]NF1'F"1^9_795,KPP+%'R;<9N
M[7H*Y=*&&73C[KB&@44IRC6H$)I9D6_RL#;:+=LJT$/(%6BHR;*W:#8+TWQ)
MW$X".P&ZI5TPLXVV-7%3%?U$#;JR@HPNDU2<*O3A+L ./+B0V[ZB1\'#V3M_
M+Y\)HXPR.K=ASQ+].5VX"!-.WINL3)XNT0?#KJ6^C7[CM8IN']UW5]@ .FUZ
M#SDHT]4=;I%:[\CUW!2#SPJ&9E[:6BU&EN1BMR VLJTPIJ3@0MX)F5MY/8^I
M=/"%EXXJ8=#2*'", !,+IC'9)-:)&GZB/CK?BQM;8Y9"/X!SW(*'JH$ATE;'
M%>E4Y39,2;\CNU?.0<P?6R/+-U,CR^/*3(6X ZOUY(#NM)].[)'4WZ"6Z$ZY
MB73K1T=(V'CVK&%B"D^N8\(X--2?C;IO<I(#C6X:?(=L:^\=G#!B_R^,:0Q2
MW?=&?!;)T%0GQWWJ'=T3>[23ZX0XL>=YZ\(PUS6?:/E1A,>YTG:]<3AO[X]H
MZE:2( :O'S!='';LZ09.;0W]NLK(4"4D@]&;/;&Q/#VSM639S[IM+D&R9P$R
M1>@(T-M%" (IDZ/]?6,J &S$1U-[2=2KG7#H<AE00X*2![Q4?9H4_32M'->M
M+5EZ?94^)L!&$R ^M_#NQ^>98[,<$3-1U@%Y,:59 #,%L;00$Q;G'E(8B+3X
M(!7&'Q9YS,_LKCGM,L(%1'6;36[.?M6,2+E8*M#(,UBHEF<<UF.95[7HU3E:
M"TK2@GRC$NX(BBHI(14#+3HRPQ-2J<>43J5(!#8V2<=I"X)0>1P6]^%TIQH?
M^I"E+'P6=%!Z$#Z4Q5594!#\T%/Y?T&H3^,5902U<ZY/)S>+<6$(SZO^ _L_
M=UT3VI.4?H-GTA.CW")KQA,Y)L8T<_,2>Z7DJ2FSD\5NJ5$-+F%:W(+L<KW=
MJ Q8D:_"2G[P&>MWU$LH-CWN2.=_'IX[I'6*\(UK9?HTD9<^?(D9#+<HM.IU
M\8V*U'IIC_+$+;3K49J&7$4A716H\1(7(I'=VGFA-B5+/YTYA2?GJFA(LNV3
M18U%IJ\B8CN+R%KMN$>.F(YAR[B>*Y"8(CLD754FK)B.JM1?Y<+#?*F^;WIX
MWL8=A$8&9[9B9E?/+CWQ,M$-8C&>1NM,A[>$=;Q_3F7\;@?8W3?$9[N_P6#M
MZ3V:$^#>^)/M^>D>VJ1"2IE!;6?G/"71,;-$3[AN#66 BB+=:Z2 ^W2?(T]<
M)D"*.<H2Z%4M9J!Z!D\.D*\>N;&EC&'9<Z^M>'K7G/3]1<KCZCFUZ[#VM>W;
MR&R]3[GHPB.SNY"^$>6@PR^8'EH*F<A.P&CK#?# UNA_1.WOEM-'\\GIXNF.
M] CU1R6H'[CSX&>"*:[!K@59XBA$+%3N;4/#RIS$87:CJELRH?L:X.0,AM$B
M_JOA7)HNO*ADHSRZJ/-*Y2V22U>Z5C-;-O8W+:!=YE62Q!;I;>?EJUB'5/C(
MR&\;P(9>-4XGF_5O1?0V*<9LUZ"%$EG77LF!JW^PX#=7B(WH&3>G@GTX653E
M*]\<5'$6S6%FH)JCRF#"VU(M:*[;^KKT9^.!BZ$L66[#)S+6-C-4 @B#330R
MN4/PX]%-*Q0C6(E5W@E1J'3=L3&Y!!^;=[NI1J4-Q8RJ(Z3 S^BXUY/].F%/
M],00**./&Q9/"QH_=$"DE8*4_1/2'!?6$>5686H XHY"!YL8L,R,J@6G9L<U
M)":<.BE_S:!>K[R*R3K>L/=5"]6A)#&)I^Z,AP0EL-0>^THON"98:&/[H5P1
M0=QJ%VY>[/HUX0+(X]LU1=>N+(+*-U=A$3-WMHF]XRF84(5_):?+ -P2OO&R
MG'?"R?[L*60V[$1*WHP3L61GB/ "-4(G*BC4<H>>50ISPHVA/'0+HDG'5ZK"
M7CAFHFQ=RNN @[A:?"#N%B+^DQV9:5FT%ZH.9?MG*JRPWZC<R)2@!$3P0[\7
M>?:;, ^R*(ANA%5^:">VS>49%=O"8Q"IS=EVG>$B5+ CRQ5.W8J<1#*RF_#$
M\^W&)+L/2%O[1 FD>M-U(:P:N[5XS<'^A[\9 ZCM#!<H?)FY4]2_XX95.<:G
MEL<WB^5E^!"X+*_9S6XOY*?:XP*H"1G"?M,N/G"O7N:<B$02,UH+HI)<$FTS
MQFC/2\C<VG*'>I*K#"<<VS]? -9M;M\>ZRMF2T8#(KJUB9JL9/^9A6#?PFN5
MW<Y'+.W(UH4">6).,,UW\3X>>%7VVT=3E3WM7.!^TOM?%=QH8EB\+':P>CW0
MG=_NH*"&&$,:@<P)6)TEJ*Y 50M#U,*.YJ2 (E^'!]!N&&'^/ULB4R;^+@.7
M?E[F]^3<^E^Y@>DJ7!"Y$BB\-/"3@GEMB(Z]]O)=--:F=A:L(FGJAI$:##:0
MA<0.'[YQ ^MFD.\4GN\K$=Q5J8XPP*U(&1'_S/GLUZNJ!BFAB,EOY+ DJ!YN
M+(6!KA3+"B<4>D1[C]U2JDH45;3TL9)3IR[I^OB\N^P&GV361)#JF?5WH,0P
MCNAZ>?(]=8:%*  _/?T^?@9,.T6+,]Q:1^4[$;JL7XLT.:B_"?878PM.'GYP
M' -19%="%ON$R[OSP>P>YKV;)J31=9+H"PV'^6U,CBFP,+[RBM8A36(I5<61
M2=1(/;N+X^PF_&TXY+;51C5!>%M&'S-NR;ML<HW+8UXLNL']HF*= <$B4BS+
M@,[8RH"8#F6E>1E!I^)NB4G">'+./%*DYI;)I/'H/T!(.BY%<PJ5M-X!J_=U
MTH)'&:'C6:*N#7]5KNZ>.[YEN,]E&L([)#@[[,,2 $!AP;?I2_/6PI\:8(?1
M%"T(#S(>6-DCR%0QJQZC'_'Y #$R?HP^'1S>7O"(DE*UUV/!&E-B'*< C%D(
MA^18(IJ-^P-F0:O=&#%B?AC&*EJXHKB*9I?]\A!JF_/>[L<,3/O^ <A$[!O5
M#Q1(<<<KVH_%Z,'R'MQ;R8G&7]2]?6#+TE9W2I3>)ONM(5X[;0P\LMN^Z,LJ
M^_[W[MW'Y ']*BJ<32ETC!_7FF4?Y,XE@O=X!RV*B&8!.,X8#AHVUV77WFRN
MTM2_UA32RS_TY.$%5I0J%;"7+ (JI!?$S0!/GSWEORRW=7V&O@EW5EU(AH1I
M&IU.:M@>^;HJZIV?F?U+0#5'G3VT#?$6'9P88('+)7WQFFMD^:5H29%YDU50
M4,&:"&/"A('9#Z3ZP#ZO('X=WI? ^,'^T>%")BQ$(\+:2>6;?!>FZJS(/?)%
MNW):NHP6K!!9QHOBI0#*M:5$+@"OI:0-8MP@&[LL]]+EE[SS,7:]2U[%Q>?K
M 3$FOPF!5H-2;SS"EET>SK#M@N?(KD >9-63G&&XEAHO5XZAP:.T:N7_GC9[
MJ+:>EM&N@5#'H< )&# .QM7R&OZ>*+O*V&A6 =&W1\1H%R^^07D.8)PL!<@S
M';.$X8]<!_4<K.'!( 6?(E(2;,'2\X2.A>BOEEJ5U167]#^,S!Q]7*U(*Z_<
M].)EFYPK:[J1(HL.23:,F8SG1%J0Z**1"MOZ160:,F_N!NO+F'S3/"NHX,O+
M'4^-Q')Q3'WORPC^)B7R/H#O8'^A3,;)Y>(S;B#N-ME(S#@RMM#&X>?D(7Y<
MQ]JKI9)7Q!4F;S[<. JR6>0&MJ!)_BBXL:&U0$[,S2<MDGX;!KA[Z,=8'#-Q
M^<,Q YU7=KHH-AE;\SBN#OD0(@,"#("SF+YP'YOAN$-&3:*:H3ASPZFPOC#O
MS!WI_30N:G8S&](G(;<\4Q4^CW-([3V[RK#EXQ61H[I&(ZE.1#0YU81>^ETH
MY1VA;O56/%A7%)*!2ZVPMR5D=OF+:%R#O=WX,$LK;?$3.@=EZOZZ\,K/A[05
MH)7>PC]KC?*64MMLW(C!'QQ8&S*4MF#&;;^?:_4 FF)L?.78B[0UGKE8-1.8
M[KJ=D]"UK6*#="E1.SJ]$?>ZMW?J;M!!Y[0+^R8Y'4.#/)L/@L@X5 C"I5#,
MT4U>,Q]\FCV1DF$T6G$KUD[E0&Y->MB]2+I3N;2+5BRCV+/M"O#29S9!1NYU
M-/R1P4:;YN,Z%U[[G%;FDH"QMH6F_7W'V0P#';(-S2*BH>82U/4-^8 &J=!D
M%);36EI+K/_<DA;A0<]PV%0X241J-R)%PNV+O"O4(+JZ"J-+".U.%<J\$";\
MAWSZ2*HVG!V0^Q7<O8(S@RW>%G%@W6#/=VFB\O=-ZOGLY^32O,^ A3!/4<38
M.7LD#J]D5'IKB-G%WMFDL!^!Z&T7P=_:K=N-=C:HC"R@'-MNI(=QOV?_MBOZ
MAW34X3S.2"[."5)! I2>ZETEPC9[0M'\':)QSZ2P[<YX_[A4#T8'K[P+*^:)
MF 1,GPB34$$PGMWA+;?]'C*%CE"PJZLR!9)E:MP3H3IY:O>R)J7)/H\A.-$W
MWE?7!U^?V\H9"LK<+!BWS*W+;/:A6GR8YXL/%#25]?*L"#?6)Q1>!7I00GA$
M\>SW6&^CMY4 573OX&9<!3^ HG0(H.)51=Z%M4%4Y0,_I$,4OLQBGS*$V O<
MZA#61AB5=H6"_P)U[C)2&L6G'QUE!<_&320 4_0L.+R.F48![B0K!!"T2,%/
M B'\J2&X(,TNQ?#=6]%<:7 B)EI$)QA$+6GNB)/&0<P &Q76((6;4D#B>*M'
M5F_^[K'4FR=Z.M_<.#?IJ+UZ'LNC,<D '$-,[RP<OB&XD%P'"U3O)*+:N.I:
M8NBT>D+U@V"[L==NR#G](.XWB6R*U5$F*^J\T$27"QZB.!3XV"!9 :.I"F\0
MS50MC0Y :"B P(-G9)^J>M*W)(F5(&<2%)/K LQC6Z#(+O<#L>#<%TX&I[Q:
M[;;S1AM9+P.NZ!WX[ G/L-G"NA!2,\0DV]XR3_0)&I(T$&?E9@G$PYER+4C?
M\/*=Q><=+2(4J<$6)K=,VM9\6*EX_Q0XF)(LL3137VFLZ[^_!##?!M&L[:-L
M'?NU'+H*R@R$?E-!*@GORJ8*SKVV<F7\BU6X. GZ D^'8YG\7>04L-:S.("9
M.VK)Q1_W"E3<AN+S>*Z1HQO"A1+M()1IN*[:^I'46I 5ER@@1W]Z]B\;?74_
MH!L:+)4E,3HB%!#&W+R?O<<5_A:ND$6WS;?C%X+3=.:9FD!I'YO+8PFN1#T(
MHDP ]V[#G-<<]@>?+^<OQX@G\\4?_WH6S[*-$^<;PT->8M7CGRUE./67(1;!
M/WL -]B_Y$:GLH+^MM?"IO(T_T2/T'']S\7&QGK)&+]P-E"QHV:'[SJO.8E#
M2&9ZOG"E:EUYASZ"V94QLT>]_WSV=UOU=*DX"=@PT5GTE:A%!ZGH6NP:7,;P
M2I3"#[^5 #X\>=6WHO:4E*QQ"WJ,*LP**]W-@X_)'\P_SBA5%$ZJ?L5S2_X5
MIY)T;G@5(PBC;-NEM86Y)C[R6OT$^MT>?5<>=#\!W%NJ)P(W,B UA2:WQJ6B
MT,HP0J+9^C;EX!=23S&:D,)9@QH3=,VIHM1+F!F?,EFU>$S$!%+GI,.'TB&\
MDY.HSPH]--_!NN"[D-$&C]DEU_@J$J63,'TY@EZ0R@^M)&YPB=VX:^+]H>D(
MRPCUI8PD% 62;RJ_R<N,=L?(V:VPD9+@5A5\,*4I=<M?$D0U[U[WQII$CFE8
MM01MW*L1+WUCB*LPDMB-M47Z_P#&":N!)3_)AZK+0M ZZI)H196 &0<<'!@_
MGGI&VX2%U.AZ=+E4B6,'Q=1D@V$W85_I5K.MQ<1WVYZJ?)HIT/TS=.1LQR#U
M]9[[XWE)<46F9[JPX-/D'?-'J8F3A!F9B6UG672LO/*C,&$.3DW-VZ0ICY=R
MVCR7:7UC[W^QV!BGF1AD@99?5_UG',.G[Q>E?;#9P1. .!'W! %O24 18(G.
M VF'PF+DKR1I YC_!8<K,K<[^7[<N?(]W&O<H1HK'?)>R&P[T7[CE#SG;ZEH
MS- KVE1\3U0AR.MFU\SM 5OP#]T9>^55Q9!_U.8!!>P?YRR Q'!23XNLKM8Y
M-)9MS(8 )=0?Y^4L+K1DW1DU!C\,MY3!CFJN2^H\+"R+OS@OG]Z<_.K]E7N7
M?*D+IGB5$',A>@?E=*?7TTO_Q.OS.:V_-YQTFUV0\_K_23H1(Q#BQO1K(V;U
M)?;,<]XS%^):O-%FO=D;=;O>!<?QBKI/+JQNY7:#2TABC#E>S 2=(@XRN6Q:
M&H<.*#6DCV5F"6"AQX:F% ?8Q)NA+6'5"98TUBV.YYF'3[628]=Q\%Z+I"7Z
MC;8 "IUL.=K[*GAANC 7$8&)C:VS;K%) 8!3*!JJ:S/HIIW4-'^/5?G,#.$=
M]2_^],VD?S'I7QS2OU K<L#@LOW0 +X?-X+D8[,8/.*!8$784?"QL@7*,:YF
M[W['AA(MZ-M&B?J_B,DX^IL6EBA^#*<81][S8.2^/.QVD5F47R_DWT#"+/+^
M2O*F'RI"#2#@(AB<-DIW):'BZ4 /04<EKUI*AH/;!$&,J!CTS#A!Y"RE# 7^
M#Z9+\@1TY#=%@IZY;-LBFT7ZRHK8<@DEPQAPUVVM3/=R3JSR GV2U(M3EYH%
M!A2.^U9SFUCG:,KQDR(:3=:#YHY_J IW4EU(7$8WH>0X=7-RN+=LM\PA7#-L
M3&('R9\R W]IIS]U(83'2>(Q_SEZ;>JE7X+;%[$HN2&X)@'P!V=FSJZQ[X<
M="6.7N\Z4267;=&-WOSHZD>6@3/6/1+A2-!T[ !M:T1D> ::IC#UY 3$<O?
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MKL,FWB(V,]*N'S1-2/\3Y_!#I/O(4"=?/Q;4R<3RS<^!,S=/ZB?01-B 8Y8
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M7$V3%4PMT$'KH^[HWN:[@W\ZHIPS=$Z-N>7NSFELHHB,K=Y8XOCRG+/9H<C
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MQE_[\.3K>SV<>EM\\-"]^^#;$.IB9/Z1\\PU#%Q671]69GO&GK#6*!CDRVF
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M]U'\PMXC.R3!AKO4Z2V"(W+9PHYX9ZUTS'$X-1BK?3G$JO5RGUM%$95Q(5Y
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M((&8+6 MB_-E8J-F:"VDJ1H=JXZN$?44#FJ-6;.J52FE>-$@G#CZ(CG:Q-.
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MNUAYCSX8&BB/E@S-'%;] ^P!J()#E:Q6SZS#DU7!&<_L%<FBW 0[:6(XLHB
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M&^_#$['@BI2J\N,#%[F0:+G >7B9]XDKPCDCCG]K5W;=RUPU-'K'T$0+U6Y
MH^K&+JIHT7:+A(_-OFZ@]%&,DTP81(I?11Z*/[V?.?/_BM(6-.)4=7OY8@I(
MK^OQSO]U^5%5X6%$0(16I_[:V\A&2@)^&YIZRKO1]Y5E;$?/I0Y_6M&R*(DX
M?[$< AZ@.4@E2.@=49,1.:Q.NCH7_V&*0))Z9CX!=J[C7Q=JI].*+-;NB=2,
MM'42>_]114D481,A;S<*G^=<^08L1S$V1!Y$(429I,1)>/B$%2+" #8W55P>
M^@[807MCU\[RSS$_@_Q+E .ORM702%I^-"-^JAPH*OJ.+Z;6KA1^"G6] C4:
M"3$0I5^3:&("CHQ^BT1,I:YLQ=@U!_$XYS2!/R;1C 9MYZD:;H^AHZHY#4?'
M53XU]NU 1LS!<&K>B/4A.B2O@]I@P\+^R72=HITH(M6+)I3T"+I:B@S=6.1!
M2] V?1AKXFG(XZT:M;KM>KY.3$HPX8?JAT3&*2,S$86JM4\^,:-E3;?S6B<6
M<KA5*=R8[L.5L9FDM'/,M*]<7Y1$ULS+DR)+"'VH?=F,G0BUN@,KCL\I).,L
MO2Y4?I25,M'PAM#>5/Y4M3%L9+?B8#:):W4'"Y-R*=7V.7I[7FU>>Q+82,^4
MYH.)@GHB[RP%]%P8/R!'CKD0&1-/LIJD:NGC:KK(J H:GJB>HJRT371?L8YU
M:RU\ T=59D\1G2K]JJ1ON&B8%S%.)I,3ONPHN*D=/K:_P1N2<X'A_@L3<,XG
MY'(A;X_2"5M8KNZ+PZX6DPW#+1&I<*P&U(=R63P-DU'J\!M,(DIR/NPGJI_8
M;J;SF?J35:EO"O=(7J#1X1TA3(W_T$HOD'PC@7TC7%$2Y?7.K:B_130^CN9R
M2V(:*2_?'^#ZGT :@CEWT>[!W&[,N9=QM258A&P]:C ,JT>@I5$IK+':9X6E
MZ2"@RIDH35&WS[O1G;W=F'')V4U7(F:LP+"^N:A=Q(U<HO*18&Y;YU'B27U"
MQW]<OKMZ=_FO=V]MU\\QAB9H-GCX"#CQH*DTC^2EW J'\-G^%CF$M\K]2[1Q
M\L>'\U_/?WY'F5$4-?KMZNKBXZ]_P*>__/OJXNJ/]S;1G*"_5(?4C(,4HT-E
M;OK5G2<B7N01<>'W1C5_4RN#OJPT^8^5(?1@=/@D$NAC;9: N9VP?CO"NAVJ
M/%I1*+ZB:!6,,LOUPG9$DH,1%I)V6*U&&=*<Q\9-/722\VTA;<H^J7*!9QDF
M,;.T*,DG(P)TX%3M/.L=FE1+%4Q.IMX>7"J6EDG!LTBI=VLLV1?S\_GY)U_9
M@+#2I>GRZ5WM_?]4;%7&8SI8:WLTN\<N#0LX.SBD.+[JVH?^JV@U!)1EQK'N
M4'6O_T^9<-\F8Y+=?L$Z^SNAR2'D8@65W%R[C'/)_:)N!T#/N\(\=A4JMXT)
MU;'= N-*S,+2$O+=P@DV>;G=_\5^=;,-.]5HD'5",?@"+9-QE636;"=#%6#9
M-9@Z>W&:?N'!#>;RR#FM\O!56QI<M6I.Q^D>];IUREXWOH%JUUPIJ<WUZA;@
M[&P6^9Z5_7G>JW626BOE@QK=& <"D:@:24*MQ4QB!-8(4JJ,E9X"-Q%DT5#Y
M0C-.**]:6]]P20W@2RLHL (+MEAU^_'C',LJ8*VM5]:IDQTF1W+O.%6F!BMB
M(1>R2N(68K90[N,%TYKPIA&#%*AME$E4W=-9+'4;ES@:2<K! HS%50KL^Q3E
MF)788]SF_ZK0%BU,C?V"4C7)5XY%XLFZC %0%E@KI_>U-$VTA2K.:O+FT3Q5
MR2(>EH5&\P@X_Q[+)^MPD2I[P30F;P;K$THS4\$+4CNWZT2Q=TDRCM'!B9WQ
M\)<JBV<,QTXXV;7Q"FY-ZDTDD& Z2R.Z%2RBYL%N.M^,RM/0.8?<7%.HVI7F
MY D/EXITEIBPSN?-R>OG$8<W71?1[IJ+V#3K&"DQ0G)]9AI!J2TCQ\LID8F+
M?!11%X#,P+(T)%NS/2D]5V"G#9;4M Y6+*HR9XV9]LGIF.;B*9&5KTV6>$>J
MW X8J9[X4E6VJ,8DV(37X(;NYLHM5#*2P.0/93 R<'14DG .=TF3&3 Y;D:.
M3:':"%NHF[-+*U/5W;D'C"S-@32IQI6F[L$><R4?51>L-!3<6P54"V &0-=*
M"5.@D\E_%U-DP=2/9<KEF IE2 =Y=_F9>[<!HK6\4'4SAWO<(QTD+U(PH8=1
M&J=C6L(*(&DLFJ4SW:W<KP59:7Z1P.@7EF+BKA=2U2'9O7K*9"I59JZOE$&5
M*.C%B"(Z.EL-U8ET9^!Z]O9+X(',"88XZR:E,:S7:1:'UPA1N'TO)X<)U=D/
M]K=^7)*->;-H!L234!(T,D',-"7'?1Y]O9%?+4S1]"OO_%^7>Y=O]_;[)F12
M,2.T;\0P6VC\Y1[Z^A>'[;\(%AA.3$%"UQ\?M#_^LR@#JIWE5WC%8B:]?OVG
M1^T__4>9<".)) 3Z;^SN>(/7'503\_3/#]I__@G]UQ7_JBX/06#":$-)+F]@
MER7KU+?>+)D=NI@.<T;3;"^?H5Z.S.+3Q&3C]YMUXZ024:0!9&#S-]Z@\7@/
M#-:YK%AE90:A'#+*UTW[\):V (<Q%\'D+),,)!T7!>:FH'V-EZ, 6/<LC?<R
MN[R6S&,5@Z5&P.<_[?W\N?%C7S<D) 6&A!1E\ =9R=-'K/* 2EB8K9NTD:K[
M%0NZ/"I4R46)9D,<"5WWT-[PMV>14PL.Y06H_>C NU,2]BWTJ56;NRT..OUR
MJQT5&84C4I(RM^)\ ]< 6TGP+J[@36\C.4Y)-/WVYNJMSWT %&[],%B%?&WP
MP\SQU0BEVP%['Y-* 4(-8'V<P_VLQKKU6-H-J/ES";*R24^WHJ:-7?2L*:PA
M 6G5M1 RHB%K&58U] -K,<^$9#;RKL1JLY[%=C$/IH:'Z_!A;Q5F?%["C \B
MP;Y*U!:0&=F&:( [M)/W=:Z9L2(CT&<\G+R%KS,%4+^F<TF)/*8("LLG2DI2
M$Z U7*-7R+Q)"4O_;K+%@)/WJ3OCXY0<0=5*I@, ,2M4OO ';[-R[)V'4]@#
M^1]T*]?W;\]]-N(7-"TBU?8Q]?RQ&-5$-P7B<[#26HDW=2@Z24VJU=E0E-2N
MPDK7\'7/8!H1<&T2]^ *+WY]NR>QLH(]8FDZVH/_!R8^^LMJZS%>Y0IU"U#L
MD,V,%_J+&G"']COXQ?T-<Y$ZI\]=18D:.A#1[2@5=K#?/_)-LT6X]13/;#4\
M1(G#C7-5WHBJ_4#G53862?1?;M).*OEH1+F9E:UL9X,@=X"O?6IIS(D8E%CB
M6[.=>#X'A=442-M:)'-,#K[7>328M1-C+FG)5(2EK,#)\/(X5057T2X>ZL%(
MO0PE39YH9@=5M5%VJ^:J]8\^"'UK=2YH]F"AWC4A==?0]XO11G;K<N_*A3EA
MIMI@F,:I*HTI;*8X5<89R"13MC6C$8'2JTPS!3 K?*GD&/VFD>&ZHM7%9_7T
M6QD0%U.E>)1/J]@9MI52TT9#M$FQH27FUZA*-5KXY>E)[XA_.U7&$]G1N8XP
M\Q5KBY5>SHIRRX(XC1=SK0!D&JAD3>IA;CR:1?N2\3SL_U%#5U3W3I_V=3@X
M[?5OVUA]4+6ZD1NRA3D)C?PO>Y1ZI*ZX4OW7.]7-6S_M'7EWV+/* A7 -29R
MCXU?G0?ZW?GG#]^;>N-MYW?U"455-UG5]M=V$BCJ@CO''E':[6+U8-<DNT2M
M]8I@$4S(PP1/C;#VEW]OY^1-I)@CZ:I<WVJ\SU)')VI#6[:Q%8(QS_+FP17+
M R\YY7 %\ZQ:0N(IT7'!I^:F62_[_;/>29TF\%<O3PYZ^PU24:H)M<'9L:ZO
M9_U="9;353_A379E9A /'VN79(3AW 52Q>;(%*)8&4W2N5'\T8":H)R6K(N$
M$ED"">"7'9N;-#@^['5L2X<=VT^-Q5'<H+*F[&Y=JC&X)45,8W!RYG/C$'92
M)/!Z;ID/_)RYI: &YR*<"ZV5V\UH5S-P$O5&B:W4N7;+2=7MUSLZL@(MO[0V
M;US9-K!S,\!T60)<NR#2KM?G&(U=^5V,"YL:HA1IP8=%!W9E_[,SHQX,\Y7O
MQ\1)J!^>;;:VW7PMS.ZW]FWD.%8NJZV2IJ"'V7''?4*JNK92,\$T!O%*'097
MO?GN"+$_'5+E!RNAI#AK+!S59WDO8Z-?=W,L$^.RUF3(TZJ]T O71C#XU8Y\
MI56K82% 0,.RT'RA&C1';S?K<_)+(ANY+]AJ+@)-2$\V)IM7M?O$.*?E!5XF
MOCN-&^N<2OZ[ZG*#X;C:3 7K\%CYH\8ZVC4^>D@"WEUC\ !.1F46JJI]=!8-
M-B0KHIAKXRC&SUP7.V08C;Y.6:S5<Y!708$P@%"6&Q[7$$_7&C5L= *ZL8!I
MN;0L:/ZJHEW?9">(_Z29<E+21LW/V ^%0_#F.KYN;#RI*JCM=!T.0C;?FK69
MHH2_A+OHRR!*X%ML 43[[JL7IXS[ '_&9%]W;0:4HTZXV)D)'9W#-,M42D)&
MD6[*QV&K>*4O!GU5"?<0-9.D=*:!<4TG:K0])PMJ*[N^!\M1L]3FG6P<W7Q*
M.7V6#:S*;E+$3S,==;_WI3%=7,+&<\UEQGL@ ',=E/4^9 ;6C30'>UD#"7FN
M%ZL7--?K@A@I31,P>]#E6BVOMEXJ5#P<7^:KMYFAE"18\4>U]LW4+QA8(H@Z
M3)U4G;Y1%]%JT42NV9FX]7:;N@Y-*X-7\O<T +FH-PLU/)6?MECJQDE;G6.6
M/U5M>I1F(S-L!+4BK\_4ZNILC99I$*:_5(6VJH<3AQBBJ99-4_2@X:MUR^[*
M_41C-Q%#,>N.T,]T+E-K:C<(0E@5^M9=(CWO'4X\YE]3[$G]<LG/HIBO0DON
M.T7=B?5ZV'BF3@1+#S!]V8?.@7$L;8JS:BPY,Q1Y5+V[1NRU.4BV/"I,#"S&
M:U<=CRD?,9"JW)7ZFZ/K1-6#-E?9>LQ=RV@F[R>W_X=_5#E?[# >'#6=4.TI
M7/(KEY3?L)RX83=Z(#/!E15N9-LV0#"]PDQ\HO69N[)B'I$DL0MC34Z8B@BJ
MQI J*'A0S7G@7!F*KZ'U0;,&$07SO)RJ*0AT3$0^'FC%"L%UEJ)BJJ<<4L*L
M_#H16#A/66VFB+JJV]4&0YX"V&A46%+I,3WO2IK9U[<F*_X2P5E#/4'OC7K%
MI7Z%UE2U3_GS2AUI*!>I;I4X2R/%G2K]\(;1EV8ZCFE%A[>689;Z]F;J8F(
M?*THX".E"EC9\@]4YM'=SOT?#;V]T_1VW],=K6CI_415E9:*^];2DNY^W$YQ
M_<M5*KQAGS34.R^L""9-T<BYKH;#,BN,Y\KCM:*50YO#2OGNL,'A2ON"7R^J
M'>C\U:5=K[_7=79G65"O-.##:*Y!SW$3Q&.X6?B*%9DAY='^_<7^"\Y&GHD
M?F_^GB&G5'^K=?@7>V3JS'+Y2O_C-6PW+": )4 4_(:,_AMZ<WKWWU\ DIEE
M^&%&,6"]A=RCGK6 #]>9F+U8%?>A_=^*Q6LAHLH)$V61KH^4L<1>8GOJGEZM
MQ[Z)> :-:,O__E"$M][/0>_XL OW<P,3^%OCS'^[UV7>,+/O9HX28N,B$F'\
MPN540#K(4QUJ,\_ITNM?L/9S_-KRVJU H%VEG%L2/:O--#&A_?:;&:%K0*CY
M$^4G8(M4LD8ZDDJIAT-ABYE$?703AS?]F-5ZE4N%/4]-F,-_,OP/,G#X7^#Q
MCM5W$&$=JW>LWK'ZW6#U5B1.\7$N>;>\W]RP/E7#U(UUH!):K1:';RX_6KW.
M&K/:6Q[_\)':)E*5&YL5)K9L:C;8+5X-CR47B,I1Y6!7/6+OMR4R6RW5<DI
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MED 64?Z%:;1ZF/ASGJ< **080GO]CEM!:G,)?).]AW3T2F,X"%6-XZSTH:K
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M ,$Y=,NAM?L5X2O6ZAP3I&4<>E.)%9J>[2CFO>JM5NV5=%N;1L^6EIWQ8=I
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M3^4<[T(98F? T]TXQ3HI[L^<QW4#5+<W)E@;7+NN*IR=W5E5>""NUZTRA<[
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MQYFD^_#_]P=<[L=;5O5>'O:.O;:K "P-1#Z!7Z;!E[TA02=(IXB%M '?4V^
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M+ )83%@&A <(RNPZB^B/$#AC6B8%'Q[A$)'@YK^U$/5I7X>#TU[_MHVM!"6
MB]:L+KX!U)P/02+]M,[<^6"K\6KIQ71&^AA!]-Z :#/.-^@:A_B8>/\L@<R4
MI"&4&D4Q(KV73V0\ N0:*V68[@*HD[T,B?<>%O&N]@Z81O'VKMZ](2S&?].R
MN*9WA>O RI,HF,"EHLU/3U2T!QA2DA*&H"(0@'PN"0/*&4DW$%=CL.C'R!P0
M<P;[^[;IN PPOXG0/B#LL/!R"2R-?"BP(Y'!)3&F_@#;+H$W,(O*HRD8S2*1
M:9G#,<C'+-$,)4E[1>AI/ Q\_C?IM4Q8B(!6#.S4]W[Y!:X#A#6CLQBC-P)/
M V@WCT)I9/\&%_'RZ)9S*U1&.QI]0_B_@.Z(LQ578EQN 1(K&HT/2=\ ?2(6
M> 425@F(T\/.%,P1&1B+]K7"LOUD8;2PP?Z#TX:U]F/1QVUX<@_Z^-Q^@C7Q
M1"2ER !5#EF(;3VJ7"05P1"*!* 6D4)5R<5"+LFF%C[YGN48X-Y'\]!*4D68
MGOB')T<^F.Z CG#I[1)3%("NC9>C?A4PHO1!,.ZC3<YK:#1DIRT<X^SV-\#G
MVL.HQ>BHC&.0]3(+0('"'^&'YCH P5'YZ9^\!MVO4.;7#/3M"9H@EK:E7@I'
MP-^W'L+W@+?F:ZH@C+MH=AG)#V\NC?R/<@L^%(B[FY;#9I[9J'$AS<2"_#!$
MO3Z[1E_V!V>5;K*A_[&+U/!>#C,B<:.C;D@1M05NH8HV/@3H=N@?'.W?DS(&
M![W]&F5L.Z*='51NK24\V_*0^M&NA-17D'1GTC]N\!\_M1!.I&(YRA/=S:U>
MRTYOS\O3.%S2)P].#SN]:[]_N-_I#5IRJ,6M %R<6078:?P/[6#H]J'0@+6%
MW+(LNX/ ZO21R[S3VV.WVFFG]]CK].[ZG=Z=5M\ZO<F>=TZ,KM.;-(9#IW=Y
MT.G==9M6=)"DD<%WV.U=5ZZ 3F]S29')Y%1$"5KY<Q'%),M1.QB510FVIW%@
M5I9[,XS"A]UZ[\>OZ5P[).[F_:@MT.K]@*LGG]Q]/7]'C^??6.<8W\KM<;)?
MY47TZOE/%JH,:@:[RAC=;FQD*7Q+[)ABNW3'^ _Y9QG-12SQXCF,<-;($NYY
M;_#!*(%;#Q!AX+%H.I5AA*9BA@MD% 7)/4I%FV-*;]@,Z MO'L&Y 6?B6OZ%
M#J_/ *=E-J? "@7DAC*.Y%P":@%6(Z;+KU'.%L;* X@;S@_;0 ]U0NA2$O9B
M1H*=CV CEKTW^A!VC'RM?MY$96./HBPOO#]+D16$IOC&@X?++%U.D[ECWM@&
MN$1 ?T]I'=N=$H-\BQ,&*)6+X)^74T3._R(?129JI;  4Y8BF.@0!F!&E(8Y
MXV>"B/T=4$(Q2<L<4"3__M7FU1T/YE\,H[E^*?MQ,=N0"]'XF%S-]O<7^R^\
M0,8QUJO!'9B_524<_:UKZ[C^#;2.6,QR^4K_X[7GU3,:CT__JLKF3D"J'*LA
MZ(5QQDX8@/W3WME,[^F;5_0='_?.[MP&<Z5__#Y%?6L"NZ]I9&=JH759^O'@
M"=N2+C'35=KUZ6,F(+8" G:"*LC?7QR_Z$!E\\'^;>UCJQ3R;T,S3PZU?V.Z
M[CM,85P[D+;]A[83DY^\./M;%%UWX]J7.83IN-F0KZ>]4R=>NP\^)VF[ P@C
M:0==D+3]@][IZ0-UCWXV!(;VO!-'SYB?W8E,',-S#&]+X8JYCH[A=5#_[O=[
M!RT*^./.25U)6THAW]U65-CSGIRU94[%.9;GOFJ5TKT)(22[=A<J71W,LH:4
M>5:-W.[<0?'Q0#183QEXYMT1ST[]T_T[STU_3 )[5O1SYYZ^WU2R[#0I.%&S
M'7!RHF8[X?;=\8E_?/QD,]B<J&D3-0]J?#Z:8^?Y&9^<Z_8PQN?C^=N<\?E$
M+?Z?%</J*AA8ZC]SH=[W^R=/UES?D<A]S<=O*AMVFA*ZRJ6>&25T%0Q.6)"P
M.#I]LJ%BCD0V- #/CC:V !]F4/J]DO]V"5+&+%1-_JC5\"A*1!)T(R[9B83
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M%@%1\E26QK;/AY;+@XBB&5%0K>.8_A:CKF/ZCND[IK\;3%]^G>E<T[JF3UV
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M$*<YJ#&YIB[07')#8-) #'_U'P/-8B* (XY&,BAH;["/-*,3$+,D9@U*B2R
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M-0$#YSK^W"ADF&%/Q+3,L3QNQTK-SG:FU*Q+[<G_'WOOVMPVDJ0+?W\CWO^
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M4H#*6BBLGYQ,+\[UWN+-%K4\L/P,Y->)9#!0I;/2Q:RV2D?VJ=2RL%EFDN;
MZNVG.-=D3912TKNS5:"C(O??\<@%O--HS-/R7L.Q:J92W$?,KM6:F>2$#J^^
MPQN%&,U+&Y,*&T99%S]86J6GVI%EIXTW]\H_;5*LV<J8AKT(4+_5"_2P+,\3
M$PM5&@MB?SZX*+^OE(JI!9>5&?6&8:25&]90A=%';.J9S#%C*J6&,Q,::KB
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MZZ60K: 6]5&PBIH(F=&R+</_M'+2J6],$=I8Y=&B$IPD!0%L"6E! 'L$I"*
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M*L;#H!-5,2[287AY=:8[4YVY"ISPF:'P7,?9$'/&J>[)ZT"%F1OBK _F48
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ML&Q<BH)-[JWCA -2^* 7)YQ2 :S+2GXP'Y /SE?R% M4X=0%P -2X8D7AA"
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MW-]G0$@,AI=O1],!I%*\A?INZKC&N(Z\;QZ2WKYY&@*4"TSOJ1E)/ V0]UP
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M(Q[UY-,.TY2+BEYAECYE*N4FFIA,)DSD6DYY[KRA%-/[7YP6>D!H>#>)<G^
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MN?VR)2"B'1@YVF-C+74_;:<8B9$N@:HADM[>?+-78=Y$^JB62 Q_054>:^1
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M9[0)D9FN<SLG&&>ZSV'G.=N/Y-^SLW"G'=A1H0]=MF?H1GIYSYR[; 7:CN*
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MP*8!U!0P*^Z%Q(>'Y:H1\[@IA@<9Y]=$V@:!6\[DX'A2J"_(]NE("V4 ON6
ML=UOR_;?%B^,QU2;F0BRS&=C^$>J"#&+-BQ4T/+5%$L>Y%I**A]$179:\R :
M?J0%$35Y:G*:(HCG9JF*N>#AJ%;!0R9=GP&+I+!!U#5L*V"0/.(_<2(G90S=
M\@H#SH.Y.H9-[HH-<'@B5J)E'R96M,X^-,.*EA-8JP>\8<3+[V^2H1CN>E?
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MTP+XNPE#)EM^_>Z8<_!+>!'0SN,>3K<>MWC<C6=G'O8'V-UP_O8G[PO# GK
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M?SM<1Q3ZN%6)CAXVR[A>-+1?;,3&-UMCCX6>.T?O49_)/>Z[=S8=%0O1.EK
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M\OYW<*A=Q@=#>/ZN]Z*M()L,@OH *+>ED1'=@R,&^@ E\Y*Y6)C@5\/!J%S
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M\[_@R=$,0\3*FF=SX&?\1@@Z=C]DBV"JZ7+:82[_'J-\(CJQA/T'/#B+7V'
MJ_ #YYDPC><D8PYEU//!ST-"U74XBTT^QN/2S,5"!$8K/B;EIO10@72.K$
MNQ*^!@R#+.#?,?[K9%!3YN6YW8@OXW+$*CI()K&\A"S+3,BO0?KT9%SVX@.N
M8FA6N66XTR LK6T=]D>;+LL[!V77LT,<ZU=W<E$=ZTF,]+/CUPM%.V?,P^>Z
MI@S$BOG3VQ#(R*%U#8IGJE5X=:F@>+584,TTUP'D_[R:P\.U3QB7YEF\RPX&
M?<#!ANXZ$_A) KFN'W+P%H';IP!!R0/EP/?OR_VCT-=P(@KEW-Q5^!"&*V:_
MX^G8SWS0MG I8/O\3[NN[\L')5.=10@4-P.[]Z(P.^$M$Q*0<]WB;Z_FH6,[
M9K#^:N*D*?Z19-PF'M2W)__;O;\* 1$^.AZ+0#9N^5RD3U[,$IDYG/V)G,#5
MGQSFT4XZP\FHU*'-N# 8Y\Y91PA_!0(M ^>0V>];258(U@G:")I]QI=4"*<H
M2J62^(X^[8U*3G^)\,D-O9]16&0N,A$A3;RF"Z<;OT@F)7])!GG6#I@.^\7A
MAXJ+33Q2$6S/&S@87H#[B=<X-B$EL_TR4I97R\F,*#-"01'E*7R2&5BU[ <+
M+">,RXQ2)0A6E7Q27*T)9A*83&!N8F[9MIU(U)_*1<A*SU*Q[&B\Q"UY-OX!
M,]:8:).E=5BW'(JZJ&P4 O-BP-AQ/4FXD4-,-[.+-3LR%PC<N++XRZNM)%,\
MF^Q'#G$,DX3_/)>$[8@ R\&C$(?]0MCYL]SR+6P1^1L]ST^+#'-68/?GTO/5
MV^,:L\YP/"RP\D%VUJ77,H Q<LOFP0IK$8I%[:<T2/1"VD!US8J,&A]6AEF_
M/<&SUUM9%?P%(Y[H;!BS0Y3ML#,8E<?8SV62Z(4Q&XJ:)/7H5"3/:V/0*SO_
M<J,D)TH[#!-19%$)3/8]\A( 12_T2#\YH#0JIY4A93;HC$NF43\_HBAS[9@[
MNV)(_0:VA%BH9F(1T%W [F2HJP:,%*<6-P4C.QGL)@(1_L,,OK/HUK0<%Q18
MEI7&,2N-!_U#5/Y@.NSHPYT*/Z?L18478H!40290YIYU'_C*I+[1%G*%@M&R
M&NOFVQ_BE[?)1X2*XG'NK(8J*IICM4F=X>-#O="2\.2ZI":I*VN-:4<?%"F^
MF0[/W#LTET"4'_QZ!G@:-<XPW_XH<U1O1=V1K*WAU8<WCZ;#K]/=^H&X\A\?
M\FG/M7:?@*'>&0UG10G:%)V /9C@9X 2BG?(>5Y66CIRDVD-I0:RHL4+O?@B
M9E#,'_U'P5G/;/A?9"0R/JQ## H]213HAZ' :&MQS=D,_TN)1=:C4Y$\K_71
M 89_3I2:,?SW/?(B#/]"]/3D8-VHG%;&G$F_8QC%TL13&OXE.;N1.CF[7/'V
M%X:W]_$JJ8_M(3B^QL37=M;<CPK6WE?K'A@^H?N;]5O7#,,F*NTO.*58L7!R
M\X9Q$-.%A^"Y?"15-457H\0X>GE4TY2C^K1@ R%L^234%6_!](\7(+S8J &;
M+,%&DI]E^R;^<VZA+\U5Y+^2#9S 9W;-9<A>QO]XI8DF3Y.^G)M0:/KX3%VF
MQN,C>BIOK8T\>G+\?KHE?:>NIN%@W/QQ?,Z>XP6MOBW<,SWE%9U20L!*$,S^
M\0*,_/.W#QST>WOD)CZSYY*9LU,M&TXX>^^\Y^B)I\:Q5V\DW&Y,49!0!"_J
M$"*!%T,%>-$'O>GT\.ZT[08@]$D(>%JLSVJ)"2D\4G@72E>,O9#"4]#2/M-X
M=6EY7^\8 9$92J.+&#A\Q'Z"(F,(OX\"1US+$GFK)S.P0_7&+W'4NEXRJ3KU
MJ@*^M&HJAZIT,JK9 NT>N\'O+1@*4J_U,TO5( -A#&$,T8DPYACBU2C!V]58
M+%<#&I=NU"C^O$&S_MMZR;)575\2XS];V56G ]6@WS%&AC)S- EI&_:_3Q;$
M:J7_G;U;F^NO(AI,\ENUM5WPT\4;R3PZT_#,EJLL-<@@K!\R;@XS;HQ=_4A/
M:MR\?UBZ_IHQT80QWW/A\&:@H\YH-.N,AB-E9EZ2PE!<81!<$O>WEPP$E[7@
MLM#2006XK!$/Z SU86=(<*D>4U)*_MP4.#0ECVJ#,O+GEQ,UCKWUZDH-,I!]
M4\N^*30?.E.NXT_4J5^^_GE$2$#OZ+,II3Q48TI5%0;!)7%_>\E <%D++@O]
MU%2!R\-# D9G4#J?2C5.;;W"H J!\X<#2AJ>@<Q-90L7$9X[N-W'!9U);N 8
M]DSYX.%-))QT]-DU/?6"B&3=4>RVO60@ZZZ6=5?HIW4"ZRYI[\=;<VTV:,LT
M9GN/)\&8ETD W7AVHG=1[1X1+!ETIA,<ZM)<P(24RI4K%8)4XO[VDH$@M1:D
M%F8)7@JDUJBQ&!B=D3X@0%6-;:G"XMP4."2D$A<^M2:<(F)(G^.);<?$4RA;
M=F5IFM9K:C7(0,9?+>.O,,M"!>,O5U@;:]TCHRF3L=&9439-/:955:$0G!+W
MMY<,!*>UX+0P9>@RX/3P2,H0KW;.FKNK0@I%L4@*%:></I(RTSYX]LKBPMR:
M6 H5HRBA%=0X]M8K9S7(0-9>+6NO,!WPG-;>1\=C:.VED')L_<EXU.F/FHN8
MD!:Y<BU"&$K<WUXR$(;6PM#GZ.39%(8>'B;1.],M@[#58^#6ZY'SE)PT,,[N
MFLA2.7IB]"EZ\KPQ5B6&^RE&%A7CW56F5[5<U:M!JGQW^*/(169ESJP</$</
MU<IFY;<G^-"ZL<",WIDT;%0VA S588'4#Z%V"VE!J'T%I"+4OHC1881)EU F
MLBOZ8?NKN0NN?J\]\/3-!\-4$_8L-C8U5]&]'\!2<)(R&K"ROVDV/-*:V,>"
MV^=)-$BEF>#MY5A5TS&'3_G.$8\L+H5H67&*7B/TO&J3K$8@Y:3=]6M%/XR.
M,1YW](FN3$YMFZFY%0Y(JQ!:MY 6A-9MH"6A]?G0^J2]XNL4P(P[_<&LH_?5
MF6IS66!]=ITBPT*_1B:<#OS6=AY?Q[3\N'I@@6.)GY%M'&]E<N)ND5'LXL."
M[/'HQK),:',']-,YA?"VJ\]DA.4^B+>T-.]8=QXP\WO77,".7IKND[D&4?SU
M,,8HV^:N?:5'D"55.U[Y]QS/I4K/*,[+?.>$ENN'H-4^+4 !+ID7<K;\PEPS
M8O9;/XQ"K@;?F"&S/YMK3,J&WV"9;UQ0E'L<EK[>US.>"PLM<XEL'JRD\@0I
M8/9-E*[O+]ORHK_ZIKZ86Q.S:\W-:7?8'XV[<WTP[TZ'K&\9PXD]FDX/4"SC
M+2<K>7_NN_;!<E-72*8]T2*GRP]4RYZY=A"[C#>TY; W'?]4<9M\[8APCG7(
MQ@_8Y@WPB0W[P^[*V.T=F0GO\8UR3:;YGW^#!T:\6NOP \AN5QS .2/2]XS3
MT_36/*$S>15JM<ZAH_V,A7OX$*/_BG\:?\U_UE_]HBT#_]&Q82]8\1>E;]4B
MGX=\67'*EXEM^$/^GO()8!T-G^5K=WP53M(0.S<U'#\#)]#%?:PB/UCG_]S+
M--+.?^_!7&MS)AX.[_4]ER\V*CDQ)J]@A[@(=X4VB>8O%H[% K'^!UX.PF/^
M^/TW/NQ,>[KW-=!2&EA:?OJ(GO;EX(/@?\)-:EMVN;F9*//"3NGJ.GP..U!,
M,^U')_0#^!R^!31@N'(C>$SR>7D:O<-$@9L&RLE"Q#,T8.7"@>#^XK2,2-E$
M]V84'R5G6CM_XU?PO/9DAEH-Z[XPVB(%L:S*O0E@-W>\TNC-NH!S?';%1[[^
M3POA#-PD6:;]14^X_H^PB+(ZIUMG4>S=R#7 D15/1J??GW9&XV'!BQ#V@3BK
MGG;KNZ[_A,*%Y_WA\Z=.G6,N])ANZI@?3<=%,QJ<+GXJBIQV-V06GO@3^$,A
M\UZ\]OS".6N+50!G&@@%$6KW)JC#.;P>N-V."[,Y@R_AY1<OZ5\SXLQ^+)V
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M$/H7V2T7-$C9+F$CTBP)_I"+R)]"@/T1/BWX'^N/7(]U;M<H;>C[4TS^A1.
M=7OP5@LW+.IOM9D]%B]"\"UNX=N"?945=K1& P25@Z%UU"\42NXY%X0/Y')
MOF"=_=#- SC@M<]F W3'Q:!]O4[7HWZAF.2$&]P3",ET\C:*=1]"ZR(+Q&9#
MQH7#!NI29PK]EC4I*O90W^B)W5R[>]X=^UP1B+Q<;+>6"@I % -],W\T:Q%I
MTGH#]RQ*7R[Z6R_&BZDUGEA=TS#F7?"BYUVP(X?=T=2<#.V!;2SL0_I;JV11
MZ6# BA/5X$A9>-FFU&T=Z<J"MNW8NS!JBZXJY%%!5S$P"NR$5Z5O(XWYNMIV
M<X(9]^>]U<,3P$C(O,/CRJ-^(:Y\S-)WZ-&]2_?\DBCRQB\B"9E@.UG"Z-*
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MR^-^$E+/_O5P=WYS5T)PKY"U<#^SW[[NV7G2283J,T.T<M*/%KB5DZZ >R_
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M((F7!Q[,#0X"!R% 4>#PSQ"5!#\88E,'-!0>+M6CA++">F.""?/[8VP;/L?
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MOE;.X?^ZE1*YKCQ4+BKWBN;D;=(4S2F. BJ:DTOP5C1'T9P"TYR+@6=QZ-M
M5$NVGEC1>4ZBP[&E.$5N\C13BMP41^L4N<DE9"MRH\A-@<D-KM58(_)'A?S+
M,IZ95_@@3J+#BMSD=*84N2F.UJTD-T=1%L-WCZ)"<5N.;\\UQV)H!_[0AC_^
M'U!+ P04    " !OAG)2&EV9S)83   NU0  $0   &%V<F\M,C R,#$R,S$N
M>'-D[5U9<^,XDG[?B/T/6#]L5,6V+,MV7=ZNGO#9XUU?8<NS,T\=$ E)V")!
M-0#:UOSZ38#W3>@H4[&LAVZ9R$QD(C\D@"0 _OJ7-]=!+X0+ZK'O>Z/]@SU$
MF.79E,V^[_EB@(5%Z=Y??OO7?_GUWP8#='%U?8=.+4E?R 45EN,)GY,/3[<?
MT=_/'F_0DS4G+D87GN6[A$DT0',I%R?#X>OKZ[X]I4QXCB^A*K%O>>X0#0:1
MX'-.L"I %U@2I/^=H,.#P]'@X&@P^CH>?3DY/#XY/MS_='1\?'3PY3\.#DX.
M#E("_A;8@%+_3M"G_8/]T?ZG+Z,4X0.V?N 90=<7*<+/T\DA.;(FQ_;DR_'D
M^'CR]<MG\A5_P_CP\.C3 4YKZBV6G,[F$GVP/FH5P5[&B..0);JB##.+8@<]
M19;^@JZ9M8].'0<]*C:!'HD@_(78^Z'4-V&?B*#EP!M,G#"0Y[O?]U*-]S;A
MSK['9T-;\J%<+L@0B 9 13BU]D(^F]"823,(8NW/O)<A% Q!TX/!P6AP-(K(
M6]21E0]X4(]%S#7%8J(YHI*26H1<\'*M5 DPC+[F&+BLJB8N*JN'6A754*N$
M7)'8,LNAJC@\./@T# I3"I6J4B(5VF&&\:*T@51!F1<PM42YYKI(M="7HNZT
MW'6@_M$0^ID$&)*(WO)\)OFRO)*PL$0SA[(?-;6HX@D6<2UO!?K7(TT]^O;M
MVU"7Q@KYG$.8J=(H+"U1";]P+U.%>C"AG@XGBGQTF!"3-VM>7H,JR4C'4G(Z
M\26Y\KA[0:;8=\#G/OO3QPZ=4F)#6'2(BFD9@E2QQ'Q&Y!UVB5A@B[16$CI_
M69M!"X^&?[^]"2+J'H0)A'2@H.["XQ(%\>+&LW34K/&2^FL0 6*@'@U&AV#S
M/@C;0ZQ4WRHT#==4(T+,2FHD<%M9C:ACJ_H_5=5<'@G:U2GJ.E?TQR !7JT.
M=1UT5772/2O^RUBALOZYHD;1R*1^F.J1']56PT5Z0+T+QCN%CV\*GZ//K?!9
M/B:OJ\ZZNICI4?!,'"/U+U/?%"+L:JWA<#[$W.*>0V LM>3EV\+!#$M/=R.C
MAE'D&5D#D@B[@K_7T5$+960&DU=[)<72 C:@B%Q'B=7#73)A"7X.DKE+*]04
M)SPK*A+-^=0/4^CFYXNMG:&E%":(0^)(H6>NS7I4SBXWIH-RL3#4)&#:CCYZ
M-F^J3W$)L"I,HA6(_C5(UB+M@))?OZS8*NFU0= RX1.3=BE;8&Q2'V/@1#Q;
MT\@8.J6+U)1&F#%/:C7TL^CI8D'9U L?P4,U$3U1IHU!&*(P?1\3%T8226[T
M$D<5/3]>-ZX @G";Y35;>,4Z15K99$H9U18<J']HD,[%1%4A5=>OPSQ'7I@O
MB'W/?M._%YP($*(;)\4=DM1Q6MBQ?&<%QD2S:K[P:>2,G(^B=GHD4Z27GR?A
M\%^_2!TNN+<@7%) 2FJ-JP7,.9E^WU/>'$1N_ ,LW >_122%"K+.TT[/-4JH
M9"1!4JE$G"=$VF/B%X2=N!J%Y.][ GJ10[:Y8!^^3Z."]TT;-0N8\C:]B&D:
MF_2=#'?PQ-1P8"%.M<TWJKBKYD)@,34W'XO*K7Y(41D;'T?WUK%<XC>/>>XR
M4#$*NM'_3YE]R4"QY36,)-S52NWIH>,1R/]H15X7[$<ET3[^B9F- G$H)<\L
M_J\<Q5<?.-:/_^MZ\0G4UCF_<T^]N*"V6IR=84<EPY[FA$B1\F$+XB8/CI0'
M8SE(O6I(1*%0%@J$]>[;@/L>,(?B.9$4&LC(EUG.)L<>&C@6?<C(_M@[>C5'
MQP_%_?0>1B1MF8#(>NZY8.R<,$%?R(TG&CNQ@:0F(!S5 B&I"'E3E%2E(WBF
M,J1JZY&Q/C*>I&?]F'N.3;BX_-.',=($#27<30@X-D! 6OR_XX4G_A,%M?2>
MWX;GC48#$U%-F/BT"4STX\;F,7*.Q?S*\5Z-AHB$J<GOGPW\KJ0B+;9W;//R
M*]Z:=(<E_/=^>N8+RDAFK*\A:G+<%[W4BOGACT"$<A1T0!0)ZEUEX*HGWW4Q
M7T(XI3-&IQ#$8"%LZ9??E,T>H%]8E)0[L"5KDUN_%MP:"M:!-Q&-$MDH$MZ[
MVL#5-]2">2PYG7$21+A2KQ:IFASXK># 4 9*A/2.,G#4%:;\;]CQ(3C&.QM/
MA8!E*BQ_;BB>4(?*JE[9FKG!K:.#@EN5:*1EJZZ9;+H,Q.OU4JJ"WN5&87BQ
M"':Z82>=\JC(7!KQ-3EZ5!* $ZG91$F?RUS1P>>>ZU*I8Z'.8>AQC+#*P;6.
MOLFAAP6'IJ2%:8V4O-Z/AG[TF%X/5OHM*F_RTU&IGSP6+#=[MYC$3]5B9Q@J
M5QD[F'S4A,QRTB9G'1>CI!(TT))06E3O. /''1^,_OL)OT P$@\PSI1Z+$_3
MY*I/!5>!A \_/J)0"%)2>B\9>.F: 1D9X[>*T2I=WN2=SP7O!-Q(L_=N,<FS
M$*E>23P0_C3'G)2G67(T3>XIR;+ M$^)0 O"D1;2.\G 28]$[?ZR'S"7RS''
M,$A8^OU2J;<JB9O<5LRBA**0EH72PGKW;3Q!MH%$6=N$V:B8;VF?,$,?HE_]
MJXK-HV",)\Y:& @%-"#@L)B:,4% 4$GO_VVDY&H08"BB"0/%K(U9>J['P9;R
M=+5!H"UWD_>+*9YV.;O>ZQM.WM5XNYFKR<OE":+*1%[OW#4S>@W.S%(U.:^8
M,$IG]WI?;2[-5Q=QZQB:/%C,(U6E_'IOKIE5JG%AD:K);_49IMY7&T@UU?BK
MG++)9VW23KWG-K$9Z]2VM6;82<T++XC$U&FU3ZN.O\G+Q2Q5^18N*$BJR<Y?
M@YIZ"&P^>V$*C/6E-L%EK4Q7#Z&?#R%U;Y+M.Q M'H(#B4MUJ.Y/GR[4DN52
M2.JJG/2S(%/?N:%3LC:\5JVQ 7I':Z78!BA22U%'B@5' B/54*P;"I1#2KL>
MG!O9V6@:RHP$-$&GF)DK[H?LH]-& = VMQK'E%JJ6X*54/M4)G+9(U$7<$$W
MA]4?%358>B]=FF!93!D:)HPS(;"1.E(<89FIB*%8>Z35[Q&_3<2;1L)-R&U"
M8C&M:8S$/GC^U'<:<:QZX&2!J7WYIE)?1&'B'M9M_%S?32@#=]7.Z;9251/@
M2O;NM7M;D@EYH4(HTDC#4NN$0J4BO/8PW#H,BW/].R(WAKPZZ4U@*\D:KP2V
MLD7#+SHKUL-K._ R3X"L);()2,4T=FL@]</C^\2E1R(DIQ8LZM7)X0V%HU*A
M3> IYM-7B4))U<%1Z!Y 6P;0J65QG\23G@TAJ%QJ$X3*#N::0RBL.YDU]1C:
M[ X4TU%K15%-:"GFZNOWJO2#U$_"1Y)G\M6KMEO0V?7=&X(%><!+S7+ADV=F
M$QY>?L1FNK0N^FRSO@:D'1=3\TU(2^>MM%(HU KIBE&D%P+%D-8,Q:H%)'W8
M6G=OU2IAJ@5K$UB*R?C,+JP^"FW)W7$42#V+OL!TY?&@&UX+X:LY1#L8K"*R
M"1[E1Z53\$B%CDQ)5#$"R$1!):J[!\_F]O89K\F-I31!I)BMKMP%V$>3[0,B
M6=1 ;W,7ZI$8S[%\!KJQ!^U,N$L9^9UC)M57[5(O-+3 ^X!%ERN.2W?A>$NB
M$\RWQ)T0+NZG9Q[FMC'*?KIJ3=!M?V8]MV9+]$<2#% [%&PD/13;@+22 _W9
MP.S+FR \AJ:@T!;%&UNCIVBA/8I#6]1WD2UTD12J]-<CJ5RN#NIJ84TP--A'
MG=UFDX(2BNKL@;(%H"1YOF#"_0H]$H).[O$S6+,^CE:NJPEF)?GR5C!+)3D#
MQ&F5=)0J%"FU>BAN XKQ/K[R\C!]: X[([E-$"O)JM= ++4',"";%,G"^GLH
M;>#R&-.U@@%[$S"*N?*2*V?Z]<%&O9\Z&&3J^9:L35XOYKPS!XUZ=V_)W4E0
M?R26QRSJ4&W<_30F"N/J&6%@0MW&D V(;8#)IV+".@>3]$B1K5H]28B3T2)4
MX&,/I8U!Z8),">>P[L9O91L>32'43EP3=(KIZQKH1%5JJ%3=^M#C9>W#CRDG
M4\>'M4 Z2ZWV:KU@1[U.NGRS'-\F]A7W7#7I\V483C0;L7-BZ\[@_4P%FC!9
MS)F7'-7,(3-4,YM#3VF*(E71%'1%*65C=B@K.Q+:XWES5Y*93J-6D=.$KF*Z
MO?HBL__7,ZQ?A_GOI(9/LM]3U5]3)<&N'>U#A90_3N5X3FXQ_T'D%5:S#;D,
M,K+!IUR_[]40!!_Q8QYCOGMB>RZF[%H25ZFVAX0_$9)*7]7_._?\Q?<]]3%!
M>D*!9 \%OZ'[4L\>:SFV'WQO"2JFCJ/.=W_?D]P'41@D<?!T]/>PQIYHZ'M4
MA_Z"25)D26E18$.@#00D  M?;MF(*7;T1QDU\R38/ 6<9$)EO6UZB_FI_;^^
M"+8XW,'\$(NY4E>,O6B^J,:(8&Z@(N384_OU'KCW0B&HGBU5 O^:Q9L:P@R6
MOK N:*4M5[)+[9T:2^^G@!TPY=P34H#A:IN_?>;+.T_^@\@'3.VH_0R9.M,>
M%NC6U"#C5V\\]WP!<\E+.IM+0ECT,D<;_.!S:ZZV]X#,;!19A;.+X25_/C09
MG\;D39XY^C;PP.16I!D;9?3\YP# Q$YQ&G)769<B2$-:9<W9[-W==ND2/@-%
MH,I7.5>32LR6Z@M/?G#;YK+@/1..KCH1@C7\[2Q/;6\!\Z;4F7D.LT$?NKWV
M7$4+K,K=U=8H7A"@@HULN"5 7S13:)O-R.IL2]5>XY$+!"V).Q@44IKKG?$Y
MW6$:3O2LI\32!OK=,U9#LZ6A(>T*1MKR9 [EW/(GNJFV9^Z5QPE8<?D&LPHV
M"[\S&UA76M29:5B+:>GS8@H16(8C\!5)YNYE);MD67Y24>B"-00=['-Y;3.=
MK**PT[WJF=$7P@65R_OI+7AU3H2$Q6)D0G;*WY*XB[/\VX>GZ^N\@[+6U9)T
MT:;GO][A"D>5E'31@BL\X4LG:/(*4VI)NFC3-8,^X1#_!V6CPWK$M2+MHHUG
MU+O%$,D>YIB[V"*^_D+R-;.R]C62==&VW\$+2H<YX7BA518%P^IINFC5C<_L
M)'P_JH2-^&OPT>L*<)IP=-'B6^K \ 33H^@$6!SGBP6[-*/*JY_.5):7=<:Z
M-@G)O D7/JFR3A?ME'%QQ[E\6]"@H@==>?QJIIH@;6BDY?LG%DH4OB#"XG01
M"J\R*T/UTV?Z+2P[=RA3P]684^RH?'_XKE*],8&I"+?FI\R^("_$\19N\=74
MRNR= 72KURE"PE(@UR^3]R;EI1NVD,)8C'6M6^BQP0D%6'?'+].2![MD1^R%
M='(A]W"7D!?.EF]AIB&)NE(N8UA5Z2Y9&,U.GA<>.W<\ 4%1;5:D$N+)@S^!
M)5'T,C*RVH1CEUHBOS**KANIRKLDY;MD9544W7K\W.Z4)SX(><T6OCQU5>99
M[_,!))X1^4H(NU&C8)+,;<^P2P%XC-]@B0B/8$7U2*:PN HO%HS?IU<3=,7.
M-E$KN$BQ?(ZC=TWDS#9@V+UF2!\'"K=UBYSAY20[9&J+RZJ2?1+%=XTK<G?P
MW4!X&U;M]#X'?B.6KF"B3;33%^LDB[U;CTEEW3_ S'C4KB-)VSI3CW3Q^R\*
ML[<:G3+FZWPF5W]=LT<-8UBPJS".9ZDU@QE7F$[S766">OI3W-RT;Z[B3JCT
M3?NY=WNF7!WLU*U,R+P%-.'H]*O![-V4V>1P>5D7T\!!;\M>45:2H&J@ZF*"
M*G?#6N9*MM1M;*=32;@*H5>>S\LC4EO>71J!U%5O@LZ8/L3 PWWB>F-J\C:[
MFB+C;W481;Q["$ZKJ\_'"'V/>DKM>U^JBNQ42L"0J8-F_Y?O+%-;C>]@M%!;
MC:\\Q_%>[UF4T<B&)T.F+L:M*S+A/O2OE!GC5Z!8UEMNS-9%V^^\%ZV=H>W&
M;%VT/778X!PO*,P,@WX;)$).7S#5H@N7XI4<5C#DWZ7H7G+X('V'$;/C5$JK
M@PLM>+N(E9(0=\UL/]C&76MX/7G';0TZ=4M+ZX@[;N<5G1;!J6]=J[6X'5L7
M;;_SE6[WTVBFDCYXE4Q3HI5S<9V].O\F5]R;VK*OC"C>=LFYVN*L2,^6"4DX
M9]>W6ZGS"@KQ4)>O)_+Z_-]XCEEX<Q_$_BFAZ@ (LY,$C+C.[45X1P4V.@_=
MU$Z'^#1RJ_?_K<D[\S:G1:XW=1M&(=E37M;!E$[^H^,E!NQ">B;I..,YU#^;
M'QX<?<D."K4D71P RA3^UFS3MR[;=,\7$/DNN#\[UQ/;K#E5I5VTI*SICYJ]
M<]1IFV!)J,ZR)Q?]/&))LA<UP:CD8J8V'%*U@"2IU=;*[!V<<!1N-0K7C_2?
M*E6$N7Q>J _U\1EF])\X&-OT"]JH,=80T)6U9XLQL&!E?OM)97,4"7?(;)C@
M<<]QP)CHRJDEN'<!,[\@0YS:A-1 UQ6C6^[:".+R.>9\.?6XFM^*JMV[;:G3
M+="=K;S).P%/J%=7Y=;<4)<&5] ("/%$S#W'3E92L.;R77W-S@LYUX<Q859_
M_\H(%W.ZT.==B-H4FCJ/JM<0\^!@P3E(I?"#Q$W:,:4Z&+:-6RA X?T+X?\S
MI];\O1VV+76ZV<G*;LA6S:0NGQ95[UAK2+LXI]*W!@FU2]KCM_A-O5/4EPEE
M]S4V4>W2NKC^F-\NG>S+7-U384\]31>MNI]"K% 'UYBMOT@1?J$BMQ2K)^JB
M74\^,-8XJJKX/6T);K(3UIRX^+?_ U!+ P04    " !OAG)2GB]9P3,,  #;
MJ@  %0   &%V<F\M,C R,#$R,S%?8V%L+GAM;.5=6W/;-A9^WYG]#USUI9U=
M7>W$B2=NQ['LCF:<V&,[G>Y3!R(A"QN*4 %2MOKK>P!))F7Q!E ""6\>8HL&
MSSG?!^#@X."B3[\\SWQG@1DG-#AK]3N]EH,#EWHD>#QK1;R-N$M(ZY>?__F/
M3_]JMYWAU>BK<^Z&9(&'A+L^Y1'#/]Y_^<GY_?/=M7--@N]CQ+$SI&XTPT'H
MM)UI&,Y/N]VGIZ>.-R$!IWX4@C+><>FLZ[3;&]$7#"/Q!V>(0NS(?Z?.H#?H
MMWM'[?Z'A_[)Z>#X]'C0>7=T?'S4._EWKW?:ZR4$_+9"X23^G3KO.KU.O_/N
MI)\H>(O<[^@1.Z-AHN#[R7B C]SQL3<^.1X?'X\_G+S'']!'A :#HW<]E+24
MSI>,/$Y#YT?W)VDBX T"[/MXZ5R1  4N0;YSOT'Z'V<4N!WGW/>=._$:=^XP
MQVR!O<Y:J@^\G?H;\J!* BX_GK42[#V/F=^A[+$[Z/6.NIO2K77QYYWR3T>R
M=/_CQX]=^=>7HIRD%02Q_>[O7Z[OW2F>H39450A(A ).3KE\>$U=64<E['(R
M2XA/[4VQMGC4[@_:1_W.,_=:P(;CK/A@U,=W>.)(VT_#Y1R?M3B9S7UADGPV
M97ARUD(+1D',H-<?K(3\\("A%+2B:PE:R/EV-]JR6;PS)E2VP<VK75&PN_UN
M-\6>TO)"]$P#.ENN!-^'(%7TB0LJ.@'QX*/W&?F"X_LIQB$O@G4'8OXH+V:;
ML202%_ENY,N:%#"WRN/G$ <>]C92A.T'@"JMV=CC4W<+^EJ;;#83Q,>R[8 S
M>D1H+G5VL1_RS1-)4KO77S>A']:/_[AE>(Z(=_D\QP''YX%W$TXQ.^<<]%]$
MC(%]VU3YHG53MGGHHS'VI1,L+ZYK -<%XE-0+WY<_AF1!?)!-3\/+Q!C2_#;
MOR$_PBK(2@HT@2W!Z5<:N.JUE"' A.W@U$-&7&CJ@DD]\[-EF$!PR^@<LW!Y
M"STUA!8A6L-<]..O6+&KY,DQ@42[E]?0GU<JU8TT8]T03S"0X=T)=PX_2:C!
M:HX0(PR[+HNP=TW0F/@D)%BK960+,82!1N"6;]$2C7VL!R!50CVM2,\_YLLQ
M@:1:(ZJK]=SA$)$ >Y>(!3"B<V@+T4R$@-@#2HE+%$>I8FE&^H0'#0""6.3?
M0F0V"B[0G(3(OZ"S&0WN0^I^5^H?):09B>]BA>JAW,Z[9N*&=;?4,SKU=1-V
M2WU3ZGN8<1&CA$L5L]/>-M4^2#B3,3I$[30(H0_BP 6?HMI4,L48]J2:+M2X
MG4!4M393+&L;46*F?L[<+46(N1LE\.O.-'T[Y[(NT>71;":EM0G,T#?O3QB=
MJ=BX-H-F5 IE4/BLU>_U^KU.K]=RYHQ0!F^>M08M)^)@*)VO/&W+><(B)293
MCSU;T>=VI9B-P?\'&VFE8A*.[".A'.S442S&??Q6<>^&'#'H=V\5=)E8,:;A
M_5NEH<Q$(*;AQ#X:TF*4]&'O93H7X_WPYO#F3[]CY!^M1OYZ7D^+<R@OT '\
MVX6>E?^*T=L=\.6@S\E@QN@M#/!>)9_IZ[^DH+0P@LM&F;]4$8.V,'S+!IV]
MRA0#MC!TRP:<L2H8H[4P0DM?XDH&YN66=6,2+(S/"DDHM6H?4Z 9LGWJOF;@
M&CX?>._(RT-^,[D!)R;UKA(0LSG#4P!,%OB:\@H;2]1U-&S7B0(  ZG$7W$
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M2G5;S&8H #4;?>4Z0#7Y3:EG><OG>>!= T;_@+XQ6T]3F#@/K[ G[K 5ID:
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M@.N9]Z\DBE-VC<B9YZ6+Y?CW#O:&P84SP['C/TZ<$-';R[L@TQF<L?12?$#
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M*#D;(IP2@:J"2D#$1<B+KD%3;UW;S %,-4U+\P"437:AR=)4 <RLW2AS%\A
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M!C%X2@-X<#8P[;%6)IAN2? "D@0MI$\T(G"HBG^_(%%\2^+?4?R 7/(<T&S
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MY,;>JVAGYBYF4[D;<GPSZ_,<+/LQ%NJ[VPAJUQ"2%[==0\A^VBYV<V:N28C
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MQ_PAC;8[PK3R:K2HGW#F5MHF0=<"7^,DHNNSV+&2V\GZ$?XV"Q+'6N\B['H
M=RR^8;>B'Y-T+C3- N)8Z".2#H6VL(WL6,ZQAK )TGO!ADW)#T&PDZP()_HJ
M^!JEIW@3[$G6*J80\8@ FZ5>O\(D2_EO.+7T)?_5R]=O\LC[;RUTNP47HO#9
M/O\DI]@S*4CQY12D4,9?,QRO<1[U2]HT/!I76@PLQ>'W#_3IU1I'<DSLA^9(
MV*_^?A9G478X82E($I +QN3K?^%#G3OADQE-BE^*(?WY=SU??E47DW^>SZCL
M)YX]X?CEYUM=8G\G]PWS2'!*]XF8;K4UFE7N^Y^2#<KY(,$(,4[_\:H2Z%C^
M51+6I B2L!" _3@@0_Z)5R%E:<(N>TE4H]\D=-NKS9PM'=32*_?6<4)9#KRZ
M3QFS,-.UBL:7[*RA1L2-%4BU_Z>@C'XM:/_O^8%OUS+M5(0'H(MUR!T;I"[.
M]>_8P:S2<._KY>J*DY\?YU8ETRY%0%$H,=*E"V-<,3YKSNN<! ^ZUMCXDIWV
M:D3<VV-)'G'Z\QMDNZ)IIR[ *)68Z=-EA"P787S[Q314-KX\SL5KQ#P&3\D'
M,49BRVE^L^V'@@YJ"9S:FR%66^,N#?L\2L. _ T'R3G[36IJVD=?'Z?E!CF/
MYBTY(<X*"5YP#+P+$JJA*X#J;YJY@>;=&[KTL1&F7B/@0ML*0?_FGH<8D ;?
M!DVKR1]I#"0,'6:OAX +P[]+ GYP=7O8WE.B:^R-+]EIMD;$O5'GY)&D/[\9
MMRN:=NH"C%*)F3[=;3S>X(>(;VW$V:=@JYU.MW]WS+9CG9:W7<>*#>)\YK?8
M7A3HD(:@:9S8*WO>#>JZX 9[TTXV>?=)4DOY#!>WW=^WW/KMH.?>*W-.M404
MSC)W$!>JHR^(&) QZG<W^9Q'!"<GC-D#30S/O!I?'1,(:Z2\S3R""RK8S&_<
M?0C0 ?4 TS:Q4K3#PUNZW=+X-J/A;[>/ 1O!U3X3A6DLE3,\R>VE-.I8MX>R
MOS->P10)KB^0Y(L4QE"\0 M :J9.V&"13IR,8'+G0]?[>Q*%YX0&VL?<+5\<
MHW2%D#>'D#R08 +%^-LT3WL5 TK+Q$+![LSV;(N3!^8B/R?T2_;(_&@7Q(:9
M3 >),4IN)>G-J MN2+)#.3\H]MT/$=74&U XR#@D'#K"USNVT$\C7G0M-U8-
MO:#E^Z-T?D3/G_U_116O?%<9C/%WPT)UU 41 C)"^^X,_G8;$/)AGT8Q3K4/
ML%J_.D;'-5+>+%QP004;*+;=C@ =4 \P;1,K1;LSX[]B0OXKIE_B6QRD-,;K
MBS3=X\3,H#N)C%%V!U%O1L[YO?R-,T0%1R190C'X(:RHMOK XD*.($'_90:)
MPVT=N3MZ@W<TR?AY7Q9D^K4*_31&[0ZTTO2WB9-O$I?\D&0(Q2L&8**ZJH,*
M"1F)ACN'^(62?9P%B=S#-?2$HR^/T7>#F#?;+_G(764P-M^%!!U4$CBM$TN%
M.\SD']DT8[5U4__FJ,Q2H>0OC>=,H&W/M&J?]NL&EJ:)C9+='J)^VF_O39-V
M]7MC#_0D':]GITCR@&*V+5H_.C55M0))P\?GI8/*=6>N=\'7BS7+8*)-)%LT
MV-AN)Y$Q:NX@ZLVJ&3]49PC,QH>@HMK: PL+&8N(.\=8K==L!&G^G\LHQF_,
MG**5P!C-MQ#TY@PYDQ?%#[Q##T97,8 RL&%XJ);60$)!VE"H@?!F'N-_.];X
MW[K6^-N)C?_N"X5K_&]UC?^M#^-W!,6P\;^=Q_C?C37^=ZXU_FYJXV=:!1S[
MW^F:_SL?YN\(C&'S?S>A^9^P'Z^2._HEMC)^]>L.M%V1\V_XG!>B">+<@)E\
M"RAM!M_4%D  VHU=J/YJ2/7.;9WOV>.KY#JA3U%<C</(X(]H.%!Z@Z9_TQ<,
MN>T7+('9?Q=0;4[0JCRHH+2[@X3C2@<.YSYQ3=,L(/]?M#NA:SN/:%!PH/H:
M1?_>(-DAQ@]QAL!\H1V@-D]H41M,,-J]0!L&)Y?_^  3')A8??T[EA?,%!H>
M+O8)?3+R0 RY5<NT2Q-0-$K,E.G"''GC9'+]2&/#,Z7C[]DIL4G'O6D*#DBP
M +/?WJEUVJ<52!HFYLIUV5)F%<?[@,BB&%V3;?_NN XF*BV//60DF[P(:'[S
M[46!#FD(FL:)G;*==@$M*]KM3/KX^R.;63;H^>P46A7S0S/O3E2:+41;M041
M@::I&RC?W?KO(@YIPIB) U>Q CVA^SA+#N8+P0%28Q8AO:2]+0UK7)7MDIPW
MD.S:!$=JJ%3@F)%NN'*T]*!RZ4[,C@+Y\DV0!7G!L*D?M=,8!T8;38^>4[+C
M_4R"HG(:CK?TPD1U50<5DJ9CF*+APB%N<;A/&/LW;^_OHHQH3R;'W[/3<I..
MAP9\G"RB&_3F[7?WOT<%P_F-O%/UM$\UD-2<&[!"' GJTYCLV=?PD0T:FW3E
M:__N.)VJM-R;;\$%%6R =.7K18$.:0B:QHF=LEV8\T6X25;[=<0,=I5E.,U$
M9F3RK$ ?!3M%=U-T;^ 7)^<W*&>&%&Y WA_0@(?J*0TF%+GE<S86*+0X0&'_
M_<]6\=\TO2'_]=_%HH OMJ\VY0N,UU0NNDT>^C&C9PZ/"7VW8:I@B*XVRB.5
M!4\P#P=9 4IM%#O\W-!XLURE*<Y2&P-L?M/>U.J4/+S^(NC#L)H.?=-^;<#2
M+5'5JN67'DTW7U#:6_ 1@;'*;A#TUSTW$.Q^@F3876@<V7>KDD!JOF[MA>YG
ML_J3('U<Q6O^G[-_[*.G@#!QTE5V$B3)(8H??@G(7FOE:$C0'ALM!AZ\A/%#
M0;Q&(?\!5YQA^(L9CM1*G8O C"AP,99(_* P98D[*M@BP7=BC[M.\"Z(UF=?
M=SA.,1/Q*GO$22WBF/B;%CE[Y#3(N_>UG"G"DFLJ_(YRQBBL358P?,\$46JA
MV@6@1^K Y0R% PJ6J#[?S9G:6:=TSA(*1PY3/0O^G^*)<)"^,>@%3NW=GV7/
M:K_7"=WA)#M<,PUDS*?X=+;C:_Y/V'"NZ*,S)LQTT_4Q.TAN8E; !:L7*,8S
MG\H:P45-U <9&M) 17 2D;_DA3[U0>/%96XP6T]%889%TOF)@68>_;MIV./1
M1=.]FU2<Q)(%AFL,PD)U5045 G*D?;$"J=A,[ A*QF?G!1T$[/7?2M"]_<N\
M$U(NU \%U=(02+435>-YIC2;P4O^YEG^^+S35UX/R88;VCU*Y-UD\!Y2]XFM
M\#(*[B,291%.62HDGL1YI&3-XA//BK*#S0&#/DU[_>OR\'"AJN(L,OM4X?W_
M_-N?WK[YX[^+;'_NLC1KA*FMEI>")CD&DB\#5+9(\IWOO$,1;L117Q\5)VA-
M=NA'*IY 3OXT$&KW),=G@+[1:/&6V4\#5V'(KQFDU\$AN"?89L>T@\*(C*"5
MHH>RCIP/VDE&,+QA !&JIR>8VB<-Q><\YCHD",-DC]?';F]H_EU$1F'03M2+
M$W!6?2=ORHP!QD4&@*/:N@0+$JGCTS)K3.PNIWB#&=_U#6-]POX;91;NTD/$
M'HE.HAZN&^>LT/Q7PO1QH=JJ HL!::B?LT&2STSN,&[:<#M?>)LH.D^<P<T)
M>I.!^UG <_B'&/;M3A7ZZ;@,/#[/&&KQ7YQ \TN4A5>(IY7HS+TXC8#KG1K<
M'47X!ZEO@ICM9$+Q7LO)P5%H\C4=0)X&!N*_P\#O*^)/71E.M]LHVXI"W7A]
M0F/^3!R.0T/K[24SHJ*XFZR'S=**F2P!5]FA[S[1#*,__!Z&R>O 1@WT"!@B
M<HR.J/A6.4U^+=/%09^?H[TI#_-N.P_O@)PRF)W7^3NAF^A,#M09W'62IV5"
M*N,;1JU?'U4CWR3GY49#GHF*8^T7Z/]^_?WKUZ_?H%V0H"?.\]_1F]<OV*]0
M^A@D?.-UGSW2)/HG^PJ?<F):_"'B+Q>O>?<NNL_2C/V1WV0)4K[R.,4AYMTR
MT;LW+Q#7OOCNV]=OWL/PNC[DJ08D %$F38 %@UEN%O&)D#<HLW&JX^^.F_A5
M6GX2,AKW^=*/G<XTX"C_CGYX\^+'/[P7OV!__<,?WS4\;XC""\0^O,.B2Q4Y
M'-'[H:1GXK]UHC"\N=/>Z) M0+,M4C.K^3QXM5Z+Q@T!N0ZB]45\$NPBMK!6
M!FUT&*E!;<2!UR!U#\>3)4_$[YF]C&(42K8P/,( /VJN2?A8D2.8.#]T$:.<
M(U)=;/(K(5D0Q7A]%B0Q"[GI*@SWVST),KP^Q9LHC POAPQ3&W-'88BZE[/_
M@@=:2R8PO,H .&JN0O@@Y5Y5L$,%/Z0B=CJ$V$3['>/V.=PNI7WM<T,O3>Y!
MI7=3P_UFAN]-#&!5_9;'.AVT_-5]3W  =%S#'^QH"LM/M.$T*-WW7;(_=:G^
MK'N#UT%RE8@.=VNQ'+O&R2U?.]MO%W93=+6WU,5A@DW%<@,$AGL98MFY =BO
MT67@UK%-R)CR=Q(E6[GE@!AC)#C/ZGI"@G15;IS9N]PQ)5>0-2E/X&+53B)$
M'^L$K=.WVE4(&Z .7Y+,T$H#H<G\YT)L&8_UG8**6U@DU0E\1NZ;P_67!D@#
MOJ*J#2X@_3YR,8#(9/YQ51V!C'62&BFWP"BD)W 7Y5@(KL^T 3?@.$=:! Y2
MOPM=Z:#D^YC7Q?I(BYR3 [OI5D;U\V%@RR(3_-I/4GTMB";#JNV\%=)22%'$
MF'50+QDG,/E? =5="=KR1P>H=A]RO?#Q#DJ;S\R]Y#D:M/EZIY.$0RA\K73J
MO@%IF3,$3)]/N%G@> 6AQQ=F6=H<#=9R7=-/QR$87E<T=;< MYS1 JO/01PN
M9/P#T^,J\RUAE$>+^%NW6RPNB&QW"7[$<1H]X?RWXQZRTB/MY$TK'5;^GK>2
M?/+++PK_X@^ W[HR@K_]V2M]W4_Q M;5#O-WF^.'O >^U6-8/41&- #M(NJA
M]VK!JFPD ^3:SS Z5%MA8)$@31 *-O-=^;G!*68P\4=@3O$3)E3T!<_E,O&,
M 4*CND)W$_;2G5NP$V4RZXHA##?1@XL::0\T-*2!"I]*%5Z%!TWL-3_CF+DP
M8<*LUMLHCKCO\@L@%GXS2,H>G@'2[GTG9RA<)ZBQA.$]NK!10QT"AXC4T>$N
M5.<VDQ<=S;:C,C&G\[ZO.DQZE'_!\(QN*/K2+N?IEN<T:R[[EDN>2YK:6;CZ
M=0?*KLBYMW).%7'3*BR=QM LO 6,-AMO:@F@XH_L/-]5X!PF-O5/-*;U819/
MVUDLLC6(V:,Q2-S7@R>1!.>[//#_'LC"6Q\Y:JQ$\"CE'J1R*YRH>"EQMI7Y
M1?R$4]$]1TIT$3.;8K\Q\:1N&O;0=-%T[S<%Y=QU8/C+("Q45U50(2"%]@LF
MA4L4;.9X*$MU48M5=C>-D>\VM= <B<)[B4*,'WB]36T*R:<.0"\J#F+3?#RK
M4U_@<&A[0JLV4<RS:.Z<&9UD6%[F;&^+:26O N03PPCI9%+>,JBI,J>I_0)G
M=LOLQA=':%PEY-[F&7E$>E=VDQIYJ[IIKS9 J9946IUOV=QR,,X$NMK<!5]-
M3+B7S*@:F"ZR7FJ3E/H(.(:N Q$UT!E@.$@;$KES<#^YVB#&:V(7*7JJ%'7N
M'X(T"OF!8T3VF5E%ZR I>VP&2+MWEV(V0&SVE6WKD&AX\O;?[SEK>7HMF</P
M(UT<J:%2@6.6^U39&:B\.($$.WF>/823%\?Z*XX>'AG;U1/+WQ[PISWO;WBU
M$<(I!8@C_,V6@SVD=AS=>V<AQ\M "H)B(8EX@R*OP3WJ- G;?4=:"W6#T3(M
M@]2- N4R("D$GU9E1%#DF#TZ*&6<KEJG:Q%T4O0[6>]NI=37MI'WE$YL!FI[
M4:]AQW6_QGG'GZ6TLL+\FP[,35#RT:B_,*Y?!0=H)E17?9NM*(J!I>8C]QW4
ML%\K/B%!FN:>M?H:&>U>]1!QH/0F40_+?LZ!YT4#C6=GL?%.8-K,O5U78$$X
M<@*)1#&3L;F+L9K:)=2AGM)M$,5&VV MWQZQW7)$[=NP_AX,Z+!VX.F;J*JN
MS%NRF-S JVN%'\6# H;;O,TO.[G@*(EYNVZ:*UQR 9+&=./0?K]451$XG1,K
M=4_Y3H*YK0\0<MYQWY</-#KN\X<1BH[[L#Q"#[GAQQ'<>,H$*)%6@-0G$6;R
MH6;W>G/GZ:+@KJ.^-W<Y;IP/S$\&T.EYY\"-9_A$(G>)X_<,9O*$V_U]&JVC
M(#G<!@3;KI"[B8Q8G'41]; 1Q!@ 6R(,XT*U5046@V*!7')! HEY%\C*2#\%
M6_;C71+$:1#R&<Q\P:Q#;00^@]2_#6?1AXR:*P\^/$1!IG0>SE'4DU0\YUJ2
M7UQ?F6=8RI=&E/$71#STKMW?DRAD&M[@A!\GPLJACE5..[4"1KVY'5^@:W1E
MGA %3PD5%OCF;6Y__#=_7V5WC_ACD/R&L_,@Y"]^'/2-<8B"N>KZ*;K1XYJR
M%!_'F;@<RC+^[&7VB%]N!3]4,/Q^7D/5Q(;J:0PF#K5EU]W'4O6:L0+ "(H5
M?(88&_2Q;D&SK5F* Y5+MH2Z8#_:'><IWW9PA%12\WI.S;D@P0;(/-.#1=L)
M7D-+\/1^?'"MK?*9'XK;L32$KIG@29;;S0?\$,5\=P'=!TRN<.K[(J/:@3KM
M >JIOZ2&RE_D98A O%6GYZ?S1I]^NWL":.C)'%JVWCW=\Z7 M3 +T<7]!J=9
M$H59_EK#ZDN0K'].#*]/63(8^9:E*4/W\]XOC!5W);KA#\#G7&5K711POO*A
MQ7T<95#\:Y0I--\GM4-@D;"7TR['5HJ I Q("I$_BE")D>]R"$&0D 2&V\MP
MY-/O!SDXMX !CO-Z/K 9=IQ5#(< +2R6:0'#02"?Z^%' 1&MQ-^N=J)#U]E7
MG(11:G:[QX*XG^C?RLR]VQ>DN=]+9Z<[0/W-[+'6G-E[U+PX7'5G=/F!7 94
M"@'#C66\\>7'O=0]A?"Y/7E!L_58EQY4^/(@UIZA07NU"#R?\!?Q%V<K<86@
MGV!=,O#0!H[1Y;M5ZNU9^8)-C#/^2UJ<<H8T7<)B^QA=S2FXH>1%(*D[U3*V
M\L] DF09*UPZXA%%3R%V!E=$^QW[<2>+#@IW[/#/!4VR-H[:BL$RD-:>0*'Y
MJH@@9]L=H0<LEPW7;.R/08JOF89=S:$]#/Q$XDZ&4SIVO,8)>OOZS9\0SL7)
M_[++!4([)A%H9]8T#\U)> "519J"[B1=B%&\#%R8P'6O"4P_;7>JR]T\WL?"
M4[CO9@DO("QHEM<P%MUI?PBAA1J&=F+0%Q^FSA56Z__>R_[5Z1WMN$\FQ+YG
M$HHG"G&<BJ+$&_R/?91&&;[%R5,48CG&&QS2AUA0$<'0))+XEV7,53N_LODH
M.6/&]5*(PV-3*4_1'QM&S)G,_NC46#YW6ROJ2BMAT1U%/1=%*Y&1*C,JA4:Y
MU$6X5.26F963XCT?#8A;6DXNH-#P+"X:YY_)=FJ#-8;S5XSU2SZ<3\TWB5:I
M29$UGO"-'N<39"<?SP&I@^_LVVL0][V=&(SIC-8+T)*-PWPF4E/TTIQ.^NU#
M[ZK2*6;6EF VYQJ]#]S]7<MK,2VTO%Q,*OB@A%?:YZDEA'M)?4#0(27UMV?L
M@%X\?J(8X2<F89 ^BGL'=Y0G,W$8$5S+/^[H"?O(=4*?HC5>?SA\9MG115R^
M5;<*L^B)6;'>R<H44EB:HU>IO!BV?,HF4&)*+&5&$1<:9929?"ZV.,+)7ZX3
M[<;9'\5'=[GPZ/Z ]CSQC6+E<=.@' $$AYG&?.ET!F'EQ$KSJ>):L)@7F!1[
M'BH^[+-/-/L;SOB<HNV4AE0MG<R(BQ>G.5'3L7KBQ?U#2('N]QGSI0P=F-/L
MF"00C-\.=FJO^$D; %]MN..<$_HE'=F4NH6.DU[41W3]M:#FK)#@!;GS=#=@
M[0VG.Q0XA9GQ;6O>J<*TY5#]>_9FI-+QT"."41>-.&"82*NR:9\R("F6-'0Z
M3WN@8ESFK8":WQRO6U\M?H":;7<KGS:%P%+OL?&:MN+IR#GOOM"[1[I/@WA]
M)AZ_P''G6:5AWQ,;TI;9ISDK+RGHX)D[A'1S!.)TI+H7AJX:TP2T?8?G#INR
MS#7>/,@P]JC@CPH!QH[=UXNBFJMRFZ6'#?51#V@:<O/0#IPO3S9B><(#1NMV
MT4\P)O41T-/Q2E\>S*0Z(18H%P*@#P?$1>!'%*40J))":YWJ)U-.Z";*3-\*
M5K\U(H4KJ<QU2#]9<GRL9=JM!S@:+1)B07:.AX%K1X\C]XQM9B<__!T=Q3J2
MQT>S_^I,Y>@4I3@^X3^+(Y2^8Q,@\Z!7,^PZY7<*[W,TN?:J@%)$U'C3G/]Q
M(;-R\0YOO?;/:$>_@\+(!F%'%+_5JM8!A)J=VCKT!A.-XDRE>)ZY4<XYL2^<
MXAV;0"+!FOU,,/]A%:]76YIDT3^-/4./GCTR.O3=>XW*5;1="A1VL%S'"%!J
MH]@E@$=:<"LYB@>/59[CM[N\E8O5K;"E5@RP[*0A-F> SER)O8"2*!4\(>XW
M,6JB#!BIZ6,NJ^PD[#:9G/HUASA,,)NZ3['\KZ+-O$;69CEL0G7$@P7:7#QL
MSCXR\7#:6(^F*<YD-T,2!?>\KSJ<M:D%TM1>U\M!-7?R@BTJ^-8=M'SC;JZE
MWK%:KA/,B^:*22F?CEA&(".KL,5Q3JO'P274.AQ'POY>PA[C!_YJ7E$D(?D6
MJ8CT82KBOBC<8].]=&ZHOFQD#+U^K0_!PH#7\/?"#,I$+Y=#Y-EY&C!@!E/-
MTER8*O%QX.SM%)W&\18./IPY+]@'[:^]^/7/NYU:!(Z5SGPKD%/28AC.M@I#
MNF=Y_W5P".Z)42<##6(N86L0]_+@K&" =I(#5/_J@JS7M5JU!QZ>/H<JX;H>
M@FLZ5TKV+%)7RZ-BCB^]7OG;:$\SXN48:0/>7OR4\^]+:)4E*F OMK&6(2<W
M1F;IEC$0(H2E*$R5=+>:BR]US&7FPD(_!8735)@YB@$T"XA2VS18.0'#]2T@
MMBH<G*Y@<-Y"01@>>A$_R;=?O)3^]E)W#G$/-_^EOU'!'%[)TPCHASUX4.G+
M@UG'HTLA0!09L:5#T=,E_,<^2C 3F86<[, O&V0L5>#]J';\(R9.;4)U1*&K
M-A<ON\KYM8R4-RC:Y9Q%)HX+MC"<V )B:J_D!<#9J&O.V8IF0I(Q*CB+*S>9
MR)C/AD&=>?;U,^M.$X8GR(_;IED8#FH!L=7L.MVL.N]L"L-#SZ,XB$-?^7$O
M=><0]W#SGQ]O"N:+R8]UH!_VX$&E+P]F'8\NA8"1'R<TQ'B=GC/<BQ:"5QNE
M$Y!16CQ,;-2UKW[B'KI/Y"SS=>P2GZ;2QY<:JQH\EJ0!(V=7-<KD390DC(+E
MC(XW^EE'#6)NP)K[T49X3J7]-J.F&L'CU.I4,%Y9U)_V_62HTZ0L'M>2:J//
MMK04AOM9P&R5C4Z7A<Z;?4[LI5PV_O]\Q^DI('QOJGI&G?]A%:_KOU ^*=]4
M.#Z8#LF>=] _^QJ*VO:;(,-G+!TS6XM.+9F]:4TKJ9^($Q4'^E$LHL\+&8-P
M):C8;4[*88B_PPA!,]DPG=<"OBU[)<IVC?@?1214"2O_QK?0F[]3/Y^_!=-6
MQ)(/ Q7C0'P@2(YD2:%YLD@[FR&Z?/OE-@N23-D1U(M^*,C0/7Z(XIA;##^8
M$\2>05!T'N-F#5GP(I"3UY  Z*3Y<I*9[V!>2#KL-=Z"*^]M7=P5+H^5XG7+
MDN T2D-"TWV";4Y5QO,:YSAC>'OHMK+?[8CH,!X0M"X9<DN(:?Q2&(=R?,IL
M!/"9C#,SHJXA6[K)J.&62U/=E*\.89EMM![@5#+-=Y:37_,5U_[64<9DL7_O
MPYSF&/3U>'@XX!FN<>++5):@RQJ+H'&!2#:A:=Q6@!(F#(V!V@*R%.!+]Y:7
MX56NJ&"+&%_F]AEBG,5[:^-;A<SPG$VMVD#W+9M]+&X/LR1)9D<\5UKDZ$EM
MX/G)1#%PP=P&;GCK[?9MD;.OG=LBMHGD'!*"VFK2D-B]XQ9=>?*V6;SH0'^I
MD^ =3?B_OD39(YNXLD?,?#Y.*8G6O,:W>&D6I8\89Y!2VQG=P>_NJK81?9NF
M/\UN:SF<UMW6^5+W.BHF ;KY37OKJ5/R$=  'N1T*)[VJP66DLF1?D]Z]=MB
MP6EAPBD.OW^@3Z_6.)+6RWYH&BW[U=]/\^=J>")'$S;9\%GEP^&&]Y[!3.MW
M^&OV@6C6#QH2-->^$0,/'2,+UDCES8LL2N[S>H,=HM1*L8M C_0"]T$!#OW*
M62/!>^I9XRIY".*\>>I)F=W)9J[7;-C%<U)7FWS/BC]AGK^U:%6L[XBA??AT
M(H#;_IJ*1*@FDLA25*%XQ6DI%JKD O> IUN[HE[@F^))T$\!WQVZVN27U)G
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M.^-C-FOLF8Q8_MLR];"9(T5!A2Q(X0[#>\>; 76F^<5"3OK0+BX!\)6H*@F
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MMFQ,-*!M;[D'PK%789CLL;H LM]<,*'J N<A+EZ]-V<.[+:-!;"M7JNGVN6
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M,H'?V"^+7['_N6=S]'_^_U!+ P04    " !OAG)2'[;*@U)    @WP0 %0
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MI(<K^2^,[E#@BM?C$:-C&'&)>D)57W>#OP+S%42,G%RNBV-B*#=:@ HBAN9
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M9GL* %;QB,4!L]O@D@.L4K2^ZM=<?3I#FVC^ZJ=JCJ#==IFFLS,+F-UF6Q/
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M Y5\G^Q2)276+A.]T&LM3=%,/[$,-UMF$BXV+,GH#R%R1MJ/-YI&5URS.G>
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MQ>UD($_SY3(FFCG'$1OPKFR:*IF">#)@XZ^/&;SIPIS:Z=)M<6':2F?G2V)
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M(,E94<+12$$;D<;VHT\].YBJ90%\%(_YI(;/JZ+\@_;=,@J0L(NR,I8SK+'
M 1F]+2IDBR"SY:FE)VA030OXU"8J7&HF*91.:29C7"3J(;5K.FH8;;Q 7@["
MJXR EG2$ZZ#R:3Q5> .4"AB3+FIX+YG!<:](3G5+A1=,G2-IQ7BO:+OM60&C
MA7^)/'!0L!$R:^\Y4/Y2;5"'5ZE=(J8"(J("^ IR:^ I&E;[G%2=$O1V[S;J
M,GHX$<BFZ-*"B>'>"#E*#XZ2#=]E*=]U+6;M;\-/<FSB9:%3VW!:U..J;P_\
M*XOW0_/M"R<31F%4A7L(XX=M^IC,5%K#BA[190IOX,R*FF^Q'&1_8W!UH;])
M73)UVEWC8]7LFYL,W8)Y@0.9@!(#Y =GK<XJ.XX)J"RPAN[][AK*CN$+M(,X
M\AL1)+]AW>#X-G0#I&V5F]C=7Q]41A+.KS'.;KV+;"NFW >-X65L5/0QSN+R
M_)K%$\<&XCQ'V\88>S+4D]Q[<'__Q\GAR>CIH\,UA/S>]TNUU&I%]A#L!+A[
M* :4CE<[>H8/<S3BJN#"ZEB:N\\/*B3^R(#7]1.^1]4^E7O.I.OQ'J'KK[2=
M+N#^W1N#?O''7CP!:GT>9ZOXW+Q8Z;2:P;O0S8-AP]S7\'!MS@_NR>%OGQRV
MDEH=< J4G;. I_%B!7&D9.E%+'T@5E@1M3FA^T*";0+T'FF.QB(^)RD+&P.)
M(L_)KP#]0X=D(315G\+LSEMM\-1"*W!MP[\EBEPH?J'T[P1:]("@=&RV[/Y>
M:*5O<G2KXL;Y/.YF%%.@01+[D0C):)PH_#&)S0R(THXC"60-D+(56U1(H^L;
M6,?'VQYIM,YTUKTC.EKG&C>5!E4&5(VH@KU4E;W_!J;LU@HTA[(ZWYO@$^BE
M'K#,=KT+5YJ_Z#0^YVC\./^HX2)EI]C3:(?%?MQO8B4GAW9XOC<3#8'6+D"O
MK3/YW6@GQN6*0N:(R\PD9<V!W-8IM]5/P^YVA@U)U((<$:1=KK11C5;#['6$
MNZGB,A\86$<AJTU%]$SFOQY37VX-(JSI#.PU+/@BUNF65V[**Y/;X)5GGW'G
MKF"VZ[/Q(/'D!+9*?68(=#D'6@6:G(_KTK#5G>S"\ [;A>D25S(6I*R:1 6@
M0#9*!)P8#Y.8+O!K9S-!LJ>9C@8-\D6&3D$VK\"P$@5-*[(JYOX117.40?N-
M-K/N0<"A(Q#"J!S=@EOIX*H4G]X&Q;\CT]!+E:L);.)7D0K(MYSH!=X?0&5
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M3T5@V&&I(E<P&_37CQG&*B/<)8$"5NKH>&\.*SR3)H(5?3.A1_ZL03]M+&M
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MR,@62CES[1#PD:2+.1?,\$3H/AR\];',YRK%J .XSA*D_Q?7EE?I>Z;_&SP
M;>\^4!!'33K)*(<Y<X)FDM><2!(5BY:,B(RS*I(_]AATAE4)4[]Z'"7N@%65
MW^E9:<5XA;G:C_C-8:1)UF/#UM8JS9S;:[E!N7?'Q@$ZI%B+"MPY6K,8Y=,Y
MGQ27QI*M,$ZL!J8 5Q*HZ;!8,]/"'_;=,7Q:L$^:-PF&&!NDRH2C\''4L/W0
MST1)U8>F2%R?->$F0B._ZR-W@V>N0V0K5 1=0C\7L]Q%P>$,%G $XJSBI'L!
MQUU023DYN$-^"\HY8:)7[UY^.+4M"52G"5,>5#S;6F/,-(_L'M,3RS5!Y\,_
M$8.!3H/#$(%++%1XVZ 7R:#E,=,V'6?W8L9>[(CDM/)55^IQW=@& U6_80*4
M0Y!#9<AV*N/2N:GYLNO,?TU^$5H7I!;F]I!^Z2%=WJQ@R,1E7$;XT%'Z<&>\
MR[;Q5-S9H=FT8(MQ")EF0L48,_C($M6Z:05;">6YRA0>LIM+]BVG5^K841"E
MU:1NKM/+5;073@T;8:8:9 XC/M=R'!\?[F%*:='9Q@K(@=89Z ;X5 :,)"ZC
M<V E8FI*>1>P_G"!=;S\1T87R;O4M$3MT:8+W^YKR#*!+&ZJ/).T$HS6GYO4
M'!HU/,MF2+=\UB*;,)0#F7$25\EL#ZX(^P#% 5(Y,J'E4E5E$;.92;@9=NY?
M(Y>*+R%T#3'UMCN_:G,+0*5MK5R7.:@)P!*+HPKN#]\S_@G=71@8_8&#.O'\
MV7-XM/_P\-GIWC$>Q^.;\1=\PU[S1[?B-7=Q'Z\*+IGW/EZ_I&H[+,K3=*WV
M:FGCD5?O"Y,NQ7@^K9\J]G47UJ!35V:];0)( YD!5'',N25'9"A7#.LTXTS"
M9@WG*JRZ,4E1=T$N*$OWQL?"#+S>2;B\@>[UU[\</3EY$6VH@0W5L&;F1=D'
MID#?55-K+BCPB=:R*CHZMA)C(,NV6NS:&CS,CJ=/B5E]#:VJ5XHFYMQ96BI%
M: *JPTIZ/F^+C4&4$]\M25&74LTO3I<L1?;23)/) (N%Y4Y@3RE-D,4QD=O>
MH U4-84>X2G\7K*]+1'5YQ'  @>&1:NY[*&]6+MQ<>RX7;;K[W7F*VG/%@LJ
M"AB!/%Y#$^S"5Y\11V"R<TY> &0COHOPE/I"E'>:C+MF4=O@K;39S/'LQ&W
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MK1NO^1X!DH+)+NC*:I7](OZ^+$.;)8; 4QBB Q;#<JS8G#:DR,TPC8\UF87
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M"^) (/24R@-*^LAGRS7:9$B7O4A3\QCW00S,D@L&R51A5!)5/4$FXN%^^CJ
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M_?SMS;OST8_X6,C:Z<-Y R>3PO,@Y/'7/^4EDHB"C=-\6,N&>=NTHH"_F0/
M\Q-FXU0"?$#RNXT 69'1WYD]( 72/Y>B:,6XD.$(3&@UR(I\P62AVLDD3W/@
M0,0.[+GB&,!91/JAK%:%S*8R&_E\AN>#=#ZIBJ):J:?#JF$A)[%FN,697G50
M().J^NF?1-M4VQ#!QN=;R :4K .U$,BDG[(J&ISQ<]BE:5VU97;@3X9&R.#6
M\M[S$/=^.CG4QQ]\0^\%;M73^X]@#/VE8_H?CMCS4CP"S$#6J#YTWG;Z2M]W
MXJ?M##_GD9X\/+S_^!L]TSVQ?PN'>B'K^4;'&>L$L/9Y5XAK!4 K)!+5$>+E
M@0I 3 ,Y3UZV$I23)B_H<WD)?\Q (@++@*EG K^@V;YD^:!@-<Q88&A?ZN Z
MK.IXM?[BJ2QV@$A2FB^+AGXS,HK+7(H2Y54S$TTHJ/J^/@<5:2S]Y46Z6U7'
MT@Z9*CP#=$D;!61(OZBE4+"=JAW_B_0*EI+X8=4]A\-D=_VVO'[CV[A^;RMV
M0+&%U*)4W/HVOFQKID>9X"V(%4&^D4K62Q*U1'NS7$Z27V6&%F'R!J4WR'VM
M.6C"' '!@7'7T*>KY&>X</"*2/]3K$>]2NU;L%-(>:2UO#A_8VU9^+GW:KY"
M:@95H:X*V3_KF< ?VP5,GJZ^Y1SP2@*J34V_@($7J*&,<]1:^<(@$X(=QP6.
MX,IF_ ,_/6T+T52@>XO)1( A$ZV<=1I_?)@CJT:+:B5KUJ6REE4815=\4E=S
MOK)X+_&_8^184J5U/G:7_GDEZHQ,;;#J4IA#9VR?I]'33E]V)^>VJ?_L0F/<
M[?X(N0VO!*["K*KA2F:)-%\[3"YZSB"32[!DD.<FDQ;^O:KJ#T04AD')">QX
M8ZV)<:N TI76.'MW.*""UU6#+%@U\+RA8_B@G%;PKY@L<*^9E%'5I96,<9=H
MA,QLZL@Q=;% N0%4KF= >TK[(,NIF$J4-K4$AIA7+;R7SH#--*3TVJU"8=:6
M2%D"95ANSIVL$O@OT0=."DY"K]I[K@8C/E=I42EGVC 9$!55P,]02@ O Z.K
M0'L0?IR @'-KZ H8N!!D-9*(G=#9:'K4(UA25LZNRLO+S*>_:4$DEE6>F0]G
M53ON6)9X!E9ZPWA\'CE+>KS+L"6RP3.$^<,QO4]G,FMA1T](<,,;N+*J9>E9
M@B$!5F9#IL.DK9DZS:GQO7+GYHQ$E+YEA1.9@$4$Y >7K2T:,X\)V#^PA_;]
M[A[J$\,7+!<:4%H]D>B+2,]#_7E<TAA/J,V@"Z#.@S%(_0\'8@(T\504*[%6
MSU9YULS@71CFWK#!^R7<YM^1>=:K- PH&/=^.KT-\PROO"R5\R2]DP4IG+\*
M7-UF>L5.:[P+1MMSH63R7A2B7G]F;=%R1U&6Z#\:XTB*1G*^W3\_>'@\@D]O
M8&?UOE_+92Y7Y'/"04#HA>I1;468I6?XQSR'HY.!'.\$';K/#]J$_LQ !$BR
M4(WQ-84UE*SAY"A90![7++ZUWPSDJE'2W%D<ZL'BH;Q'W"8LQ)K4#/P8B-2R
ME#4+-1B0_&VJZ;-.[<ZV"L\'O@)R"_Y;H\Z!^@=JOU:C@]TB_5#M+O:=, =?
ME1B.9<^YH^:;L0@QGH1Z+Q(A$#8Y=.&/J5 S($HSCS20*@JL 79ED$W3-[%.
M;#B>:;+)<C;E!AV[:P.>!%8A!CB2!LY2-H;3#2S9[A6JLVM4O%,*>#PX_LN^
M4;W]^[TG5)>=X,1&?DCL@H<^XZ'[3[V?<U6)%'4Y,-N.IMZJYK*XH?;.81B/
M5."!/0".M!!YMN,AV_*0]#9XR/E'/+EK^)'ZC'\DGI*2ES*?28 9-E\T\,]\
M/FYKQ:Y?XW=A1R4)-ZGG@I35D@@=QS'O+.15>'FT=8N_MF8UREU:\VC0/UP5
M&(1B"QPFF(+12:'SF2S]*XD>"X4F?JYFW2N!B\@;M [+'#T ._EY3=K/;H/V
MWY#WX+DLY00.\8O(38IEIOF"<BI*%%?FDHSU-!*:;Z\2)TWD73^;+ HX*H]:
M._)M-!@ ( Y.[P=K.LLRG>)8K$?Q;=M*,Z ![*+HELGZCS97><,.L696*:F3
ME)8B+X3^ ([!KC2SWH[;<PJ?K7&*N\#%UC=-WL9-^Z=(Z9$;O&2>W$'U(UGJ
M(8<$0"?+IE\@F,03.Q"87Z 2SEL*9YX>HSI$5U#HFQ/Y5-WW<5(S& 1?N%*2
MBD)5\;+P]\%7M.$9R21X$F_<SJK[]+LRN16-#)ADLZ&GYD\GCXZ?]<9A+ $-
M"Y]>$4.#>ZH]BHA BEAG>^R%Z;>Y#I,S12X+#EG E[,V90VPD[E%N<5XV_.2
M_A:D"N"UI(0T?$"43AC&@4C.,;KN?,,43 KN3X'THM@]3J!:F.N^:.MTAE;=
MR7WR=.$1U!VI9?<8(T1H*S95^L%&/9'<_Y[7,CE;>6$\CK&%?],'O 2UE(.:
MDZJMDS48>C:2M8(-6Q],Z/RT":KG$GT*/Z+S0$GLEO( /X16+KQ<*[11]9L]
M21F<V347.64XZ$6;3W+\"*Q@N.4?D:[@"&#9S8RB5J!2%P7GEG$VEV'RFT^A
MH]MT;7<3=\IL^*9&+S<*HEF^Z,B"2W8;;A*1 7QJ6#\[/3YY N:Y)?"W<'=L
MA*GB!!@!S*H\P-W()SE.C*A TQ+F<);^%6'2ZW/PU7A3:YV>!]]]??;^Y=E_
M)>_I<[^*^H-LDG<81GOXZ/Y#,"WW'G2=FM%*32;+%*FJ=,8.ZXPZELY"CH:$
MJ0IZ4;C,3M+ZLBIM:6*8VCJ5I,O1Q,F+P*H=\QEZ'\VUHL?6,R0&-QA$,ZF'
MT7@JSEMU#FGW3B]+VU/[@8N%F6[RTLS<7,!G-H8X K&[DDLT*7'0,HI#P^!
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MM(-+]L6:FRJ&4>CND!N)?]/G;]N@VT[<V-BZ<D 7HF5Z ?3NARC)6KG>?B9
M[]KUZ'@;G$O!<"?K@$N&AX[N':Z$KES^PE6G&@.B]<]T5=4?XNGURCV<K3YO
M.GOT!3 =,-WYIP\GRPO3NQ_0)3<PHT@E]W?T^Q9>M2B7Q- SO7'MM8V +\US
M+TW8G2->L 5ER=MR#= 7*'0IY^,JRW6\8T+ 8XL6CB4-EH=P=O "CX4?"1!M
MAM82P#3N'%VW'BW<G.W_ BKIU&FJVEU<U>NM;:.>3F)A.\_+>%(_CI7G)T[U
M;+IMV8TZA0Z"DN\OL"CE,4BZ%H7(YW0M3#D2Z/"L4A-J*#?>8V&A/<YC.#J,
MK!ODQ+:AGJE3@4E%1.UX76"BDV[=&\L<8G^-SKO@.VF;[1D)B)2VR%'%@K<*
M&=]_H8;:)0S+%+N_Z":W.Z>9%PC@4JNGM)-<<MS9G2#9BW-(=%8<I2J01HC5
M='3,2Y$7+F%!:@F#J8A*%MJECL5FQ(R1T6*B& /RD"ZN(\ P-IM*\#IA! UN
M,&S<'(Y#<!0 E=R<XE%XEX&4Q =.XM8>)&>,]<2),=)J.DE9<"*<$+MLR8T_
MAQ5WL=H^F<A%H2JK=QORYM!&'Y'')\>_7H)F8VXP):<L<^!EFNI#X#O\.^..
MU>Z: TN:<7DO;KWA[T/?99I67XZHPSXN-L,E^J))L;$,0V+5C@YQ51/]PZ)*
M/P!Q]N8-Q9L[H/N$"I*OU72"?M8(_)S0E-^-,/R,<?-M_$9%+B>?ZA[RO4&-
MRZS.\LDD3S&GF;BDT!VXUTDFY@)=2:D@O)3("M BB7*\=$ZT5<7&U).\FWNH
MN26(0583 X\(L46J'8X3$2W%&DU46$.&,P?G<#ANOG9EE$ L,NPVU*!!,Y?9
MVEY)3J^FB8;YC91^@'6^ZU&?&__QE:9-N--QQR$>4N.\:)N%\_SH#XP+LPNN
MW5!P[6077/NZV&_,P'2=]- E"\4NW'%3I,(=QG2. REM6"VK_8J8K.JQ/F/:
MCPC17,H/S"G^U9:V)%C[-A=X06NLYV4 ;8VKC]R8$ULQMUFS(H^AV*0+-3.8
MYAQ;UT@HH% B$BPSK(BQ'B:OW$(Z313Z.$GLV]6.!2^8'_!9='C!5PTPBZEI
MH-2^F63P%@,U'S179Q.]MU@&Q[38<C0"!BF[!V:AY6QNL&K5 C/$<-*V"SEC
MTG;&[J88\]O*>+^\Q$677DUV@3\7JS7Q(9M6E*1>P8DN-,/7QSPQ?8/UT;I<
M"_PX/;2,U;YJ(UE-K9\W>5 [M/J* 78*W"VF[6RNP+VMJX8!<%]:]RU;<V^(
M!MW?S])K.39>5UP@?$EDC2^"&K @O'0AM"O;$FN:I#/HABRV*9K,%-=!>WD*
MQM;:=*#+E=(L#(UU[;JS +Y5VMH<9[Z(N1\5-QP4+EF>=GCD+N-A*Z)_?!L9
M#V?U.&]JZX\&PE]@HO[6I'W&N$Y-C92FF+K0+41!2Q*N+<44R1G@(I#]V;Z:
MB3<LHH(./O'WK@Q7Z$]&Z?*D9'A/[5GR=T3MJFI&@1-P CR^$*M)6_A?0,=4
MG=LQ3#X^M_*@5LPR6(C&Z1Z92X.>&T2EU\G1"YQOHV/0,-J(>OP Q14:;,8[
M-ZW: +FV<V)72+ALWV1<>J!M/).66]5691%C);4_@G.<2[\KM,.M NMRD:<N
M:' V!X4DA:=] CK3")+XLX$L/#L[LR"%,.;S2C6XH;\*I>",6UR2&JH[.'?;
MJPD3P]Y5P;[9=Y2+:^9S=N;Q,.=R]/V-I-+8!%[@<:G,F,4'15/XF/)Q&,U>
M5[7J"QUYK;,\W!V'^AE!BP8YGK[R95*=3>B1-9TIXN/YT:V^6S8:_I-3PL%,
MUB2%G_..+>X<U(]>ZH10;[;#/]ILRM60IM:%>XS7F+CMU3BZS30+)OM45Q40
M%VGKQL!D_@OT7Y7EII</\8/(>^)IU8^]Q7+%?DI.7HDR*Y5XP(?)%8A83=\'
MD9(6H'!3[;*?D,W>%-*V64_GV6O4(A,]1-0KDPI"]40T'S/XE97Y)H[&(R *
M6D4H(L:PL?V8&$!M@>HN,B+J#&_M)713YC7(<UQYRIAO&K2?VT61(ITKWYZ*
MNPBYA!+]N"MWPBV@QRCN07S$(S&Z;)+V>]#5^7BG,&RG,#RYI11)I2%M_N%=
MSNW=GOVU0,']R94G!^,6?0STJ*_VU8X_(_M<)HE9!OXUX#,&5[HEH[N&2XES
M<D&D>56NN(DY_"X49"8&_UM)4N=]0_&.ESG?</TEPQ;LK^//#+LZ8_/7DPIN
MWV)/)R)D,/.W62(V/!4OW'U,/4NP.Y;>*,5>&*X@A.?H0BNE6Y&E^\E*P% J
MX!!_M'G-+&S/J$->6SXT45KLIX0B&3])HXXB)2E>\,#$ZYZY[=C)=NSDY/@V
M^ EVU9Q>,U'@XGHU95Y= +$@4&]JZ:6'C66SDKH=IF$;,1V26-=Z$UC#&,#5
MU@JCPB"=2BP@HW8XR$6\-)^^ 6!2*=CHY,]CIYG_<=\^-_8)ONU5_N,_WTP0
M6O47(HQ=WYB;"D^<?C?AB3O+^;;K&W-R<AN<[W>XQ[HCQ/;N%K_RV/3Y"M(_
MXX+"RT%J=/LZ>E-\]&(K&HM)"_-,0YT@"YK)HH-IH[M9.'.Z$*N=&-Y2#)_>
M"O)HFZ+.Y-#3+>5\JE0VN6!M;;TK7C-P+HSV+?1.0H*?/\.ZGU]DN\0@/6<T
M5S7\Z*$9T;\1D4N-O%;B^'PFEZ!=:D=002 Z\A+?SJ"?D7#4=/X6.7F&<$/(
M'Q6AT\,?)6?-1L!0DQ!8(&MIXV;YO/<2]T7PT!&48XOR$*@D/EJ[#HM\7",J
M(M: F [I*P0J=KG#9AB[%%PU[\*>^X74G5([:143D1<T#<J1UF!S/!QLQ,TD
M.GW+K.+^;;"*<W-7*1:U-7O02(,VA:"^%/]C$\?\T*?H/OCM=/POFSZ9VHC6
M?@A"V$X+0?[( CD#M0YHRXA!&4<?F:WSA:27?9/4H'O.**5)Y'1Q>UP3_?B$
M?&W[EM7QX@7>9>K.HIN+HF>/ 8]4=?6B1B%X):.=D3^/_"6<TT51&3,M[4,?
M/#FK6RSAZFHP/6\3-PM[[#C"EASAP>TH#_4RAV.^5N[CI7 63$2*OB_[ WFQ
M"^!H*.)W1: P!!$+ &,DW896-&X*?GDLY^KL2'5+4GUX*T87NBGK:V1NL(/3
M=L%PG$^[?5RN&Q$+FUS40]X@JQE5BAQ$0 \N)H:?IM!(ISH-+P@J3;J0T#6Z
MH=0GLLF,/]=/+2<[#CL24>RHL)GX@_)'+R[HI:._HX/Q/>\&L;$E7[\UM=E!
M6*:R,?S>U!.[1DG1M&JOLX6(-MK[G,X#WMVS[>[9K72R>$T90=?+(^%L(C#3
M-+P7&6RPAYF&Q2:-Q^4_<0&%B5-B<(6N5;\RHEK,HZ=ZGWP2W\I,%DAZ;/FX
M^+?2D I#?=0IN8I2)5$I1#QO&XRH&4)@:I#S,"HO07\BW$M0"XL1Z%.@RDTE
M5SGE&:ZZ:>N2\SL7C<,X&W6=.KK$EY!V19;5R&[")Q#L<4(]V+VU=NJ#O(00
M[A\9]5BCC%SD9(ATAAN(IX..Z=(7K]3+;W<]M[R>MP)T<X9X>M=$,\F'\?FX
M2U+&Y$W(IW1MD.Z 5@A/O6[Y0@8"T*/H4O>-S-K"EI?A)0M]/G&SMAW1;4=T
MMY)K^#,S2F! OXC5]0B/FG*$(7=NJI,V7LZW[D0!M$;M%S*-BPN_YD18G6Q$
M)8$4T;,]YL#D].OBAR/]SALQ9=U-:GQPV^EG4NC0/GUS4>=EFB\*[C5':4P[
MFMV.9F\IW:7%^"1JQ-?!,.GCE>RL=@EOKM-@Z@TV2HS:S:X<JOQ0E7L[5%@L
MX3?B W>5X=(ZTXOB&7F@37:''<4ZP73#<"\TCECX)J*N@+_;9/!=8/FF LOW
M=X'EKYUG;1=8/KV5E)H@EJ<UI&NYYN+R>?8WZ)PS/81-[>*>FWY'8^K1NFCK
M%(P0.;)-E#M-AKUT+U,2>$FW7@NS0#U!>SKW8HD^6D+%FG''%' MA[2GD\@H
M1;Z_2Q\Q.S\O,2BH-F7+?D3<?"\GH[*LS/:0>TADFB=3K_40(<YY=J+8/2?\
M4A:M,M#[?>[.AJ,#7ES1NI]XCR;^<;F2NS&WB==H=D,NGIV*LIV*<GHK>20O
M+.CL=0K2@EQX85I8Q@TKV<4]ZJ>PB"ASY= JN?:%.C\S"6+5C >IB%JYW>($
M&X!-K$LG=MIS#&HOSX>ZFE&.JS+A*$;K!<, <4H6=541#@S#'6HT;@Z%&2-3
MF*)D0O[2[I @D9?@YW,O&X9@"HK"=@6,H=H& F(5QL/&, 3N$?NTB&U,VII8
M*:<T8^4%&Q6YZ3ELT86'X1<0*,>!%>=1MZ3=A=[N0M]*+L[/5#(#ZV]AS=L'
MU7['RXH>= ($,3<7ZT*J$A9N*'LN5-KB^$AH$XE9,_#SE,<.[&C=T9$[<)DB
M4?A"M5A4"JZ'>0D>6$EX3<<]# .!=2=I@:T.UZ0:I)03;X7^@)"Y-@W>CN[^
MZG7R^ZN+U^?OWR>___W\W?F;OT5E!UA3;VVWB&.ZD)'.X\T8^3#3O=*HD:(8
M5XA^Q*ZTN(WW%]/YLWR9$*?XCWN$#H"6!P,NC*D$Z3_N'=]+4J "?0?MOQ>(
MEJ#_K2?-;^ ]+,1"R:?F!^RJBJ;-0VW9-#7^'U: X%=AY/OW**D )P'KNY>8
M#U[;(O(O-/X[W"[["X]%^O0SKHIL:]J[+J&=_?/=F^>OWHR25Z]?$!7\>-1D
ML-@CWJ6O8*NVH*UX5WU:^Z[6==E:[A\^>OR79_I^F160!94<'_[P<&$0TP2B
MT'T9PK\='OM\_=3;P,MW[>'QX8/3RW?-B<]O=L>.U%'RLZPFZ+Q._U.L-]Z^
M^P\/GWSWNW?\X."E3 ].CT^//^'B?L,;]%K,Y;6O)*[X>Z.HSW 7O]BVW:ZX
M^X:)X *AT+:^-M_PAKR8(92 RP%X0QDF]987Y"[0_Q&92O [,*-VYMOW:+Z=
M_]_S%[]=O/KG^7=GXGRKZ_HTT^UN2.^=K;69K?42?B>2<P6T+K:57W>?2JY[
M+^ZH2OMU6CM?<HW?H&5BI=3II5+JT8/#DV]:)P\XV2CY]>5.&_\R"52[W+GK
MY<X]N/NY<Y^RZ[=AR[S']IT(WG5R,VOZ7O?U# $8EQIF>IEC_/@N;?".9VW*
MLQ[N>-87][^X)L%WYT9]_=MZ9<_LN[/9._:U*?MZ9-C7CT?C*ELC%SN:-?,"
M?OA?4$L#!!0    ( &^&<E(XQ?^:!DX  'Y$ @ 3    879R;RUE>#$P,C5?
M-#8U+FAT;>U]:7/;2+;E]Q<Q_P'/_?J%%$'+DKQ4V:Y7$;)%5RO&);DEN7HZ
M)B8Z0" IH@T";"R2U;]^[I8;%HJ4)8NBV1^Z+)( $IDW;][EW'-_^<_#D_?G
M?_\T#/YR_OO'X-/G=Q^/W@=/GCY[]K?G[Y\].SP_Y"]>[.SN!>=%F)5)E>19
MF#Y[-CQ^$CR95-7LS;-G5U=7.U?/=_+BXMGYZ;-)-4U?/$OSO%0[<14_^?5_
M_<<O^!G]5X4Q_K=*JE3!/\++(G^JON[M[K_\QXM7+W?@=_#M,_WU+\_T!?_Y
M]&EP_%OP/L\N55&I(KA\N;.[L[_S<C=X^A1_,,KC:_CO?_PR"\KJ.E7_\Z12
M7ZNG89I<9&^*Y&)2O9V&Q462/1WE595/W^S.S"=5/J,_Z8HDBU56O=G]\]MQ
MGE5/KQ1>^V:4IS%_4";_5F_V]N'G].<XG";I]9OS9*K*X%A=!:?Y-,SDISB0
M-UE>3,.4;U[A'([A _@T4_RKR[!(0GAB(#]\\NOPZR09)56P!V_X\I=GLU_O
M_*WFCII>$*]\\NM_9Z-R]K8Q!/^)-!7.J")XCBJ^86I?S)_:X)W]_2WG]Y<P
MR,(IO,D__I)^V7_U<O_Y\]>OX.-GX:\'?YR>O#LZ&01'Q^]W^J?>?TF9B?T7
MWR12]__>^[O[N_!BAY_?#W\?'I\'GSX>'-^\MHTWDC]3-:[>[+W<>?[SG[V7
M?.I^UC6L)?:/3)2,O_WJ?<N+GWN+%JLH+T)473R0)[^>#=^?'YT<!WL[+.):
MT/'2^3>HX3V+-(&[-%ZQGLU4$84EWOZWX?'P]  UZNFGD[-A</(A./_+D";\
M;7 X_'!T?(2//],/7'81W!G_:>?5ZS_?^=PN(5;G$T7[*<C'007_GJ4@K4E)
M_[;[*8MV A; +*XC-86A!Y_PEUOXN__^T\_[^[MO\0/ZY][;;6]E\!FSNIC!
MH:(?\TD_)@]4%H[2QL,&01@<JC2\"@L5P.K-9 &]Y[W/I[,PN]:/#,(L#I*J
M#,[J49G$";RJH@=<P$14@?I7G537 =XRIH\3>I5@ E.97C_]5PW*89RH.)@5
M>3E3495<XFC'2:2*DNZMIK,TOU9PTZM)'N#(AJ!/$AS\T'P%-PZC2,TJ^3E-
M%5X-7\"=+Y-8X01,@ZNDFL!;PF<S&&@5%M<P(M!+JJS@'S1)\H+>7!Y5.&WP
M0DF4S,(*QEM-PDING60705E'DP"$N<RS4C\D3@IX(9#0\(MJW!QG;^^GM_!3
ME8[QG:Z2- W"LJSAWV$0I;!H19"@L,+T1+P*O(A)848L3ZHFSA++ \RRE%4>
M?9F 'H2Q#? 7A1I=PZ?)M$[AMC!TOJ<:@]#"[_/N<8[4)$S'=->R*E1V 3_*
M[-6Q*N%E<;8+-0WA765@W;-Y[HP3WR5#T<#Y-#(Z4G CF()+F&D8EYE9> !(
MP=1[TVD(=X&94T&IHKH <TOQQ.1UY;Y^$,YPO4*<YP#W@=U4L$W*&L45[G]:
M@V2]?/7\Y5:TO?5B6\_K[V'Q156P3T%X\2>E_N(X+./P7\$9/DA^Q;OI\6NH
M<9ZF^16MLBJF($L@ RFN3:S&H,UCG,A25;A"L-HC!3]^<V=O3>-.*M /T3?.
MPQ)OK97<03Q-L@0D/:SR0E2==\2UYQ8NGBIX1J 2W&4D&^]R4'M!SG]$(*\J
M*WDOPQ_3I*J4V;?FIV%0)O!F8>'\!L0?AR[[+1C7681W,3+8<VO<K5>3!#03
M*"_\39&4L&IP4997 <@P;3O8\%=Y<)S3*;+[^JW6JL$AZ:^\L)H7EPD>A&NU
M<]?G\(.LMUYN/)X67F98)'EY]_)RL/ -U%<ZJJY0&8.>&ZNBH*7-\60*"SAD
M:EI_.&@N<CBA8,'X-"5#RFC)@6S()(O2&@XX5D$G,Q*-@?QY $I/10F+QBE.
M$WQU"H='D41XCO&O/F=)Y^?R9O!]T?<5"MEA@B<L_&,(QSUH6-2I_*SU$Y/@
M/7C3?"BK)35#&%P5N#,S%"&5PN8J\BR)@CB/:CJ'0)G2D<P*%=>9%2_.,=D:
M)>UZ.,C@]<E^0YG)>"U81F!]?"GQ3MYA",J@]1JH'LIZ]$^T5N"&_G.C/(L3
M3]O07==I74GW+KF6CLX>.YK2M\+68Y:LY1\O*_$X%T=HK69@=IVJ2Y75.#DQ
M'7M[KW]^-2!C;(IG2LRZ!$TZL*8C.)U@E^!O^?,"'!.4[@*-KP'\>4$&+.T'
MM'7Q*:#J*OYL/6;>3'Q6UFD%W\GT!S?.OR@<F,LLK.H"9I]-:-=O@8&.\BP,
MQN@=H;$-3E>I%8!(,,\]>3?F%V@)H &1H*V198IL$6OQ@_<&Z@?6KH2# -?9
M,<OA$O!NPAE.Y-,B!'V&YQ[.1<AWP:?%.=V>W:?T&F\%"Z+_@K%/<]!9\"EZ
M&E5(]YR2X4V^0I?[8H>P5H+1>^XN>S#I(P3]S2K5=B8?*.+610I=\ZA0,;J5
MHY L29" L)S 4O$XQ(V[RNLT#B8A_'ZDX+2;A4FL'4LP60IVGMB,0*>?(P#B
M(?>^4[ %BYN3;4WA!'8&R;JM1#N4VT$R%FGEYTS"F,= 'F+,YR6,3<$ P0]V
MWG*^8* 4N%+AQ([O)EB,D?Y"/W067JBGHT*%7YZ&8]!K;\+T*KPNWUXE<36!
M:^$Q3_JE]X$"VJN\7_HVP@/MVR&H2 YU'3I69$<D]8:C-4;C#74O;0,G>@+.
M'HQ:F<=XCCILM#-6VO_]I[U7NV_W?EX/I6AS%-'L'WC=/_;^\7R/DQ3M[U[\
MX_E^WW=PW7/^3B]8,^2XJ(*][9@">X#CV0<JL88S'/WP*UA+/![!UKE,\KI,
M,=9GHJ0<08!9>FH^B<4X;48(\9<9.9>M\"UJ6GS6)&0-&CJ& M@122Y!!/T4
M<E[0 )@WE9WA2?>QV_1,\$4F,&(*+L$C:W!P,0 (;O'3"L3%OJFH;^=U0#:Z
M7H=MF#&_$\<.^;1+,*Z)A]TTC%4[*CB%W04REFJ3R"Z$L2LHIX5W $,DYX/'
MSLAZ["J] [Y&DS"[@*F+EK4N<.[.K WHWHG=@.<OVFX 7D2FOAC_UMJG&#;Y
MN&LUP1_"I)#X<?!'F-:+NUJRK]F>(AOZ.K@ K9_Q^6 788R/$$OY$A_A7QHK
M]/HIL M'Q$4.NQRNP,@N[S0O*/I6.Q&P7I/\"ER[8L#67^+>$[,F,84CR?;Z
M5YU7DLS()'K.Z(C@ -P]':9"X]#*RZ$"(Q!<ZX,:EI-<P+^:NYQ=EY6:#G00
M_K<T'\&]=!0>8]BX2G_/BR\R'B-\I/W8FLST&!Q'1<GO!GS.RLSP0TT8G-0&
M3 Z%\%06*:TIZ%E&26 V!W7$K #W"5^<]80\P<\SC5F\<=ZRO'$E:C"Z%)?U
M=@-+P[)BJ<"HH+*I*_J,5:28$CR(T!_#6NVX8SB_6L'NI4-Z4S4=J<(/X\LY
MAL=TF):Y?T!WGL+FO%J3F)%,,0>C;Q]9=T/:2_NT,+ET(26!ZP*V6]GV/W70
MU$T!>M;QR[5:$#?"3S-QB[.\.84,[[A&)1'VI!#X9)#<L!-J#H,B*;_@K> %
MQBJI,/_=$\,A[!;^M%!Z-==V:>S,W3:2 _/46FMWYDGKZZ2.B:(ZP?ZP;!_Z
ME&LW9D(@&7LRRW6.:KV7A/)DW[ DI6P80F9L%F.IQ3C#</(0S-K%_0\VB' 9
M@JUDFY67!*5#]BMA$4H,K(.;AXXT?LCG<UB6JFKF<\BZQG4I\S2)R18=A24#
MJN 9=::3%!)LQS0?1E2O!_!\& !:"\4%6LJ%RHN+,$O^+19OX=P5/W"/(QO=
M$1Q/8U1&0^9UA2]#5MUE3IG$&9CF!4F3^R6+83*=@@4(XZ6H>H)J5T31C<A+
M-#Z_XC#[/_," 5TR@B6?: *X @NS0":Y'_Q1IW0;MG4E"\232&$)W#GXDRD9
ML:#5,C#TP>6P.=%M[\7J&4,B9JG2OD7S%6EQNL3#\ZM\0>A>\($>*0STHLCK
M&1O2>+^HXC !KG.D"A@T_&8KN=QF0X4A(\ZT)VY4#R;_-LN^_ (C*@1=A"56
MNMN>;:W=#6M"JLL9E$P(HE,H#L2"839G!/+#P/I&@LFDB<:%#Q/K485S4=A+
M!/P?!J2U3V'$'RE[\"#3W''0/,@XY""\(5$@Q_.37^G _(1N>_\5#_<>>V\=
MEX*C4;#3G1A45]3) MXR<)>5P)-GX34J_H$Y7ZZ2DD(>!".EQ"7=SL?"@LIF
M5\9Z,NZI&P;6X%@O.TH2]B]V7Q\L:<JZEUK%'RL;L6V@,EB-7]1@UF 4"G/W
M=7HA .JU#..>,4H"G"^9ATDR6Q*UT;5;HSS-BS=_VJ7_=>R^)[^&B^8/LVO.
MELO@;)[%SZ\,.G(N R>99'+Q\652DBU#,$0T#"Q>I=R^,=[5:S%LJ9T+*DGH
MFE(7BZRF'%P&I0!V2:T,^)O,RZ*>:8,*QX$8I$H2/<UL#A@X55T&')<MV81H
M3PR%D]KI* (KZ??>7B^9UN'L)0-%L.93#-+CY21.HN?_:W<'I'C/:N!!0TH&
M7HPH_F==5IA0*_NC=,_7;\([H+MW ^O!F\X2Q;.H@3W-H![Z6HCM&>C4 ;P$
M7J*^HI^5"!*+$D"4-Y#MY4!36S#3;80$<920Y4!A^8^]/VY_+0BM;%@KRV7Q
M#V.X5A41GOGYI2!?S2>2='$O;L]K,$67$D9NS8ZLUF']YLP0T T^F8E\6C>M
M]_:LK"P@2H\N7B^I-3K]%J%ZM]S,A@FTWV^]04=+;/M.LCYA$+3@.+(O=U'/
MH'-GP@T#7:/1#3%<JT7I0^Y_2Q"SL2'&!:>U0K(L;!#SUO.X7O6R^_=3+WMP
M^/O1\='9^>D!/>7D@Y3*.I^?G 8'G\__<G)Z=/[WX/PD.!M^A#$%OYT>')\/
MAV?!P?%A<#@\'Y["%</@X&\'IX?K45Z[%6Y[$^P*U/-7%)=8;AU@NJT;*E$G
MA-K)75K5C03#,R9J*->JHL>M?>2U@ENC.Y_N3QA;)!WC353??/M! N>XQ:FV
M$>FP!L> HIJF0)G+F#B@4%8:Q^;4P#A%+X/ ^C@]-_ZV^D=1; ^YE,FB2XFA
M9*IA:F#C;)&N3"VFJ3@:B_X26GOXWY$&7L?]?K&)9&E+4QX]X""V^\SNNO!O
MBSNNPFHLLQPV%V@3@07]MS0900NN8WN><R?H<9GC_%8%A+H:L*^R\-8%A ,=
M'XCRZ4@#G61/PORIBQQVX\# ."@O<\U(T"*8P@\TOG\=A.'VTM#OSG"8-$+/
MB4\GG#]:F\<_89>WFB\4R&D>)^,NO=57'.F>#:X1/)!2J04/&#&C:?X'VKGI
MJL6DY']"I5;A-*?4HH&)B^+%*[3P#S0;!I,@*+U_^/DM5[VU61YWGNSY#Y$G
M>_@=MRH)IBW8^!T&YX)VZ0,.7'AL4LQL$:2'L 9:[TC8*!PEJ8 ,+D'3$%K"
M %KP@EE>Z&,2_URQ=]1GRTH-*K@+O_?A-^#6Y<(F0J/@WZ$78/B]@X#=BK8I
M#$PF8]P22ZD(,L$XSXRD@VID [)@[L-)]/BG>>%Y]F8+LQGY#*WPM!+7L5 S
MA;4'! 'DVG;,ERITA#7S X)BL/(: ^UA*Q!AZOYTF1-BI C.$U6&.R)2A/8G
M*&&B(]*8.^,$'D;LWS(_E]31]]-/-!]I#!8W!ZB!49KQ(LE@R,1R46[3@Z;(
MBL6#<&H8:' XK-*.RU1U][\ZW3$&-R66>R;EK*ZH5IUKS'MJU?E:,8TL=*"L
M9YAS+-4-CWWD<9L#FOU(LXJT613TNW:%5V!/CQ+&@R$J,M4, V4S2N*6_)',
M:)OTD<\>:,4[#S(V[?"N>)=8]S[+BUT419YTQ+Y<V[!G)+XM!C:[?.#AC6&M
MTF2::#G ':@L=PSK>2)>8^ZA@<FYVZL&YMYLB,BU.O[0S6?C9>F=XE(4.X$!
MB$P:<@)1'H]?GN([EZ<C^/<T,PR"7=)TW*(KRT3;>IM^0!\3W9ZI=Y(KY7,X
ML10B>S3D=6!%,DV,&B=%$"'Z=9J4)4F)KW-(#/&HB'0JT*]QH](VOSQQCFZW
MX2X>MM%H_*KZ2U^_;>E#K?E*V\XNHXPZ5TKB1YB4T?R6[I3+$9],1W51<EEQ
MHVX9;J"3R6*O1VF83 =!FI>P*>-P&G*YHOJ*'&_*.62[=QTXM*"&:<9#D/PB
M4]>E0%R"L<(R:WTHPDTMX)K>D>,=;!$B\@5I,27Q/\-%H#I.>($TO,(W>P9W
ML'JHB4LF)C-B2BS@&KBD-+*B^9+TN @K)JR?^C.4&G9TP':H"P*049@*Y\-J
MH!&) U,==,1K9)122.\OS46A9$E4=85Y^498V<B'Q1 _:@6C[ES!?,A!MB^T
M:C_5P)*R4]/D%8JK09&3IZH/ <^H% %$/%<1%M>H(D!R2,QRQHU?VVU.<I5H
MQ'B4UW"14 VUL0&=9+7YC-UM$!/*&5G&6:4S"JBZ=+RZ0S?"LZBB)T^1;J&,
M"L5;<:%$U!MWDK!,Q48BQ9]R!VLTD!.QM98L59DTK^_@RT4TOW#B4H2>@O)A
M)>1.YK4%Z2:DM_IP-H^"9TF<M"\JZL4SW2"]F[OI'TQCN1T[82R"AZO_ENLH
M0%?!5TDY0? 8$BJ7;B37 02!+Q37A7(1JIZ?(U\WD4_M@\),=,F:(Y3B+0ZI
MPX&DRE(C'(TSLV4)M9QA/J-L16R4D[/0H,3!\N)IJR9)*8X7F4W@CJ-CN"TL
M79Y'+S7Q'Q,.$35Y;5U.M8;#V? "^DO]LWSQ-X%3"T\F94M(G5.+]GJHJ0<T
MS/CY5K@=\-'+1\06+#.Q*8L909MLI% 8:)(QBMN.*+GD\3;28PS2I"2C0EYI
M[BK/75CT($=,1Z:)AJFLRY%?&'6:1_#%!6[>#,\>^$- T\CT"5(ZE;A);@F+
MR[EZM)$)ZZX3Q"1$8^;*P""PV4R"U13?PLB>[%B9&^;UNDSR5(RB!I='X=0R
M.7O5W]-.L0YLWH'!D \6O)ZGCFO*PJIFO4UW@O\>'YP='ORU4^87;DWP*#(:
M+]8VH[%>X*_G]P/^.CL_>?^_@Z.SL\\'[SX.@\_'A\-3IUW"[\/3WX:G9V^#
ML\_OSLZ/SC_C6#;(KFX;EL/51V59H[;I0QA-PZ_)M)[.2:0;PGHR\"[#)#5>
M+Y(/DO_2%[39&_RTNSO8W=V5N_8 X/'4-ZAK[Z <^;T?/B!E%O=^$)<73KEF
M:&8>CX.VV5IQ)CH(\/ 6P@8\'")\MY3, ^)5#/%F6.-I<=D4 .*4 ,=R*O">
M.;+CQ(;(WNN#<,.GX5<Z2+&$B\XZT'18">J8P=K0-^6NDB&#"84W+XEH4CO-
MA%O2*V-FP:\AT\&EV ,ACQQ[TGN;;1?T%RN9"S'(FO.]D(SX]$!N=,Q]74N)
M4;8>(UAY\'(R(7\:>!29/&(T$,RH[VS 9PV. W+?X6FN*#:?HIUZ)NS$&FJY
MN+$%O6(]S+!<SUA*X+\6U=#:R/*XQ3:HC$7<M7_C@M9(PRZ#:TUUT:$5>D3T
ML0<3[A[S^5[JKA(I&>I2Q8Y ^?4_8.$%.O"8C ?-JG'>)"[G FH/82)V/TG#
MLC2^RT!X"S2_K?Z[!-NTPI^#.&.ZR'YH:Q=,%P<VD'OZO\@(^!:#5J5]:P=2
M$P9VI&(.CCI_D.\N%CEG D/!"*&^T"=7$7Q),@_(;X9L3?-F/19Y.G&BB=+,
MA1D(& [#/&7A>]J?((\DT0@+YP:^1HS>2P*;3?2U6W#C*J^6VG8>B*/N%08F
MXF@1;PR^C2!DL16,I"5?S+21%-MU5VWNG'772M):,QV&'K645^K8=9=G*/PH
M[!>RNPD'I\3"\ \&DA 6Q1HAB653Z;6*O.X]/=I52%$<>"):3@L(IVL;9?2&
MF3?GG9:+R_)ACTLV+BP*UA:%.P^AS)?[@&[X*WO1&(MBG=1AQ)@\6NL9G2_B
M(RGP[KV8W-;;:BN'!$O'"<*+BX)3&HV!;24[:F?097?-*XU;8GS;Q&&DJ^5H
M"R_S=D(=9A!0J5JH!H#8]TB^B7&&SOLYHEUJ-=V29V>E.B3-8JJ]J=,?&YQG
MQZ5H:G%_,*Y@=F@-&M3JS*)NC5 9:E[ [7"C1SFFF/PH"IRV1>C\@FOLQ()L
MS:"SQSO)%XQM.X;[I0.3_Y>8;Y3697*I&L&J8%QPO,DY-PSYN[ZA-O9\Z\LF
MIRBO(YIOXHQS0/98>Z02D+>Q>++D6-'QO,[":ZW,0+9KHJ!K#O2QFVAW#U#X
MG4Y-%O@3DK!S2]K3F?41EP7C%GSTMN+4*/3U=&K -2[Q!FLDRD$H8?XEZ!#(
M<EAK> [(SM1XED("8.ZFMQE?.K8% 4:=-0_3@28@I*,_J6J/-TKN1S8)&C_R
MMYS3K8.9J:O%76/K5*<RS%GK^_<R*_TG8HAV*#->Z5L,- Y/SA5?#Y5D '&'
M0IE)T8Z8 /6U0"OC8>9>["Z[-IHX2O=7-"@MLQZ#QFH4K2G5.36*%M"3#66]
M)K+#3YL"8:%G:(^UE:I>81/@EA<V[GQ31.G54$8'NCE7:)"+-AK@AE[6*IK\
M<FVCR0\XJ:L";6:#-U67IMS1!80-: \M9H29V!]N>\<4ZR::6V0[&PL &U80
MXN3:NW%H-.O-BH%T 9U)KH[&7S_E;C4F%.CFIPN?=[-C/'B91'5AFB7LN?SH
M1%NY8VL [KR!,$4/=P4DK5IA:E%'3*4A)#E5%SDFT5E9T;#[!]R!E')/6VU2
MMKI?4JC",::<!>:3HM7%IU_@^@.:AIK1PKT&QM/4'G #4B$,SUO="(QM S1F
MH]^<4Z&V_PB[008A6XUXUIK$OP:J!A)P7FR;T"VU0V].18Z1,X&1M04P69QA
M 5?-O9(M'8J.J$3*H).V#K:M6'VZT3EK&=O=+LQB6W^KA87(_(V*!P1Z,J89
M1A@1%D<2SE+38EZ>3V5J14;(=NDGYI/ V!=EN,+6N^WY7JR$;3C4O/P[FO,=
M%=U B[(U79T$1B_5BR3ZFR,S:XO):MMXU7M)"<LO\! + F*IDCA+UO @M]\R
MR2AL(0HZ:,BLN=Q@^M@JI4YJ=BO;3B^DU#S%WC3:&VK]9B8_*2B126K:<7<B
ME-NFS1?-J^[SU=>)VHD8/)!Z\4ZO?M6PX/Z78Z SR^?Z,AN:%LK4O[B?3/WP
MX]%O1^^./AZ=_WTM$O"_::%MQ&JH@?U(L6!U( [OIG,[;@HX5PJFDR1=R\W8
M[Z)A.^<),"Q+O!:H5-NT%5UQL6[ML'ST:+TVU,O[A+Z<?,)G;-B*YA82-2/T
MB['GX*YD;AP_0#\GS7^ C)[.CWM:43OQ7@FYX-ST-S?H0/,S>X'_<+BE/]*;
MGHX)1SQ0V<P1:OJ9YBQ[S*+4/0\N4H*00'YYKYV81F1VG*=I?D5.:!>VFV*Y
M=*F@=W5TWN2)NXDREB+$Z!0.IWHU5F52M/)!CWL5[P%;,=26MLL'WE($#:?%
M!I2U%\ORY9+%=._[A27N)K[OKJXFE//Q4$O6H]K;M72/_52B/GNH;I6R1@'=
M5VL;T%VIC;HJ(5[,]-V>[V2>WI!]?0Z;=,48.UK*2U<:4ZC#TTI.WOIK;S@"
ME4J6]USHAKJ(5(S#-RH+KE6(^5 .?VFE8E6EW"@QA_&=D\NN2ZWRT".W>:MC
M/)P0MKY@)RC0LWJ\$+X7HZPDONPRXR')EJJDCEFBD,A5 ?<@1 CG3I<XKG0=
MD@WQD$PL8'2[3"$."Y #+#',/_/H?MS9:%CI8N6:$*")<Q7.9+N.=YXAZ(VS
MOY)]UFA6F[)U0=Z^V',*0J>UZ\R0P/@&^R,WNN^AKO9W$$D.O6K#[6:Y;Q+M
M< 5LSHBG)*-,_@#%]B(A%G;-S()@!8QW%'F61+A<$DDWZRK>@.7FIPCQM<:4
MM3(.7"6G$78^ ON3P&[$-O-A>/H5=/M:E\714#YJEV1*4U3J?+T?"N[.V>,/
M1#);::D?A[CU*!-B?YCAB"> X<.C, /;?J)<-*VE[2&5-*MTJ6-+]SUV[KHE
MN%;/)T5>7[#+BG6SX T)!!<V5"D5K3)'W+H-.Y98T64HCE.'7+H;C';!##Z/
MBF2DMCLY.]U$/*4]',_=2R-+G@WN:BICVC4:!,@L"NR^7MB,@3GTJ%D#T7[U
MNE)&5^!1][8)CGF$HK"P++R[=A)%RLB#D[DWW ,$.\4**YRNB*#M9MY$[5;Y
M!1LC%!))8$TN<TV,8TA1N-UD,"KR+TR)@&V59MC&0![>?+).0(6RNZ5?%F,2
M6KM:7Z5]?E]'VV)PEL*D69)D9B*:Y+F0HL #N]0]6E:Y4USN7:[!L_*:.M!D
MJZE;NRBC1B>DM#1:S5!\T.81 I#JVJG\=WXQ)]1DMB.7$IAHEL$L:#BI&<];
M;F;]R/?!P@2Z[U"^I>5$I@PZ2.G65V%1(!R"YZBSMZD6.THD@1JJHYN8BQ,I
MV6S4&HIAGL)8D;Z&3:#6703\TM9H)-5Q+I@$M"ZX65DOZF#GVY;Y80-%GPP,
MVM#SF52>:9WG'"X1'&(<RFO[W_1 JWW,3LXU) @3=YUE0$[_3R(TOG!,Q&Z^
M:F-=-D*-<]T1_6*,2J6'D.C0B\XJVS/4#%WJ:N1AA=/&U?V9TT!,A7%7DI*4
M7XM!T1W<=K."51N\-:H?7V]2C9!3!*55)?QVG+#?JIU!5G*%(J>-E]>CVIAG
M$@L%A:9A\,=/M#M;/M,?E]CJ#JX\ *=>%^MW-0&=^Z8)W'"4)M(6,#>7M J_
MW#G?[L>1A=DRA]"(C*W+)*_+]/HIFFMMS$3E&'RNC<<^R. &/:7ENK"5M69\
MG5YT*WQD,U?*[ O[/!Z1&?:\BN'&S!O*'(R#"'.H2L>X\'5I5I5Y]R0Z4$T2
MD!+T):\'!%"I0<G1RI77,(BI,1O<%VHT%N"C&0]2N88?1C4M<'[C2UZI49E4
MXKK"9R&C*R]S7#(4";@1P][Y!6<A6E:8!NA]KO8N+9&9NZPU7\%#:[_6>J4'
M?EK;],!Z02A>W2>$XN#3I]/A^R-N'W5Z]-M?SC=PBL7@%!U8Q-M!*VZNX_0#
MN/V(T&3]NCV&S>[,:]3T\5'OK_M&)]QJHW4@P6]:FEN"!^;T(>U$$CRVY;W[
MJE'"C)*7,FP99PLN<;^^%*NN4=39!&C&"KD288+3ZZX\62=PI8%961_>]WO(
MWIX;I-=[C_SSCA:Y"Z%F:H7:P+3NC&W79NUNQ]@'+9BC4C3)H@X8:6A Y[VZ
M:%*9%L+ \A?..0\"0RAZ%XVB?G34\D_W8W*?#L_.3X_>GP\/ [&^-]U6YZB3
MX["JV?3KZ32XK+W=<YOYUG;W16QK:T[CQA!;;"'<U\5-R;6553?ZV6E(UP&"
M](;ZWM_NV)J#.:$R78&/AKC33F'+)'C/I*O"J>+:1$Q5;AO6]&B2J$O#TP=*
M[ZD-&<4=5:B45Z%W!R_C]KK/#4(^&CVX6GOR[HUT.8HI;G<#(.NSCFKRYA/+
MJ6<[$>NVA850JM2).C>(FL)&%>.-$*:N(/)EKKNF-<=E ^HZ*0 _,AP\K>3G
M6%)-,S9IO7W>]>!^C5(E-CI\0ZWW0'HH>,1 C>Q!7!>F2[%SO91T2JEC%!6U
M<F#\XA#1_?P:1="359+J1DE.@*#Y %$#!3;<J):8 E]\,O')NI.Q%MQC5 +7
MB==99!5'W*67#3EG%-%$)1K%#J\NM:PW):LZ,E4>V8&)LE\'#8HOJ<3'@XVG
MDY15A_05MH:_F^_U)[#@X372_$ISCL';+_3NPJ,E\9M97I:J=/LOZ!?]M@&R
MR]0<I2M/9B4D-14/.C+KYH(!M_?J!#=(SPZ;OL0+S?KT':XFH;]>@?V?US:P
MOU*GZZI@X.\/]W_JG&2K#/QO*R?MB&.P "P U"LE[&;"%]E$[&#5NJ+.4A5?
MF [WJS(JGPU;91$%R(5Z-BF17SSF6+PFS1+ZB(CH4LW1@)0?U,1'GSP]AE ?
M3\S0(^6R(QHY -_.R)_T*-/$-AT0!X]J71^P>R_TP84@:JQ,QT2&@?4;JXUY
M"YF.39]M!@VRA+]E0")S&Q795G>FEQHW^V*+L+T7R!0A"QEWA#ZR?6_2;:XF
M=B'GOF4-<22Z)I^?:+ D>+D!+GHD&PRE,2\MD) 1HWW@'PH>- Z0 <=]:7+R
MX,YD9-K$23_+.YK@>.*#[8^,E$UHQQ:SNF[S:+SQ:01-<\VPX1M:26@?8'<6
M0AV4"::*PDP11L1!'[ISA[M@X04W!A&\&TF5P!NY04YN!\ @'H,A;EAI,AW.
M2UDOR/V"L1;6*6KT"O!PR;(",NFE,<9ZI MM03-:7J'9Y+I$X7$MTK+MN1G(
ML;#O>4TJ?1M/4%K_J@G0IXEM7:J;35E5ST'^A^T0WEK!Q8)HG26XLH1<">*$
MU0OZKVD$U>'-WA1#&C@!) >GZP:,W,YN6,NOSW6G/*K?KW?DRNQZVC7LP!L5
M J-W'#9^7W+TFWST)<IE9H-]"TZ$P)>_=3;\5AYZ9MC5<X(1I$UI^-;9#](\
M0P[T4=]4.:$WT@F"[^5S9$>@O3]XON#G[Y0O^'Q\M,'GW")=@,W#OCU;0'=9
M,EF UWBX'-ST0L&5:#9-"==S!QD*H=P1-*<#CV.PIDV<[LTYBA\M ?%028<.
MGZ?!0M@CFE+.$"O!&3L-EJ0B/:RX>D9S;!E?Y\7NZX.!7F+%5-,4)!?+@6/&
M@VZWC9[>%$T^()P&T(YX$TX]YW1Z0]1['?OF>_:]9=F,N+JO>$NZFOD$-#I#
MU\T -K=OK8?)QREPQKI)/K408E)U@C-Y*B#&'A&!2?\HC/YHYZFL[&U^WGD&
M]+?S9>2XX\@@A65JRBYY5*%;CS^NZ6"B KS(&8R;PZC;WG-CGR >O2O9;%^Z
MQ<9%MU-ZTLQ&U-W334C#M_(HP&[S4-K]0E,QK'3?"6/L6Z;0;BZ$K+,4IKTG
MB:V5SH*">/K\-KR!J_!O1.N8=^^=>5,$H2>;9JGD#,-8.5TN;)L>JK=D\A +
M$>T1/W/P]<('V]!!4O#N(+G3JA42&PSI2LXEC2+$21A+"!0N,,K23=5P/&ZA
M%BIKE1]YO;;YD4TVY%<#!2#%S3X][6K;#IV+JU'!L"U_16914D3U%+F'(ZD4
M8SWOZ=!2)[^3*4:]^4O;QK"[F;AC1E"L+\^ZS0GTKTNWH4=+I_4H&Q."TXRE
M7!UI*C>=[C9M36AID1R>^P',#&7?^RDTVJ'Z]?!+[Q[XO 1DYN &7$LSA-M!
MS6..EF:XW( XT 'T6Z]VRU5_QW?W=N+I@7D4)Z9/WZ' 4H(AC.$R3/$Y,@U=
M:!#7(7;ZSSJ/,4&Z/M^C05KIEZF:A,[N#9[:S3"\=2*8O!\ N*1"NL3[.R?P
M&("R;!:OG<+C0P2M6-B2\W1P,\G6E4DSZ3L;B6D^;WY""4NFS'??DDCTLX<_
M.N3[]?V$<#\?KS/H>\GB'^QF(8U5/V=%8R,M&Y[=HAZIN+\JK$27^D*=TIW
M.W)[:#<7?$,@#R..'2,3'3&7^KK_,C?XVTUZXAZE?;69XT(I#8SMX';J'%7?
MD%KE4DEF3F2,KX9EY=3[ZQ MS&\2^_G6@6 Y^JW+CKC&CZYH]G;O1],<'OUQ
M=#@\/@R&?_U\],?!Q^'Q^::@>ZY2ZK=2E]5%<^S=N>FBWNOFE'([84>M+-CX
M=J).C::Q9)QP-*D10]*YH&:7J&8GK_Z!VAP.#]9H-O"=J7V9*K=-;$J>@Z$I
M&H-T?/4C60O/44.+V8Y2TDG9 [Z@6@+QTN4%-\52B?8&KT/%:SH2A3<=!//2
M2W.$Q.9(FA,_'Q%G;JG,+4OKBLFT:E<1T6DW3B9)142@'*J2+?07%I-%H84D
M$QL7S>)V3W@1I('(PC2\=G%.NN; 7N>,OSN2JY\X=?L%SF4CU!6>WI7:/&")
M-01T,C[J?IY>:[Y$LX/\>\RHC01RS^1M-)IN(MZ]3.V5;Z=^-4]?1V][DN*1
M=@TJMW]<@.0YPA 8:O:GPB,Q7GA?Z0W5N6\Z"]Z<?:.I\K@/%FD>FO'^Q[42
MA!34:(4I"J<^B R/[H(;M$J<)79ZLB\^%O5UEA1D2XZ4QO\PW#7,LIHZK5D=
M4(93U:P[;CQ_O<H+]G;7-GZ^4A;/JD34,9%[/_4%[7#1JKSSVH2M2AVWNM'Z
M>#1AJMLY,VOF1.[=CQ-YW@;1>J7VCUNCWH,/V9BP^5'OWB+)O3U0LGJ_2]5N
M>T.GR5@A^FX08#,EV!9.H]#.)B5D2/GI'[*<_(_FESW SR]J>$02FH)1TZBY
MZR9)%H6S,(*Y\";A.&^-=$YAUJ(51U2U:PH?..^*Z)21, C;=R6F4JSB5F6D
MA(<H1D6=C&K64H47G0/C/Y\B]BV2)MS<)[Q9-M'U6JS0!]V=%_#6515&$VX,
MRQS@.I26JDM#3,1-8HF<&_G:ZP(!1>B Z:I6N.5EDDLO:78%'(I0)(S%BR_S
M9$,UUJ;R\X[I@Z@O876<5WA(&?^_N6G#[4$7'%2@8RYJC,N-V2FZR2Q @NDB
M%AT >] X706W,3;%!KIYA^F,VLK.;H$$2BQ)21?6;?9VM1@YJL0G2L7J*_M=
M,@7O'T$) :]Z,%6X)07U6=1E51K2UY'*U#BQ]0W-*[B!-.X'J6@J>:\D&G[K
M7T#0!KPOJ3-]V:#!PE Y%?D8\T%&]]*UG5K6!H<R1CD(!BD2U!?"0=T3P:$F
M=M1%4M>0-+D/F[2[62[:DEK[Z(4<*4_9>5H,)Y%2&8]]U]X]D.(#B\7O)!9=
MV_4#*_$9D3W;O+]SQ@YT^8HG8IJ?GM7G5.$"MPZV:)+@>556:B;_Q%_$\F\0
M2U+H^+7^-WUOOICE-9(5X\0AOE#^+),11G8'098H9#;)U&RBP B8TFGV%&<L
MA#_'H?<G&,+FWW%8PYHY7XX*_UJ,)6&/3?N))>P.8R2AOE3VD,/MR)6D8!66
M#! J^M 8$WP)8NG><D[?$(G/PI:)@/6.K"KL=H>O2R5/*LEO<"_@:+5MM?:R
MQ<S(JB9*J"LTO"*<V/B4,6[J4*.O%WH4PL&+/*4/83^$%P8= Q:*HA9@<A;S
MFU)0_GKAV^=7V=P7$3(:_1*/GGGH[K$EAPH-1>-2OM,K7W0:W>=>+8)E^^ZN
MWZ#*#R>Q0DW*C;J>@.E.Z0H"3C?Z"3,ZB(>&N.^1'1<'$/6?"<,*#46IPQY6
M6-PX[CL)<]JN/9(\EH8M;*PVVLLYFS)6H"RZH^BQ,X?&5D0\(J/,O1(B.E5%
MF_9CNSW.(.:^P?=@YAB#0+P1L7V$->3>W)E)-Y,K!R6(AZ(\E^O1" >3^UMO
MXDF1@%]C+O9<(D^3P+/-U'1-+_'^;[+8^_<4@#CX/\'?CL[_\I>3CX='Q[]M
MP@[=RE!W;($=\1O+9V?DP55K)-2#OC*.D PFBTFY- 3<CO?A<>9:7H<IG+9@
M_IO=7ME,[#@IRDK:<)9B=T@G*]E<>4F?YU/5,!=("7U0B#5)]2^J\*LQ\ ;<
MRX/U_'HE6/;6-L&R2:?\:A+%E%O_HMRN6*6MRLT+(]S^J6NC VX^%/>E;!9T
M0F!+<T0I1PH.;KGC!)8,X1HJ$' )Q!>FGCLJ;3&L-#';PK:&6[*%?I@;RQ<=
M5/4;9^2?^+!W+M^(ZXAY4!B]36]$C"ZNR>2^8JNXK@]BXHS:'/+2BDAJ#37I
MG*(4"A/+C_+\"SH!TO21(>PN?<EV$X:2>)2P7G1!:L5 N[F=DNP@T!0B;A:2
M#J?8SF+JUN&<O/M G^ULU@\R/7,610?2>LJ\/:BF*?HTXMIB%-&[K']E[9+V
M!(S1YJVK25XD_]9>N!/ ,EVRF-RHLTN:@*R\Z+9Q*L*^IGB9T^JNC;'9"@V]
MD*E==%\09)V= 15ON_ S?MOKUN_9AL"=.K_J1'YG%%57B[YI^#69UE/2@C7K
M49C^0@A9N&1+E:6Q7-#V@?%FBE*6K'9#C)L'::+S8%B_6E._N*""$YB 0(LT
M\T[+7$N!3A3PHCB: +92'-(XN=6).R_U3&LN(TOM:9L; VO=<]!?DVJFM=G\
MU<%-)YH]8DIQDLSR:U[ZI:T29!)CSS?Q4+3!UP(IKMKT#(OL&C.Y([70#LJ\
MWI-7:*"2,XD*&TD YO>7[-\],+4F,IY>4TK+5BZKN'1(QTI$OC-1ENX\YA=8
M8Z(^TS*YU)[YX9W1Y_?4(LNK4E^?//AY@[TYK!R93DIWNQ-G1596":A297J[
MYAFV<6*@JBDM=X'_.J*.\BH: \/JPD'FS>N6:1E+?](@Y'*=7?/96)J\^@Z,
MU%('>,0:EI&R#ZG#33^1V08W)?ZWC[7#8^AH9'LH/\3VN<:!ZEVJ(:7V'7&B
M=4B/,#9F'DH%BHOU'*L/1L_H.=VZ>5+9]C36BB0!">&J"S@0WVD>:"9')PF7
M>98T8,QRGW_ IYN8%4EN6)LM&0V/*E A[$76OTCA729?@RF([D0*JC.\Y'I.
MR+-GQL@%(EKLWC@I' ]UQ9E%WRN1>&D:7K>, ^P4:GZB7Y>>*U:Z%5";E("M
M$:958LG@7,H9..BXHKRS]U!;UC[4!7HW0OOFU?*BS#E"YA#A8I/O%"MW<)T9
MDS+'$?LV)AKO?'FU\_QE\WQQ/GL$Y\N+>PIV#D]_/SKFWHLG'X+A[Y\^GOS]
M]^'Q^2 X/STX/OLP/!T$'X<'?PSQZX-W9\/C]\-!,#Q_OR8.WSW@L7Q0XM"
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MXA=<UIHE J:0DJ*YM'Q"UP]+Q?AN(,QHYZ@(/@U9@*BM51#&\'18#UEGLBW
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M+"8D"1OPEF2#X;7"Q284\TZH%F[U1!+/*PIF_?]JD];<XD*F)"D=4CI'?6S
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M@;[!.5# XXF7AB 607?0!!!"8%U[$Z)2_%CVG[&$98.@ 2%7 J)Y !G 1T_
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MS1MIL0 $AR+@K(7-]L6*F3J]D*+>D[U??Y'WFS'UA.$_>BF6B<\U+3@B09C
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MZM;_Z%N7U>P13?N\JEC )@P+9%1XC36CK'"NZ";[&4H/39"'W_81!P?B<+@
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M@TO9L4QW&;(OR-I5N.I_7--7VW8Q\"]UI@4O7!^7"B@[EPQLJ=O;45"LP23
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M1SLKB/]&^18OC[BJ ]GS])(\/-2&02>_?X_0\3[+NHQ9U::ID>FBD7Z(?I#
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MQJ)9'L3%U2[=?@GR&V4,?$.C,I0^<9( .35%D0U[@U=PL,\/IN=ED>P%5]&
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MG6;I68U9/R0D7*4LZ11(SJRWOQ.8W<\E1^;%8OJ6U)<!AY)%2_4^P"ECESR
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M+@[Q6++J\KV:CILSL+=!N&A $\:ZTU%[_T=LB7Y;:;]183ZGF^OL\TJ'O?'
MK.QY<G](7E5;-$!;O&3LES^E$4;SZZCGC68K K^KO%^MKRY:OZ+%K-B=;A!L
M1)IY8EHLP/GW[L/2\=1_SWM9I_W#^@MXO/KO7%>YF__^4>JO0[O)FK^2A]RT
M9I1+I='KQN*%G\(/]?*LZ:-UWJH50Q8];%X-M)NE-WE9&!(#J7$S9_M/F2$O
M!IXQR+)\Z;$?/QU^^2JK;[FN>KRM'FZ9R2U5K*3<HEA0E#[!>?_^7F/@=(1!
M 7"73U9V5[HLE>(VM>]+MZ"4JDT--44E8H.ONXO(BBTE,W6?<&K^)61'H&(E
MJP.'5):>H7*OE..UT'P[R$P(Y/7ZJ60H0?K+JVNB]8;';UY"0^P_=<!$<R7#
M5J</NYZX@!\-E+*?E0XRC&3;P6K&I\I/\_A9,R9338%6(C*=]KU/X'SCT9=?
M31NT+:?DO+4\=(5]</"D4RJ6=SB+^VI ]3!V#YCN5$<78W' +L_<'IS4+J9D
MJN]MBJ6./WK,%2^S,$^ODM1E1@.6P\96+[L,'I#0F?X65?>U1BC#HBIBLA=3
M,$G$^=+4P9.5!MOPC*GXM^GRTNFTF<D2N1;EO*ZO3"3H$V=U+@]%+T/&R&-<
MR>\/Y_!\(5OV8NSG"Q2 "_T%11$PW7JJBP,-( P(6VCK8Y)?<R6S:Y3L"S<H
M=AJ,T-;/*)7I03)0 L\OYX&W9W(PQNJQ[4GD/D/6^<)+R%R-X*RGH$8_\=+B
M<U[R6YL>N#GN5LS>'A+61T6%9>'G_>X.MX9$^5GE![P3>;<8M2U8Y<W=.$D'
M;1DLYU,!(+SFXSU=<YM%@>'PC<M>WV+J,I;YL0:GU-6@/.GG!9F>J1MH@-6[
M[FX!FYM=1@5 6O(R<7)4+Q<: !I=,G.F>Z2=X /V])R]23ZQ71U ,;B<:--?
M9?DDN;,+Y^7&UG/*HMJTFNZW5B;*95&="4=7I\]R9RC+@D)O.3SND)' ?F>H
MG#@S,JT4Z:GS53$U5!Q<?9CI0N!:/CD6Q7W9C,W=C$^%4"54W;N@$X8$!.K9
M,S)6CJM)D[58DX[2ZYF:3UC+4- /:GQ*(G CO(BP'%O>)+)0P[&OYOC:")2T
M-0)<T&1[#:  .*6G9&N$US';,D0V&I$_?&8;\>0MH:W>D?"5B(QNLZ)"R$VY
M^N?4\ C2, L]K&#,P/#]'VROT](P2Z@-ACJ0T;B[<,^DOH7M4F 0#S[](VR"
M;YS <8ENL7JRB*(#DRR;&9-O',3J?V^NP5^../ 0-$_@E]_G.BZG:$#TJ]%3
M_-]5W(\DP,9D/]+!_$<(R3=&['F:^M_Y;?9_RHA-\B9L#.*[R1C9KSO+5L0;
MG%Z%"]*^MN\^:4'H/W4J%V.>Y)D-L1V +K'1F!@KGC^=5O4=G7'9H;+M!O?P
MC[J8-?:O-#A7A;(^#]_18(8V:4VZRZ&&^Z=&<1FBKP5,7BC06=<T56,H41B&
MJ4CYCPS:6J.<[HFJ65?!?-7WN!18PCUYNNS*]3O7A/%](]-.WNQ,^UTZ&79.
MM; ?-8>-'A=05V!)2,K5G\+)HV:R-@Z]JQ+,C4F?=F0K>U9K]N8IX+2HS#I+
M:WHO#!@Y"P<*=+WDJ^ ,]VP"G+NC2I?=KOA<J?1T"NN\X^IZ*T/,L]GMS:KA
MM)^HF'WJE&&7:*%P9^]M(>HS2(./EYRF<TE\()O&DJUV'W6 MM/8C?=>7=GC
M'Y)Z.EKI@UJ#2E>$([JZ,J*65LO61=]1T>/*M?9J 8E=/$"1JXM%C V>P]8?
M#_AMI(IK/@^HC^WI+I@CM"7=O.YDEYH/!5@*9D_BQ@M>F2O;,K.@S"]WM=M=
MHS0O]WLB<G1W>9>_W<5=HGR8RQKN^@S:N>AD>MA6H/(D@GY01V061FBX,GR#
M5X5#F7'U<P*01UI4,H!I?JN6@[7?JEE,K<U@S,#<Z[; 6%Y%#'5@KMU=$3JW
MS1JUSR[ZZYT IJ$68=-7&8BPQD:#-]<>A4QD3CJMR"9GX-]0#6OHM]#HP5-Z
M_6DF[O%UU_FQ;,=DK894MXQ\F)I,7'(7:0E)O<D>5ROJ)->$1J[84EN@_6M\
MZ^# )I)]3D3.6_NTQE8&Z,/P"AAAOBI.+'#<Z?EIXCQC5EE6_=YZEPX_FZ.1
M-6@[*4](0J/4GS(/59#9:!GC^+KR"D]-N.D[J*DN[>V*P5)" HXQG\S1M"#;
MO4UZ>MK#Z2$CR19.F0Y%/;^V^9L'XJ4]LD04"IRM9C -O7X[%8W;9BH(2=&)
M0)C98;;71<D8T7Y!W/YG=.E::("WH.;XD40VX>?E<^,EE&ZS=4]*.Z&?<G2F
M7$BA4?4TO7BMF&N>&9LE 5'$2?PY$9&&G3KHV9.UT^8IF)-#_"TZ]ON1:B@W
M'>ED\S[SLCN71=*LGX$U#&L+O/G/KC<,:T*N3[N;?NY9-;KBD[%VQ-LQ%H&H
MU#9DF6K%WB756= \86W7<UAK2!04Y(O,6"15,W;M_SNZ+?V<5_]WSJO_.$>W
M7WK,\).9@JN-<^O5GYBJ0R<>O*E_B!\7YYS?@R(MC3J_P@7<[D # MT^OE02
M=AA\=BC$UA^7Z>"R2+8!WDG/A:WP8/1_+QVD.1K@P_D<8SSZ0\_V8/,&YTY0
M>^ 3C<+Y<)U"-* AL@BCWC>WGI^8[*;^()?.*'5"S$>Y-4C-&*/PX^IWHM[=
MH#M>!+= $>IPDP.*"C0 QH[B\W2"OCHB$Z$5DG:G0[*"N$^O&8*G([[%),TJ
MZH%[G\ZCD 6(OL,QL<81S8W? B<[;'Y,^!/;3VQ_4FQ0YJF,X51$SFQ>N6^)
MS.#3P1?QWI!8RKO8S+2E)3"L#<B[\T+;-C0@@1W%']/<KT5=,'[(VI?()@O]
MFY7BS\3@8/X7:\N?V'YB^_M@^V5;:03\G0PX37FC 0A*8;PBJ_91ULJZ&,>C
M,)*9VE3\,/Z1$=.\63$;WXM\U^:_78 ^!JZ=Y\\6_Y-@^]7WQ^+OW_>PQ:P*
M?O.LT>T21#[M[*,\KF-5PEO7O"*Z($T#62J1'/! 5AF=%]_4>HO!WZNH_::W
M4!1^=&E$T6P13W]F%A,:H&LI;%6VU13Q%L*2=O</V+?]X?B-_>1E+WPTH$U#
M$PW(9\6@I3S"Q6C5[\![I$/ =<BW +>W?QBQU_V>7Q-?MOZU!WD2]A\6@70S
M$]RN!P>N-P"72D>'OSLKN3#:]\>'0%W8I_XAM :T:/Z=ZV7O)05VZI 8%59@
MM4K*ZYN+S,?F>V%G):<L%Q+4P4[0GY?_ZG+-V3PQ&T+XXA7@P+>N[7:@\*M@
M3H"]"9:F0$[V@MDQSB]=W00CR%AP1P4E.59P_NH;B5]Q[R71--0F+49<HC3@
M7H?*5A^F%(L#U7^-R]CXNUID'J0+A">N_B?#YB',D3#N)X8VS38GQ":HNJ<H
MQ[%? N( WWJE;'CB9&;?@VO?WH"K_/F8)RF@YU_FLJ%RC#\:@ ?6IY@_$^=>
M*IT8)LI  ]H?PV$;-#?V]0&;?YI7^N>\_&N"C5_%H/-=('6^_K5)]M;3*\IL
M^M^1;PQUB^8W-4\:LJ1 WK[](SY7_9>I*@ALO@_[-BN($66>ITK$-ISHL0*1
MU5<\\)9K,L46R\G&Z$?3V>#>.SVH,\N53-\L==$^_9L=N7<V>JQ2:A11-[PP
M4],#?^#9YJ?O[X1E:6^HE/O9CYL7$']_'3CKO)9X<+48#:@;@V+NH9VB^9MR
MQ-,-/KN[.(N507:Y$4:GF><7.=" [;+4[^\_C;"NWYR=.!IC;X)]+_[[^]>T
MJK%_POD)YX^%TSW^5]D'/,[G@!^&IYC[E>/%$VUP;Y(KK7Q5Z;"?*I5MV7S$
M0C=*[G'-\RA+5R%O;\1KC+QR<U#G [AA>PBX0F2&!GB6TNU4'ZJ<7M9# Z:M
MM [9)GW^:=ON)YR?</[?<$#O!\ +GT$F1P3^)WFVP.]&A/XT@8>4X >D:[9E
MV)?@=L;0K(<,;WS5IHJS_+*4[.7)* O#BL2,(2RY^'_H.OOW8B#Z=NPO(5*M
MZSB,\,[$E996#%QC?7D-K$&]ELO*JN6\$Q_;%1^G5'"3(1^]:SCMM.C7E;_'
MYCN5"UC0L;?A3K2A3C)U\VV%?] (5P_3OZNN-$JL)DV&]6\.21I&<#XS)]QL
M7MVX"P\(4@H/"D@LW.#ISJ:9W<SN6AKT!9,+"1>V^\M8*RJJ>9@2ZJ5)U2G^
MZ)2,_X1A8>R#7CC@ML9/X.%,5'?IXM :\#)LX<D@<'T #3#3G\-8RWA+-KZ(
M'AO,:V_]W417_Z!N21AG]ES%__W7>DW+;'EF@->.3B]L3 "X?V+S;VR#2YMN
MS:7 ]U':5V=IEY!-N9,7S%K ^NO@63E+\,&-;R.;LO;10]9VV03MWH5,5J83
MK:\V_KRM@H$,+FFR)JQ"VI<=R-;'MC^$-220E@X:3W3CR!U=&1^2[UDUOC0'
M)5":]7Q2LKH<Y*R%7WOA4LBV<?FN(DJ^.?'<"6/#/+!D:^!4#UI1#3/<SH*[
MR#:US]4R%O1/?+D4/F;@^-2E8.ZA\8WA&X\\Q3(Y(.--']<16B;O @B]&2Z5
M-IKMD34B#3$MM <\G:<Q50Z@O5V?A\^HKA 3I3%\V$/,Y#]KF\=?&:) [_JD
M\-@OSV[7PZA_7.;L66019Z>0W&9(^3WWL" LI?F>$T8I5$4CTL<>>,5!A*II
MD!\OQV4I5$!W?I_T+F A@="+52-3952H_64K:V>\-&6520N(/?:P?)!ON#@P
MEO9QF)=XZL52+T9$/%_@I8V<2XI'B(Y<R,CXMB%="XU ?VN3MMW8E^#H)*P&
MK@LB[[N<CW>D['?2GR>P+(:\),VI>BLQG\RO3!K%*)=')ZF9<9(RU1J.!.Z^
M12CO[8YU;7D-?DID-[7&.3HN<(8CY3,18,4;8][59'YM[R)-5]@[Q/'TQB:G
MU^:6QFZ6M=XTX;ED&KD:D[4+.5_:-=3FZ%H8;TIC61&\!H^P:,FG#]MF(GZ5
M;H_I5S[#=/$AR1U6Q:CRKN6]\7-0KZC(G!&PZ=2E^G-PW*N5"5XZ*6,CJWDT
MX*I4$E/D&!7OU3(>EDIFZKC#=;WIJZ7D9;OO1IL6#"9:&BVV@V3GFY4>B1I2
MJ97"B%IREN2K)[8.@1"!&!U(1I]9T>VGP?0J2Z_N8]]OK=7\C*@DR)QC<>A4
M8I*%6#AQ3-G</QR'KAO;SG_$[VF:E+F !G!RJ8%WAPJ<!VI84RS +T!&XI<C
M)YXP7A5T:&6N59)3R[Q:5FIN&R$OGW8D\"D%,B,L^7<WL/Y9N0"-4W<443(T
M4JA:X)%C 5>!&H(1,ZD08#J$<>*9\# Y$&%RST.PQ=V35,U8Z'<'KO[N3]>_
M98A_-['E6M&AQ!G0 /M3>-=?>T%X+'(C(Q!HP 8'[/2N3E_I1P^QU-CI,AKA
M\<W;R![!3JIR,Z&>/(MA:;>.3,[(%H>96?OE'G_8GD@[&F 8=H)[8/+>S6/,
MK]'A^FTGO\[PUT)?+F/F0&X^?&:UN![7S/$>5HJIW;<@J4X5[LZ1:I[ BGDR
M%>(\/&[O"$4]DZS91 (/<*:+R:/*PL'Y1'SFCX'$[T:N79<[R'=N<6M"W=KE
MM;0S$*OA]=&]%*1P:?BPP,WF"L)Q"]4_IE00/;QE>^*0$R5\)<REK[0EWNIV
M@)52'S3<#7?H:99,IG!0KI^,M6A>'!0*7(@@/)TGW".+Q;S#!S'0<R>3!5"_
M-0>G]0:JW=:&.A)QJ?-YQXS#7/23#-W5D"+=L6;K?+L&_DO\?F7&[0-E&P.C
M=8[TK74"X#9[)4PC@\^C<VK,C>=G%9HI(TTS RYL7,CW10.D!QR%R!776;AH
MKI"VO9[1JIB!4)!?G=?ZH&/^X/ZE_KB<S*O-G&\TCF.W/ YWEIOA7D2U=:"1
M#-M7$ @](%A"S,YS/0E1FC+1XVHQ1R47(\<0@$-Q;9,^ ]2?6"].';HQ*1!A
M_9R9.>C>P:J!S!1Y^9G(PT""R6K<!=,!LMQ"M2-(FG:MG*8)-[M9A!Y2LS=E
M9P['8?\\E=K@XM7PK,?WA0Z0[!JS/1_X$XE5.,IC''.U"PM(6FF_EB?E1ZI<
M<K'40R[U6QV?72-LLS6(A/?J??D\+D7-P_TP4/(- K?;T<*N].K:602%\FGQ
M<@\IN-VH"M,2)=\V;.K>YXYZ --4W&P8!S:G9F-M@UOP2-9C^K/R]#35%%/8
MXJ@-/#%K:K[]@__.1DB!* +3U>Z\I#L\33S%&TX>_D'#6KE4G[;")ARJ_#:U
MP 8+2?I*!_6-<K4JX+\UL_W&@<T\E3& T:I +&@ N;'_(2<2;PDSABP?_"'[
M')^0&'LDQ$\5T\PJY_&@SIP?=*QF*.K&UVG\W81I:5*=H-_MIO^[W?I_U*'J
M?B3>!9B:HP&[N\QGB? R$)4L&@#] )Q E1;K:R'>^V)T:NWG?TF^0+9MDU=R
M9B\VT4GZ8*98TXDR+^A3/ER'_:Z4[W@"4'BAQEG$:')DE8@N1@?K]?%],L7&
MV1JQ>2$^.(,T[ZS]="\:(+P91,X%%3O?W%RPK^I2B4H>9RK/:/=ZJ;Z)WW9_
M;\<^L:/DWILP8_OYJ\K0.9"2]FT?NYN%$U#4YWR8[I#Z0&/1-&OW"NJ1,U-*
M!HT^ 1UHGXV?/S1*LCF_---X4BROM%^>U\P.X-*JGSW%T1L!*4N]?FLF0!"A
M3=>X?L6 /5!2ZV3Y*=G[->"Y:[Y]8^0I9TNJ"W_D!U62XJ]19D*GD-$G%O9*
M1J54+\TV,\TWLU9476*E*X-ER9-)>#;;4$]+WUQ^9L?>6:-A,?N)P]3JCFY@
MRU:(@B'1=GNSLQ>E16(C7$G<HY%BL0JNM2)#.B1G8KPX\&DBSF0&],T3N%#%
MWX&,@4;AEJPQ%9+]"1HP5-Y?D]DH,,;8O#@"-R93.Q9M5[!/_)3NEXH;$I[I
M*4*0)R^=5I7@9S-G1;DF02WL_:BUG/X$ K-WQHHO-IR0H_>YHM<C86PVEZ."
M/S[V<.QA86S@Q/MTKJO'"W-55$O1*,JMBLDE"@V1JD.RM)W>DN=4H]6@2IX<
M3HT5$+C!* DS_!6XVV$-)1RE(IS2@F.&::GG88;.WDC^M#5]8D.C,=?0R%ME
M1W1M<*>"IQ[T<R(&_C<<R\.7+41-D\E4\&4T'&:F>;>X0?QDK(RF Q8X &(Y
M@"-3+,F'._+8,JJ@^-UF9*0QW?,/'35?2>@'8*N&#JN571*.@N'A3Q?,P0WR
MJ>>9&VC &)%K9<N4V[F;=M+M<-Y@B04B8X\ZDD)Q_+,G@77CBR<)+^9/GI;4
M,.?P['CW/SJ+&=*]Z E@T)%^)"KDFE6VL?$U65NGI%;I@X=6<B.[+%,J<54<
MT;MZ9/:D;\&3;)LSLHZNXFTK;&AW3:)R75_J?MK@!D-UJ"RC4YN.><'#G8(C
MADBH./1&1/6'ZX4,=$U#<W<_IU.-HLB9(BR4#H0I65(J"()_SGC_DC/>[=N:
M8;W78O3?[K$R%T>RQ#$$I4L1Q6D8O!,M6]>--*%0_-1J/OSTQFU5LW+ #F&Z
M;!Y(1V<LO2R=*>X(2@1(\++Y2NBV+<HSF]%+;L^QSA>:6),3@%M;8'%)OS^M
M9(KH Y9AP,QPUF$5SZ=0?4[NQ17;LYL5 E/5(ZV[8E6@.B*#MLIG$KPH0\C<
M,OSYX($24-9P6^_N=!OXGG%(\LK>:HS@D>?73N& UY+S[\8^'Q1<!)NML[MS
M]BM2$G=2J!-8FNND8[&T;VSYJ<?]FPN_<-=+OC9.55M*@%?M>E<-3[+>>DS@
MAK/[3C1[86$W:$A$1W"VYUIG\I1A#V.' M,*F5PKOP\N,CBV-K8P7<&C/RB&
M'G+&($Z^*QCQ23^O.4M(^TEBU* [=-78/[O'K0H8FYK2R5,O\5J"#/N#J @M
MS#RK1EJ8.LW;C'9(_%VFX:J^Y9CA1.X985N][9M5+?T:RQ9^NJ9RHV9<:_SF
MEU_S"+:;!HRJUHYRR.H:?7&Q@6_R-1JJ\",KG=VBO,RV3M0# ZB'LSYWA*RQ
MQ^\,^S[OS>=Z'KK(2.* F_84XA*>+% +WP1=SA)DR<R^'U[JUX!BWG/$TZHH
M8R![<7-^4,=QKD5V)W!<1D(2HAGT<8(5Q;BSX':>S6)+NIL8*GFO-?U! FVU
M.%F8;,PAPU. O!,MX-;\07:\B^9"%O,V<\$)A&^1P#P]E>H_.':PH2\,\IXV
M=!-3/GAEVXW#SV%\<>BQ4@C(EP^U9GWI!%[V8:;-8;S0W?G5L+-4JN #3\N3
ME8'L=5833PX5CD4L/-TPO=@F@> QV=3QW"29R]&JKVRW0 F[=$==TS[>535W
M6)_&70=<"C M+)#)/H:KKI';Z4]PK2Q0B$\==BD2)PW-E;@?\L<S,QS>)=[B
M1CSPV%POWT"L3Q5YT/;JN2AOK>WQ'F%F5UZ?;ED%9R3[ZO&)E';8AFM/1 \:
MD'.07S6N6%K:/ZPB5_^:J8$0K [2CV"5(>!QKJXD"I@(LX3+>/F+!WZRX*T-
M+)*V":7!?2U+]A5!^G*7/"42.8[_A79DLED_Z@L)P_81C;K<+?M]9F!_E1*>
M1%FOU;6[Y,ZF42%58<J.K)(DJA$G,$" &2M[CNY0"H2]Y_<9K3^-U7\B8_4/
M<]E?3KP)7%!ZAX)I_.*"(OQK%Q07OG@L68,Q0A]'(&D7G_!3F9Z+OF">AAV7
MO&F$IC@'&I! #D-<9Q]NT,ZDE)>/TTIF%DE[%:[CC ;@^C4G[C<,HP$7L>AV
M/GGHH0&BG."=6SHJ<%8P+^^1_<;?O$WM$&+R]=UH3V&#FM$TDHV.'-R#9X*\
M2@IN2-XU0^Z4H@%?WLA^DT1H)MZ*(^T,_O[9'Z7JIB/;Q.+.J!G))M& [Q__
M3JSGTZC]6S\Q_<3T#\'4^,T'7R_70VP8*?;89GONS6,"$E86T[ !2)TXD4ON
MZX?D-6C P)?<5./$DK E \P<JFR8I3O+DK^-(B/T!R[[%* NXP)G51'%*!=]
M-&#F09Y7H>))"&VW9Q Q9 L-^.X_J=\](8ZY*=A=Z.B^ GLU&N C-==S,@M"
M ]Y<A'XWM%E.F[F7)#:61_Y&<:GKI+!H[.)$4^^4:MCWS_XH-5<=]>PGII^8
M_C&8#NG>FNS=7:,[7$4#BO.>_3!TC8 -F\3'C5-\@P>;$FK6Q&T\5\=]\5BI
MAYD$<IF5^YP'Q[P9TIV@QA@MK$/DC]S ^R]LXK'HCK2#V.\5!>M0:YVR9+(*
MB10R/DZ!L%[[HS/MLW^_HWNXXOBCZ@!80N&@ 6T&6FA _K]YJ[KM0G\@'OGC
M_+*AD.D]!MBY1S-RO?07O^QF#VU,$V)4O_4E[F6C[#_8+_L'5\K-]>_=%P!.
M!W^P!O=?TC-).M0*(39CA,?2 C:'OJE).'6]X"J6,PG4RB?SGR?_DQ/V'M1=
M!9/ZG6NFYSP8PRI_[=<9>1Y[W/",R<]JL;_X;1! -['/4FK,9J:1/OPJIW/?
M7#$?_UFJ\B<](9":BTNO(9^GV]N_L9_?Q2RNCTQ-RJ>?\T-^*,"T,A%8>.,7
MSSN [K<'4K\U<'+*:Z:?)_^/DWQVY7#,PC<)-Z!Q0+2NE0[_&$4R<9Z$!CBH
M';T[[U/M>T#B^?/L[WGV;PFB2/^S!%':L>=//JV+UT=GO"P$<MOKDVE V3^G
M;.5C)GBYOSCF_&''KV8MYZ$?0OD_78I'"*(!MY4T4!69*&_0"'N]%RTB57FG
M=G-C[$/4R[[LS,C82FS^%;J=,B3/NBL:X 4^/4PS'PRM42.P5>Z*'R)KP'2[
M\9W6O.7S$TR5^]  /)M&VO+$XV7,*J5UZ ;K:!QKK)Q4,^1&<L*NN4V!IQ-1
MM=]+._ T+MC[?/1YRUE3!^^'IV6_?T(G!YDKEBOR&P7*#JVA >R$(()E1^E7
ML.]+ 7__S$]8/V']&6"I[$JA'@YC9+^'Q3NQHO*\WM9$M<"N\ZE<=W'-?:G4
M$_=<]GQ!EP([X;"7N[G@F@\@MAL;N8LII?^(C-M:]2BX=,LY_&_4#)@SA-*F
MA=-TKT%FP;-6"%/X/@J)!ARN8,RM\EFH0<_9/D:W3%T[!$?XE?K95Z54F" ,
MO"@.:]  &/#<#?C](Z>U)HM/-I],;'W*OX$BG_85LP%N]Z !QM#OGQ OT#G1
M===U%LEF]_FQC!\>^0GK)ZP_":S\>\IH0&AQ+GC8&]QE2?A]@3FS8M8#371$
MI4:2K5_W:)M)7?W?!6O2LCU7>*43^GEPGI-$C!C"DMOQ1UF_?SG^'@F? 2FQ
M#!^N63$$?8+PZ@4!\BW7Y[!]\QAYZM*"OLQL+).I>:?OY'QHY^Q.@+0,B&JE
M@ @71RVOMS,?WWMGP!=G:!1S>>";/*D?L+%EI&>-60A8.;O?A6#=Y[#D9#88
M.&RCM1*??1%( &<?&5ATJBTA&]HP_ZM,?QI&_7Q<&V2R#&&O663UB(PH>#^W
MT5?\)Y:\%O>A(@T7M\#I&LOU8WM(:B:B0'*(:>_E(0MCU-F;RFS5,!TYPXXC
M ?,42,@/C"@_!IAOY[Q!5*,!=[R!AXC$4SQ5;+]OV509XK%DC:?P$"PS!4@9
M##9'BK\F5?F?'P0JM4J9S%,9<#441^V--0/$C:^8UAQ\_=_Q'OM-7PM%!#]&
MI5M' TX/T8!1>$U_+??,,-(/8U.M#__HNV[^_\=W_>/,]ZFL3-@EOD^G^OJN
MPU]X2YP2496PR3S*_H*FAP*8'E;,\6]?J*)9[]R@_Z0! >R"/]"R5@\Y%B?K
MBG@F"! 5):,!^BB_W;DR/NB[HXPNAL%MAGN?V^40>(9F?F^[=GGOV0Y.\PBA
MCN:A\-II@T$J^3[K@E @3Y)2_;V X71]N[14Y00_3KZ,B0675@B*S@1AMS?E
M2;\IJ"9THL_'V.<W<#*<YR*SK5:]LUF]]EE4QW^OPK'^I7.!*/"FM1^SC-IA
M%!J09]3Z%JG!##D8W4H8,?@X;7ZA7/,IF9F2NW2Y>I:=O7MN_U"-?)JY"Z7/
MABW/2G2GEU1,5S'"9]9_U5MU38$BCI#G)O;2@WP-382G-8H^3'W8L<E=C[KZ
M-A4%P1<[EWR1EJ.$&Z7N8(1LOD?KY0]:RK*%Z2J$"D[R96@ (%Z^56/:FFNF
MM#AT2P_PEH_W7I#,5&7N)GW3F'(U1XC%L*19P//7ZG>!E(LE_M%<=?B*#+EZ
MS7$=\F*O= G[*V'O3/;(!X'KT$.RF*1*IJE=]C%Q\_SE+,O3H]BD9NJ8P"\^
M# RWV93E3C5/K3,M<O0X)\/K7EY[1779;+] %(&9;V_%WT-5 _?(P/4ZTZ.)
M>($KU U%=WL*;.!1A<;-2M:3?IMT(A\&UZ:8^@XD;ZC6!3&+;G0;[%$/&7&W
MU-'"F:Z/6?)$4Z6TX9(<3$+V@%?,P3MQ+D%KGNH6E/=;HV]AAX6^PBXG&W#Q
MFY4Z+\*I$;GE'U<1\\CJ@/YB:03N78_02-@;W+2%RM#>57$6<%N(+1I@=.-T
M6&2G7+.HWX/3T][S5?!#9NK"]58;_<'=KX).:, U;\%^CBB><#T:-Y(N6QB!
MZ&VK.<W*6-50#= EP.?4Q_=HE[+C3 ^=T@XJTJ9+M3?<,J+GE2[I5)Z))20%
MLM['_9(,?'28MW9RUNJ&!?/Q4+QHT;V.J4!2@N;",9*]S^/)G$@\<':QM$.<
MJ^#IP^G5BN>P1W"MNYV3#E.A;/S&-9/XM;(M*-K^K6LW]"$X%^HUL78\=V/Z
M^P_S1/2\.S,G6X6#DE7HU]A;:XAFT0 "2V&/\K'#G?WXCEPKIKOW%U#@=/5[
MC3/3M T.[CWB;54'+Q<-/@$?P:%X5R:>3@Y/*.1Q4HT<Q9LVZ1N_OHWJK[SN
M.CH:P7R_Q<U36KUV%^97@IAQ#Y305$[N98N\+X8#L$4,X^_&-P6;6PO?#4=]
MT$3>WMF:;JJC,U)4K8Y_%ASAS7J6K"QTN*J!2UH;FB6@D27N3)$ZPLDU4U<2
MM#8FP<"+W]98D96-QRZ7RY%<ZOWT?C#;X&'+IB=^WUPB"5+3IB"U<* @;OQ.
M")]%!%;M.:AV!PT(<+@WN^YXHU+ *03GB\S)W20WM^$HI&+ORP,Q-V#1394Q
MTC:4J5G<T5PM52/MY7Y.!T(!>B%/A69R&Y[Z2W8+,Z93M939H:DDD01>??%,
MT#E.=N-]<+%UI T[5<O5%J]2\:P</7/XBRW4DVNW?"9D7/GGIBY7A35Z 3W%
M9S;T\![,'&!_ F:N&X I#JWZ]2QXRB66*NB"Z=*?[>2,LW!&6Y97+!R+T2L-
M'TP:=QM4LT,%KA;7'@5?$2_5;FVA)$@9P+.2( RM3N/ ]:'3T*P1244#GKI<
MVOA:_1QDY@J<8K,WOC=S3H:4F+N=Z=I#3?P\@\TV@GHN0IATN7L[!4<S_&5>
MY6:(RW&CAM%Y!/]]Y-=YANNP1(65H7<LSV]EW;Q,B^_*'"1.;3&F_?8T,O*Y
M3'E]B%%QA1E=@EP.IC_4J @B;X_YC7UL/X]+#P[KGL#\PT+9FT;<[9%M%B.7
M7GQ+P9P2O53KD<_&J\*;>$.PVUU2:8AR*?@BD>YT*X-?BH 6= ;4C!3"RH0@
M56SMYZBVN3AN&G &MHIA)RWE(8;E^AR$K+B1(I[[Y(TI=0HAO9#AM<\J(>5=
M"*+-=&MKOQJUL<(:UASQ\MD<D57L;9HK:,"QG_YH/HYT\V@\SJ3A[CFH0?S.
MKFQ@[)F"T.V!T1'96Z_JZ6GN8MOK3HGL>- 2AK;,JU0%GZ3MM"ZI5RQX.6[I
MM#QY8F=5?^]$:?'-^0:U5^F,_F%D)2C;8 I11!6].5IX_&6^E]K6.)(R-P->
MIIAI'YE+JA.[YB[XSI$J4*,A4M#Y873,W9O075/8O,%0V&R>E/*@ [M%26'9
MX"UIY=6@NR#]FM-$JO[61TX2W[,"_XNFP?R5,K"O</!M%:"%84Q'D_-XD#\=
MDCNZCFI>#*-*%%#_;G*2_^^Z;>JG9E)5[#>(<?FJG<P -*#$:O!]6NSF=9C5
M:#M= JC?(?&],2V<;X:;ZXZO9$7DS5:Z@BM55BKR17".,?@I5B33ABS]JB'9
M='T7EYZ_@4D/+LFQGI3I[EQU;1Y;H4)^H*/0"?.5"8$7A$V$Q"Z6QX_.KD!M
M<.(JF,R3<:\0/IJ/F40\ZL'V/L1YFQC1R4WS"E]_0)S8O,SN S=3Y,:[X,Q%
MDR9[HZ&\^-*(HG$#R1#)U NDM@IYEI:)Q3XCDG&5E6DNY.%/=L&!>AX2'JLD
MQ42U1V^"(&+LLG-,\;.UE&/]K;*ZJ+YJ!Q\3UTLT74Y5/0UYW.HP]VI0M!6M
MS$1'3H79> 9KXZSVA_.8HRZ&GE=?<2I,(VD;RDZ[Q)\S3$9)BH5O#-4]HZ4(
MZ-EQDPMCC!E[_N6P4X=N)U.S>,!#VBXJ+.VBN4*JW,C-MGG^=7&JG0UCZOYQ
ME2#GA#O-OKL#8CE10^+$JSK#4%LK>\[\HPE5KAGQ>!X]F5+!GIMB-ZV)C_4G
MJ=& YEIWE4'REI;N.:$I)K.05*LO9@'/G.?*/3B?G?HU"%F98B4\]$QROK5\
MJE6.T$NEN?TR5)Y<<CS!OE.PO+_*AG E& &6@RK[RH3R,?@^Z>'+U(])2R8(
ML/6.FT@?W"/T.1W*?U<P96!)G%=1H1J;=A^W0^7RT;I1N;\XX^A*:#UYC-7V
M)'1;H$X2^FE;&Z/Z^KH)E#L,RQGWSYZ84K29KD.RTI!,_1Q<\+FU.8,B/[8T
M*\.SPR[-["=KBF,*QQL*@7+YFO=:8KS'"AIV/45II;YV3)ED,B5_^S!ZBVKZ
M= ,8DM]CTLMYN$E6TD[=B$./A?U("XSG8CS= -<P,/BZEPNMB*)AYP81/IZ%
M+^X!S=-<$UL(3VYRP-9??V.,MW)95HG<GPV*X+/4U4]3%Q##G3\=EI^#7M1#
MI*#8J_VC[YCWWL(5VS\')9</S/HI^JN\8O2Y0W2]<1O TV4"OY.*9^VS,6X'
MTVCQP$MV43$8>&:DK49V8&U':?>ZX*G0Z6#+\!?6@D !*E"EH4)A6J'"U]RF
MH_K#_$Q5A'S:Q$0-/$I#WT9H[ KFU;%K-)H0\B423. EZ2^M>(XR4'/W:A<U
M2>FQ B7)6,US@Q3GV;S+>_LD<%-4[QTH;(K3OA8ER9P_RSR) ?N+TH#FZBVY
MS$*YB[?&/SM.0G?RE$@4H _['P_,.3EX/[[GR-\C7.A 3_"I_ZYE:DBR-*D.
M:^'<],T+J,FB^S,-X(\%BCME>9E3*VZ>M:4+O%TT:4_F9;&B<"^T;:HA<NKA
MM.R^M^VV27N7.T-$S KVLL7)=Q@3O?.?URB.,KYXQ/.DY(*179:R ZG!$,6G
M#GZJE>X;<Y$QIRH0*_[WI#Z)U^10IR'(?;U3GJA6(-&3RG@<J%W[G80WFM>@
MK63#'EKP$G\HH>R+L%:QOG#>RT)C "%@WKT95,#C@:U2/0W\>ZZVH<*?MD^6
MJDS56@F_PJLI*J;R(L<3/F0!^/P_"U_]A=!DQNLB?/. F[Q5;/SE6Z6^8K"S
MV/JT(_ $RQ@\C(UYU4HNLHV;E)U&P_DO;5*Y29HF":Z*[K%S<',7)0HTPV&B
M+]WHFKC)5A5G%?T502-<S%47U)X&"UR1:&_MKYSVBZ%IGGY[V'\=6D8O1>LR
MV8J(&?&;.0J/>BIO8Q9ZW7YQGLX7U,N1FW=P=G^3\ZGN;, 33:=/$?H.JWL:
MPP;AR:R*,;(]"?@#!XI=UHITUTF((^X(F+%<>M>;F '*&#Z ^9WB?[W+J^30
MS=N"]W9<O&;8;([0CU*\VFGX<6U>H^>2?RJ=.IMOU$ZL?%&U@7]UM(U G/>3
M$B\Q>X,:)2%Q,Z::@"%61A"W1N9.?&U@N1^G3"QUEOGZDDQ16#5VPF&1'>E\
M_OVTA[J]=UBTU%YC6SJZ]CM;Q<OKZ>ZSB#,;&2#R2KJ,^ZD,'$)27:_8$9KV
M6)HU<Q-;"";0!+7T;^%%+T08NBI3L-"F.:P; 3_48*>[Q*B(/^XU<M@WW3ZD
M62=41DBEC4WDENNH3V3';8R7T!7H;WCOK&9M#$OAR*3'.3,C%"W$8#Z4>EH1
M+\*++JVN&QW*7B8R>!#<  E)PLU.?<VFL) C[EKI+.#M^C3X_P;3__Q*\$_S
ME0!SY"NVW@@J@Q_=+216GG_MVFH#_X106/($&E3TYQO&-]+;;@'/'8>HV1T\
MTU$R7$4:"X63?897/C_K19KBMSGM,3YN,@N@)3S,[S_=Y71HSX_^G!V-?:*I
MF327,@#C4<MRGTZVALQYD%PKOV>TIG$O_JOD6Y?E,.3Z#>F^A6&;_%3!?JG%
MN 7\T>5U T]U-G7UJ$9K7Z_)4;YR,4G(?KR95-7. HZK3;;<LM-5>@ND$/^X
M>104G#INV'X\><$FSTS[K3>97,=J%&Z0^J+EU]Z4&#3 MBYB29@\D*G:T<[W
M5,ZCSH6JN&=0/55",R"=5>]6EEIS6L26FP_9LG#W!\?9"M/J\L$I28/+1"5H
MP#V#T\"-J(3+H S&9R[AH?>7[^3K:FU5=*Q6XVB[9>3V#?09.Z:XZ"N9*!D4
M9RD2,00FVY];RED[TN&"7HT9*K\H"9XQJQ [STX@YJQH< Y=?:KE_&R1BLD-
MGQ12'WYW14;Z&2)*PY-=-M0<!B_O\.N-6?"F7D@I?[$7"JGF7RD0HF1*<;#9
M[-G$$46ZQHK55>9#Y8?';/#$D,N\#6F"9P\=D.L9&3<BC(GKRDZB94HG8\HU
M4E-JUAH?#=:HAZV1&->X*].K=:MDECK4W5#2I]*[-=A7)W569AH&5=!ZU1'C
MM6=E_9;,,&'L7A*F=X:/L%'E.%:7Q$QVDVNR@(DTU![0/B>L[[S@N*3R27G7
MNOL+H*?4C3,BG-(Q7#NR\/WL!Z=L2*&TA7K)FL>C]PT\HT03DER<Z6\^7'S(
M(K<9 ED4O;=SVMI(F6IB,&7X:"/=J>T&]3F6XX%ZH+ST_<Q4*HCUQF_F_?JM
MC=?&?]:0IW0D)1H0C)E4SMW0@(UU8POCJ!T02@HSJ1RN?W/0LS5% WSV!1L]
MS$J^Y<F/_[UY\G_O\3_.JZ]JS.=OQN.#UUZRJ38QH+#UI?N2QI#5B]V4+L?;
MY/"NUP]ZZ#'&D^K::7-X D/98,D)Q3S57CJX1W]D9]A7+V;)ZD73#:<3[4=T
M'D-=X 9XZ*K->?QS2L,L+*=K))O&L+)D2@A-1)7N[,*GN<7]??K=]"18[UR=
MW]+>S@G-()PK/?^\O*%,VWPT069L_AO7%-G@2EF4.L)F0SB DVK3O.VEG8@.
M>RI"0]7(FM[Q9;L5%?F$7/U!5C*;K7_ ])>MFE8U^>IF#UE0BFZ@B$QY>0L%
MD\&::X%XGT/.I/+1YLMMRM$PAN FZ^6Q6KF#?,4&?:U#G_.%*.U-8M@D0Y!K
M+HN.K8_\M(ZI?OC6/*T?#U9Y=!YF?5B/<@;0/R:WDP'3MM3BGFY--YX^"+G-
M>>T!6TI,VR[8;V$P5;'Z_K%A)I;L+NY0K]+ZJEIKEL'')97P[?H),<N<P4!=
MF?1S-;Z966:ZIO0TEWQ\R\7-U+)0WNME>F_R!:7Z"QP58Y/-W.!?X^)XJ&!L
MAY<HL:P^)86,Z+#/G+.=J537N%<[?3#T2 OIX5//NRIIEY%7%NN]VM[!IK]E
M+U#68&6S0;DX^65DA"HN)+$57FU#+$%3[IU_VT>RY7UVDA.5C_JNLU_ZX&7G
M2+6M2F5<Z!P9P^>UJ"F"R+&YH>89U63YFQY$789KV77=*4[%.B:?4K$)S,>7
M%&<*3F[\$N@$A.KI']5C3Q\@+?'ONY0K_I_VKCNLJ67;;T5 04$0E(Z*"(A(
MD4@1".4$!$YHTJN(=$/32!&(4BP1B(""-$%Z"Y'>NR""H*$**$A'0H=00_+"
M^>,]\'S?N_?<>[CW%/_8WY<]>\WLM2<S:_UF9I6"X]W=%"W4/&Y^B#C3#H)L
MQI1QME=(@>*T%,/J2-K'J]K!TFT%R6B,MEES=&HX" YF:$BHM0LW>2<0)KIJ
M>-C5E 0\P@?VR,A$,B@NG+\UY,^Q AIDP>:6,HVD0K2ZQ=/QT LF/Q\X+Y9,
M%W [QP&4H:CM)#UXE_B@\-2EZ*I 7FL2$" ,KE]!J(V)CSY=.Z%]CEY,@/M%
MJR'QP\*5/&+344RO[US46TV,17M9W&5%9(<"L?7I[$#RE?I.//KSB+*P[IS@
MMT^MD,Z[QLUOV1/MC1M3DB,+JR[-*[]U\%.P&DQQ]E R+"L+&]&LA"W68E'F
M=*)&N?8#O!^C36!RHJ#R6/_:M^,>H,(AV'X?X;:RBFM.-E/[VJ@MVC#')-48
M86D^Z%+Q)%[>&X2V,"0_YLS,;]HHV)6)OFMP5ZJ\!'JZOZC'TVZQZ9GB95&+
M6:>W( $]F)V^H]C_C._HOYT$;\^N?R9SHKY.]_#D\, A:\%W#*]N^NJ2-5.<
M.O'^*F)UK+JN,IO=O(&#N6/"6OK<Q(I&"@F0WZS>7!P<4MEY8V;:4AH<I8$L
MW0K/0'R4FR,2BM>T=_Y^7Q[XX_&/Q_^QQWIR^$OHPL"QDD%0\D(:] ,K!3Z%
M^*ZS>I(;3@)\30B"_(4SUI/55Y7C3Z\_F\R*[Y6.W**8)0%S+8A [ITWCN_+
MHWK_7PJ.EA*C'P0_"/YP!+AVXA%$$WFA0:Q$K,!S*#;Y=,A"WV=P:]UY'J.T
M!CY<1#Q='6+W4N)X;%8&]1S&RM1P/$XX"OM0,W9%C3^QPK]@KYUKUD-VI6
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MR\?)2J[FV78RK>("Q :M(0GXJH8(YLB;/J$<R!R_59E$%J7&9.6W_RK!CCB
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M?'^M=''@A3G>3FBI41)-E6Y@:=,*TV;EK88^KG=X\6T>*,D\F'&EH*]XG]Y
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M?HD<L/L(X7M( 32U,T0,0YM56C[?[:YDTM,P;1M&YKTF]QO/7G/VCZ6?Y(>
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MM$_[<_O=C3<4D?P4I-[_ 5!+ P04    " !OAG)2*U)H@JTA 0 DK0$ %@
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M2?-6SJ75.DW'UC#TVQ'9Y7%6?,_-CF51T2FYHG+88WE\'(H_!166H[DV;=I
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M$)*#@;9.;"?&V:5SI,NY%K"9J7'<.<763F->.3:C,R($*YVXA]3[!&?7QPF
M0&I4T<7N;H[42+S^=\<@<M3]B8?)>2E%0O$7>\.6^R_RE$_X0D)LE34EAD8=
MZW%J!0CNHSM;%P8,RE'=56-E3VH;HNA]*T1O)#$_?2>-H$=IO<&*ED[.?$,X
M(*T3I;T[D0[10FWCEZ41BACKPMD-B\NU=)]ELVB?AAMN],2LFVFU(:]@',TJ
M1SC'+_G&]M+*C7/+BQXP%.7#^),"#5J3FGI<VK>P0G.SI.OU4S[)MSX[;R_J
MONU8<G?;#&% W"U3;\,SH!)#"W#9#V APX7W(IJ68C*YZR<62X7M+;9.4EJ,
M6:%HL586W85;H=;2;M0H?E'%X*BMH2+8[%<3R^!]FU&)4N5=@9Q8A9*XR!JY
M<J*%T@#-<@W=!>Y0:\X81JUSF4\WY+W73;V1I!*WRVC5(R8W<W0SA%4 2/>S
M!FMMA:O.!L/.*Q04.@GOIKWQB[J8&US+,P'';#&^<FC^2/SM,M.V( J4<O;\
MIFF3ECGM41SWTYBM"NYA_#HH/2;JLO?L%2_>&W=C59C5PK,!(O8Y0S)[U$J7
M(<;-I<BH<[.(OK'5)XZS2SOZ50(#XMGTL0M;JN6M\1]-J.H5(UG3HG5OG\\S
M]J*9HMWML2WT',-#44&;.NB!=CY924=?KK(4>WQM9]"A:&VJU](<Y?,Q9*N3
M\_>=ARD:M*XFEI,$H(3JDR[O>NUI>$M%?4P+ :"O(BY887+<ZI0VS>]7)-[O
M5Y+"&C<X)&:L0!X+K/VR;H=3J(1X)HW)2A=:JK@Y[74CV.YTS9$N>9@;Q"]:
M0N=[T]EK[SZK"7O]]O85MO7CI2 O2#LEM7UB^K6&-W>ZG]76*S*K,KWA3,<:
ML$;,IWQK)I\V^C"Y)<4_3M7IEWKU+M8;7Y7^)2_-@@"\M+R<'&H-;6.EK,6\
MM.=N6-!0V\K^^%/QLD8E0"$F=I'XYZ5?@]CK")AI1WD:ZT'>('W0@3#GVIU(
M"OQKHD=8J;']223)MT\6%EREO0H/INZ<OV.4KAR$S'5+SHO-70L2&W+R##1Q
MW!WF2_$(KMRF)Z9!(/F^7_GE7?W:OXA?11^=R9&XV#;X?=+:GM/P^2+P_EL)
MSK EB/CSX&I])9KO5,]M.Y*\>^E.TZV";Z4BD;&"X^G,89W:*[%&_M<2XA<S
MB$Q@#N3F+@^J]X2L'Z].?G\8<;!:16US6JN2/(Y<N6ZQGU;F#2$7V4%@J5<.
MEN)[8N.DW%4%8BP.5F;(4*MOO+IW,BQ'Y3LXW1=$#S\L3$'G%),/72XYC,D,
MA%C5E;^YS7%1/S/22KFMH,-7J@U) 7,Q"]8.],S_R/Q5I7ZNJU,^6U)BV<7N
M</2YM$B(LP\K'<HVN'++6: /8BSEXW;.0-27.M5G7MDQ#9-1\&!&M'Q84KTA
MQ?Q*]A6.N^(-G$N+S3?EW-;-:T*QHO,LE#IT,HJMPA_5+ILG<4*>.(JWU^-?
M^B_8H+K>[G\J+Y^FF2J[M2L3+78G<N7+Z\GBON+A%;WL;5/K"^-?JZ,/)T)?
M-#[(NV\UE'/$HE*KWWU"90YO)\?I/D1QM1]&&JSQE\0I8=GF1"&+%CZ+(E?6
M@FA>">FV3?1T>:U$O5.Y"6^G&EBU""[$%&EP?!V3R<O.:YI+ES1]??[R4R]I
M%@)0JK?#0R;B;]$0?DNU-$86M?.FD6M!2.BI/'M=A*479]@R6=@=:PXA#/-X
M 4Q%?6P_\)*ZD/,N4XU"0"&'M_47%C(VN,EBF>R-.2%_=<;<M W[O/M[E$DW
MF2ADG.1$?_/#7]<G;/5G%/[2D$VBK>Y[RP77NJ?YQ2/8?FL0T<UW^OE!Q#P/
M-@2K3@ L(:?B!NY<1^T$@&%VLL=?LCGB:<=]MU1G!C;_IW/I'N$_,&KBQ; /
M?@,$X(ND+>S<">5%S(#1H)<R;:=MN]:-K[=YF$^#DPOMI;_?R2GA0G7(A<*R
M6Z]CH=6A9JB5;&_V\+O<X8;]'K,OB"#:YE(17OIC>,JI#;6&H,'SSPU_'(=?
MQ.[IX?DQT2U8*5R"HP=+Q^APV37N*R\HJQ@[,X234*);/.?5WBD;L;9_SX>4
M*CBK74L_PE[XG?K>NR(8%=$^8.OI23[TC:9K1T@]TF.*$F$RA!+!)KA0$8#:
MV9-K8QH#H38-&,>LS0F_6'A^WH)A,9LTCE_K]?B00Y#4J(L-H"I9O=)5MESJ
MP%O;[[8?5,,ME$__94*@MYEC<R*ROB\TI#(E^'S24]_/?&V7TR\X#CMVX]E<
M?N#9UTZP11IY>N)$7[O.&[+2\#R:^!*06ZHX?]E@PGIJ728-/<9AOK'%=DZ9
M)52A[J#/*]EI!I$)NU'6J& ==SC&_8SWUW1,0T;0QXX[INBRV%R[:QO:%I/]
MG;(MC+5</Z,OD$JF)HU;2&%<?,5_IO@ZLS]FO-"/]>38#,_GCP\_3#%351:9
MGNEBFH\AG\(JGVI6+5Q1V/S==\/H<5C%\=.KP(EV(,E1ZRR-_9:]OUQGA/>D
M"9_I'>6[C]=CW]VC+X6_QM^HJ!GD&D3P1$]LSQC<L7&J(]TTSKA611^@M:#!
MI#"40W=-Y8:8A"T;+0>R_/RXQLKF;?5YW.52&A*N.O]%[3T))\Y//)Z]=R'W
M# *(%KQ' S@"<V9$Z<9NWFQ#F<BZPBDR$A31OK)-4O>TMJ>L]VF2%J.$5]OH
M#BUXA^FHM*Z&K]]=Y'(;&(&K?>#MC[0Z\BE?FDB)K4"9GV^^-L+Q?,NQ6C?&
MTZ05$XPZ4D&MO#A)>U\3=><AT;7N7%]9%+4! 6B!'M/L(#=1!&"-W##H)KP[
M#KY9#Y<QVXWFRSFR7M:,^F4)EH4K^^HPB30O[J93HRB>B:?F*6_W)U.#)!7G
M![#OH=3P<5T"D%GE@Z<E +&Z:@0 840 WI41_Z>G*K*YC*D#)[7'.FX57; 4
MG8;!9C[+#8/'$9.:+.6W)U^^"XSRRJ"15 ]T;&$4SG:8S$QW:ONY)0UYY Z]
M%*-5$:R#:4$8FWV"/0L;?!_=H>2:SAGZ"+5G!C-92JQYLSGP,L9564P^&_)6
M<I2&H9]ER-(MWDGIT+8D #R:<<^01HZY*!=LV(0ASC]\%<_^=0\K?H<Z+>)Z
M*D5K&4RDW4\5I1\AAZ7Z<&.2O?$%#<=$;;+SJQH/SRU=BRY)U!>\\@X(=<?!
M3C.SR>/(3SFJ!*L[YG30,_O9E/39-=\>B/Q'9X%/&/64-)_V)/0KI]P/SP.\
MCC\0 '8!%L\HB#'F2\FDHVE0+\,'YZ2>U<U8<\,J8R37"8,)*J:P[O$<!!#.
M=!YK9A.;$@P?[*Q!53PC9;.ZG/P%[:\S(B@10>]DD\ADG"L@6^'U=2L9^7@.
M>6Y]'&5ATB@@*\PJYA+6PG)[VB# 9<$)JG*K6J;ZO?-O$9B]*I-N^B(DRBIO
MV4#(PB(OM3IXS76,E0RU4I$O.$.#YBPLL;K*D_)X /[^2MN&N,67S'N%IG:)
MY0Y[2I+[CM7&[)S%<RA?XNH[ADFPE)9TBIK!U='*4B.3[MB/' ]6*9@/Z67#
M?P<Q./A,(%YMK2!MX^Y[1ST-*ON$@N?/*_E_SQ [P]^%ZP)&O^VRPA=DSH7S
M?OJ_'WQ,VZE^CT@S-H+XQJHRKO9E8FRL8[JYGM7'?^((WF=8S.R[ZQ5##[/4
MK8XPVCVXX_AF@I'D&^0AX('1@UX.;T-L)NZY>2 S95%]&6,-I986PYZZI(>O
M&V17)E*?U21D'>O(?=^6$ @TH7Z?T."PW[1M@-8*>X):>>NBYAO_0*&-:M$#
M8FDE\+[*\JU?;O*&F\6D*4?4^O/O1!PU3%J6'@\QB*2J(6&B::>56[#-=Q=Q
MXA9AMH*ZQHJ<@I<?OBAD$0U/XZ#>J@MW:WO\6.>FQK>&:8NQ-7?\%;3GR4@-
MHW?^I;9"4]S<!6(*K-^HD5>?:C.?5DY*WBT!UOMW#('?NN,,&X&.//<?>Z"]
M#TV?T[^7WVV2L3X>J;B:P9@_Y=9\HT:. '@CY_46RG 4'Q^O*Y>JJ_@%C/W>
M_SF-"2Z>79N@]F$,;'FERZO3<F\13;US=:-F#$Y) "J=MB^9'XM*?:"^'F<H
M2Q5]D(%^%(-1SF18ZA?5@2'PJK:X\N#C4MY<NY,/C_))U8+M'>4"#J4:^7S=
M"F!/6K<W%#EWN^JF7HC!+Z6T&^H:P[SQ*].]'DKD8C>!N<690A@'_OZT.+YV
M!"\('GPM/?#@>^/U:8_PMLS9D++;DYHN(_.54(R6%T[(B]S<;YK]&3^M/E'M
MR0V:+_-:- XZF[IVC/L.-8,Q<4KTTS$6LV^++:] ES1"\?5-CRUBI3IOGV=^
MK[\G^KNJ^(OS+3G578-BD]>?XL*=)$I&8QZ6"72=S&1G]^60D\=?3']F?//3
M-H.E]K9C%4(*4U:RJG3?J62H%H03%HXRJM+%Z=Z&%P=HZ+^9.QZ+UX_8)K)<
M6X!-/B\FL_JYYF8$I?1RW+)M&S+;H+O@^_IW9OC+3M)/1R5,LV2P9"%^^QRT
MV>[]"EJ[;P%4T6F.BO.F)*C4WB[ K(('?ZY*D^_>I&X6S.]12_^CN/CZ4:'F
M74IF3(1A]9C3?M.UN2ZQ=ILDA^ NB[E#2*DG*_G8K#GJM]3UZLW77%RW.Q_L
M6/CFP8K58SK]\A!%#,9<%VXK<.\DY>^>JY1G=C@<Q$0\&I[S/I7\)G:OT6K)
M/Y _E])][.=F^YRO:S1SHIOJS.21X>ZM YR/SA=,2,YZ]='#1(^LC^R7<D2Y
M&A;E0GPD5V;XP/17G DF+PD"\".]B?M+LH%*2M1K:[4(M?&8C0$HF@L9]9P$
MG^M2:LH5>;>[ B /(<[G&T<7R;,2@->;YN7!VJ'F-::V[I<>?+I%U+(6.CS6
M *6'=V<6@32_$ #^7HPCF.?T$:>[\#7E0O6IINB")]"?:9H/IE5%0IRL2^^V
M4(OV$'T[RLT*;T=KW1H_L+RFM=@UZ!FEX?0^*^$:_Q:$ER<M9S102Q^=_YJK
MIFY4I!11FA.8JW<Y4'Z-O1@3XJ6,R5M4@0T=]9B_>6B]':-M0B=/A;9]N\VF
M==5R,L(HQ9N]"_J".'G]2,>PJB100I_1-7]+FMI,?[MI=3VS8C'0;[NKU6 B
M\>.=NWNJ#)>IKU>]3W673XAWR<<JU%5$;\L%_<C..]"YX#8.V0#QI"DF[9(I
M1GCFXIN?B[51U'Y "8G[1%G:0B"D;:QFT:PAN?,^T6*T,JM)^K2?SBNSHDX8
MOVLBJVQC89WDCL!L]Y8LV8+CEON='G-5PRV#:"(O^ND1CYU8L]T->>&Q ..B
M]7J+"F8R)_$M8WU7:E'@,I_D,(Q4:\BI$EIE'R>;-[=B^ [;$FI]/'[=)M=!
M!A'C];-R6GO_F-:>7,9VA2F&F4IA>>5=H7),3=E"G*J7H>IZ($51CPKZM\^/
MIIDF6Z[Z6C'V:&/_F(,GG]":#<4P>*>,!U,U_EL=FX22(7&JU.T!5[_1:9[6
M&?;/(W.U#6C9HT<<-O-/?KJM?\L/>#"DF3OODRS96QW)!=G>=T%C^77-OHE?
MU,L5U+.6-U9:SW%"]L#%;=N3:P>Q<EX!9<1%03O3,6I?![U8;)HA,QLU-0BN
M847.=Q5*3  I"VFINTE>+9YW* ":K="1_^[E[2-FN(+C8%7#T\\H_8-*J_/A
MWT:(?N>%LNK%SRRDLSPN;'T_WL071#:)OIU&TNB[P")A.>$XMD[UI#;A[O.8
M+,9-6>E\3-'0H<JXI*E_@_L'O;?NE(@IFC8,M"UY.S]3J#-C@:'$2NSF[J-J
M,9GT*SXSC(.23ERK,HE5W%G,P,NC .1'B0V)LH0H#P;=B%3V^;5LQ*QUY!C6
MI<BN62Z1M,YV^$FLXKVJH'7M=+?TXTUSRAC)S:8[H-OK-6:35A^(LA?<>1]Y
M1-,[O7[5,>-ZE2/9U_9W::4Q]9,7*%?-MO,+IUH^286*M)']+@M2@#>L&WQ*
M,;C#-\\[FD9'7YQ+Q^4T;(I;+=N@<C0)#76*CO=G:=K,$E=GFT,/H#*6S6A&
MCZ*%9-5=/C77D=6G*0H4";>,%_Y*[ZKR>Y-$ -A2H"<+&=V&Q*7P;]9#!&#S
M+5[+>-BORKJ_9T/8?MA-@XNG2,NZ"#6:]+9D#+ZUI4#^N=TWR!"$=8M9U2(N
M-X9_YS74.E4HA/P\O91>-\#*&0<3T:;RNDAV<HX,)R"YHZX[$''2 2LT-L_-
M"Q6R*8$-=(II>.2HN^0;<S@ILIW._&KYA@6*DU7"#])$VODR,1^MA7BHS#Y]
MY=R7_X MUIIO+/\VUZ/_-FKP2\D+[SMA93X+XB4S?(.E<RVUYVU9E+5HJJ,U
M;\G!3F5J/\Z;2V0A;)WTZZ=&,*&E#A/ZG0D423"GB>4THRT=LN\O1R F^3[6
M:(K6?O6QL2WN!TF^47>_0<(I5[4#]%3B=A3N!T;WS]W\[9XZ)A)6(HFC*ET8
M]6J8+!5;))KF=&FWBM<D<R^-<O7,YJ>.6VYH1C=X!U(JHBS?<J-I7PN741EX
MNL=4N@9N9LL),+4>,GIG?)K,2^S82G6AT!+4\C ES2SA<G:B)*6>VU3_52SP
MVU<S)G#1DFK&(O=-#;6ZRXWS#\-O#SR_4>R(@.6WR7.45XP[6S6]VFK=OGO[
M_&(TZ</HK')9R>Q-QK2QH@G-4JYXI1M<VF_W* *CS%%.5<W%"W&R][R\A(L=
MCL.E,_@G?7?Z54S6XTPRU"W2J%>]Z.A+=6(:RQK2H.T:CKI#3X:5/WHZS?@R
M&&V1RHF"9BE*EFI747);8!*\V=U- +:\Z#J\;"-4])U*GEDQ_<!6<5I<0:LK
M1#;?K 4*V&PP!*"K6-*&I*)#Y5<;F:9&AQ0\7*JY^4U9)EV8H"RE^+>"8H<?
MSPR2N<Z+!7<OJ[@XC]JV,"XE[X2RIR]H'/&JJ;E>>+#3X6@_IFNZAC:V-&.J
M4Z".,Q@82#TY-4RR.\E$610B[),N*_Q^%CIUB!-5%7XZ-+6:J_&D4"^?NBZ^
M_G/5V,#RR-KOJFDM(TR89$+NO+G8R+/[^CI,K)@!W?#LTHUT[GKT06=8CH/C
M\Y<TL4_U)^3O:MU1W3&!7J[L#%9)T?T0='*H\$O..P;?Y#$Q';62C399F>@\
M+LFW&PE+DH:PG^@+>$C^8O',5MG4?:7V(Z1L='2T[%=MLDC[S0W+]EM*]Y:L
M:W"GQ<BK7H$J]U%;E8=2W$S!,MGU!=),FGXQVOJEC3<68,Y9<9:T4ZJ,Y8*O
MD;UR\@?B"UW8"+"1.3A$GI#K&'@HWW0MCLAEZE3#<;@@-=0&[6>O+G]6KQPO
M93 197MX.39R$6<!-1E#\80A)"<="[Q(+"LGFL=LZ*^ ];%,Q'BX42-KS;LF
MJLQ\X#$_K^=9X8@=9BC;_%K-J)0>?)@FIA)K>YP;I]44^Q/'US]5(]'9F=PF
M+4GG\W2AU/E(^EA6<<'R.BQ\3_-'66G)D\HG4NI1 \$QBE/>--E9&T&"PP?[
M0P<-UC[G4\F[GW#=.V*SACP2D#EM-;$-\V**TFKS:^UPA7@6U7VUGJTX/_S<
M:^ :S-+LR]#!+X.-F;EY3J&Z%_WBZ<BT*]PER+D$7IU"C=9(:\]FVE+.K::3
M9,A5KU++ATU#6_L-;<[.Z@(!1?>D 5NVDV%HA3P[""<ZK(_AA_6Y:%56<RW%
M:"G1!G$2-RR/0)\YB!S$.^#[MZ>"7 A QZ.2K&KNC"]O:..=^1IVF&8M%2L&
MYT>$]FN?C I?\^^ -,;*7#^F7-:3M0[TR(/IG.SVZ]*T/_:^#2P*DL)+'>Q1
M&H[Y+23M*[ZQYQKSBR$F;9B7(.)0SL5OP-<<C56,L[]GVB]D^TLL-4G]=I\P
MDX>.5A94,3FY3_8D^/#+O.B:W+8^*$5>P)3MZ374#7G!$N44)NLC78@1BR:L
MYT'@*J5) ,J\>NSO:Z#?H.>6J4Q]6>2W!53L/02>^^FZEFT.O[^VU* A\+Q/
M#FHVDH=)@^>J>O99,S_-,34$YOT7Y?J4%ERN.^S"DJ&4=G&*+J) Y1[5R(DM
M]HK>$'+ILP/\ #RJ:WR&C:J?[)KYQQ@%G%2MQF[0>SW2=-N0:RJHU$LXI4Q\
M+=#2+^,NG*0ZZ1V.=$(/A(IL@?B=VN'P<S7SY'VC3UAJJF.#U1@OTVF>-JAC
M>6J+5')Q+:_LU4 E=Q\I5B$48X=0WX3%>D?KXTEHJ&SX)";*M2:()'Q>?NFS
M\N+:/0G3&<4$&D$E!DDZVBVO+P?FEPQ,X.U,I[S."VB2#]%Z%)FA;!#+Z7'3
M^08-]Z$AO7&7S(;49NVL-3H6^;4=,^^$>9%K4_8&7^XMU,V'+9)PD*"RATN]
M)ZZ$;"?D?I!D44+D41CU'O??7HQ7<S+YWDE_W);0*18Q;L,$;>X26,RXNC$V
M4566E*5IG=KY]%U1<-?"%6<8AUF\!>JWQY3\9L'/+KY.L4 W"[CU0JD8E'E#
MICK/QNZGA.MKC2E/O+[__$J%(UUX%3F3C\OGZ3B4"[TT\R+DX:@:ZW)IQ>C;
MK[OSS-*""_%--=N()6=,3P=C5"+"/G.=F[?,F?JZ;,YC=U?1]#OZ9*OHH]"<
M-PLK#P[L6,K1DYU&!5AJR*I)D.#@/O3:AO9/N9/)32KAJQ0Y7BT'S"MUFREP
M.ACM[)9 @=!,^NMS9>[ "6M&"%55',_E0K7W?!TJ'[=S:O:3EKR#^$>%2[!T
M;@6_ODQ.G8]ZGW <+UAWGFH\U5 @9Q+,P4;#;,B:\2T#OB3W,.H+$#-E1]L.
MOU<;R,ME(@G>85E1U2<LF\FKC=+S<"I+.]J:6^D\Z6.D9CG\II>@Q&I\O)M3
MJ8*/M<AYY(V:GS4M!Z4\]TYGK$"S9&3@F@I:?!I8#1.P\LA6@4\EEA3V)HGQ
MCH)^B87<F1SE_#L9[_W<-9P,=*9V1<5TBB;L3P1$:GFSPN.!K'#>_Q(CQX8B
M,C^37J+R$>FY($J,\8<X$7=-^#B8>XOA;?@K@[*2B<.E;GST8MT^\O)52"5'
M_E'.DE^7J#37Z?VZ7N_W>>A5C+C([LA_JU&J0(F_\Z5??<>_79IM?[+\L7+$
M*0[VY1U3@?RGT1-^Z>6\!IKOT8R0US,T;^8T#OW#;GI4+'_'&Y75[?<HYC1_
MB+U8:L%!T8UIC8WFGZ9>UG''?'C/7JU"1  N^;?.)"&/" #8&IB8T+65DK=-
M)#O00AVN9R6P/JUCCF05-7>BT6Q2+EGBTB37B[Q"WLIH&8K8$7F./:QMD$[(
MC?=QARV.C&9<A?EHH6^E"U;1>%RU^MHY:00I==36'1!V=MPPY*^*;)O'R6A0
MR+$N0"I_=;X\U^O#3)$Z+B9_#:9GYCNCU+)ZYS)29#E\VRZ?\4MTKR:5?U9I
M7IK]8ZMJ@W>"MS8:%-@Z!2*@I%C!7E6Z.A[H)@$X&9W5ON_0#R4GO=@TV+D.
MO1P@E^W@ZD#[:F<@I(;[^+/X?H>WGK:N]'?G71_&\.A.UOQY.7&#\><'$1EW
MM@Q>7*QNIGNEQ<%Z4*=$G9JB*O\B3NF*[8.J<<^/^Y-]!, V%3AE(GU%:5F0
M.R11[$2G'JI9.;NDT&#H^ZUK#*&M(EXC<O=S4[_SY-<3N:2WD^95U]N\VQ/U
MXB]ZC"]W6(S+2N7"PDDB="J-O7%=:SW[DJ5*AI5I.X%*WTL=F9^EH1I:3YRZ
M:TV-;6VDM6537D ?&CXMHE$H (A>D#J8\*8NRSW=EJ1AB=8UP7C--[G/39F9
M2.B*]LA>*:\9RQ^4)9O?.J>4V-\ML3ED'+U",Z2M-0$6UA]FL4V_'V_BJ8<#
M5"7?U^"]-Z5$Z!)/?6]O=IVR5SF7S#5^CAN:)VYC?VXCUZ&EI"7^V?"GMS)E
M:"-''N:Q,,=P\IP*5#A.M98RG]E0?O;,U$814_$9!P0 Y[!34*1?Q#WA'S=/
M6VH=.=1,#_-1&9D;$5*:S2!VUMA[:KL>/C'>*)0#B^/24!M]^G2>D_0R4M%4
MXM%&7_.S \;7.E71XIH8T_E F67;/UJ?\Y4"@CZ4?5[IG]@=W!*^H2HT[5WY
M_#9[?M;[(DW-7:NLQ.[Y7(SZO+'PY1FEUJ>K3]1#L!7F%A^S?]H=L@]H53]@
MPV\<'4GZA7,9N!O$U_(J/8_4(&U-=@D5%N$NWZN9;CX.Z)KN5UV,\7-NFL/1
MM7]P4OXA\<E*+=3QY4'I!.]AW,I*<^:9,])C4(MM?ES?I^[9#?7F\P\WX_(G
M:KS2V,?-AVR'7:1PZ:[$OY^S7I0+RD(,*A9*RS\[(*%.B!/?;V(=5AU<'-H:
M31Z3X#T?RAGCU_LCX'HVQD6GMGDXT2;1B[]EEI](>NY)O0R?1X^Y#X3_4F&A
M?:))4XJ)Y60.JD;_L<%:3HKFFNUUTM:82RTP8?D^B0_2NTM)?,=/&FYG15],
MY(W5D:#7UWY!(A]>J/<>S^.NI^>M(E :< >UTN#J+.S$*/UA.?W"3]--@WW*
M"W9!3"[B6I7M[59]-Z8P)V,XZFGCVMW9NTM1.]9T[?)T($ICJ7=@=1::]?-U
MJ<GPJRFPI_7+B^5.\F'PM^?8[1Y@\V8[ 1.)[_)31/FQ=M3\P&5[/.WGN&'-
MO8!"SCVFOL"NV\0G>NEL*%Q,F.=LN0.K;7PM='O2OONHU(1W-4E*\H!"W_&J
ML7%'_L\6VPL[_-074Z(U26SL6:\/2VB8'.E4[C4/PB9S9XY95.>LHZOJE)B'
MQLU;N]NJ4.D?;1?4H_Q$[FQ]>04125C]\203S?.JTH6Z[_Q$I/MQ^:LBM/R0
M2N8B=J6>GZ\H7BOY)"+Q5M5;C1(AVT-5#DJ*OA"SIU0[9C9=K2Z7ILPE\$KM
M_M'>*L+40?1E*^$<.JX8\Y>=(I[:0Y[^5R@ZGN]O>KVB626?.LGP6ZFR?,/*
M.B8I?4">Z;/:/YGQ]"?#R9,&&=XHU8YIN7N=0L;9+RV#\;0J!N>.V):"_F1(
M\Z#<K/63CM"?B*U$&# GI;U]Q3(KM:A?X]8AR<72V#8E5%)KA1E98T1HRT#B
M[C)<T-#6T9$DH<1[;%#P46>#-K45D:ZVFA</-&R*VIKEG;82#0D)M?;=_]E@
M=FZ8\VX8U41DSZ20[_50'1F=C)J* #-3&VZSL B]4X]V][=U+2=+EW9XBP_C
MJJ)_KMQ^VQ8+%?AE,8VH2RM9JTY>^<@5,H'?:EYG>13]VI ^G10M]%[Y>UO[
M8T&9\\]?D2[!T_RXJ+-O);S-C"Q6EHWU\[:']JYB1>;5+:_<X_YV>5R, )1\
M#.69*(1EM-@:(V/TRAMN^45: ;AHF2#)L4$5682;"H.Q_N'4S)[L<0!IR8;A
MNV\+5URV'K5.OK9/A]\4R$<+1W!_F:_;;S",YG;-5%^U X(GUTWU=#V<\O30
M5?FW^Y"ACF !WRO6N@CK[QR[XVA)U4(M&LDN[$J*VS._+".,$ D1D>A3?Q2]
MLNME8QSM2K0^4:_&Z\7$7R9?JF%BV+2ORNID/8>@6T_,&NMIOZD(<+XV_[F*
M)S8G?2/+G$S37C-NR+WSZ$/ 4'KP.,T(>)JY9>I"_"K<O UGO@F<A+C/W$1U
M#+Q=&C:9@66="H9,]@Y(3PX33]0G\S^9,A_L4ZY<Z]-[LU;H[S NHS<6_E6\
M_='UX=ME+DJHLNQLC,S1 _6"*R/+AVI23H^^4CX\&;=4DN1."'_#[AK\:F(=
M.]B+,6Q]M.9WN[HQ>F)EKNY9?$_WX88<?U[QW*]<M%+BE]QO3DY+L2O*>E$_
MY<H%*K(R9!$>2E$E16JY!S[(WH4 PSF<K@F:I+HPW_+><]1]*O555RO5[J_R
M59<MF-&MO5$\85E/+Y.+R,:<KC1\YSV,'A.6#M$G(>=.#%\7OV,ZO#PJP=1P
M<=I =5[TC?.+V+$O$G(4.PHH?_N\;:XZI7<EFVE%JIRL*@[K?&5A[&(/BKK;
M2(R>,JIICMV,\NW,^++NC^WW;]&=G5I[?A+28];-;6/\=OX]:_9$O8R2_OV+
MX31WOP)6ETPTIJ?"1VG4HNU-5GGQM/4NK%$!6I2_#DEVCZ=;7ZZ';ZQEA7(?
ML9@,%_?T#1K[,1]%-D+=%C1HGCNM1/-<%TS)Z;])Q-)<E4F;Q&3'EV=.$BL;
M>WTQ<Z'2+OOC1-OA@5QR?N#U^H/;!. B1E<;U7$PE-)M,[RR;,TPE5^Q'IV0
M!'V)5:1%P@O7_9J:$!.YMHO>KIJN,,3]K.()M2,96FMSO00-$2[;K)&Y>=1.
M]#5/>UF-ZVQ6QKY+\%G)*:US9I.JY[/YV*D?;USL4%7BX>YU?&)KG#=D\#L.
M&TW:.DMI\Z-JL<#<K$V,35XGSYULVUV@8O3WK/;@CN"BC6$Z;91Q_3EE_BUJ
MZ>KM+E,Z@RHE Q?]$U:G? Q/QXD^XE=)P#V7\VR)/QLJX@D 4>D6L3+H]ASN
MT:K:[:WJ=T_,#G[[7=I8R]N0JBLU:RW5&XD;_V:Y(ZUN26Y^;[$G*C#_=0L_
M#57D-H27]<.67J/-'#>:9M^P6E?Q_*1WSPKQFR[%+K]MWDQ-U:D/UINM.0Y*
M&PG-]VE=JZK>7Q4ER8[2B_TQ9R@%GS<M1K(8;WZ3%3A_D29;>BKH2%-TIKZ>
M7R_Y9V>:[W#\>[^\9E2>^C6MZQW\H5$M!KH_@K6R8J.[,J1>2&H(;QC+2I<R
M/<B5MEL:@+R3+KU"_)4 6(T0@"HOT^% ^(@H,]]!66=XC8X&RW"OV_6("/^U
MZ839WN4 \WE'!)7Y>KSIP&6%(85^SH&^N/Q(2H?QL7T[R3Y64S+TGLCWV6GG
MSLJUW-[]W9LG?>KW>%!.QZGCP94LZFUC8L86TXJR=VJ4EE<%-J1IA@ZSPC6J
MM[^5&NCG;:A[NS=3H:K&0YU%EFK3&91ZMK5982=+^EI4,.Z54\N:,<^( B?G
M=V_@XK>?R+!"3;;LBE83MITK1A,,34Z:(%C1;YBNUJ,9KNIR4_^W;,G3$:(!
MBSPL-^6*A0+$%W,?9;>C@0O *@$(0]S-"M'.?3S<-9JOH:LJT9#3FT%I[) H
MXQ9AV&S:DW$SEIT ^! 3?SHJ<^ED/9?2;M)H6#U^M6TWY+V\N]OZRW7S4>KW
M$S[W=3KU<_7'WD0=VQ_1E @NEI>_&KJQ>_^EDIO?[*N#X@&:OE)[OU3:DHU,
MU?[Y$."0H\JG4IM!8CLL,[Q0V=EM>B?0YS;1/)+%-N-ZQPD!0$N6+B"O6& B
MVL:JR3VN3=W?V%7E=FWG(_UT(#DRJ)4VLX)@T>\75^5A*8D3[T^B/F%<3[KW
M5/%B&/H'>L2 ]+6L0 'FV<J&M/!<<JN%@6C:=W_O#J]]'1WOBO=NDAQDNLUQ
M4_,B 22!3D4#\/EIHY^-2TE1H<2[ TW0ARBA7Z,+HY);CV:UR+[S0D0VS3NH
M<3DES_>8%6.$3DP.#6O*5F\L:I'-PJ(7.AT%"JP<S;O$; L[15]N&1, 5!1F
M!__F+=(2S]UPPJO/:$ C&VBDJ_<[V=2<^YF=07)4XH?RC:0('T_Z>/XCEH9+
MMF&>A5Y(2G/[']VQWVX^8MA[^8:T9JBJH+"AJ=_+1 U193JSFFJ"D>J\91!F
M[[+ ^Z1&^T5$PTL"$#"N.N]"ICC?D6SP86I&"__Y&>13671XOHZ&T5II3*F!
ML/ WN=]QR,+OQAB#C<DN'[]3+;)7GA,5D=O,O/M=#A'M\F2!*GJ,U1\#GB.^
MMCQWG3GXJ0U6.W<#F<_)R7ZY+K&KLZB7CC(E:'BK8EG*!PZGUMLMJ_LT/V"(
MML^.S:SF8OT/,B<V])I=@?/6X6MVV1-JZ]%&)T.IMO!0IVN6;JOO8+J=8S\X
M;V(2J:,NC&JG@\7.5"8H:N%!993:Y*/1A?K:6HUWTOT<&Q2PH[*B<!;E+EV(
MCD.?RK:*Z+SEQ;;,=>69PSN.*6_<^WB28K=&]#5L6^+-8(EMAD,YU56WEN@4
M<A6M3BE+P5YH0& J 2PH]36C,[BJ76G+ZQA)KYY:+W+UO"\C[/3&P-S)LXH<
ME,A;2?/RS: ;>Z5ZJT_.J>)(_%BH^>/4.G1[!8;#(RTF[5(L(EO'&N4.9\E4
MLXP^*UQB5[:\#=R475PWJ\H/QMH^=D@<:^9XQ6M-KV<V!U^L6AMYE#=47FA=
M-!3\ZHO&K%XZ4CP%-9.PP"*_8COFY=D4%7^Q../]*N*>.1>U7HV/1WJIH8%9
MGTA<N;82=63K__1C]7_MN.B<;VJJ6D9O8ZVP1/G8PHL D&<H$8 ,TYCO3;0;
M7.E#=JDV+)=J?HR3@HUS6QMD;U,$AY4<5/QE?'K?1C?C=P)D43,Z6\#&M6LX
M5P7<_$6= 'SRZL+M"RC),V#,*33B:[X\<-#"&)S])<DG'_Q]%W0I ?C5( Z=
M.1)#SGO;P_<I:@E <P@$U2"!/"$U@\\J5(%)&V.*?SE[3(7LC/GKUFQ<RA?*
M?]5&4;R4_4:0!O]\:!E*P!I/@PQ!KK$0@%@FK/TZ:J>UX*;G>Y>C-)#0H<OR
MX].9%4JL"#GDA'@*/MN1C:<+B<$1;4-W%L;O@88Y;47NDX;B3^'H;#S-40A\
MC9(2=T@ %I50L]\) .)#T%'=  %H156 \LAUX; FT'F8$0'XP;J(QPMY0E"(
M1@$"<!<&WZDA (S0>4N8(?X%B@#,NN E+*]@$2?'H3O^J03@_Y4 ?36=&"F6
M>MD/6Q])>+#"&.0:!0$X0AGJ-9.@OA=H9[>\W)Y=!+UW$?H&N49%NOF'=8F0
M8=UW>.M.!/[%#@& DX#&7@!UN'/V51!S2RP;GA&\N@]!8 ;_E1N_@;;:B6"V
M^[,3C$;R)@*P=A5YM-L P2C(2E# /[/AX)UY!."U8MOL/EDUZ$V[E38XKPG"
MXRT!")DA /L7+4^/5;#"1R 7!9#G]RT",$\%FA1WS@FYDPS]RURZG !TTQ9/
M+4#G?9"X<W1XO/9?.<(Q]P.@H'-27$Y78OXRCWX.W24I.KH=@S$'Q;P;0@"0
M[Z/0S>9([G<I#<\4P[?_RD,/E?XBDL$SQ2SF4%SE%N3XW*A_*B56^'3@Y#SH
MO4!0'I\9^ ]VRM/?XYF@[E)9\!_\PWC<)>@\TR!TC<:>  2%,&/@2Q0FR%[?
MU7_[QAZLR\CMW?T(E\#^D0&,^4D^[IP@ =BI1JAK4:X-KCHGV0Z4\,-SH:?7
M54%[FR?AB?,QV@.*Q\2)^7NLUJ UD7K@?:4,W.$(&!*CT#4J6U"&*C^?0VX0
M&=YM$,&2:J&R_X_O[L0,E]9]MT\L:@YV0VCCVX?@:W0V!.#%.I[Z8,ASE-Y<
M_@?EO4M@ +$.A>Z2"FFMR!;CZ6XU@#PV7;X5@/?[RL S*S.YZW#@\KL)B@\0
M@N^ IRL$\LL/CL68@&&6 !Y%N5Q*T&H9O;Y:6&$G'_S+L=GXLX!*,3]+C#5+
MHQNS_VDY]/,^ 3A&58'Q(X"G]E>#=#-703_L9F#,)G9PQ*5([NQ_RE \BOQ/
MJ^$VZP1@;]X1=)8AEO?P/?2=M -<="D?/&EA8=U?7A /'SV+P9C.\( )_39T
M9Q!A3GO+RLH$#("@#LCC2O"N$73G9_;$(/[N4L8>Z]E)\V\'*:Z2XDXDX*TS
M:"CVN 5<'.6W\],)NCI&>7K(>WHE'WMR=K.#=2QFEY23 'S8%?D+CVP\[5$8
M 5CMISS==QP/:@,C2;X</ENA\@\*AY7P=](\V*YW&1'-O!SD]A=Y\K>CQ/&T
MB$CHZFLXAM*B7;#T7G?U:RH"\+ #VAV!]^7![8*[D+%_N*$1&)/FFP0@'7P^
M)P=!504\)@"R' 3@J]^A);O(\5+&47?V/W:-_ MW23;SP?HZ.<*H3R+,"(#:
M(?SO^_(%[4+YPRD+J/T=++N#X^"]L RLX"SS"266&#*O\L^IQ;02U$D+'_CI
MT!UOW0Z??X99_0&?HS\+@K_,#S= _J !)RAM159D5?"T+M&!I'BB&%3V/Z<(
MYZR8OU)Z#-M=7#''NNU.+)Z P48V'D, UFOPQ/"#XLF"[,FVXZO^TG#1!2@J
M#48 \"GP.2D"8!*#T6R$$P -)(J) )2"PK'.0+J#?_4<QU"=_9U0%YA%)\&^
M#7D"'CNO10)PX@2>E5F<PYF */Q]UG[+7E@,EL<"S(AYLY@K!& L!]SW98$9
M*9/2"-EN>VDQ^P^2'Q<@J'CL_8-&,'#UX*U:Z.MC>WB<8<V@RA@']JU<"OX9
M+!0+6IQ*S@6Z,_K/M?I;^]H'8$YGIWQ& #ZFWP!U@[9KF0Z<'JC\64[)T/0_
M6(4K1O/N->B<E07\*"8!MZ6UBW#)BBD16;KW.V-/O!U:%<0%]]?%%OSO/^T)
M8((O%C8:/V8M<ND+>[87T+*[:-\)9S:L&%5W.<A?-]A,;!Q9]BQQTI0M=BWS
M;V\6KD3UON,:T8&FDC&IY'I*AB P/IKC3U_/*O<_.2_,Q.)X>^(D#69ILV58
MC0F(]L'3-H-)37X/K\^ J<I[=?=S:HQ9>!T8%D=MLWM;/#AL(>F+ !D \GB@
MSL,$OUFQ,2M@^<QRO+<?S$-5^?"!2#!JP4 92P.)B..?5"+GSZ%6L1CX(EB\
M[C9*@W<AF./L(_/@% &\*MQ27.J?:\%,8>*#Q0P<AP^!?B1OR]B;)P Q8*7X
M!X5I;XKGB&,N7$#O[#_60N>=[#'@.C*P(&2:6*)>PCSP 5#TWAF2@(2*$P!6
M8OPI=%%ENX'TEB$V#M_\#(H5FH2>D S\#1;4/ <K+1T4AZ4!M;RH\@:\HJ'#
M'<XNJF!OL(*!^4G/\F@2'D67^U,NSQ 4=!DLZ2W@D9QW_@4F8V'X*8875+T!
M+ EW00([<Z4#($0 P_MN 7*G^@^:NHB:Q9W+ H-A$FO7)-RR)88\/A)!XLE"
MP73G/8!_Z7&&253^(I0SO)5J'GERACP":_X E+^(I;3N36D/)NZ!ND"PIWO(
MC6EPK%D>6AEH?/7QC)[("0D2U&50Y%7C[=+8W(Y8_# \"HJGHJ0\DQ8R_C<1
MW#L(@'#&+ $XOX*<=P8O[M:<?>45]$ %_(?0F1IE27_=\P?I@.>1//0 5$E$
MO=S?[ L^$ HJT0=OG8[ OW3YNS&?@ 8S_8.Q1+#LK!#PR@SZ-XP5&GIF9TH0
M9%DD61W6V6)/X'#L]>0SV]'ASLWB\9>LL>:0EMP,S/5Q[?^T?@F5]SK#YV%P
MQB,-NOR?<M5@+RO_1_:E,R_4X,YUX8Y \XV!S$!,V[R) *6UO@]>V2!Q>RI8
M#D8>'/&93LG2A8>4+HF@Z9+.?"A-B3$%6X&[("8.! 4D]T*NT4)WZC=!HO0@
M!&$ 50HX$[P3K"9W>^ @XG((#)Y<1NXMXT##:RKB:3?A/P3ALYZ@!5Q.2&).
MM^L) $990NODPID%P/HE"H(:L5G\<79RAM7AL0OV^$SC2)>(&J9F#3%!_[J<
M,^7!CN=N-WSGBWD]QE]%J76]^B<!*+,:1I9+Q)Q<F#PK7)+R+0>1#?@ 9.,\
MZ*QID";D]/>9Q-Z;^)?O0%;/&C)^7^' OZR>/?JMC7N9 _]Q:Q*/"S]3M\1F
M=F\5?=L%8UICN7\9!.B@6-.@G)^>0H]^E:V>$C\ YTXUN%-JN)4]9/\*&+'(
M)V>*;C+X8(^QFDQXVJUQ'#&8]YK[E(.$-Q@6'U9UG6Z9[QQ>B 4%GW0Y/>2_
ME[W^POI49AB/16"T^[2.%3>E_29"%WQWL$+3*OB7B<BCR3, XJ-]YA($[G!T
M#?Z+T1;$%M"=UC_HY2\7S&#E>2]?]0(LYI"PU0Q4C1?DY,(95'%2^2<U0Q Q
M/K7/V*< $022'(0A?[WPT,4_.ADCQ@<$\:2#NH[ UQ@<S^ :Z<)*CC*=1M7Y
M_>/D)LI3CH=G<"@?A[%$?;*7L9-F#/P$/>B MT8[P+]#3+["!V+:]S(P)A,#
M6+"A4X[YQZR)YU2F"Q\ POF=H3_"CT'W5L%0"4K"\JZ&[H:.H:![BVC923QM
M]1<P3L^^OI#]ESE"%=\/!ES&'?CI/G)>Y= K!GL,%KG97###2L]C,P\:*;$8
MK-8MD'1I"1BI(<@EN[_,'8?@7TK@J_VS>)P(1AN7!N)+>6^PBUH'!8?!>0-=
MB,$;T.M]3 OIM8MD-H#\=PTPP<+?@L@'<GKH.)S8VJ=I, 0$9E/O?#:%#S1"
MC[YFIT.^0\Q:/#\U[_6 H6^+"<8'GGW_'01NQGBV,X@&W_F%>'3*58,]!5-
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M>^Y;2+BHD:>]@Q$<2(J3RA/P9ME8T>4.@!5?GD2)_LN T\1X:U)ZH.:: .Q
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MD41CE?N(G/IW[94=IXMTP%7RX4?0+_5IR&N_?,.G8R_O37U2/T"B_>?@[1U
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MJ-Q>DJ]H][.;AQ=-&951"',5Y<RL2^+I21ZWOQ>P""Y;.ZI_,ZWV(WWVMR<
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M;U%WGNMIY0YR@ Z<[CUM;@ZI]@NXOZ=4'Y;= ^6EB'..(YVLLGW',QG!450
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M*P2=GA"AKLYY]>R1H&%YL)TH#&#>[%RH1>4478P!U(,Q@(""]<#'J$^>KAA
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MB\B@^5;T814&T#Y11UZ[TS3+VDITE_LD%*:N'R #"UILH,\L^JL'WNG;SV,
M,QY*N\/Z035'UI<C/=XCVI'@=?$"*5A@)3Z[F[_JH3(0KFY8LG=G>FY:TJUQ
MMK/(B^*.!XGU%F/@:ED90?(L[@PY6K,;]= "R<X-28"Q*V )-K M=/2W0^T6
M93]R]_GU1';A5"8>;-WCK-QBUV$B%#DLJ [,ZFA_PQ\;G@VQUU]W4\\.UM:6
M,W9DC?@NIWO;+:[/@%"O/K:PE6F <S23[UOUHJ\BX!T:%Y[O<*BN;O98M;G0
M3TP!=A%/GNN<R9F>UMEC;5Z FW/(5*&^U:HW7-I TIP]K9(Z/3:E/>U=/ZDZ
MTT6)"^02!3Y?7\TY+IA?E+UO.L=1H\/),%#P-D+4/;JJLI&=UTY29N6=_&&F
MWNH,0]'(]O8A?CPNP09>G&BK=7BUL=,1"IJ?$E,6=43XU$Y0G[BJO&%HF[5:
M(49^L;HVZN-HA%JRNADM@')'^]L:R91+H,Z:D>8'[=,[FX9U\NMNMJ>C/:1?
MY<5?#JL)<\!O(W..N\ZIUL^5XI6G6X>+:W1]>]WWX&[; V*5(SBL9KA,^Y!A
MU0=55K<>8-_*%Y>QCG_T_..J$+?SYR..S+N^Z],!5@MWK8-P;'BGY3$ T\%J
MM_T=TK63N+!6#HJ'VTLE4?E>.OX'48V&<HIC!KX20,7-^!>Z1RV-L,TRQ%HY
M,<3-0? %7^F+@A%>FG+Q'MO9W8_(&+0?]>SY*N)-AHZ*:<9W:WN[$[YGE:[P
M7+@V#OEJ2J#AG^=S_3.R)P+'FY:SSC07#T9H?L:[ BB9E4'L@/WX$%ASE]B!
MU!R)8/S5>MV*-\HX?4NG<3NE/4221A7#%@[(>S9W91A"GT&[MD#E^6+ +#/@
MV#TKA+KK^S>-!C63-!>S^D<(%Y46JJ]U]?&I*G.360-D;Z'17M?Q= W/AC/4
M1=?94K(^_6?I^Q]WP[:-?#4</?1SNI6<WF'X3D)5V\"J%&MZLT [/],^JLC8
MHED&K<MR?Z0/H;0G+.2^\,BPX$@T<-S"FND/(#T,(,7/%@. &6  H5H#'ZAJ
MP@G5ZMLS5/5-,8 ;7C48@ SA AK=@ '0I*+O7#BC VG;+RY@Z,<JX\VG& "/
MO<*IBF*:=;57U#)\UV^CX?#%-FAG TLR.D%S1 C0:O(4;!:! 2Q\=A>&@99I
M!M&J$G0$HQ(/#%XM I/S@9=E.J1+6%+BM)2#^. ABO<Q;^=G_*OW6P63MEZD
MH3SK]B^ANS.#+/9$@<P!>D%D\@!@;]GGM8X. _<[J<RFAD/?V'X4\F$ ON[W
M+@@0H!,D+ 2X6_@6 TBN7D%C $1[>54/L,3GIP'_.5UL^#,95SB*8ZQAU0J+
MT@W-*+,__)#F,U9HNX208W$^AN#  Q 27 SKG[;'RL8/.8"U9,?<9]0%L)U=
M#(#J\6\WI1G:=#.1H21;AOUAR%0TV:;!H9 NEL_,H?GMU-&PQL>98X?=@;P<
MW1C G'XK!B#MV'>!!B[(_F$RBYE8%O3.7J5X+9;4"!R+ 335!:$_;L#/4:"V
ML#],ID,%*WK ,MQPB)?#!UD*FP_3ARW-@?)-__";U/BY_/0F"W@KGUQ5+^(3
M,6I]+<<F(D9PYFE'3^[+K8([P.O/?3+'5-#>+V&W9B5N!K&F[1,MZ3T0E%40
M9-GGS "R57SA"S84^,[=3$![G:1%Z!9?PL,L]C=LPI4=DZIE3$-RAU-AJL]D
MLPKYL7(TQ;*7_@Y'[ 0CPI!:;BH7MV,,3DX?V*FAK1L]L(+2E\U*91P&Q\&:
M2@9AJT;5V#5W8-<OSHK^J%!XCOK\6\=+.=7^K7NR+::C9G^3DRM=2G"8JCX$
M^W#ZL#":'+&!?0#,P-V\0_@9)5?#SKYJA\)IPZ6@!O?%92CI4FJ'T&2)D5CY
M,R,NT,]!<Z_60(>\>K#9Q=2(F ,OG!Z)]O1%MT!><1G7S-]-[0]39N9>1N'&
M>88I_#@B6]&_*EKK.!]-*]8(VEMX@97^_^ZH,T.Z.QHS]\HJS4?C8&*1S5I0
M9H'R\&Q$/^$-4[I[T(P=^)FRS[Z'-N(>R$T,D6($AF_HXWT;*9L,41/WS#>*
MIWSY5=9:=^0/6C@$+_D*%RC=9.ZA??@W-4_@+_K,@9VKXH]4AMJ^/Z@E['>*
M$OH<UH?$^W_K#2%;H0K;\1*$-!SV#@V-8P!M*7^8J4&_V#W#E(WB]<)"ZFS5
MY]X<A3"/D?;QIJWG9T[,!\\G:*.SA"!"/I3=W*@0.]#-20G\C<&E]M6RT2G=
M"17+AR#H!U=_L,3K!4:R%<%9PIE>;G9$&Z\4G?TWH0F^C7<C_%.Z-$:;&I'+
M2HS#69?X\X'J .T7CY4F#)D#FKN.==B2ER_7"D2SQS"#5K :HQ>FF()]!G>@
M?6=T5K"=/:P?E/7'W_V'R 8WW8SMJ4Y"L!!."'4Z\TJ*>&C_A(F$[8?!EV!B
M1)F]P:Z//JS_X%+J81@ F:YLL -U/DB[K)0JH;KT6Q.E7KPMMJ>C1"P*^EPC
MNU/+KHHD87#L))?VR9!:N4X0A_]*0#6_9;@6] >*[&?-A<@2=T%961&MXAU%
M_$>'5K.]=1QJP_,^2G$Z[EF*/ZIT'ST&/6_+,\0SJXF3*B][%D76 YGA>F\A
MZY:(]0H\7=719 .R#^WI7:;U5)YD"L1!HB6P5$?J'RW9^WU[U$S\^;FA-#T%
M4:F1%__9?SFMX6]M(\^9/QO":B\6X5"'I)[5?6BO)*P2O?_21:H)JWB%]6>'
M@2>[JL<;H-,S'S3Z%J!8!GSN"$==2&'E>@UH5?(?!C0)_\_^?_;_=^O/:#!Q
ME4E/*L'V_+LDN5G!L[XV41.S0L.I9/^[LFO;')EEM15UP?+6O#_JV\/EY#-4
M9$C5*?Z=4X?_E?I?<\^EUIEN@'@SCW^M\5,<@6UR<J,]WJ!RGP0^Y .=XV.A
M!TX!8P<5E3:<[OGMY]]B^X;[Y^4_+__;7[8^OA[9 !NCGPXVM19(ER'_W;^R
MLU>=I)7@FZ/R*Y:G@J'V.@YJW_ 3O+[.X7G(>YSCH0[T&P(*,D8'\=F>OJ!_
M2IOCQB9/7XE]J5O^T?U5_UW3L)]L=<27%H,R68[H)&>S)=W>V:3EN'P%L]#?
M!QM6VH"=I69)#X/_O/KGU7_]U6SJ)X/'@@_?] J?0I\'7C.R*?>Z6UT5FP@[
M='&F(9IG7-,S^9HV 0D(<FBFRU-A*525(U6[K#AM^C<]Y_AO;>U:\8#.&^T6
M^IG4GVK__/KI/IH%-#=:S7ZZ,M\> "NOE3^F  J6/Y;R:0;97X!$U)RDY4X\
M2;1\= ?R'3D,OVPS$H1M)R[L/B;SJC7XV1#@4;6R>]&,*HS-WW?' .YB  :]
M=2D?MKW_5WS_O[9G-KQF!:SSL #8'-;7+GYR;LUM?_NE6!;(M0'G+%R:DML7
MY6PY#R(VK[9P?S+9<"9*=&KF\QXF 2/6"_'X.M=C;HEK4#:<PGJB<A"V\V"=
M8SV>^H<C/@77S]<#BM[#8=+J]VS,BF5(-6_\,@T0NM<>>G\W"+(W9Q0]_V:9
MV_&#Y\+184'YO,N6Y6*B"3Z-^:LOB>_ 7?K<>U<36?:81Y-:3HTV?6'5/IE(
MM "O$Y7L</E!NZ,US6ZER^*+SN;DZVF%W$C1>5C%&E'*E(1I"640:W3P,8IC
MF#VR^M+7N/-+D!P,7$ S(3^Y.#=%4LS><W;]2)SXS&L/A7= >EN%$+F-T-O3
MRDQCZ2\"'CH!]_L)J8\*VNH5^H\"#I7L)M5\0Y%IMV>W".?K<X8*YX8/)]TW
MG A(5VGE3K*#*B<X57]W*/]?:__PEZ/^2U%RA\M.6[B+1-NH9(K\RE<-673C
M8_M3VR.&ZK;7_MWMMU*9$D<.B%JX[PH%>(!M>7D$BX L.).XV2B5P[2.R&\2
ML675'X\'J;-HQ'B3'-Y,$8>K@Z,]*/>$)AUB^47]ND?A_(_%#<4;<"\XAM="
M1).PXOR7[][_?X4$_Y$0CYE4%B=2NW[@$R&3O[4]H>)A! YO:.Q(#T^#$>>*
MWNU6@JO!?CIN?E:#\$SM*_'];)V)RIXTF'0)T3)C(FQ8-4UP.K\X ^=S.86T
ML])\>F"6$?7^LI:-_I=9+_&]S&9H P44WY6ELGRW+9[!;W.R_"QAFP:>:7[(
MSF:^(&:*)GT*/^3A1N-@ ,>.JS-$NT>(C_PR0UP".&[AQ3R@J!*SPW5H4DJ$
M_+7?']KR^X9+U!I'V^=_^,"A"[IGQ$(OSQK5P#%ER)CO6HAB"P"MOC5 X6(
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M9N&V1+NC>890P/!B^%K@T[J>,$)D)X&.0DWB,7E)53&3WM/&B"\[0_R'>QB
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M1HP>W8C\BLZB 6R,/-^,JJY&^X1:H!/=H\M$'.JM>1'F!A%2C%&M:U2U>8E
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MI3#&YD!E@SZ/N*FTZ5I'34Q7LY4U'J]E+Z *SK7AW"9A(3%W$8YM#T8L7YM
MIWSV\^>ED2%R7IR=#;^CY7=')1^?R3N\NC6RPG7Z$6BU,=K<S(^2Q0&JKK@K
MTK$1:2%M.?-*2%3]H-PWZ:R>'7VR\5.5M86EA,@F=<D(C7&>W1XZ-SMBDK>:
MB!BR73Q?MIPE5H2BS!4V=)=?$'63BJ- ;$=DN&&!W3U^3PD? >5VB@2/Q\:<
MS*?JR$TQ/0AE<-QBNXOM^=0%Q]5 O9T%==^7FT=IKGZ3ADT8&[4I95-A@KVZ
M2L@Q@16,UK7EK;DKAC:MLP7W=GLJ<0YS$O002N\AZJ&#6_^F<:U+CFC?N^@^
MR1AY7>(<V<;,S2*B7<41-Z]J0P)R+D8CV14DE/=<+G+WL#PI-DLA:N:V:SQ1
MBM'$5N(,#:R!NN]#]"+%>06?]_=Y#.45])/UA#8\/*DL/-T[W/#4-Q,.V#1,
MC+R,)B_:^*YIXM]1?U*1X3K\7B9=R'9+ []F;0H>+/A(<_YK0\I#]@0!&@?"
MEV/+ZHWV?H3N6C,98!O,^8GV)(^T#F]2G*!=\,EH=OFA/8=QAT^AK79*VO#)
MLWK?S]=HVX4Y,^\F'_5@PL1B$)9R+0U/ZQ-F?O'[4(@])3+N>+&;;R.\!K]Y
M'8/HR)UV9Z<',N@74/U$&#PZ^S<[JH2G^D[V CU?GO$6%&TGIG2"61/VWLC2
M$%%?QWC726$I-H0RO3X[Q+ O<7*%V&J3>*\2.-'W?!KV7JGAI<36-VY.D:QF
M+NBEB7J.089A6L.0OR.W^V%=&@N^+*]H>L"\EN$C=!DR7@>WYZ#(.!V@;_6X
M=G\ G </K ]F/3XC0RX_F40 CW.<2"[$+I2IJ3]*IJW&.['"K$@9S-<?EXE%
M.B8F*;>"C37K%8A*8&,1:.>YB'%$QD5I.YT=EY8 FQ90[1HZO%\XGX-F%1L;
M&3S!<.V_XES:_#1:#2M#[RB5,O>?=79PM[HO7L%!Q.*P\P:5V0@MK*R%1V90
M2$#U;$<-Y6G.S\&65P%75X.KOS1@V$]_N!;* <V GOES _<PB#'"?7:]+2-3
MG-(%)1/GJ3*6KO6'P7)BFHRE#9MUA\'-N?&4I^$$GW+SP1AE3,S<CA^X3W!\
M_.S40$HN/H$@::7@S+;,-E<R;N'LCRFF!EC/]COL5*7H9CW-WLU098,8_RTY
M+Q!X_Y:A7FWVSN9:LWY0/[$&[??C$16:FS>KVW*$F-V%V2#+K'^+US,X+U@V
M Y:2OR-7.Q@T(XJ\(B)#V[+.3]4G42\15#JT1(X)+6-E-\M0?F[+CQI*QZCC
MX"@TYN3+B'%1::1K-&]SHN#*"+='N09M/3J_ 5&8=FK* R"0ZQ3R=$P6GO(:
MO3K>E6709=!O0"Y[FW,K14/KA>PQC468%5E:'!!BK2I7T[^NY]+"W?0 D$QS
M8)IMNR=O5J;3OS2WC),MYY+80791)\>P/F;1&UCO_384GU>%"QL2EZDH4RG>
M-;&,_]AC\Z0G[=>+ *!@GI"C^TCGL>'@/MSO ;#DSZR6% *AK3C<CVK<K=$(
M>VHLN:WEKBA(KJ^4TKOZ(5HB4.-89&<=G]^SKH>ITETD>V1A@^BP'V<K5*&E
M+N,,T5&.5DSPO7.@"%.Q%Q^?5\=!D9^/$S$R5?*]:G3"F*IR<@J+IH6//'!W
M_9C;<B0K2:]JO+%3"R8M%8E0'<@I=1^#?Y]GXGU<#TOE9@K@^$FT45V8YV%9
MHLCSJQ+>=VUI690C53QDP1)73RKWMA@/^]LUB:&==(1>X *CA5<[=^E2(5G"
M$"7$1E5J>L*F<]+'WLR6T<T=PKUW,ECX[,3,N%;#D[=*"B^53GU#SD.@80A5
MDG?M@L#S0DO,6B"==1;]Y:]8/8]Z\F#H%[?VSZ26:N3ZZ3]WE)NL1Y23*]?#
M2FBRUROZ@*VXSY2KTM5NIX%#!<G'9F,B=LHJPZQ.U3?ZM'2H#KDR$D24;<-:
M,+RK9+4.K7C%/C,AO5'JR>JNBD3M***BN4RKH)0@[<-;/5A3,6DX9 ,F +*.
M)O;JL%>5XPL+MOT"9YX]X])^8[POQ'S%]CA9Z"CHVOM>'?CMR&-2L(JIMC3*
M&:8<)23+$AE@..MIJ'I@5<]4^1M'/0"XN1:E08N&#1-OH>9U4M)OGCX=B6;F
MN.1#:DB4-Y0^GGF6ZI9X)/JBR2X_.]I2PYG7]  L[S=+-",3LG<:(=^@TR>/
MW)=H_H$#@:AKM.H1:C\+UOA!4 0D#Q>>*06SB8C8%66#N4DZM-1<-B:2JZRU
M<+=:?M*1UZ1Z!*N/+>[J5'J1,$<05-=/.$&IO[]X1O2"<-@_85+U3;P$AJ:U
M+]<N,#D*N-Q@^*9WAC!.9[T&("5LA05#C@DV@[> SD]4&L;I0K]%M9F_/'M2
MC\;H*O*Y@E?CH_IPX/$H^HT<JZ,9-D801G[=R%)AJU_:SLRGQ[4 V)A[O:L
MXLZCDCO96F"4QVLM1,Q_C0S9CTI/J9+ S.UA,0'<4P2=Y4X*B]B5-*IS]R"/
MB^ULABTGPK9RDC_;C4<HBK08]I.+M1[.+-+NS^\/W/6;O6AJL[(:UH2H2\(F
MH/8%M8.[NOR%E!U[P.?,:B"!] /L%YI]&=?)]8,1#I"?I;A);Z+J!9XO?[D&
M=:?^X%C0:]0+R?/QZG F[;\ZOON^G;)CG24'"57&U4JIIC4C5#W<TTM,M[.]
MX):AA6*XYB,^><JM1(*6>B=ZK%^7E])#C"C*3>>3,OW8/[1AA0EEBT=SK>.-
M[,C[-\:SA@8Z"QQHQ[,UZ)]VF/RHV\[K)>69&N,??6OE1WV6"8@4V> D2ECQ
M<O="B$=,KDS.#Q[5=\?/+&W"W[]FG4G-VQJQ\>0?ZV*N:TSK_Q%P);?'K 1B
MZW'/_^79O/QO#F;\UT]D5;E'F?!X42<LQ;W?A[\XPX]X #SKISS%:K@-!KA_
MU:;_DZ0\3/OQ !#?;>E60=&5<@'^0:K^5>6O*G^KP@4L=LI3+>4_:L>(%*N"
MUE$$E@!;3;!O+PWNWT!97^F.CAA,W=(]?P ,!0^M,3P /K=27AW6W09K<^$G
M_\_^1];-,I@(VFA9Y@B]]V4#OI3YDVE#PM*M6ONWV(K/8B?+KE=H8G\P<:%S
MYV77E5TJO'ST.^C@W\7\.Y/ %]UT5OR!/P2+^9.I/[!_VQIJ=X^+"MQLW3S&
M^X,GVIS 2E[*U?CPF^0#0)10[$O.'SRN5%6">LPI?PI,^2=3,O)?:OVEUE]J
M_5=1J^3O;V=KIQMMD)S >S<Y7>^9G"Z5WC\ ,MT7UYAHSAC)+7Y/M^7ZIP?4
M</&:1'D/K#H(I0C,(R2T='/3_BTZ(.T?[7/_K7V%L61R7OS?(@^L_K#-\M]L
MHT+6O5T(M;K'??T/T_R=)6!#1E'*5>PPN>T/R_R=!85+T);YMPB!P7\8YA\\
MF0*Q8ZH&0[=T'_ZTR]^9$/JC4T ;P']()/,G#Y:YV_C_4&IQ5^K\[#KP'Z*J
M_LF#^)<^?^GSES[_]^CS.\S7)O_S#LF^SD\**7].&?B@$>/8Y$"RZ\3^\&6_
MJ;6!?8UB>/\F]G\-!+KR-7.%[.R\1@[N329UW$!\4F_[7S %U7]BH?O[[%+\
MM]37NGTNDS]^W\C2^EO0+>.KY3I\/%6%\?^LI%[_$85I#K@SM:WYMQ^Y6)%0
M52F\R-;_+N)IQ5=UF=Q*<]RBI?)(<0.,&@G,:3<F)MX,103G?6C&&KF569FU
M*TKJN$XHBZ5/"F*):8AN\55!J54U>.7[9L2-*&^,_8"=KK[\B0"-]0]N_AK]
MC*9=(V4RZW(O%TS'%3F3FMJA>-*"7Y0H9&Q ",#MJS9KIJ_$L*^4Y[F\K@5H
MZ6X\_4GB]?L4&/2R16&8S1269F!@V,N5>%YQ%?=B%P18S*Z;Q^VL5VJ@;>?;
M\')\CYRQL"(2!Q!:Y6W3N55=7)7K6!VZ2XW';^3LY$Y;91TZR\36SZ[='0KW
MIRAO;(+5V7U-'-XW68])NV87&\*C;W\ 8#3'S83.6*A X-T,PJ/^R5V[XN11
M^%'+BW@V&?15/E&B,NU66'%LD\80DT5?]<.!D,S)$/UP$-]D(M$/<9]CV:$E
M!D18=N5B.XG7,,UD]M<A\]AD]+=<LA0+L/Z>([LVSA\8J=#I7NX*4])X\,HF
M'L*\JH%G>*.3@\G2^B1/C_"8Z_%L<W_ XC[&>:$HN=</7\F"NVC/#,4W^.P\
MT9F,/?M!=PR(M=D5C;H\-?=XXQN!,B -N"DT4I+Q#$D;<5DLG,0C9EG??-*)
MG>V7GLS\I RBL'E%)K9V=D5\!XGY EF28:!6RB!#7_./$PR,V*"%*.[V24%X
M:*H^7+>CN*0"*U.44&!5=*$:H4K*U<.?;_27+[\KM(.\NQH^>-C-?[3%'3-9
MJ.^K?'@WOY^05]L89U?YI+@=JU6)8^Y>V#) 2) Y;K*9V@OX9EPQN#^^ARM-
M+.Y3(.4;.<H\5W^BJ8V)9D9C5%[2\-/)R&K59)W.U^1XAPR(X]90&?W+V.5]
M=!4[QO44F^$5"<??:Y'=,3LI3)WNF\D[2'<"^9"1RA$W##RH)P-XMJ#XS2R7
M%@["QXXGC04)ZYBWGKN1_KQC6WKWX!568:/MT:08(1V.-L;35X_,_SD>JK0%
M1YY&E'B"-GQ& &=26ELR,)=QC<3&<)JTDI>A3.3P(IANXE;,K%!Y!?@\%_X"
MQ4)^K!IW.U;/GZ"Y!3[ESHZ],-^T,\/4J(TEZE!01;%1G<!39E7!I&]([H<?
MDPE+1?]5::O-7UOO3)^QWIA_$/&% ]G:V'C6IB9_XT 5CTF<38+*:EMELH91
MA$TGNVAQIT;0\%-S4ZV.0XB8EP1U1CJCL7I5C,+]J%TP@;]._, FJ;+DNWZV
M"#=-]"8[Q8IR_=F2VF6X<X)G]]"P>V%UV8MMDF7G_,6.#ST77\U?7)*1^%;"
M]@CU2;YJ.9:4;>N]*K'5KM _V"*E 7]W5;.I[P27SA*?[M8>4)/AA,:>H<3*
M,,/V,PV-.G:8XP\U3RM_VJDMS N5"G[MI;!YAAI$9G[Z)'<*ULW>B%^TL*WM
MZ%O;K9N#\9GL7-C?M&C,=R[WA-E@AZ'4@5X3KL_*-+FQEMJ7^J&;DJ;YJ;)H
M2Y1Q_;@#RV9-X,K[N+D*66VD)"KSTR)GF^F2[ G\T-5G&S6'B7D\.(UJN30E
M.?CO_<*@3KI-+6,\0QAVVYX?AJ6IY;O[(S4GQI_T<_=0%-051_'3R"?$B&=_
M&WOUW9(%R<23X'S7H"P(RLYK!Y'7S?@853UZY5&>)(1/6$LN<%:D6N]4/CO9
MI2]EZ14PRQ;JYL1>4 '_ONB*B.^VYD9%6;#Z=J8S->^')=SS!X%S#7V2F!CY
MH%@Z&BODR48Z?I3)R@"*>M,->48!!IS\B[G5=NS0LD%,Y*V<XSU-U:@8W&IL
MGQK#B::&!0J9-L=>UR91^UIG3\^3,"2375E=,HO$F"<!I)UHYRBI^);H4I"#
M&VW;,\&2I&G(,8B\*[,15NZB_GK06^-U0X*;078%+R6A-8GF2$W3^#+(9()#
M)P:*T*%;WUC1-.S(IG7;93E<P<_!WQ]$]D7F#<-ZD@9SSCO08$5=5<VPPX'H
MW.@,"Y/41-OQ;C1Q>!==B<YE@_@XM+G/IEB"YN=W(VTQA4\I L9O":4G\,%^
MD.UZBW8.HP49I'AF+I1N)(:>S3SM,5_U;#M"5B>3P@Z>O@D U3TQHE@PV6_#
M2+NB0LIBIYEFY%1:<]QIY5/JEP*:>W&2BOR=29(.^ S/3>'!J\%GDF,[@B !
M"[M9B7FCCEZ&[-S_*T-V2XWQ=N*W2:CG]-^_&ZPH*>]6R&@)YH'N&0HZYHY3
M-_ 50K78T>>&T P>,:-B<?5>0Q!-6R_]W9P9/O!=O+J@5+_W@FDBZ_9YV"%_
M)J6O65;^2CVW[@A(.W+LO@77$=0%&W>;%Y((7#\CIJM>8NU?J^)3]N>^5FEF
M&IXYU87F/4M+0]XDOEZEA+!I*9<7SJY'V'SD-@65>?HXF-A/$:KGJI1IF>D>
M7I9(UDIYP8B^<8=]!ZQ5;'=R2Z72\13+N4JSEDF:@C8VZ])\)6IJ<&6I^) C
M)09'/<^Z%"83<U8PF>4^)$U5M'9EI\5?H0GH.G[^A8_O,7'*4UA\KGU>'U5;
M6Y5.%_8 P &?@-J.$OK/9_Q2]0=H%*9BBSCKU"2$HX54$N;#"Z35"XN:B$=5
M#2#[$X,)J_K\']?M2->.0=QQA7?E@D_L,L?+<L;<9B-^*O>A$5QGM)UD=9D,
M?DYBA6W,WD9H:!%^SFF\[]!/O5I/]$GDBJ7&+:<(0!P#P<M(+4;I^#W'?DHF
MS MC:$[%#@=XGV;/3-.^F_!+_P6)8F**&BPQ*?#+$"J!1?9C)QJ+\:$(CQ.(
MTHR<,<<[V #QJK"7B(FOS5VE,M:*><D^?C5LPM1C#C@2;7$2"V<]G9S,KZB*
MTIEKJF-:OL'X9!@"]K0FO>%CAF?X6$\!O\GYOOA!3Q:OV)'GJE>K.U9 W%R_
M=\X^HBF=8^V.6Q >.A/X,428;/_LM)B_F7&$YR;>P;VP/1XQL):>T@!-R[Z7
MQU9NAM-IS5Y5]P+.YRE(,Y8Z"9K(Z:G[5*>Z@UK0YFIGE]LA-']0H_,#MW^N
M?$].9(  VW(?*$1H79I*B6L]D] 5:U,H1=,ROX9[VKU1:F0GZ '^\,5PGH9+
M,$GE:@VK\31[Z+V;+:-+;<,U86'I@%"[H!*$6\K,CVR4G59:XLY[,ITN92ZY
M5<4CKNIQ+ ?^+T?B_YMRW((V[T4L'P#.+0D?X3_*KI[:@L].[I"]S<,WWFZG
M.:IQ&RP&-5(UX]34!SLI3H'ID^,I!AK==JP1PP[G(PG!1.XA&;1?WAB.<W0/
M(5Z/'%$I^7[,FNURPB@O%>_ @-3P.0S\$*E'VW>+>0I-6.F[<S,FUMM[;G)<
M 7_]*\/;6S,&WTNZJ\.C@K:OD;O5%>_H;OT!\$*<3+3D$=K9SARD^]PEY.L,
MV7_?0(]--+C6RB^ .AW-ZE@+TD(ZJ\B 30W?]J<YNX=6KR?2"9<KM^NKO8,/
MZGR -,8[;3C?SNF=N\]+]. !]U,K[/L#[-JI"DTFX<34.$]7R9^1%R)^.1PU
M+.@4ZFCQ,MKL=>)HK358]BHQ(@BA/G(UD(Y""YA6RXE.&-ZFQ$Z2.1+<==X9
M&Z!FQ&49"32G+YK/$#@O/',*.=JAH/:S'-.IJXB3QGS563?G<XS: 7!=P*N&
MUU\VE!$ORPG#/,3;J,A[N:\TC)#&6-8N0\M*OD>6<X>-0]\$MFL[Y'AQN@'Q
M=TB6FFWTCMY]4]"9C<,V.!D;39(XM-WR?SD.,_&UY.^7B^R 6\J)N+A.!@C?
MM$K+FZPZ53XI(^.Z,O%YKL2I>OEJ40O<ZOE"Q[K>< Z7NW3,0!EV<B!DVH3;
MEH$>TW:=6.#AA-G=3%/M0#!<)]"EGM):?RF/4/MMNWY^/KBT7WXVDZ5 I/EP
M=3<%4)!O[9T?=#C53C 3%L9,+?Q*0#( =3-/<CF*K><>V]95I-J!N8.[*F&3
MZ?7F+/ZLU#*IC],SY4P)=[Z>' ;+K[^H,BZ'MA5&;U_56P59'1XV<;$4O?IX
M;X0ZQWGA.KLK3H;U):L99=%1Q:,J-G9L$SJV7.H<@Z0CF!W*)/%>0'A\1CD0
M<OH+=6!Y&YJQ0@QW_$+7UC.DD!+12H$*1#-06-7.."!4+$&'3BBY?N%_D0(8
M/4JZ#9^!W_GP.K=@[/'4-:*XG4BB=^]3I=4B!0CZ)VP)=J;Q.E#L*G-]"VZW
M%%EVA8L<&:#=OHPFE0J<;2?\0+#B%QZ<=(_8<&N-F'Z8Y;PD1BR=S-<;M>[M
MYG0/<S/"R&"XQYXC<$<P2Z/PQM&KWZ=N];:,6;[BL<YA=^*J[._WM^'B<#5(
MHT1UR+(Q%9S?KO2-M7\ZDO%S$^48#R%X^=<5M>#4Q&[)I7;!K.12@T\LAK_;
MJ% 2T[.E)==+S1)LA"Z3I9M%;&AF/YPV)GUMU=&O:FA3WXADN"N4A]2/U1%C
MA>S^,']N;3-?$?!QL76:U8D7XF*W-2H_Q%V:0X^4=E;8R(G?U-*1;B0$R*:-
M5OSDC1AS!(W7?03AP-*>(IOKO,%DFBYN%NJ7X;N1+R(GP%BWPC6'&\WN0C[;
MM.HO)/'">^B+6,';XF0H < :VGBMQ#ZYL5\'%&KT=G4>E9L"1*>#=D6'QJ$P
MOQ?N=4ZOX*#)#3IS63HL_+K5XY(4>!NZSX":SQVW5MWHPM)!@@E2H++19ZW%
MT$9:I^5].CL&:$%ZOAJ%G))W=%\:&F!%%'<[45N0HH+E_*C[X%Z7K>[J@U>)
MV-/78S!-<N3O76O,)8<QG[5;Z_TFLA=28X5^S9G]A$=ZIRBC>(GXTB*/RWL[
M-H_0W7X[=U@M4!<GY_W_XMM*__T!/U&&!T"LNM8#H$P.>(JK-Z&N7DF2F.!I
M:G[<T:Y(<&OE*,T-*FS@^;'WH9GPL#GKXW*4J->M<M&L# W36\Y8&$KFHT\)
M;A19:1A LR+D4@);Z^??[.]-B("#W'?192&LOF;"']XVJ"+'D6&W3]:$+X=5
MI]:5;3:DW*@D>S2U3Y-Y P2UW^[0^SFY,G1L9P4MZ_?8\RP^G_MAQ;L67BP7
M]O)F( X%OQ">9,0PYG1Z,X!U_,,(!Q_*&2)2 1H9=GN9%;'$AK%H6V<7]'46
M[NG8.-ED)0"U'%&-@"6OC\Y1XMKH87WBQF5,CMO"J@USO6-B)OW)+LR<[V4J
M3;=E^W34XM=ZIR?E,&CO\:G4W[YG;)C"6?XVB#7ML22MK(;E<\>8:(194WD4
M/!5&L/RM'VL:[4.D>)^5R-'V NR\_*?W;?=:[, N<$;=]XV\OA"ZW8B=;3Z1
MH_E,4+3L&:_0]@(-N-U;\W9&*_G]L!)B#_+WN:,,8N=%T+;[+_2VTCF)C_CC
MD]J'&#*NV"HBJ =,L-#/YHI*Y)(Z$YL3;*R#[W&DJ=^*-LBH_Y+3B&$ZI:2N
MZ].3@\Q[]1G65H_NE>6%N*+RJ^US9F[A>;_02^%+A7:L(@ ]34Q,,,HK%<D;
MEWZ="MD9:Q[&S)QI3;@-O//CNI="IXEE</\@HG%1Y.:$#DWWO@[>OYT)R=RM
M&OJ*C":"+_/D:[%4E]+BU!<&H0Q;,1C)F*9E6,TGK-)?WA4U%.*RW==8V*M&
M02O&E92AGOGM5#"^NA@K!6?M4V-LJ=R9'8(A]AFSIKHX3XQO %&N)B5O35(@
M"JPEY%<U9Y'0S!SN6F+$-XVTU3*Q/ &-R!2_;PP\D?.F]*$_KMDJT.+94M<5
MG.<Y$+&[)QILU V/;@Q>+MKEZQ5*3O?0#\0^ ! Z;&QQM[T)0^Y[BN;;7^J[
M$I '5F>RH:IF*)<7&V-7)XW>LJ(/->P3R@SZK6X  O H+U'QA1=6@9Y#U[<R
M3MX=+:3 [N1BX!2B'%8J1<72:YXKP*P(B(&^8H8#B!BD)SCYC3?J=T_Z>4O=
MRV#_ELD'7=6L0%\/98$JW&P^T@J1N'0<@N]PH%E&/?@ @$/I#C&;XSX_ &SE
MV,]]V/Q-JI? ?93IGM=*8(J$/'V==H".&7I7F7=GQ(_$6*]F15^%+@\=_?TK
MS>X?]IM%U]J*FFK.WC+C*A'Z:4/ME%<OW,4N"!\ DGKM1R*EVI67TC/NF'CQ
M@%Z?*-C4[K7XE)M0.D^_"6Z \/>&BD!LA9AW)3[+'4U@F:_S>/<#?DOV0\F=
M(EYW-F,I(&.Q;K4(^Q]'\^FPK&$VUJ5HQIQQ4RES@^<B8N_ .B%TES'9(>%8
MNQ_1+62$+R!ES[?0RV3,(2[O;UA[YY[@>NPWU4>J0T\YW5>868WWD15+'8@B
M+#VMFET[T&Q[[]^O'-Q+LZ5_.I+41(PY93@4(P%9HJS<U2+A\+2!G=(FHRN6
M^5LFIC3'SN2J9_=3*62'7[M?/$W.]^*QN:<VM#ECA%IQ$.6=:%CTB/D(+/F8
M@GD<?$[+=?<WWD-3(5N$UY_/]=PSJJQ<!1)2J7JY9Q>@,O^MO>^.:G+IUG\5
MI2F@*'CH*$B1IHAT"(@T$1"D=Z6#(2(@$$H$%!2$  HH2@3I*$T30D>Z"-(-
M2!5"[Z$&3+G1<X[ZW=_W6^O<>SW?NM]=_+'7K#7O[/W,,WDSLZ>\LW-=MTC[
M^NR+>]H1G6I"R?T/6&YF%;1^;GT:4#;9Y3.?(BD2(<$OPORN F[EG&F%6DFI
MR@H)RCK95BBV6I0\I5KVY%Z3)U&XK'%NI!QVZ:+HQ'+S@+?$/M<U,M"<4*LO
MZ[RG)&> :<K=MQEJ?<>&&>'W.9(-?&-%7FB_&3>0+TP0=O8=>ZG+/J5YU>T>
M7XJRJ8E!/=/%=MM]5E:MS//LQ)$T]R/4.K>B+WOV>'*Y7(GNJ:Y]OUF<D&>9
M53@.I\XG7%,]6=%RHFBNELH+'XD>;W414[PR]C3*SU#88BSVM;CD:5FB>UIE
MI^%\ [M3GN JZ>UKH7L":AY6/AV_96"\][R<8W?L*CO#P78IY+QSL*9>I:$Q
M2U\Z4?/]0KNO:;=/@/[1(7=YXRI$!O\#_L2UHF%NI5-;=WT"%%(,-S\@[3/=
M[K*:8T_1/):GNC(7?"0>:QRDK_,QNT=\<H^C2Z=\Z=:5D5<N-NS6 DL!7YY^
M*MR@ZQ5-8KY=([0 S AY1847VLY/T(MIC;R(%'G6^=]9[DW^_2AF[N]?LSJ+
MM5KN_[8?:O8M>&-&5/B$D8'ZV<M_Y>N2?R:OJCR6]4('%()T?56]1TSH)QQV
M=DPRC7J1@V"+ED7Q'F_PS W5#>YUS$ZRH><5/4M_SC6_D^#'+1ESZ$1-SE/5
MD\0 @\PY7S34!&6?(ZGMY5!X.(&&41H1C#J!MS6^?^&T'V)1+&(/.XM3<];"
M%'(!R6$-NHAH&JIV-ED3\**\6+7V\R83^2_+AN5QGLCIMO62Y$)3R)KLX$>F
ME?(6_?.X,#(09-+Q0*I5!$(U1)N/U3]^N>G\:O8-M@ZLJ>/*Z]:QQU(05.P)
M1XA,ZWP8X@D)E98_JV;>Y=SSH.FX$)6?=7\M3?:8IF3YAO!XVB)O3Y<N>M:'
M#.R;\@$D"*IC\SHUB/[:J44E-N(LZ6S1F\B@$Y,GM*:/W;N=TZ0!-1H1U)4>
MX9+LWC%?G+AR3R+],JL 5<VYNT'[?*$%"?N@8YC"Z/=%#H.OA9KY8\M8#&8^
MS(@[TV5U:Z]#EPLAEBDL'81'3VV_T/ 0#V*H[^Q\;&Q/\P5G?K)^U_.Z,HEY
M+)SITBV6 >WT^XJ:K,73L?;HT_Z6T+5GT^?.+]<5$M/.+27DZ6?KR+6E'9(O
MWJB=<146,:M#",3#1=!UB>B2Z-FL3'V&?K>2:MXJQ!(&TTTWOC\MU'I45I'S
M%O:<3 QL@LV>#-@6P^2[NI"_K><*E,:/6[YL(0,8*YU>N(H"_4/+KJ8WX(,"
M7L<2)%MC*]Z@T18(QP]>$A":R&B-=9.9+X&?KC26>[EQ\\0V@+K%<%(7?-ZO
M-5Z;@T80^%=FH XT(G[[&S$*)S9H2/OC\*:0VZ:N$X<CWW96"H/3YHXE>;9U
M/VGG,RQ=3>)?Y-Q)YN-/?%$_?IP^>!.' 8%6AT8NF'49:+!H  5>S36K@B-!
M5R@=-TLWQJ,B(QJBE?RV[2HSBT+=4A.M$HC^<854V^F>R_ETK0Y='7[Q R(?
M(/6G]=*P3D'O \94L_U*!@Y8JYU'T!K*[>^W?E^*[2Y9]E;USYE-"O97NV9V
M]U/*]F_S"&&?E*-NJ^9RSQHWS>^D[F]?]J@TSA5CS/-[G*VW?"&%Y$L&;CO8
MU!\)5"^BECJ>S\_/PKFFWUTS$8QI)IZ)VC9!ELLF-9CLH!&JX:Q1[P?[E-:2
M,W/]')=05W+[W;S,K"7OQL5115#U=_F@8],MGB7Q)50-^HQL"1^G&7=(Y4[D
MY?%P5^9@L#^?O#+HNEF.>K:&S*REU@LPF7HZYMBS4=+[81W-K&AC%:H^"2_P
MVKF6"J$;&M0_T^U3$44K<'.9]K[57BA627B-S]$F/C#O(D;':#$[*R?W)#%Z
M.>2<JJ/+]0:M5OY]]O:^>4ESXDEUTL<X/[6&Q^EK'-?84Q ..FA9GVKMZJDO
M,!\;V#+DX60_U)L4S(FJ[LI';D\$86H#<[';YN;0PSI/!"YY2MF+<:!&"_+Z
MOI"<(-'7P<=7<.61_)'CGSZF.?S&.YUI5(.&&^"";Z,](Z@_I21$[ M)KD8P
M)_N/@RW-2VO"61DX14..\65Y8I#378G@X ZCM1)BLK0JZPB'\O9XC$-"@5#?
M7=F<7.M,,9\YI'6;6# M.-!QK"4UFL_7WR#R@0.8,SBK@KVE=UTU9ZX<C'O6
M=-W\L4#;\A PCY W0>GX:DWF&^@=[89F%H[410KERH7^K8L?_[:[JZ=&7$OD
M(Y(V6[7$%4N&$->OECPW0"2X10H/4<AG_$]"X_TKPN;]%3G< 6'HU1"Y%V\V
MF%<^P1[><:FH9RLHIOU T'!@3MWTZDLC@YN/,I+$UO]'2V2_[&W*#<HUGXU[
ME?20-B%FSRD]_<^G(@@GDWD(E&DC\0ML)5_AI8A[KU%YJ%R"GHI/^ZGL3>JX
MKYO_D"^;0GMK?BZ93F+^P$2"]9&(-7AC^ (#'RD$,[JU8$ ,R8!UR@^2B)%
M(1F@<XH@ Z!Y,A \2OAZ^."-&AEXOD$&:B D%OLO5%I?CR6@B5^.PNQ<>=89
M2R@/KMT6(0-UYFEDH&.'#(RBR0 ]:$RTDPQ,$V'+@V3@KAGI;3=HA@M,L=G(
MT\^N2:3*KUGN3Z4G RN)+K U4LW6(L4 '*\C!=JFC#U?-LG F FH2 J^0V,)
M&RW6W&6TRVB7T;\EHU,UD>MG.?8$E_&1_"FV]?':2-@VD6>K'G;7M275=:\T
MGU[)+!E0;+Q":NBF,*T;)>%9/,M$PTC,8!X23).X,CJF2> ? !%(\"]C-779
M/XH=A5USA:V-02BC!'V^>AK-3Z7@/\'H$^]G?CW]54-<$?I)V8W]$*Q.-YWR
M9(8,5'-\(_14DT*HBV)/!F]$!OJ3;0EX2\H/L1>^H"M!"A0C \LA&FF[0+M
MNT"[0+M NT"[0+M ?P\00U@CNZ1V8A5@3_)'4WRR?_#IM"%IL[K':?31BK ;
MQL^_NVM&.C?C;'_RY(S.^F6K.^VS%<9^L['\H^!9%XO+5Z.5ASR_>EX7Q14>
M48P*=M5,K\-&&4A'877ZZ; _*)Z"+2C]R4-SDSN)#"BSDH&MMUFNN11..S(_
M.*U#OG.*^,&I_CLGZ@R>E8<SHVL[H.7P;Y[M=T 6T$^&T[\PZ7P]70_[\ODR
M>^S/5?G:VL\U_J&UH3]:^WLM5=Q4*:ZJ<C3%54TGX2%??=L@CC\\R2MDX.KL
MGSXCJ&B]9GN%XF57[]^S2V:7S"Z973*[9';)[)+Y/T;F)=UXU4%>:J(7&; :
M)0C_1,%<ETI+*&,6,PR:?IP6)S)HR/,/?I;FSVMD+W^LN*7_M-AU[U^X9B<;
MJ)L^="FV$<JN*6M07 9*<#>F7=<59V/56A#[V#MQ6C7.=.:7!FC_3[(G_MN]
M$2^[OR7YO)="(X7R^'_M#E=.UIOLEI?:F6+='#.]9^O;57AYLCUU!38/).7D
M2$B(+8CQEY?':NY3\RJC"=$/=5FRB_$S4S04<K@ZQ!T>I?0V_F_:H_I7[D_]
M$!.GLKR6=+.@8C#[U#D[?GK\J>HJN321"A;:BS<-8A9Z7J2B*L)7VQ5RK*0D
MQ3^/?$QY,5\SZ'L,H?Y2+(/9W_6&[7VM^9"8Y]$*D@G"R.&2H7Y*%=E^;17_
MD&]1[$YE?DN$)06+YH1>Q#W^S]>$O2-H8?3@G^<?<B0@)N[QU4XC:E+/-?DQ
M!Y !!OP'[^B+KEP0<%=?V[4;#<Y4($,0O7XD^R/TB%B/U$M+<TAPR_T,]!WF
M;F:OF#T@;ZCO*SB+7Y11U4>I82=LO6^RI?EI6VD5_-5GV).:2BY4>?AZ3[&J
MDD==;3BX[-*I!H=KA? H><G1S(I!:[$W7"\6DVB#<'TL$3B;53&U"YV00U/"
MSV&?U=T(6F!1@ES)ZD%E\S/$AQ[R]N@QS&VI8%XW>=VJ\*?B:2Q#.!V9I>A7
M([:R<T'J=H':9?%*FG75%UXW<Z!5IN,>S<^;5Y\Y(E%/Z8'NKTTY^CH7JIHJ
M\\.:E^\$IV]G M[*@C7=8 (X7=4? MV*%UI%L&TV*=MO)55YL8\V<+1"[M&'
MBR06(:]E?9(5]^P;*?2;)EWTI7270[9$NIR:X\%R%A[8,^)G1\-4N$PC*B'@
MPOEC[+;]TZBR\./BG[2V'V&SE-/7<L=Q/I4CIQ_6%UNTK38\1=AIU#;K6TP$
M.I*!HS4-2H(-Z9.H4F[=%IXXP15>,O#6K:->Q"O'9IZ;[Q%7GU?"@^=+4[>5
MN"OA3<H*5<6X7M:XS+>O7WM.U:4X7>?61/.M%EH5BN+\!W$P%;&WJTD/-Z#
M'$J":S;9Y+YKSG!&SI9KN8B=Y%3N#(AY/=_90(?-#M'DSWCB&%6$\I,"2".W
M(<&NAS$;7KRH+]'6-$0&PEU'CP6W]UF<&%B0?_)T@FZK!!>#P#<"T*H; PFD
M^.='1/,=T57R82<6XIP;5+P^!O2!69>%98(6T\]-[O01$A?/DLJR-U(9GBY'
MLCN&Y\*R6QV]G5#@O$-44\\A^DU/CC5&,UN?60I\&G(S'VEA+QY$2H@:$XHC
MG9YO?\<69Y7+E]U6)5Q-A;I-T,;1G2E<>E+GV2/JI<*%#J]TOCKN?B JRF4B
M1@>V$=NR%;'=Z!6%"[L8H"H*]<&VEH;1?XY5TIXUAS$=%;RG:))WFIJPAX3+
M)K!)@SY!4V$BB]Q.MIYLJYOP'KE4QN5ZDDA/H&:6=H#[<?4HHAN(&I1OUXJ3
M''V/F.O1Z!5'XCG<1S12>0GS#U<<%TN>OL(7X.S7O/NO.?53&U=[)+@6^A #
MWI;'I+'U2*4<:WT(KCPT.<387-2"50K*H>I:(&AFV;KP6<1\/B"6^60PNG2.
MJ>HF PZF99GRH@Z7[VN_J!!L6R"2%/8U@A4[2<]S,ZR&.-Q\;G!&=VP:[^X"
MJ6[WGKSG/[A#W2'7+$=TH1(9EXC.0'6*ZD6+A 178";E]\UH%E-&N%G%P^.'
MQQD.VR[TU'5>DY8D VS-!E;9#4T]&?@ AP'5V_U1F:N$!V!.:6C 5!7-^>-(
M#N:,0W96A]=3:=SEGT&EHWUSWDN6X(X-$L?EF1KZDEPLN%$X9CJ?Z"OFI:@2
M5_K:HUS%??"+RY5>CI01/71#B]>PV_]D74C+X)K]^BO0G9W,_(X[?*_-+UM9
M5-SG:V>DX^>$>F%NGU@I>#)>R(1/6/\T&;^E/ABG&+&T8Z]$5/=4EL0L(R&1
M,C*WNM^I5S2-V&"1T6%\/-'0ZS;R;TIQ< (?!K-JQ>GE>61O7L!T/S02BVAB
MT,&:9#O>?#J6W)\.MV?OW+]\;^>]FPU54>]U9T?M3$-Z:5IL7*,N%AQ@T%5)
ME7GN 9PSB8Y=L3XO^LG\<N0:[%!033W.&F\RPQJJ$"(E&J2D65QH@MD8/G)I
MI23.N="LP]/5?Z_XA(HQ8U?OQ*$ W*P*)RHBK#TM4SP]%5_B'JWC A%M07HL
MR4^89N%ON+6^4$D>2*W63WA?9#<2$;FV:#N6E>28W9+ODCQ1$BK;EK/(Z^B!
M/W@&CBG7#T^>7$*/O=A:<DRD.WC-4!F?RMC^3\X>4&N3<JL3- I_3Y ADO24
M\3?V5SH-A<(8[\%6.(][<F+R@@1R(M2EEZ=:.K!UFW[##;L.VQ8.YB<#!=)D
M8&<_6,.JLJ-UXX*NS3N/XE>U!03IZNK;6)\RQI2NB,MN]7ZA8E1U%@J/;<;'
MQX5>A-*2UA\8F0ICW;4)HN?HQ.S%,MUR3+3Z,@QWB PV&+HBU(H32K+X]1O:
M-Z\?+##>IE:N0UV.NC@HLW-=\VS%DALZ<B-%;"S)ILMPH-V95B#<^@O=;.FM
M@D8S^? K"7R\.WT,6-M#KM#G$3%/LT?4_/VA[^,TJ6CX$-E<9Y:M$Q[H4C^'
M'"#BQXTA.2P/^LI37EG9E%2U'C50=S#[*W%!_@OR*Z_6_*MR*9$?<2Q2_6 ,
M?9%2HW(DE7T[?]25[J6IE<QB 9&F88@T[&-3\-:L)71X/?AHUX)4Z['(X2R(
MF%/24BJ//[P&E*\- ]\@@;J76.DL]H6J=.]3,,*6S>KC@N,\82P)BRF5OF<_
M7;1=6+5G%IZ3PRK28V917GV;12D7W3)??1Q]^M%]B^_Y<PO2.^-*-.Z:FVB&
M?V+WX7"NS7%DI7:!GH14/^OV^CQ'3AO<^V6\[&=GU 6(\O#K4;T5S_"96&Z=
M5BFM6%^Y98ODH3Z,[G4>+;A!C_0UE[1[9]-OG<I8W\S.[((\'-# ]=D4;U_/
MGPUJ]@L23W3RZ;MRI=CQG43H6'4ZRMNX=F; KQ1W06;'*=HWT[SI@: ,U=5'
MB-OBNKX)S[9DSQ1?S(+[3&;G(RE_EXR)?WUHUN2B%<=,>.12X'F/ H'R9X=+
M+H&ML%DTJ8VN[CM<Z'O(^\CY+,>82UPM#W*YFMSU(H'Q)1*GF<U,<G"2TL:@
MFD-C.B2)G[LY)L$$="=YK]OYR<QR/V.TV$M9(:4J3^N-HWLZ_)+JI(,%4$@T
MPM5.QW0$H0<25]<L]!/OL$VZ%!_P!"L/VRGF5O9(N0GZ5) 8"4S[P&@&W+EY
MBS$"I2D";X 3 M(E=(H3 1_UCQ! /8H&,*Z%-2O+H1.+$G0\IQ>?]5FJ _Z"
M#;JF>N!3/#0#JEZ>.9:*%^]D7Y*@46JAKF*J&U#I),@X7KW-+=M$\+7OV\CG
M<[[NH;@&H7M*@A[EJ%%&G0-86O$OWPY H@1" W*=0OU,7>*9)4T+Y+;.]1I0
MNM&MV\@@S?/('O$+\,T+GUB:/'D);@4A*WWJG868K<"MI,//FOKV<47T[FER
M?T-I]6F/RN.NON.#L,-*#?.>>^^:-4ES!K,51%*8>7?0#+@&"U;W72M+F:[8
MIPB.?AG/Q.F,8I<)6Y2ROD4&3,+'_4]6\9<K2Q?H^;W]JC.)[*"U\(."+79&
MQOUM-LQ3')J.Y6+W5HZ.;86N+[.XR$!\^#L_L#1]3&2M'41Z=K L\>\]K:&:
MDUJ"+C$L65%G?AC/IY)*,MH3E8X':74AS9&EO*,'/]]/UK/0S[^FME)Q*9(-
M#$*B6'LF3D8_3[E7?TO1AV^D(D^(BDIM)2$Q*K4UG8V_XDULL8@L%Y/!VP)/
M$M.,KK?#,=.H/=>)SV0'U]O/VMQ5!^SFE ]WHY@8LNY</?VI.8PGJ?:\ M$?
ME")X-U#0?4Q!.W_1PSG%,:BA34/S-RQ+C3K 4C_/<\!;S!"W],)UP2%VLK$"
MH-OAIAFS;OSZQD!JR_7O?DQ^+^ Z='4Z=O(=Z5&<GW*W!)O.N(&G7%G<K<<Q
MTDR/F"YM?FLA@NEGL$SC:U6QWC>J4KPA_+*M3&IQ%C(C'#TH)48Q@1T)Y1$I
M8T.]W^SL#FFJ6:Q?IDF1J%T\JEM66)@L2@;RQ,_ ]9X43.MT+ZR[TRZ\NGI8
ME4>=IVTGN>R?AW22U-_07<\[!_T]R:"+-5!GN?!+9T&J7 FO3&\.-T/8ARX!
M\9=3SX;T"%:?@@J', RGH#8J+(=K.5?01G%J5'CV&^B[X,;2^_N.WZ+=)*1"
M[;LS7D05"9G/))L\/ZOCG&UI^6[80C;TX;;QCE!:R=8!,\JL6.6OQ*WZK\BO
MC''UOT6,2\G Q\+NO#_2AR<"&/^?R2[+_B'##ZZB-W0F+[;>A2TE3]6,\>"8
MB#2#9( [E?%UY 09^)&13CI,!@Z1@<Z@&MP<,"]4H/]S!FA7<U?S5VIF_=X[
MA8_PX!A[R,"1*47O[3P>O"9!E0RH1A#=QA<$8B(CIV$4'1HB-<_&[Z9AG5<I
M_^' AOZ9G +?GW) WXL]%O4V,E4@ [1DX!YHYC09R.=9@>/#2&%,.UUMK/*G
M1%+(P!U8 \_Z;S ,_#N<R]0!+A86RCRQ#C3.M',0-*])X"/QDH'4>A+2:___
MMR)RH<WJZEXUWP%^AN6LM7_QHFST!\0/W!B[XBX#J^4?$+#OL*?-=IGM,MME
M]F_)3/WWN6MS\QC%[!+6T@=;>$Z0@GZ<@OX%AOW([.O(]^K;!XD%D)\[1GL\
MK$&.#,1BT=-:I15G*71J*';5*':S_Z #6F>'89X$-FNK>\$HE8D@A>G_V0JP
M&2E*%?>T>3\RE?DYA^?/<IV<NVJ[:KMJNVI_NUJ"!VC#?;U [<_.S972L<8%
M@L:YTDF";4K5;FR2OIJ67^]T_::_2 ;@!G]:4![%;YSX=9YH 0(C=P(5(Y>Q
MQF]<#\I-I7/Y7W GZ:[\/4+^]!]02P,$%     @ ;X9R4D]BH"CZ=P$ ^.\!
M !8   !G86XU<6HT=7,U8V4P,# P,#,N:G!G[+P'6%3-EBZ\6Q DYR"I5:)$
MB9(;1**21$ R"D@2$,FQ,9!!! 0D(XB@A!8E1\D@.;;D')O49)H.M_U.F._<
M?\[<,W/.G?//S&V>]3Q53^_>NZIVK7>][ZHJ<#]Q\P"UEIJF&@ "@0!K_!^
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M)S-/'053ZZ3W<_(AQ[VWFND>+]J_0L$E]C.^9*TI*6&;%C*!+<]N?>/C7:<
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M5Y"+7O1C;OV(34T< $+!\Z?-VKU<]W2>+[J'&0Q& 6Y3+M"U5?#YEA$13,+
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MNTX5+$,S/MB*+YT:;^G/T;DJZK6XBJ+7"52^%WIFLSJS")6OFG%9(/J5.'$
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MB%JQ,DK2Q.=Q3LM4;7$T_&SK^J&[YU7M@.,I$5Q_-%"Y\#0917"IFL/T.O,
M;)]AO:+=E[,]+2YBK?I..G/."VY6EAM/==TM2@!WELU3G]8L;HXKC379V\/"
MC/17EJTIL\-++(<"@W*=?9R=Z1-4Y(+&DMSKUCW,O<L>,M8A/;9NAJ;-Z#^K
MV0*D,8Y9D+VC\/!=B;H9,9%O*8F.AKR7F=>.<J@L<O.>1T]UK!7Q\>Y_^AWP
MUL0&=)H:O?0YUB3\-GTDVE(S=524!48:I2]J3$_4"<9C3C,>A@(N0ZK/6';;
MA.24QZQTTR;];%7)[_IV2H#@0^9-86@WNT6S#2&7DH+(/.WE+NEVK_\I6@#.
MU_L]N8U?K'6\>,SL+>NKTI^WP3ZC(ZJMS^@J[6:PI7@:$7X^2@NF^W$CNJ43
MH7SU>]K#"J9W@SXYF1]T;V!V;\=5B+LA4#C@AE",MO2/[",'.3W=A*E5#MN2
M$Z5M91ZZ58V;/;PSNCM#?74NX/I,3( >J%<H\;S[P\9ON24]4,29?N9(E=PY
M*2":R&8E#SOIQK( ;%/?/;),=;4 0.9&B[N("5?.(]4;*OM\Y_L<AZ!5 D)[
M)]ZY1#CZ0.UVSY? 9,18N/\OA=%U@\=**%AC:;/SM&E PE:K#OEU0A;FG;.H
M2J2;0'C^#LM/(GBQ+>^)\XG!> BV"0;IHF0F^< <$M1U/JC)9=XE#?;F)YF*
MCE3S">K"\)W%UT\0N;+N%#Q4@EK!SU[?%2P2K*\/7]'=&=O,?:7.Q[N:I7)
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MES0G)_H$+? QL8.# 3LP"1\O(9KV,^=0D!H/CU@:RA^>D.P(==&<__'=^CP
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MP.QG'U3FZW27U>F[7TQV)MN.;- (\'?4JTE8:$E[S\.'W"RZYAP0K15Y,_]
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M5X5ME%*[IFM0T<B_#M]_R0[@=_[J_^FHIHJ!['-",#YXA+C%, ?_2PE>B8_
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MCJ8/NW<>EM_[:JY.A@/8AJ7US]+L2H[RUVU'=AXF$:/@L:U0D8[Z;P^$%D7
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M<'N/-L:C'F4WHX+V16REZV=S$VMS<>!$EWN97P[$\?["\>[8=J*\U/-63.^
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M-VS5"X%@S8.FZLNYG)Y65FMQVD!=T$P!Y6^/X6K1*4OD*"*"N^T5\]LA%'\
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MM_79]#;5I!0)%@Q>GUP"X]+(#B)GB!KJ8U=H@-XS(?Y175L'-S3SU88&^M9
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M,\"OT";)?*FBJ?!L3S6N>5A'S\?VZ!X![NVG,G#W2K<M<M[!LW31ZSCW7VV
MK>I-0[R(>UW'33D2P9X5HS$!>^;B1?@X852K/#D$5I>B,UN,EJG/C+BACB'>
M#A[PY_,!'1/7F)E%;^O?-U]." /-_M >>2_$.H.<_L6:S-OA;#+OR CU1* 0
MVT[*_J_Q/VLHZ_C031.8B<@9U(L-VT*O4<\QC1MEYW_RFXY0BX^3 M%T] @
MN]_:Z=L4[.A")H U#+.:!:.A&N'?S3@($EO;[L54-/):0$\1%8B,'BE>.^HQ
M!@RLJ;O(0S;^#'<K'%N>?+79C/F_&@@,_:]ZFQ+V@S^TKH=6'7VBG_B"^<23
MX873K?8J$<J&]Q2<HU[/HJ@<]=7RT-.B;:HFD^S+F:IR.+-U?_*W0=IFVDW#
MM.B&+($/LV:M'0V1NWZ(II@YPK9%<'/-%A[52,[G*$7'VDN ?B+W93_ %8G;
M#C<</QY!!*''O@@8^&CB[#7NKC6&D.B?]LQ>D/:\SQSB8HRZC3PH01U&SN*%
M(3E6)DLV7W[W311X%P^0^%&MKMAF0T_  *_%C_\5RD;;MT;X$\[76CGT6A1T
MN&N4OWQ@P.;+T*6]3%).FW:" Q"!R!3:E-MZ.V1]@HK-R)_S^FZ)E<]M2E'A
MYU/5EJ"WX&'=B]? 'KK;4Z5<W+O<PC?%@]I8__M;]%\%5ZYN_V*$CK(E01CJ
M:_),#**R9]1A11:F$L1+]IR@A/:=D<=6#I;M;5?$C[;:AO.7FJKZ7ZAQO-6?
MT*MZ!^K-V:6R7,(O3=@YGO6O#:_#1)D(2W/"!9BZ91R1\TS3+\DFMJ"&3%U%
MB#WMV?'.?.KB1)TOM71[?#[]V>A=:;I(\-0WK*#-)8&G+[O:<4P/O8$QOA_@
M^H?6^"]@RD1^GE#]U\R6%=[3?1H5!_-?<RL:.@]7&YC;9MRH:3=CQCOVM1RY
M/]I6MP5U9V?/NVSZZ#,EN?9+J>S&2F ><(A*/"T.DZ@]&579E='8W=Z^OH>&
M1/6*L\$&*M:7:-O/!;&_OI!M+E62YW-YIAW*%*/WQH;_)'LX"J[$?YC*N/2Q
MDI $M8F>N $B5@J;?A$T0[8ETH&^J2,\&=0N[6O6FA6S]N.UN"U;$#UUB(?Z
M?J7?)MZ1 0I;#VJ7806NK(2:E T+].>A5J%RRK/2XI'+INJ=FV\YV.3+[[)9
M) F\^E(OR*J,!Y"Z\#%3^ME1M+N3<F_EL"TE IMCURD2 0D1=/4PZG-P?@=,
MIHFI%&=10)?U?$P'0"D:B# MU55JRR)ZB!$U@ I'SNC9W:0AF3H_\R9'.%&$
MKODID](NM)X^^YS4H_V4JW&4? W#)2G#T.=]7)_P*[#"AR>,Z*^?(=E!M]#@
M*%EX8XSM0FJGU9)N[&K%L]LXA1 ;J=0](K%LYN<45"-OHZ#G(E#]4[S,FU>A
M^KSQ0C2:/E*IUZ@9YXX$ O<&+51%1./XJ,NFBVH;I^B3!:M9QCJ]!H+B!KK#
MPX=*:O"<$+>H+%_;1NZ;N#<+OXMWU04/$!IAK"E5=E]3, 5+I94/!A9]#*"B
MG[@WQ=[+*WOT^#8@CYU!V-_>Y)0<D7]O)/P-:3"I7SQM?UFZ?)A0GY$RH,W
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M]/0:PR)_-^:^YGRE"9[]QZ?-2ZZ2CN2T9R'AR&,R%M%ON! O&PQ;R_7%RVT
MEQD5,T_.9:RUJCXW."L?L3(='<>*VOT(T+EXP7A#+\(QN.:0_E>!X<73OH *
M9G,;9$U;T\UNP(=P'9S4\NN 0] D$97BKX>5YU./ )_[<QG?WMV/_.\[2!=A
M?[UK\NS%9KQHNSY><WY+X><0@A50&?)9/_G>^'??G+-QEAV\+,[QUW<)_S9.
MZQ)=A'^8:[7M00_D<0]_AQV+'>8VZO?KM^KS\+2!FW7$O\U&IC$>*?8;]4 >
M_Z.!?>?\357<&G-N_E/C8:G,X.N"B_QXT1*O;X^ "D>5@6AL+WRJ8OCHP5^]
MM]/B]\]W;_X/>6\=%66_M@U?A*(((@@"DDI*2 M(#*BD4B(A*24E)9U#MR""
M(#D@#0**= W2W:'42#=##0,,,[PSW#ON_:WG?;^UGGO_\^SGCVLM8C',7-?O
M/(_C.-/)%P%J=)XKTZ+L?=C)1'YG^1QHU"D4XDK%WFW%OK_ZK"^>=_U-\:E:
M1+LGLHU737L88?A@9V*KU3*]O.CKH$:&Q%[*1DF#5M8@_L.-JDXNH=I=,(L,
MG;"6K93\P)EX16VD(\2[]Y63MA5^:2[EP7J2@#[_RPS!&QD=#1G3S8Q\%7$Y
MU?61U,Z)]P1H13:\QD]&#O7KAP1-HK\R(A8G'PY&IZH&Z7PX52RQS_E%JPU8
M2J>' "Y>X%!)A^O9#FP=^76$[VFI!SCN-CYH\+JS4 ^^89TXU9&W]T,B5$'0
M@FF:I=&;])\19:UKC0Y/OR7UU$&K(]5VOD>/=[V.7&!+I*50G,Z^TR4,G')^
M.:GLYYI;TE<IT&=M6S13%)*Y3?D<GP8_YX87^7]HI?C?KV)')W[R^Y8LT4=4
M5P@%8F96'F,J!VU2EB%^/W4$R;L/J:X3G1:0=>/V,Q7)[_VDM&?G-@ME\AWT
MNOR+,MQ/D1IM@D'0O 0YTTY?V>0H8>)I8)J=SG^,WB"^N>R"V<Z$SZ1H'K"?
M^.D[(2G=#[.7G9/]GKJBF@[?JJ6" '"Q&FX^?$,;FUN$!5/M.9#H- ))(@,)
M,B&4)< 9G -D&8N"C+>XI%<'.EU;?<<.+[;5->_H7&JRK4)E?Z7T[9Q&EJ9"
MD58G[WV@(J.N3+.4X&)& V/)6"0,!5U-P;VX_^7KIM$KB\=+YP HA* P!H;!
M[>(&Z0ETQI'W(#S!@_,*1$@GIRLX5T&$0/N%4Z\\_\I0M0@7?6L]A-D+B]M_
ME(]E1%:CCJR_&1*+SXSRTIG@YL_![K>9$L!> 5+0LHUE["/-6?W+3Q1[B<,H
M/)H&6T5O.1D^YH%8LQ+0$-D+8$2@)(%6S[4(B=2;&1LFK^T]:$&I?_L>V:DF
MJM+P84/:"O-Q0,\&=N/+]@A5>?+P96J?5VE^+GA;E#K4O_O5VI"3D_=*ISZ9
MO+@LJ$Z2X3Q7KPS(<Y%'F=F+#^9Z]B-C)>_9>K)>S1/IZ. R9#&X":,5@=D0
MP_,-BGP7;YKME]T>?E.!.@<(;8[FU#&3U6X)'Z /B*"K,G3O]FZV!ILR7)UZ
M]AL_"B.R/@1*=J +F:Z5[<RG6KP=DY\%#78I+A:@]!KC\2_BDW1T1I29?4TN
M==FTGG5KB.,N/Z40DKGUCZ-8]G#<1Z?,)H,5(K>[)!#[?=6GW-OUC*LSI$&_
M2&F!5A)4VA+EEIG@LJ-@=JQ.Y"U'M3*)X=F[7KEPK42T5>,)2R61-W3/U%^*
M/7+Q[.9"[SN76=T-@2_N1_EDU=G7(2/UQ/_AH;(_NHCT0]$;.;:H%7K1S&(M
M[>6TFG?4<+)D]"5A ]$[>$$TO\5QB.(\%4(7\-0L_!QXUT^#-3IU^K*SB@_1
M1%B8M.N< VL^F\8M;#)0)&YV>P+=I$.-^92SS^_KE6G,G ,9G"<6)TK[OU7?
MH3?$$D[B_79$UJ!S?T DOM9[R6R[FG- .[N1M)G"D"SI^(9&&D30*81I8W0B
M^B-ZJU40>Y!<<%:6"6/_Q4$7!2Y24SMH)Q2VOY:.5$$JO (-6'7'(H,=DL^!
M(*P!1PHLD]PYN$]W8?A=TA8^'/TN,)\C?'\ S,6"A<FTH^R/='=.<D&;="/1
M]R7#8UZ@3WPY 77=3YEB)IAO@UZRE0E?)/5CFV;[[Q-@EJ__U/F24>%3UGQB
MIU-X@=5]+MYII8.)O]08\[!02K?TO-.<"^P&^C=#Z4J#SKP$&;FG$,RPL6ZZ
M<.D&D71MJ?)DLS158Z)N267UQX7G.S>"*A4TM3',_=)9"Z0<,BC9ZLK:-UV_
M%T6(PH2OV4ETI$S$$<;<L0-9Q\6"!&B%\28\U%JUI1FKTWX:BK2YL^E^8XX1
M&F726RL>P-Q6$VG<*<OQ7/'VML9[=X#H]V(#-";>@"J%O>OI%P>B"Z01JU5^
M#)/V#3?!67,MMYZ*$^@QP<TRR!:?VS2Q[#7<KAS3]K+R-G\?/MTSH+#ZXAR8
MYSP.. =DOIT#?F 4%Y!-@RM^/"R1WFF?CVGO,.?4H>EDQ3 4_ZK7^62-8=WK
MJ_O8X'[[E2ZC#*L#-PU3NI?OWZ8I!8=>)62]^B ]M\ZR4CKN$U>B*4#_P8I@
MP 4>YL@C.IG!F?PZ.<+D;I=C=NV2IA]EMZ..9K!$8\);/'('8YO^/;((_?:Z
MP2.YQD.WA\]%X9;.L?S7H9@B>(,H.LPB#QVK6!NI^-MPA$H<I"ESRT?)Y]0A
MS&%G4<QC7D(M2Y)LU<@BRT-U4'=7[NB;BR$\U3LGI&EGSK9Q[U)[5?T\PW.I
MA_/WB=N<E]-^QSB=ZK#-V[WMF)PO031,7HGO*.=+5.-P;&[.)(6'ZB5,8JCW
M5]_"[>Y$"T@N5KH]"1A;J#$.T2Y_/)]LZ<JL)F QZ,A=,G:8:JA'&;FFJ$7G
M^'/9\XP3?V<9LWNVF3ITLN<0[G2Q1"X><Z.1"54-0J*A'87'>CT,H#8]1$D3
MG)>1Q]ZT<^<T!=C\^Q +[O]/6,<0[<A$ UZ2!Y_"F3#!W&] >V8;ECJ_+0?'
M-.2\5]/^NZGW?Z3@#\E^P$[(=3!-QJ<Z@^-__HY1XMA8R ?4X7ZH(>?1^?^:
M%8FGO=AG[2:WGV:1.I5%9T 5MA0 GKAYIB729<W4.]#6\?(<R'V\W\,/=B=V
M <%P]$+Z)3714B4#*E[VSJ1/ZYMKF!)?JZZ$U\:SS5#WN4!WTY>A,^#BV(E
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M9C,)5M[M3:R? \R@KDR_M4^:R3FH_I]83@,4?[JQ\GHY]S#+HX_<&0+ERP6
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M&7B@%Q-4*TQQA<* 1!XTS@R7=T:M=[!@:-:ZU>;Z1"7 Q6K*%MCW,;E!XA;
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MK0G 3^W837MT33)LQ7DJ&P!,_3%;N$F).ETS.8P(E7E.R8\G)I+?D1?50QT
M#<UOL6 <0$7S1.V?)19/CJ7PLS'J0>Y3;L#FLB-"C] S][""_!D4ATU5<GT0
MMCK?'^B-Z_2>22S$T@O7#RE8\95"NR9W.) %'!A]56DGI.D?P02GB/N7E?XN
MR.L>P#@&W_IM'!&<K41_&DQ9](E%FF'@)PLQK][$S@W,$B&M@)-LN^X# ^@<
M0P(X31V0_X4W*^&[(E5 &[T RK!$K:(J **=.^*\O4_790 B=C&R01PH8?5.
M"8'U94Z/H.,Y?U',@E"E#OPI&G[03Z_8]/PL<1,)N6C,&!)S_86TTSFN3Q%D
M<">O&O>ZOA+#9@#JMH>X8)50-)S1^5U<V6PL:NPBD#G5PYH:KG!:0?F;49ZB
M!^0%&L^W(2>)9G.:W)%;UQX7.!#E46"/BKNG2\[_],&UC#R('!6[Z+^CLT-R
M>@&(?[:G^JZDL5[%]BK7;Y+?X_JS>B!BCQT[Y879_IC<-S0%1F=,!XB26(;-
MTXQW!3]9'5NFWG2^Z;!JO2?. -9;7ZD:<2WF#!ESJQ9X136#1["^+D/OWBI1
M: ]W+?S\+GMT*4'2RNN>^+I1E-:7$CN>[;9;6,-X>B;@3[2NC37.J/!MNYR:
MY*K.VXEF:Y<\0\Z!MMGGEM8NL^*WVLVOKG;EK'+LE\GN4:75A865E9A@J0'K
M$[Z)!B\P>4L&<6QK_%2#J-MH8*<] : DCLPD>Y+: 3/9$RE-\G2HNA:ND>C4
M.:"@ENM&M3@54R5I7;16YY9J<UQIP<=]W=MR3:S,A.%_-3[][:)<BEAXTQK/
MG6%P^L*&_QD_"=8#Z7:4Q;U7*,M]P)G(-I6]X6L],ZRF\B24+50J*LU[+$%#
ML;]^X]\E"?]^.65(#]UWM?I2>G@2Q[=-7Z'<2=>4<4;<O<<>NT"SXP*]L;Z^
MLL'?NCS#5< !4D6O'7^C^*)G!YOJ>RN_Q/,J#IKGZ.N!MME)WP/)WN+/6?'(
M>4+<7"@9L"ESX_BFW 2TVL%UV^+V/4N5 -U7$!\O1^ZAXFN/]^P_+M!%F'R-
M^[6@WE_K]*-D"HA<,'&PX^D?$>$!$^]%34PV:.792#-_0,]_JWY-WA(MP^S6
MC''=%GKR_0>KVA\+=[TUAGPTYJ=MT5P]U'4CI1&@N_;-H*ZARS'?W(O7C1AW
M=ZHMWK9<>?7DXS5+3^GL1B^[].;Z\L EDJMF.@2C+")+#U(4HB15',QR9YN/
MZNRJQGO9AP/.^KTO-=RSLZ,D1W<-W44#[8#2?W4@_JRL;+/_)6Y=@3?\=TSZ
M6XA:]0_!Y2^M\*?$>&'I/_'&=EV[,^$O/\H_(M3K?U-<0T037CIG 5O@S?_#
MWGN'1;ED^>.MB* D4;) H^2<HT"#2A9:<@8E0TO.R5:BY"2@Y!PDYPP2FR Y
M2DZ24Q,;:)IOW]F=O=[YW9G][<[,SFSXXSS/6_V\=:K>JCKA<ZKJ]#SHZI9Z
M;VXVM)L:AFKZ)>^'E%Y)8MQZ7C5:%T7^V>P0"1OECS3(;R=+ 53C"$=42+!A
MO5@>H5$T1\6W!0X^/!D_5;</ $0\9<G:N \6!W\*)WRB^F*:I]G/)(6^EMSV
MW"3#YX6)'&._P]N-'<Q;GZ84:!9H?]E^;9#A$D2>)->[SKPH/4^W[CO2DSMK
MPCI??B>:<[@[L)FXS[TK\>V%!F@>#0R]6QJ>AM7Y8$3/5C9_!-SP,7J'A%U!
M*&Y/?".T)X"CK25('C"/2YB<[N[N#1WD,Y%/T8G@P+P<W):X?2NS%\1>[R0V
M>+X6>AX2_]!:,VW/0B@6 )W[^@=;X..:ER!937]9]L=K+D*F]Q4[:*]T@AT*
M>MLLL?:Q9I7&6.)-8[L<SQX?%UA]>A(Q+V91AP8GM-,*U3@UJK^$9TC^9N$9
M!P.> S\4$\28ZNS[R#U7YEL!_0Y12-9X]W!V%ZY>'G7)Y6HO[WRK!UL)KH%.
MF]_PW,"?:82$COM-W70E8Q3A9E59[,/NNF#6=:#&XW<B"UAN.K:X[2[E\U<%
M@Z8T1X<KH!5],3M#_*J'"X(JP[8YO/PA[\*5W(17^.>',.AC:?Q_1/EDX'T#
MOS907":@V!#Q/\)&@HCAJA$B4N2VV\''J80Z5?MH0Q#5QA=UCRSIAI[MNRH0
M_N;%XVDP>U$3\LWS-94;QBEI9V1I&*W-W$,IFTZ(X^[C[ZM"*E\ CIL)QSJ'
M$23S%CHM'XXK1\VKM3-CG,Y8OC(9B*2L%WDHII3E+/0:53;[N -ZM%9Q[1$O
M,;?^8"BSS+"S/RU)]/ !*C7C(QX@"CKBX\LWQ/4T7/P6>7P,@09K]1&W$,E(
MN1S92>Q\5XPW'_$#Y]^)!#,7+PM]G\GP4707"ZA8@=X#NW+$V 7,,\LC6Z7%
M1*Z8,";R"D$X#+4)D##OV.+&]LI\H.M!4>__[!0Z_W)FQU5VJ*%4G3(:?#-9
M.^71:/9X)4X?F;:&7"93=OU-BYN#I[$1R"NT^?0.!E460M?W@)<[FM'0MMP)
MZ/K:S!'?KT\WMJ'3&J"C,X*K4R;4"%J*4FNA^V4&_/E> N-._2*>WXO9O]GE
MG-Y5DBULP4,H'74L0\L5[KL+S36>] ,\_P/M[-R;;;5/93")H7*IME>9)%T$
MWS% O-Y7G"T#I=;8#$P-(B8M_SK?_$^(K)ENM%*ACSY53_8;R?FK$0% OWV"
MB3A@_(2AO&*TKU0ZQA[W-I9._++O?N,PNXU^=)M<T"=?F.V&HF9%^0C?_H>A
M9\:KV2&6W[1C _#!=*G9 .>WQ&4'TVR3";?L?6!]D?FKQF7$(Y/QB <[!VYG
M6C6C=)RY;[II5LU!5XX&Z1*X">H^=^BA]<%:*.+5=0,X-&3?W!JWJBG)1EV>
MJB718[) GT4LJX^FE^A)8#4KK)%_I0&$4S7GTTIWRN#B]NF5R"4%H.ZJ9H43
M6Z^=H5QGK7^*E>11X*(GQ0G$?61MFGE%6.Z>R!5VO]M"<#.-+B(<NU#C^U+%
M$49OAP^,.G;2S7.9^G.^H8XE274,+!;;_\-7P$LLYW]=0!AT<4+Q3N%Y8EK+
M2<7%Z5&^S!N2)4QU/F!*I$3]:+&-J0*.Q-1S\20HKX87E1@L$&GOOE2=_*.*
MYI,OM9]C:A_?C<T3W'B7@^8>QK"'PXG$_&ZI'Z03"[TDQF[G>I_JRL9;1#K3
M&;\_3P"<NA6G?:[NY!&F7-+E9[>;QSQ8"WDM6A\7\X5_N=[]C="YYVGQVO_X
M._A_))4HQ8KX%XW1E";AF+R?'O8$?@;&,589TM($YQBYM3C>HX4R@.4M$Z4U
M9U^1,9")HQO3@2$OA]+D$MW<0A!30YEN7!TN7Z[.04T2'9ME4.>;5VLG.89_
M"%U^<G_VPX?CZ@]V<K.N:\9I=W:$4M[7=6\Q NV/ULC+.3^0%^AH<0'I_,L-
MBU[ZQ"MY.!EP?3KIRR%7;:37RAY3NOKG.$W]UN95@Y03ZP>6L^[&$[_ IOM<
M674_9O)SAZ7D0ES_%KCIW[8W@10(%6_7G<EZIS9VZ;$U'B5!@B)[PDT#L0B-
ME$V:*)O<B![W\L:2B08HN1M4:]RLLG&X1#1HUQ>OH7=OL,G1WFVTDYKR-4E+
M=@\?;800YPDE>JY$T+9$QQ#_^R#]JH_"=@X>*T:2ISF\^$M9XY-E",']&3G^
M*#LC&MGP6A8P^(<NWPV#BV'.0K.JR,CH]*<RR@E+T"452S*,W7A1S\ET90EJ
M[VO W1A9M%[L2QVH0@HOZA+@61&X6]OSA?>4!FX&;^7],;?63$O9OL#5/CW\
M7+U7^N66>H!:**$$M?-!O.TI1WI*LRLHZLL"#N]509'QG@VJ,K=-G'F(D]/X
MX+BT*7G>L>D=$\%DDU/S_8/&>8JA/5H>MO@CGYWVM#=V3!A059EXA?IP0377
MH%CM 0"=,4-C%VQI+2WA^=F=HITH'!'VAA]W* ^](<7#3E<NES)C;QI?J'T^
MC/KXRBY7/'!3KX.:'%X<!K'/MJR0I/?+6I:VN^L[6?+XG>!;2LBD1U>,/>;1
M9X;*2,9/'J7"V^>:BOFSAC-/PUX;<<Q6D[]XSR7FSO]YB0"/,\ I$T.6KC:V
MYMM*NGCLT!#6DZO\9? %*0QU*Q<Q#L91<!3\4+7)L8L:%':KD:D5$#=4_N^Z
M?4FLXRW=.P'F6-[#3B6?/@1 =2H,F.%@E/0X&IKB:"I1[L%<#/VTZN=[&BP=
M)Z'53BT7V-/7@ 4TB*0 _:9T7D%D5'-1O^?9LK4*6E^YC,BZ!OP[KT<4%"^A
MBI^AWH)J+\"7Y@IH!!U6<H4RA&?^7"A)Y)9F0C,&_F_@>U9"8E7O-4\\9AQ^
M\7TNG8:E]PX_S(NIL:J2(F+:YG&@RS?W<%(Q;TA_7N;6=FW+>#=T$'8&E+L&
MO-F$'A-6_2&)'1_TIP+_D1E3)U!3'_;?=$#^"?AFWR[+N0\88Y<3)9@O08P/
M29)3^AIRST!AJ\"3<>BGDNQ=-"Z>YCS#.BS\,KI:MKKF[F2G5QV[[Z#SR[7;
M_XB%QDB".VQH:MA-06+H6)^\79,6FFY?J++O.4@1GI*S+@RLL0DE%0;J['G)
M+'D"'^C*$*^=6 1QUU.K329:>4BG+\;S6C;3!EJ MBCTA*\![X:PLA"V;:?B
MY)4619*6=,+1&EOC-7J"[QK-W9?E;-AM'TD<T-CR@T*$=Q&:CA+8$C0^/ 3*
MVK#V:6&Z9)Y)QIC+=!VUE[?-D;3U@E<8[-#]H7R:8:<^RS@+-O:5J+?;A:\(
M-3?^#7T3L!\$L#4S6DT<414OM?DN1$)C&9)#!D,G[[>Y9DF&<&V. B?J(PC=
M2& &3:0%HG'QKU[UD,*]K18"&FF-ES[&IIDG+!NV\"7+'J?A+0CP=#[+?STN
MN=9X)#6"!!:YA2C/4,;,W:9?J<4B'Z3#T"=)7:(KA2L.U'+2N23=,Z)]GP3U
M5YYHIIJR2@@QG)GM-WUR=40JG89OWF:?DPP7OX"],'I37?HJE\88V!UCD.M,
M%*,K1ZE*9O+:/Q(W]JS0$ \AW]ZNW&U]IB#:\M;\$C9=LX&1A&J=@&Z8UJ'E
M2$&[8LK@NUO)<T&/K)KTT(9G:?J-!/*[D/^1<?I_HYQZK*>%/'@BP8!<-DP?
MV-EKR6AO*QZIMGUHW)S0&;]W[!^VM[]DP?UM!51$LS=\F_CZTUDWI&6='RAV
ML':\0ONJ0KF/G]0/TO0Y21&QQ)G&3MK9U@%SFW3#Q1ICXL04;_SB<65_NEK;
MLCQ6ENW\S]] _3-$&1@F*O=E8V1:QU) >MDS$O9(P1I66FS#B>U6TO&M?+O^
M?<V[HQ_FC(>4=_?XH406"5SL[NZD"9E^X,_7 *785JM48DY.^DN!$-/2NND2
M1C9P*=&-!3?'=A)Q\NIH5IZ=D4@35]$R*E"RM>:C105O[T=-=9.A*28[.?PN
MM][QIF I9=1?_.4[//_%^%U7X.U].'XZY#11\?&:K&RWUXVHW9A^4[ M?^$N
M9@>8*,^N>]N'F9EAYY-VA@A3P:D'=5%>^[JVY:0@(488/$?:LCIN"?*1J8@U
ME0"BH;%K[YP]]^RN]R85%^8SXZPMD4^.KXW%NB,>(K,'9H_[.2RFSW!XDHD+
M& /X-XPL38?W[_.3FUD@;I;G*8J]SZE!NT>?_B8^S'(J$5H,K0TO%JMVG7\J
M5!&$GI8#SUIBA!*8,AK E;_OG&>KF[_ZDOTI"7!;+NU61E7V07,#7LFTR4@Q
MR3T>74"D>#*$(=IRYP7+4R@.>(@I(\OG3K&9UJN@'[$(-<EHRX]S529.ZD%O
M;!;K22ITY:A:OQ+R(&%B0@6I!V';J<?8#6CMX53\P?E53?3EMWJ6DXFP+]I/
MS>I+:P-H[)M&,?BE0V;S>GDT0W[99.WZ/2"E8(U&?';0276447-\S34@PJ)E
M%MC;;%&-?JP%;7^Y!G ;*LQ< V"5AGL$/_1JPP._V0.1#><HOTIE*4<@U___
MF)[RH*A&J>A1=UF'+]N.'2 -W[BK_FU3?J>E=<:WUQK&Z\U7:?CC,=E>[.5!
M?A=-H_,*8WE"AJ@FA4*D\DBA@E1NYGS?$/%#U2-1U-/:,,/.9H;Q!+(U2[;%
M.NNR+_DO9U=*WE;>V!&QVB1QX ](/C5QFV2G?&Y"X*41:]]\]\"DF3(:TI?8
M*M;9!FB5_+H_=K*M'_N7[S/\E)"V7N0G6"U!1?7'E?0O"'KK#TEJ+3!6/7]2
MO@F_WOYJCGWC+OEG@U#$8U-N6)K-!]^F#[C:(12D.(\>)<O8<:LR=X$>4"CN
M.(PI:SA=B6^KMP1T#="R=_17J4%38A5G-!Y7$6^J($DG,LMXLD\R9S%G7Y$C
M*X*/]G<N*_*N >8AKI>&GW^<:ZV[9IO?+4UMZ_U(3S6L$WS<8.AS\:VZ@.["
M/^L!U^!'!_L=)=8/DTA0GINM"H1*FCW:V($GJ: DC^]IE7"#E%\Z4T&EZ; 4
M<?JCW^O\OZ+ZZ#^FS@5XF_\FJ/[E-P'W\SH;CY!7&<',N/_N.:DO'CGYEIF;
MA_/SLO?)8.)9%P0>R[MOV2Q5#0I5=?3:<01N?;N-5=>:1B"114.=R1?5'=U5
M+MT:%: 6OASH'"X0-<7"U,-8FG9+MBW:(]IC=/M=(Z(H6W>^DFM:;_"^ (4Z
M!C! T45'H\"R<'-X0;NGF139>BQ^C-E7J?F@"*DP<IPLN;/L ZFC%8K*Q+!*
M55*T=?/LJ*:F*Q<D>=$:N2P[^SIRZ';GW]*:O'(;P'NZWG9F;_F^?WBF4MI.
M=I;WPJQF(XT@Q6E\=(?_L:BBL=?L,240)@9Q5*X?MA%]G2;^@9 ]=HSKKB86
M;3%DTO8X$4^)ENI'EBHSZO#H?)*P ,E<\?%S96)NU4<'PG.]*X]@P+$\:]2!
M0&+QIK+!]#;/9W5MKX"%6N.DE99LY[&_''']K_PC^P(2GM;;Z;;\8PP6M%$Z
MLN];[0@>%XR=:KA2^*]JQ)6=QS\0&).PCWE6577+HQ)XSTMRF<JA:Z&=PCZ\
MET&2SR;S?512I!M9X4)H26YUC0G[-[-CZ;?#%34YWMNI56->B@=KR!EWN5NC
MUBYA7?M<'B::VG!SV4I4[VC5JI^DNUVKF3)26P4JO_0RE%4*9EY5?Y&,K_32
M=?8P^,SP;D^^!? N^QY? ZVS-Z]M.*=^AS.2UX ,+EL0'S8.!I1'LH[9-NJO
M /'=I+M .WEOK-]IK=3-M="24[H4V7,[*@?O23%DS)ARDKG-=&I2J-4KU632
M)[F2G9_O.+9NZA.TU>[Q+=S<FDZNO T)HA/7,T8$AV.AQ#0ZCQ"P)>*YTPI<
M([?Q8%E2RF*N]NV1NB+2#G&V@_WV']%]LGY:$9]M<58//7:)!R;Y!;&SDOM=
MXGE=A\J6":C=1A9>Q.%I2H1/X_@QF8B^3[4W4!_2K$?0ZC? :_RJW)RG5CX_
MQGS>8/>0)O6;4:. .N'@8^;>@G+?'3RGUX5)Z1#^J=[B:M?:7J:,^A<^O[<U
MUOP>\00]T2SHB>Z[!LB?7_S)#RLP*,Z:;2!B !7,5$*V]P?+" <'0P\%2J[L
M=$[K?WV>#NSRU":X7.A)4B12UL^=_EUI<;D&X!QWES1*GSV@<:Z.</ !?8#K
M27EPM@FK.T,00><I-#+KVN,(\M8$>>76,?N=-Y8&?$U-B/?BL1SM1@/PQ]:K
MUH.@;+L4H5'C$:2V*RX+B>!C*>49_K*E;6V93M?0?#S*PPK[H5?CX"">(*0Y
M3Q<.49C:.][^YRJJY3OVKU_?U>KNBBZW4[P&?.[6+$""AJR/M5Z-G;"Q[VX>
M[F;:I!F#4C#M4^Z,6)^ B)[AH53(/O:J(V9E)/L]O"YN339S5(P_5//=.:V[
M-YVVP253HL/2MQ,BV"ES-7^JT>!]R9FJ.HCT=)AX"Q*4O>'V5,1W*"IA<N0M
MK9NOYCA-:759%8_\U  8HRZOF7%#7'T&8@B1/B(W.N0^PK\SJ -M3Y0]O@*J
MP7'[CJ3]'S-6WP9O!QMLYWS&6UI_YR\G)9<5?4(%%^QH>YF JZN70[T$DYA[
M=PT0CUVKXA__%A_OJ-<KYZY7QSB?7O2:F-AXLG4I,R C'[;^RR:[]L@_TH,@
M3ES&XSY)OKT/EKME+6*-*X,1"<VV5):@IA8%+7/>GK\JN.1Y.#6):-O7\Q:)
MZ$V'8X6H=@AZ*,A9GLI4QISYBKZ*W3S7K(_$;B6_77IBB[61T,VPUJ_Q[!K
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M,=(>I.''?R4%NRYN,T1&=]\UN51+$:GW!&,9UE/R,DG(U!%KMJZQXWR-JUA
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M]=LY4=#"&/3"BBX9=N"-T>N8IT5$Y4Y)%2CB98\G$C,P1<FU7C@^YSJ*;OY
MI95K//F%LT+RM*3R7&%]Y_N:<7*3?6I;J2G\C4 S+GJJ??;F9;GO&6.$"JQ\
M-1RH?0(E1CX?=]ITGL'1-1V-87O,Q-,KLB*:\#*=67]WZWY>U+8F;U%5X6@I
MO='350()7CVT/"$MC9<+/+\7/8KCKZ01BG0>\'BK#FY'L49T-N,V-QQV:!(^
M>ZQ(MC,#WM1+;77YGH-X7XI/I^I[[%$E/908M]7FV!A;;6Z]%/%PRBWGXG1B
MY$ZFY[- 'GP".OMS3; !Y&"FHV+;HZL,MUI#8/DFU\2!'_N1H(K(<6$?Z$,S
MXYCSE8Q,67E-;9TV.?O ["U I':+O&-[C4!&D2VW])<?BB=B+L&'^KRPMXPC
MC:;X@<L62Z]Y >3W\.HV)*FD;-WV88(ZQ#^*(S*_5FS%T]PC,Z%AQ(C0"0Q(
MB(YP:"JT=FS,:$Q&FJ\ [VR1I![$ZK:RQ_89>\G?,.QP)=XJDXUY'MW5&C7&
M$S5+$?PQ&T>P@M+LEQS.A7W_J0M&K ^5X4JQV5MVEI.\@M-F-"P9Z^2;J?+?
M<T:E>I,68Z++/3&),7=G74@<YEY0PN['68?4+GIJ& 0N-[%V\"A0^14/DO6Q
MIJL&L^W:=X7)2?:SD^S,9!0L&.IN5JO,S<G>)XMWI,C.< MN[^"68W\?FQFZ
M6-&E9CX=\D2/F+E6),BB/J'R;_%W%7\GPOCFI0B7O@8\AXMU15AGP1R,:)AG
M706D/30<O0PGV&&?79=RP@G'FU\CM[$Z*4J'4%S]^60ZKV\%S^LDD9Q+62 B
MEJ>WIHGG4ZE#X8D?OIG^$,:)"KV"C*G16DR3UL^O/\S;VV>ESEU*O:^-R)15
M?#K(<F<:7J-F^TR7?QWM2[QY/.I%<:0["W-E^V;B'-:\"<,Y*60<0;H6S\WK
M6XF,;D1FOMWBNI2DJC<^*I:1YG"0^T[KK'R8,Y%;/&R@>=#>25&U5P7-L')-
M?:-UK]'Q04PK1HE]_VO%97;SSA36IG)Q.@KZ1EP-NKD:%WQN&-WH16%=DNZ4
MP7=M\?7:80/[Q4'$B\HK#P4J)=5\RQ?BNN7?6W<DM]5$C9>3S=7@?F\?#''X
MIP.W<[&PQ#Q. 5"1V$ ;K_SB,]9I^H>5'J5?R8@[$?M=1XBG^F*/*L)7=E]\
MW3<26 &NZ#DEE 0U4V^?<EMYE(WS;5=/=PXL"Y-O=W=)*<#3)^1$08^3"GBY
MQ#NR+17P8V7SK3X_^').56FQ@]1>;KC"D"EM*AO%6YE=<<!%U@%.+R9E<F9[
MW'-TYA2 L73#K.50IZ@DS12DW,0)^X.V>K9ZTYD9.89QLQ<. L'Q70E[N;E(
M_E%G' 58\)Z47V-!:%()/TL$G[%-H=>IS16!3$:C@Y"H_;+A75A13N5$5">^
M40!O5?;,^*?P=>*:@\$N38^20,ZL\1R>IJ">C^'R*Z*78WWX*Z1T^]9=7W)V
MC4>82HA';1O5X22HP[U!'6N6+I(.B[":#:%M7=0-N!(:E]S!6_"O^N[?^>UA
M8]UEM<C1?%+I2+#'5HW$EYS3V>-ZIHRZL*=_+DO!7R36!QTI#!4'XQ]J:V_+
MD;V+8GV=D*#8\'AS-%F;25*_PB9X<)A?;:+R$^=*4(:V]%/N'N)TN0(+YLXV
M)9XY3&*8@1L*[TD'AES3Z)I?/,XZZ4,[#V"V\^5DWY$@WJ<!3Z/$$-T$]?;Q
MK)B$JE,J*0</U_!7XU[/+Q1C0\O]&)TNNX:P5".*G#\*5=46O,R7RE;6;D)_
M1I;)WW\K_C].Q+U(M$Q'$:A= XK5Q]7Q('*^>B,V?-O1;>23$"(A?J?53+[O
M/)HA,C%(@:J#I'ER]J*<))O&M=:ZF09;FZH0^!TOT.LB+84ER\<*L<+0<L%>
M?+?-^894A,H\I9AI ^AT:"(E[*"A/8%_Q]428Y#-W,']FQ;S2:?KE5%T8H+U
M.26JUT:T6AHKPLNTR#+UNXAB4@'$V?5^Y6@ID%GT+>4D+1RC?5)'.M[6/A\1
MK"]_:K;,X/6.>^SNR3XQ@O4%W(D;9P[>3SH;!VK$RATI?8V07#HIC;ZS6I>B
MV<7H>OX1OWTD)\SCI=SN GC,,5=8X.5D1* IPC9#%W+4!W"[U\IF(:>!HU>U
M'\"_<,>246>X4::Y5<*^7*4.ZRII<;*P?W&78[O]WH:@Q1E):9[6]\&!V@W)
MDV)U<9R--@G@RR:W&X/1NL%J!6TL_2>[=LG"X@$<+05;U"P(@7K_-C.+8M)^
M4S+<&QB@HF=+R?=/KP&M/9ZD81QO=E9"@UYIMG4\"=4L:LW8/)WF&C&NEC3]
M<6[&9B=E-^I%/DR]E/!PIONU8\S=&J*GC<)Z+A.7>@ZYK+EUP/=\R4_ !WM-
M')\+\:2%,YYTDTVWZB(A3Q8GD3Z-4JB+:P!CB>RHZ)-<BPM:2P%E=XV=T*+P
M7-I;,=MJC?R+_4_:)LXBOXL6UIB0'CT4VAX]*OQAP,&KOXL@RJ]<677?;UTX
M)_-Z=@*\># J3H[V27$$#<13S%$!D"&DX&*R8-M9?+P&F%=L86'^.T:T&W*S
M'OC^> Y#KV&\R, L9?M)>[4,HZCZ(.'M=9O\!Q0.\N(RJ<BGUX#HLHQK0!T0
MY3<N SL]DH$;87G"RN3B>*E&K@%]XMQ1"%^#U$(WH.($\AFD<+:Q;7F*2:+(
M?S'FR@KZ /%, 6Y:+@4EOR^#*E83,LT@^R 3WZ/MER\(5>U'@I<LEH.G@??<
MMBQI(_>"S)X$>$,F*MTPB\-,;<K/"XBP?<#[ $"_O8=FF]@#<$OXUK)GR"AA
M+QWL!]DFS..8VO=F>8FR'%,N-#8D]W:B-2:1LEY7^G]T UUO/Y1?3%5QE!;5
M[=?GS+OS\H$]]:*FE!3?SIZEO-4#E>BF>FH"\=0\M),Z>@VH,N4Q4&1S$&:D
M,PGG-3@0T8QQFT3)*Z6BC@V_:1:&QQ9I.I-X?"^244DF;\Y[BG$3NUM,LH1Z
MLG#]@#'T]=C.QQ!A0QK\3R!W*,LI2RL\/-4V#V%P;O/ -?:!?&!]>6AP@D-%
MC6,\1\<E16/Y!,]PIA\\X@-!",>.DR(5LOO'HZ22I]X$HS'ZZ3%*!T#_2! .
M&0;&ONPZ$A7;@V0833-K&B-W%'4+D]LA,/RA '=>13OB1C>]*AJC9D2A)]O2
M,=$YU6(B'_,''^ VBSQ]<MZ@EX@BX:A]=.GHYG4-,%N_<IG8/-G4S_F\S$JE
M^DRD$/Q!72Z2.D_F)<0_>&&9>""Z>B,N8$2VVO]JDD7*TDU0L>7@;=07Q:(,
M*1N![@8] 8_UW"5Y^[#*61AI8+N(8GNLG!B1J6=)JDJ!E_1XR7KB)>E3R*?'
ME]]Z.R(<PV.KEC@?YGY8CQZ &-NZ4^RQB !U!D;X=W5U=0,/3B,L(68C]R;O
MW[MCLQJ.-*I; -PA72:>BHW-PN%84WZGM)2D:A^6DD@QUC8<2Q$2)=5IZ-F2
M^@RJC0AQS'*+6U$4X);#?8[)HG1*AW&\KXLBF^!OTLX5R8DY)1NEUG[TWG:@
M]F'W\VL V5.> ,/*1S37@%K6*2LKIDY6VG@@!9&E:BA-"5.N-UKU%X(I__J_
M'OW;T4&8"VKT!6)B,G[@_C3SR^X.<PR+XG8=A.]B2-'CM?MP?=+0]_="XH2*
M(U0/@('\GN><)96K<<LO;!T\QDT1YDMTPA3/&;?[7>K'3#+[/;,<\Q0-)L:.
MT$B$$YJ[8?!H;#$LE+NM_WY*V./0"<V Q9%&+4Y^ E*W '6WF<=8B1:T,VCH
M:W!B:0PQMJBNKH:WVV3>Y'L) ,JOT2&,E^2<":H%$AIJ;)AK=P8OFY@+U?2R
M&;,O,3)&Y"#& Z@'_.5N^RHDKZY2=_97?=Q9:XVR6GQ;WW+ B7<$;UK?/Y>;
MHPLE-GD]Z=L%&6=#TF=87K2.6[,9!QSXX.12 JT*BMT(VN<?U0D*3MPU%S-Y
M5IE:+#($YW(6KM+!*H\.BV X:(Q_2XT(@61M7.2W5$25,<9]?\KE"'L1ZISC
MEOFBL@91Q.<Q&]UJ[#33T=TI>^L5Y86)9MF&./X04F"7(=$DJK?]]K,C 3$>
M*V_'=A&9#XM:50I\B>:SQNV<0R>Y)[67"N>Z@V,&G8=3AV+/I XP4PHLC6HF
MST:^2:K>ZI+(%=4([!*:(%SJCG^BRB+H_/6[_EK0(@&^!:G15F_KVR'QG>C[
MG6\_;^I03 8X1=RKQ,N?9EN[^<(=Y"IT#;BAL,VM3LM:'7D58P]1!#]!-*$1
M]EM_M"J_.XI"+\X>VA'HG.\U0++DZ3B2/VN[.E)G2R"$CPM:H(H4-;Y0V:)^
M.%*ER,#.<3AN4O&!2790\OU[Y;OPX."=/;7\ZH7/@4N&Y_03T),U:)$=\.ZN
MP66[ 7U5R'YO(NF61E/TI$)%^<BHHL^]N+Q$$NXASFRU(21OEIN]J3['L'5'
M+F?E259!-GGQWHK3#*3[H 1C T4U)CYN6;+0_]H5QRMS@-L'2_FDWT7\5ME!
MB%OKC%0T"E+P<J$I*D2Z/<=1/Z[BX*S=8W=%?UZ+0&Q ?\4H.Z)99"(G:*F?
MM;VZ"X]GF$9#V$BD9NRLB&4Y4ZA!T'4T_5[6J"X%&D_9)?]GSD/=(@UCT58:
MNFE&6"9QVQU&O(RB/]@K(XF>GJASV'4XO"7[O>(=-'ZDJ;D6&@P]9"FY<M&9
M^)@0&Z')W"&?[-;&[-D/&1L[ "*#)H![FG)Z"^^N :M*I=< AWKY(.2+E2YH
M(W@<94X*)V@'S8AHSK"/"L:EE<(TE%8N)JF;Q9,0O)>,9X'*C#T$$8L7%Z<E
M)EM<D"[KRDL-1/E$#O&AAD,K=Y=]ZKK.B&6!>&!1G+J_CDJNMK[J6?PY58G/
ML5 C]])W3EN ;I!F_^<(]9="P/6)TF4X.,1+T?D)PH,LH]*_K&[\K6UGPZ6F
M\0J1ZT%X1ME-W=Y%@KP2G@.SP&*K:9/!;$B_,85"@+]^H! E'.66^U!.N+3M
M4"-7E51G=K*FZ8LA;?E!;FCQ?I6<D[X5<0!*W _7!LD"(D3$=!C.M,L.L^D(
MT/Y(D$5= _+)5XAUY0[P2\R79?D]^PU8XV6^^>VQM9-M61XA&C0FO%09@C+X
M!.:57XWV)@;-3/K*#Z\U2NWDB>PYT9+3/VQ8B 5MIZ<T\\ % T]JWS0^C9(O
M7T1^R02<W=)8[^ DM!+!+/J8X-1''MO])NU-J.<DP4J(0@&(4"M[+^.L!I/X
M4]2[5.Y%_+9ZSA#0(?XH: '46Q#'H>P]D%HP'.LE6J?9Y/G=8G>UKQDXAC0M
MUILV6"9SRJ5]J^[*104NX5_0T Q0[3OH^I1D;PT$GTE933QP-?</S2<?M^)6
M5E $O<P(9E%Z^4^ SO_NZ'\0J;ADK:L"+TK)AMQL*I02Y(Z2).MR8^3?H,K+
MR.^IC#?.J&9P?HVM8%% \T6DO[(F@7VWDK5>^Y63A!*/+(WZ%HMJ6:C)"CW]
MT(HX-0*J/,160COV6FM:!E/"[COEA49)B"@_:5!E247\X5KH?M 504N5K;+:
MVFQ=>- *2V_+A$!\U-I+2R@AVZYT\JUA[\]OU>._*7[UI%RKSZL4DSYJFZ0P
M*WG+F&+:=0)T'4U!3LI("2I7R->>CU7\"'9M&IE8C[,4)X,WAU983JBT4R45
M'<GK*XE]W6*9#!"E*MR@YA1TD*[0X8FU1';V#-P1&O"8S!I6VZJ&B$Y4CL4$
MG\6F))Y?I'B@B,<'.R)VHVQ:7A]AV!Z1"DUCO5AKNAO,0L_(/O!"FL'YW+VY
MMU19BIA1Z+\JNOJ/)$W0"@'!X+(BI;8DG[U0I,#F#1A0?H,I)U%I8R166R4A
M'V\X=JF?19'T:75IW/.H93T2I8 JBXR O3WF_@$EASE_^Y<(ECT0E4"S31I7
M//N/Q;W-B&R72E45B-'&,HORVNJE_."025G6L*@*DXF=^OL]UD%SA"/4'$H/
M"SP)*)<3R6?#/NW>-0B1(DP,[UR".]N=G=K*U,]1I@9XT3IGZHO-K16)?2OI
MHS$N357=UM:!M1=\=H:-\UG+:O?0V@IWL\"*L4LD,U(K8_<L*=L)*<(S/)H$
M-&K2U^);<#GVO!+??PDJJ;%)T#YT]3"J\=)?>C)X?TJK+9Y+BHVR6XOR0?CX
MI#)X6G[SXQ';LX]F\V5-E7MJH^PZ,(6J2A?<H8X\+2<Z7/5ZIL(!<KF>ZK9@
MIK0_?SOV?P;=UE\K'-HF2;!N?*J=\W"UYVLX]\+VINK6='9Q6*Z"M\NE4:CY
M;*KD%B3E8#7@J#/E<5-,H4I1?824.G"2?U#/K4]R#"EE=]%YV IY]8.]*$'0
M>D^(PPY[>^3=$P(<1,PE5$(D:PC'%'^QV/%=5CB4I?4:X+>M7>^CJ*!T,!NS
MB2W'6YFN_]'YD4A"[L$U0'\$[+>_FY7J*;G6S_<:3!@GND[V1<<E=87AH#!U
M:D2W,[LW=.)T5,#\<%#B89K061J!_,@)J[>AH@]J*H:HE\S$02Q,KY#@-M@<
MY/\&U19!J5P2IP)N+!2BN5PK[Q\::K3,/R]LPRG@=7B7(DC39WS0#W!QTHQ#
MV*HW#+/SY]NNNKKOBL^1['7 :XX>?RY<F+=(>3A4V7+<-MF957?)LA\;P/,4
ME>H/\"@B7IE6AX_R%S .\RW<;XM^<?\'9SK[0^;]E Z*JN5D\\MGG:X>WKO5
M%?:O+;Z04/$+L[GW4:(,PP >62/N+^5HR*>RR[;?:S=3CB_H#6>VN&DPN)A.
MY=*\_H"*[4" E.MUYYXI!8]JAB@(%,*A%FW/:/'3!)_B2YFX>:K$:RB"VAWY
MJD4\Y5A%.X@%V8!/B"X<):@[)0>$M@T<5QH\0SSGQ(79J\@KL9>FX9OKZ_@$
MMRZ-B1V_"HI()JQ1L6K6QXFE707L*B' CC$3[T04:;4$STCC7 FQ;=GI6."^
MD6J'A03I9$56J[:.EG">UI5%_6D>63&7&%]]YW]X\.OO'ER++]F"R8Y26 S)
M.=)B+X:F-N_88:WKQ/:X??CL9;S49WX-4*.S?%MXHQ/@%,D7=^$A=MQM\OQ;
MN;'5\>KEW=5C C*][6:NVHIP3DY%+=S("@X*)9G^8WY#F$?5F(=_3L*T2[I]
M3LT^AV(2_;=W4*PTK!;^D&Q$!@GB0W1GAI4=C+Y>EXW=-B""#J_#W/\L#3]1
M=:+JZEF'ZL8\D*3TH1H!?^=0]WHI1D+=4IBM<F-CTTB56Z;NI2A)-&?=XQ0_
M#XU;T\Z308WF>7TY"\GTA1(^<NGDT:I[8K=9%GS3$Z7@#+D9\R)S^B(XJ=4$
M38_7R6R?H24@6E^WG<U>052YA[G#8N &-&U?]LQE>#:[8?9Y13=/%.F-3Y[X
M.74M5!*:BE7CM'H]N;-9'>$-<M,+Z<6&JI_WD,K7@#M\#D"&MF4<Y_6PXH?V
MR-XAK)R03W@]U0^ZS'%J.QMM,":I[%]2:2KIEI17IUMQ\$8P?6NX!K"MU;YV
MM3LU8('3";-)U%33YJEMR2S##HM=)J7'BRO=OHOB$8W*)\9= W8WU[A%][8O
M7F)5\+(PF[_Z<EN.$: .T5=J._G.SEE43/[VL).E#*A'<51R'UPLLP0FV)S4
MB!;[T1'PY -N;[/9?+"NT*HZ_S!2DG@WNRMU,>^XSN@CKR+F%E7?+&&*!49#
M]?A>-KSH]&.G>!]>O:ROK;"8>]&G$FO&(Z_$/)/#(&T!6?PV$=_PV!\HMH;Q
M72_# H%XG'MO5BZ?Y[VU&&W&<M3'&PC$SS[8M1;E6](PT28.>=4W&R">VP1P
M=IDN3G9G#IY 3;ACJ06;&H$ D"=JX^8C506$W*JY<X+12ES&D<=T%]2QZQ,.
MEA=*N6;.$7=F+49E6';K*[U[4M'6<E<_OD,=J]7581V/4/O>I0]V&GYQ<,#P
MMSB[!N\U"? /U7^X&?E[$Q:S,>FI3+CMDOT'9S[M#+&:]P' '"C%ALEHX9SN
MU?W9"HR>4*B_^/+ _.:R>X:FA:Z7R8FJZA 6^]+@G3#!=E<*?<3[_G99JO2]
M0C YC0O_9X) 4=.<&3Q.I0DV:,7'-W+TTD=1WF4PXGEE"?*$VV$DOIGMKQ]\
M%L"MB.KCWH+0=J60-<")-'*ZW-(2&%AV5D.[O@908DQ-JO^2DOO1@<E%$2J&
MO7"X$[-4K4[:2+2[%0L#(T5-(S5(5.BBLZDPSA5DVESN?7JX0D-IC#45O,&4
MAJ\ 'A4UYD=R%FY-V,\\=7U3)HW'64%"Q30A*EP *VJN6)K9H*G[?!.,UQOS
M<"5])6E25PK@6"\=7^)?GZ@[MIQ@F<F=1;+UG'DRQ9VA KITMQ:*+9G+!V?(
MM.95O+6A-&[4$?Z]BX#_EY,9S9DYB!Q9:QLV_B=:>R,T,3/?<"1VYP+)!Y>4
M+:@IQM(F$K4GBMDICGH/HY\(]7;=]D@ZX9\8DI8F\ "L+H9:+=PS;52R/IX2
M?3<7&M:#+&<MS&-G*RI\S*W35D;+[8#EH"2'W/+XA\?(_M[$F@#WSLK $3.8
MP^G/^<; E!D/7@;&0;+3WDEC=Z=A%^W1UE>'N^F).C"9OG*CF3"R8$EACM&[
ME&0[<!=7&L!J=M3I#J&X)74W[14FV<UD"<KJHL51U_SF[.RM&@KUV<S[C2QD
MH+$'$\5NT'9N"P>P(_U83<TDV?U9A;'W4_AM-19I=R=/+?,LST@<*.F&/S)2
M\8A,BD$6$SUML6<W;N]F/2@S2\H57L$BWXW0V<I+PTUFE:@>]7I"'0H;\'LD
M8U2[D))3=W* MPJ8T7%+N<#C2T6<8./?V,(P:[!BPGB@?% 5D)G^+%LXEM;W
M-ODSKXWV9F\(QV"K:X@K;D+NAWUG[$>OAK_VWC-QZL%*V-Y(PW4:HC4DU-_J
MYX96MI56T@L!/-<JBAH?8%9_=L\).4?!^'*T",55;3P6*0]Y]16);G0QOB_>
MHP^U0M$VCEG3VBU_7[E[AXK'4<-+&WC:."$._&!S]$/;AAM)R-PS.$E6_"7Q
M1^[GM3?ZJ\8NPK")=\1J+/Y4@*_9_P3+X/_H_^C_Z/_H_^B_/[$TG53,38O>
ML:=O$)2C%7I]7$!,/,:P-J%U*P+X*=LUO9W#,\(#T"9.T;"[S"X+_>K/B*05
M3#WFWC(\&RJ&&(YP'!=<,6 [[RK'':[W.HS68-R"#U8YE>K.(%ZZG]47[;;I
MB;2U6#@L:1U?O+QQ#<#N7[_"]8B_.F:Z!OB9':$"Q!10%\2YWD53EI,N<36\
M?@F[P6VU \O,AU;545M1FT6,%ZI=ICCAP=S18)O*&S%_A@/1IJAU6J?#4-7&
MN:ZQD(HR.-TFMH4RB U"]X:<S%2+&@T7/%&$B8,79"><EQO*/W%AU52;8'.R
M((%L=EBM6X5G1Y3NO]PT>#3*'Q?%MB<H!UP(>Z]A^/5(@@BT1-YX#4B/4+D&
M-/L##T+GH4.P?.C"TZQZ>$J@N3W=??T]B_#ON!;:+R^C1HKUW'P5JLNK&Z-W
M,:MZ;@I+]B9=#MV&_CITF;_V1BT2,2B9(G?/D(5(Y3R2&%=,4LQJ('Y9GU.K
M-GI^8,6IFT?Y8SZLF, *D/UGO[X1DBZA)?:=+5PY]F5T[9;L\=D7 [;QCF;2
MFN:1??P>CM<WM0S),;_2!@-J_MP<I.=!ZM]&V.(8ZMVR!&#[QAF'M^?G6NJL
MI19F5H5]C>RRVY F?YN)]JH6$-*VH WCL9;]=)E?/ZA G'5\(&3I,J1VJG!J
MAA"G =?;RA!_*ZA@8TBOX(G 4+&V_(^R?H#RS]V&MO&Z7P.>4:._R_NN;Y<!
MG37>&^.@[]3: 8>T[(>N2 ^-[(4@OH:'3!S%-J*526;T+*XUPQY#F)R_VX,B
M*DZ#46>_J,(]]6^&VX3-&N \T> T+^NT$-\[393B@[R6WU,5YYANM/PZ=Q&_
M,E)#/ENN&D$^R]%A"Z=QK/<NBYLE>$%]#?!W5M&3H2K0$]AGUW3_N@Z4![3^
MV4]H/9@OK5\/*N$P&RM1D^%U)T&8AO0!YW=3BYPPNE! 06K-F7C,:O=/X@;0
M^4T)O#_+IR7?+?#%"%T0I\TM:Y8X)=Y: OFJW"V2B^R$.9T*/L6A\EA05!JN
M[>_/0WUN$%\3A4G X<H#H>XPH@KCR?]'V7M'-=5]6\-!5!0%! 7IH/2.=*0*
M4@/2:RA*#R$@O8N"@+30!*3W3D @(1":TGLG2.B]]RKUX[GW'>.[OV\\^MWW
MWPS./FNO.=><:Q_.V1L7Z8RUJJ3-+3P-U2CH<CG\9$!#GL[Y=K$L,X- [5\'
M*>$A\0@5DR "5E:,<%\#ABB$C0*AR]Q.SAM#E:7(ZL51ERUF+E-M(%-$DI*T
M(T<- R"M>D.:QOW?^3WV@65(P!TVM+R59"FM7)3P5@)$PS[L$:!"*75<@-:M
MI+$P<92FN ;\*RYZG#[ 7%MFO\I)R[?&?9LYW!).'H(F,VU>I*-=KVAF)[>0
M%%\#S3>G"  *?V*VN_H><T*N,16D.YHZ\_8GQ74B:J\TMC/=QKP-D[<5U=.#
M=*GD4,NS@#_&H&GD,?RJ"NWMR2._.@&I*&3-'T"]TCLB<'XSM$6RO+U&PO9B
M*<K)=%5LX)\-D_\E!3J7'"V4]A7;\>Y4.9'Q-XI"]VDYMJ6B&R_(E>V=&^PU
MRJDD_S8U[5<<A7\7*?;2Z 6)9P+GK-QE!Z)R>M$5>HZ;H#R(MR;&3B#,LKJ^
M6G'!^?,*TXUV25/X_7L:!:X!)&N&23U0>V%QCOH%=ME/&RBX\QD1#+H,^BU(
MD8.?0![^6P$_!2=-P@97ZP]:"50?$[CD-4RN:7J0?_\IQ:0J4#(? O6#FC-^
MJZZ^W99A3>\J!0=8_ >9_T,W@:X+7(1]VT"P XY''R-K;AQ1#37^4+I..6JX
M$<%4$P$5VB;9G@T%=/RQ-BKS/<H41[D#D?7].]\L->78];VMX4PS82X0CA#X
M<LUS&Q!$_DE\'_^/'6G2:\ ?-!N)J#?L-D">JW[>X/3\R5 @^=FMD&=GRZ5;
M 5V7^"SP924U/J#UCR&DM;=BA3*]XJ,FHP72'2UDDJ\2-_0V!8&J2J5DX]V"
M=4&BK\C91_[H5:2YM#7YR@FEW$\4K":LW>:T+VU3T\,%@!N(JJ =$D5'VB-V
MNE4U0T#P'[C0>PT(143P;0-!Q3&5;3BL3V)>]:N9?-W8>0)^Z25MS_U^N/1T
M08>IXP@KFH&?_J]L,#0TJ<V'\'8RQ355?YF7]F [PLNU3J>RN>7^988H*LH4
M/!X]X:XR@.OWA_PAF,8..P2^'8G:ZW!94BC8"_O>X0?N<2<4]PT8&EE94KQ
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M<Q H4.0$H+%-W OR1RG9N;*^ADG3"5-(5$H_^BM;#,]@Q>8Y$[Y99\LBYBR
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M@.9="7CX].,#6I%I@S19EQX^H+UH_UQH[VXK!@[-,6$.L:99O%^@',T9 WU
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M$B-AN--VMF#8:<7-X*K.K1U__U-$PZBAA%"_SJC Z6$Q5%Z-_1WCF'#HK'S
MJ?S<17'5J#A__CH*Z,X:PY%+Y;-JE$V\JICQL(P0C!(R81AAJJXO!S/)\4V
M')&-=0IVPPT,SK,3T5=8OU69*I<(_/;72G=RK'V"^117_GFTP%R6,P'Q\AXW
MWMY/\7=+H26TP4U7NV\Z"6)7G3>6RW+]'24D<M/@* ]MN4 EQ3A>3SSQY1])
MU](=E'E>L)K]SP?KP<&-BYY[3T?9I4C0:PT" ZY*?5Q*'A3]KZVHK?=+8<,*
MR(J1'9[YJ17CA9[.A4CEM+.F,4V$-ZA#5]_(J8059TSXO:%!IZM Z/>VP.['
M;1Q1&'MHG5HV.(%W,HPM;<4W:S(R7AZPJU!O8HIC,_=5T=XR\,UK/A7E#SKE
M!3;QE&EI5<*/</$?J?/<N;>JD MPBIHR-O1(5S7V4T(!"]T5'-SM)VD_^W.4
MC>8'32BADQ;<8Z))SM5$2B[%FI+<TCU0'WLEFAXR]#]S"IB0X+"R,:\.G(N3
ME5^ L-VL5/JR(S7]\&HG#,''+[5D^AH<IY?4G+?!P01S//=B^\]D8+Y\D-S(
M'VAQ\^[G[J@5.R(VUII#4EM3?'"ES?LUOOL$=01H9J(@K91=/TK )"[NK;KU
M]N9CKY7PNE?'E;S[2\8-1H%^G[WT_,!V5?'1H.+:$MLG_"FQ1X+]TQX,JG4C
MU@W\QJT"*SQ+*MJ4@%;@O0NF!2[)F3=QTURR'.*:0LL /S*OX4-4;6/#R,J
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ME& R.4=ZB^Y;(N!0 N+H(UV%)AY!>KM_QRJ^$'TXY='&GX+1*;N(>W -.#N
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M#'>UK-:P>E0KYHBB<9+P+68?:ZOBG_Q)C4'%EQL)_;).>UZP>$BQE>ZUX'!
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M@.N[/?20)%K3(:G#)V7'\Q1'QJXQS-PQJE8A6RM=>)(=?,?,76W)(/QJ:JH
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M#V5';E^$-VA,\L74YC&SAJ(+_-F?)]?I&!@!,,B,')UC_4:(>"L]_U'M*_/
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MI5Y[V@6$.NIC!)L4[M.X-Y:9]WXXO1-<RW*S'F/.$']@^7$Z%$Q/AO:S,3#
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M2P$"% ,4    " !OAG)2&EV9S)83   NU0  $0              @ %OV0,
M879R;RTR,#(P,3(S,2YX<V102P$"% ,4    " !OAG)2GB]9P3,,  #;J@
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M,#(P,3(S,5]P<F4N>&UL4$L! A0#%     @ ;X9R4FC=6F[B-0  OF0! !,
M             ( !?\H$ &%V<F\M97@Q,#$Y7S(X,RYH=&U02P$"% ,4
M" !OAG)28T8TLV@[  "J@P$ $P              @ &2  4 879R;RUE>#$P
M,C!?,C@T+FAT;5!+ 0(4 Q0    ( &^&<E(XQ?^:!DX  'Y$ @ 3
M      "  2L\!0!A=G)O+65X,3 R-5\T-C4N:'1M4$L! A0#%     @ ;X9R
M4K,C"0WI @  21$  !$              ( !8HH% &%V<F\M97@R,3%?,3(N
M:'1M4$L! A0#%     @ ;X9R4A)"']_^!   [$(  !               ( !
M>HT% &%V<F\M97@R,S%?."YH=&U02P$"% ,4    " !OAG)2X,+XF<H(  "6
M20  $               @ &FD@4 879R;RUE>#,Q,5\Y+FAT;5!+ 0(4 Q0
M   ( &^&<E)UBF0%N0@  ,)*   1              "  9Z;!0!A=G)O+65X
M,S$R7S$P+FAT;5!+ 0(4 Q0    ( &^&<E+;T$^S'P4  &4Q   0
M      "  8:D!0!A=G)O+65X,S(Q7S<N:'1M4$L! A0#%     @ ;X9R4AE#
M1^#YFP  8%(! !8              ( !TZD% &=A;C5Q:C1U<S5C93 P,# P
M,2YJ<&=02P$"% ,4    " !OAG)2*U)H@JTA 0 DK0$ %@
M@ $ 1@8 9V%N-7%J-'5S-6-E,# P,# R+FIP9U!+ 0(4 Q0    ( &^&<E)/
M8J H^G<! /CO 0 6              "  >%G!P!G86XU<6HT=7,U8V4P,# P
<,#,N:G!G4$L%!@     1 !$ 500   _@"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
